FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Patel, D
Martin, J
Josephson, K
Alessi, C
AF Patel, D.
Martin, J.
Josephson, K.
Alessi, C.
TI Earlier morning rise time predicts better functional outcomes of
post-acute rehabilitation for orthopedic patients.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Geriatrics-Society
CY APR 29-MAY 02, 2009
CL Chicago, IL
SP Amer Geriatr Soc
C1 [Patel, D.] Western Univ, Pomona, CA USA.
[Martin, J.; Alessi, C.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Martin, J.; Josephson, K.; Alessi, C.] VA Greater Los Angeles, North Hills, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2009
VL 57
BP S110
EP S110
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 425BL
UT WOS:000264611900312
ER
PT J
AU Steinman, MA
Patil, S
Kamat, P
Knight, S
AF Steinman, M. A.
Patil, S.
Kamat, P.
Knight, S.
TI A Taxonomy of Reasons for Not Prescribing Guideline-Recommended
Medications: Results from Physician Focus Groups.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Geriatrics-Society
CY APR 29-MAY 02, 2009
CL Chicago, IL
SP Amer Geriatr Soc
C1 [Steinman, M. A.; Patil, S.; Kamat, P.; Knight, S.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Steinman, M. A.; Knight, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2009
VL 57
BP S49
EP S49
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 425BL
UT WOS:000264611900138
ER
PT J
AU Wilton, N
Hammond, D
Tio-Matos, I
AF Wilton, N.
Hammond, D.
Tio-Matos, I.
TI Rapidly Progressive Dementia- a Diagnostic Conundrum.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Geriatrics-Society
CY APR 29-MAY 02, 2009
CL Chicago, IL
SP Amer Geriatr Soc
C1 [Wilton, N.; Hammond, D.; Tio-Matos, I.] VA Puget Sound, Tacoma, WA USA.
[Wilton, N.; Tio-Matos, I.] Madigan Army Med Ctr, Tacoma, WA 98431 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2009
VL 57
BP S23
EP S24
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 425BL
UT WOS:000264611900064
ER
PT J
AU Yung, VY
Walling, AM
Min, LC
Wenger, NS
Ganz, DA
AF Yung, V. Y.
Walling, A. M.
Min, L. C.
Wenger, N. S.
Ganz, D. A.
TI Advance Care Planning and End-of-life Care Preferences in
Community-dwelling Elders
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Geriatrics-Society
CY APR 29-MAY 02, 2009
CL Chicago, IL
SP Amer Geriatr Soc
C1 [Yung, V. Y.; Walling, A. M.; Min, L. C.; Wenger, N. S.; Ganz, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Walling, A. M.; Wenger, N. S.] Univ Calif Los Angeles, Hlth Syst Eth Ctr, Los Angeles, CA 90095 USA.
[Ganz, D. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2009
VL 57
BP S97
EP S97
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 425BL
UT WOS:000264611900275
ER
PT J
AU Odden, MC
Shlipak, MG
Tager, IB
AF Odden, Michelle C.
Shlipak, Michael G.
Tager, Ira B.
TI Serum Creatinine and Functional Limitation in Elderly Persons
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Aging; Creatinine; Kidney disease; Mobility limiation
ID CHRONIC KIDNEY-DISEASE; BODY-COMPOSITION; CYSTATIN-C; EXERCISE CAPACITY;
RENAL-FUNCTION; OLDER-PEOPLE; ADULTS; HEALTH; RISK; ASSOCIATION
AB Creatinine is a commonly used measure of kidney function, but serum levels are also influenced by muscle mass. We hypothesized that higher serum creatinine would be associated with self-reported functional limitation in community-dwelling elderly.
Subjects (n = 1,553) were participants in the Study of Physical Performance and Age-Related Changes in Sonomans, a cohort to study aging and physical function. We explored three strategies to account for the effects of muscle mass on serum creatinine.
We observed a J-shaped association of creatinine with functional limitation. Above the study-specific mean creatinine (0.97 mg/dL in women and 1.15 mg/dL in men), the unadjusted odds ratio of functional limitation per standard deviation (0.20 mg/dL in women and 0.23 mg/dL in men) higher creatinine was 2.27 (95% confidence interval [CI] 1.75-2.94, p < .001) in women and 1.42 (95% CI 1.12-1.80, p = .003) in men. This association was inverted in persons with creatinine levels below the mean. Adjustment for muscle mass did not have an important effect on the association between creatinine and functional limitation. These associations remained after multivariable adjustment for demographics and health conditions but were statistically significant only in women.
In elderly adults, higher creatinine levels are associated with functional limitation, consistent with prior literature that has demonstrated reduced physical performance in persons with kidney disease. However, the association of low creatinine levels with functional limitation suggests that creatinine levels are influenced by factors other than kidney function and muscle mass in the elderly.
C1 [Odden, Michelle C.; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA 94121 USA.
[Odden, Michelle C.; Tager, Ira B.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
RP Odden, MC (reprint author), San Francisco VA Med Ctr, Dept Gen Internal Med, 4150 Clement St 111Al, San Francisco, CA 94121 USA.
EM michelleodden@berkeley.edu
FU National Institute on Aging [R01-AG09389, R01-AG027002]
FX This study was supported by grant R01-AG09389 from the National
Institute on Aging. Dr M. G. S. is supported by grant R01-AG027002 from
the National Institute on Aging.
NR 29
TC 24
Z9 24
U1 0
U2 1
PU GERONTOLOGICAL SOC AMER
PI WASHINGTON
PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAR
PY 2009
VL 64
IS 3
BP 370
EP 376
DI 10.1093/gerona/gln037
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 419AC
UT WOS:000264190500006
PM 19181716
ER
PT J
AU Neuwelt, EA
Hamilton, BE
Varallyay, CG
Rooney, WR
Edelman, RD
Jacobs, PM
Watnick, SG
AF Neuwelt, Edward A.
Hamilton, Bronwyn E.
Varallyay, Csanad G.
Rooney, William R.
Edelman, Robert D.
Jacobs, Paula M.
Watnick, Suzanne G.
TI Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative
magnetic resonance (MR) contrast agent for patients at risk for
nephrogenic systemic fibrosis (NSF)?
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE nephrogenic systemic fibrosis; magnetic resonance imaging; ferumoxytol;
i.v. iron
ID CENTRAL-NERVOUS-SYSTEM; BRAIN-TUMORS; IN-VITRO; GADOLINIUM;
FERUMOXTRAN-10; FERUMOXYTOL; ANGIOGRAPHY; NANOPARTICLES; FERUMOXIDES;
PARTICLES
AB Gadolinium (Gd) based contrast agents (GBCAs) in magnetic resonance imaging (MRI) are used in daily clinical practice and appear safe in most patients; however, nephrogenic systemic fibrosis (NSF) is a recently recognized severe complication associated with GBCAs. It affects primarily patients with renal disease, such as stage 4 or 5 chronic kidney disease (CKD; glomerular filtration rate < 30 ml/min per 1.73 m(2)), acute kidney injury, or kidney and liver transplant recipients with kidney dysfunction. Contrast-enhanced MRI and computed tomography (CT) scans provide important clinical information and influence patient management. An alternative contrast agent is needed to obtain adequate imaging results while avoiding the risk of NSF in this vulnerable patient group. One potential alternative is ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, which provide enhancement characteristics similar to GBCAs. We review our experience in approximately 150 patients on the potential benefits of the USPIOs ferumoxtran-10 and ferumoxytol. We focus on central nervous system (CNS) MRI but also review imaging of other vascular beds. Safety studies, including USPIO administration (ferumoxytol) as iron supplement therapy in CKD patients on and not on dialysis, suggest that decreased kidney function does not alter the safety profile. We conclude that for both CNS MR imaging and MR angiography, USPIO agents like ferumoxytol are a viable option for patients at risk for NSF.
C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol & Neurosurg, Portland, OR 97239 USA.
[Neuwelt, Edward A.; Watnick, Suzanne G.] Portland VA Med Ctr, Portland, OR USA.
[Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA.
[Varallyay, Csanad G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Rooney, William R.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA.
[Edelman, Robert D.] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA.
[Jacobs, Paula M.] NCI Frederick, SAIC Frederick Inc, Natl Canc Inst, Canc Imaging Program, Frederick, MD USA.
[Watnick, Suzanne G.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol & Neurosurg, 3181 SW Sam Jackson Pk Rd,Mailcode L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
FU NIH [NS33618, NS34608, NS44687]; National Institute of Neurological
Disorders and Stroke [NIB1B EB007258]
FX This research was supported by a Veteran's Administration Merit Review
Grant and NIH grants NS33618, NS34608, and NS44687 from the National
Institute of Neurological Disorders and Stroke to EAN and NIB1B EB007258
to WDR. AMAG Pharmaceuticals Inc. donated ferumoxtran-10 and
ferumoxytol.
NR 28
TC 111
Z9 115
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2009
VL 75
IS 5
BP 465
EP 474
DI 10.1038/ki.2008.496
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 406UJ
UT WOS:000263320100010
PM 18843256
ER
PT J
AU Fried, LF
AF Fried, Linda F.
TI Creatinine and cystatin C: what are the values?
SO KIDNEY INTERNATIONAL
LA English
DT Editorial Material
AB Recent studies indicate that serum cystatin C is a better marker of glomerular filtration rate (GFR) and is a stronger predictor of cardiovascular disease and mortality than serum creatinine. Before cystatin C can gain wide acceptance, information about factors that affect generation, elimination, and analysis is needed. Stevens et al. analyze non-GFR-related factors associated with cystatin C and creatinine levels. The results will be useful in interpreting cystatin C levels in research and clinical practice.
C1 [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Fried, Linda F.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA.
RP Fried, LF (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Mailstop 111F-U, Pittsburgh, PA 15240 USA.
EM Linda.Fried@va.gov
NR 9
TC 8
Z9 8
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2009
VL 75
IS 6
BP 578
EP 580
DI 10.1038/ki.2008.688
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 412KH
UT WOS:000263723200003
PM 19247381
ER
PT J
AU Roodman, GD
AF Roodman, G. D.
TI Pathogenesis of myeloma bone disease
SO LEUKEMIA
LA English
DT Review
DE multiple myeloma; osteoclast; osteoblast; bone disease
ID KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; ADVANCED
MULTIPLE-MYELOMA; TUMOR-NECROSIS-FACTOR; RECEPTOR ACTIVATOR; IN-VIVO;
INHIBITS OSTEOCLASTOGENESIS; OSTEOBLAST DIFFERENTIATION; MARROW
MICROENVIRONMENT; OSTEOPROTEGERIN LIGAND
AB Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. 1 The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.
C1 Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Sch Med, Pittsburgh, PA 15240 USA.
RP Roodman, GD (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Sch Med, Res & Dev 151-U,Univ Dr C,Room 2E113, Pittsburgh, PA 15240 USA.
EM roodmangd@upmc.edu
FU Multiple Myeloma Research Foundation; Department of Veteran's Affairs
FX Preparation of this article was made possible by research funds from the
Multiple Myeloma Research Foundation and from the Department of
Veteran's Affairs (VA Merit Review Award). The materials are the result
of work supported with resources and the use of facilities at the VA
Pittsburgh Healthcare System, Research and Development.
NR 75
TC 137
Z9 146
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2009
VL 23
IS 3
BP 435
EP 441
DI 10.1038/leu.2008.336
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 416VC
UT WOS:000264032600002
PM 19039321
ER
PT J
AU Hysong, SJ
AF Hysong, Sylvia J.
TI Meta-Analysis Audit and Feedback Features Impact Effectiveness on Care
Quality
SO MEDICAL CARE
LA English
DT Article; Proceedings Paper
CT Annual Research Meeting of the Academy-Health
CT Academy Health Annual Research Meeting
CY JUN 09-10, 2008
CY JUN 08-10, 2008
CL Washington, DC
CL Washington, DC
SP Acad Hlth
SP Acad Hlth
DE audit and feedback; feedback intervention theory; meta-analysis; quality
of health care; health services research
ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE; PERFORMANCE;
INTERVENTIONS; IMPROVE
AB Background: Audit and feedback (A&F) has long been used to improve quality of care, albeit with variable results. This meta-analytic study tested whether Feedback Intervention Theory, a framework from industrial/organizational psychology, explains the observed variability in health care A&F research.
Method: Data source: studies cited by Jamtvedt's 2006 Cochrane systematic review of A&F, followed by database searches using the Cochrane review's search strategy to identify more recent studies. Inclusion criteria: Cochrane review criteria, plus: presence of a treatment group receiving only A & F; a control group receiving no intervention; a quantitatively measurable outcome; minimum n of 10 per arm; sufficient statistics for effect size calculations. Moderators: presence of discouragement and praise; correct solution, attainment level, velocity, frequency, and non-native information; feedback format (verbal, textual, graphic, public, computerized, group vs. individual); goal setting activity. Procedure: meta-analytic procedures using the Hedges-Olkin method.
Results: Of 519 studies initially identified, 19 met all inclusion criteria. Studies were most often excluded due to the lack of a feedback-only ann. A&F has a modest, though significant positive effect on quality outcomes (d = 0.40, 95% confidence interval +/- 0.20); providing specific Suggestions for improvement, written, and more frequent feedback strengthened this effect, whereas graphical and verbal feedback attenuated this effect.
Conclusions: A&F effectiveness is improved when feedback is delivered with specific suggestions for improvement, in writing, and frequently. Other feedback characteristics Could also potentially improve effectiveness; however, research with stricter experimental controls is needed to identify the specific feedback characteristics that maximize its effectiveness.
C1 [Hysong, Sylvia J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Hysong, Sylvia J.] Dept Vet Affairs Med Ctr, Hlth Serv, Res & Dev Serv, Houston VA HSR&D Ctr Excellence, Houston, TX USA.
RP Hysong, SJ (reprint author), Baylor Coll Med, Dept Med, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM hysong@bcm.tmc.edu
RI Hysong, Sylvia/B-8420-2008
OI Hysong, Sylvia/0000-0002-9063-5207
FU NHLBI NIH HHS [R01 HL079173, 1R01HL079173]
NR 29
TC 114
Z9 116
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2009
VL 47
IS 3
BP 356
EP 363
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 412VT
UT WOS:000263753000013
PM 19194332
ER
PT J
AU Wolf, MS
Shekelle, P
Choudhry, NK
Agnew-Blais, J
Parker, RM
Shrank, WH
AF Wolf, Michael S.
Shekelle, Paul
Choudhry, Niteesh K.
Agnew-Blais, Jessica
Parker, Ruth M.
Shrank, William H.
TI Variability in Pharmacy Interpretations of Physician Prescriptions
SO MEDICAL CARE
LA English
DT Article
DE pharmacy; physician; prescription; sig; instruction; medication;
variability; health literacy
ID DRUG WARNING LABELS; LOW-LITERACY; MEDICATIONS
AB Background: The clarity of prescription drug instructions is a health literacy and medication safety concern.
Objective: To assess the variability of pharmacy interpretations of physician prescriptions.
Design: Identically written prescriptions for 4 common medications (atorvastatin, alendronate, trimethoprim/sulfamethoxazole, ibuprofen) were filled in 6 pharmacies (2 largest chains, 2 grocery stores, 2 independents) in 4 cities (Boston, Chicago, Los Angeles, Austin).
Measurement: Components of the instruction were coded as dose, frequency, administration route, timing, indication, and auxiliary instructions.
Results: In all, 85 labels were evaluated. Dose frequency was omitted on 6% of instructions ("take 1 tablet for cholesterol"). Timing was explicitly stated on 2% of instructions ("in the morning"). All prescriptions included indications; pharmacies transcribed these onto 38% of labels. The prescription for alendronate stated not to lie down for at least 30 minutes after taking; this was transcribed with 50% of instructions. Reading difficulty was above recommended levels for 46% of instructions; with 14% greater than a high school level.
Conclusions: Efforts are needed to ensure patients receive clear, consistent information supporting safe medication use.
C1 [Wolf, Michael S.] Northwestern Univ, Inst Healthcare Studies, Ctr Commun Healthcare, Hlth Literacy & Learning Program,Feinberg Sch Med, Chicago, IL 60611 USA.
[Wolf, Michael S.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA.
[Choudhry, Niteesh K.; Agnew-Blais, Jessica; Shrank, William H.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Choudhry, Niteesh K.; Agnew-Blais, Jessica; Shrank, William H.] Harvard Univ, Sch Med, Boston, MA USA.
[Parker, Ruth M.] Emory Univ, Sch Med, Atlanta, GA USA.
[Shekelle, Paul] Greater Los Angeles Vet Affairs Healthcare Syst, Div Gen Internal Med, Los Angeles, CA USA.
RP Wolf, MS (reprint author), 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.
EM mswolf@northwestern.edu
RI Agnew-Blais, Jessica/L-9236-2015
OI Agnew-Blais, Jessica/0000-0002-0755-6867
FU American College of Physicians Foundation; Disease Control and
Prevention Career Development Award [K01 EF1000067-01]
FX Supported by grants from the Prescription Drug Labeling Project funded
by the American College of Physicians Foundation, and by a Centers for
Disease Control and Prevention Career Development Award K01 EF1000067-01
(to M.S.W.)
NR 18
TC 31
Z9 32
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAR
PY 2009
VL 47
IS 3
BP 370
EP 373
PG 4
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 412VT
UT WOS:000263753000015
PM 19194338
ER
PT J
AU Schauer, IE
Reusch, JEB
AF Schauer, Irene E.
Reusch, Jane E. -B.
TI Nonesterified fatty acid exposure activates protective and mitogenic
pathways in vascular smooth muscle cells by alternate signaling pathways
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID ELEMENT-BINDING PROTEIN; GROWTH-FACTOR-I; KINASE-C-DELTA; MEDIATED
DOWN-REGULATION; OLEIC-ACID; ANGIOTENSIN-II; CARDIOVASCULAR-DISEASE;
DOCOSAHEXAENOIC ACID; INSULIN SENSITIVITY; ENDOTHELIAL-CELLS
AB Vascular smooth muscle cells (VSMC) are dynamic cells exposed to fluctuating concentrations of nutrients on a daily basis. Nonesterified fatty acids (NEFA) have been indicted as potential mediators of atherosclerosis and exaggerated VSMC remodeling observed in diabetes, and in vitro data support a model of VSMC activation by NEFA. However, recent observations suggest that metabolic stressors such as oxidants and NEFA may also simultaneously induce cytoprotective events as pail of a homeostatic "off switch." Our group has established that the transcription factor cyclic adenosine monophosphate response element binding protein (CREB) is important for maintenance of VSMC quiescence, differentiation, and survival. We therefore examined whether acute physiologic NEFA exposure would regulate CREB in primary cultures of bovine aortic VSMC and explored the relationship between signaling to the cytoprotective CREB and the activating mitogen-activated protein kinase pathways. In vitro exposure of VSMC to 3 classes of unsaturated NEFA leads to significant acute, transient, dose-dependent, and repeatedly inducible CREB activation. As expected, extracellular signal regulated kinase, P38 mitogen-activated protein kinase, Akt, Jun N-terminal kinase, and protein kinase C (PKC) pathways are also activated by NEFA. Using a battery of pharmacologic inhibitors and antioxidants, we demonstrate that CREB activation is mediated by a novel PKC isoform and is reactive oxygen species independent, whereas extracellular signal-regulated kinase activation, in contrast, is mediated by reactive oxygen species and is PKC independent. These data suggest parallel and mechanistically distinct stimulation of separate stabilizing and activating pathways in VSMC response to acute NEFA-mediated stress. Furthermore, the down-regulation of CRFB in models of chronic metabolic stress reported in the literature would be expected to disrupt this homeostasis and shift the balance toward VSMC activation, consistent with emerging models of atherosclerosis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Schauer, Irene E.] Denver VA Med Ctr, Denver Res Inst, Denver, CO 80220 USA.
Univ Colorado, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA.
RP Schauer, IE (reprint author), Denver VA Med Ctr, Denver Res Inst, Denver, CO 80220 USA.
FU National Institutes of Health [R01-DK064741-01]; Department of Veterans
Affairs (VA Merit); American Heart Association
FX This research was supported by grants from the National Institutes of
Health (NIH T32 and NIH R01-DK064741-01), the Department of Veterans
Affairs (VA Merit), an NIH P01 vascular core grant, and the American
Heart Association. We appreciate the technical assistance of Jody
Gunter, Dr Peter Watson, and Matthew Hockin, as well as the careful
reading and advice of Dr Boris Draznin.
NR 50
TC 7
Z9 8
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
J9 METABOLISM
JI Metab.-Clin. Exp.
PD MAR
PY 2009
VL 58
IS 3
BP 319
EP 327
DI 10.1016/j.metabol.2008.10.003
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 414RH
UT WOS:000263882400009
PM 19217446
ER
PT J
AU Karaoglu, A
Aydin, S
Dagli, AF
Cummings, DE
Ozercan, IH
Canatan, H
Ozkan, Y
AF Karaoglu, Aziz
Aydin, Suleyman
Dagli, Adile F.
Cummings, David E.
Ozercan, Ibrahim H.
Canatan, Halit
Ozkan, Yusuf
TI Expression of obestatin and ghrelin in papillary thyroid carcinoma
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Papillary thyroid carcinoma; Obestatin; Ghrelin
ID HASHIMOTOS THYROIDITIS; FOOD-INTAKE; HORMONE; PEPTIDE; GROWTH; TUMORS;
ADENOCARCINOMA; DISCOVERY
AB Ghrelin and obestatin are two peptide hormones with opposing roles in the control of appetite: orexigenic and anorexigenic, respectively. Loss of appetite is a common, serious complication of many forms of malignancy. The goals of this study were to investigate: (i) whether there are differences in ghrelin and obestatin peptide expression in thyroid tissues from a series of papillary carcinoma cases and normal controls, and (ii) whether there are correlations between tissue ghrelin and obestatin levels in series of papillary carcinoma cases and normal controls. Immunohistochemical analysis showed that in sections of benign human thyroid tissue, anti-ghrelin antibody reacted with intense staining in colloid-filled follicles. In benign thyroid tissues, colloids displayed plentiful dispersion in comparison with papillary microcarcinomas, whereas colloids in malignant thyroid tissues were uncommon. We found markedly lower tissue ghrelin levels in thyroid tissue of patients with papillary carcinomas, compared with normal thyroid tissues (P = 0.001). Immunohistochemical analysis also showed that obestatin in papillary carcinoma stained positively to various degrees. Obestatin tissue levels in papillary carcinomas tended to be slightly higher than those in normal thyroid tissue, but this was not statistically significant (P = 0.29). We also report that thyroid tissue of patients with Hashimoto's thyroiditis produced ghrelin and obestatin at similar levels as in normal thyroid tissue, even though colloid in Hashimoto's disease is scarce. We conclude that depressed expression of ghrelin, but not obestatin, is specific to papillary carcinoma, and this difference might constitute a diagnostic tool to differentiate papillary carcinoma from normal thyroid tissue. We currently do not know how these peptides are regulated and what factors are involved in papillary carcinoma, which inhibit the expression of ghrelin but not obestatin. This issue warrants further studies.
C1 [Aydin, Suleyman] Firat Univ, Firat Univ Hosp, Sch Med, Dept Med Biochem & Clin Biochem, TR-23119 Elazig, Turkey.
[Karaoglu, Aziz] Firat Univ, Sch Med, Dept Med Oncol, TR-23119 Elazig, Turkey.
[Dagli, Adile F.; Ozercan, Ibrahim H.] Firat Univ, Sch Med, Dept Pathol, TR-23119 Elazig, Turkey.
[Cummings, David E.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA.
[Canatan, Halit] Kuwait Univ, Hlth Sci Ctr, Fac Med, Dept Pharmacol & Toxicol, Safat 13110, Kuwait.
[Ozkan, Yusuf] Firat Univ, Sch Med, Dept Endocrinol & Metab, TR-23119 Elazig, Turkey.
RP Aydin, S (reprint author), Firat Univ, Firat Univ Hosp, Sch Med, Dept Med Biochem & Clin Biochem, TR-23119 Elazig, Turkey.
EM saydin1@hotmail.com
NR 25
TC 16
Z9 16
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD MAR
PY 2009
VL 323
IS 1-2
BP 113
EP 118
DI 10.1007/s11010-008-9969-0
PG 6
WC Cell Biology
SC Cell Biology
GA 403XU
UT WOS:000263116100012
PM 19039650
ER
PT J
AU Punathil, T
Katiyar, SK
AF Punathil, Thejass
Katiyar, Santosh K.
TI Inhibition of Non-small Cell Lung Cancer Cell Migration by Grape Seed
Proanthocyanidins Is Mediated Through the Inhibition of Nitric Oxide,
Guanylate Cyclase, and ERK1/2
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE nitric oxide; mitogen-activated protein kinase; grape seed
proanthocyanidins; guanylate cyclase; tumor cell migration; lung cancer
cells
ID HUMAN HEPATOCELLULAR-CARCINOMA; ACTIVATED PROTEIN-KINASES; SKH-1
HAIRLESS MICE; TUMOR PROGRESSION; SYNTHASE ACTIVITY; OXIDATIVE STRESS;
BREAST-CANCER; EXPRESSION; GROWTH; ADENOCARCINOMA
AB Tumor cell migration is considered as a major event in the metastatic cascade. Here we examined the effect of grape seed proanthocyanidins (GSPs) on migration capacity and signaling mechanisms using nonsmall cell human lung cancer cells. Using in vitro migration assay, we found that treatment of A549 and H 1299 cells with GSPs resulted in concentration-dependent inhibition of migration of these cells. The migration capacity of cells was reduced in presence of N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase. GSPs suppressed the elevated levels of endogenous NO/NOS in A549 and H1299 cells and blocked the migration promoting capacity of L-arginine. Treatment with guanylate cyclase (GC) inhibitor 1-H-[1,2,4]oxadiaxolo[4,3-a]quinoialin-1-one (ODQ) reduced the migration of A549 cells whereas additional presence of 8-bromoguanosine 3'5'-cyclic monophosphate (8-Br-cGMP, cGMP analogue) restored the migration of these cells, suggesting a role for GC in migration of A549 cells. GSPs reduced the elevated levels of cGMP in cancer cells and also blocked the migration restoring activity of 8-Br-cGMP. The mitogen-activated protein kinase kinase (MAPKK) inhibitor, UO126, inhibited the migration of A549 cells, indicating a role for MAPKK in the migration. Additionally, UO126 and ODQ inhibited the migration restoring effects Of L-arginine in L-NAME-treated cells, suggesting the involvement of cGMP and MAPK pathways in NO-mediated migration. GSPs inhibited L-arginine and 8-Br-cGMP-induced activation of ERK1/2 in A549 cells. Together, these results indicate sequential inhibition of NOMOS, GC, and MAPK pathways by GSPs in mediating the inhibitory signals for cell migration, an essential step in invasion and metastasis. (C) 2008 Wiley-Liss, Inc.
C1 [Punathil, Thejass; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Res Ctr, Dept Clin Nutr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Dept Comprehens Canc Ctr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
NR 36
TC 24
Z9 25
U1 1
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAR
PY 2009
VL 48
IS 3
BP 232
EP 242
DI 10.1002/mc.20473
PG 11
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 415OI
UT WOS:000263943000007
PM 18680102
ER
PT J
AU Rani, CSS
Elango, N
Wang, SS
Kobayashi, K
Strong, R
AF Rani, C. S. Sheela
Elango, Narayanasamy
Wang, Shou-shu
Kobayashi, Kazuto
Strong, Randy
TI Identification of an Activator Protein-1-Like Sequence as the
Glucocorticoid Response Element in the Rat Tyrosine Hydroxylase Gene
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID CYCLIC-AMP; RECEPTOR-BINDING; PHORBOL ESTER; TRANSCRIPTION FACTORS;
PROMOTER REGION; AP-1 COMPLEX; DNA-SEQUENCE; C-FOS; EXPRESSION; CELLS
AB Glucocorticoids (GCs) generally stimulate gene transcription via consensus glucocorticoid response elements (GREs) located in the promoter region. To identify the GRE in the rat tyrosine hydroxylase (TH) gene promoter, we transiently transfected PC12 cells with a 9-kilobase (kb) TH promoter-luciferase (Luc) construct. Dexamethasone (Dex) stimulated Luc activity, which was abolished by mifepristone (RU486). Serial deletion mutations revealed a Dex-responsive 7-base pair (bp) sequence, TGACTAA, located at -5734 to -5728. Deletion of just these seven nucleotides from the 9-kb promoter completely abolished the Dex response and partially reduced the response to phorbol ester but not to forskolin. The Dex response was fully retained in a construct in which most of the 9-kb promoter was deleted, except for 100 bp around the -5.7-kb region, clearly identifying this 7-bp sequence as solely responsible for GC responsiveness. Conversely, deletion of the proximal cAMPresponse element (-45/-38) or activator protein-1 (AP-1) (-207/-201) sites in the 9-kb promoter did not affect Dex and phorbol ester responses. A radiolabeled 25-bp promoter fragment bearing the 7-bp TH-GRE/AP-1 showed specific binding to PC12 nuclear proteins. Using antibodies against the glucocorticoid receptors and AP-1 family of proteins and primers for the TH-GRE/AP-1 region, we detected a specific DNA amplicon in a chromatin immunoprecipitation assay. This 7-bp TH-GRE/AP-1 sequence (TGACTAA) does not bear similarity to any known GRE but closely resembles the consensus AP-1 binding site, TGACTCA. Our studies describe for the first time a novel GRE/AP-1 site present in the TH gene promoter that is critical for glucocorticoid regulation of the TH gene.
C1 [Rani, C. S. Sheela; Wang, Shou-shu; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Rani, C. S. Sheela; Wang, Shou-shu; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Elango, Narayanasamy; Strong, Randy] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Kobayashi, Kazuto] Fukushima Med Univ, Sch Med, Dept Mol Genet, Fukushima, Japan.
RP Rani, CSS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM kadapakkam@uthscsa.edu
FU NIA NIH HHS [AG022307, U01 AG022307]
NR 41
TC 15
Z9 18
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAR
PY 2009
VL 75
IS 3
BP 589
EP 598
DI 10.1124/mol.108.051219
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 410EE
UT WOS:000263559500016
PM 19060113
ER
PT J
AU Elder, GA
Cristian, A
AF Elder, Gregory A.
Cristian, Adrian
TI Blast-Related Mild Traumatic Brain Injury: Mechanisms of Injury and
Impact on Clinical Care
SO MOUNT SINAI JOURNAL OF MEDICINE
LA English
DT Article
DE animal models; blast overpressure wave; blast-related brain injury;
improvised explosive device; mild traumatic brain injury; Operation
Enduring Freedom; Operation Iraqi Freedom; pathophysiology;
postconcussion syndrome; posttraumatic stress disorder; shell shock
ID POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; SHELL SHOCK;
RAT-BRAIN; EXPOSURE; IRAQ; WAVE
AB Mild traumatic brain injury has been called the signature injury of the wars in Iraq and Afghanistan. In both theaters of operation, traumatic brain injury has been a significant cause of mortality and morbidity, with blast-related injury the most common cause. Improvised explosive devices have been the major cause of blast injuries. It is estimated that 10% to 20% of veterans returning from these operations have suffered a traumatic brain injury, and there is concern that blast-related injury may produce adverse long-term health affects and affect the resilience and in-theater performance of troops. Blast-related injury occurs through several mechanisms related to the nature of the blast overpressure wave itself as well as secondary and tertiary injuries. Animal studies clearly show that blast overpressure waves are transmitted to the brain and can cause changes that neuropathologically are most similar to diffuse axonal injury. One striking feature of the mild traumatic brain injury cases being seen in veterans of the wars in Iraq and Afghanistan is the high association of mild traumatic brain injury with posttraumatic stress disorder. The overlap in symptoms between the disorders has made distinguishing them clinically challenging. The high rates of mild trumatic brain injury and posttraumatic stress disorder in the current operations are of significant concern for the long-term health of Us veterans with associated economic implications. Mt Sinai J Med 76.111-118, 2009 (C) 2009 Mount Sinai School of Medicine
C1 [Elder, Gregory A.; Cristian, Adrian] Vet Affairs Med Ctr, James J Peters Dept, Rehabil Med Serv, Bronx, NY USA.
RP Elder, GA (reprint author), Vet Affairs Med Ctr, James J Peters Dept, Rehabil Med Serv, Bronx, NY USA.
EM gregory.elder@va.gov
NR 26
TC 113
Z9 117
U1 1
U2 26
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0027-2507
J9 MT SINAI J MED
JI Mt. Sinai J. Med.
PD MAR-APR
PY 2009
VL 76
IS 2
BP 111
EP 118
DI 10.1002/msj.20098
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 427OE
UT WOS:000264787800004
PM 19306373
ER
PT J
AU Julian, LJ
Vella, L
Frankel, D
Minden, SL
Oksenberg, JR
Mohr, DC
AF Julian, L. J.
Vella, L.
Frankel, D.
Minden, S. L.
Oksenberg, J. R.
Mohr, D. C.
TI ApoE alleles, depression and positive affect in multiple sclerosis
SO MULTIPLE SCLEROSIS
LA English
DT Article
DE genetics; multiple sclerosis; quality of life
ID WHITE-MATTER HYPERINTENSITIES; APOLIPOPROTEIN-E POLYMORPHISM; DISABILITY
STATUS SCALE; LATE-LIFE DEPRESSION; COGNITIVE IMPAIRMENT; EPSILON-4
ALLELE; DISEASE SEVERITY; NEGATIVE AFFECT; E GENOTYPE; ASSOCIATION
AB Background The role of apolipoprotein E ( ApoE) alleles has received recent attention in depressive disorders, the ApoE epsilon 4 conferring greater risk for poorer outcomes, and the ApoE epsilon 2 allele providing some protective effects. Depression is common in multiple sclerosis (MS) and the role of ApoE alleles is unknown.
Aims To evaluate ApoE alleles in relation to symptoms of depression in a cohort of patients with MS participating in the Sonya Slifka Longitudinal Multiple Sclerosis Study (Slifka Study). To examine risk and protection, depressed mood and positive affect were each investigated with respect to the ApoE epsilon 4 and ApoE epsilon 2 alleles, respectively.
Results Of the total 101 participants, 22.8% were ApoE epsilon 2 carriers and 21.8% were ApoE epsilon 4 carriers. Hierarchical linear regression analyses suggested that after controlling for demographics, disease duration, and disability, ApoE epsilon 2 significantly predicted increased positive affect (R(2)Delta = 0.05, F(1,94) = 5.44, P = 0.02) and was associated with decreased severity of depressive symptoms, although this did not reach statistical significance (R(2)Delta = 0.03, F(1,94) = 3.44, P = 0.06). ApoE epsilon 4 did not significantly predict depression status.
Conclusion The presence of the ApoE epsilon 2 allele in this study is suggested to be protective against depressive symptoms in our subsample of patients recruited from the Slifka Study. These findings are consistent with reports in psychiatric populations linking ApoE epsilon 2 with decreased incidence of depressive disorders. Further investigation would be warranted to understand the role of ApoE genotypes and risk for depressive symptoms. Multiple Sclerosis 2009; 15: 311-315. http://msj.sagepub.com
C1 [Julian, L. J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Vella, L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Frankel, D.; Minden, S. L.] Abt & Associates Inc, Cambridge, MA USA.
[Minden, S. L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Minden, S. L.] ABT Associates Inc, Cambridge, MA USA.
[Oksenberg, J. R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Mohr, D. C.] Northwestern Univ, Hines VA Med Ctr, Dept Prevent Med, Chicago, IL 60611 USA.
RP Julian, LJ (reprint author), Univ Calif San Francisco, Dept Med, 3333 Calif St,Suite 270, San Francisco, CA 94143 USA.
EM laura.julian@ucsf.edu
FU NCRR NIH HHS [UL1 RR025741]; NICHD NIH HHS [R01 HD043323, R01
HD043323-03]; NIMH NIH HHS [K08 MH 07272401A2]
NR 37
TC 12
Z9 13
U1 2
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER
JI Mult. Scler.
PD MAR
PY 2009
VL 15
IS 3
BP 311
EP 315
DI 10.1177/1352458508099478
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 423AF
UT WOS:000264468100006
PM 19244396
ER
PT J
AU Oh, SJ
Morgan, MB
Lu, L
Hatanaka, Y
Hemmi, S
Young, A
Claussen, GC
AF Oh, Shin J.
Morgan, Marla B.
Lu, Liang
Hatanaka, Yuki
Hemmi, Shoji
Young, Angela
Claussen, Gwendolyn C.
TI RACIAL DIFFERENCES IN MYASTHENIA GRAVIS IN ALABAMA
SO MUSCLE & NERVE
LA English
DT Article
DE MuSK antibody; myasthenia gravis; racial differences
ID ACETYLCHOLINE-RECEPTOR ANTIBODY; ONSET
AB Demographic, clinical, and laboratory features were compared in 235 white and African-American (AA) patients with myasthenia gravis (MG) at the University of Alabama at Birmingham Neuromuscular Disease Clinic from May 2003 to January 2008. Seventy nine percent of patients were white. Acetylcholine receptor antibody was positive in 71% of white patients and in 59% of AA. In patients with seronegative generalized MG, the rate of positive muscle-specific tyrosine kinase antibody (MuSK-Ab) was significantly higher in AA than it was in whites (50% in AA vs. 17% in whites). Ocular MG was seronegative in 75% of AA patients. In AA, MG occurred earlier and more frequently in females, whereas, in whites, disease onset was later and more common in males. Another significant difference was a higher percentage of abnormality on repetitive nerve stimulation in AA. There was also a tendency for more severe forms of MG in AA. There are racial differences in MG between whites and AA in Alabama. These racial differences highlight the need to study biological factors in the pathogenesis of MG and to assess different approaches in diagnosis and treatment. Muscle Nerve 39: 328-332, 2009
C1 [Oh, Shin J.; Morgan, Marla B.; Lu, Liang; Hatanaka, Yuki; Hemmi, Shoji; Young, Angela; Claussen, Gwendolyn C.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Dept Neurol, Birmingham, AL 35294 USA.
RP Oh, SJ (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, Dept Neurol, Univ Stn, Birmingham, AL 35294 USA.
EM shinjoh@uab.edu
FU NINDS NIH HHS [K08 NS057664-01A2, K08 NS057664-02, K08 NS057664]
NR 21
TC 13
Z9 13
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD MAR
PY 2009
VL 39
IS 3
BP 328
EP 332
DI 10.1002/mus.21191
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 411NR
UT WOS:000263656800007
PM 19127534
ER
PT J
AU Fotuhi, M
Mohassel, P
Yaffe, K
AF Fotuhi, Majid
Mohassel, Payam
Yaffe, Kristine
TI Fish consumption, long-chain omega-3 fatty acids and risk of cognitive
decline or Alzheimer disease: a complex association
SO NATURE CLINICAL PRACTICE NEUROLOGY
LA English
DT Review
DE Alzheimer disease; cognitive decline; dementia; fish consumption;
long-chain omega-3 fatty acids
ID N-3 FATTY-ACIDS; TUMOR-NECROSIS-FACTOR; CEREBRAL-BLOOD-FLOW;
DOCOSAHEXAENOIC ACID; CARDIOVASCULAR-DISEASE; DIETARY SUPPLEMENTATION;
SECONDARY-PREVENTION; VASCULAR DEMENTIA; BRAIN-DEVELOPMENT;
PROSTAGLANDIN-E
AB Long-chain omega-3 fatty acids could have neuroprotective properties against dementia, which is becoming a major global public health issue. We conducted a systematic review of the literature to establish the association between eating fish (a source of long-chain omega-3 fatty acids) or taking long-chain omega-3 fatty acid supplements and the risk of cognitive decline or Alzheimer disease (AD). We identified eleven observational studies and four clinical trials. All three observational studies that used cognitive decline as an outcome reported significant benefits, whereas only four of eight observational studies that used incidence of AD or dementia as an outcome reported positive findings. None of four small clinical trials provided convincing evidence for the use of this approach in the prevention or treatment of any form of dementia. In summary, the existing data favor a role for long-chain omega-3 fatty acids in slowing cognitive decline in elderly individuals without dementia, but not for the prevention or treatment of dementia (including AD). This apparent dichotomy might reflect differences in study designs with regard to participants, dosages, the ratio of long-chain omega-3 to omega-6 fatty acids, or the choice of outcome measurements. Large clinical trials of extended duration should help to provide definitive answers.
C1 [Fotuhi, Majid] Sinai Hosp Baltimore, LifeBridge Hlth Brain & Spine Inst, Ctr Memory & Brain Hlth, Baltimore, MD 21209 USA.
[Fotuhi, Majid; Mohassel, Payam] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, Memory Disorders Clin, San Francisco, CA USA.
RP Fotuhi, M (reprint author), Sinai Hosp Baltimore, LifeBridge Hlth Brain & Spine Inst, Ctr Memory & Brain Hlth, 5051 Greenspring Ave, Baltimore, MD 21209 USA.
EM mfotuhi@lifebridgehealth.org
OI Fotuhi, Majid/0000-0002-0980-1176
FU NIA NIH HHS [AG 031155]
NR 77
TC 144
Z9 148
U1 6
U2 66
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1745-834X
J9 NAT CLIN PRACT NEURO
JI Nat. Clin. Pract. Neurol.
PD MAR
PY 2009
VL 5
IS 3
BP 140
EP 152
DI 10.1038/ncpneuro1044
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA 414VE
UT WOS:000263892500009
PM 19262590
ER
PT J
AU Asselbergs, FW
Mozaffarian, D
Katz, R
Kestenbaum, B
Fried, LF
Gottdiener, JS
Shlipak, MG
Siscovick, DS
AF Asselbergs, Folkert W.
Mozaffarian, Dariush
Katz, Ronit
Kestenbaum, Bryan
Fried, Linda F.
Gottdiener, John S.
Shlipak, Michael G.
Siscovick, David S.
TI Association of renal function with cardiac calcifications in older
adults: the cardiovascular health study
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE chronic kidney disease; cohort; creatinine; cystatin C; elderly
ID MITRAL ANNULAR CALCIFICATION; GLOMERULAR-FILTRATION-RATE; CHRONIC
KIDNEY-DISEASE; PERITONEAL-DIALYSIS PATIENTS; SERUM CYSTATIN-C; VALVE
CALCIFICATION; HEMODIALYSIS-PATIENTS; ELDERLY PERSONS; ALL-CAUSE;
CREATININE
AB Background. Aortic valve sclerosis (AVS) and mitral annulus calcification (MAC) are highly prevalent in patients with end-stage renal disease. It is less well established whether milder kidney disease is associated with cardiac calcifications. We evaluated the relationships between renal function and MAC, aortic annular calcification (AAC) and AVS in the elderly.
Methods. From the Cardiovascular Health Study, a community-based cohort of ambulatory adults >= age 65, a total of 3929 individuals (mean +/- SD age 74 +/- 5 years, 60% women) were evaluated with two-dimensional echocardiography. Renal function was assessed by means of creatinine-based estimated glomerular filtration rate (eGFR) and cystatin C.
Results. The prevalences of MAC and AAC were significantly higher in individuals with an eGFR < 45 mL/ min/1.73 m(2) (P < 0.01 for each), and cystatin C levels were significantly higher in individuals with MAC or AAC compared to individuals without these cardiac calcifications (P < 0.001 for each). After multivariate-adjustment, an eGFR < 45 mL/min/1.73 m(2) was significantly associated with MAC [odds ratio 1.54 (95% CI 1.16-2.06), P = 0.003] and not associated with AAC [1.30 (0.97-1.74), P = 0.085] and AVS [1.15 (0.86-1.53), P = 0.355]. In addition, cystatin C levels were independently associated with MAC [odds ratio per SD 1.12 (1.05-1.21), P = 0.001] and not associated with AAC [1.07 (1.00-1.15), P = 0.054] and AVS [0.99 (0.93-1.06), P = 0.82]. Furthermore, the prevalence of multiple cardiac calcifications was higher in subjects with an eGFR < 45 mL/ min/1.73 m(2) and increased per quartile of cystatin C (P-values < 0.001). In addition, a significant trend was observed between an eGFR < 45 mL/min/1.73 m(2), increasing levels of cystatin C and the number of cardiac calcifications (P < 0.05).
Conclusions. In a community-based cohort of the elderly, moderate kidney disease as defined by an eGFR < 45 mL/min/1.73m(2) and elevated levels of cystatin C was associated with prevalent MAC. In addition, a significant trend was observed between an eGFR < 45 mL/min/1.73m(2), increasing levels of cystatin C and the number of cardiac calcifications. No associations were found between renal function and AAC or AVS.
C1 [Asselbergs, Folkert W.] Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands.
[Mozaffarian, Dariush] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Mozaffarian, Dariush] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA USA.
[Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Katz, Ronit] Univ Washington, Coordinating Ctr, Seattle, WA 98195 USA.
[Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[Fried, Linda F.] VA Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA USA.
[Gottdiener, John S.] Univ Maryland Hosp, Div Cardiol, Baltimore, MD 21201 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA.
[Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Asselbergs, FW (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM fwasselbergs@hotmail.com
RI Mozaffarian, Dariush/B-2276-2008
FU Netherlands Heart Foundation [2003T010]; Dutch Inter University
Cardiology Institute Netherlands; American Federation for Aging Research
and National Institute on Aging; Robert Wood Johnson Foundation [R01
DK066488]; National Heart, Lung and Blood Institute (NHLBI)
[N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103]; [R01
HL073208-01]; [R01 AG027002]
FX Dr F. W. Asselbergs is a research fellow of the Netherlands Heart
Foundation (2003T010) and the Dutch Inter University Cardiology
Institute Netherlands. Drs Shlipak, Fried and Katz are funded by R01
HL073208-01. Dr Shlipak is also supported by the American Federation for
Aging Research and National Institute on Aging (Paul Beeson Scholars
Program), by the Robert Wood Johnson Foundation (Generalist Faculty
Scholars Program) and by R01 DK066488. Drs Fried, Shlipak and Siscovick
are also supported by R01 AG027002. The Cardiovascular Health Study
(CHS) is supported by contracts N01-HC-85079 through N01-HC-85086,
N01-HC-35129 and N01-HC-15103 from the National Heart, Lung and Blood
Institute ( NHLBI). A full list of participating CHS investigators and
institutions can be found at www.chs-nhlbi.org.
NR 28
TC 15
Z9 19
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAR
PY 2009
VL 24
IS 3
BP 834
EP 840
DI 10.1093/ndt/gfn544
PG 7
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 410UY
UT WOS:000263605000024
PM 18840892
ER
PT J
AU McLaren, DG
Kosmatka, KJ
Oakes, TR
Kroenke, CD
Kohama, SG
Matochik, JA
Ingram, DK
Johnson, SC
AF McLaren, Donald G.
Kosmatka, Kristopher J.
Oakes, Terrance R.
Kroenke, Christopher D.
Kohama, Steven G.
Matochik, John A.
Ingram, Don K.
Johnson, Sterling C.
TI A population-average MRI-based atlas collection of the rhesus macaque
SO NEUROIMAGE
LA English
DT Article
DE Rhesus macaque; MRI; Atlas; Macaca mulatta; Priors; Brain mapping;
Probabilistic
ID AUTOMATED IMAGE REGISTRATION; HUMAN PARIETAL OPERCULUM; PRIMATE
CEREBRAL-CORTEX; SURFACE-BASED ATLASES; NONHUMAN PRIMATE; TEMPLATE
IMAGES; HUMAN BRAIN; PROBABILISTIC ATLAS; MONKEY BRAIN; BABOON
AB Magnetic resonance imaging (MRI) studies of non-human primates are becoming increasingly common; however, the well-developed voxel-based methodologies used in human studies are not readily applied to non-human primates. In the present study, we create a population-average MRI-based atlas collection for the rhesus macaque (Macaca mulatta) that can be used with common brain mapping packages such as SPM or FSL. In addition to creating a publicly available T1-weighted atlas (http://www.brainmap.wisc.edu/monkey. html), probabilistic tissue classification maps and T2-weighted atlases were also created. Theses atlases are aligned to the MRI volume from the Saleem, K. S. and Logothetis, N. K. (2006) atlas providing an explicit link to histological sections. Additionally, we have created a transform to integrate these atlases with the F99 surface-based atlas in CARET. It is anticipated that these tools will help facilitate voxel-based imaging methodologies in non-human primate species, which in turn may increase our understanding of brain function, development, and evolution. Published by Elsevier Inc.
C1 [McLaren, Donald G.; Kosmatka, Kristopher J.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
[McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA.
[McLaren, Donald G.; Kosmatka, Kristopher J.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
[Kroenke, Christopher D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA.
[Kroenke, Christopher D.; Kohama, Steven G.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA.
[Matochik, John A.] Natl Inst Drug Abuse, Intramural Res Program, Neuroimaging Res Branch, Baltimore, MD 21224 USA.
[Ingram, Don K.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Nutr Neurosci & Aging Lab, Baton Rouge, LA 70808 USA.
[Oakes, Terrance R.] Univ Wisconsin, Waisman Ctr Brain Imaging Lab, Madison, WI 53705 USA.
RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace 11G, Madison, WI 53705 USA.
EM scj@medicine.wisc.edu
RI McLaren, Donald/G-9906-2011
OI Johnson, Sterling/0000-0002-8501-545X
FU National Institutes of Health [RR000167, AG11915, AG20013, GM007507,
RR00163, AG029612]; National Institute on Aging
FX This study was supported in part by the National Institutes of Health
RR000167 (UW), AG11915 (UW), AG20013 (UW), GM007507 (UW), RR00163
(ONPRC), AG029612 (OHSU) and the Intramural Research Program of the
National Institute on Aging. This study was also supported with
resources and use of facilities at the William S. Middleton Memorial
Veterans Hospital, Madison, WI, USA. John Matochik is now at the
National Institute on Alcohol Abuse and Alcoholism. The assistance of
Erik K. Kastman, Brent W. Thiel, Michele E. Fitzgerald, Ron Fisher,
Scott T. Baum, Josh Smith, Ricki J. Colman, Ph. D., Andy. A. Alexander,
Ph. D., Barbara B. Bendlin, Ph. D. and the Waisman Center for Brain
Imaging was greatly appreciated. We would especially like to thank Drs.
Kadharbatcha S. Saleem and Nikos K. Logothetis for providing a digital
copy of the D99-SL atlas. GRECC Manuscript Number: 2008-31.
NR 66
TC 103
Z9 105
U1 4
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAR
PY 2009
VL 45
IS 1
BP 52
EP 59
DI 10.1016/j.neuroimage.2008.10.058
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 414KR
UT WOS:000263862900007
PM 19059346
ER
PT J
AU Sani, S
Shimamoto, S
Turner, RS
Levesque, N
Starr, PA
AF Sani, Sepehr
Shimamoto, Shoichi
Turner, Robert S.
Levesque, Nadia
Starr, Philip A.
TI MICROELECTRODE RECORDING IN THE POSTERIOR HYPOTHALAMIC REGION IN HUMANS
SO NEUROSURGERY
LA English
DT Article
DE Cluster headache; Electrophysiology; Hypothalamus; Microelectrode;
Periventricular gray; Single-unit recording microelectrode
ID DEEP-BRAIN-STIMULATION; CHRONIC CLUSTER HEADACHE; TRIGEMINAL AUTONOMIC
CEPHALALGIAS; OCCIPITAL NERVE-STIMULATION; NEURONAL-ACTIVITY;
HYPOCRETIN-RECEPTOR-2 GENE; G1246A POLYMORPHISM; FOLLOW-UP; AREA;
EXPERIENCE
AB INTRODUCTION: Deep brain stimulation of the posterior hypothalamic region (PHR) is an emerging technique for the treatment of medically intractable Cluster headache. Few reports have analyzed single unit neuronal recordings in the human PHR. We report properties of spontaneous neuronal discharge in PHR for 6 patients who underwent DBS for cluster headaches.
METHODS: Initial target coordinates, determined by magnetic resonance imaging stereotactic localization, were 2 mm lateral, 3 mm posterior, and 5 mm inferior to the midpoint of the anterior commissure-posterior commissure plane. A single microelectrode penetration was performed beginning 10 mm above the anatomic target, without systemic sedation. Single units were discriminated off-line by cluster Cutting in principal components space. Discharge rates, interspike intervals, and oscillatory activity were analyzed and compared between ventromedial thalamic and hypothalamic units.
RESULTS: Six patients and 24 units were evaluated, Units in the PHR had a slow, regular spontaneous discharge with wide, low-amplitude action potentials. The mean discharge rate of hypothalamic neurons was significantly lower (mean +/- standard deviation, 13.2 +/- 12,2) than that of medial thalamic units (28.0 +/- 8.2). Oscillatory activity was not detected. Microelectrode recording in this region caused no morbidity.
CONCLUSION: The single-unit discharge rate of neurons in the PHR of awake humans was 13.2 Hz and was significantly lower than medial thalamic neurons recorded dorsal to the tat-get. The findings will he of use for microelectrode localization of the cluster headache target and for comparison with animal studies.
C1 [Sani, Sepehr; Shimamoto, Shoichi; Turner, Robert S.; Levesque, Nadia; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94112 USA.
[Sani, Sepehr; Turner, Robert S.; Starr, Philip A.] San Francisco VA Med Ctr, Ctr Clin, San Francisco, CA USA.
RP Sani, S (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Room M-779, San Francisco, CA 94112 USA.
EM sepehr.sani@ucsf.edu
NR 47
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD MAR
PY 2009
VL 64
IS 3
BP S161
EP S169
DI 10.1227/01.NEU.0000334051.91501.E3
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 411MN
UT WOS:000263653800020
ER
PT J
AU Wu, YN
Johnson, SW
AF Wu, Yan-Na
Johnson, Steven W.
TI Rotenone reduces Mg2+-dependent block of NMDA currents in substantia
nigra dopamine neurons
SO NEUROTOXICOLOGY
LA English
DT Article
DE Dopamine; Magnesium; Voltage-dependent; N-methyl-D-aspartate; Brain
slice; Tyrosine kinase
ID METHYL-D-ASPARTATE; RECEPTOR CHANNELS; PARKINSONS-DISEASE;
CORTICAL-NEURONS; TYROSINE KINASE; MG2+ BLOCK; CELL-DEATH; COMPLEX-I;
RAT; INHIBITION
AB Rotenone is a pesticide that has been successfully used to produce a rodent model of Parkinson's disease. We reported previously that rotenone potently augmented N-methyl-D-aspartate (NMDA)-evoked currents in rat dopamine neurons via a tyrosine kinase-dependent mechanism. In this study, we investigated the effect of rotenone on the current-voltage relationship of NMIDA-induced currents in substantia nigra zona compacta neurons recorded with whole-cell patch pipettes in slices of rat brain. In a physiologic concentration of extracellular Mg2+ (1.2 mM), a 30 min perfusion with rotenone (100 nM) produced a marked increase in current evoked by bath application of NMIDA (30 mu M), especially when measured at relatively hyperpolarized currents. In the presence of rotenone, NMDA currents lost the characteristic region of negative-slope conductance that is normally produced by voltage-dependent block by Mg2+. The voltage-dependent effect of rotenone on NMDA currents was mimicked by a low extracellular concentration of Mg2+ (0.2 mM) and was antagonized by a high level of Mg2+ (6.0 mM). Moreover, we report that the tyrosine kinase inhibitor genistein blocked the ability of rotenone to augment NMDA receptor currents. These results suggest that rotenone potentiates NMDA currents by a tyrosine kinase-dependent process that attenuates voltage-dependent Mg2+ block of NMDA-gated channels. These results support the hypothesis that an excitotoxic mechanism might participate in rotenone-induced toxicity of midbrain dopamine neurons. Published by Elsevier Inc.
C1 [Wu, Yan-Na; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Johnson, Steven W.] Portland VA Med Ctr, Portland, OR 97207 USA.
RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM johnsost@ohsu.edu
FU Veterans Affairs Merit Review Grant; Portland VA Parkinson's Disease
Research, Education, and Clinical Center; American Parkinson Disease
Association
FX This work was supported by a Veterans Affairs Merit Review Grant, the
Portland VA Parkinson's Disease Research, Education, and Clinical
Center, and a grant from the American Parkinson Disease Association.
NR 40
TC 15
Z9 15
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD MAR
PY 2009
VL 30
IS 2
BP 320
EP 325
DI 10.1016/j.neuro.2009.01.002
PG 6
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA 429HY
UT WOS:000264912700020
PM 19428506
ER
PT J
AU Levin, M
Naseri, A
Stewart, JM
AF Levin, Marc
Naseri, Aynan
Stewart, Jay M.
TI Resident-Performed Prophylactic Retinopexy and the Risk of Retinal
Detachment
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; ARGON-LASER PHOTOCOAGULATION; FELLOW
EYES; BREAKS; DEGENERATIONS
AB BACKGROUND AND OBJECTIVE: To examine the natural history of retinopexies performed by ophthalmology residents at universiry-affiliated clinics and to determine the rate of progression to rhegmatogenous retinal detachment.
PATIENTS AND METHODS: Charts of patients receiving prophylactic thermal coagulation between 1997 and 2006 were reviewed retrospectively. Outcome measures included subsequent rhegmatogenous retinal detachment and additional prophylactic treatments.
RESULTS: Review of the medical records identified 166 eyes with peripheral retinal lesions treated by residents, with an average follow-up of 2.4 +/- 0.2 years. At presentation, only 43.4% of patients were symptomatic. Two (1.2%) eyes developed rhegmatogenous retinal detachment during follow-up, with each arising in a previously healthy area of retina in a patient with a history of detachment of the fellow retina. Twenty-five eyes (15%) received at least one additional prophylactic procedure.
CONCLUSION: The rate of rhegmatogenous retinal detachment following prophylactic retinopexy performed by residents at hospital-based clinics is low, supporting this standard practice. [Ophthalmic Surg Lasers Imaging 2009;40:120-126.]
C1 [Levin, Marc; Naseri, Aynan; Stewart, Jay M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
[Naseri, Aynan] San Francisco VA Med Ctr, San Francisco, CA USA.
[Stewart, Jay M.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
RP Stewart, JM (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room K301,Box 0730, San Francisco, CA 94143 USA.
FU Thai Man May See, Inc., San Francisco, California; Research to Prevent
Blindness, Inc., New York, New York
FX Supported by Thai Man May See, Inc., San Francisco, California, and an
unrestricted grant from Research to Prevent Blindness, Inc., New York,
New York.
NR 18
TC 7
Z9 7
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2009
VL 40
IS 2
BP 120
EP 126
PG 7
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 418SU
UT WOS:000264170000006
PM 19320300
ER
PT J
AU Rutar, T
Porco, TC
Naseri, A
AF Rutar, Tina
Porco, Travis C.
Naseri, Ayman
TI Risk Factors for Intraoperative Complications in Resident-Performed
Phacoemulsification Surgery
SO OPHTHALMOLOGY
LA English
DT Article
ID VITREOUS LOSS; CATARACT-EXTRACTION; TOPICAL ANESTHESIA; VISUAL OUTCOMES;
EXPERIENCE
AB Purpose: To determine the risk factors for intraoperative complications in resident-performed phacoemulsification surgery and the effect of complications on postoperative visual acuity.
Design: Retrospective case series.
Participants: A total of 320 consecutive eyes of predominantly male (96.6%) and elderly patients (mean age 1 standard deviation = 73.1 +/- 10.0 years) undergoing phacoemulsification surgery by ophthalmology residents at a Veterans Administration Hospital between January 2006 and 2007. There were no exclusion criteria for type of cataract undergoing phacoemulsification surgery.
Methods: Data were collected by review of patients' electronic medical records. Collected data included the patient demographics, ocular comorbidities, cataract features, resident, resident experience, attending, right or left eye, anesthesia type, wound type, phacoemulsification technique, preoperative and postoperative visual acuities, and presence of any intraoperative complication. Multivariate models were constructed to determine potential risk factors for intraoperative complications.
Main Outcome Measures: Major intraoperative complication rate, risk factors for major intraoperative complications, and best-corrected postoperative visual acuity.
Results: The major intraoperative complication rate was 4.7%, which included 3.1% of cases with vitreous loss. The strongest association with a major complication was the presence of a case identified as challenging preoperatively, which had an odds ratio of 6.0 (95% confidence interval [CI], 1.5-24.1, P = 0.01). The challenging features most strongly associated with major complications were mature 4+ nuclear sclerotic cataracts and zonular pathology (antecedent trauma and pseudoexfoliation), which had odds ratios of 18.9 (95% CI, 3.1-117, P = 0.002) and 26.2 (95% CI, 4.3-159, P = 0.003), respectively. A major complication decreased the likelihood of achieving 20/40 or better visual acuity within 90 days of surgery (95% of uncomplicated eyes vs. 71% of complicated eyes; P = 0.009).
Conclusions: Residents performing phacoemulsification surgery achieved a low overall rate of major complications. However, specific features of cataracts, such as mature nuclei and zonular pathology, carried increased intraoperative risk. Anticipating risk may help to decrease surgical complications further and to counsel patients appropriately.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:431-436 (C) 2009 by the American Academy of Ophthalmology.
C1 [Naseri, Ayman] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA 94121 USA.
[Rutar, Tina; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
[Porco, Travis C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Prevent Med & Publ Hlth, Francis I Proctor Fdn Res Ophthalmol, San Francisco, CA 94143 USA.
[Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol Proctor Fdn, San Francisco, CA 94143 USA.
RP Naseri, A (reprint author), San Francisco Vet Adm Med Ctr, Dept Ophthalmol, 4150 Clement St, San Francisco, CA 94121 USA.
EM ayman.naseri@va.gov
FU Man May See, a nonprofit organization; University of California
Institutional Core Grant For Vision Research [NIH P30]
FX Supported in part by an unrestricted grant from That Man May See, a
nonprofit organization, and by the University of California
Institutional Core Grant For Vision Research (NIH P30).
NR 16
TC 51
Z9 52
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2009
VL 116
IS 3
BP 431
EP 436
DI 10.1016/j.ophtha.2008.10.028
PG 6
WC Ophthalmology
SC Ophthalmology
GA 416KQ
UT WOS:000264005400011
PM 19167084
ER
PT J
AU Grady, D
Cauley, J
Stock, J
Cox, D
Mitlak, B
Song, J
Cummings, S
AF Grady, D.
Cauley, J.
Stock, J.
Cox, D.
Mitlak, B.
Song, J.
Cummings, S.
TI EFFECT OF RALOXIFENE ON ALL-CAUSE MORTALITY ACROSS CLINICAL TRIALS
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
CT 9th European Congress on Clinical an dEconomic Aspects of Osteoporosis
and Osteoarthritis
CY MAR 19-21, 2009
CL Athens, GREECE
C1 [Grady, D.; Cummings, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grady, D.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cauley, J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Stock, J.; Cox, D.; Mitlak, B.; Song, J.] Lilly Res Labs, Indianapolis, IN USA.
[Cummings, S.] Calif Pacific Med Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA.
RI Cauley, Jane/N-4836-2015
OI Cauley, Jane/0000-0003-0752-4408
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI ARTINGTON
PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP,
GUILDFORD, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2009
VL 20
SU 1
BP 13
EP 13
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 536AE
UT WOS:000273012800027
ER
PT J
AU Bradfield, J
Warner, A
Bersohn, MM
AF Bradfield, Jason
Warner, Alberta
Bersohn, Malcolm M.
TI Low Referral Rate for Prophylactic Implantation of
Cardioverter-Defibrillators in a Tertiary Care Medical Center
SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
LA English
DT Article
DE implantable cardioverter-defibrillator; sudden death; sudden death
prevention; left ventricular dysfunction
ID SUDDEN CARDIAC DEATH; PREVENTION
AB Background: Implantable cardioverter-defibrillators (ICDs) for primary prevention became standard of care after the publication of the second Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Objective: To determine the percentage of patients in a Veterans Affairs medical center appropriately referred for primary prophylaxis ICD and to further categorize the reasons patients are not being referred.
Methods: Echocardiograms obtained since the release of MADIT-II in 2002 were searched for a left ventricular ejection fraction (LVEF) <= 35% and <= 30%. We randomly selected 120 patients per year from 2002 to 2006, for a total of 600 patients in each group. Data were reviewed to determine the number of ICD recipients and the reasons patients were not referred.
Results: In the LVEF <= 35% group an ICD was implanted in 28% of 392 eligible patients. Nonreferral (58%) was the most common reason that eligible patients did not receive an ICD. Patients were not referred for ICD because of appropriate contraindications in 26% of cases. Overall mortality was 29% (15% with and 31% without ICD). In the LVEF <= 30% group an ICD was implanted in 33% of 388 eligible patients. Nonreferral (51%) was the most common reason that eligible patients did not receive an ICD. Patients were not referred for ICD because of appropriate contraindications in 24% of cases. Overall mortality was 28% (18% with and 32% without ICD).
Conclusions: After the publication of MADIT-II and SCD-HeFT, only 42% of eligible patients with LVEF <= 35% and 49% of patients with LVEF <= 30% were offered a potentially life-saving ICD between 2002 and 2006 in our medical center, sometimes with considerable delay. (PACE 2009; 32:S194-S197)
C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Bersohn, MM (reprint author), Cardiol 111E,11201 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mbersohn@ucla.edu
NR 8
TC 18
Z9 18
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0147-8389
J9 PACE
JI PACE-Pacing Clin. Electrophysiol.
PD MAR
PY 2009
VL 32
BP S194
EP S197
PG 4
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA 452TA
UT WOS:000266562900045
PM 19250092
ER
PT J
AU Hanlon, JT
Weiner, DK
AF Hanlon, Joseph T.
Weiner, Debra K.
TI Methadone for Chronic Pain in Older Adults: Blast from the Past But Are
We Ready for It to Return to Prime Time?
SO PAIN MEDICINE
LA English
DT Editorial Material
ID ANALGESICS
C1 [Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Dept Med Geriatr Med, Dept Pharm & Therapeut, Sch Pharm,CHERP, Pittsburgh, PA USA.
[Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Dept Med Geriatr Med, Dept Pharm & Therapeut, Sch Pharm,Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Med Geriatr Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Med Geriatr Med, Dept Psychiat, Pittsburgh, PA 15260 USA.
[Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Hanlon, JT (reprint author), VA Pittsburgh Healthcare Syst, Dept Med Geriatr Med, Dept Pharm & Therapeut, Sch Pharm,CHERP, Pittsburgh, PA USA.
FU NIA NIH HHS [R01 AG027017]
NR 8
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1526-2375
J9 PAIN MED
JI Pain Med.
PD MAR
PY 2009
VL 10
IS 2
BP 287
EP 288
DI 10.1111/j.1526-4637.2009.00560.x
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 415CC
UT WOS:000263910900002
PM 19284485
ER
PT J
AU Boros, LG
Deng, Q
Pandol, SJ
Tsukamoto, H
Go, VLW
Lee, WNP
AF Boros, Laszlo G.
Deng, Qinggao
Pandol, Stephen J.
Tsukamoto, Hidekazu
Go, Vay Liang W.
Lee, Wai-Nang Paul
TI Ethanol Diversely Alters Palmitate, Stearate, and Oleate Metabolism in
the Liver and Pancreas of Rats Using the Deuterium Oxide Single Tracer
SO PANCREAS
LA English
DT Article
DE palmitic acid; stearic acid; oleic acid; fatty acid ratios; deuterium
ID INTRAGASTRIC INFUSION; METABOLOMICS; ALCOHOL; LIPOGENESIS; FIBROSIS; FAT
AB Objective: To determine tissue-specific effects of alcohol on fatty acid synthesis and distribution as related to functional changes in triglyceride transport and membrane formation. Methods: Tissue fatty acid profile and de novo lipogenesis were determined in adult male Wistar rats after 5 weeks of ethanol feeding using deuterated water and gas chromatography/mass spectrometry. Liver and pancreas fatty acid profiles and new synthesis fractions were compared with those from control rats on an isocaloric diet.
Results: Fatty acid ratios in the liver indicated that there was a more than 2-fold accumulation of stearate to that of palmitate, with an apparent decrease in oleate content. On the other hand, in the pancreas, there was a 17% decrease in the stearate-to-palmitate ratio, whereas the oleate-to-palmitate ratio was increased by 30%. The fractions of deuterium-labeled palmitate and stearate were substantially reduced in the liver and pancreas of the alcohol-treated animals. Deuterium labeling of oleate was reduced in the liver but not in the pancreas, consistent with the oleate/stearate ratios in these tissues.
Conclusions: Long-term alcohol exposure results in opposite effects on the desaturase activity in the liver and pancreas, limiting fatty acid transport in the liver but promoting the exocrine function of the pancreas.
C1 [Boros, Laszlo G.; Lee, Wai-Nang Paul] Harbor UCLA Med Ctr, Dept Pediat Endocrinol & Metab, Torrance, CA 90502 USA.
[Deng, Qinggao; Pandol, Stephen J.; Tsukamoto, Hidekazu] Univ So Calif, So Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90089 USA.
[Pandol, Stephen J.; Tsukamoto, Hidekazu] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA.
[Go, Vay Liang W.; Lee, Wai-Nang Paul] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Los Angeles, CA 90095 USA.
RP Boros, LG (reprint author), Harbor UCLA Med Ctr, Dept Pediat Endocrinol & Metab, 1124 W Carson St,RB1, Torrance, CA 90502 USA.
EM boros@labiomed.org
FU NCCIH NIH HHS [P01 AT003960, P01 AT003960-01A1]; NCI NIH HHS [P30
CA042710, P01-CA42710, P01 CA042710]; NCRR NIH HHS [M01-RR00425, M01
RR000425]; NIAAA NIH HHS [P50AA11999, P50 AA011999]
NR 30
TC 5
Z9 5
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2009
VL 38
IS 2
BP E47
EP E52
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 415AC
UT WOS:000263905700031
PM 19248221
ER
PT J
AU Mamikonyan, E
Moberg, PJ
Siderowf, A
Duda, JE
Ten Have, T
Hurtig, HI
Stern, MB
Weintraub, D
AF Mamikonyan, Eugenia
Moberg, Paul J.
Siderowf, Andrew
Duda, John E.
Ten Have, Tom
Hurtig, Howard I.
Stern, Matthew B.
Weintraub, Daniel
TI Mild cognitive impairment is common in Parkinson's disease patients with
normal Mini-Mental State Examination (MMSE) scores
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Mild cognitive impairment; Parkinson's disease; Mini-Mental State
Examination; Neuropsychology
ID DAYTIME SLEEPINESS; DEMENTIA; DYSFUNCTION; POPULATION; PROFILE; COHORT;
SCALE; AGE
AB Purpose: Cognitive impairment occurs in the majority of Parkinson's disease (PD) patients, but little is known about detection of mild cognitive impairment (MCI) in this population. We report on the frequency and characteristics of cognitive deficits in PD, patients with intact global cognition based on Mini-Mental State Examination (MMSE) performance.
Methods: One hundred and six PD patients with normal age- and education-adjusted MMSE scores (mean [SD] score = 29.1 [1.1]) were administered standardized neuropsychological tests assessing memory, executive function, and attention. Impairment on a cognitive domain was a low score (i.e., >= 1.5 SD below the published normative mean) on at least two measures or tests (for memory and executive abilities) or a single measure (for attention).
Results: Mild cognitive impairment was found in 29.2% of PD patients, with 17.9% demonstrating single domain and 11.3% multiple domain impairment. Memory and attention impairment were most common (15.1% and 17.0% , respectively), followed by executive impairment (8.5%). Depending on the measure of disease severity chosen, increasing age and disease severity, anti-anxiety medication use, and a suggestion for increasing severity of daytime sleepiness were independent predictors of cognitive impairment.
Conclusions: Cognitive deficits are common in PD patients with "normal" cognition based on MMSE performance, suggesting that MCI is under-recognized in clinical practice due to routine use of insensitive screening instruments. In contrast with some previous reports, early memory impairment may be as common as either executive or attentional deficits in PD. In addition, psychiatric medication use and daytime sleepiness may be reversible or treatable contributors to cognitive impairment. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Mamikonyan, Eugenia; Moberg, Paul J.; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Siderowf, Andrew; Duda, John E.; Hurtig, Howard I.; Stern, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Duda, John E.; Stern, Matthew B.; Weintraub, Daniel] Philadelphia Vet Affairs Med Center, PADRECC, Philadelphia, PA USA.
[Ten Have, Tom] Univ Penn, Ctr Clin & Epidemiol Biostat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Center, MIRECC, Philadelphia, PA USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA.
EM weintrau@mail.med.upenn.edu
FU NIMH [067894]
FX Funded in part by NIMH grant #067894.
NR 43
TC 88
Z9 94
U1 2
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD MAR
PY 2009
VL 15
IS 3
BP 226
EP 231
DI 10.1016/j.parkreldis.2008.05.006
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 424RJ
UT WOS:000264584700009
PM 18595765
ER
PT J
AU Aragaki, DR
Nasmyth, MC
Schultz, SC
Nguyen, GM
Yentes, JM
Kao, K
Perell, K
Fang, MA
AF Aragaki, Dixie R.
Nasmyth, Mary C.
Schultz, Scott C.
Nguyen, Gretchen M.
Yentes, Jennifer M.
Kao, Kaly
Perell, Karen
Fang, Meika A.
TI Immediate Effects of Contralateral and Ipsilateral Cane Use On Normal
Adult Gait
SO PM&R
LA English
DT Article
AB Objective: To determine the effects of ipsilateral and contralateral cane use on gait kinematics and peak vertical force in young healthy adults.
Design: Prospective observational study.
Setting: Veterans Affairs Healthcare Center.
Participants: Fifteen healthy adults of aged 26 to 52 years (mean age 31 years) with no gait impairment and minimal experience using single-point canes.
Methods: The Pedar-X Mobile System plantar pressure measurement system was used to collect kinematic data from subjects walking in 3 different conditions (relative to a randomly "assigned" limb): contralateral cane (C), ipsilateral cane (I), and no cane (N).
Main Outcome Measures: Peak vertical force, cadence, percentage swing phase and double limb support, and regional plantar pressure ratios.
Results: Peak vertical force (normalized for body weight) was reduced during both cane use conditions on the randomly assigned limb when compared to walking unaided (P<.001). The peak vertical force was 7% to 11% lower for the assigned limb than the opposite limb when a cane was used on either side (P<.016). Mean cadence was higher when participants ambulated without a cane (113 steps/min) than with a cane used on either the contralateral (98 steps/min) or ipsilateral (98 steps/min) side (P<.0001). Mean cadence did not significantly differ between the cane use conditions (P=.93). Regional plantar pressure ratios did not significantly change on either limb in any of the tested conditions. Double limb support slightly increased with cane use (P<.016).
Conclusion: Both ipsilateral and contralateral cane use reduced cadence and mean peak vertical plantar force on the limb advanced with the cane in healthy young adults. Double limb support increased with cane use likely due to the reduced cadence and initial unfamiliarity with using an assistive device. A clinical implication of these findings is that prescription of canes for either ipsilateral or contralateral use effectively offloads a designated lower limb.
C1 [Aragaki, Dixie R.; Nasmyth, Mary C.; Schultz, Scott C.; Nguyen, Gretchen M.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90073 USA.
[Aragaki, Dixie R.; Nasmyth, Mary C.; Schultz, Scott C.; Nguyen, Gretchen M.; Kao, Kaly; Fang, Meika A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Rheumatol Sect, Los Angeles, CA 90073 USA.
[Perell, Karen] Calif State Univ Fullerton, Fullerton, CA 92634 USA.
[Yentes, Jennifer M.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
RP Aragaki, DR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, 11301 Wilshire Blvd,Mailcode 117, Los Angeles, CA 90073 USA.
EM Dixie.Aragaki@va.gov
OI Yentes, Jennifer/0000-0001-6550-7759
FU Office of Research and Development, Rehabilitation Research and
Development Service, Department of Veterans Affairs [F3873R]
FX This work was supported by the Office of Research and Development,
Rehabilitation Research and Development Service, Department of Veterans
Affairs (Grant F3873R).
NR 27
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAR
PY 2009
VL 1
IS 3
BP 208
EP 213
DI 10.1016/j.pmrj.2008.10.002
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA V24LF
UT WOS:000208411200002
PM 19627896
ER
PT J
AU Koepsell, TD
Forsberg, CW
Littman, AJ
AF Koepsell, Thomas D.
Forsberg, Christopher W.
Littman, Alyson J.
TI Obesity, overweight, and weight control practices in US veterans
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Obesity; Overweight; Veterans health; Weight control
ID RISK-FACTORS; PREVALENCE; HEALTH; CONSEQUENCES; FACILITIES; BURDEN;
ADULTS
AB Objectives. We assessed the burden of obesity and overweight, as well as trends in weight control practices, among U.S. veterans and users of Department of Veterans Affairs (VA) health care in a large national survey.
Methods. Data were combined from the 2003 and 2004 Behavioral Risk Factor Surveillance System surveys of U.S. adults (n = 558,426), a large telephone survey conducted in all states.
Results. Some 24% of veterans were obese (Body Mass Index [BMI] >= 30 kg/m(2)), and 48% were overweight (BMI 25-29.9 kg/m(2)). After adjustment for age and gender, obesity prevalence was similar between veterans and non-veterans, but overweight was about 3.8 percentage points more frequent in veterans. Among veterans, obesity was more common among users of VA care, especially those who received all health care through the VA. Obese and overweight VA users were significantly more likely than non-users to report advice from a health care provider to lose weight, but no more likely to report that they were actually trying to lose weight.
Conclusions. Obesity and overweight pose special burdens on veterans who use VA care. These results strengthen the case for system-wide interventions aimed at weight control. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Koepsell, Thomas D.; Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Koepsell, Thomas D.; Forsberg, Christopher W.; Littman, Alyson J.] Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
RP Koepsell, TD (reprint author), Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst 152E, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM koepsell@u.washington.edu
FU Office of Research and Development; Cooperative Studies Program;
Department of Veterans Affairs
FX This material is based upon work supported by the Office of Research and
Development, Cooperative Studies Program, Department of Veterans
Affairs.
NR 27
TC 29
Z9 29
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
J9 PREV MED
JI Prev. Med.
PD MAR
PY 2009
VL 48
IS 3
BP 267
EP 271
DI 10.1016/j.ypmed.2009.01.008
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 426WL
UT WOS:000264738900013
PM 19297689
ER
PT J
AU Glynn, SM
Randolph, ET
Garrick, T
Lui, A
AF Glynn, Shirley M.
Randolph, Eugenia T.
Garrick, Thomas
Lui, Anna
TI A Proof of Concept Trial of an Online Psychoeducational Program for
Relatives of Both Veterans and Civilians Living with Schizophrenia
SO PSYCHIATRIC REHABILITATION JOURNAL
LA English
DT Article
DE clinical trials; family services; schizophrenia; mental health education
programs
ID COGNITIVE-BEHAVIOR THERAPY; MULTIPLE-FAMILY GROUPS; RANDOMIZED
CONTROLLED-TRIAL; ATTITUDE SCALE; INTERNET; INTERVENTION; METAANALYSIS;
DISORDERS; SUPPORT; TELEHEALTH
AB Objectives: Family psychoeducation has been found to reduce relapse in schizophrenia but penetration rates are low. In this study, we evaluate the feasibility of an online multifamily group program for relatives of persons with schizophrenia that can be accessed from participants' homes. Methods: We explored participation rates and evaluations of a 12-month multimodal website intervention. Using a quasi-experimental design, we compared illness outcomes (factors on the Brief Psychiatric Rating Scale, hospitalizations) of persons with diagnosed schizophrenia, and relative distress outcomes (somatic concerns and anxiety/depression subscales on the Brief Symptom Inventory) from relatives participating in the intervention (n = 26) to archival data we had from comparable dyads who received customary care (n =16). Results: The majority of participants in the program attended more than half the core online support sessions, expressed high levels of satisfaction, and found the technology easy to access. There appeared to be little impact of online participation on clinical status of persons with schizophrenia or relatives' distress, although there was a trend for fewer hospitalizations in the online group. Small sample size is a factor in interpreting results. Conclusions: Online interventions for relatives of persons with schizophrenia, while feasible, present unique challenges. These include 1) assuring access to the intervention in populations who do not own a computer; 2) addressing privacy concerns; 3) overcoming the special challenges of conducting groups in real time; 4) managing emergent situations adequately; and 5) questions about efficacy.
C1 [Glynn, Shirley M.; Randolph, Eugenia T.; Garrick, Thomas] Univ Calif Los Angeles, Semel Inst Neurosci & Biobehav, VA Greater Los Angeles Healthcare Syst W Los Ange, Los Angeles, CA 90024 USA.
RP Glynn, SM (reprint author), VA GLA W Los Angeles, B151J,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sglynn@ucla.edu
FU NIMH NIH HHS [R21 MH62135]
NR 34
TC 19
Z9 19
U1 1
U2 15
PU CENTER PSYCHIATRIC REHABILITATION
PI BOSTON
PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA
SN 1095-158X
J9 PSYCHIATR REHABIL J
JI Psychiatr. Rehabil. J.
PD SPR
PY 2009
VL 33
IS 4
SI SI
BP 278
EP 287
DI 10.2975/33.4.2010.278.287
PG 10
WC Psychiatry; Rehabilitation
SC Psychiatry; Rehabilitation
GA 586RM
UT WOS:000276929700006
PM 20374986
ER
PT J
AU Salzer, MS
Katz, J
Kidwell, B
Federici, M
Ward-Colasante, C
AF Salzer, Mark S.
Katz, Jason
Kidwell, Betsy
Federici, Matthew
Ward-Colasante, Carol
TI Pennsylvania Certified Peer Specialist Initiative: Training, Employment
and Work Satisfaction Outcomes
SO PSYCHIATRIC REHABILITATION JOURNAL
LA English
DT Article
DE peer specialists; knowledge gain; employment outcomes; job satisfaction
AB Objective: Certified Peer Specialist training initiatives leading to paid peer support positions are increasing nationally. This longitudinal study examines a comprehensive set of outcomes associated with such an initiative undertaken in Pennsylvania beginning in 2004. Methods: Certified Peer Specialist Training participants in three regions of Pennsylvania responded to a 60-item, multiple choice knowledge test based on the Certified Peer Specialist training curriculum. Additionally, these individuals were asked to provide permission to be contacted up to one year after completing the program to obtain employment information related to their experience as a certified peer specialist. Results: Ninety-seven percent of the trainees successfully completed the program with a 22% increase in knowledge. Eighty-two percent were working one year later. Peer specialists were very satisfied with their employment; felt accepted by co-workers and reported receiving good, but infrequent supervision. Conclusions: The results suggest that these initiatives can be successfully implemented, although greater attention is needed to ensure that new jobs are being created for trainees and that they are being property supervised like all other employees.
C1 [Salzer, Mark S.] Univ Penn, Dept Psychiat, CMHPSR, Philadelphia, PA 19104 USA.
[Salzer, Mark S.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
[Katz, Jason] Univ S Carolina, Columbia, SC 29208 USA.
[Kidwell, Betsy; Federici, Matthew] Mental Hlth Assoc SE PA, Inst Recovery & Community Integrat, Philadelphia, PA USA.
[Ward-Colasante, Carol] PA Dept Publ Welf, Ofc Mental Hlth & Subst Abuse Serv, Harrisburg, PA USA.
[Salzer, Mark S.] UPENN Collaborat Community Integrat, Philadelphia, PA USA.
[Ward-Colasante, Carol] Penn Off Mental Hlth & Subst Abuse Serv, Philadelphia, PA USA.
RP Salzer, MS (reprint author), Univ Penn, Dept Psychiat, CMHPSR, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA.
EM Mark.Salzer@uphs.upenn.edu
NR 4
TC 10
Z9 11
U1 1
U2 2
PU CENTER PSYCHIATRIC REHABILITATION
PI BOSTON
PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA
SN 1095-158X
J9 PSYCHIATR REHABIL J
JI Psychiatr. Rehabil. J.
PD SPR
PY 2009
VL 32
IS 4
BP 301
EP 305
DI 10.2975/32.4.2009.301.305
PG 5
WC Psychiatry; Rehabilitation
SC Psychiatry; Rehabilitation
GA 435LU
UT WOS:000265346200009
PM 19346209
ER
PT J
AU Kamat, A
Cox, LA
McDonald, TJ
Nathanielsz, PW
Li, C
AF Kamat, Amrita
Cox, Laura A.
McDonald, Thomas J.
Nathanielsz, Peter W.
Li, Cun
TI Maternal 30% Global Nutrient Restriction (MNR) Increases Fetal Baboon
Liver beta 2-Adrenergic Receptor (beta 2-AR) Immunoreactivity (IR) at
0.5 Gestation (G) but Normalization Occurs by 0.9 (G) Despite Continuing
MNR.
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the Society-for-Gynecologic-Investigation
CY MAR 17-21, 2009
CL Glasgow, SCOTLAND
SP Soc Gynecol Invest
C1 [Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Kamat, Amrita] Audie Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Cox, Laura A.] SW Fdn Biomed Res, SW Natl Reg Primate Ctr, Dept Genet, San Antonio, TX 78284 USA.
[McDonald, Thomas J.; Nathanielsz, Peter W.; Li, Cun] Univ Texas Hlth Sci Ctr San Antonio, Dept OB GYN, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2009
VL 16
IS 3
MA 239
BP 138A
EP 138A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 410WU
UT WOS:000263609800240
ER
PT J
AU Marder, SR
Cohen, AN
Hamilton, A
Saks, E
Glynn, S
Hollan, D
Brekke, J
AF Marder, Stephen R.
Cohen, A. N.
Hamilton, A.
Saks, E.
Glynn, S.
Hollan, D.
Brekke, J.
TI CHARACTERISTICS OF HIGH FUNCTIONING INDIVIDUALS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Marder, Stephen R.; Cohen, A. N.; Hamilton, A.; Glynn, S.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Marder, Stephen R.; Cohen, A. N.; Glynn, S.] Mental Illness Res Educ & Clin Ctr, VA Greater Los Angeles, Los Angeles, CA USA.
[Hamilton, A.; Hollan, D.] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA.
[Brekke, J.] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 11
EP 11
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700036
ER
PT J
AU Copeland, LA
Zeber, JE
Parchman, ML
Lawrence, VA
Hosek, BJ
Miller, AL
AF Copeland, Laurel A.
Zeber, J. E.
Parchman, M. L.
Lawrence, V. A.
Hosek, B. J.
Miller, A. L.
TI PRE-DIABETES AND DIABETES ASSESSMENT IN VETERANS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Copeland, Laurel A.; Zeber, J. E.; Parchman, M. L.; Lawrence, V. A.; Hosek, B. J.] S Texas Vet Hlth Care Syst, VERDICT HSRD, San Antonio, TX USA.
[Copeland, Laurel A.; Zeber, J. E.; Miller, A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Lawrence, V. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Parchman, M. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 36
EP 36
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700109
ER
PT J
AU Wirshing, DA
Rosen, J
Pierre, JM
Erickson, ZD
Guzik, LH
Mena, SJ
AF Wirshing, Donna A.
Rosen, J.
Pierre, J. M.
Erickson, Z. D.
Guzik, L. H.
Mena, S. J.
TI SUBJECTIVE EXPERIENCE MEASUREMENT IN PATIENTS WITH
SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER USING THE NOVEL ANTIPSYCHOTIC
MEDICATION EXPERIENCE SCALE (NAMES)
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Wirshing, Donna A.; Rosen, J.; Pierre, J. M.; Erickson, Z. D.; Guzik, L. H.; Mena, S. J.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 36
EP 36
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700108
ER
PT J
AU Horan, WP
Wynn, JK
Kring, AM
Simons, RF
Crosby, SM
Nori, P
Mancini, L
Tripp, C
Green, MF
AF Horan, William Powers
Wynn, J. K.
Kring, A. M.
Simons, R. F.
Crosby, S. M.
Nori, P.
Mancini, L.
Tripp, C.
Green, M. F.
TI ELECTROPHYSIOLOGICAL CORRELATES OF EMOTIONAL EXPERIENCE IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Horan, William Powers; Wynn, J. K.; Crosby, S. M.; Nori, P.; Mancini, L.; Tripp, C.; Green, M. F.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Kring, A. M.] UC Berkeley, Berkeley, CA USA.
[Simons, R. F.] Univ Delaware, Newark, DE USA.
[Horan, William Powers; Wynn, J. K.; Crosby, S. M.; Nori, P.; Mancini, L.; Tripp, C.; Green, M. F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 45
EP 45
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700135
ER
PT J
AU Wynn, JK
Horan, WP
Simons, R
Kring, A
Nori, P
Mancini, L
Crosby, S
Tripp, C
Green, MF
AF Wynn, Jonathan K.
Horan, W. P.
Simons, R.
Kring, A.
Nori, P.
Mancini, L.
Crosby, S.
Tripp, C.
Green, M. F.
TI ELECTROPHYSIOLOGICAL CORRELATES OF EMOTION ANTICIPATION IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Wynn, Jonathan K.; Horan, W. P.] VA Greater Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA.
[Wynn, Jonathan K.; Horan, W. P.; Nori, P.; Mancini, L.; Crosby, S.; Tripp, C.; Green, M. F.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Kring, A.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Simons, R.] Univ Delaware, Newark, DE USA.
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 45
EP 45
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700136
ER
PT J
AU Mathalon, DH
Roach, BJ
Ford, JM
AF Mathalon, Daniel H.
Roach, B. J.
Ford, J. M.
TI ELECTROPHYSIOLOGICAL EVIDENCE OF ABNORMAL AUTOMATIC ACTIVATION OF
SEMANTIC NETWORKS IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Mathalon, Daniel H.; Ford, J. M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mathalon, Daniel H.; Roach, B. J.; Ford, J. M.] San Francisco VA Med Ctr, Psychiat Serv 116d, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 50
EP 51
PG 2
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700152
ER
PT J
AU Condray, R
Steinhauer, SR
Siegle, GJ
Keshavan, MS
Montrose, DM
Chakraborty, B
AF Condray, Ruth
Steinhauer, S. R.
Siegle, G. J.
Keshavan, M. S.
Montrose, D. M.
Chakraborty, B.
TI EFFECTS OF WORD FREQUENCY ON SEMANTIC MEMORY IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Condray, Ruth; Steinhauer, S. R.; Siegle, G. J.; Keshavan, M. S.; Montrose, D. M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Condray, Ruth; Steinhauer, S. R.; Siegle, G. J.; Chakraborty, B.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
[Keshavan, M. S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 57
EP 57
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700173
ER
PT J
AU Greenwood, TA
Light, GA
Swerdlow, NR
Geyer, MA
Radant, AD
Braff, DL
AF Greenwood, Tiffany A.
Light, G. A.
Swerdlow, N. R.
Geyer, M. A.
Radant, A. D.
Braff, D. L.
TI LARGE-SCALE CANDIDATE GENE ANALYSIS OF ENDOPHENOTYPES FOR SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Greenwood, Tiffany A.; Light, G. A.; Swerdlow, N. R.; Geyer, M. A.; Braff, D. L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Greenwood, Tiffany A.; Geyer, M. A.] San Diego VA Healthcare Syst, San Diego, CA USA.
[Radant, A. D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Radant, A. D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 122
EP 122
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700356
ER
PT J
AU Miller, AL
Velligan, DI
Maples, N
Li, X
Copeland, L
Dassori, A
Moore, T
Mintz, J
Zeber, J
Boone, C
Evans, L
Rodriguez, J
AF Miller, Alexander L.
Velligan, D. I.
Maples, N.
Li, X.
Copeland, L.
Dassori, A.
Moore, T.
Mintz, J.
Zeber, J.
Boone, C.
Evans, L.
Rodriguez, J.
TI CONTINUITY OF CARE AFTER PSYCHIATRIC HOSPITALIZATION
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Miller, Alexander L.; Velligan, D. I.; Maples, N.; Li, X.; Copeland, L.; Dassori, A.; Moore, T.; Mintz, J.; Zeber, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Copeland, L.; Dassori, A.; Zeber, J.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res, San Antonio, TX USA.
[Boone, C.; Evans, L.] Ctr Hlth Care Serv, San Antonio, TX USA.
RI Mintz, Jim/N-7385-2014
OI Mintz, Jim/0000-0002-8299-5851
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 131
EP 132
PG 2
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700381
ER
PT J
AU Yao, J
Condray, R
Reddy, RD
Keshavan, MS
Montrose, DM
Matson, WR
McEvoy, J
Kaddurah-Daouk, R
AF Yao, Jeffrey
Condray, R.
Reddy, R. D.
Keshavan, M. S.
Montrose, D. M.
Matson, W. R.
McEvoy, J.
Kaddurah-Daouk, R.
TI 3-HYDROXYKYNURENINE AND COGNITIVE IMPAIRMENT IN FIRST-EPISODE
NEUROLEPTIC-NAIVE PATIENTS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Yao, Jeffrey; Condray, R.; Reddy, R. D.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
[Yao, Jeffrey; Condray, R.; Reddy, R. D.; Keshavan, M. S.; Montrose, D. M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Keshavan, M. S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA.
[Matson, W. R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA.
[McEvoy, J.; Kaddurah-Daouk, R.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 151
EP 151
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700437
ER
PT J
AU Schooler, NR
Green, MF
Kern, RS
Deng, BH
AF Schooler, Nina. R.
Green, M. F.
Kern, R. S.
Deng, B. H.
TI FUNCTIONAL CAPACITY AND INTERVIEW-BASED MEASURES: RAND PANEL JUDGMENTS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Schooler, Nina. R.] Suny Downstate Med Ctr, Dept Psychiat & Behav Sci, Brooklyn, NY 11203 USA.
[Schooler, Nina. R.] Washington DC VA Med Ctr, VISN MIRECC 5, Washington, DC USA.
[Green, M. F.; Kern, R. S.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Green, M. F.; Kern, R. S.] VA Greater Los Angeles Healthcare Syst, VISN MIRECC 22, Los Angeles, CA USA.
[Deng, B. H.] Claremont Grad Univ, Dept Psychol, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 305
EP 306
PG 2
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700888
ER
PT J
AU Muller, AM
Wirshing, DA
Guzik, LH
Erickson, ZD
Mena, SJ
AF Muller, Anna Mia
Wirshing, D. A.
Guzik, L. H.
Erickson, Z. D.
Mena, S. J.
TI IMPACT OF A SHORT-TERM SKILLS-BASED INTERVENTION PROGRAM ON LEVEL OF
INSIGHT AND ENGAGEMENT IN FOLLOW-UP PSYCHIATRIC CARE
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Muller, Anna Mia; Wirshing, D. A.; Guzik, L. H.; Erickson, Z. D.; Mena, S. J.] W Los Angeles VA Med Ctr, Schizophrenia Res Clin, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 310
EP 310
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700901
ER
PT J
AU Rassovsky, Y
Lee, J
Sergi, M
Nori, P
Crosby, S
Green, MF
AF Rassovsky, Yuri
Lee, J.
Sergi, M.
Nori, P.
Crosby, S.
Green, M. F.
TI MEDIATORS AND MODERATORS BETWEEN NEUROCOGNITION AND FUNCTIONAL STATUS IN
SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Rassovsky, Yuri; Lee, J.; Sergi, M.; Nori, P.; Crosby, S.; Green, M. F.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Lee, J.; Nori, P.; Crosby, S.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Sergi, M.] Calif State Univ Northridge, Northridge, CA 91330 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 312
EP 313
PG 2
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700908
ER
PT J
AU Caponigro, J
Valenti, LM
Molz, AR
Luther, J
Paldino, DM
Haas, GL
AF Caponigro, Janelle
Valenti, L. M.
Molz, A. R.
Luther, J.
Paldino, D. M.
Haas, G. L.
TI RELIABILITY AND VALIDITY OF A BEHAVIORAL MEASURE OF SOCIAL COGNITION IN
AN INTERPERSONAL SETTING
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Caponigro, Janelle; Haas, G. L.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA.
[Valenti, L. M.; Molz, A. R.; Luther, J.; Paldino, D. M.; Haas, G. L.] Mental Illness Res Educ & Clin Ctr, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Caponigro, Janelle] Univ Calif Berkeley, Berkeley, CA 94720 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 317
EP 318
PG 2
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700923
ER
PT J
AU Haas, GL
Valenti, L
Caponigro, J
Molz, A
Goldstein, G
Luther, J
AF Haas, Gretchen L.
Valenti, L.
Caponigro, J.
Molz, A.
Goldstein, G.
Luther, J.
TI DISSECTING SOCIAL INFORMATION PROCESSING DEFICITS IN SCHIZOPHRENIA:
CONTRIBUTION OF AFFECTIVE AND NON-AFFECTIVE COGNITIVE COMPONENTS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Haas, Gretchen L.; Luther, J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Haas, Gretchen L.; Valenti, L.; Caponigro, J.; Molz, A.; Goldstein, G.; Luther, J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 331
EP 332
PG 2
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964700965
ER
PT J
AU Wood, AE
Kennedy, A
Martin, LM
Kilzieh, N
Sellars, VS
Tapp, A
AF Wood, Amanda Ernst
Kennedy, A.
Martin, L. M.
Kilzieh, N.
Sellars, V. S.
Tapp, A.
TI PILOT PROGRAM FOR MEDICATION OPTIMIZATION: SOMETIMES LESS IS MORE
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Wood, Amanda Ernst; Kennedy, A.; Martin, L. M.; Kilzieh, N.; Sellars, V. S.; Tapp, A.] VA Puget Hlth Care Syst, Tacoma, WA USA.
[Wood, Amanda Ernst; Martin, L. M.; Kilzieh, N.; Tapp, A.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 349
EP 349
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964701013
ER
PT J
AU Green, MF
Horan, WP
Shokat-Fadai, K
Sergi, MJ
Waldon, C
Ofek, A
Kern, RS
AF Green, Michael F.
Horan, W. P.
Shokat-Fadai, K.
Sergi, M. J.
Waldon, C.
Ofek, A.
Kern, R. S.
TI INITIAL EFFICACY DATA ON A SOCIAL COGNITIVE SKILLS TRAINING PROGRAM
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Green, Michael F.; Horan, W. P.; Sergi, M. J.; Waldon, C.; Ofek, A.; Kern, R. S.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Green, Michael F.; Horan, W. P.; Waldon, C.; Ofek, A.; Kern, R. S.] VA Greater Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA.
[Shokat-Fadai, K.; Sergi, M. J.] Cal State Univ Northridge, Northridge, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 350
EP 350
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964701017
ER
PT J
AU Nuechterlein, KH
Green, MF
Kern, RS
AF Nuechterlein, Keith H.
Green, M. F.
Kern, R. S.
TI TRANSLATION AND CULTURAL ADAPTATION OF THE MATRICS CONSENSUS COGNITIVE
BATTERY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Nuechterlein, Keith H.; Green, M. F.; Kern, R. S.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Green, M. F.; Kern, R. S.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 372
EP 372
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964701079
ER
PT J
AU Kasckow, J
Gurklis, J
Thompson, R
Crofutt, R
Murray, T
Richmond, I
Haas, G
AF Kasckow, John
Gurklis, J.
Thompson, R.
Crofutt, R.
Murray, T.
Richmond, I.
Haas, G.
TI TELEHEALTH MONITORING OF PATIENTS WITH SCHIZOPHRENIA AND SUICIDAL
BEHAVIOR
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 12th International Congress on Schizophrenia Research
CY MAR 28-APR 01, 2009
CL San Diego, CA
C1 [Kasckow, John; Gurklis, J.; Thompson, R.; Crofutt, R.; Murray, T.; Richmond, I.; Haas, G.] VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth, Pittsburgh, PA USA.
[Kasckow, John; Haas, G.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA.
[Crofutt, R.; Murray, T.; Richmond, I.] VA Pittsburgh Hlth Care Syst, Nursing Serv, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2009
VL 35
BP 374
EP 374
PG 1
WC Psychiatry
SC Psychiatry
GA 415VP
UT WOS:000263964701084
ER
PT J
AU Antoun, TA
Palevsky, PM
AF Antoun, Tania Abi
Palevsky, Paul M.
TI Selection of Modality of Renal Replacement Therapy
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; INTENSIVE-CARE-UNIT;
CONTINUOUS ARTERIOVENOUS HEMOFILTRATION; CONTINUOUS VENOVENOUS
HEMODIAFILTRATION; RANDOMIZED CLINICAL-TRIAL; INTERMITTENT HEMODIALYSIS;
CYTOKINE REMOVAL; FAILURE; MULTICENTER
AB The proliferation of new technologies has led to the availability of a broad range of options for the management of renal replacement therapy (RRT) in patients with acute kidney injury. We provide a review of the published literature comparing the continuous RRTs (CRRT) with other modalities of renal support, including intermittent hemodialysis and the more recently described "hybrid" therapies such as sustained, low efficiency dialysis as well as compare arteriovenous and venovenous and convective and diffusive modalities of CRRT. While there is clear evidence that venovenous therapies are superior to arteriovenous therapies, current evidence does not support superiority of convective when compared with diffusive therapies or greater survival or recovery of kidney function with any individual modality of RRT. Selection of modality of RRT should therefore rely on the resources and expertise available.
C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Antoun, Tania Abi; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15260 USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 53
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-0959
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR-APR
PY 2009
VL 22
IS 2
BP 108
EP 113
DI 10.1111/j.1525-139X.2008.00540.x
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 435XX
UT WOS:000265377700002
ER
PT J
AU Palevsky, PM
AF Palevsky, Paul M.
TI Intensity of Continuous Renal Replacement Therapy in Acute Kidney Injury
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID CONTINUOUS VENOVENOUS HEMOFILTRATION; ULTRAFILTRATION FLOW-RATES; SOLUTE
CLEARANCES; RANDOMIZED-TRIAL; SEPTIC SHOCK; FAILURE; HEMODIALYSIS;
SURVIVAL
AB The intensity of continuous renal replacement therapy (CRRT) is generally assessed on the basis of small solute clearance with dosing usually expressed in terms of total effluent volume per unit time (e.g., ml/kg/hour). Although several clinical trials have suggested an improvement in survival with higher doses of CRRT, results have not been consistent across all studies. The results of recent trials of intensity of CRRT are reviewed. The largest and most recent trials suggest that there is no additional benefit to using effluent flow rates in excess of 20 ml/kg/hour, although earlier studies suggested improved survival with doses of 35 to 45 ml/kg/hour.
C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Univ Drive Div, Renal Sect, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Univ Drive Div, Renal Sect, Room 7E123 111F-U, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 16
TC 4
Z9 8
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-0959
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR-APR
PY 2009
VL 22
IS 2
BP 151
EP 154
DI 10.1111/j.1525-139X.2008.00543.x
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 435XX
UT WOS:000265377700009
PM 19426419
ER
PT J
AU Krogh, K
Perkash, I
Stiens, SA
Biering-Sorensen, F
AF Krogh, K.
Perkash, I.
Stiens, S. A.
Biering-Sorensen, F.
TI International bowel function basic spinal cord injury data set
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; spinal cord lesion; constipation; fecal
incontinence; colon; rectum
ID FECAL INCONTINENCE; COLONIC TRANSIT; DYSFUNCTION; LESIONS; POPULATION;
MANAGEMENT
AB Study design: International expert working group.
Objective: To develop an International Bowel Function Basic Spinal Cord Injury (SCI) Data Set presenting a standardized format for the collection and reporting of a minimal amount of information on bowel function in daily practice or in research.
Setting: Working group consisting of members appointed by the American Spinal Injury Association (ASIA) and the International Spinal Cord Society (ISCoS).
Methods: A draft prepared by the working group was reviewed by Executive Committee of the International SCI Standards and Data Sets, and later by ISCoS Scientific Committee and the ASIA Board. Relevant and interested scientific and professional (international) organizations and societies (approximately 40) were also invited to review the data set and it was posted on the ISCoS and ASIA websites for 3 months to allow comments and suggestions. The ISCoS Scientific Committee, Council and ASIA Board received the data set for final review and approval.
Results: The International Bowel Function Basic SCI Data Set includes the following 12 items: date of data collection, gastrointestinal or anal sphincter dysfunction unrelated to SCI, surgical procedures on the gastrointestinal tract, awareness of the need to defecate, defecation method and bowel care procedures, average time required for defecation, frequency of defecation, frequency of fecal incontinence, need to wear pad or plug, medication affecting bowel function/constipating agents, oral laxatives and perianal problems.
Conclusion: An International Bowel Function Basic SCI Data Set has been developed.
C1 [Krogh, K.] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, DK-8000 Aarhus, Denmark.
[Krogh, K.] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark.
[Perkash, I.] Stanford Univ, Palo Alto, CA 94304 USA.
[Perkash, I.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Stiens, S. A.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA.
[Biering-Sorensen, F.] Copenhagen Univ Hosp, Rigshosp, Ctr Neurosci, Clin Spinal Cord Injuries, Copenhagen, Denmark.
RP Krogh, K (reprint author), Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, Norrebrogade 44, DK-8000 Aarhus, Denmark.
EM krogh@as.aaa.dk
FU Coloplast A/S, Denmark
FX Coloplast A/S, Denmark has supported this study with this data set with
an unconditional grant. We are thankful for comments and suggestions
received from Susan Charlifue, Lawrence Vogel, Dan Lammertse, William
Donovan, Inge Eriks Hoogland, Karen Smith and Peter Christensen.
NR 20
TC 35
Z9 37
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD MAR
PY 2009
VL 47
IS 3
BP 230
EP 234
DI 10.1038/sc.2008.102
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 415AG
UT WOS:000263906100008
PM 18725887
ER
PT J
AU Krogh, K
Perkash, I
Stiens, SA
Biering-Sorensen, F
AF Krogh, K.
Perkash, I.
Stiens, S. A.
Biering-Sorensen, F.
TI International bowel function extended spinal cord injury data set
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; spinal cord lesion; constipation; fecal
incontinence; colon; rectum
ID FECAL INCONTINENCE; ANORECTAL FUNCTION; COLONIC TRANSIT; ABDOMINAL-PAIN;
DYSFUNCTION; LESIONS; POPULATION; MANAGEMENT; PHYSIOLOGY; DISORDERS
AB Study design: International expert working group.
Objective: To develop an International Bowel Function Extended Spinal Cord Injury (SCI) Data Set presenting a standardized format for the collection and reporting of an extended amount of information on bowel function.
Setting: Working group consisting of members appointed by the American Spinal Injury Association (ASIA) and the International Spinal Cord Society (ISCoS).
Methods: A draft prepared by the working group was reviewed by Executive Committee of the International SCI Standards and Data Sets and later by the ISCoS Scientific Committee and the ASIA Board. Relevant and interested scientific and professional organizations and societies (around 40) were also invited to review the data set and it was posted on the ISCoS and ASIA websites for 3 months to allow comments and suggestions. The ISCoS Scientific Committee, ISCoS Council and ASIA Board received the data set for final review and approval.
Results: The International Bowel Function Basic SCI Data Set includes 26 items providing a thorough description of bowel- related symptoms as well as clinical assessment of anal sphincter function and description of total gastrointestinal or segmental colorectal transit times.
Conclusion: An International Bowel Function Extended SCI Data Set has been developed. This Data Set is mainly for research purposes and it should be used in combination with the information obtained from the International SCI Core Data Set and the International Bowel Function Basic SCI Data Set.
C1 [Krogh, K.] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, DK-8000 Aarhus, Denmark.
[Krogh, K.] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark.
[Perkash, I.] Stanford Univ, Palo Alto, CA 94304 USA.
[Perkash, I.] Va Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Stiens, S. A.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA.
[Biering-Sorensen, F.] Copenhagen Univ Hosp, Rigshosp, Ctr Neurosci, Clin Spinal Cord Injuries, Copenhagen, Denmark.
RP Krogh, K (reprint author), Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, Norrebrogade 44, DK-8000 Aarhus, Denmark.
EM krogh@as.aaa.dk
FU Coloplast A/S (Denmark)
FX Coloplast A/S (Denmark) has supported the work with this Data Set with
an unconditional grant. We are thankful for all comments and suggestions
received. We thank Susan Charlifue, Lawrence Vogel, Dan Lammertse,
William Donovan, Inge Eriks Hoogland, Karen Smith and Peter Christensen.
NR 31
TC 22
Z9 24
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD MAR
PY 2009
VL 47
IS 3
BP 235
EP 241
DI 10.1038/sc.2008.103
PG 7
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 415AG
UT WOS:000263906100009
PM 18725886
ER
PT J
AU Vosler, PS
Chen, J
AF Vosler, Peter S.
Chen, Jun
TI Potential Molecular Targets for Translational Stroke Research
SO STROKE
LA English
DT Editorial Material
DE molecular targets; neuroprotection; translational stroke research
ID ISCHEMIC-STROKE
C1 [Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, BST, Pittsburgh, PA 15213 USA.
[Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, BST, S-507, Pittsburgh, PA 15213 USA.
EM chenj2@upmc.edu
FU NINDS NIH HHS [R01 NS043802-05, R01 NS045048, R01 NS056118, R01
NS044178-05, R01 NS043802, NS44178, R01 NS045048-05, NS56118, R01
NS036736, NS43802, R01 NS044178, R01 NS056118-03, R01 NS036736-11,
NS45048, NS36736]
NR 8
TC 17
Z9 20
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAR
PY 2009
VL 40
IS 3
BP S119
EP S120
DI 10.1161/STROKEAHA.108.533109
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 410QW
UT WOS:000263594200039
PM 19064800
ER
PT J
AU Keil, DE
McGuinn, WD
Dudley, AC
EuDaly, JG
Gilkeson, GS
Peden-Adams, MM
AF Keil, Deborah E.
McGuinn, W. David
Dudley, Andrew C.
EuDaly, Jackie G.
Gilkeson, Gary S.
Peden-Adams, Margie M.
TI N,N,-Diethyl-m-Toluamide (DEET) Suppresses Humoral Immunological
Function in B6C3F1 Mice
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE DEET; immune function; Gulf War Illness; PFC response; T-cell
subpopulations
ID LISTERIA-MONOCYTOGENES INFECTION; REPELLENT N,N-DIETHYL-M-TOLUAMIDE
DEET; NATURAL-KILLER-CELLS; GULF-WAR SYNDROME; PYRIDOSTIGMINE BROMIDE;
INSECT REPELLENT; HOST-RESISTANCE; TOXIC ENCEPHALOPATHY; MOSQUITO
REPELLENTS; RISK-ASSESSMENT
AB N,N-diethyl-meta-toluamide (DEET) is a particularly effective broad-spectrum insect repellent used commonly in recreational, occupational and military environments. Due to its widespread use and suggested link to Gulf War Illness, this study examined the immunotoxicity of DEET. Adult female B6C3F1 mice were injected sc for 14 days with DEET at 0, 7.7, 15.5, 31, or 62 mg/kg/day. Due to differences in the dermal absorption of DEET between mice and humans, this study eliminated this confounding factor by utilizing sc injection and measured circulating blood levels of DEET to assess bioavailability from sc administration. Effects on lymphocyte proliferation, natural killer cell activity, thymus and spleen weight and cellularity, the antibody plaque-forming cell (PFC) response, and thymic and splenic CD4/CD8 lymphocyte subpopulations were assessed 24 h after the last dose. No effect was observed in lymphocyte proliferation, natural killer cell activity, thymic weight, splenic weight, thymic cellularity, or splenic cellularity. Significant decreases were observed in the percentage of splenic CD4-/CD8- and CD4+/CD8- lymphocytes but only at the 62 mg DEET/kg/day treatment level and not in absolute numbers of these cells types. Additionally, significant decreases in the antibody PFC response were observed following treatment with 15.5, 31, or 62 mg DEET/kg/day. Pharmacokinetic (PK) data from the current study indicate 95% bioavailability of the administered dose. Therefore, it is likely that DEET exposure ranges applied in this study are comparable to currently reported occupational usage. Together, the evidence for immunosuppression and available PK data suggest a potential human health risk associated with DEET in the occupational or military environments assuming similar sensitivity between human and rodent responses.
C1 [Keil, Deborah E.] Univ Nevada, Clin Sci Lab, Las Vegas, NV 89154 USA.
US FDA, Silver Spring, MD 20993 USA.
[EuDaly, Jackie G.; Peden-Adams, Margie M.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29412 USA.
[McGuinn, W. David; EuDaly, Jackie G.; Gilkeson, Gary S.; Peden-Adams, Margie M.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29412 USA.
[Dudley, Andrew C.; EuDaly, Jackie G.; Peden-Adams, Margie M.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA.
[Gilkeson, Gary S.] Ralph Johnson VAMC, Med Res Serv, Charleston, SC 29425 USA.
RP Keil, DE (reprint author), Univ Nevada, Clin Sci Lab, 4505 Maryland Pkwy,Box 453021, Las Vegas, NV 89154 USA.
EM deborah.keil@unlv.edu
OI Keil, Deborah/0000-0002-5787-8514
FU U. S. Department of Defense [DAMD17-99-1-9013]
FX U. S. Department of Defense (grant # DAMD17-99-1-9013) to D. E. K.; the
Veterans Administration Medical Research Service to G. S. G.; and
internal support from UNLV.
NR 74
TC 7
Z9 8
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD MAR
PY 2009
VL 108
IS 1
BP 110
EP 123
DI 10.1093/toxsci/kfp001
PG 14
WC Toxicology
SC Toxicology
GA 410VO
UT WOS:000263606600012
PM 19141786
ER
PT J
AU Wu, JD
Lin, DW
Page, ST
Lundgren, AD
True, LD
Plymate, SR
AF Wu, Jennifer D.
Lin, Daniel W.
Page, Stephanie T.
Lundgren, Ashley D.
True, Lawrence D.
Plymate, Stephen R.
TI Oxidative DNA damage in the prostate may predispose men to a higher risk
of prostate cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID DOUBLE-STRAND BREAKS; ATM ACTIVATION; T-CELLS; ANTICANCER BARRIER;
MEDICAL CASTRATION; NKG2D RECEPTOR; NK CELLS; EXPRESSION; LIGANDS;
STRESS
AB DNA damage has been associated with prostate cancer risk. Men who were referred for initial prostate biopsy for elevated prostate-specific antigen or abnormal digital rectal examination are often found with no cancer but have a higher risk of developing prostate cancer than the general population of men in their lifetime In this study, we investigated whether DNA damage is one of the factors that predispose these men referred for prostate biopsies to a higher risk of prostate cancer. We found significantly elevated levels of 8-oxo-2-deoxyguanosine immunoreactivity in the prostates of the referred men (n = 50) in comparison to the control prostates of men (n = 32) with no indication for referral for prostate biopsy. Twelve of these control men were healthy middle-aged men and 20 of them were older men whose conditions were diagnosed with bladder cancer but with normal serum prostate-specific antigen and digital rectal examination and no evidence of prostate disease. In all the 8-oxo-2-deoxyguanosine-positive prostates, we detected phosphorylation of the ataxia telangiectasia mutated kinase and expression of the immune-stimulatory molecule MIC in the prostate epithelium These data suggest that 1) oxidative DNA damage has occurred in the "referred" but pathologically normal prostates, indicating that these prostates may be subjected to genomic instability and eventually neoplastic transformation; 2) in response to DNA damage, two surveillance pathways, represented by ataxia telangiectasia mutated phosphorylation and induction of the NKG2D ligand MIC, were activated to prevent tumorigenesis.
C1 [Wu, Jennifer D.; Page, Stephanie T.; Lundgren, Ashley D.; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA USA.
[Lin, Daniel W.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[True, Lawrence D.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
RP Wu, JD (reprint author), Box 359755,325 9th Ave, Seattle, WA 98104 USA.
FU Department of Defense New Invastigator's [W81XWH-04-1-0577]; National
Institutes of Health Temin [1 K01 CA 116002]; Pacific Northwest Prostate
Cancer SPORE Pilot [P50-CA97186]; National Institutes of Health
[K23DK65083, CA 085859]; Veterans Affairs Research Service
FX Supported by Department of Defense New Invastigator's Award
(W81XWH-04-1-0577), National Institutes of Health Temin Award (1 K01 CA
116002), the Pacific Northwest Prostate Cancer SPORE Pilot Award
(P50-CA97186) to J Wu and S.R. Plymate; National Institutes of Health
Award (K23DK65083) to D Lin, and Veterans Affairs Research Service and
National Institutes of Health awards (CA 085859) to S.R. Plymate
NR 37
TC 8
Z9 8
U1 0
U2 4
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD MAR
PY 2009
VL 2
IS 1
BP 39
EP 45
DI 10.1593/tlo.08217
PG 7
WC Oncology
SC Oncology
GA 529WW
UT WOS:000272550900005
PM 19252750
ER
PT J
AU Kramer, BJ
Jouldjian, S
Washington, DL
Harker, JO
Saliba, D
Yano, EM
AF Kramer, B. Josea
Jouldjian, Stella
Washington, Donna L.
Harker, Judith O.
Saliba, Debra
Yano, Elizabeth M.
TI HEALTH CARE FOR AMERICAN INDIAN AND ALASKA NATIVE WOMEN The Roles of the
Veterans Health Administration and The Indian Health Service
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; AMBULATORY-CARE; PREVALENCE; AFFAIRS; VA;
AVAILABILITY; DISPARITIES; COMMUNITY; TRAUMA; ACCESS
AB Background. Many American Indian and Alaska Native (AIAN) women serve in the military and are eligible for healthcare from both the Veterans Health Administration (VHA) and the Indian Health Service (IHS). Little was known about these women's patterns of health care utilization when VHA and IHS executed a resource-sharing agreement in 2003 to improve access and health outcomes.
Objective. We sought to describe women's healthcare utilization in VHA and IHS.
Methods. We conducted a descriptive secondary data analysis of linked IHS and VHA administrative records from fiscal years 2002 and 2003 for women among all IHS beneficiaries who were veterans or used VHA for health care (n = 64,746).
Results. Among these IHS beneficiaries, 4,338 (6.7%) were female veterans and 1,518 (2.8%) were female nonveterans. Comparing IHS services to VHA, the VHA provided the majority of outpatient specialty care to veterans, providing 89.9% of diagnostic and imaging services, 84.4% of mental health care, and 78.1%, of physical medicine and rehabilitation. Conversely, the IHS provided the majority of ambulatory and inpatient care for obstetrics and gynecology to these veterans. Dual users received primary care from both organizations. Nonveterans generally accessed VHA under sharing agreements and their use of health care was generally limited to outpatient diagnostic and imaging.
Conclusions. The VHA seems to supplement healthcare provided by the IHS for female AIAN veterans, as well as for a small proportion of nonveterans. The VHA and the IHS have developed specialized and complementary expertise, which might be aligned to serve the needs of female AIAN veterans.
C1 [Kramer, B. Josea; Saliba, Debra] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Sepulveda, CA 91343 USA.
[Kramer, B. Josea; Saliba, Debra] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA 90095 USA.
[Jouldjian, Stella; Washington, Donna L.; Harker, Judith O.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Saliba, Debra; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res Ctr Excellence, Sepulveda, CA USA.
[Saliba, Debra] RAND Corp, Santa Monica, CA USA.
RP Kramer, BJ (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, 16111 Plummer St 11E, Sepulveda, CA 91343 USA.
EM Josea.Kramer@va.gov
NR 38
TC 3
Z9 3
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAR-APR
PY 2009
VL 19
IS 2
BP 135
EP 143
DI 10.1016/j.whi.2008.11.002
PG 9
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA 423CA
UT WOS:000264472800007
PM 19272564
ER
PT J
AU Bates-Jensen, B
Guihan, M
Chin, A
AF Bates-Jensen, Barbara
Guihan, Marylou
Chin, Amy
TI ASSESSING A BIOPHYSICAL DEVICE TO PREDICT PRESSURE ULCERS IN SPINAL CORD
INJURY
SO WOUND REPAIR AND REGENERATION
LA English
DT Meeting Abstract
C1 [Bates-Jensen, Barbara] Univ Calif Los Angeles, Sch Nursing & Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Guihan, Marylou; Chin, Amy] Northwestern Univ, Ctr Management Complex Chron Care, Edward Hines Jr VA Hosp, Inst Healthcare Studies, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1067-1927
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD MAR-APR
PY 2009
VL 17
IS 2
BP A45
EP A45
PG 1
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 418ZJ
UT WOS:000264188600158
ER
PT J
AU Raugi, G
Reiber, G
AF Raugi, Gregory
Reiber, Gayle
TI REDUCTION IN TIME TO HEALING AND AMPUTATIONS IN RURAL CARE SETTINGS
SO WOUND REPAIR AND REGENERATION
LA English
DT Meeting Abstract
C1 [Raugi, Gregory; Reiber, Gayle] VA Puget Sound, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1067-1927
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD MAR-APR
PY 2009
VL 17
IS 2
BP A20
EP A20
PG 1
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 418ZJ
UT WOS:000264188600056
ER
PT J
AU Craig, TJ
Petzel, R
AF Craig, Thomas J.
Petzel, Robert
TI Management perspectives on research contributions to practice through
collaboration in the U. S. Veterans Health Administration: QUERI Series
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID QUALITY-OF-CARE
AB The Quality Enhancement Research Initiative (QUERI) is a unique quality improvement program designed to connect health services researchers to Veterans Health Administration (VHA) management and operations, as well as to provide the science and initiative for making change. Through this process, QUERI stakeholders have learned that success and impact in improving healthcare quality and outcomes largely depends on coordination and collaboration among numerous VHA programs and organizations working to develop and implement evidence-based clinical policies, practices, and quality improvement strategies. This Commentary discusses some of these collaborative efforts and perceived successes in achieving common goals from the viewpoints of two closely involved VHA Operations/Support stakeholders.
The Commentary is part of a Series of articles documenting implementation science frameworks and tools developed by the U. S. Department of Veterans Affairs Quality Enhancement Research Initiative (QUERI).
C1 [Petzel, Robert] US Dept Vet Affairs Midwest Hlth Care Network, Minneapolis, MN USA.
[Craig, Thomas J.] US Dept Vet Affairs, Vet Hlth Adm, Off Qual & Performance, Washington, DC USA.
RP Petzel, R (reprint author), US Dept Vet Affairs Midwest Hlth Care Network, Minneapolis, MN USA.
EM tlc1963@earthlink.net; Robert.Petzel@va.gov
NR 10
TC 5
Z9 5
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD FEB 26
PY 2009
VL 4
AR 8
DI 10.1186/1748-5908-4-8
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 433KK
UT WOS:000265202500001
PM 19245708
ER
PT J
AU Baldys, A
Gooz, M
Morinelli, TA
Lee, MH
Raymond, JR
Luttrell, LM
Raymond, JR
AF Baldys, Aleksander
Goeoz, Monika
Morinelli, Thomas A.
Lee, Mi-Hye
Raymond, John R., Jr.
Luttrell, Louis M.
Raymond, John R., Sr.
TI Essential Role of c-Cbl in Amphiregulin-Induced Recycling and Signaling
of the Endogenous Epidermal Growth Factor Receptor
SO BIOCHEMISTRY
LA English
DT Article
ID CLATHRIN-COATED PITS; EGF RECEPTOR; TYROSINE PHOSPHORYLATION;
DOWN-REGULATION; RING FINGER; MEDIATED UBIQUITINYLATION; ENDOCYTIC
SYSTEM; EPITHELIAL-CELLS; EARLY ENDOSOMES; UBIQUITINATION
AB The intracellular processing of the epidermal growth factor receptor (EGFR) induced by epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) has been studied meticulously, with the former resulting in EGFR degradation and the latter in EGFR recycling to the plasma membrane. However, little is known about how other EGF family growth factors affect the trafficking of the EGFR. Additionally, although both EGF and TGF-alpha have been shown to effectively induce initial c-Cbl (ubiquitin ligase)-mediated ubiquitination of the EGFR, limited information is available regarding the role of c-Cbl in the trafficking and signaling of recycling EGFR. Thus, in this study, we investigated the roles of c-Cbl in endogenous EGFR trafficking and signaling after stimulation with amphiregulin (AR). We demonstrated that a physiological concentration of AR induced recycling of the endogenous EGFR to the plasma membrane, which correlated closely with transient association of the EGFR with c-Cbl and transient EGFR ubiquitination. Most importantly, we used c-Cbl small interfering RNA (siRNA) duplexes and a c-Cbl dominant negative mutant to show that c-Cbl is critical for the efficient transition of the EGFR from early endosomes to a recycling pathway and that c-Cbl regulates the duration of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) phosphorylation. These data support novel functions of c-Cbl in mediating recycling of EGF receptors to the plasma membrane, as well as in mediating the duration of activation (transient vs sustained) of ERK1/2 MAPK phosphorylation.
C1 [Baldys, Aleksander; Goeoz, Monika; Morinelli, Thomas A.; Raymond, John R., Jr.; Raymond, John R., Sr.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Lee, Mi-Hye; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA.
[Baldys, Aleksander; Goeoz, Monika; Morinelli, Thomas A.; Lee, Mi-Hye; Luttrell, Louis M.; Raymond, John R., Sr.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA.
RP Raymond, JR (reprint author), Room 213,Colcock Hall,179 Ashley Ave, Charleston, SC 29425 USA.
EM raymondj@musc.edu; raymondj@musc.edu
FU Department of Veterans Affairs Merit; Research Enhancement Award
Program; National Institutes of Health [DK052448, GM063909]; American
Heart Association; Medical University of South Carolina, Division of
Nephrology, and Dialysis Clinics, Inc
FX This work was supported by Department of Veterans Affairs Merit and
Research Enhancement Award Program grants (to J. R. Raymond, Sr.), by
National Institutes of Health Grants DK052448 and GM063909, by an
American Heart Association (Mid-Atlantic) fellowship (to A.B.), and by a
laboratory endowment jointly supported by the Medical University of
South Carolina, Division of Nephrology, and Dialysis Clinics, Inc. (to
J. R. Raymond Sr.).
NR 50
TC 30
Z9 31
U1 2
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD FEB 24
PY 2009
VL 48
IS 7
BP 1462
EP 1473
DI 10.1021/bi801771g
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 408JK
UT WOS:000263431100005
PM 19173594
ER
PT J
AU Collins, P
Mosca, L
Geiger, MJ
Grady, D
Kornitzer, M
Amewou-Atisso, MG
Effron, MB
Dowsett, SA
Barrett-Connor, E
Wenger, NK
AF Collins, Peter
Mosca, Lori
Geiger, Mary Jane
Grady, Deborah
Kornitzer, Marcel
Amewou-Atisso, Messan G.
Effron, Mark B.
Dowsett, Sherie A.
Barrett-Connor, Elizabeth
Wenger, Nanette K.
TI Effects of the Selective Estrogen Receptor Modulator Raloxifene on
Coronary Outcomes in The Raloxifene Use for the Heart Trial Results of
Subgroup Analyses by Age and Other Factors
SO CIRCULATION
LA English
DT Article
DE coronary disease; hormones; raloxifene; randomized controlled trial;
risk factors; women
ID HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; HORMONE
REPLACEMENT THERAPY; BREAST-CANCER; PLUS PROGESTIN;
CARDIOVASCULAR-DISEASE; CLINICAL-TRIAL; RISK; INITIATION; MENOPAUSE
AB Background-The Raloxifene Use for The Heart (RUTH) trial showed that raloxifene, a selective estrogen receptor modulator, had no overall effect on the incidence of coronary events in women with established coronary heart disease or coronary heart disease risk factors. We provide detailed results of the effect of raloxifene on coronary outcomes over time and for 24 subgroups (17 predefined, 7 post hoc).
Methods and Results-Postmenopausal women (n = 10 101; mean age, 67 years) were randomized to raloxifene 60 mg/d or placebo for a median of 5.6 years. Coronary outcomes were assessed by treatment group in women with coronary heart disease risk factors and those with established coronary heart disease. Raloxifene had no effect on the incidence of coronary events in any subgroup except in the case of a post hoc age subgroup analysis using age categories defined in the Women's Health Initiative randomized trials. The effect of raloxifene on the incidence of coronary events differed significantly by age ( interaction P = 0.0118). The incidence of coronary events in women < 60 years of age was significantly lower in those assigned raloxifene ( 50 events) compared with placebo ( 84 events; hazard ratio, 0.59; 95% confidence interval, 0.41 to 0.83; P=0.003; absolute risk reduction, 36 per 1000 women treated for 1 year). No difference was found between treatment groups in the incidence of coronary events in women >= 60 and < 70 or >= 70 years of age.
Conclusions-In postmenopausal women at increased risk of coronary events, the overall lack of benefit of raloxifene was similar across the prespecified subgroups. (Circulation. 2009; 119: 922-930.)
C1 [Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London SW3 6NP, England.
[Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6NP, England.
[Mosca, Lori] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
[Geiger, Mary Jane; Amewou-Atisso, Messan G.; Effron, Mark B.; Dowsett, Sherie A.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.
[Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
[Kornitzer, Marcel] Free Univ Brussels, Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Brussels, Belgium.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Wenger, Nanette K.] Emory Univ, Sch Med, Atlanta, GA USA.
RP Collins, P (reprint author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield NHS Trust, Dept Cardiol, Sydney St, London SW3 6NP, England.
EM peter.collins@imperial.ac.uk
RI Effron, Mark/P-9300-2015
FU Eli Lilly and Co, Indianapolis, Ind
FX This study was sponsored by Eli Lilly and Co, Indianapolis, Ind.
NR 31
TC 66
Z9 69
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 24
PY 2009
VL 119
IS 7
BP 922
EP 930
DI 10.1161/CIRCULATIONAHA.108.817577
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 410RT
UT WOS:000263596500004
PM 19204301
ER
PT J
AU Casarett, DJ
Fishman, JM
Lu, HL
O'Dwyer, PJ
Barg, FK
Naylor, MD
Asch, DA
AF Casarett, David J.
Fishman, Jessica M.
Lu, Hien L.
O'Dwyer, Peter J.
Barg, Frances K.
Naylor, Mary D.
Asch, David A.
TI The Terrible Choice: Re-Evaluating Hospice Eligibility Criteria for
Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CONJOINT-ANALYSIS; PATIENT PREFERENCES; PALLIATIVE CARE; NURSING-HOMES;
HEALTH-CARE; FAMILIES; SERVICES; LIFE; MANAGEMENT; ENROLLMENT
AB Purpose
To be eligible for the Medicare Hospice Benefit, cancer patients with a life expectancy of 6 months or less must give up curative treatment. Our goal was to determine whether willingness to make this choice identifies patients with greater need for hospice services.
Patients and Methods
Three hundred patients with cancer and 171 family members were recruited from six oncology practices. Respondents completed conjoint interviews in which their perceived need for five hospice services was calculated from the choices they made among combinations of services. Patients' preferences for treatment were measured, and patients were followed for 6 months or until death.
Results
Thirty-eight patients (13%) said they would not want cancer treatment even if it offered an almost 100% chance of 6-month survival. These patients, who would have been eligible for hospice, did not have greater perceived need for hospice services compared with other patients (n = 262; mean, 1.75 v 1.98; Wilcoxon rank sum test, P = .46), nor did their family members (mean, 1.95 v 2.04; Wilcoxon rank sum test, P = .80). Instead, independent predictors of patients' perceived need for hospice services included African American ethnicity, less social support, worse functional status, and a greater burden of psychological symptoms. For families, predictors included caregiver burden, worse self-reported health, working outside the home, and caring for a patient with worse functional status.
Conclusion
The requirement that patients forgo life-sustaining treatment does not identify patients with greater perceived need for hospice services. Other characteristics offer a better way to identify the patients who are most likely to benefit from hospice.
C1 [Casarett, David J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Casarett, DJ (reprint author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM casarett@mail.med.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU Paul Beeson Physician Faculty Scholars Award [R01CA109540]; Presidential
Early Career Award for Scientists and Engineers
FX Supported by Grant No. R01CA109540, the Paul Beeson Physician Faculty
Scholars Award, and the Presidential Early Career Award for Scientists
and Engineers (D.J.C.).
NR 39
TC 32
Z9 32
U1 4
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2009
VL 27
IS 6
BP 953
EP 959
DI 10.1200/JCO.2008.17.8079
PG 7
WC Oncology
SC Oncology
GA 409NR
UT WOS:000263513000019
PM 19114698
ER
PT J
AU Grande, D
Asch, DA
AF Grande, David
Asch, David A.
TI Commercial versus Social Goals of Tracking What Doctors Do
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Grande, David] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Grande, D (reprint author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
NR 2
TC 6
Z9 6
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 19
PY 2009
VL 360
IS 8
BP 747
EP 749
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 408CN
UT WOS:000263411300002
PM 19228616
ER
PT J
AU Qaseem, A
Shekelle, P
Owens, DK
AF Qaseem, Amir
Shekelle, Paul
Owens, Douglas K.
TI Is Too Much Intervention Recommended in the ACP Osteoporosis Treatment
Guidelines? RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
ID BONE-MINERAL DENSITY
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA 90401 USA.
[Shekelle, Paul] RAND Corp, Santa Monica, CA 90401 USA.
[Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 17
PY 2009
VL 150
IS 4
BP 286
EP 287
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 410FI
UT WOS:000263562500018
ER
PT J
AU Qaseem, A
Shekelle, P
Owens, DK
AF Qaseem, Amir
Shekelle, Paul
Owens, Douglas K.
TI Agranulocytosis After Consumption of Cocaine Adulterated With Levamisole
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA 90401 USA.
[Shekelle, Paul] RAND Corp, Santa Monica, CA 90401 USA.
[Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA.
NR 9
TC 15
Z9 16
U1 0
U2 3
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 17
PY 2009
VL 150
IS 4
BP 287
EP 289
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 410FI
UT WOS:000263562500019
PM 19153405
ER
PT J
AU Ross, JS
Gross, CP
AF Ross, Joseph S.
Gross, Cary P.
TI Policy Research Using Evidence to Improve Healthcare Delivery Systems
SO CIRCULATION
LA English
DT Editorial Material
DE health policy; delivery of health care; policy
ID ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; BYPASS
GRAFT-SURGERY; ELDERLY MEDICARE BENEFICIARIES; RANDOMIZED
CONTROLLED-TRIAL; 30-DAY MORTALITY-RATES; AGE-BASED DISPARITIES;
SHORT-TERM MORTALITY; CONFLICT-OF-INTEREST; TO-BALLOON TIMES
C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA.
[Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, HSR& Res Enhancement Award Program, Bronx, NY USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
[Gross, Cary P.] Yale Univ, Sch Med, Gen Internal Med Sect, Dept Internal Med, New Haven, CT USA.
RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM joseph.ross@mssm.edu
NR 92
TC 3
Z9 3
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 17
PY 2009
VL 119
IS 6
BP 891
EP 898
DI 10.1161/CIRCULATIONAHA.107.729855
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 408JZ
UT WOS:000263432600018
PM 19221232
ER
PT J
AU Mendez, E
Houck, JR
Doody, DR
Fan, WH
Lohavanichbutr, P
Rue, TC
Yueh, B
Futran, ND
Upton, MP
Farwell, DG
Heagerty, PJ
Zhao, LP
Schwartz, SM
Chen, C
AF Mendez, Eduardo
Houck, John R.
Doody, David R.
Fan, Wenhong
Lohavanichbutr, Pawadee
Rue, Tessa C.
Yueh, Bevan
Futran, Neal D.
Upton, Melissa P.
Farwell, D. Gregory
Heagerty, Patrick J.
Zhao, Lue Ping
Schwartz, Stephen M.
Chen, Chu
TI A Genetic Expression Profile Associated with Oral Cancer Identifies a
Group of Patients at High Risk of Poor Survival
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; PLASMINOGEN-ACTIVATOR INHIBITOR; ADVANCED
LARYNGEAL-CANCER; GROWTH-FACTOR-BETA; NECK-CANCER; DIAGNOSTIC MARKER;
INVASIVE FRONT; HEAD; RECEPTOR; LAMININ-5
AB Purpose: To determine if gene expression signature of invasive oral squamous cell carcinoma (OSCC) can subclassify OSCC based on survival.
Experimental Design: We analyzed the expression of 131 genes in 119 OSCC 35 normal, and 17 dysplastic mucosa to identify cluster-defined subgroups. Multivariate Cox regression was used to estimate the association between gene expression and survival. By stepwise Cox regression, the top predictive models of OSCC-specific survival were determined and compared by receiver operating characteristic analysis.
Results: The 3-year overall mean +/- SE survival for a cluster of 45 OSCC patients was 38.7 +/- 0.09% compared with 69.1 +/- 0.08% for the remaining patients. Multivariate analysis adjusted for age, sex, and stage showed that the 45 OSCC patient cluster had worse overall and OSCC-specific survival (hazard ratio, 3.31; 95% confidence interval, 1.66-6.58 and hazard ratio, 5.43; 95% confidence interval, 2.32-12.73, respectively). Stepwise Cox regression on the 131 probe sets revealed that a model with a term for LAMC2 (laminin gamma(2)) gene expression best identified patients with worst OSCC-specific survival. We fit a Cox model with a term for a principal component analysis-derived risk score marker and two other models that combined stage with either LAMC2 or PCA. The area under the curve for models combining stage with either LAMC2 or PCA was 0.80 or 0.82, respectively, compared with 0.70 for stage alone (P = 0.013 and 0.008, respectively).
Conclusions: Gene expression and stage combined predict survival of OSCC patients better than stage alone.
C1 [Mendez, Eduardo; Houck, John R.; Doody, David R.; Lohavanichbutr, Pawadee; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA.
[Mendez, Eduardo; Futran, Neal D.; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Rue, Tessa C.; Heagerty, Patrick J.; Zhao, Lue Ping] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
[Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA.
[Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA.
[Farwell, D. Gregory] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Sacramento, CA 95817 USA.
RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,M5-C800,POB 19024, Seattle, WA 98109 USA.
EM cchen@fhcrc.org
OI Yueh, Bevan/0000-0003-1380-1053
FU National Cancer Institute; NIH [R01CA095419]; National Center for
Research Resources [1KL2RR025015-01]; Fred Hutchinson Cancer Research
Center
FX National Cancer Institute, NIH grant R01CA095419 (E. Mendez, J. R.
Houck, D. R. Doody, W. Fan, P. Lohavanichbutr, B. Yueh, N. D. Futran, M.
P. Upton, D.G. Farwell, L.P. Zhao, S.M. Schwartz, and C. Chen), National
Center for Research Resources grant 1KL2RR025015-01 (E. Mendez, T.C.
Rue, and P.J. Heagerty), and Fred Hutchinson Cancer Research Center
institutional funds (C. Chen).
NR 36
TC 31
Z9 31
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2009
VL 15
IS 4
BP 1353
EP 1361
DI 10.1158/1078-0432.CCR-08-1816
PG 9
WC Oncology
SC Oncology
GA 410QI
UT WOS:000263592600028
PM 19228736
ER
PT J
AU Fulop, T
Pawelec, G
Castle, S
Loeb, M
AF Fulop, Tamas
Pawelec, Graham
Castle, Steven
Loeb, Mark
TI Immunosenescence and Vaccination in Nursing Home Residents
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; T-CELL DIFFERENTIATION;
INFLUENZA VACCINATION; ELDERLY-PEOPLE; CYTOMEGALOVIRUS-INFECTION;
SIGNAL-TRANSDUCTION; LIPID RAFTS; AGE; MORTALITY
AB The elderly population continues to increase in most countries. Concomitantly, the number of individuals who are institutionalized is also increasing, unfortunately, with more and more individuals being institutionalized at greater ages. These elderly individuals are very different from healthy, community-dwelling elderly individuals, in that many are considered to be frail and have various chronic diseases. It is apparent that the immune response diminishes even in healthy elderly people and that the pathologies that occur in nursing home patients, together with malnutrition, further impair immunity required for an effective vaccine response. Therefore, it is important to take secondary age-related effects, attributable to factors such as chronic diseases, inflammation, frailty, nutrition, functional status, and stress, into account when assessing vaccination strategies. Despite these alterations that can affect immune function and their potential interaction with vaccination, vaccination is still worthwhile and is recommended for elderly nursing home residents. Research efforts should continue attempts to elucidate the immunological basis of impaired immunity in nursing home residents to design improved prevention strategies for this vulnerable group.
C1 [Loeb, Mark] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada.
[Fulop, Tamas] Univ Sherbrooke, Fac Med, Div Geriatr, Program Immunol,Res Ctr, Quebec City, PQ, Canada.
[Loeb, Mark] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.
[Pawelec, Graham] Univ Tubingen, Sch Med, Med Res Ctr, Tubingen Ageing & Tumour Immunol Grp, Tubingen, Germany.
[Castle, Steven] Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA.
RP Loeb, M (reprint author), McMaster Univ, Dept Pathol & Mol Med, MDCL 3200,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM loebm@mcmaster.ca
OI Pawelec, Graham/0000-0002-3600-0163
NR 52
TC 29
Z9 29
U1 1
U2 5
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2009
VL 48
IS 4
BP 443
EP 448
DI 10.1086/596475
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 396IP
UT WOS:000262585700013
PM 19140756
ER
PT J
AU Musher, DM
Logan, N
Bressler, AM
Johnson, DP
Rossignol, JF
AF Musher, Daniel M.
Logan, Nancy
Bressler, Adam M.
Johnson, David P.
Rossignol, Jean-Francois
TI Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A
Randomized, Double-Blind Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID COLITIS; METRONIDAZOLE; DIARRHEA; DISEASE; OUTBREAK; THERAPY
AB Background. Vancomycin is the only US Food and Drug Administration-approved drug for treatment of Clostridium difficile infection (CDI). Metronidazole has been widely used for this purpose but may be inferior to vancomycin, especially for hospitalized patients with severe disease. We report a prospective, double-blind, randomized controlled trial comparing nitazoxanide with vancomycin for treatment of CDI.
Methods. Fifty patients with CDI were randomized to receive vancomycin or nitazoxanide for 10 days. An initial response was considered to be the absence of all CDI symptoms between days 11 and 13, and a final response was considered to be lack of symptom recurrence by day 31.
Results. One patient fulfilled an exclusion criterion and was removed from the study. Twenty-seven patients received vancomycin, and 23 received nitazoxanide; 23 and 18 patients, respectively, completed the full course of treatment. Initial responses occurred in 20 (74%) of 27 patients treated with vancomycin and in 17 (77%) of 22 patients treated with nitazoxanide (95% confidence interval, -24% to +28%). In those who completed therapy, response rates were 87% ( 20 of 23 patients) in the vancomycin group and 94% ( 17 of 18 patients) in the nitazoxanide group ( 95% confidence interval, -18% to +30%). Times to complete resolution of symptoms were similar in the 2 groups (). Two patients in the vancomycin group and 1 patient in the nitazoxanide group experienced Pp. 55 relapse within 31 days after beginning treatment. Sustained response rates were 78% ( 18 of 23 patients) for the vancomycin group, and 89% ( 16 of 18 patients) for the nitazoxanide group ( 95% confidence interval, -18% to +35%).
Conclusions. The small sample precludes conclusions about noninferiority of nitazoxanide to vancomycin. Nevertheless, this is the first recent randomized controlled trial to compare any antimicrobial agent other than metronidazole with vancomycin. Results suggest that nitazoxanide may be as effective as vancomycin in treating CDI.
C1 [Musher, Daniel M.; Logan, Nancy] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA.
[Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Bressler, Adam M.] Dekalb Med Ctr, Infect Dis Specialists Atlanta, Atlanta, GA USA.
[Bressler, Adam M.] Dekalb Med Ctr, Clin Microbiol Lab, Atlanta, GA USA.
[Johnson, David P.] Bay Pines Vet Affairs Med Ctr, Div Infect Dis, Bay Pines, FL USA.
[Rossignol, Jean-Francois] Romark Inst Med Res, Tampa, FL USA.
[Rossignol, Jean-Francois] Stanford Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA.
RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Rm 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM daniel.musher@med.va.gov
FU Department of Veterans Affairs through Merit Review Funding; Romark
Laboratories; Infectious Disease Section at Baylor College of Medicine
FX Potential conflicts of interest. The academic departments of affiliation
for D. M. M., N.L., A. M. B., and D. P. J. received funding from Romark
Laboratories for studies of nitazoxanide. The Infectious Disease Section
at Baylor College of Medicine has received funds in D. M. M.'s name from
Salix for studies of rifaximin; from Genzyme for studies of tolevamer;
and from Merck for studies of pneumococcal vaccine. J.-F.R. is an
employee and owner of equity interests in Romark Laboratories.
NR 19
TC 84
Z9 88
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2009
VL 48
IS 4
BP E41
EP E46
DI 10.1086/596552
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 396IP
UT WOS:000262585700027
PM 19133801
ER
PT J
AU Samuvel, DJ
Sundararaj, KP
Nareika, A
Lopes-Virella, MF
Huang, Y
AF Samuvel, Devadoss J.
Sundararaj, Kamala P.
Nareika, Alena
Lopes-Virella, Maria F.
Huang, Yan
TI Lactate Boosts TLR4 Signaling and NF-kappa B Pathway-Mediated Gene
Transcription in Macrophages via Monocarboxylate Transporters and MD-2
Up-Regulation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INDUCED INSULIN-RESISTANCE; DIET-INDUCED OBESITY; SKELETAL-MUSCLE;
ADIPOSE-TISSUE; MESSENGER-RNA; EXPRESSION; ACTIVATION;
TOLL-LIKE-RECEPTOR-4; INFLAMMATION; HYPERLACTATEMIA
AB It has been shown that lactate induces insulin resistance. However, the underlying mechanisms have not been well understood. Based on our observation that lactate augments LPS-stimulated inflammatory gene expression, we proposed that lactate may enhance TLR4 signaling in macrophages, which has been shown to play an important role in insulin resistance in adipocytes. In this study, we demonstrated that lactate stimulated NTD-2, a coreceptor for TLR4 signaling activation, NF-kappa B transcriptional activity, and the expression of inflammatory genes in human U937 histiocytes; (resident macrophages). Similar enhancement of the inflammatory gene expression by lactate was also observed in human monocyte-derived macrophages. The essential role of MD-2 in lactate-augmented TLR4 signaling was confirmed by observation that the suppression of MD-2 expression by small interfering RNA led to significant inhibition of inflammatory gene expression. To further elucidate how lactate treatment enhances TLR4 activation, we showed that the augmentation of inflammatory gene expression by lactate was abrogated by antioxidant treatment, suggesting a critical role of reactive oxygen species in the enhancement of TLR4 activation by lactate. Finally, we showed that alpha-cyano-4-hydroxycinnamic acid, a classic inhibitor for monocarboxylate transporters, blocked lactate-augmented inflammatory gene expression and nuclear NF-kappa B activity, indicating that lactate transport through monocarboxylate transporters is required for lactate-enhanced TLR4 activation. Collectively, this study documents that lactate boosts TLR4 activation and NF-kappa B-dependent inflammatory gene expression via monocarboxylate transporters and MD-2 up-regulation. The Journal of Immunology,2009,182:2476-2484.
C1 [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Center, Charleston, SC 29401 USA.
[Samuvel, Devadoss J.; Sundararaj, Kamala P.; Nareika, Alena; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Center, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU National Institutes of Health [DE16353]; Department of Veterans Affairs
FX This work was supported by National Institutes of Health Grant DE16353
and a Merit Review Grant from the Department of Veterans Affairs (to
Y.H.).
NR 49
TC 58
Z9 61
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2009
VL 182
IS 4
BP 2476
EP 2484
DI 10.4049/jimmunol.0802059
PG 9
WC Immunology
SC Immunology
GA 404BS
UT WOS:000263126300078
PM 19201903
ER
PT J
AU Lane, R
He, YS
Morris, C
Leverenz, JB
Emre, M
Ballard, C
AF Lane, Roger
He, Yunsheng
Morris, Christopher
Leverenz, James B.
Emre, Murat
Ballard, Clive
TI BuChE-K and APOE epsilon 4 Allele Frequencies in Lewy Body Dementias,
and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease dementia; dementia with Lewy bodies; apolipoprotein
E; butyrylcholinesterase
ID ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; APOLIPOPROTEIN-E; HOMOCYSTEINE;
RIVASTIGMINE; PROGRESSION; DEFICIENCY; DEPOSITION; NEURONS; PLACEBO
AB Apolipoprotein E (APOE) epsilon 4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample. associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE epsilon 4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other enotypes. Subjects with hyperhomo-cysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE epsilon 4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders. (C) 2008 Movement Disorder Society
C1 [Lane, Roger] Nova Pharmaceut Corp, E Hanover, NJ 07936 USA.
[He, Yunsheng] Nova Pharmaceut Corp, Cambridge, MA USA.
[Morris, Christopher] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
[Leverenz, James B.] PADRECC, MIRECC, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Leverenz, James B.] Univ Washington, Seattle, WA 98195 USA.
[Emre, Murat] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey.
[Ballard, Clive] Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England.
RP Lane, R (reprint author), Nova Pharmaceut Corp, 59 Route 10, E Hanover, NJ 07936 USA.
EM roger.lane@novartis.com
FU Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Novartis
FX This study was funded by Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA. Novartis sponsored Alpha-Plus Medical Communications
Ltd (UK) to provide editorial assistance with the manuscript.
NR 22
TC 22
Z9 22
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD FEB 15
PY 2009
VL 24
IS 3
BP 392
EP 400
DI 10.1002/mds.22357
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 412TN
UT WOS:000263747200011
PM 19006190
ER
PT J
AU Handforth, A
Martin, FC
Kang, GA
Vanek, Z
AF Handforth, Adrian
Martin, Fredricka C.
Kang, Gail A.
Vanek, Zeba
TI Zonisamide for Essential Tremor: An Evaluator-Blinded Study
SO MOVEMENT DISORDERS
LA English
DT Article
DE essential tremor; zonisamide; clinical trial
ID PLACEBO-CONTROLLED TRIAL
AB In this evaluator-blinded open-treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser (lose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12-week extension phase. The primary efficacy outcome variables were blinded rater videotaped/drawing tremor score changes at the Treatment and Extension visits compared to Baseline, based on Fahn-Tolosa-Marin and Postural Tremor Scales. Subjects also rated Functional Disabilities. Primary outcomes showed reduced tremor scores at the Treatment (P < 0.00001, n = 25) and Extension (n = 16) visits, at mean doses of 252 and 225 mg/day, respectively. Subject ratings indicated 200 mg/day was superior to 100 mg/day, whereas 300 mg/day produced no additional benefit, but instead was associated with more adverse symptoms, most commonly somnolence, poor energy, imbalance, and altered taste. Future double-blind placebo-controlled trials are warranted. (C) 2008 Movement Disorder Society
C1 [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Martin, Fredricka C.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Kang, Gail A.] Vet Affairs San Francisco Med Ctr, Parkinsons Dis Res Educ Clin Ctr, San Francisco, CA USA.
[Vanek, Zeba] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Handforth, A (reprint author), VA Greater Los Angeles, Neurol Serv W127, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM charles.handforth@med.va.gov
FU Veterans Affairs; Ralph M. Parsons Foundation, Los Angeles
FX A.H., F.C.M.. G.A.K. were supported by Veterans Affairs and A.H. by the
Ralph M. Parsons Foundation, Los Angeles. The statistical analysis was
performed by Jeffrey Gornbein, DrPH, UCLA SBCC/Department of
Biomathematics, UCLA David Geffen School of Medicine, Los Angeles.
NR 10
TC 23
Z9 23
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD FEB 15
PY 2009
VL 24
IS 3
BP 437
EP 440
DI 10.1002/mds.22418
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 412TN
UT WOS:000263747200019
PM 19117357
ER
PT J
AU Volpp, KG
Troxel, AB
Pauly, MV
Glick, HA
Puig, A
Asch, DA
Galvin, R
Zhu, JS
Wan, F
DeGuzman, J
Corbett, E
Weiner, J
Audrain-McGovern, J
AF Volpp, Kevin G.
Troxel, Andrea B.
Pauly, Mark V.
Glick, Henry A.
Puig, Andrea
Asch, David A.
Galvin, Robert
Zhu, Jingsan
Wan, Fei
DeGuzman, Jill
Corbett, Elizabeth
Weiner, Janet
Audrain-McGovern, Janet
TI A Randomized, Controlled Trial of Financial Incentives for Smoking
Cessation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID LONG-TERM ABSTINENCE; PREGNANT SMOKERS; TOBACCO USE; HEALTH;
PERFORMANCE; PROGRAMS
AB Background Smoking is the leading preventable cause of premature death in the United States. Previous studies of financial incentives for smoking cessation in work settings have not shown that such incentives have significant effects on cessation rates, but these studies have had limited power, and the incentives used may have been insufficient.
Methods We randomly assigned 878 employees of a multinational company based in the United States to receive information about smoking- cessation programs ( 442 employees) or to receive information about programs plus financial incentives ( 436 employees). The financial incentives were $ 100 for completion of a smoking- cessation program, $ 250 for cessation of smoking within 6 months after study enrollment, as confirmed by a biochemical test, and $ 400 for abstinence for an additional 6 months after the initial cessation, as confirmed by a biochemical test. Individual participants were stratified according to work site, heavy or nonheavy smoking, and income. The primary end point was smoking cessation 9 or 12 months after enrollment, depending on whether initial cessation was reported at 3 or 6 months. Secondary end points were smoking cessation within the first 6 months after enrollment and rates of participation in and completion of smoking- cessation programs.
Results The incentive group had significantly higher rates of smoking cessation than did the information- only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P< 0.001) and 15 or 18 months after enrollment (9.4% vs. 3.6%, P< 0.001). Incentive- group participants also had significantly higher rates of enrollment in a smoking- cessation program (15.4% vs. 5.4%, P< 0.001), completion of a smoking- cessation program (10.8% vs. 2.5%, P< 0.001), and smoking cessation within the first 6 months after enrollment (20.9% vs. 11.8%, P< 0.001).
Conclusions In this study of employees of one large company, financial incentives for smoking cessation significantly increased the rates of smoking cessation. (ClinicalTrials. gov number, NCT00128375.).
C1 [Volpp, Kevin G.; Pauly, Mark V.; Glick, Henry A.; Puig, Andrea; Asch, David A.] Univ Penn, Sch Med, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Pauly, Mark V.; Glick, Henry A.; Puig, Andrea; Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Troxel, Andrea B.; Wan, Fei] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Troxel, Andrea B.; Wan, Fei] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Asch, David A.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Troxel, Andrea B.; Pauly, Mark V.; Glick, Henry A.; Asch, David A.; Zhu, Jingsan; DeGuzman, Jill; Weiner, Janet] Univ Penn, Ctr Hlth Incent, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Glick, Henry A.; Asch, David A.; Zhu, Jingsan; DeGuzman, Jill; Corbett, Elizabeth] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Audrain-McGovern, Janet] Univ Penn, Sch Med, Transdisciplinary Tobacco Use Res Ctr, Dept Psychiat, Philadelphia, PA 19104 USA.
[Galvin, Robert] Gen Elect, Fairfield, CT USA.
[Galvin, Robert] Yale Univ, Sch Med, New Haven, CT USA.
RP Volpp, KG (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM volpp70@wharton.upenn.edu
OI Weiner, Janet/0000-0001-5810-5807; Corbett,
Elizabeth/0000-0002-3552-3181
FU Centers for Disease Control and Prevention [RO1 DP000100-01, RO1
DP001168-01]; Pennsylvania Department of Health; Aetna; Pfizer; General
Electric; America's Health Insurance Plans; Merck; MedStar
FX Supported by grants from the Centers for Disease Control and Prevention
(RO1 DP000100-01 and RO1 DP001168-01) and from the Pennsylvania
Department of Health, which specifically disclaims responsibility for
any analyses, interpretations, or conclusions.; Dr. Volpp reports
receiving lecture fees from Aetna and grant support from Aetna and
Pfizer and owning equity in General Electric; Dr. Pauly, being a board
member of Independent Health, owning equity in General Electric,
receiving lecture fees from America's Health Insurance Plans, and
receiving grant support from Merck and MedStar; Dr. Glick, owning equity
in General Electric; and Dr. Galvin, owning equity in General Electric.
No other potential conflict of interest relevant to this article was
reported.; We thank Quincy Greene for his contributions to the analyses
for this article and Donna Tomlinson, M. D., for assistance in
implementing this study.
NR 27
TC 264
Z9 265
U1 2
U2 41
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 12
PY 2009
VL 360
IS 7
BP 699
EP 709
DI 10.1056/NEJMsa0806819
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 405YQ
UT WOS:000263260500007
PM 19213683
ER
PT J
AU Varkey, AB
Manwell, LB
Williams, ES
Ibrahim, SA
Brown, RL
Bobula, JA
Horner-Ibler, BA
Schwartz, MD
Konrad, TR
Wiltshire, JC
Linzer, M
AF Varkey, Anita B.
Manwell, Linda Baier
Williams, Eric S.
Ibrahim, Said A.
Brown, Roger L.
Bobula, James A.
Horner-Ibler, Barbara A.
Schwartz, Mark D.
Konrad, Thomas R.
Wiltshire, Jacqueline C.
Linzer, Mark
CA Memo Investigators
TI Separate and Unequal Clinics Where Minority and Nonminority Patients
Receive Primary Care
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT 29th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 27-29, 2006
CL Los Angeles, CA
SP Soc Gen Internal Med
ID PHYSICIANS; HEALTH; SATISFACTION; VALIDITY; MODELS
AB Background: Few studies have examined the influence of physician workplace conditions on health care disparities. We compared 96 primary care clinics in New York, New York, and in the upper Midwest serving various proportions of minority patients to determine differences in workplace organizational characteristics.
Methods: Cross-sectional data are from surveys of 96 clinic managers, 388 primary care physicians, and 1701 of their adult patients with hypertension, diabetes mellitus, or congestive heart failure participating in the Minimizing Error, Maximizing Outcome (MEMO) study. Data from 27 clinics with at least 30% minority patients were contrasted with data from 69 clinics with less than 30% minority patients.
Results: Compared with clinics serving less than 30% minority patients, clinics serving at least 30% minority patients have less access to medical supplies (2.7 vs 3.4, P < .001), referral specialists (3.0 vs 3.5, P < .005) on a scale of 1 (none) to 4 (great), and examination rooms per physician (2.2 vs 2.7, P = .002). Their patients are more frequently depressed (22.8% vs 12.1%), are more often covered by Medicaid (30.2% vs 11.4%), and report lower health literacy (3.7 vs 4.4) on a scale of 1 (low) to 5 (high) (P < .001 for all). Physicians from clinics serving higher proportions of minority populations perceive their patients as frequently speaking little or no English (27.1% vs 3.4%, P = .004), having more chronic pain (24.1% vs 12.9%, P < .001) and substance abuse problems (15.1% vs 10.1%, P = .005), and being more medically complex (53.1% vs 39.9%) and psychosocially complex (44.9% vs 28.2%) (P < .001 for both). In regression analyses, clinics with at least 30% minority patients are more likely to have chaotic work environments (odds ratio, 4.0; P = .003) and to have fewer physicians reporting high work control (0.2; P = .003) or high job satisfaction (0.4; P = .01).
Conclusion: Clinics serving higher proportions of minority patients have more challenging workplace and organizational characteristics.
C1 [Varkey, Anita B.] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL USA.
[Varkey, Anita B.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Varkey, Anita B.] Loyola Univ, Med Ctr, Chicago, IL 60611 USA.
[Manwell, Linda Baier; Bobula, James A.] Univ Wisconsin, Dept Family Med, Madison, WI USA.
[Linzer, Mark] Univ Wisconsin, Dept Med, Madison, WI USA.
[Wiltshire, Jacqueline C.] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA.
[Brown, Roger L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Brown, Roger L.] Univ Wisconsin, Sch Nursing, Madison, WI USA.
[Horner-Ibler, Barbara A.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
[Williams, Eric S.] Univ Alabama, Culverhouse Coll Commerce & Business Adm, Dept Management & Mkt, Tuscaloosa, AL USA.
[Ibrahim, Said A.] Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Ibrahim, Said A.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Schwartz, Mark D.] NYU, Sch Med, Dept Med, New York, NY USA.
[Schwartz, Mark D.] Vet Affairs New York Harbor Hlth Care Syst, New York, NY USA.
[Konrad, Thomas R.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA.
RP Varkey, AB (reprint author), Loyola Univ, Med Ctr, Dept Med, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM avarkey@lumc.edu
OI Konrad, Thomas R/0000-0002-5269-0440
FU AHRQ HHS [5R01 HS 011955]
NR 25
TC 53
Z9 53
U1 3
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD FEB 9
PY 2009
VL 169
IS 3
BP 243
EP 250
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 405DK
UT WOS:000263202600006
PM 19204215
ER
PT J
AU Jung-Hynes, B
Nihal, M
Zhong, WX
Ahmad, N
AF Jung-Hynes, Brittney
Nihal, Minakshi
Zhong, Weixiong
Ahmad, Nihal
TI Role of Sirtuin Histone Deacetylase SIRT1 in Prostate Cancer A TARGET
FOR PROSTATE CANCER MANAGEMENT VIA ITS INHIBITION?
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID FORKHEAD TRANSCRIPTION FACTOR; PROMOTES CELL-SURVIVAL; ANDROGEN
RECEPTOR; LIFE-SPAN; FOXO; EXPRESSION; GROWTH; P53; LONGEVITY; DISEASE
AB Prostate cancer (PCa) is a major age-related malignancy, and according to estimates from the American Cancer Society, a man's chance of developing this cancer significantly increases with increasing age, from 1 in 10,149 by age 39 to 1 in 38 by age 59 to 1 in 7 by age 70. Therefore, it is important to identify the causal connection between mechanisms of aging and PCa. Employing in vitro and in vivo approaches, in this study, we tested the hypothesis that SIRT1, which belongs to the Sir2 (silent information regulator 2) family of sirtuin class III histone deacetylases, is overexpressed in PCa, and its inhibition will have antiproliferative effects in human PCa cells. Our data demonstrated that SIRT1 was significantly overexpressed in human PCa cells (DU145, LNCaP, 22Rv1, and PC3) compared with normal prostate epithelial cells (PrEC) at protein, mRNA, and enzymatic activity levels. SIRT1 was also found to be overexpressed in human PCa tissues compared with adjacent normal prostate tissue. Interestingly, our data demonstrated that SIRT1 inhibition via nicotinamide and sirtinol (at the activity level) as well as via short hairpin RNA-mediated RNA interference (at the genetic level) resulted in a significant inhibition in the growth and viability of human PCa cells while having no effect on normal prostate epithelial cells. Further, we found that inhibition of SIRT1 caused an increase in FOXO1 acetylation and transcriptional activation in PCa cells. Our data suggested that SIRT1, via inhibiting FOXO1 activation, could contribute to the development of PCa. We suggest that SIRT1 could serve as a target toward developing novel strategies for PCa management.
C1 [Ahmad, Nihal] Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA.
[Jung-Hynes, Brittney; Ahmad, Nihal] Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA.
[Nihal, Minakshi; Zhong, Weixiong] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA.
[Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.
[Zhong, Weixiong; Ahmad, Nihal] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA.
RP Ahmad, N (reprint author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.
EM nahmad@wisc.edu
FU National Institutes of Health; NIEHS; Molecular and Environmental
Toxicology Center Training [T32ES007015]
FX This work was supported, in whole or in part, by National Institutes of
Health, NIEHS, Molecular and Environmental Toxicology Center Training
Grant T32ES007015 (predoctoral traineeship to B.J.). The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked "advertisement" in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
NR 62
TC 91
Z9 97
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 6
PY 2009
VL 284
IS 6
BP 3823
EP 3832
DI 10.1074/jbc.M807869200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 400MO
UT WOS:000262872500051
PM 19075016
ER
PT J
AU Offner, H
Vandenbark, AA
Hurn, PD
AF Offner, H.
Vandenbark, A. A.
Hurn, P. D.
TI EFFECT OF EXPERIMENTAL STROKE ON PERIPHERAL IMMUNITY: CNS ISCHEMIA
INDUCES PROFOUND IMMUNOSUPPRESSION
SO NEUROSCIENCE
LA English
DT Review
DE stroke; spleen; Treg cells; macrophages; immunosuppression
ID REGULATORY T-CELLS; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM;
MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERFERON-INDUCIBLE PROTEIN-10;
CHEMOKINE RECEPTOR ANTAGONIST; MESSENGER-RNA EXPRESSION; INDUCED
IMMUNODEPRESSION; TRANSCRIPTION FACTOR; LYMPHOCYTE SUBSETS
AB The profound damage to the CNS caused by ischemic lesions has been well documented. Yet, relatively little is known about the contribution to and effects on the immune system during stroke. We have focused on both early and late events in the peripheral immune system during stroke in mice and have observed an early activation of splenocytes that conceivably could result in immune-mediated damage in the developing CNS lesion, followed by global immunosuppression that affects the spleen, thymus, lymph nodes and circulation. While this second immunosuppressive phase may not directly enhance infarction size, it without doubt leads to an inability to respond to antigenic challenges, thereby enhancing the risk for crippling systemic infection and septicemia in stroke survivors. These novel findings advocate the need to develop or effectively utilize agents that can block early neural splenic activation and modulate immune cells specific for brain antigens as a means to prevent mobilization of T and B cells carrying a cytokine death warrant to the brain. Equally important for the recovering stroke patient are approaches that can derail the second phase of immune dysfunction and restore the ability to mount a defense against systemic infectious insults. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Offner, H.; Vandenbark, A. A.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Offner, H.; Vandenbark, A. A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Offner, H.; Hurn, P. D.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Vandenbark, A. A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU US Public Health Service NIH [NS33668, NR03521, NS49210, RR00163];
Biomedical Laboratoty R&D Service, Department of Veterans Affairs
FX The authors wish to thank Ms. Eva Niehaus for assistance in preparing
and submitting the manuscript and Dr. Wenri Zhang and Ms. Susan Parker
for the preparation of cerebral blood flow autoradiography in the SCID
mice. This work was supported by US Public Health Service NIH grants
NS33668, NR03521, NS49210, RR00163, and the Biomedical Laboratoty R&D
Service, Department of Veterans Affairs.
NR 62
TC 104
Z9 113
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD FEB 6
PY 2009
VL 158
IS 3
BP 1098
EP 1111
DI 10.1016/j.neuroscience.2008.05.033
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 409TW
UT WOS:000263529700013
PM 18597949
ER
PT J
AU Yang, JJ
Cohen, A
Hersh, W
AF Yang, Jianji
Cohen, Aaron
Hersh, William
TI Evaluation of a gene information summarization system by users during
the analysis process of microarray datasets
SO BMC BIOINFORMATICS
LA English
DT Article
CT 1st Summit on Translational Bioinformatics
CY MAR 10-12, 2008
CL San Francisco, CA
SP Amer Med Informat Assoc, Int Soc Computat Biol
ID BIOMEDICAL LITERATURE
AB Background: Summarization of gene information in the literature has the potential to help genomics researchers translate basic research into clinical benefits. Gene expression microarrays have been used to study biomarkers for disease and discover novel types of therapeutics and the task of finding information in journal articles on sets of genes is common for translational researchers working with microarray data. However, manually searching and scanning the literature references returned from PubMed is a time-consuming task for scientists. We built and evaluated an automatic summarizer of information on genes studied in microarray experiments. The Gene Information Clustering and Summarization System (GICSS) is a system that integrates two related steps of the microarray data analysis process: functional gene clustering and gene information gathering. The system evaluation was conducted during the process of genomic researchers analyzing their own experimental microarray datasets.
Results: The clusters generated by GICSS were validated by scientists during their microarray analysis process. In addition, presenting sentences in the abstract provided significantly more important information to the users than just showing the title in the default PubMed format.
Conclusion: The evaluation results suggest that GICSS can be useful for researchers in genomic area. In addition, the hybrid evaluation method, partway between intrinsic and extrinsic system evaluation, may enable researchers to gauge the true usefulness of the tool for the scientists in their natural analysis workflow and also elicit suggestions for future enhancements.
Availability: GICSS can be accessed online at: http://ir.ohsu.edu/jianji/index.html
C1 [Yang, Jianji; Cohen, Aaron; Hersh, William] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
[Yang, Jianji] Portland VA Med Ctr, Portland Ctr Evaluat Clin Serv, Portland, OR 97239 USA.
RP Yang, JJ (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
EM jianji.yang2@va.gov; cohenaa@ohsu.edu; hersh@ohsu.edu
OI Hersh, William/0000-0002-4114-5148
FU NLM NIH HHS [1T15 LM009461]
NR 17
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD FEB 5
PY 2009
VL 10
AR S5
DI 10.1186/1471-2105-10-S2-S5
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA 439BS
UT WOS:000265602500006
PM 19208193
ER
PT J
AU Landrigan, CP
Volpp, KG
AF Landrigan, Christopher P.
Volpp, Kevin G.
TI Evidence-Based Evaluation of Physician Work Hour Regulations Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID INTERNS; MORTALITY; REFORM; RISK
C1 [Landrigan, Christopher P.] Brigham & Womens Hosp, Sleep & Patient Safety Program, Boston, MA 02115 USA.
[Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Landrigan, CP (reprint author), Brigham & Womens Hosp, Sleep & Patient Safety Program, 75 Francis St, Boston, MA 02115 USA.
EM volpp70@mail.med.upenn.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 4
PY 2009
VL 301
IS 5
BP 484
EP 485
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 402CS
UT WOS:000262992400012
ER
PT J
AU Higgs, MH
Spain, WJ
AF Higgs, Matthew H.
Spain, William J.
TI Conditional Bursting Enhances Resonant Firing in Neocortical Layer 2-3
Pyramidal Neurons
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE burst; resonance; oscillator; frequency; cortex; pyramidal cell
ID HIGH-FREQUENCY OSCILLATIONS; CAT SENSORIMOTOR CORTEX; WHITE-NOISE
ANALYSIS; IN-VITRO; CORTICAL-NEURONS; SUBTHRESHOLD OSCILLATIONS;
SYNAPTIC-TRANSMISSION; COINCIDENCE DETECTION; EXCITATORY NETWORKS;
DYNAMIC PROPERTIES
AB The frequency response properties of neurons are critical for signal transmission and control of network oscillations. At subthreshold membrane potential, some neurons show resonance caused by voltage-gated channels. During action potential firing, resonance of the spike output may arise from subthreshold mechanisms and/or spike-dependent currents that cause afterhyperpolarizations (AHPs) and afterdepolarizations (ADPs). Layer 2-3 pyramidal neurons (L2-3 PNs) have a fast ADP that can trigger bursts. The present study investigated what stimuli elicit bursting in these cells and whether bursts transmit specific frequency components of the synaptic input, leading to resonance at particular frequencies. We found that two-spike bursts are triggered by step onsets, sine waves in two frequency bands, and noise. Using noise adjusted to elicit firing at similar to 10 Hz, we measured the gain for modulation of the time-varying firing rate as a function of stimulus frequency, finding a primary peak (7-16 Hz) and a high-frequency resonance (250-450 Hz). Gain was also measured separately for single and burst spikes. For a given spike rate, bursts provided higher gain at the primary peak and lower gain at intermediate frequencies, sharpening the high-frequency resonance. Suppression of bursting using automated current feedback weakened the primary and high-frequency resonances. The primary resonance was also influenced by the SK channel-mediated medium AHP (mAHP), because the SK blocker apamin reduced the sharpness of the primary peak. Our results suggest that resonance in L2-3 PNs depends on burst firing and the mAHP. Bursting enhances resonance in two distinct frequency bands.
C1 [Higgs, Matthew H.; Spain, William J.] Vet Affairs Puget Sound Hlth Care Syst, Neurol Sect, Seattle, WA 98018 USA.
[Higgs, Matthew H.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Spain, William J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
RP Spain, WJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Neurol Sect, Mail Stop 127,1660 S Columbian Way, Seattle, WA 98018 USA.
EM spain@u.washington.edu
FU BLRD VA [I01 BX000386]
NR 82
TC 39
Z9 40
U1 0
U2 2
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD FEB 4
PY 2009
VL 29
IS 5
BP 1285
EP 1299
DI 10.1523/JNEUROSCI.3728-08.2009
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 403GZ
UT WOS:000263072400005
PM 19193876
ER
PT J
AU Krumholz, HM
Ross, JS
AF Krumholz, Harlan M.
Ross, Joseph S.
TI Relationships with the drug industry: More regulation, greater
transparency
SO BRITISH MEDICAL JOURNAL
LA English
DT Editorial Material
C1 [Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Dept Med,Sect Hlth Policy & Adm,Sch Publ Hlth, New Haven, CT 06520 USA.
[Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
[Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, Bronx, NY USA.
RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Sect Cardiovasc Med, POB 208088, New Haven, CT 06520 USA.
EM harlan.krumholz@yale.edu
NR 7
TC 5
Z9 5
U1 1
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-8146
J9 BRIT MED J
JI Br. Med. J.
PD FEB 3
PY 2009
VL 338
AR b211
DI 10.1136/bmj.b211
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 414OX
UT WOS:000263876200004
PM 19193612
ER
PT J
AU Machida, K
Tsukamoto, H
Mkrtchyan, H
Duan, L
Dynnyk, A
Liu, HM
Asahina, K
Govindarajan, S
Raye, R
Ou, JJ
Seki, E
Deshaies, R
Miyake, K
Lai, MMC
AF Machida, Keigo
Tsukamoto, Hidekazu
Mkrtchyan, Hasmik
Duan, Lewei
Dynnyk, Alla
Liu, Helene Minyi
Asahina, Kinji
Govindarajan, Sugantha
Raye, Ratna
Ou, Jing-hsiung James
Seki, Ekihiro
Deshaies, Raymond
Miyake, Kensuke
Lai, Michael M. -C.
TI Toll-like receptor 4 mediates synergism between alcohol and HCV in
hepatic oncogenesis involving stem cell marker Nanog
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID VIRUS CORE PROTEIN; NONSTRUCTURAL 5A PROTEIN; C VIRUS;
HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; VIRAL-HEPATITIS; TRANSGENIC
MICE; UP-REGULATION; LIVER; ACTIVATION
AB Alcohol synergistically enhances the progression of liver disease and the risk for liver cancer caused by hepatitis C virus (HCV). However, the molecular mechanism of this synergy remains unclear. Here, we provide the first evidence that Toll-like receptor 4 (TLR4) is induced by hepatocyte-specific transgenic (Tg) expression of the HCV nonstructural protein NS5A, and this induction mediates synergistic liver damage and tumor formation by alcohol-induced endotoxemia. We also identify Nanog, the stem/progenitor cell marker, as a novel downstream gene up-regulated by TLR4 activation and the presence of CD133/Nanog-positive cells in liver tumors of alcohol-fed NS5A Tg mice. Transplantation of p53-deficient hepatic progenitor cells transduced with TLR4 results in liver tumor development in mice following repetitive LPS injection, but concomitant transduction of Nanog short-hairpin RNA abrogates this outcome. Taken together, our study demonstrates a TLR4-dependent mechanism of synergistic liver disease by HCV and alcohol and an obligatory role for Nanog, a TLR4 downstream gene, in HCV-induced liver oncogenesis enhanced by alcohol.
C1 [Machida, Keigo; Tsukamoto, Hidekazu; Mkrtchyan, Hasmik; Dynnyk, Alla; Asahina, Kinji; Govindarajan, Sugantha; Ou, Jing-hsiung James] Univ So Calif, Keck Sch Med, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, Los Angeles, CA 90033 USA.
[Machida, Keigo; Duan, Lewei; Liu, Helene Minyi; Ou, Jing-hsiung James; Lai, Michael M. -C.] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
[Tsukamoto, Hidekazu; Govindarajan, Sugantha] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
[Tsukamoto, Hidekazu] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90033 USA.
[Raye, Ratna] St Louis Univ, Dept Pathol, St Louis, MO 63103 USA.
[Seki, Ekihiro] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Deshaies, Raymond] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.
[Deshaies, Raymond] CALTECH, Div Biol, Pasadena, CA 91125 USA.
[Miyake, Kensuke] Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan.
[Lai, Michael M. -C.] Natl Cheng Kung Univ, Dept Microbiol Immunol, Tainan 701, Taiwan.
RP Machida, K (reprint author), Univ So Calif, Keck Sch Med, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, 2011 Zonal Ave, Los Angeles, CA 90033 USA.
EM kmachida@usc.edu
RI Lai, Michael Ming-Chao/I-7001-2012; Deshaies, Raymond/B-8354-2014; Seki,
Ekihiro/K-2481-2016
OI Deshaies, Raymond/0000-0002-3671-9354; LIU, HELENE
MINYI/0000-0003-4837-5373
FU pilot project; National Institute on Alcohol Abuse and
Alcoholism/National Institutes of Health (NIAAA/NIH) [P50 AA011999, AI
40038, CA123328, CA108302]; Medical Research Service of the Veterans
Administration
FX We thank Qing-gao Deng, Jiaohong Wang, Sean Vorah, and Jeffrey Huang
(University of Southern California) for mouse experiments; Michael Karin
(University of California at San Diego) for discussions; Paul Robson
(Genome Institute of Singapore, Immunos, Singapore) for Nanog-promoter
luciferase construct; Steven Weinman (University of Texas) for
suggestions; and Moli Chen and Alex Trana for histological service. The
study was supported by pilot project funding; the Animal and Morphology
Cores of the Southern California Research Center for ALPD & Cirrhosis
(P50 AA011999) funded by the National Institute on Alcohol Abuse and
Alcoholism/National Institutes of Health (NIAAA/NIH); NIH Grants AI
40038, CA123328, and CA108302; and the Medical Research Service of the
Veterans Administration.
NR 34
TC 117
Z9 129
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 3
PY 2009
VL 106
IS 5
BP 1548
EP 1553
DI 10.1073/pnas.0807390106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 403HV
UT WOS:000263074600048
PM 19171902
ER
PT J
AU Perez, VI
Van Remmen, H
Bokov, A
Epstein, CJ
Vijg, J
Richardson, A
AF Perez, Viviana I.
Van Remmen, Holly
Bokov, Alex
Epstein, Charles J.
Vijg, Jan
Richardson, Arlan
TI The overexpression of major antioxidant enzymes does not extend the
lifespan of mice
SO AGING CELL
LA English
DT Editorial Material
DE aging; antioxidant enzymes; transgenic and knockout mice
ID MANGANESE SUPEROXIDE-DISMUTASE; ADULT DROSOPHILA-MELANOGASTER;
UBIQUITOUS OVEREXPRESSION; TRANSGENIC MICE; EXPRESSION; CATALASE
AB We evaluated the effect of overexpressing antioxidant enzymes on the lifespans of transgenic mice that overexpress copper zinc superoxide dismutase (CuZnSOD), catalase, or combinations of either CuZnSOD and catalase or CuZnSOD and manganese superoxide dismutase (MnSOD). Our results show that the overexpression of these major antioxidant enzymes, which are known to scavenge superoxide and hydrogen peroxide in the cytosolic and mitochondrial compartments, is insufficient to extend lifespan in mice.
C1 [Perez, Viviana I.; Van Remmen, Holly; Bokov, Alex; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Perez, Viviana I.; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Van Remmen, Holly; Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Van Remmen, Holly; Richardson, Arlan] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Epstein, Charles J.] Univ Calif San Francisco, Inst Human Genet, Sch Med, San Francisco, CA 94143 USA.
[Epstein, Charles J.] Univ Calif San Francisco, Dept Pediat, Sch Med, San Francisco, CA 94143 USA.
[Vijg, Jan] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA.
RP Richardson, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM richardsona@uthscsa.edu
FU NIA NIH HHS [1P30-AG-13319, P01 AG019316, P01-AG-19316, P30 AG013319,
R37 AG026557, R37-AG026557]
NR 18
TC 145
Z9 145
U1 1
U2 13
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD FEB
PY 2009
VL 8
IS 1
BP 73
EP 75
DI 10.1111/j.1474-9726.2008.00449.x
PG 3
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 400ON
UT WOS:000262877900008
PM 19077044
ER
PT J
AU Simpson, TL
Saxon, AJ
Meredith, CW
Malte, CA
McBride, B
Ferguson, LC
Gross, CA
Hart, KL
Raskind, M
AF Simpson, Tracy L.
Saxon, Andrew J.
Meredith, Charles W.
Malte, Carol A.
McBride, Brittney
Ferguson, Laura C.
Gross, Christopher A.
Hart, Kim L.
Raskind, Murray
TI A Pilot Trial of the Alpha-1 Adrenergic Antagonist, Prazosin, for
Alcohol Dependence
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Noradrenergic; Prazosin; Alcohol Dependence; Human Clinical Trial
ID RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER;
PLACEBO-CONTROLLED TRIAL; DISULFIRAM TREATMENT; DOUBLE-BLIND;
GENDER-DIFFERENCES; DRINKING; ETHANOL; NOREPINEPHRINE; ABSTINENCE
AB Current medications for alcohol dependence (AD) show only modest efficacy. None target brain noradrenergic pathways. Theory and preclinical evidence suggest that noradrenergic circuits may be involved in alcohol reinforcement and relapse. We therefore tested the alpha-1 adrenergic receptor antagonist, prazosin, as a pharmacotherapy for AD.
We randomized 24 participants with AD but without posttraumatic stress disorder to receive either prazosin or placebo in a 6-week, double-blind pilot study. Medication was titrated to a target dose of 4 mg QAM, 4 mg QPM, and 8 mg QHS by the end of week 2. Participants received 5 medical management treatment sessions. Participants were reminded 3 times each day via a text pager to take medications and to call a telephone monitoring system once daily to provide self-reports of alcohol consumption and craving, the primary outcome measures. Results were analyzed using mixed linear regression adjusted for drinking days per week at baseline and week number.
Twenty of the 24 (83%) subjects completed. Among the completers, the prazosin group reported fewer drinking days per week than the placebo group during the final 3 weeks of the study. Since only 1 woman was randomized to placebo and only three women completed the trial, the following results focus on the 17 male completers. The prazosin group reported fewer drinking days per week and fewer drinks per week during the final 3 weeks of the study; average total number of drinking days for the placebo group 5.7 (SEM 1.9) versus 0.9 (SEM 0.5) for the prazosin group, and average total number of drinks 20.8 (SEM 6.5) for the placebo group versus 2.6 (SEM 1.3) for the prazosin group. Rates of adverse events were equivalent across conditions.
Prazosin holds promise as a pharmacologic treatment for AD and deserves further evaluation in a larger controlled trial.
C1 [Simpson, Tracy L.; Saxon, Andrew J.; Malte, Carol A.; McBride, Brittney] Univ Washington, Ctr Excellence Substance Abuse Treatment Educ, Seattle, WA 98195 USA.
[Simpson, Tracy L.; Meredith, Charles W.; Ferguson, Laura C.; Gross, Christopher A.; Hart, Kim L.; Raskind, Murray] Univ Washington, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98195 USA.
Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Simpson, Tracy L.; Saxon, Andrew J.; Meredith, Charles W.; Ferguson, Laura C.; Gross, Christopher A.; Raskind, Murray] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Simpson, TL (reprint author), 1660 S Columbian Way,116-ATC-S, Seattle, WA 98108 USA.
EM Tracy.Simpson@va.gov
FU University of Washington's Alcohol and Drug Abuse Institute
FX The funding for this study was provided by the VA Puget Sound Health
Care System, Seattle, Washington Center of Excellence in Substance Abuse
Treatment and Education and by a grant from the University of
Washington's Alcohol and Drug Abuse Institute. The authors wish to thank
the following individuals for the invaluable assistance with this
project: Lynne Hyerle, M.A., Norah Sullivan, ARNP, David Hoff, PA, Craig
Jaffe, MD, and Kathleen Ang Lee, MD.
NR 63
TC 72
Z9 73
U1 1
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD FEB
PY 2009
VL 33
IS 2
BP 255
EP 263
DI 10.1111/j.1530-0277.2008.00807.x
PG 9
WC Substance Abuse
SC Substance Abuse
GA 397KS
UT WOS:000262662200007
PM 18945226
ER
PT J
AU Suhrie, EM
Hanlon, JT
Jaffe, EJ
Sevick, MA
Ruby, CM
Aspinall, SL
AF Suhrie, Erin M.
Hanlon, Joseph T.
Jaffe, Emily J.
Sevick, Mary Ann
Ruby, Christine M.
Aspinall, Sherrie L.
TI Impact of a Geriatric Nursing Home Palliative Care Service on
Unnecessary Medication Prescribing
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article
DE palliative care; unnecessary drug use; Medication Appropriateness Index;
geriatrics
ID ADVERSE DRUG EVENTS; OLDER-PEOPLE; HOSPICE CARE; APPROPRIATENESS;
POLYPHARMACY; MANAGEMENT; QUALITY; LIFE; THERAPY; PAIN
AB Background: There is a lack of studies concerning improvement of medication use in palliative care patients in nursing homes.
Objective: This study was conducted to evaluate whether a geriatric palliative care team reduced unnecessary medication prescribing for elderly veterans residing in a nursing home.
Methods: This was a retrospective, descriptive study of patients who died while residing in a geriatric palliative care unit between August 1, 2005, and July 31, 2007. Prescribed medications were evaluated using the Unnecessary Drug Use Measure, which contains 3 items from the Medication Appropriateness Index concerning lack of indication, lack of effectiveness, and therapeutic duplication. This measure was applied at 2 time points: on transfer/admission to the palliative care unit and at the last 30-day pharmacist medication review before death. Paired t tests and McNemar tests were used to compare medication use at these 2 points.
Results: Eighty-nine patients were included in the study. The majority were male (97.8%) and white (78.7%), with a mean (SD) age of 79.7 (7.8) years. The median length of stay on the unit was 39.0 days, and the mean number of chronic medical conditions was 8.4 (4.3). At baseline, the mean number of scheduled medications was 9.7 (4.3). The number Of unnecessary medications per patient decreased from a mean of 1.7 (1.5) at admission to 0.6 (0.8) at closeout (P = 0.003). The decrease was seen in all 3 categories of the Unnecessary Drug Use Measure.
Conclusions: The geriatric palliative care team was associated with a reduction in the number of unnecessary medications prescribed for older veterans in this nursing home. Future studies should evaluate the impact of decreasing unnecessary prescribing on clinical outcomes such as adverse drug reactions. (Am J Geriatr Pharmacother. 2009;7:20-25) (C) 2009 Excerpta Medica Inc.
C1 [Hanlon, Joseph T.; Sevick, Mary Ann; Aspinall, Sherrie L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Suhrie, Erin M.] VA Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA 15206 USA.
[Hanlon, Joseph T.; Ruby, Christine M.; Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
[Hanlon, Joseph T.; Jaffe, Emily J.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA.
[Hanlon, Joseph T.; Jaffe, Emily J.; Ruby, Christine M.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, Pittsburgh, PA USA.
[Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Sevick, Mary Ann] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Aspinall, Sherrie L.] Hines VA Med Ctr, VA Ctr Medicat Safety, Hines, IL USA.
RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot 151CH, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM sherrie.aspinall@va.gov
FU National Institutes of Health [P30AGO24827, ROIAGO27017]; Veterans
Affairs Health Services Research and Development [IIR-06-062]
FX This study was supported in part by National Institutes of Health grants
P30AGO24827 and ROIAGO27017 and Veterans Affairs Health Services
Research and Development grant IIR-06-062 to Dr. Hanlon. The authors
thank Yazan Rournard, NIS, MBA, for statistical support.
NR 21
TC 18
Z9 19
U1 1
U2 7
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD FEB
PY 2009
VL 7
IS 1
BP 20
EP 25
DI 10.1016/j.amjopharm.2009.02.001
PG 6
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 413RK
UT WOS:000263810000003
PM 19281937
ER
PT J
AU Spira, AP
Stone, K
Beaudreau, SA
Ancoli-Israel, S
Yaffe, K
AF Spira, Adam P.
Stone, Katie
Beaudreau, Sherry A.
Ancoli-Israel, Sonia
Yaffe, Kristine
TI Anxiety Symptoms and Objectively Measured Sleep Quality in Older Women
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT 60th Annual Meeting of the Gerontological-Society-of-America
CY NOV 16-20, 2007
CL San Francisco, CA
SP Gerontol Soc Amer
DE Anxiety; sleep; older adults; depression; actigraphy
ID OUTPATIENT ELECTIVE SURGERY; COGNITIVE FUNCTION; ADULTS; POPULATION;
PREVALENCE; DISORDERS; LIFE; DISTURBANCES; INFLAMMATION; DEPRESSION
AB Objectives: Few studies have examined the association between anxiety symptoms and objectively measured sleep quality in older adults. The authors determined this association in a large cohort of very old community-dwelling women. Design: Cross-sectional. Setting: Participants' homes, sites of the Study of Osteoporotic Fractures. Participants: Three thousand forty women (mean age: 83.6 years) enrolled in a prospective study of aging. Measurements: Participants completed the Goldberg Anxiety Scale (ANX), the 15-item Geriatric Depression Scale (GDS), and >= 3 nights of actigraphy-a method of measuring sleep by recording wrist movement with a device called an actigraph. Elevated anxiety symptoms were defined as ANX >= 6. Elevated depressive symptoms were defined as GDS >= 6. Results: Participants' mean ANX score was 1.4 (standard deviation: 2.2); 9.2% (N = 280) had ANX >= 6. Elevated anxiety symptoms were associated with greater odds of poor sleep efficiency (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 1.34, 2.23) and time awake after sleep onset (OR: 1.64, 95% CI: 1.27, 2.11). Associations remained after adjustment for GDS >= 6, antianxiety medications, and other potential confounders (sleep efficiency OR: 1.50, 95% CI: 1.15, 1.97; time awake after sleep onset OR: 1.33, 95% CI: 1.01, 1.75). Anxiety symptoms were not associated with other sleep parameters. Conclusion: Findings suggest that elevated anxiety symptoms are independently associated with poor objectively measured sleep efficiency and elevated sleep fragmentation in very old women, after accounting for significant depressive symptoms, medical comorbidities, and use of antianxiety medications. (Am J Geriatr Psychiatry 2009; 17:136-143)
C1 [Spira, Adam P.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Spira, Adam P.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Spira, Adam P.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Stone, Katie] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Beaudreau, Sherry A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Beaudreau, Sherry A.] Sierra Pacific Mental Illness Res Educ & Clin Ctr, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Ancoli-Israel, Sonia] San Diego Vet Affairs Healthcare Syst, San Diego, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
RP Spira, AP (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,Hampton House,Room 794, Baltimore, MD 21205 USA.
EM aspira@jhsph.edu
FU NIA NIH HHS [R01 AG027576-24, R01 AG005407, 2 R01 AG027574-22A1, R01
AG005407-23, 2 R01 AG005394-22A1, R01 AG005394-24, T32 AG000212-14, R01
AG027574-24, R01 AG005394, AG05407, R01 AG027574, R01 AG027576-22, L30
AG030938, R01 AG027576, L30 AG030938-01, T32 AG000212, AG05394]; NIAMS
NIH HHS [AR35582, R01 AR035582, R01 AR035584-21, R01 AR035584, R01
AR035583, AR35584, AR35583]
NR 41
TC 22
Z9 23
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD FEB
PY 2009
VL 17
IS 2
BP 136
EP 143
DI 10.1097/JGP.0b013e3181871345
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 548DC
UT WOS:000273938800006
PM 19155746
ER
PT J
AU Gehrman, PR
Connor, DJ
Martin, JL
Shochat, T
Corey-Bloom, J
Ancoli-Israel, S
AF Gehrman, Philip R.
Connor, Donald J.
Martin, Jennifer L.
Shochat, Tamar
Corey-Bloom, Jody
Ancoli-Israel, Sonia
TI Melatonin Fails to Improve Sleep or Agitation in Double-Blind Randomized
Placebo-Controlled Trial of Institutionalized Patients With Alzheimer
Disease
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer; sleep; agitation; melatonin; dementia
ID CIRCADIAN-RHYTHMS; NURSING-HOME; DEMENTIA
AB Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation. Design: Randomized, placebo-controlled study. Setting: Nursing homes in San Diego, CA, metropolitan area. Participants: Subjects were patients with probable Alzheimer disease. Intervention: Melatonin (8.5 mg immediate release and 1.5 mg sustained release) (N = 24) or placebo (N = 17) administered at 10: 00 P. M. for 10 consecutive nights. The protocol consisted of baseline (3 days), treatment (10 days), and posttreatment (5 days) phases. Measurements: Sleep was measured continuously using actigraphy. Agitation was rated using both the Agitated Behavior Rating Scale and the Cohen-Mansfield Agitation Inventory. Treatment effects were examined both across the 24-hr day and separately by nursing shift. Results: There were no significant effects of melatonin, compared with placebo, on sleep, circadian rhythms, or agitation. Conclusion: This study failed to find a beneficial effect of exogenous melatonin, consistent with a number of other studies. The lack of efficacy may be related to the absence of a true treatment effect or to the superphysiologic dose of melatonin used. (Am J Geriatr Psychiatry 2009; 17:166-169)
C1 [Gehrman, Philip R.] Hosp Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Connor, Donald J.] Cleo Roberts Ctr Clin Res, Sun Hlth Res Inst, Sun City, AZ USA.
[Martin, Jennifer L.] Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Shochat, Tamar] Univ Haifa, Dept Nursing, IL-31999 Haifa, Israel.
[Corey-Bloom, Jody; Ancoli-Israel, Sonia] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Corey-Bloom, Jody] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
RP Ancoli-Israel, S (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,Mail Code 0603, La Jolla, CA 92093 USA.
EM sancoliisrael@ucsd.edu
FU NIA [AG08415, P50 AG05131, K23 AG028452]; Research Service of the
Veterans Affairs San Diego Healthcare System
FX This study was supported by NIA AG08415 (to SAI), P50 AG05131, NIA K23
AG028452 (to JLM) and the Research Service of the Veterans Affairs San
Diego Healthcare System.
NR 10
TC 63
Z9 67
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD FEB
PY 2009
VL 17
IS 2
BP 166
EP 169
DI 10.1097/JGP.0b013e318187de18
PG 4
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 548DC
UT WOS:000273938800009
PM 19155748
ER
PT J
AU Ullian, ME
Beck, CN
Walker, LP
Fitzgibbon, WR
Morinelli, TA
AF Ullian, Michael E.
Beck, C. Nicole
Walker, Linda P.
Fitzgibbon, Wayne R.
Morinelli, Thomas A.
TI Thiol Antioxidants Regulate Angiotensin II AT1 and Arginine Vasopressin
V1 Receptor Functions Differently in Vascular Smooth Muscle Cells
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; EXTRACELLULAR
DOMAINS; DISULFIDE BRIDGES; OXIDATIVE STRESS; LIGAND-BINDING; RAT;
IDENTIFICATION; RESIDUES; TRANSACTIVATION
AB BACKGROUND
We compared the effects of the sulfhydryl-containing (thiol) antioxidant dithiothreitol (DTT), which disrupts disulfide bonds, on cell signaling through angiotensin II (Angll) Type 1 receptors (AT1Rs) and arginine vasopressin (AVP)V1 receptors (V1Rs). The AT1R contains two extracellular disulfides bonds but its ligand contains none, whereas the V1R contains no extracellular disufides bonds but its ligand contains 1.
METHODS
We measured radioligand binding, intracellular calcium responses, and extracellular signal-regulated kinase phosphorylation in cultured rat aortic vascular smooth muscle cells and alterations in urine osmolality in intact rats.
RESULTS
Preincubation of cells with DTT, a maneuver designed to target receptor disulfides, resulted in concentration-dependent decreases in specific (125)I-Angll binding to AT1Rs and acute angiotensin-stimulated intracellular calcium mobilization but no decreases in specific (125)I-AVP binding to V1Rs or AVP-stimulated intracellular calcium mobilization. In contrast, preincubation of the ligands with DTT followed by acute exposure to the cells, a maneuver designed to target ligand disulfides, blunted calcium mobilization to AVP robustly but to Angll only minimally. In intact rats, the increase in urine osmolality caused by subcutaneous injection with the AVP analogue desmopressin was significantly diminished when the analogue was preincubated with an excess of DTT.
CONCLUSION
DTT inhibits cell signaling to Angll AT1Rs and AVPV1Rs, at least in part through disruption of disulfide linkages, but the pattern of response depends upon whether disulfides of ligand or receptor are targeted.
C1 [Ullian, Michael E.; Beck, C. Nicole; Walker, Linda P.; Fitzgibbon, Wayne R.; Morinelli, Thomas A.] Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
RP Ullian, ME (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
EM ullianme@musc.edu
FU Dialysis Clinic Incorporation, Nashville, TN
FX These results were reported in preliminary form at the annual meetings
of the American Society of Nephrology in San Diego, CA (November 2006)
and in San Francisco, CA (November 2007). These studies were supported
by funds from Dialysis Clinic Incorporation, Nashville, TN.
NR 29
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0895-7061
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD FEB
PY 2009
VL 22
IS 2
BP 221
EP 227
DI 10.1038/ajh.2008.323
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 395PZ
UT WOS:000262537300019
PM 19039312
ER
PT J
AU Risa, KJ
McAndrew, JM
Muder, RR
AF Risa, Kathleen J.
McAndrew, Janet M.
Muder, Robert R.
TI Influenza outbreak management on a locked behavioral health unit
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
ID CARE WORKERS; VACCINATION; DISORDERS; SERVICES
AB Background: In January 2006, 8 patients on a locked behavioral health (BH) ward were identified with influenza-like illness (ILI) based on syndrome of fever. malaise, myalgia, cough, and rhinitis. Two patients initially had rapid antigen testing positive for influenza and confirmed by polymerase chain reaction. All patients present on the ward (N = 26) had been ordered influenza immunizations 6 weeks earlier: 46% (12/26) were immunized, 42% (11/26) refused, 12% (3126) had no record of immunization. All direct care staff who worked on the unit during the outbreak had been offered immunizations in the fall: 55% (22/40) were immunized.
Methods: When first symptoms were identified, provider notified infection control nurse and hospital epidemiologist, who instituted control measures: patients were confined to unit, unit was closed to admissions, nonimmunized asymptomatic patients were offered immunization, temperatures were recorded every 4 hours, and nonimmunized providers were offered immunizations and prophylaxis. Patients with ILI were either admitted to acute care and placed in Droplet/Contact Precautions until afebrile for 48 hours or managed on the unit with modified isolation. All patients remaining on the unit were instructed in hand hygiene and respiratory etiquette: asymptomatic patients were offered oseltamivir phosphate prophylaxis; and previously nonimmunized patients and staff were again offered the vaccine.
Results: Twenty-six patients and 28 staff were on the unit during the outbreak. Eight patients and 8 staff members reported ILI within 5 days. Of the ill patients, 3 had been immunized, 5 had not (2 refused, 3 reason unclear presumed to have refused), and 4 were admitted to acute care and placed in Droplet/Contact Precautions until asymptomatic for 48 hours. Of 22 patients who remained on the unit. 4 were symptomatic: 18 asymptomatic patients took prophylaxis, and I refused 8 (89%) patients who had earlier refused vaccine were immunized. Of the 40 staff members, 55% (22/40) were immunized, and 20% (8/40) were symptomatic (all presumptive, encouraged to remain off duty). Fifty percent (4/8) of symptomatic staff had been immunized. After 7 days, no new cases had been identified, and the unit was reopened to admissions. No ill effects resulted from the prophylaxis.
Conclusion: Prompt detection of ILI and institution of control measures effectively contained the outbreaks the relatively high immunization rates among both patients and staff helped curtail spread. Refusal of immunization is a long-standing problem among BH patients and staff. Our study shows importance of immunization in preventing outbreaks in inpatient BH settings. Recommendations included development of more aggressive immunization campaign for patients and staff who historically refuse and continued high priority for provider vigilance in immunization campaign and surveillance for symptoms. (Am J Infect Control 2009;37:76-8.)
C1 [Muder, Robert R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM Robert.Muder@va.gov
NR 13
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD FEB
PY 2009
VL 37
IS 1
BP 76
EP 78
DI 10.1016/j.ajic.2008.05.008
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 409BI
UT WOS:000263480800013
PM 18945518
ER
PT J
AU Khurana, SR
Bamer, AM
Turner, AP
Wadhwani, RV
Bowen, JD
Leipertz, SL
Haselkorn, JK
AF Khurana, Seema R.
Bamer, Alyssa M.
Turner, Aaron P.
Wadhwani, Rohini V.
Bowen, James D.
Leipertz, Steve L.
Haselkorn, Jodie K.
TI The Prevalence of Overweight and Obesity in Veterans with Multiple
Sclerosis
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Multiple Sclerosis; Body Mass Index; Obesity; Overweight; Health Status
ID BODY-MASS INDEX; SELF-REPORTED HEIGHT; UNITED-STATES;
GENDER-DIFFERENCES; DISEASE; EXERCISE; WEIGHT; ADULTS; RISK; POPULATION
AB Objectives: To estimate the prevalence and factors associated with overweight and obesity in veterans with multiple sclerosis (MS) enrolled in the Veterans Health Administration (VA) and to compare the prevalence in this group with gender-specific published rates for the general population of veterans receiving outpatient care at VA medical facilities.
Design: Cross-sectional cohort study linking electronic medical record information to mailed survey from 1999 to 2004. A total of 4703 veterans with MS enrolled in VA who returned questionnaires as part of two cross-sectional studies. Main outcome measures included body mass index, demographic information, Veteran RAND 36-item Health Survey, frequency of physical exercise, and other health conditions.
Results: Overall, 28% of female and 42.8% of male veterans with MS were overweight. Another 25% of women and 21.2% of male veterans met the criteria for obesity. Compared with a historical cohort of veterans enrolled in the VA, veterans with MS had a slightly higher adjusted prevalence of overweight than did veterans in general (42.3% vs. 39.6%, respectively) but a lower adjusted prevalence of obesity (20.1% vs. 33.1%). In adjusted logistic regression, age, smoking, and lower levels of pain were associated with a lower likelihood of overweight or obesity. Being male, married, employed and having arthritis and diabetes were associated with a greater likelihood of overweight or obesity.
Conclusions: Overweight and obesity are a problem for more than 60% of veterans with MS in the VA. Screening for overweight and obesity should be done routinely. Interventions to prevent and manage excessive weight in individuals with MS should be developed and evaluated.
C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA.
[Khurana, Seema R.] Univ Miami, Dept Rehabil Med, Coral Gables, FL 33124 USA.
[Bamer, Alyssa M.; Turner, Aaron P.; Wadhwani, Rohini V.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Turner, Aaron P.; Leipertz, Steve L.; Haselkorn, Jodie K.] VA MS Ctr Excellence W, Seattle, WA USA.
[Bowen, James D.] Evergreen Hosp, Multiple Sclerosis Ctr, Washington, DC USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117,1660 S Columbian Way, Seattle, WA 98108 USA.
OI Turner, Aaron/0000-0001-6897-8003
FU Department of Veterans Affairs Rehabilitation Research and Development
Service Career Development Award [B4927W]; VA Center of Excellence in
Substance Abuse Treatment and Education; VA MS Center of Excellence
West; VA Office of Quality and Performance; National Institute on
Disability and Rehabilitation Research, Department of Education
[H13313031129]
FX This research was supported by Department of Veterans Affairs
Rehabilitation Research and Development Service Career Development Award
(B4927W) to Aaron Turner, Phl). Additional support was provided by the
VA Center of Excellence in Substance Abuse Treatment and Education, the
VA MS Center of Excellence West, and the VA Office of Quality and
Performance. Additional support was also provided by a grant from the
National Institute on Disability and Rehabilitation Research, Department
of Education (Grant #H13313031129).
NR 35
TC 32
Z9 32
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD FEB
PY 2009
VL 88
IS 2
BP 83
EP 91
DI 10.1097/PHM.0b013e318194f8b5
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 398NX
UT WOS:000262739900001
PM 19169174
ER
PT J
AU Kurahashi, K
Sawa, T
Ota, M
Kajikawa, O
Hong, K
Martin, TR
Wiener-Kronish, JP
AF Kurahashi, Kiyoyasu
Sawa, Teiji
Ota, Maria
Kajikawa, Osamu
Hong, Keelung
Martin, Thomas R.
Wiener-Kronish, Jeanine P.
TI Depletion of phagocytes in the reticuloendothelial system causes
increased inflammation and mortality in rabbits with Pseudomonas
aeruginosa pneumonia
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE counterregulatory response; bacterial clearance; macrophages
ID TUMOR-NECROSIS-FACTOR; RETICULO-ENDOTHELIAL SYSTEM; CONTINUOUS
MECHANICAL VENTILATION; ALVEOLAR EPITHELIAL INJURY; NOSOCOMIAL
PNEUMONIA; FACTOR-ALPHA; HOST-DEFENSE; NITRIC-OXIDE; IN-VITRO;
UNANESTHETIZED SHEEP
AB Kurahashi K, Sawa T, Ota M, Kajikawa O, Hong K, Martin TR, Wiener-Kronish JP. Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 296: L198-L209, 2009. First published November 21, 2008; doi:10.1152/ajplung.90472.2008.-Phagocytes of the reticuloendothelial system are important in clearing systemic infection; however, the role of the reticuloendothelial system in the response to localized infection is not well-documented. The major goals of this study were to investigate the roles of phagocytes in the reticuloendothelial system in terms of bacterial clearance and inflammatory modulation in sepsis caused by Pseudomonas pneumonia. Macrophages in liver and spleen were depleted by administering liposome encapsulated dichloromethylene diphosphonate (clodronate) intravenously 36 h before the instillation of Pseudomonas aeruginosa into the lungs of anesthetized rabbits. Blood samples were analyzed for bacteria and cytokine concentrations. Lung injury was assessed by the bidirectional flux of albumin and by wet-to-dry weight ratios. Blood pressure and cardiac outputs decreased more rapidly and bacteremia occurred earlier in the clodronate-treated rabbits compared with the nondepleted rabbits. Plasma TNF-alpha (1.08 +/- 0.54 vs. 0.08 +/- 0.02 ng/ml) and IL-8 (6.8 +/- 1.5 vs. 0.0 +/- 0.0 ng/ml) were higher in the depleted rabbits. The concentration of IL-10 in liver of the macrophage-depleted rabbits was significantly lower than in normal rabbits at 5 h. Treatment of macrophage-depleted rabbits with intravenous IL-10 reduced plasma proinflammatory cytokine concentrations and reduced the decline in blood pressure and cardiac output. These results show that macrophages in the reticuloendothelial system have critical roles in controlling systemic bacteremia and reducing systemic inflammation, thereby limiting the systemic effects of a severe pulmonary bacterial infection.
C1 [Kurahashi, Kiyoyasu] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan.
[Kurahashi, Kiyoyasu; Sawa, Teiji; Ota, Maria] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA.
[Kurahashi, Kiyoyasu; Kajikawa, Osamu; Martin, Thomas R.] Univ Washington, Sch Med, Med Res Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Kurahashi, Kiyoyasu; Kajikawa, Osamu; Martin, Thomas R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Hong, Keelung] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.
[Wiener-Kronish, Jeanine P.] Univ Calif San Francisco, Dept Med, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.
[Wiener-Kronish, Jeanine P.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
RP Kurahashi, K (reprint author), Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM kiyok@med.yokohama-cu.ac.jp
FU National Institutes of Health (NIH) [HL-49810, HL-55980, HL-30542,
AI-29103, GM-37696, HL-073996]; Yokohama Foundation for Advancement of
Medical Science; Yokohama Academic Foundation
FX This study was supported, in part, by the National Institutes of Health
(NIH) Grants HL-49810 and HL-55980 (to J.P. Wiener-Kronish), the NIH
Grants HL-30542, AI-29103, GM-37696, and HL-073996 (to T. R. Martin),
the Yokohama Foundation for Advancement of Medical Science (to K.
Kurahashi), and the Yokohama Academic Foundation (to K. Kurahashi).
NR 69
TC 10
Z9 10
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD FEB
PY 2009
VL 296
IS 2
BP L198
EP L209
DI 10.1152/ajplung.90472.2008
PG 12
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA 399CP
UT WOS:000262778300007
PM 19028978
ER
PT J
AU Ricono, JM
Wagner, B
Gorin, Y
Arar, M
Kazlauskas, A
Choudhury, GG
Abboud, HE
AF Ricono, Jill M.
Wagner, Brent
Gorin, Yves
Arar, Mazen
Kazlauskas, Andrius
Choudhury, Goutam Ghosh
Abboud, Hanna E.
TI PDGF receptor-beta modulates metanephric mesenchyme chemotaxis induced
by PDGF AA
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE reactive oxygen species; calcium
ID CARDIAC SARCOPLASMIC-RETICULUM; SMOOTH-MUSCLE-CELLS; PROTEASE-ACTIVATED
LIGAND; GROWTH-FACTOR RECEPTORS; AKT/PROTEIN KINASE-B;
SIGNAL-TRANSDUCTION; MESANGIAL CELLS; ALPHA-RECEPTOR; HYDROGEN-PEROXIDE;
OXYGEN RADICALS
AB Ricono JM, Wagner B, Gorin Y, Arar M, Kazlauskas A, Choudhury GG, Abboud HE. PDGF receptor-beta modulates metanephric mesenchyme chemotaxis induced by PDGF AA. Am J Physiol Renal Physiol 296: F406-F417, 2009. First published November 19, 2008; doi:10.1152/ajprenal.90368.2008.-PDGF B chain or PDGF receptor (PDGFR)-beta-deficient (-/-) mice lack mesangial cells. To study responses of alpha- and beta-receptor activation to PDGF ligands, metanephric mesenchymal cells (MMCs) were established from embryonic day E11.5 wild-type (+/+) and -/- mouse embryos. PDGF BB stimulated cell migration in +/+ cells, whereas PDGF AA did not. Conversely, PDGF AA was chemotactic for -/- MMCs. The mechanism by which PDGFR-beta inhibited AA-induced migration was investigated. PDGF BB, but not PDGF AA, increased intracellular Ca(2+) and the production of reactive oxygen species (ROS) in +/+ cells. Transfection of -/- MMCs with the wild-type beta-receptor restored cell migration and ROS generation in response to PDGF BB and inhibited AA-induced migration. Inhibition of Ca(2+) signaling facilitated PDGF AA-induced chemotaxis in the wild-type cells. The antioxidant N-acetyl-L-cysteine (NAC) or the NADPH oxidase inhibitor diphenyleneiodonium (DPI) abolished the BB-induced increase in intracellular Ca(2+) concentration, suggesting that ROS act as upstream mediators of Ca(2+) in suppressing PDGF AA-induced migration. These data indicate that ROS and Ca(2+) generated by active PDGFR-beta play an essential role in suppressing PDGF AA-induced migration in +/+ MMCs. During kidney development, PDGFR beta-mediated ROS generation and Ca(2+) influx suppress PDGF AA-induced chemotaxis in metanephric mesenchyme.
C1 [Wagner, Brent] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA.
[Ricono, Jill M.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
[Arar, Mazen] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
[Wagner, Brent; Choudhury, Goutam Ghosh; Abboud, Hanna E.] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA.
[Kazlauskas, Andrius] Harvard Univ, Sch Med, Schepens Eye Inst, Boston, MA USA.
RP Wagner, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM wagnerb@uthscsa.edu
OI Gorin, Yves/0000-0003-4048-6925
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK-33665, DK-50190, DK-55815]; National American Heart Association;
Juvenile Diabetes Research Foundation Regular Research Grant; National
Kidney Foundation Young Investigator Award; National Kidney Foundation
of South and Central Texas; Department of Veterans Affairs Merit Review
grant; Department of Veterans Affairs Research Career Scientist Award;
National Institutes of Health Loan Repayment Program; American Heart
Association Fellow-to-Faculty Transition Award.
FX These studies were supported by National Institute of Diabetes and
Digestive and Kidney Diseases Grants DK-33665 (H. E. Abboud), DK-50190,
and DK-55815 (G. G. Choudhury). Y. Gorin is supported through a
Scientist Development Grant from the National American Heart
Association, a Juvenile Diabetes Research Foundation Regular Research
Grant, a National Kidney Foundation Young Investigator Award, and a
National Kidney Foundation of South and Central Texas, Research Program
Award. G. G. Choudbury is supported by a Department of Veterans Affairs
Merit Review grant, Regular Research Grant from the Juvenile Diabetes
Research Foundation, and by a Department of Veterans Affairs Research
Career Scientist Award. B. Wagner is the recipient of the National
Institutes of Health Loan Repayment Program, National Kidney Foundation
Research Fellowship, National Kidney Foundation Jack C. Kent Third Year
Research Fellowship, and an American Heart Association Fellow-to-Faculty
Transition Award.
NR 64
TC 9
Z9 9
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD FEB
PY 2009
VL 296
IS 2
BP F406
EP F417
DI 10.1152/ajprenal.90368.2008
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 399EH
UT WOS:000262782700022
PM 19019919
ER
PT J
AU Karlawish, J
Rubright, J
Casarett, D
Cary, M
Ten Have, T
Sankar, P
AF Karlawish, Jason
Rubright, Jonathan
Casarett, David
Cary, Mark
Ten Have, Thomas
Sankar, Pamela
TI Older Adults' Attitudes Toward Enrollment of Non-competent Subjects
Participating in Alzheimer's Research
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID INFORMED CONSENT; DISEASE PATIENTS; CLINICAL-TRIAL; PROXY CONSENT;
DECISION; CAPACITY; ETHICS; HEALTH; VIEWS; RISK
AB Objective: Research that seeks to enroll noncompetent patients with Alzheimer's disease without presenting any potential benefit to participants is the source of substantial ethical controversy. The authors used hypothetical Alzheimer's disease studies that included either a blood draw or a blood draw and lumbar puncture to explore older persons' attitudes on this question.
Method: Face-to-face interviews were conducted with 538 persons age 65 and older. Questions explored participants' understanding of research concepts, their views on enrolling persons with Alzheimer's disease in research, and their preferences regarding having a proxy decision maker, granting advance consent, and granting their proxy leeway to override the participant's decision. Additional questions assessed altruism, trust, value for research, and perceptions of Alzheimer's disease.
Results: The majority (83%) were willing to grant advance consent to a blood draw study, and nearly half (48%) to a blood draw plus lumbar puncture study. Most (96%) were willing to identify a proxy for research decision making, and most were willing to grant their proxy leeway over their advance consent: 81% for the blood draw study and 70% for the blood draw plus lumbar puncture study. Combining the preferences for advance consent and leeway, the proportion who would permit being enrolled in the blood draw and lumbar puncture studies, respectively, were 92% and 75%. Multivariate models showed that willingness to be enrolled in research was most strongly associated with a favorable attitude toward biomedical research.
Conclusions: Older adults generally support enrolling noncompetent persons with Alzheimer's disease into research that does not present a benefit to subjects. Willingness to grant their proxy leeway over advance consent and a favorable attitude about biomedical research substantially explain this willingness.
C1 [Karlawish, Jason] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA.
Univ Penn, Div Geriatr, Leonard Davis Inst Hlth Econ, Ctr Bioeth,Ctr Clin Epidemiol & Biostat,Alzheimer, Philadelphia, PA 19104 USA.
Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Karlawish, J (reprint author), Univ Penn, Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM jason.karlawish@uphs.upenn.edu
FU NIMH [R01 MH-071643]
FX Supported by NIMH grant R01 MH-071643, a Greenwall Faculty Scholars
Award in Bioethics to Dr. Karlawish, and the Marian S. Ware Alzheimer
Program. The authors thank James Beaver, Paige Brookstein, Maysa
DeSousa, Lauren Fisher, Kristin Harkins, Margaret Rice, Samantha
Schwartz, and Elizabeth Taylor for their assistance in data collection.
NR 28
TC 32
Z9 32
U1 0
U2 7
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD FEB
PY 2009
VL 166
IS 2
BP 182
EP 188
DI 10.1176/appi.ajp.2008.08050645
PG 7
WC Psychiatry
SC Psychiatry
GA 402RT
UT WOS:000263031500011
PM 18923066
ER
PT J
AU Choi, JE
Lee, SS
Sunde, DA
Huizar, I
Haugk, KL
Thannickal, VJ
Vittal, R
Plymate, SR
Schnapp, LM
AF Choi, Jung-Eun
Lee, Sung-soon
Sunde, Donald A.
Huizar, Isham
Haugk, Kathy L.
Thannickal, Victor J.
Vittal, Ragini
Plymate, Stephen R.
Schnapp, Lynn M.
TI Insulin-like Growth Factor-I Receptor Blockade Improves Outcome in Mouse
Model of Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE insulin-like growth factor; lung injury; lung fibrosis
ID RESPIRATORY-DISTRESS-SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; IGF-I;
PULMONARY-FIBROSIS; SIGNALING PATHWAYS; MULTIPLE-MYELOMA; CROSS-TALK;
CELLS; EXPRESSION; MICE
AB Rationale: The insulin-like growth factor-I (IGF-I) pathway is an important determinant of survival and proliferation in many cells. However, little is known about the role of the IGF-I pathway in lung injury. We previously showed elevated levels of IGF-I in bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome. Furthermore, immunodepletion of IGF from acute respiratory distress syndrome bronchoalveolar lavage increased fibroblast apoptosis.
Objectives: We examined the effect of blockade of type 1 IGF tyrosine kinase receptor (IGF-IR) in a murine model of bleomycin-induced lung injury and fibrosis.
Methods: Mice were treated with a monoclonal antibody against the IGF-I receptor (A12) or vehicle after intratracheal bleomycin instillation.
Measurements and Main Results: Mice treated with All 2 antibody had significantly improved survival after bleomycin injury compared with control mice. Both groups of mice had a similar degree of fibrosis on days 7 and 14, but by Day 28 the A12-treated group had significantly less fibrosis. Delayed treatment with All 2 also resulted in decreased fibrosis. A12-treated mice had significantly decreased apoptotic cells on Day 28 compared with control mice. We confirmed that A12 treatment induced mouse lung fibroblast apoptosis in vitro. In addition, IGF-I increased lung fibroblast migration. The primary pathway activated by IGF-I in lung fibroblasts was the insulin receptor substrate-2/phosphatidylinositol 3-kinase/Akt axis.
Conclusions: IGF-I regulated survival and migration of fibrogenic cells in the lung. Blockade of the IGF pathway increased fibroblast apoptosis and subsequent resolution of pulmonary fibrosis. Thus, IGF-IR may be a potential target for treatment of lung injury and fibrosis.
C1 [Choi, Jung-Eun; Lee, Sung-soon; Sunde, Donald A.; Huizar, Isham; Schnapp, Lynn M.] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA.
[Haugk, Kathy L.; Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Thannickal, Victor J.; Vittal, Ragini] Univ Michigan, Med Ctr, Dept Med, Div Pulm Med, Ann Arbor, MI 48109 USA.
RP Schnapp, LM (reprint author), Box 358052,815 Mercer St, Seattle, WA 98109 USA.
EM lschnapp@u.washington.edu
NR 36
TC 30
Z9 32
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2009
VL 179
IS 3
BP 212
EP 219
DI 10.1164/rccm.200802-228OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 398ML
UT WOS:000262736100006
PM 19011156
ER
PT J
AU McEvoy, MD
Sabbagh, MJ
Taylor, AG
Zavadzkas, JA
Koval, CN
Stroud, RE
Ford, RL
McLean, JE
Reeves, ST
Mukherjee, R
Spinale, FG
AF McEvoy, Matthew D.
Sabbagh, Michel J.
Taylor, Anna Greta
Zavadzkas, Juozas A.
Koval, Christine N.
Stroud, Robert E.
Ford, Rachael L.
McLean, Julie E.
Reeves, Scott T.
Mukherjee, Rupak
Spinale, Francis G.
TI Aprotinin Modifies Left Ventricular Contractility and Cytokine Release
After Ischemia-Reperfusion in a Dose-Dependent Manner in a Murine Model
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS;
MYOCARDIAL-INFARCTION; INJURY; HEART; RISK; METAANALYSIS; INHIBITION;
NEUTROPHIL
AB BACKGROUND: Periods of ischemia-reperfusion (I/R) during cardiac surgery are associated with transient left ventricular (LV) dysfunction and an inflammatory response. In this study, we examined the potential dose-dependent effects of aprotinin (APRO) on LV contractility and cytokine release in the setting of I/R.
METHODS: An index of LV contractility, LV maximal elastance (E(max)), was measured at baseline, 30 min of ischemia, and 60 min of reperfusion by microtransducer volumetry. Mice were randomized as follows: (a) APRO 20,000 kallikrein-inhibiting units (KIU)/kg (n = 11); (b) APRO 4 x 10(4) KIU/kg (n = 10); (c) APRO 8 x 10(4) KIU/kg (n = 10); and (d) vehicle (saline; n = 10). APRO doses were calculated to reflect half, full, and twice the clinical Hammersmith closing schedule. After I/R, plasma was collected for cytokine measurements.
RESULTS: After I/R, E(max) decreased from the baseline value by more than 40% in the vehicle group as well as in the APRO 4 x 10(4) KIU/kg and APRO 8 x 10(4) KIU/kg groups (P < 0.05). However, E(max) returned to near baseline values in the APRO 2 x 10(4) KIU/kg group. Tumor necrosis factor (TNF) increased 10-fold after I/R, but it was reduced with higher APRO doses.
CONCLUSIONS: This study demonstrated that a low dose of APRO provided protective effects on LV contractility, whereas higher doses suppressed TNF release. These unique findings suggest that there are distinct and independent mechanisms of action of APRO in the context of I/R.
C1 [Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Cardiothorac Surg, Charleston, SC 29403 USA.
[McEvoy, Matthew D.; Sabbagh, Michel J.; Taylor, Anna Greta; Reeves, Scott T.] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA.
[Spinale, Francis G.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Dept Cardiothorac Surg, 114 Doughty St,Rm 625, Charleston, SC 29403 USA.
EM wilburnm@musc.edu
FU National Heart, Lung, and Blood Institute [PO1-HL-48788, RO1-HL-59165];
Research Service of the Department of Veterans Affairs; Bayer
Pharmaceuticals; Foundation for Anesthesia Education and Research
FX Supported by National Heart, Lung, and Blood Institute Grants
PO1-HL-48788, RO1-HL-59165, Research Service of the Department of
Veterans Affairs, Research Fellowships from Bayer Pharmaceuticals, and
the Foundation for Anesthesia Education and Research.
NR 27
TC 6
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD FEB
PY 2009
VL 108
IS 2
BP 399
EP 406
DI 10.1213/ane.0b013e31818cdb13
PG 8
WC Anesthesiology
SC Anesthesiology
GA 396KG
UT WOS:000262590000003
PM 19151263
ER
PT J
AU Sonnen, JA
Larson, EB
Gray, SL
Wilson, A
Kohama, SG
Crane, PK
Breitner, JCS
Montine, TJ
AF Sonnen, Joshua A.
Larson, Eric B.
Gray, Shelly L.
Wilson, Angela
Kohama, Steven G.
Crane, Paul K.
Breitner, John C. S.
Montine, Thomas J.
TI Free Radical Damage to Cerebral Cortex in Alzheimer's Disease,
Microvascular Brain Injury, and Smoking
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID ALPHA-TOCOPHEROL; VITAMIN-E; DEMENTIA; F-2-ISOPROSTANES; SUPPRESSION;
SUPPLEMENTS; INCREASE; TRIAL; RISK
AB Evidence supports a pathogenic role for free radical injury to brain in Alzheimer's disease; however, clinical trial results are only mildly encouraging. Examining brains from The Adult Changes in Thought study offers a unique perspective. Selectively increased free radical damage to cerebral cortex was associated with Alzheimer's disease, microvascular brain injury, and current smoking, but not with antioxidant supplement usage. Our results support suppression of free radical injury to brain as a therapeutic target for Alzheimer's disease and microvascular brain injury; however, future clinical trials should consider other antioxidants or doses than those identified in our study.
C1 [Sonnen, Joshua A.; Wilson, Angela; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Gray, Shelly L.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA.
[Kohama, Steven G.] Oregon Natl Primate Res Ctr, Beaverton, OR USA.
[Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Breitner, John C. S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Breitner, John C. S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Sonnen, JA (reprint author), 11838 22nd Ave SW, Seattle, WA 98146 USA.
EM jsonnen@u.washington.edu
RI Crane, Paul/C-8623-2014; Sonnen, 37382016/H-3738-2016
OI Sonnen, 37382016/0000-0001-9267-8705; Crane, Paul/0000-0003-4278-7465
FU NIH [AG23801, AG05136, AG006781, AG 000258]; Nancy and Buster Alvord
Endowment
FX This work was Supported by NIH AG23801, (T.J.M.) NIH AG05136, NIH
AG006781, (E.B.L.) NIH AG 000258, and the Nancy and Buster Alvord
Endowment (T.J.M.).
NR 15
TC 32
Z9 32
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD FEB
PY 2009
VL 65
IS 2
BP 226
EP 229
DI 10.1002/ana.21508
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 415KM
UT WOS:000263932700017
PM 19259965
ER
PT J
AU Baldwin, SW
Heinze, EM
Chan, G
Hansen, J
Clements, J
Nishimura, R
Reeves, M
Weisbart, R
AF Baldwin, S. W.
Heinze, E. M.
Chan, G.
Hansen, J.
Clements, J.
Nishimura, R.
Reeves, M.
Weisbart, R.
TI Antibody-Mediated FoxP3 Protein Therapy Induces Apoptosis in Cancer
Cells In Vitro and Inhibits Metastasis In Vivo
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Baldwin, S. W.; Reeves, M.] Loma Linda VAMC, Loma Linda, CA 91342 USA.
[Heinze, E. M.; Chan, G.; Hansen, J.; Clements, J.; Weisbart, R.] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA.
[Nishimura, R.] Olive View Univ Calif Los Angeles Med Ctr, Sylmar, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2009
VL 16
SU 1
BP 37
EP 38
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA V16GF
UT WOS:000207857400116
ER
PT J
AU Lohavanichbutr, P
Houck, J
Fan, WH
Yueh, B
Mendez, E
Futran, N
Doody, DR
Upton, MP
Farwell, DG
Schwartz, SM
Zhao, LP
Chen, C
AF Lohavanichbutr, Pawadee
Houck, John
Fan, Wenhong
Yueh, Bevan
Mendez, Eduardo
Futran, Neal
Doody, David R.
Upton, Melissa P.
Farwell, D. Gregory
Schwartz, Stephen M.
Zhao, Lue Ping
Chen, Chu
TI Genomewide Gene Expression Profiles of HPV-Positive and HPV-Negative
Oropharyngeal Cancer Potential Implications for Treatment Choices
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMAS; HUMAN
BREAST-CANCER; PROGNOSTIC-FACTOR; NECK-CANCER; HEAD; SENSITIVITY; RISK;
STATHMIN; E6
AB Objective: To study the difference in gene expression between human papillomavirus (HPV)-positive and HPV-negative oral cavity and oropharyngeal squamous cell carcinoma (OSCC).
Design: We used Affymetrix U133 plus 2.0 arrays to examine gene expression profiles of OSCC and normal oral tissue. The HPV DNA was detected using polymerase chain reaction followed by the Roche LINEAR ARRAY HPV Genotyping Test, and the differentially expressed genes were analyzed to examine their potential biological roles using the Ingenuity Pathway Analysis Software, version 5.0.
Setting: Three medical centers affiliated with the University of Washington.
Patients: A total of 119 patients with primary OSCC and 35 patients without cancer, all of whom were treated at the setting institutions, provided tissues samples for the study.
Results: Human papillomavirus DNA was found in 41 of 119 tumors (34.5%) and 2 of 35 normal tissue samples (5.7%); 39 of the 43 HPV specimens were HPV-16. A higher prevalence of HPV DNA was found in oropharyngeal cancer (23 of 31) than in oral cavity cancer (18 of 88). We found no significant difference in gene expression between HPV-positive and HPV-negative oral cavity cancer but found 446 probe sets (347 known genes) differentially expressed in HPV-positive oropharyngeal cancer than in HPV-negative oropharyngeal cancer. The most prominent functions of these genes are DNA replication, DNA repair, and cell cycling. Some genes differentially expressed between HPV-positive and HPV-negative oropharyngeal cancer (eg, TYMS, STMN1, CCND1, and RBBP4) are involved in chemotherapy or radiation sensitivity.
Conclusion: These results suggest that differences in the biology of HPV-positive and HPV-negative oropharyngeal cancer may have implications for the management of patients with these different tumors.
C1 [Lohavanichbutr, Pawadee; Houck, John; Mendez, Eduardo; Doody, David R.; Schwartz, Stephen M.; Zhao, Lue Ping; Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA.
[Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Biostat & Biomath, Seattle, WA 98109 USA.
[Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA.
[Mendez, Eduardo] Vet Affairs Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
[Farwell, D. Gregory] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Davis, CA 95616 USA.
[Mendez, Eduardo; Futran, Neal; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Mail Stop M5-C800,1100 Fairview Ave N, Seattle, WA 98109 USA.
EM cchen@fhcrc.org
OI Yueh, Bevan/0000-0003-1380-1053
FU National Cancer Institute [R01CA095419]
FX This study was supported by grant R01CA095419 from the National Cancer
Institute (Dr Chen).
NR 24
TC 60
Z9 61
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0886-4470
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD FEB
PY 2009
VL 135
IS 2
BP 180
EP 188
PG 9
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 407QQ
UT WOS:000263379800012
PM 19221247
ER
PT J
AU Cohen, AN
Veena, MS
Srivatsan, ES
Wang, MB
AF Cohen, Alen N.
Veena, Mysore S.
Srivatsan, Eri S.
Wang, Marilene B.
TI Suppression of Interleukin 6 and 8 Production in Head and Neck Cancer
Cells With Curcumin via Inhibition of I kappa beta Kinase
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID B KINASE; TRANSCRIPTION FACTOR; CYTOKINE EXPRESSION; TUMOR-GROWTH;
CARCINOMA; SURVIVAL; ACTIVATION; PROLIFERATION; ANGIOGENESIS;
DIFERULOYLMETHANE
AB Objectives: To evaluate the effect of curcumin on production of interleukin 6 (IL-6) and 8 (IL-8) in head and neck squamous cell carcinoma (HNSCC) cell lines and to determine the mechanism by which these effects are modulated. Curcumin suppression of HNSCC is believed to be partly due to inhibition of the transcription factor nuclear factor-kappa beta (NF-kappa beta). Interleukin 6 and IL-8 are cytokines induced by NF-kappa beta activation with elevated levels in the serum of patients with HNSCC.
Design: We treated HNSCC cell lines CCL23, CAL27, UM-SCC1, and UM-SCC14A with increasing doses of curcumin and measured IL-6 and IL-8 levels using an enzyme-linked immunosorbent assay.
Setting: Levels of NF-omicron beta, I kappa beta kinase (IKK), and phosphorylated I kappa beta were analyzed bymeans of Western blot. The IKK activity was measured in UM-SCC14A cells using an IKK-specific I kappa beta alpha substrate after treatment with curcumin.
Main Outcome Measures: Reverse transcription polymerase chain reaction was performed to determine the effect of curcumin on the expression of IL-6 and IL-8.
Results: Curcumin treatment resulted in dose-dependent inhibition of IL-6 and IL-8 in all cell lines. All cell lines had similar NF-kappa beta levels; however, UM-SCC1 and UM-SCC14A had significantly higher I kappa beta kinase levels and required considerably higher doses of curcumin before inhibition of IL-6 and IL-8 occurred. Curcumin treatment resulted in inhibition of IKK activity and inhibition of IL-6 and IL-8 expression.
Conclusions: Curcumin significantly reduces IL-6 and IL-8 levels in HNSCC cell lines. This mechanism appears to be mediated via inhibition of I kappa beta-kinase activity in the NF-kappa beta pathway. Interleukins 6 and 8 have potential use as biomarkers to measure the efficacy of treatment with curcumin.
C1 [Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Los Angeles, CA 90095 USA.
[Veena, Mysore S.; Srivatsan, Eri S.; Wang, Marilene B.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
RP Wang, MB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Room CHS 62-132,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mbwang@ucla.edu
FU University of California, Los Angeles, Academic Senate; Veterans Affairs
Merit; National Cancer Institute [CA116826]
FX This study was supported by a grant from the University of California,
Los Angeles, Academic Senate (Dr Wang), a Veterans Affairs Merit Grant
(Dr Srivatsan), and grant CA116826 from the National Cancer Institute(Dr
Wang).
NR 34
TC 27
Z9 28
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0886-4470
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD FEB
PY 2009
VL 135
IS 2
BP 190
EP 197
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 407QQ
UT WOS:000263379800013
PM 19221248
ER
PT J
AU Saha, S
AF Saha, Somnath
TI Rectifying Institutional Bias in Medical Research
SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE
LA English
DT Editorial Material
ID CANCER CLINICAL-TRIALS; CONSPIRACY BELIEFS; AFRICAN-AMERICANS; RACE; AGE
C1 Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA.
RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd P3HSRD, Portland, OR 97239 USA.
EM sahas@ohsu.edu
NR 14
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 1072-4710
J9 ARCH PEDIAT ADOL MED
JI Arch. Pediatr. Adolesc. Med.
PD FEB
PY 2009
VL 163
IS 2
BP 181
EP 182
PG 2
WC Pediatrics
SC Pediatrics
GA 402CM
UT WOS:000262991800013
PM 19188652
ER
PT J
AU Silber, JH
Rosenbaum, PR
Romano, PS
Rosen, AK
Wang, YL
Teng, Y
Halenar, MJ
Even-Shoshan, O
Volpp, KG
AF Silber, Jeffrey H.
Rosenbaum, Paul R.
Romano, Patrick S.
Rosen, Amy K.
Wang, Yanli
Teng, Yun
Halenar, Michael J.
Even-Shoshan, Orit
Volpp, Kevin G.
TI Hospital Teaching Intensity, Patient Race, and Surgical Outcomes
SO ARCHIVES OF SURGERY
LA English
DT Article
ID QUALITY-OF-CARE; ACUTE MYOCARDIAL-INFARCTION; CLINICAL COMORBIDITY
INDEX; ICD-9-CM ADMINISTRATIVE DATA; DUTY HOUR REFORM; HEALTH-CARE;
MEDICARE BENEFICIARIES; NONTEACHING HOSPITALS; ADVERSE EVENTS; BLACK
PATIENTS
AB Objectives: To determine if the lower mortality often observed in teaching-intensive hospitals is because of lower complication rates or lower death rates after complications (failure to rescue) and whether the benefits at these hospitals accrue equally to white and black patients, since black patients receive a disproportionate share of their care at teaching-intensive hospitals.
Design: A retrospective study of patient outcomes and teaching intensity using logistic regression models, with and without adjusting for hospital fixed and random effects.
Setting: Three thousand two hundred seventy acute care hospitals in the United States.
Patients: Medicare claims on general, orthopedic, and vascular surgery admissions in the United States for 20002005 (N = 4 658 954 unique patients).
Main Outcome Measures: Thirty-day mortality, in-hospital complications, and failure to rescue (the probability of death following complications).
Results: Combining all surgeries, compared with non-teaching hospitals, patients at very major teaching hospitals demonstrated a 15% lower odds of death (P < .001), no difference in complications, and a 15% lower odds of death after complications (failure to rescue) (P < .001). These relative benefits associated with higher resident-to-bed ratio were not experienced by black patients, for whom the odds of mortality and failure to rescue were similar at teaching and non-teaching hospitals, a pattern that is significantly different from that of white patients (P < .001).
Conclusions: Survival after surgery is higher at hospitals with higher teaching intensity. Improved survival is because of lower mortality after complications (better failure to rescue) and generally not because of fewer complications. However, this better survival and failure to rescue at teaching-intensive hospitals is seen for white patients, not for black patients.
C1 [Silber, Jeffrey H.; Wang, Yanli; Teng, Yun; Even-Shoshan, Orit] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.] Univ Penn, Dept Crit Care, Philadelphia, PA 19104 USA.
[Halenar, Michael J.; Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Hlth Care Syst, Philadelphia, PA 19104 USA.
[Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA.
[Silber, Jeffrey H.; Even-Shoshan, Orit; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Halenar, Michael J.; Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Romano, Patrick S.] Univ Calif Davis, Sch Med, Div Gen Med, Sacramento, CA 95817 USA.
[Romano, Patrick S.] Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA.
[Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Rosen, Amy K.] Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Ste 1029, Philadelphia, PA 19104 USA.
EM silberj@wharton.upenn.edu
RI Rosenbaum, Paul/H-8687-2012; Romano, Patrick/N-4225-2014
OI Romano, Patrick/0000-0001-6749-3979; Halenar,
Michael/0000-0002-8703-3811
FU National Heart, Lung, and Blood Institute [R01 HL082637]; Department of
Veterans Affairs [IIR 04-202]; National Science Foundation [SES 0646002]
FX This work was funded through National Heart, Lung, and Blood Institute
grant R01 HL082637, Department of Veterans Affairs grant IIR 04-202, and
National Science Foundation grant SES 0646002.
NR 52
TC 74
Z9 74
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD FEB
PY 2009
VL 144
IS 2
BP 113
EP 120
PG 8
WC Surgery
SC Surgery
GA 407QP
UT WOS:000263379700004
PM 19221321
ER
PT J
AU Sugimoto, M
Yamaoka, Y
AF Sugimoto, Mitsushige
Yamaoka, Yoshio
TI Virulence factor genotypes of Helicobacter pylori affect cure rates of
eradication therapy
SO ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
LA English
DT Review
DE Helicobacter pylori; eradication therapy; virulence factor; cagA; vacA;
tailored regimen
ID GASTRIC-ACID-SECRETION; PROTON PUMP INHIBITOR; ANTIBIOTIC-RESISTANCE
PATTERNS; RANDOMIZED CONTROLLED-TRIAL; CAG PATHOGENICITY ISLAND; ADULT
DYSPEPTIC PATIENTS; OUTER-MEMBRANE PROTEINS; TRIPLE THERAPY; VACUOLATING
CYTOTOXIN; NONULCER DYSPEPSIA
AB The cure rates of Helicobacter pylori infection by using a combination of a proton pump inhibitor (PPI) and antimicrobial agents are mainly influenced by bacterial susceptibility to antimicrobial agents and the magnitude of acid inhibition during the treatment. Currently used empirical triple therapies do not reliably produce a a parts per thousand yen80% cure rate on an intention-to-treat basis. Therefore, tailored regimens based on relevant microbiological findings and pharmacogenomics are recommended for attaining an acceptable a parts per thousand yen95% cure rate. Recently, virulence factors of H. pylori, such as cagA and vacA, are reported to be major factors determining the cure rates. Individuals infected with strains with cagA-negative and vacA s2 genotypes have significantly increased risk of eradication failure of H. pylori infection. These virulence factors enhance gastric mucosal inflammation and are associated with the development of peptic ulcer and gastric cancer. H. pylori virulence factors induce proinflammatory cytokines, such as interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)- which influence mucosal inflammation and/or gastric acid secretion. When physicians select an H. pylori eradication regimen with an acceptable cure rate, they might need to consider H. pylori virulence factors, especially cagA and vacA.
C1 [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
Baylor Coll Med, Houston, TX 77030 USA.
RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,111D Rm 3A-320, Houston, TX 77030 USA.
EM yyamaoka@bcm.tmc.edu
FU National Institutes of Health (NIH) [R01 DK62813]
FX The project described was supported by Grant No. R01 DK62813 from the
National Institutes of Health (NIH). Its contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the NIH.
NR 105
TC 29
Z9 34
U1 1
U2 2
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 0004-069X
J9 ARCH IMMUNOL THER EX
JI Arch. Immunol. Ther. Exp.
PD FEB
PY 2009
VL 57
IS 1
BP 45
EP 56
DI 10.1007/s00005-009-0007-z
PG 12
WC Immunology
SC Immunology
GA 409NI
UT WOS:000263512000006
PM 19219527
ER
PT J
AU Nareika, A
Sundararaj, KP
Im, YB
Game, BA
Lopes-Virella, MF
Huang, Y
AF Nareika, Alena
Sundararaj, Kamala P.
Im, Yeong-Bin
Game, Bryan A.
Lopes-Virella, Maria F.
Huang, Yan
TI High glucose and interferon gamma synergistically stimulate MMP-1
expression in U937 macrophages by increasing transcription factor STAT1
activity
SO ATHEROSCLEROSIS
LA English
DT Article
DE Diabetes mellitus; Glucose; Atherosclerosis; Interferon gamma;
Inflammation; Matrix metalloproteinase
ID MATRIX METALLOPROTEINASE-1 EXPRESSION; CARDIOVASCULAR-DISEASE;
DIABETES-MELLITUS; PLAQUE RUPTURE; HISTIOCYTES; LIPOPOLYSACCHARIDE;
ATHEROSCLEROSIS; MECHANISMS
AB Recent diabetes control and complications trial and epidemiology of diabetes interventions and complications (DCCT/EDIC) and other clinical studies have reported that glucose control in patients with diabetes leads to a significant reduction of cardiovascular events and atherosclerosis, indicating that hyperglycemia plays an essential role in cardiovascular disease in diabetic patients. Although several mechanisms by which hyperglycemia promotes atherosclerosis have been proposed, it remains unclear how hyperglycemia promotes atherosclerosis by interaction with inflammatory cytokines. To test our hypothesis that hyperglycemia interplays with interferon gamma (IFN gamma), a key factor involved in atherosclerosis, to up-regulate the expression of genes such as matrix metalloproteinases (MMPs) and cytokines that are involved in plaque destabilization, U937 macrophages cultured in medium containing either normal or high glucose were challenged with IFN gamma and the expression of MMPs and cytokines were then quantified by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Results showed that high glucose and IFN gamma had a synergistic effect on the expression of MMP-1, MMP-9 and IL-1 beta. High glucose also enhanced IFN gamma-induced priming effect on lipopolysaccharide (LPS)-stimulated MMP-1 secretion. Furthermore, high glucose and IFN gamma exert the synergistic effect on MMP-1 expression by enhancing STAT1 phosphorylation and STAT1 transcriptional activity. In summary, this study revealed a novel mechanism potentially involved in diabetes-promoted cardiovascular disease. Published by Elsevier Ireland Ltd.
C1 [Game, Bryan A.; Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Nareika, Alena; Sundararaj, Kamala P.; Im, Yeong-Bin; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
RP Huang, Y (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU Department of Veterans Affairs; NIH [DE 16353]
FX This work was supported by a Merit Review Grant from Department of
Veterans Affairs and NIH grant DE 16353 (to Y.H.).
NR 22
TC 15
Z9 16
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2009
VL 202
IS 2
BP 363
EP 371
DI 10.1016/j.atherosclerosis.2008.05.043
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 408HY
UT WOS:000263427300007
PM 18586252
ER
PT J
AU Hammad, SM
Twal, WO
Barth, JL
Smith, KJ
Saad, AF
Virella, G
Argraves, WS
Lopes-Virella, MF
AF Hammad, Samar M.
Twal, Waleed O.
Barth, Jeremy L.
Smith, Kent J.
Saad, Antonio F.
Virella, Gabriel
Argraves, W. Scott
Lopes-Virella, Maria F.
TI Oxidized LDL immune complexes and oxidized LDL differentially affect the
expression of genes involved with inflammation and survival in human
U937 monocytic cells
SO ATHEROSCLEROSIS
LA English
DT Article
DE DNA microarray; Atherosclerosis; Oxidized LDL; Oxidized LDL immune
complexes; Fc gamma receptors
ID LOW-DENSITY-LIPOPROTEIN; THP-1 CELLS; INDUCED APOPTOSIS; HUMAN
MACROPHAGES; HEME OXYGENASE-1; ANTIBODIES; RECEPTOR; ATHEROSCLEROSIS;
ACTIVATION; PROTEIN
AB Objective: To compare the global effects of oxidized LDL (oxLDL) and oxLDL-containing immune complexes (oxLDL-IC) on gene expression in human monocytic cells and to identify differentially expressed genes involved with inflammation and survival.
Methods and results: U937 cells were treated with oxLDL-IC, oxLDL, Keyhole limpet hemocyanin immune complexes (KLH-IC), or vehicle for 4 h. Transcriptome profiling was performed using DNA microarrays. oxLDL-IC uniquely affected the expression of genes involved with pro-survival (RAD548, RUFY3, SNRPB2, and ZBTB24). oxLDL-IC also regulated many genes in a manner similar to KLH-IC. categorization of these genes revealed that 39% are involved with stress responses, including the unfolded protein response which impacts cell survival, 19% with regulation of transcription, 10% with endocytosis and intracellular transport of protein and lipid, and 16% with inflammatory responses including regulation of I-kappa B /NF-kappa B cascade and cytokine activity. One gene in particular, HSPA6, greatly up-regulated by oxLDL-IC, was found to be required for the process by which oxLDL-IC augments IL1-beta secretion. The study also revealed genes uniquely up-regulated by oxLDL, including genes involved with growth inhibition (OKL38, NEK3, and FTH1), oxidoreductase activity (SPXN1 and HMOX1), and transport of amino acids and fatty acids (SLC7A11 and ADFP).
Conclusions: These findings highlight early transcriptional responses elicited by oxLDL-IC that may underlie its cytoprotective and proinflammatory effects. Cross-linking of Fc gamma receptors appears to be the trigger for most of the transcriptional responses to oxLDL-IC. The findings further strengthen the hypothesis that oxLDL and oxLDL-IC elicit disparate inflammatory responses and play distinct roles in the process of atherosclerosis. Published by Elsevier Ireland Ltd.
C1 [Hammad, Samar M.; Twal, Waleed O.; Barth, Jeremy L.; Smith, Kent J.; Argraves, W. Scott] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA.
[Saad, Antonio F.; Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA.
RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Cell Biol & Anat, 114 Doughty St,630B POB 250776, Charleston, SC 29425 USA.
EM hammadsm@musc.edu
FU NIH [HL079274, POI-HL55782, HL061873]; South Carolina COBRE in
Lipidomics and Pathobiology [RR17677]; American Heart Association
Scientist Development [0435259N]; University Research Committee of the
Medical University of South Carolina; Department of Veterans Affairs
FX This work was supported by the following NIH grants: HL079274 (SMH),
POI-HL55782 (MIN), HL061873 (WSA), and the South Carolina COBRE in
Lipidomics and Pathobiology (P20 RR17677 from NCRR). The work was also
supported by an American Heart Association Scientist Development Grant
(0435259N) and a grant from the University Research Committee of the
Medical University of South Carolina to SMH, and funding from the
Department of Veterans Affairs to MLV We acknowledge the technical
assistance of Alena Nareika and the MUSC Proteogenomics Facility
(supported by RR016434, RR16461, and MUSC URRF) and their personnel,
including Saurin Jani and Victor Fresco. We thank Charlyne Chassereau
for assistance with lipoprotein isolation.
NR 54
TC 29
Z9 30
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2009
VL 202
IS 2
BP 394
EP 404
DI 10.1016/j.atherosclerosis.2008.05.032
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 408HY
UT WOS:000263427300010
PM 18597759
ER
PT J
AU Craske, MG
Waters, AM
Nazarian, M
Mineka, S
Zinbarg, RE
Griffith, JW
Naliboff, B
Ornitz, EM
AF Craske, Michelle G.
Waters, Allison M.
Nazarian, Maria
Mineka, Susan
Zinbarg, Richard E.
Griffith, James W.
Naliboff, Bruce
Ornitz, Edward M.
TI Does Neuroticism in Adolescents Moderate Contextual and Explicit Threat
Cue Modulation of the Startle Reflex?
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Adolescents; context; explicit threat; risk for anxiety and depression;
startle reflexes
ID FEAR-POTENTIATED STARTLE; POSTTRAUMATIC-STRESS-DISORDER; ANXIETY
DISORDERS; ACOUSTIC STARTLE; PERSONALITY; DEPRESSION; RESPONSES;
TEMPERAMENT; PREVALENCE; VETERANS
AB Background: This study evaluated the relationship between neuroticism (N), a probable risk factor for emotional disorders, and modulation of startle reflexes (SRs).
Methods: One hundred thirty-two adolescents with varying levels of N but without anxiety or depressive disorders were evaluated in contextual cue and explicit threat cue paradigms.
Results: Within the explicit threat cue paradigm, N potentiated SRs more in conditions that were intermediately associated with threat of an aversive biceps contraction than conditions that were the furthest from and conditions that were the closest to the same threat. Also, N potentiated SRs across the entire experiment, regardless of experimental conditions, in male and not in female subjects.
Conclusions: These results suggest that adolescents with high levels of N show greater sensitivity to contexts intermediately associated with threat. Results are discussed in comparison with other studies of groups at risk for anxiety and depressive disorders.
C1 [Craske, Michelle G.; Nazarian, Maria] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Naliboff, Bruce; Ornitz, Edward M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Ornitz, Edward M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA.
[Naliboff, Bruce] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Waters, Allison M.] Griffith Univ, Sch Psychol, Mt Gravatt, Qld 4122, Australia.
[Mineka, Susan; Zinbarg, Richard E.; Griffith, James W.] Northwestern Univ, Dept Psychol, Evanston, IL USA.
[Zinbarg, Richard E.] Northwestern Univ, Family Inst, Evanston, IL USA.
RP Craske, MG (reprint author), Univ Calif Los Angeles, Dept Psychol, 405 Hilgard Ave, Los Angeles, CA 90095 USA.
EM craske@psych.ucla.edu
RI Griffith, James/O-2551-2016
OI Griffith, James/0000-0002-4840-8692; Waters, Allison/0000-0003-2453-793X
FU National Institutes of Health [MH065651, MH065652]; Virginia Friedhofer
Charitable Trust
FX Supplementary material cited in this article is available online.
NR 33
TC 16
Z9 16
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD FEB 1
PY 2009
VL 65
IS 3
BP 220
EP 226
DI 10.1016/j.biopsych.2008.07.020
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 395QK
UT WOS:000262538400006
PM 18789433
ER
PT J
AU Sorror, ML
Storer, B
Sandmaier, BM
Chauncey, T
Storb, RF
Maloney, DG
AF Sorror, M. L.
Storer, B.
Sandmaier, B. M.
Chauncey, T.
Storb, R. F.
Maloney, D. G.
TI TANDEM AUTOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) FROM HLA-MATCHED RELATED OR UNRELATED DONORS FOR
ADVANCED LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT Tandem Meeting on Biology of Blood and Marrow Transplantation
CY FEB 11-15, 2009
CL Tampa, FL
SP Amer Soc Blood & Marrow Transplantat
C1 [Sorror, M. L.; Storer, B.; Sandmaier, B. M.; Chauncey, T.; Storb, R. F.; Maloney, D. G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Sorror, M. L.; Storer, B.; Sandmaier, B. M.; Chauncey, T.; Storb, R. F.; Maloney, D. G.] Univ Washington, Seattle, WA 98195 USA.
[Chauncey, T.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2009
VL 15
IS 2
MA 178
BP 66
EP 66
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 402MC
UT WOS:000263016800179
ER
PT J
AU Xu, GF
Mclaren, DG
Ries, ML
Fitzgerald, ME
Bendlin, BB
Rowley, HA
Sager, MA
Atwood, C
Asthana, S
Johnson, SC
AF Xu, Guofan
Mclaren, Donald G.
Ries, Michele L.
Fitzgerald, Michele E.
Bendlin, Barbara B.
Rowley, Howard A.
Sager, Mark A.
Atwood, Craig
Asthana, Sanjay
Johnson, Sterling C.
TI The influence of parental history of Alzheimers disease and
apolipoprotein E 4 on the BOLD signal during recognition memory
SO BRAIN
LA English
DT Article
DE Alzheimers disease; risk factors; BOLD; event-related fMRI; d-prime
ID MILD COGNITIVE IMPAIRMENT; GENETIC RISK; BRAIN ACTIVATION; HIPPOCAMPAL
ACTIVATION; EPISODIC MEMORY; DEFAULT-MODE; FMRI; DEMENTIA; APOE; AGE
AB First-degree family history (FH) of sporadic Alzheimers disease and the apolipoprotein E 4 allele (APOE4) are risk factors for Alzheimers disease that may affect brain function prior to onset of clinical symptoms. In this functional MRI (fMRI) study, we used an episodic recognition task that required discrimination of previously viewed (PV) and novel (NV) faces to examine differences in blood oxygen level dependent (BOLD) signal due to risk factors in 74 middle-aged cognitively normal individuals. The group effects on this recognition task were tested with a 2 2 ANCOVA factorial design (FH/FH and APOE4/APOE4). There were significant APOE4 and FH effects in the left dorsal posterior cingulate cortex and precuneus, where decreased risk resulted in greater activity during recollection. Recognition performance was positively correlated with BOLD signal in the left posterior hippocampus, parahippocampalretrosplenial gyrus and left superior frontal cortex regardless of risk factors. To examine condition-specific group effects, both the PV and NV faces were tested further in separate 2 2 ANCOVAs. Both models revealed an APOE effect, with the APOE4 group showing stronger signal than the APOE4 group in anterior cingulate cortices, while a FH effect was found in the dorsal cuneus and medial frontal cortices with the FH group showing stronger signal than the FH group. Finally, interactions between APOE4 and FH effects were found bilaterally in the fusiform gyrus. These results suggest that risk factors and cognitive performance each influence brain activity during recognition. The findings lend further support to the idea that functional brain changes may begin far in advance of symptomatic Alzheimers disease.
C1 [Xu, Guofan; Mclaren, Donald G.; Ries, Michele L.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Atwood, Craig; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA.
[Xu, Guofan; Mclaren, Donald G.; Ries, Michele L.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Rowley, Howard A.; Sager, Mark A.; Atwood, Craig; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Madison, WI USA.
[Xu, Guofan; Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Madison, WI USA.
RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace 11G, Madison, WI 53705 USA.
EM scj@medicine.wisc.edu
RI McLaren, Donald/G-9906-2011
FU Department of Veterans Affairs Merit Review [AG21155, AG20013, AG27161]
FX Department of Veterans Affairs Merit Review Grant (to S.C.J.); AG21155,
AG20013 and AG27161.
NR 54
TC 56
Z9 56
U1 3
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD FEB
PY 2009
VL 132
BP 383
EP 391
DI 10.1093/brain/awn254
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 408BI
UT WOS:000263407700012
PM 18829694
ER
PT J
AU Faroqi-Shah, Y
Dickey, MW
AF Faroqi-Shah, Yasmeen
Dickey, Michael Walsh
TI On-line processing of tense and temporality in agrammatic aphasia
SO BRAIN AND LANGUAGE
LA English
DT Article
DE Morphology; Agrammatism; Verbs; Reaction time; Tense; Adverb; Syntax;
Anomaly; Aphasia; Comprehension
ID FUNCTIONAL CATEGORIES; BROCAS APHASIA; GRAMMATICAL MORPHOLOGY; VERB
INFLECTIONS; QUANTITATIVE-ANALYSIS; GERMAN AGRAMMATISM; GREEK APHASIA;
PAST-TENSE; COMPREHENSION; DEFICITS
AB Agrammatic aphasic individuals exhibit marked production deficits for tense morphology. This paper presents three experiments examining whether a group of English-speaking agrammatic individuals (n=10) exhibit parallel deficits in their comprehension of tense. Results from two comprehension experiments (on-line grammaticality judgment studies) suggest that these individuals are impaired for tense comprehension, and furthermore that their deficit is more pronounced for morphosemantic rather than morphosyntactic aspects of tense processing. Results from a third experiment (an elicited production study) indicate that these individuals exhibit parallel production and comprehension impairments for tense. Across the three experiments, the consistent pattern was that of a significant difficulty in associating verb forms with a pre-specified temporal context when compared to all other processes. Implications for current models of agrammatic tense and morphological deficits are discussed. (C) Published by Elsevier Inc.
C1 [Faroqi-Shah, Yasmeen] Univ Maryland, Dept Hearing & Speech Sci, College Pk, MD 20742 USA.
[Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA.
[Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Faroqi-Shah, Y (reprint author), Univ Maryland, Dept Hearing & Speech Sci, 0100 Lefrak Hall, College Pk, MD 20742 USA.
EM yshah@hesp.umd.edu
OI Dickey, Michael Walsh/0000-0002-9068-3313
FU University of Maryland, College Park
FX This research was supported by a General Research Board award from the
University of Maryland, College Park to Y. Faroqi-Shah. We thank Heather
McIntosh for helping with timing of verbs. Monica Sampson and Kristin
Grunwald helped with data analysis. Sarah Camponeshi and Isabelle Dunn
helped with transcription and coding of narratives. The authors are
grateful to the aphasic participants and their families for their
participation in this research.
NR 72
TC 26
Z9 26
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0093-934X
J9 BRAIN LANG
JI Brain Lang.
PD FEB
PY 2009
VL 108
IS 2
BP 97
EP 111
DI 10.1016/j.bandl.2008.10.003
PG 15
WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences;
Psychology, Experimental
SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences &
Neurology; Psychology
GA 406GT
UT WOS:000263283700004
PM 19081129
ER
PT J
AU Fishman, J
O'Dwyer, P
Lu, HL
Henderson, H
Asch, DA
Casarett, DJ
AF Fishman, Jessica
O'Dwyer, Peter
Lu, Hien L.
Henderson, Hope
Asch, David A.
Casarett, David J.
TI Race, Treatment Preferences, and Hospice Enrollment: Eligibility
Criteria May Exclude Patients With the Greatest Needs for Care
SO CANCER
LA English
DT Article
DE treatment preferences; conjoint analysis; utilities; interview; Medicare
Hospice Benefit; services; palliative care; African American; race;
economic; finances
ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; CONJOINT-ANALYSIS;
CANCER-PATIENTS; NURSING-HOMES; PALLIATIVE CARE; HEALTH RESEARCH;
MANAGEMENT; END; COMMUNITY
AB BACKGROUND: The requirement that patients give up curative treatment makes hospice enrollment unappealing for some patients and may particularly limit use among African-American patients. The current study was conducted to determine whether African-American patients with cancer are more likely than white patients to have preferences for cancer treatment that exclude them from hospice and whether they are less likely to want specific hospice services. METHODS: Two hundred eighty-three patients who were receiving treatment for cancer at 6 oncology clinics within the University of Pennsylvania Cancer Network completed conjoint interviews measuring their perceived need for 5 hospice services and their preferences for continuing cancer treatment. Patients were followed for 6 months or until death. RESULTS: African-American patients had stronger preferences for continuing their cancer treatments on a 7-point scale even after adjusting for age, sex, finances, education, Eastern Cooperative Oncology Group performance status, quality of life, and physical and psychologic symptom burden (adjusted mean score, 4.75 vs 3.96; beta coefficient, 0.82; 95% confidence interval, 0.22-1.41 [P=.007]). African-American patients also had greater perceived needs for hospice services after adjusting for these characteristics (adjusted mean score, 2.31 vs 1.83; beta coefficient, 0.51; 95% confidence interval, 0.11-0.92 [P=.01]). However, this effect disappeared after adjusting for household finances. CONCLUSIONS: Hospice eligibility criteria may exclude African-American patients disproportionately despite greater perceived needs for hospice services in this population. The mechanisms driving this health disparity likely include both cultural differences and economic characteristics, and consideration should be given to redesigning hospice eligibility criteria. Cancer 2009;115:689-97. (C) 2008 American Cancer Society.
C1 [Fishman, Jessica; O'Dwyer, Peter; Lu, Hien L.; Asch, David A.; Casarett, David J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Fishman, Jessica] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA.
[Fishman, Jessica] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Henderson, Hope; Asch, David A.; Casarett, David J.] Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Asch, David A.; Casarett, David J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Casarett, DJ (reprint author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM casarett@mail.med.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU American Cancer Society Mentored Scholar Research
[MRSGT-08-013-01-CPPB]; University of Pennsylvania's National Institutes
of Health [R01CA109540]; Veterans Administration Advanced Research
Career Development Award; Presidential Early Career Award for Scientists
and Engineers; Abramson Cancer Center; Center for Clinical Epidemiology
and Biostatistics; Center For Health Equity Research and Promotion
FX Supported by American Cancer Society Mentored Scholar Research grant
MRSGT-08-013-01-CPPB (to J.F.), the University of Pennsylvania's
National Institutes of Health-funded Center of Excellence for Cancer
Communication Research grant (to J.F.), grant R01CA109540 (to D.J.C.), a
Veterans Administration Advanced Research Career Development Award, a
Presidential Early Career Award for Scientists and Engineers (to
D.J.C.), and by grants from the Abramson Cancer Center (to P.O.), the
Center for Clinical Epidemiology and Biostatistics (to J.F.), and the
Center For Health Equity Research and Promotion (to D.J.C. and J.F.).
NR 68
TC 37
Z9 37
U1 2
U2 7
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008-543X
J9 CANCER
JI Cancer
PD FEB 1
PY 2009
VL 115
IS 3
BP 689
EP 697
DI 10.1002/cncr.24046
PG 9
WC Oncology
SC Oncology
GA 402GY
UT WOS:000263003400028
PM 19107761
ER
PT J
AU Raitt, MH
AF Raitt, Meritt H.
TI Are n-3 Polyunsaturated Fatty Acids Antiarrhythmic in the Absence of
Ischemia?
SO CARDIOVASCULAR DRUGS AND THERAPY
LA English
DT Editorial Material
ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; FISH-OIL SUPPLEMENTATION;
SUDDEN CARDIAC DEATH; VENTRICULAR-FIBRILLATION; RISK; TRIAL;
OMEGA-3-FATTY-ACIDS; MODULATION; PREVENTION; CHANNELS
C1 Portland VA Med Ctr, Portland, OR USA.
[Raitt, Meritt H.] P 3 CARD, Portland, OR 97239 USA.
RP Raitt, MH (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM merritt.raitt@va.gov
NR 18
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-3206
J9 CARDIOVASC DRUG THER
JI Cardiovasc. Drugs Ther.
PD FEB
PY 2009
VL 23
IS 1
BP 1
EP 3
DI 10.1007/s10557-008-6151-6
PG 3
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 396JJ
UT WOS:000262587700001
PM 19005746
ER
PT J
AU Singh, M
Peterson, ED
Roe, MT
Ou, FS
Spertus, JA
Rumsfeld, JS
Anderson, HV
Klein, LW
Ho, KKL
Holmes, DR
AF Singh, Mandeep
Peterson, Eric D.
Roe, Matthew T.
Ou, Fang-Shu
Spertus, John A.
Rumsfeld, John S.
Anderson, H. Vernon
Klein, Lloyd W.
Ho, Kalon K. L.
Holmes, David R.
TI Trends in the Association Between Age and In-Hospital Mortality After
Percutaneous Coronary Intervention National Cardiovascular Data Registry
Experience
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE age; percutaneous coronary interventions; mortality; temporal trends
ID ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE PROFESSIONALS; SCIENTIFIC
STATEMENT; GERIATRIC-CARDIOLOGY; CLINICAL CARDIOLOGY; AMERICAN-COLLEGE;
HEART-DISEASE; RISK SCORE; ANGIOPLASTY; COLLABORATION
AB Background-Temporal trends and contemporary data characterizing the impact of patient age on in-hospital outcomes of percutaneous coronary interventions are lacking. We sought to determine the importance of age by assessing the in-hospital mortality of stratified age groups in the National Cardiovascular Data Registry.
Methods and Results-In-hospital mortality after percutaneous coronary intervention on 1 410 069 patients was age stratified into 4 groups-group 1 (age <40, n=25 679), group 2 (40 to 59, n=496 204), group 3 (60 to 79, n=732 574), and group 4 (>= 80, n=155 612)-admitted from January 1, 2001, to December 31, 2006. Overall in-hospital mortality was 1.22%; in-hospital mortality was 0.60%, 0.59%, 1.26%, and 3.16% in groups 1 to 4, respectively, P<0.0001. Overall temporal improvement per calendar year in the adjusted in-hospital mortality after percutaneous coronary intervention was noted in most groups; however, this finding was significant only in the 2 older age groups, group 3 (odds ratio, 0.94; 95% CI, 0.92 to 0.96) and group 4 (odds ratio, 0.95; 95% CI, 0.92 to 0.97). The absolute mortality reduction was greatest in the most elderly group, those over the age of 80 years.
Conclusions-In-hospital mortality after percutaneous coronary intervention has fallen for all age groups over the past 6 years. However, the largest absolute reduction was seen among patients 80 years of age or older. (Circ Cardiovasc Intervent. 2009;2:20-26.)
C1 [Singh, Mandeep; Holmes, David R.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA.
[Peterson, Eric D.; Roe, Matthew T.; Ou, Fang-Shu] Duke Clin Res Inst, Durham, NC USA.
[Spertus, John A.] UMKC, Mid Amer Heart Inst, Kansas City, MO USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Anderson, H. Vernon] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Klein, Lloyd W.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Ho, Kalon K. L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Singh, M (reprint author), Mayo Clin, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.
EM singh.mandeep@mayo.edu
NR 27
TC 36
Z9 36
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD FEB
PY 2009
VL 2
IS 1
BP 20
EP 26
DI 10.1161/CIRCINTERVENTIONS.108.826172
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 575EC
UT WOS:000276048500005
PM 20031689
ER
PT J
AU Handrakis, JP
DeMeersman, RE
Rosado-Rivera, D
LaFountaine, MF
Spungen, AM
Bauman, WA
Wecht, JM
AF Handrakis, John P.
DeMeersman, Ronald E.
Rosado-Rivera, Dwindally
LaFountaine, Michael F.
Spungen, Ann M.
Bauman, William A.
Wecht, Jill M.
TI Effect of hypotensive challenge on systemic hemodynamics and cerebral
blood flow in persons with tetraplegia
SO CLINICAL AUTONOMIC RESEARCH
LA English
DT Article
DE spinal cord injury; autonomic nervous system disorder; orthostatic
hypotension; angiotensin-converting enzyme inhibitor; tilt-table test
ID SPINAL-CORD-INJURY; POWER SPECTRAL-ANALYSIS; HEAD-UP TILT; ORTHOSTATIC
HYPOTENSION; TRANSCRANIAL DOPPLER; PRESSURE VARIABILITY; HUMANS;
AUTOREGULATION; INDIVIDUALS; OXYGENATION
AB Individuals with tetraplegia have impaired central control of sympathetic vascular modulation and blood pressure (BP); how this impairment affects cerebral blood flow (CBF) is unclear.
To determine if persons with tetraplegia maintain CBF similarly to able-bodied controls after a hypotensive challenge.
Seven individuals with chronic tetraplegia and seven age-matched, non-SCI control subjects underwent a hypotensive challenge consisting of angiotensin-converting enzyme (ACE) inhibition (1.25 mg enalaprilat) and 45A degrees head-up tilt (HUT). Heart rate (HR), low frequency systolic BP variability (LFsbp), brachial mean arterial pressure (MAP) and middle cerebral artery CBF were measured before and after the challenge. Group differences for the baseline (BL) to post-challenge response were determined by repeated measures ANOVA.
HR did not differ between the groups in response to the hypotensive challenge. LFsbp response was significantly reduced in the tetra compared to the control group (-38 +/- A 51 vs. 72 +/- A 93%, respectively). MAP did not differ between the groups at BL but was significantly lower in the tetra compared to the control group post-challenge (55 +/- A 13 vs. 71 +/- A 9 mmHg, respectively); the percent change in MAP was significantly greater in the tetra than in the control group (-29 +/- A 14.1 vs. -13 +/- A 9%, respectively). However, CBF did not differ between the groups at baseline or post-challenge; the percent change in CBF post-challenge was not different between the tetra and control groups (-29 +/- A 13.2 vs. -23 +/- A 10.3%, respectively).
Despite impaired sympathetic vasomotor and BP control, CBF in persons with tetraplegia was comparable to that of control subjects during a hypotensive challenge.
C1 [Handrakis, John P.; DeMeersman, Ronald E.; LaFountaine, Michael F.; Spungen, Ann M.; Bauman, William A.; Wecht, Jill M.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[Handrakis, John P.] Sch Hlth Profess Behav & Life Sci, NYIT, Old Westbury, NY USA.
[DeMeersman, Ronald E.] Columbia Univ, Teachers Coll, New York, NY 10027 USA.
[Spungen, Ann M.; Bauman, William A.; Wecht, Jill M.] Mt Sinai Sch Med, Dept Med & Rehabil Med, New York, NY USA.
RP Handrakis, JP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM john.handrakis@va.gov
FU Veteran Affairs Rehabilitation Research and Development Service; Center
of Excellence for the Medical Consequences of SCI [B4162C]; Vidda
Foundation
FX Veteran Affairs Rehabilitation Research and Development Service, Center
of Excellence for the Medical Consequences of SCI (B4162C), James J.
Peters VAMC, the Vidda Foundation.
NR 28
TC 11
Z9 11
U1 2
U2 3
PU DR DIETRICH STEINKOPFF VERLAG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY
SN 0959-9851
J9 CLIN AUTON RES
JI Clin. Auton. Res.
PD FEB
PY 2009
VL 19
IS 1
BP 39
EP 45
DI 10.1007/s10286-008-0496-6
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 409NA
UT WOS:000263511200007
PM 18850311
ER
PT J
AU Akhtar, S
Meeran, SM
Katiyar, N
Katiyar, SK
AF Akhtar, Suhail
Meeran, Syed M.
Katiyar, Nandan
Katiyar, Santosh K.
TI Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell
Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding
Protein-3, Tumor Cell Proliferation, and Angiogenic Factors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BREAST-CARCINOMA CELLS; SKH-1 HAIRLESS MICE; IN-VIVO; THERAPY;
MECHANISMS; ACTIVATION; APOPTOSIS; RECEPTOR; ANTIBODY; MITOGEN
AB Purpose: Lung cancer is a leading cause of cancer-related deaths worldwide. Here, we assessed the chemotherapeutic effect of grape seed proanthocyanidins (GSPs) on human non-small Cell lung cancer (NSCLC) cells in vitro and in vivo using a tumor xenograft model.
Experimental Design: The effects of GSPs on human NSCLC cell lines in terms of cellular proliferation were determined. The chemotherapeutic effects of a GSP-supplemented AIN76A control diet fed to nude mice bearing tumor xenografts (A549 and H1299) were evaluated in terms of biomarkers of cell proliferation and angiogenesis and on insulin-like growth factor binding protein-3 using immunohistochemical detection, ELISA, and Western blotting.
Results: In vitro treatment of NSCLC cells with GSPs resulted in inhibition of cellular proliferation. Administration of GSPs (0.1%, 0.2%, and 0.5%, w/w) as a supplement of an AIN76A control diet resulted in a dose-dependent inhibition of the growth of NSCLC (A549 and H1299) tumor xenografts in athymic nude mice (25-76%; P < 0.05-0.001). The growth-inhibitory effect of GSPs on the NSCLC xenograft tumors was associated with the enhancement of the levels of insulin-like growth factor binding protein-3 in the tumor microenvironment and plasma and antiproliferative, antiangiogenic, and proapoptotic effects.
Conclusions: This preclinical Study reveals for the first time that dietary GSPs have the ability to inhibit the growth of human NSCLC tumor xenografts grown in vivo in athymic nude mice. More studies are needed to develop GSPs as a pharmacologically safe agent for the prevention of lung cancer in humans.
C1 [Akhtar, Suhail; Meeran, Syed M.; Katiyar, Nandan; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
NR 35
TC 43
Z9 45
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2009
VL 15
IS 3
BP 821
EP 831
DI 10.1158/1078-0432.CCR-08-1901
PG 11
WC Oncology
SC Oncology
GA 405HK
UT WOS:000263213600011
PM 19188152
ER
PT J
AU Lee, CC
You, NCY
Song, YQ
Hsu, YH
Manson, J
Nathan, L
Tinker, L
Liu, SM
AF Lee, Cathy C.
You, Nai-chieh Yuko
Song, Yiqing
Hsu, Yi-Hsiang
Manson, JoAnn
Nathan, Lauren
Tinker, Lesley
Liu, Simin
TI Relation of Genetic Variation in the Gene Coding for C-Reactive Protein
with Its Plasma Protein Concentrations: Findings from the Women's Health
Initiative Observational Cohort
SO CLINICAL CHEMISTRY
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; CORONARY-HEART-DISEASE; SINGLE-NUCLEOTIDE
POLYMORPHISMS; CRP LEVELS; POPULATION STRATIFICATION;
CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; HUMAN GENOME; RISK;
ASSOCIATION
AB BACKGROUND: Although common genetic variants of the CRP gene (C-reactive protein, pentraxin related) have been associated with plasma concentrations of high-sensitivity CRP (hsCRP) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations.
METHODS: In a case-control study of diabetes nested in the Women's Health initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma hsCRP concentrations. Thirteen haplotype-tagging single-nucleotide polymorphisms (tSNPs) were identified and subsequently genotyped in 3782 postmenopausal women.
RESULTS: The allele frequencies for these tSNPs and the haplotype blocks defined by these tSNPs varied significantly by ethnic group (P < 0.0001). Consistent with prior studies of whites, rs3093068, rs1130864, and rs1417938 were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L). The associations with rs3093068 and rs1205 appeared to be stronger in Asians/Pacific Islanders than in whites (geometric-mean increase, 1.65 mg/L vs 1.25 mg/L, respectively). Minor alleles at rs3093075 and rs3093039 were associated with substantially increased hsCRP concentrations, whereas rs1800947 was associated with lower hsCRP values. All haplotype-based association results tended to be consistent with the associations seen with single CRP SNPs.
CONCLUSIONS: Our large multiethnic case-control study of postmenopausal women provides evidence that common genetic variants in the CRP gene are substantially associated with plasma hsCRP concentrations in this case-control subcohort. The data also suggest ethnic variations in these associations. (C) 2008 American Association for Clinical Chemistry
C1 [You, Nai-chieh Yuko; Liu, Simin] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
[Lee, Cathy C.; Liu, Simin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Lee, Cathy C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Song, Yiqing; Manson, JoAnn] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Song, Yiqing; Manson, JoAnn] Harvard Univ, Sch Med, Boston, MA USA.
[Hsu, Yi-Hsiang] Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Dept Environm Hlth, Boston, MA 02115 USA.
[Nathan, Lauren] Univ Calif Los Angeles, David Geffen Sch Med, Dept OB GYN, Los Angeles, CA 90095 USA.
[Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Liu, Simin] Univ Calif Los Angeles, David Geffen Sch Med, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
RP Liu, SM (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Box 951772,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM siminliu@ucla.edu
RI Liu, Simin/I-3689-2014
OI Liu, Simin/0000-0003-2098-3844
FU National Heart, Lung, and Blood Institute; US Department of Health and
Human Services; National Institutes of Health [R01DK062290]
FX The Women's Health Initiative is funded by the National Heart, Lung, and
Blood Institute, and the US Department of Health and Human Services.
This study was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases R01DK062290 from the National Institutes
of Health.
NR 35
TC 23
Z9 24
U1 0
U2 1
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD FEB
PY 2009
VL 55
IS 2
BP 351
EP 360
DI 10.1373/clinchem.2008.117176
PG 10
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 401ED
UT WOS:000262921300019
PM 19095725
ER
PT J
AU Lu, Y
Chen, QY
Corey, E
Xie, W
Fan, J
Mizokami, A
Zhang, J
AF Lu, Yi
Chen, Qiuyan
Corey, Eva
Xie, Wen
Fan, Jie
Mizokami, Atsushi
Zhang, Jian
TI Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE MCP-1; CCR2; Cell invasion; Osteoclast; Prostate cancer
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHEMOKINE RECEPTOR EXPRESSION;
ENDOTHELIAL-CELLS; TUMOR PROGRESSION; SOLUBLE RECEPTOR; METASTASIS;
CARCINOMA; MIGRATION; MECHANISMS; INVASION
AB Prostate cancer (PCa) frequently metastasizes to bone resulting in a mixture of osteolytic and osteoblastic lesions. We have previously reported that monocyte chemotactic protein-1 (MCP-1) is chemotactic for PCa cells, and its receptor, CCR2 expression, correlates with pathological stages. However, the role of MCP-1/CCR2 axis on PCa progression in bone remains unclear. We first evaluated the serum levels of MCP-1 in patients with bone metastases or localized PCa by enzyme-linked immunosorbent assay. We found that MCP-1 levels were elevated in patients with bone metastases compared to localized PCa. We further determined the effects of knockdown CCR2 or MCP-1 on PCa cell invasion and the tumor cell-induced osteoclast activity in vitro, respectively. PCa C4-2B and PC3 cells were transfected stably with either CCR2 short hairpin RNA (shRNA) or a scrambled RNA. CCR2 knockdown significantly diminished the MCP-1-induced PCa cell invasion. In addition, the MCP-1 production was knocked down by MCP-1 shRNA in C4-2B and PC3 cells. Conditioned media (CM) was collected and determined for the CM-induced osteoclast formation in vitro. MCP-1 knockdown significantly decreased the PCa CM-induced osteoclast formation. Finally, MCP-1 knockdown PC3 cells were implanted into the tibia of SCID mice for 4 weeks. Tumor volume was determined by histopathology and bone histomorphometry. MCP-1 knockdown diminished PC3 tumor growth in bone. We concluded that activation of MCP-1/CCR2 axis promotes PCa growth in bone. This study suggests that MCP-1 may be a target for PCa progression.
C1 [Lu, Yi; Chen, Qiuyan; Fan, Jie; Zhang, Jian] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA.
[Chen, Qiuyan] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China.
[Corey, Eva] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Xie, Wen] Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA.
[Xie, Wen] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Fan, Jie] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA.
[Mizokami, Atsushi] Kanazawa Univ, Grad Sch Med Sci, Dept Urol, Kanazawa, Ishikawa, Japan.
RP Lu, Y (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA.
EM luy3@upmc.edu; zhangj2@upmc.edu
RI Xie, Wen/M-1768-2016
FU Department of Defense [PC061231]; University of Pittsburgh Cancer
Institute CCSG
FX The authors thank Dr. G. David Roodman for his helpful discussion, Dr.
Zhong Cai for his technical help, and Mrs. Donna Gaspich for her
editing. This study was supported by Department of Defense PC061231 and
University of Pittsburgh Cancer Institute CCSG (J. Zhang).
NR 37
TC 48
Z9 53
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD FEB
PY 2009
VL 26
IS 2
BP 161
EP 169
DI 10.1007/s10585-008-9226-7
PG 9
WC Oncology
SC Oncology
GA 407JK
UT WOS:000263359200009
PM 19002595
ER
PT J
AU Graham, DY
AF Graham, David Y.
TI Efficient Identification and Evaluation of Effective Helicobacter pylori
Therapies
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
ID II CLINICAL-TRIALS; SEQUENTIAL THERAPY; TRIPLE THERAPY; IRON-DEFICIENCY;
INFECTION; ERADICATION; METAANALYSIS; REGIMEN; EFFICACY; DESIGNS
AB Annually hundreds if not thousands of patients fail empiric H pylori eradication therapy. Failure occurs in part because routine post treatment testing, which provides an early warning of increasing antibiotic resistance, is not universally done and physicians are generally unaware that cure rates with legacy triple therapy (a proton-pump inhibitor, amoxicillin, and clarithromycin) in most places has fallen below 80%. We propose first, institution of routine post eradication testing and second, abandonment of the "better than another therapy" approach to separating acceptable from unacceptable therapies. Instead, we propose using results-based outcomes (ie, >95% cure rates). H pylori should be evaluated as other infectious diseases (ie, few would compare a new antibiotic for pneumonia with the previous best choice whose effectiveness was now impaired because of resistance). Randomized comparisons should be restricted to studies designed to improve (eg, simplify or reduce costs) high cure rate therapies while maintaining efficacy. We also discuss potential ethical issues such as those including known or suspected low cure rate therapies. Legacy therapies cannot be identified as "approved" or "recommended" even if both statements were true. Instead patients and ethics boards must receive "full disclosures" both before and during studies that include all that might affect a patient's decision to enter or to continue. Finally, we provides advice regarding trial design using "best shot" pilot studies to efficiently identify tentative effective regimens which are then confirmed in randomized trials all the while minimizing patient risks and drug exposure.
C1 [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
[Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA.
RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320 1111D,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM dgraham@bcm.tmc.edu
FU NIDDK NIH HHS [DK56338, P30 DK056338, P30 DK056338-07]
NR 26
TC 56
Z9 57
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD FEB
PY 2009
VL 7
IS 2
BP 145
EP 148
DI 10.1016/j.cgh.2008.10.024
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 410QE
UT WOS:000263592100007
PM 19026766
ER
PT J
AU Spiegel, BMR
Ho, W
Esrailian, E
Targan, S
Higgins, PDR
Siegel, CA
Dubinsky, M
Melmed, GY
AF Spiegel, Brennan M. R.
Ho, Wayne
Esrailian, Eric
Targan, Stephan
Higgins, Peter D. R.
Siegel, Corey A.
Dubinsky, Marla
Melmed, Gil Y.
TI Controversies in Ulcerative Colitis: A Survey Comparing Decision Making
of Experts Versus Community Gastroenterologists
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; QUALITY-OF-LIFE; COLORECTAL-CANCER;
CROHNS-DISEASE; SURVEILLANCE; GUIDELINES; CYCLOSPORINE; MANAGEMENT;
VIGNETTES; PROVIDERS
AB Background & Aims: Despite the development of consensus guidelines in ulcerative colitis (UC), there remain several areas of uncertainty in the everyday management of this incompletely understood disease. We performed a national vignette survey to measure variations in decision-making in areas of controversy. Methods: We constructed a survey with 3 vignettes to measure decision-making in 4 areas of controversy in UC: (1) dysplasia management, (2) mesalamine dosing, (3) diagnostic testing for underlying Crohn's disease, and (4) treatment of steroid-refractory inpatient UC. We compared responses between a group of community gastroenterologists and UC experts. Results: We received 192 responses (36% response). Compared with community gastroenterologists, UC experts were more likely to endorse colectomy for both unifocal and multifocal low-grade dysplasia, use narrow band imaging and chromoendoscopy for surveillance colonoscopy, use high-dose mesalamine for inducing remission, use long-term mesalamine for cancer chemoprevention, order computed tomography enterography to evaluate for Crohn's disease, and to have a lower threshold to call for surgery consultation in steroid-refractory UC. There was little agreement regarding the optimal frequency of surveillance colonoscopy, even among experts. Most respondents favored using infliximab over cyclosporine in steroid-refractory UC. Conclusions: Community gastroenterologists and UC experts vary dramatically in their approach to many areas of uncertainty in UC. The only area of consensus between groups is the use of infliximab over cyclosporine in steroid-refractory UC, itself a controversial decision. These data suggest that current practice patterns are highly disparate and focus attention on specific areas of disconnect that should be further investigated.
C1 [Spiegel, Brennan M. R.; Ho, Wayne] Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Spiegel, Brennan M. R.; Esrailian, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Spiegel, Brennan M. R.] CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Targan, Stephan; Dubinsky, Marla; Melmed, Gil Y.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Higgins, Peter D. R.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Siegel, Corey A.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Spiegel, Brennan M. R.; Esrailian, Eric] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ulca.edu
RI Higgins, Peter/A-3511-2009
OI Higgins, Peter/0000-0003-1602-4341
FU Veteran's Affairs Health Services Research and Development (HSR&D)
Career Development Transition Award [RCD 03-179-2]; Crohn's and Colitis
Foundation Career Development Award; NIH [IK23DK078678-01A1, 2P30 DK
041301-17]; Procter Gamble
FX The authors disclose the following: Dr Spiegel is supported by a
Veteran's Affairs Health Services Research and Development (HSR&D)
Career Development Transition Award (RCD 03-179-2) and the CURE
Digestive Disease Research Center (NIH 2P30 DK 041301-17). Dr Corey
Siegel is supported by a Crohn's and Colitis Foundation Career
Development Award and NIH IK23DK078678-01A1. This study was supported by
an investigator-initiated research grant by Procter & Gamble.
NR 31
TC 24
Z9 25
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD FEB
PY 2009
VL 7
IS 2
BP 168
EP 174
DI 10.1016/j.cgh.2008.08.029
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 410QE
UT WOS:000263592100011
PM 18952199
ER
PT J
AU Roodman, GD
Hiruma, Y
Kurihara, N
AF Roodman, G. David
Hiruma, Yuko
Kurihara, Noriyoshi
TI p62: A Potential Target for Blocking Microenvironmental Support of
Myeloma
SO CLINICAL LYMPHOMA & MYELOMA
LA English
DT Meeting Abstract
ID MULTIPLE-MYELOMA; BONE MICROENVIRONMENT; OSTEOCLASTOGENESIS; DISEASE;
PATHOPHYSIOLOGY; INCREASES; MUTATION; ALPHA
C1 [Roodman, G. David; Hiruma, Yuko; Kurihara, Noriyoshi] Univ Pittsburgh, Pittsburgh, PA USA.
[Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 10
TC 0
Z9 0
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1557-9190
J9 CLIN LYMPHOMA MYELOM
JI Clin. Lymphoma Myeloma
PD FEB
PY 2009
VL 9
BP S25
EP S26
PG 2
WC Oncology
SC Oncology
GA 472EE
UT WOS:000268111400019
ER
PT J
AU Beales, JL
Edes, T
AF Beales, Julie Leftwich
Edes, Thomas
TI Veteran's Affairs Home Based Primary Care
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Article
DE Home care; Chronic disease; Non-institutional long-term care;
Interdisciplinary team; Home based primary care
AB In response to the anticipated growth of the veteran population with chronic disabling diseases, the Department of Veterans Affairs (VA) established Home Based Primary Care (HBPC). This article focuses on that program, a home care program that specifically targets individuals with complex chronic disabling disease, with the goal of maximizing the independence of the patient and reducing preventable emergency room visits and hospitalizations. HBPC programs provide comprehensive longitudinal primary care by an interdisciplinary team in the homes of veterans with complex chronic disease, who are not effectively managed by routine clinic-based care. HBPC is very different from and complementary to standard skilled home care services, in population, processes and outcomes. HBPC targets persons with advanced chronic disease, rather than remediable conditions. HBPC provides comprehensive care of multiple co-morbidities, rather than problem-focused care. HBPC is delivered by an interdisciplinary team, rather than one or two independent providers. Currently operating in three-fourths of VA facilities, HBPC expansion continues to be driven by clinical success and the highest satisfaction of all VA services. VA HBPC is a model to emulate for the care of persons with complex, chronic disabling conditions, improving quality without added cost, and maximizing their independence through comprehensive longitudinal interdisciplinary care delivered in their homes.
C1 [Beales, Julie Leftwich] VAMC, Richmond, VA 23249 USA.
[Edes, Thomas] US Dept Vet Affairs, Home & Community Based Care, Washington, DC 20420 USA.
RP Beales, JL (reprint author), VAMC, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.
EM julie.beales@va.gov
NR 9
TC 47
Z9 48
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD FEB
PY 2009
VL 25
IS 1
BP 149
EP +
DI 10.1016/j.cger.2008.11.002
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 421ZM
UT WOS:000264396800012
PM 19217499
ER
PT J
AU Dong, ZM
Aplin, AC
Nicosia, RF
AF Dong, Zhao Ming (David)
Aplin, Alfred C.
Nicosia, Roberto F.
TI Regulation of Angiogenesis by Macrophages, Dendritic Cells, and
Circulating Myelomonocytic Cells
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Macrophages; dendritic cells; myeloid cells; neovascularization;
arteriogenesis
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; ADENOSINE A(2A)
RECEPTORS; COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; HUMAN
PERIPHERAL-BLOOD; NECROSIS-FACTOR-ALPHA; ADIPOSE-TISSUE; MYELOID CELLS;
BREAST-CANCER
AB Angiogenesis during reactive and pathologic processes is characteristically associated with inflammation. Macrophages and dendritic cells present in the inflammatory infiltrate contribute to the angiogenic process by multiple mechanisms. Macrophages produce a broad array of angiogenic growth factors and cytokines, generate conduits for blood flow through proteolytic mechanisms, and promote the remodeling of arterioles into arteries. They can also inhibit angiogenesis and cause reabsorption of neovessels by inducing endothelial cell death. Dendritic cells can stimulate or inhibit angiogenesis depending on their activation status and subset specificity. Dendritic cells stimulate angiogenesis by secreting angiogenic factors and cytokines, promoting the proangiogenic activity of T lymphocytes, and trans-differentiating into endothelial cells. Inflammatory infiltrates associated with angiogenesis also contain Tie2+, VEGFR2+, and GR1+ myelomonocytic cells which actively regulate the angiogenic process through paracrine mechanisms. In this paper we review our current knowledge of this field and discuss how recent advances have provided the rationale for novel therapeutic approaches against cancer.
C1 [Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S 113, Pathol & Lab Med Serv, Seattle, WA 98108 USA.
[Aplin, Alfred C.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S 113, Pathol & Lab Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM roberto.nicosia@va.gov
NR 171
TC 32
Z9 32
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD FEB
PY 2009
VL 15
IS 4
BP 365
EP 379
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 415VF
UT WOS:000263963500004
ER
PT J
AU McFarland, BR
Klein, DN
AF McFarland, Brian R.
Klein, Daniel N.
TI EMOTIONAL REACTIVITY IN DEPRESSION: DIMINISHED RESPONSIVENESS TO
ANTICIPATED REWARD BUT NOT TO ANTICIPATED PUNISHMENT OR TO NONREWARD OR
AVOIDANCE
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE depression; reward; punishment; appetitive; approach; withdrawal;
behavioral activation; behavioral inhibition
ID BEHAVIORAL ACTIVATION; MAJOR DEPRESSION; AFFECTIVE-DISORDERS; TRIPARTITE
MODEL; ANXIETY; SYSTEMS; PSYCHOPATHOLOGY; INHIBITION; DIMENSIONS;
THERAPY
AB Objectives: This study compared depressed and nondepressed participants' emotional reactivity to anticipated reward, anticipated punishment, failure to obtain a reward, and successful avoidance of punishment. Experimental design: This study compared residualized change scores on target emotions for currently depressed (n = 19), previously depressed (n = 19), and never-depressed (n = 43) participants during four experimental conditions: anticipated reward (cash), anticipated punishment (cold pressor), nonreward (failure to earn cash), and avoidance (successful avoidance of a cold pressor). Principal observations: Currently depressed participants' reactivity in response to anticipated reward was significantly diminished compared with never depressed participants', and marginally diminished compared with previously depressed participants'. Currently depressed, previously depressed, and never-depressed participants did not differ significantly in their emotional reactivity to anticipated punishment or to nonreward or avoidance. Conclusions: These results suggest that depressed individuals' diminished emotional reactivity may be mainly it state effect and may be limited to anticipated reward. Depression and Anxiety 26:117-122, 2009. (C) 2008 Wiley-Liss, Inc.
C1 [McFarland, Brian R.; Klein, Daniel N.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.
RP McFarland, BR (reprint author), Birmingham VAMC, 700 S 19th St, Birmingham, AL 35233 USA.
EM brian.macfarland@va.gov
NR 37
TC 36
Z9 36
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD FEB
PY 2009
VL 26
IS 2
BP 117
EP 122
DI 10.1002/da.20513
PG 6
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 406PN
UT WOS:000263307500003
PM 18972567
ER
PT J
AU Utzschneider, KM
Prigeon, RL
Faulenbach, MV
Tong, J
Carr, DB
Boyko, EJ
Leonetti, DL
McNeely, MJ
Fujimoto, WY
Kahn, SE
AF Utzschneider, Kristina M.
Prigeon, Ronald L.
Faulenbach, Mirjam V.
Tong, Jenny
Carr, Darcy B.
Boyko, Edward J.
Leonetti, Donna L.
McNeely, Marguerite J.
Fujimoto, Wilfred Y.
Kahn, Steven E.
TI Oral Disposition Index Predicts the Development of Future Diabetes Above
and Beyond Fasting and 2-h Glucose Levels
SO DIABETES CARE
LA English
DT Article
ID BETA-CELL FUNCTION; HEPATIC INSULIN EXTRACTION; HIGH-RISK; 1ST-DEGREE
RELATIVES; PREVENTION PROGRAM; TOLERANCE TEST; SENSITIVITY; RESISTANCE;
SECRETION; MELLITUS
AB OBJECTIVE - We sought to determine whether an oral disposition index (DI(O)) predicts the development of diabetes over a 10-year period. First, we assessed the validity of the DI(O) by demonstrating that a hyperbolic relationship exists between oral indexes of insulin sensitivity and beta-cell function.
RESEARCH DESIGN AND METHODS - A total of 613 Japanese-American subjects (322 men and 291 women) underwent a 75-g Oral glucose tolerance test (OGTT) at baseline, 5 years, and 1.0 years. Insulin sensitivity was estimated as 1/fasting insulin or homeostasis model assessment of insulin sensitivity (HOMA-S). Insulin response Was estimated as the change in insulin divided by change in glucose from 0 to 30 min (Delta l(0-30)/Delta G(0-30)).
RESULTS - Delta l(0-30)/Delta G(0-30) demonstrated a curvilinear relationship with 1/fasting insulin and HOMA-S With a left and downward shift as glucose tolerance deteriorated. The confidence limits for the slope of the log(e)-transformed estimates included -1 for Delta l(0-30)/Delta G(0-30) versus 1/fasting insulin for all glucose tolerance groups, consistent with a hyperbolic relationship. When HOMA-S was used as the insulin Sensitivity measure, the confidence limits for the slope included - I only for Subjects With normal glucose tolerance (NCT) or impaired fasting glucose (IFG/impaired glucose tolerance (IGT) but not diabetes. On the basis of this hyperbolic relationship, the product of Delta l(0-30)/Delta G(0-30) and 1/fasting insulin was calculated (DI(O)) and decreased fron NGT to IFG/IGT to diabetes (P < 0.001). Among nondiabetic subjects at baseline, baseline DI(O) predicted cumulative diabetes at 10 years (P<0.001) independent of age, sex, BMI, family history of diabetes, and baseline fasting and 2-h glucose concentrations.
CONCLUSIONS- The DI(O) provides a measure of beta-cell function adjusted for insulin sensitivity and is predictive of development of diabetes over 10 years.
C1 [Utzschneider, Kristina M.; Faulenbach, Mirjam V.; Tong, Jenny; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Utzschneider, Kristina M.; Faulenbach, Mirjam V.; Tong, Jenny; McNeely, Marguerite J.; Fujimoto, Wilfred Y.; Kahn, Steven E.] Univ Washington, Dept Med, Seattle, WA USA.
[Prigeon, Ronald L.] Baltimore Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA.
[Prigeon, Ronald L.] Univ Maryland, Sch Med, Div Gerontol, Baltimore, MD 21201 USA.
[Carr, Darcy B.] Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seattle, WA 98195 USA.
[Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
RP Utzschneider, KM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
EM kutzschn@u.washington.edu
OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X
FU Department of Veteran Affairs; Veteran Affairs Geriatrics Research,
Education, and Clinical Center; National Institutes of Health [DK-02654,
DK-31170, HL-49293, RR-00037, DK-35816, P30 DK-17047]
FX This work was supported by the Department of Veteran Affairs and the
Veteran Affairs Geriatrics Research, Education, and Clinical Center,
National Institutes of Health grants DK-02654, DK-31170, HL-49293,
RR-00037, DK-35816, and P30 DK-17047.
NR 25
TC 185
Z9 190
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2009
VL 32
IS 2
BP 335
EP 341
DI 10.2337/dc08-1478
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 402MV
UT WOS:000263018700024
PM 18957530
ER
PT J
AU Metra, M
Dei Cas, L
Massie, BM
AF Metra, Marco
Dei Cas, Livio
Massie, Barry M.
TI Treatment of heart failure in the elderly: never say it's too late
SO EUROPEAN HEART JOURNAL
LA English
DT Editorial Material
ID EJECTION FRACTION; MORTALITY; TRIAL; MANAGEMENT; MORBIDITY; DIGOXIN
C1 [Metra, Marco; Dei Cas, Livio] Univ Brescia, Dept Expt & Appl Med, Sect Cardiovasc Dis, I-25100 Brescia, Italy.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Metra, M (reprint author), Univ Brescia, Dept Expt & Appl Med, Sect Cardiovasc Dis, I-25100 Brescia, Italy.
EM metramarco@libero.it
OI Metra, Marco/0000-0001-6691-8568
NR 15
TC 10
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD FEB
PY 2009
VL 30
IS 4
BP 391
EP 393
DI 10.1093/eurheartj/ehp024
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 410UN
UT WOS:000263603900003
PM 19181708
ER
PT J
AU Nyholt, DR
Yu, CE
Visscher, PM
AF Nyholt, Dale R.
Yu, Chang-En
Visscher, Peter M.
TI On Jim Watson's APOE status: genetic information is hard to hide
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Letter
ID ONSET ALZHEIMERS-DISEASE; ASSOCIATION; GENOME; GENOTYPE; RISK
C1 [Nyholt, Dale R.; Visscher, Peter M.] Queensland Inst Med Res, Genet Epidemiol & Queensland Stat Genet Labs, Brisbane, Qld 4006, Australia.
[Yu, Chang-En] Univ Washington, Sch Med, Dept Med,Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol & Geriatr Med,Geriat Res Educ & Clin, Seattle, WA 98195 USA.
RP Nyholt, DR (reprint author), Queensland Inst Med Res, Genet Epidemiol & Queensland Stat Genet Labs, Brisbane, Qld 4006, Australia.
EM daleN@qimr.edu.au
RI Nyholt, Dale/C-8384-2013
OI Visscher, Peter/0000-0002-2143-8760
NR 13
TC 33
Z9 34
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD FEB
PY 2009
VL 17
IS 2
BP 147
EP 149
DI 10.1038/ejhg.2008.198
PG 3
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 395CJ
UT WOS:000262499600003
PM 18941475
ER
PT J
AU Tsai, TT
Trimarchi, S
Nienaber, CA
AF Tsai, T. T.
Trimarchi, S.
Nienaber, C. A.
TI Acute Aortic Dissection: Perspectives from the International Registry of
Acute Aortic Dissection (IRAD)
SO EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article
DE aorta; aortic dissection; mortality; follow-up studies
ID TRUE-LUMEN COLLAPSE; INTRAMURAL HEMATOMA; COMPUTED-TOMOGRAPHY;
TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VASCULAR COMPLICATIONS; PULSATILE
FLOW; FALSE LUMEN; PART II; COCAINE; MANAGEMENT
AB Acute aortic dissection is a rare but deadly disease first described over 200 years ago by the physician to the late King George II on necropsy. Over the ensuing 2 centuries, the understanding of the pathophysiology, presentation, diagnosis, treatment and follow-up has matured. In an effort to understand the contemporary treatment of this disease, the International Registry of Acute Aortic Dissection (IRAD) has enrolled over 2000 patients over the past 12 years. In this article we summarize the key lessons learned from this multi-national registry of patients presenting with acute aortic dissection. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
C1 [Tsai, T. T.] Univ Colorado, Div Cardiovasc Med, Dept Internal Med, Denver, CO 80202 USA.
[Tsai, T. T.] Denver Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr, Denver, CO 80220 USA.
[Trimarchi, S.] Policlin S Donato IRCCS, Cardiovasc Ctr E Malan, San Donato Milanese, Italy.
[Nienaber, C. A.] Univ Rostock, Rostock, Germany.
RP Tsai, TT (reprint author), Univ Colorado, Div Cardiovasc Med, Dept Internal Med, Denver, CO 80202 USA.
EM thomas.tsai@ucdenver.edu
RI Trimarchi, Santi/J-7361-2016
OI Trimarchi, Santi/0000-0001-5996-3264
NR 58
TC 134
Z9 164
U1 3
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1078-5884
J9 EUR J VASC ENDOVASC
JI Eur. J. Vasc. Endovasc. Surg.
PD FEB
PY 2009
VL 37
IS 2
BP 149
EP 159
DI 10.1016/j.ejvs.2008.11.032
PG 11
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 407HX
UT WOS:000263355300005
PM 19097813
ER
PT J
AU Jacobs, JV
Nutt, JG
Carlson-Kuhta, P
Stephens, M
Horak, FB
AF Jacobs, Jesse V.
Nutt, John G.
Carlson-Kuhta, Patricia
Stephens, Marilee
Horak, Fay B.
TI Knee trembling during freezing of gait represents multiple anticipatory
postural adjustments
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Freezing of gait; FoG; Parkinson's disease; Balance; Anticipatory
postural adjustment; Gait initiation
ID PARKINSONS-DISEASE; STEP INITIATION; MUSCLE TONE; MOVEMENT; LEVODOPA;
COORDINATION; ONSET; CAT
AB Freezing of gait (FoG) is an episodic, brief inability to step that delays gait initiation or interrupts ongoing gait. FoG is often associated with an alternating shaking of the knees, clinically referred to as knee trembling or trembling in place. The pathophysiology of FoG and of the concomitant trembling knees is unknown; impaired postural adjustment in preparation for stepping is one hypothesis. We examined anticipatory postural adjustments (APAs) prior to protective steps induced by a forward loss of balance in 10 Parkinson's disease (PD) subjects with marked FoG and in 10 control subjects. The amplitude and timing of the APAs were determined from changes in the vertical ground-reaction forces recorded by a force plate under each foot and were confirmed by electromyographic recordings of bilateral medial gastrocnemius, tibialis anterior and tensor fascia latae muscles. Protective steps were accomplished with a single APA followed by a step for control subjects, whereas PD subjects frequently exhibited multiple, alternating APAs coexistent with the knee trembling commonly observed during FoG as well as delayed, inadequate or no stepping. These Multiple APAs were not delayed in onset and were of similar or larger amplitude than the single APAs exhibited by the control subjects. These observations suggest that multiple APAs produce the knee trembling commonly associated with FoG and that FoG associated with a forward loss of balance is caused by an inability to couple a normal APA to the stepping motor pattern. Published by Elsevier Inc.
C1 [Jacobs, Jesse V.; Nutt, John G.; Carlson-Kuhta, Patricia; Stephens, Marilee; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA.
[Nutt, John G.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA.
RP Nutt, JG (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, OP-32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM nuttj@ohsu.edu
FU National Institutes of Health [AG06457]
FX We thank the subjects who participated in the protocol. We are grateful
for the help with data analysis from Edward King, Michael Amos, and
Christine Ryciewcz, and for the technical assistance from Dr. Charles
Russell and Edward King. This study was funded by the National
Institutes of Health, grant AG06457.
NR 35
TC 93
Z9 95
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD FEB
PY 2009
VL 215
IS 2
BP 334
EP 341
DI 10.1016/j.expneurol.2008.10.019
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 400TG
UT WOS:000262890900016
PM 19061889
ER
PT J
AU Sun, DX
Martinez, CO
Ochoa, O
Ruiz-Willhite, L
Bonilla, JR
Centonze, VE
Waite, LL
Michalek, JE
McManus, LM
Shireman, PK
AF Sun, Dongxu
Martinez, Carlo O.
Ochoa, Oscar
Ruiz-Willhite, Lourdes
Bonilla, Jose R.
Centonze, Victoria E.
Waite, Lindsay L.
Michalek, Joel E.
McManus, Linda M.
Shireman, Paula K.
TI Bone marrow-derived cell regulation of skeletal muscle regeneration
SO FASEB JOURNAL
LA English
DT Article
DE CC chemokine receptor 2; CCR2; chimera; inflammation;
monocyte/macrophage; myogenic progenitor cell
ID HEMATOPOIETIC STEM-CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
CC-CHEMOKINE RECEPTOR-2; SATELLITE CELLS; IN-VIVO; PROGENITOR CELLS;
CCR2-/-MICE; ALTERED INFLAMMATION; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS
AB Limb regeneration requires the coordination of multiple stem cell populations to recapitulate the process of tissue formation. Therefore, bone marrow (BM) -derived cell regulation of skeletal muscle regeneration was examined in mice lacking the CC chemokine receptor 2 (CCR2). Myofiber size, numbers of myogenic progenitor cells (MPCs), and recruitment of BM-derived cells and macrophages were assessed after cardiotoxin-induced injury of chimeric mice produced by transplanting BM from wild-type (WT) or CCR2(-/-) mice into irradiated WT or CCR2(-/-) host mice. Regardless of the host genotype, muscle regeneration and recruitment of BM-derived cells and macrophages were similar in mice replenished with WT BM, whereas BM-derived cells and macrophage accumulation were decreased and muscle regeneration was impaired in all animals receiving CCR2(-/-) BM. Furthermore, numbers of MPCs (CD34(+)/Sca-1(-)/CD45(-) cells) were significantly increased in mice receiving CCR2(-/-) BM despite the decreased size of regenerated myofibers. Thus, the expression of CCR2 on BM-derived cells regulated macrophage recruitment into injured muscle, numbers of MPC, and the extent of regenerated myofiber size, all of which were independent of CCR2 expression on host-derived cells. Future studies in regenerative medicine must include consideration of the role of BM-derived cells, possibly macrophages, in CCR2-dependent events that regulate effective skeletal muscle regeneration. - Sun, D., Martinez, C. O., Ochoa, O., Ruiz-Willhite, L., Bonilla, J. R., Centonze, V. E., Waite, L. L., Michalek, J. E., McManus, L. M., Shireman, P. K. Bone marrow-derived cell regulation of skeletal muscle regeneration. FASEB J. 23, 382-395 (2009)
C1 [Sun, Dongxu; Martinez, Carlo O.; Ochoa, Oscar; Ruiz-Willhite, Lourdes; Bonilla, Jose R.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
[Centonze, Victoria E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA.
[Waite, Lindsay L.; Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
[McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Shireman, Paula K.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA.
EM shireman@uthscsa.edu
FU UTHSCSA; San Antonio Cancer Institute [CA54174]; Nathan Shock Center
[AG013319]; Veterans Administration Merit Review; San Antonio Area
Foundation [Sun-UTHSCSA-060104]; National Institutes of Health, National
Heart, Lung, and Blood Institute [R01HL074236, F32HL090196]; [AG19316]
FX We acknowledge the expert technical assistance of Michael D. Wetzel and
Jimmy Wewer in these studies. A portion of the statistical analyses was
expertly performed by Lee Ann Zarzabal. The flow cytometry portion of
this work was performed at the Institutional Flow Cytometry Core of the
University of Texas Health Science Center, San Antonio (UTHSCSA). Images
were generated in the UTHSCSA Core Optical Imaging Facility, which is
supported by UTHSCSA, CA54174 (San Antonio Cancer Institute), AG013319
(Nathan Shock Center), and AG19316. These studies were supported, in
part, by a Veterans Administration Merit Review grant, the San Antonio
Area Foundation (Sun-UTHSCSA-060104), and the National Institutes of
Health (R01HL074236 and F32HL090196) from the National Heart, Lung, and
Blood Institute. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health. The authors have no relationships that pose a
conflict of interest for these studies.
NR 71
TC 53
Z9 53
U1 1
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB
PY 2009
VL 23
IS 2
BP 382
EP 395
DI 10.1096/fj.07-095901
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 400TZ
UT WOS:000262892900010
PM 18827026
ER
PT J
AU Sun, W
Hu, W
Xu, RJ
Jin, JF
Szulc, ZM
Zhang, GF
Galadari, SH
Obeid, LM
Mao, CG
AF Sun, Wei
Hu, Wei
Xu, Ruijuan
Jin, Junfei
Szulc, Zdzislaw M.
Zhang, Guofeng
Galadari, Sehamuddin H.
Obeid, Lina M.
Mao, Cungui
TI Alkaline ceramidase 2 regulates beta 1 integrin maturation and cell
adhesion
SO FASEB JOURNAL
LA English
DT Article
DE retinoic acid; protein kinase C; Golgi; sphingolipid
ID INTEGRIN RECEPTORS; ALPHA-5-BETA-1 INTEGRIN; MOLECULAR-CLONING;
CARCINOMA-CELLS; SPHINGOID BASES; DOWN-REGULATION; RETINOIC ACID;
GLYCOSYLATION; APOPTOSIS; EXPRESSION
AB The polypeptide core of the integrin beta 1 subunit (beta 1) is glycosylated sequentially in the endoplasmic reticulum and the Golgi complex to form beta 1 precursor and mature beta 1, respectively. The beta 1 precursor to mature beta 1 conversion, termed beta 1 maturation, regulates the cell surface levels and function of beta 1-containing integrins, beta 1 integrins. Here we demonstrate that the human alkaline ceramidase 2 (ACER2), a Golgi enzyme, regulates beta 1 maturation by controlling the generation of sphingosine. ACER2 overexpression inhibited beta 1 maturation, thus leading to a decrease in the levels of mature beta-1 in T-REx HeLa cells, whereas RNA interference-mediated knockdown of ACER2 enhanced beta 1 maturation in MCF-7 cells. ACER2 overexpression decreased the cell surface levels of beta 1 integrins, thus inhibiting cell adhesion to fibronectin or collagen, whereas ACER2 knockdown has the opposite effects. Treatment with all-trans retinoic acid (ATRA) increased both the expression of ACER2 and the generation of sphingosine in HeLa cells and inhibited beta 1 maturation. ACER2 knockdown attenuated the inhibitory effects of ATRA on both beta 1 maturation and cell adhesion. In contrast, treatment with phorbol myristate acetate (PMA), a protein kinase C activator, decreased the expression of ACER2 and sphingosine in T-REx HeLa cells, thus enhancing beta 1 maturation. ACER2 overexpression inhibited the stimulatory effects of PMA on both beta 1 maturation and cell adhesion. These results suggest that the ACER2/sphingosine pathway plays an important role in regulating beta 1 maturation and cell adhesion mediated by beta 1 integrins. Sun, W., Hu, W., Xu, R., Jin, J., Szulc, Z. M., Zhang, G., Galadari, S. H., Obeid, L. M, Mao, C. Alkaline ceramidase 2 regulates beta 1 integrin maturation and cell adhesion. FASEB J. 23, 656-666 (2009)
C1 [Sun, Wei; Xu, Ruijuan; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Hu, Wei; Jin, Junfei; Szulc, Zdzislaw M.; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Zhang, Guofeng] NIH, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA.
[Galadari, Sehamuddin H.] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates.
[Obeid, Lina M.] Ralph H Johnson Vet Adm Hosp, Charleston, SC USA.
RP Mao, CG (reprint author), Div Gen Internal Med, 114 Doughty St,Rm 605 STB,POB 250779, Charleston, SC 29425 USA.
EM maoc@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health [R01CA104834]; Veterans Affairs Merit
award
FX This work is supported by the National Institutes of Health grant
R01CA104834 (to C.M.) and a Veterans Affairs Merit award (to L.M.O.).
NR 40
TC 21
Z9 24
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB
PY 2009
VL 23
IS 2
BP 656
EP 666
DI 10.1096/fj.08-115634
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 400TZ
UT WOS:000262892900036
PM 18945876
ER
PT J
AU Baddley, JW
AF Baddley, John W.
TI Pinpointing prognostic indicators of fungal infections in transplant
patients
SO FUTURE MICROBIOLOGY
LA English
DT Review
DE Aspergillus; Candida; mortality; prognostic factors; transplant
ID SOLID-ORGAN TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; STEM-CELL
TRANSPLANTS; INVASIVE ASPERGILLOSIS; RISK-FACTORS; IMMUNOCOMPROMISED
PATIENTS; FLUCONAZOLE PROPHYLAXIS; ATTRIBUTABLE MORTALITY; CONTROLLED
TRIAL; RECIPIENTS
AB A number of advances have been made in the prevention and treatment of invasive fungal Infections (IFIs) in transplant recipients. However, despite best clinical efforts, patient outcomes are often disappointing. The study of prognostic indicators of IFI for transplant patients may aid in the development of improved prevention measures, or determine more aggressive treatment pathways. Owing to the rarity of IFI, appropriately powered studies are often difficult to achieve; moreover, a lack of standardized outcome definitions make study comparisons difficult. Herein, prognostic indicators for mortality in transplant patients with IFI are reviewed, with a focus on invasive aspergillosis and invasive candidiasis
C1 [Baddley, John W.] Univ Alabama, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Baddley, JW (reprint author), Univ Alabama, Birmingham, AL 35294 USA.
EM jbaddley@uab.ed
NR 40
TC 1
Z9 1
U1 1
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1746-0913
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD FEB
PY 2009
VL 4
IS 1
BP 77
EP 84
DI 10.2217/17460913.4.1.77
PG 8
WC Microbiology
SC Microbiology
GA 412VO
UT WOS:000263752500011
PM 19207101
ER
PT J
AU Artifon, ELA
Kumar, A
Eloubeidi, MA
Chu, A
Halwan, B
Sakai, P
Bhutani, MS
AF Artifon, Everson L. A.
Kumar, Atul
Eloubeidi, Mohamad A.
Chu, Adrienne
Halwan, Bhawna
Sakai, Paulo
Bhutani, Manoop S.
TI Prospective randomized trial of EUS versus ERCP-guided common bile duct
stone removal: an interim report (with video)
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article; Proceedings Paper
CT Digestive Disease Week Meeting/108th Annual Meeting of the
American-Gastroenterological-Association
CY MAY 19-24, 2007
CL Washington, DC
SP Amer Gastroenterol Assoc, Amer Assoc Study Liver Dis, Amer Soc Gastrointestinal Endoscopy, Soc Surg Alimentary Tract
ID MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASOUND;
MANAGEMENT
AB Background: EUS is being increasingly utilized for the diagnosis of choledocholithiasis and microlithiasis, especially in patients with biliary colic. Simultaneously, there is also a rising interest in the use of EUS for therapeutic interventions.
Objectives: Our goal was to assess the effectiveness of EUS-directed common bile duct (CBD) stone removal to compare its safety and effectiveness with ERCP-directed intervention.
Design: interim results of a prospective, randomized, single-center blinded clinical trial.
Setting: A single tertiary care referral center.
Patients: Fifty-two patients with uncomplicated CBD stones were prospectively randomized to CBD cannulation and stone removal under EUS or ERCP guidance.
Main Outcome Measurements and Interventions: Primary outcome measure was the rate of successful cannulation of the CBD. Secondary Outcome measures included Successful removal of stones and overall complication rates.
Results: CBD cannulation followed by stone extraction was successful in 23 of 26 patients (88.5%) in the EUS group (1) versus 25 of 26 patients (96.2%) in the ERCP group (11) (95% CI, -27.65%, 9.88%). Overall, there were 3 complications in the EUS group and 4 complications in the ERCP group.
Limitation: The current study is an interim report from a single center report and performed by a single operator.
Conclusions: Our preliminary analysis indicates that Outcomes following EUS-guided CBD stone retrieval are equivalent to those following ERCP EUS-related adverse events are similar to those following ERCP. ERCP and EUS-guided stone retrieval appears to be equally effective for therapeutic interventions of the bile duct. Additional studies are required to validate these preliminary results and to determine predictors of success of EUS-guided stone removal. (Gastrointest Endosc 2009;69:238-43.)
C1 [Kumar, Atul] SUNY Stony Brook, US Dept Vet Affairs, Stony Brook, NY 11794 USA.
[Artifon, Everson L. A.; Sakai, Paulo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
[Halwan, Bhawna] Suny Downstate Univ, Med Ctr, Brooklyn, NY USA.
[Eloubeidi, Mohamad A.] Univ Alabama, Birmingham, AL USA.
[Bhutani, Manoop S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Kumar, A (reprint author), SUNY Stony Brook, US Dept Vet Affairs, Stony Brook, NY 11794 USA.
EM atul.kumar2@va.gov
NR 9
TC 15
Z9 16
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD FEB
PY 2009
VL 69
IS 2
BP 238
EP 243
DI 10.1016/j.gie.2008.05.020
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 402JF
UT WOS:000263009300008
PM 19185687
ER
PT J
AU Shub, D
Darvishi, R
Kunik, ME
AF Shub, Denis
Darvishi, Roham
Kunik, Mark E.
TI Non-pharmacologic treatment of insomnia in persons with dementia
SO GERIATRICS
LA English
DT Article
DE aging; circadian rhythm; dementia; insomnia; light therapy; sleep
hygiene
ID ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; OLDER-ADULTS; SLEEP; DISTURBANCES;
MANAGEMENT; EXERCISE; PROJECT
AB The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia. Sleep disturbances and associated cognitive and behavioral symptoms in this patient population can be a significant contributor to morbidity, mortality, and caregiver burden. Despite the frequency with which sleep disorders are encountered in primary care, few evidence-based guidelines are available to guide physician treatment plans. Sedative-hypnotic medications are commonly prescribed but are associated with significant adverse effects and have limited efficacy data. Non-pharmacologic treatments can be safe and effective adjuncts or alternatives to medications but are often underused in clinical practice. This article reviews practical applications of modalities such as light therapy, exercise, and sleep-hygiene modification in treating insomnia In persons with dementia.
C1 [Shub, Denis; Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Darvishi, Roham] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Darvishi, Roham] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Kunik, Mark E.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
RP Shub, D (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
NR 16
TC 20
Z9 20
U1 4
U2 11
PU ADVANSTAR COMMUNICATIONS INC
PI WOODLAND HILLS
PA 6200 CANOGA AVE, 2ND FLR, WOODLAND HILLS, CA 91367 USA
SN 0016-867X
J9 GERIATRICS
JI Geriatrics
PD FEB
PY 2009
VL 64
IS 2
BP 22
EP 26
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 409UN
UT WOS:000263531400004
PM 19256583
ER
PT J
AU Liu, CF
Rubenstein, LV
Kirchner, JE
Fortney, JC
Perkins, MW
Ober, SK
Pyne, JM
Chaney, EF
AF Liu, Chuan-Fen
Rubenstein, Lisa V.
Kirchner, JoAnn E.
Fortney, John C.
Perkins, Mark W.
Ober, Scott K.
Pyne, Jeffrey M.
Chaney, Edmund F.
TI Organizational Cost of Quality Improvement for Depression Care
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Quality improvement; depression; primary care
ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC ILLNESS CARE; TRANSLATING EVIDENCE;
COLLABORATIVE CARE; HEALTH-CARE; MANAGEMENT; IMPLEMENTATION; IMPACT;
INTERVENTIONS; INNOVATIONS
AB We documented organizational costs for depression care quality improvement (QI) to develop an evidence-based, Veterans Health Administration (VA) adapted depression care model for primary care practices that performed well for patients, was sustained over time, and could be spread nationally in VA.
Project records and surveys from three multistate VA administrative regions and seven of their primary care practices.
Descriptive analysis.
We documented project time commitments and expenses for 86 clinical QI and 42 technical expert support team participants for 4 years from initial contact through care model design, Plan-Do-Study-Act cycles, and achievement of stable workloads in which models functioned as routine care. We assessed time, salary costs, and costs for conference calls, meetings, e-mails, and other activities.
Over an average of 27 months, all clinics began referring patients to care managers. Clinical participants spent 1,086 hours at a cost of $84,438. Technical experts spent 2,147 hours costing $197,787. Eighty-five percent of costs derived from initial regional engagement activities and care model design.
Organizational costs of the QI process for depression care in a large health care system were significant, and should be accounted for when planning for implementation of evidence-based depression care.
C1 [Liu, Chuan-Fen; Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA.
[Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA.
[Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] S Cent Mental Hlth Illness Res & Educ & Clin Ctr, N Little Rock, AR USA.
[Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR USA.
[Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] Univ Arkansas Med Sci, Div Hlth Serv Res, Dept Psychiat & Behav Sci, Little Rock, AR 72205 USA.
[Ober, Scott K.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
[Ober, Scott K.] Cleveland VA Med Ctr, Cleveland, OH USA.
[Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Liu, CF (reprint author), VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM chuan-fen.liu@va.gov
FU Health Services Research and Development, Department of Veterans Affairs
[MNT-02-209, MNT-01-027]; TIDES/WAVES/COVES
FX Joint Acknowledgement/Disclosure Statement: Funding provided by Health
Services Research and Development, Department of Veterans Affairs (grant
numbers MNT-02-209 and MNT-01-027).; We would like to acknowledge the
support and assistance from TIDES/WAVES/COVES project research staff in
submitting detailed project records and contributing their comments to
this paper. In addition, we would like to acknowledge the participation
and support from our three VISN partners (VISNs 10, 16, and 23).; There
are no contractual rights to review the manuscript before submission,
but there is a requirement that Health Services Research and
Development, Department of Veterans Affairs, be given a copy of the
accepted manuscript before publication. The views expressed herein are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs and other affiliated Institutions.
NR 42
TC 25
Z9 26
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD FEB
PY 2009
VL 44
IS 1
BP 225
EP 244
DI 10.1111/j.1475-6773.2008.00911.x
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 394TM
UT WOS:000262470800014
PM 19146566
ER
PT J
AU Rosendorff, C
AF Rosendorff, Clive
TI The Chicken and the Egg Sympathetic Nervous System Activity and Left
Ventricular Diastolic Dysfunction
SO HYPERTENSION
LA English
DT Editorial Material
ID MYOCARDIAL-INFARCTION; RATS
C1 [Rosendorff, Clive] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA.
RP Rosendorff, C (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM clive.rosendorff@va.gov
NR 8
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD FEB
PY 2009
VL 53
IS 2
BP 108
EP 109
DI 10.1161/HYPERTENSIONAHA.108.126177
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 396XM
UT WOS:000262625400002
PM 19124677
ER
PT J
AU Du, YH
Chen, AF
AF Du, Yan-Hua
Chen, Alex F.
TI A New Role for Caveolin-1 Regulation of Guanosine Triphosphate
Cyclohydrolase I and Tetrahydrobiopterin in Endothelial Cells
SO HYPERTENSION
LA English
DT Editorial Material
ID SIGNAL-TRANSDUCTION; VASCULAR-DISEASE; ACTIVATION
C1 [Du, Yan-Hua; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA.
[Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA.
RP Chen, AF (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, 2W109 151L-U,VAPHS,Univ Dr, Pittsburgh, PA 15240 USA.
EM chena5@upmc.edu
FU NIGMS NIH HHS [R01 GM077352, R01 GM077352-02, R01 GM077352-03, R01
GM077352-01]
NR 10
TC 3
Z9 4
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD FEB
PY 2009
VL 53
IS 2
BP 115
EP 117
DI 10.1161/HYPERTENSIONAHA.108.123356
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 396XM
UT WOS:000262625400005
PM 19104002
ER
PT J
AU Hernandez, MD
Mansouri, MD
Aslam, S
Zeluff, B
Darouiche, RO
AF Hernandez, Maria D.
Mansouri, Mohammad D.
Aslam, Saima
Zeluff, Barry
Darouiche, Rabih O.
TI Efficacy of Combination of N-acetylcysteine, Gentamicin, and
Amphotericin B for Prevention of Microbial Colonization of Ventricular
Assist Devices
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS INFECTION; CENTRAL VENOUS CATHETERS; BACTERIA;
BIOFILM
AB We assessed the in vitro antimicrobial activity and the in vivo efficacy of dipping ventricular assist devices in a combination of N-acetylcysteine, gentamicin, and amphotericin B (NAC/G/A). Ventricular assist devices dipped in NAC/G/A exhibited broad-spectrum antimicrobial activity in vitro and were less likely than undipped devices to become colonized with Staphylococcus aureus in a rabbit model.
C1 [Mansouri, Mohammad D.; Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA.
[Mansouri, Mohammad D.; Aslam, Saima; Darouiche, Rabih O.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Aslam, Saima; Zeluff, Barry] St Lukes Episcopal Hosp, Houston, TX 77030 USA.
[Hernandez, Maria D.; Aslam, Saima; Darouiche, Rabih O.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA.
RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA.
EM rdarouiche@aol.com
NR 10
TC 13
Z9 13
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD FEB
PY 2009
VL 30
IS 2
BP 190
EP 192
DI 10.1086/593205
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 394YV
UT WOS:000262490000013
PM 19090771
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Date of Birth in the Occurrence of Inflammatory Bowel Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE birth date; cyclic pattern; environmental risk factors; epidemiology of
inflammatory bowel disease; hospital statistics; seasonality of births;
time trends
ID CROHNS-DISEASE; ULCERATIVE-COLITIS; RECORD LINKAGE; TIME TRENDS;
CHILDHOOD; MORTALITY; RISK
AB Background: It has been Speculated that prenatal or perinatal exposure to infections affects the risk for developing inflammatory bowel disease (11313). The aims of the study were to investigate the seasonal and monthly variations of birth dates among patients with Crohn's disease (CD) and ulcerative colitis (UC).
Methods: The Hospital Episode Statistics (HES) comprises data of all patients admitted to hospitals in England. The data between April 1997 and March 2006 served to analyze birth dates of subjects with CD and UD, using the entirety of patients in the HES as controls.
Results: Monthly birth dates were aggregated for the same months across Consecutive birth years from January 1920 to December 1989 to determine whether a seasonal birth pattern existed among patients with CD and UC, No different seasonal birth patterns were observed between IBD patients and controls. A second analysis of individual months of birth, year after year, found that rates of births among 11313 patients fluctuated from month to month. These fluctuations were different for CD and UC, with an overall weak correlation of r = 0.078, P = 0.018. There was a slight trend for stronger correlations to occur during more recent decades of birth, with r = 0.237 (P = 0.009) and r = 0.168 (P = 0.067) for the last 2 decades 1970-1979 and 1980-1989, respectively.
Conclusions: The patterns of birth dates among IBD patients do not support the contention that seasonally or monthly varying environmental factors during early childhood shape the Subsequent risk of developing IBD.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 20
TC 10
Z9 12
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD FEB
PY 2009
VL 15
IS 2
BP 206
EP 211
DI 10.1002/ibd.20730
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 402TU
UT WOS:000263036800008
PM 18831526
ER
PT J
AU Weamer, EA
Emanuel, JE
Varon, D
Miyahara, S
Wilkosz, PA
Lopez, OL
DeKosky, ST
Sweet, RA
AF Weamer, Elise A.
Emanuel, James E.
Varon, Daniel
Miyahara, Sachiko
Wilkosz, Patricia A.
Lopez, Oscar L.
DeKosky, Steven T.
Sweet, Robert A.
TI The relationship of excess cognitive impairment in MCI and early
Alzheimer's disease to the subsequent emergence of psychosis
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE Alzheimer's disease; MCI (mild cognitive impairment); psychosis;
cognitive neuropsychology in dementia; assessment of cognitive
disorders/dementia
ID INCREASED FAMILIAL RISK; LAST 2 DECADES; RATING-SCALE; MOUSE MODELS;
SYMPTOMS; DELUSIONS; DIAGNOSIS; DEMENTIA; SCHIZOPHRENIA; HALLUCINATIONS
AB Background: Psychotic symptoms in Alzheimer disease (AD + P) identify a heritable phenotype associated with greater cognitive impairment. Knowing when the cognitive course of AD + P subjects diverges from that of subjects without psychosis would enhance understanding of how genetic variation results in AD + P and its associated cognitive burden. This study seeks to determine whether the degree of cognitive impairment and cognitive decline in early AD predicts subsequent AD + P onset.
Methods: 361 subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis were evaluated every 6 months until psychosis onset.
Results: Severity of cognitive dysfunction was a strong predictor of AD + P up to two years prior to psychosis onset. Cognition did not decline more rapidly prior to onset of AD + P.
Conclusions: Individuals who will develop AD + P already demonstrate excess cognitive impairment during the mild stages of disease. Genetic variation and brain pathophysiology may lead to a cognitive risk phenotype which is present prior to dementia onset.
C1 [Weamer, Elise A.; Emanuel, James E.; Varon, Daniel; Wilkosz, Patricia A.; Lopez, Oscar L.; DeKosky, Steven T.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weamer, Elise A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA USA.
[Miyahara, Sachiko] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
FU National Institute of Aging [AG05133, AG027224]
FX This study was supported in part by USPHS grant AG05133 and AG027224
from the National Institute of Aging. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institute of Aging or the National
Institutes of Health.
NR 46
TC 22
Z9 22
U1 1
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD FEB
PY 2009
VL 21
IS 1
BP 78
EP 85
DI 10.1017/S1041610208007734
PG 8
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA 408NI
UT WOS:000263441300010
PM 18814807
ER
PT J
AU Kim, MS
Casserly, IP
Garcia, JA
Klein, AJ
Salcedo, EE
Carroll, JD
AF Kim, Michael S.
Casserly, Ivan P.
Garcia, Joel A.
Klein, Andrew J.
Salcedo, Ernesto E.
Carroll, John D.
TI Percutaneous Transcatheter Closure of Prosthetic Mitral Paravalvular
Leaks Are We There Yet?
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE paravalvular leak; perivalvular leak; mitral valve; prosthetic valve;
3-dimensional echocardiography; percutaneous transcatheter closure;
rapid prototyping
ID AMPLATZER DUCT OCCLUDER; VALVE-REPLACEMENT; HEART-DISEASE;
REGURGITATION; HEMOLYSIS; ECHOCARDIOGRAPHY; COMPLICATION; MANAGEMENT;
OCCLUSION
AB A potential complication of mitral valve replacement surgery is the development of a paravalvular leak (PVL). Percutaneous transcatheter closures of PVLs using a wide array of devices have been reported in the literature, although the procedural success rate of this approach remains variable. One major challenge of transcatheter mitral PVL closure lies in the ability to adequately visualize the area of interest to facilitate defect crossing and equipment selection. Furthermore, the current spectrum of devices available for off-label use in the closure of these unique defects remains limited. This review examines the current state of transcatheter. prosthetic mitral PVL closure, describes our institution's experience using advanced imaging modalities for procedural guidance, and illustrates some of the limitations associated with using existing devices in transcatheter PVL closure. (J Am Coll Cardiol Intv 2009;2: 81-90) (C) 2009 by the American College of Cardiology Foundation
C1 [Kim, Michael S.; Casserly, Ivan P.; Garcia, Joel A.; Klein, Andrew J.; Salcedo, Ernesto E.; Carroll, John D.] Univ Colorado Denver, Aurora, CO 80045 USA.
[Casserly, Ivan P.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Garcia, Joel A.] Denver Hlth Med Ctr, Denver, CO USA.
RP Carroll, JD (reprint author), Univ Colorado Denver, Anschutz Med Campus,Leprino Off Bldg,Room 524,124, Aurora, CO 80045 USA.
EM John.Carroll@ucdenver.edu
NR 27
TC 67
Z9 71
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD FEB
PY 2009
VL 2
IS 2
BP 81
EP 90
DI 10.1016/j.jcin.2008.10.012
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 613HP
UT WOS:000278970300001
PM 19463407
ER
PT J
AU Morasco, BJ
Rifai, MA
Loftis, JM
Indest, DW
Moles, JK
Hauser, P
AF Morasco, Benjamin J.
Rifai, Muhamad Aly
Loftis, Jennifer M.
Indest, David W.
Moles, James Kelly
Hauser, Peter
TI A randomized trial of paroxetine to prevent interferon-alpha-induced
depression in patients with hepatitis C (vol 103, pg 83, 2007)
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Correction
C1 [Morasco, Benjamin J.; Rifai, Muhamad Aly; Loftis, Jennifer M.; Indest, David W.; Hauser, Peter] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA.
[Rifai, Muhamad Aly; Moles, James Kelly] Salem VA Med Ctr, Salem, VA USA.
[Morasco, Benjamin J.; Rifai, Muhamad Aly; Loftis, Jennifer M.; Indest, David W.; Hauser, Peter] Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA.
[Rifai, Muhamad Aly; Moles, James Kelly] Univ Virginia, Sch Med, Roanoke Salem, VA USA.
[Morasco, Benjamin J.; Rifai, Muhamad Aly; Loftis, Jennifer M.; Indest, David W.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Loftis, Jennifer M.; Hauser, Peter] Portland VA Med Ctr, JENS Lab, Portland, OR USA.
[Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA.
RP Hauser, P (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR USA.
EM peter.hauser@med.va.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB
PY 2009
VL 113
IS 1-2
BP 201
EP 201
DI 10.1016/j.jad.2008.10.001
PG 1
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 402IN
UT WOS:000263007500024
ER
PT J
AU Hedrick, SC
Guihan, M
Chapko, MK
Sullivan, J
Zhou, XH
Manheim, LM
Forsberg, CW
Mambourg, FJ
AF Hedrick, Susan C.
Guihan, Marylou
Chapko, Michael K.
Sullivan, Jean
Zhou, Xiao-Hua
Manheim, Larry M.
Forsberg, Christopher W.
Mambourg, Floss J.
TI Assisted Living Pilot Program Health Outcomes
SO JOURNAL OF AGING AND HEALTH
LA English
DT Article
DE assisted living; residential care facilities; long-term care; outcomes;
longitudinal design
ID RESIDENTIAL CARE; FACILITIES
AB Objectives: Assisted living programs demonstrate variation in structure and services. The Department of Veterans Affairs funded this care for the first time in the Assisted Living Pilot Program (ALPP). This article presents resident health outcomes and the relationship between facility characteristics and outcomes. Method: This article presents results on 393 ALPP residents followed for 12 months after admission to 95 facilities. Results: A total of 19.8% residents died, and the average activities of daily living impairment did not change significantly. Half of the residents remained in an ALPP facility, with the average resident spending 315 days in the community during the 12-month follow-up period. This article found a limited number of characteristics of structure and staffing to be significantly associated with outcomes. Discussion: If differences among facility characteristics are not clearly related to differences in outcomes, then choices among type of setting can be based on the match of needs to available services, location, or preferences.
C1 [Hedrick, Susan C.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Hedrick, Susan C.; Chapko, Michael K.; Zhou, Xiao-Hua] Univ Washington, Seattle, WA 98195 USA.
[Guihan, Marylou; Manheim, Larry M.] Northwestern Univ, Evanston, IL 60208 USA.
[Mambourg, Floss J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Hedrick, SC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM susan.hedrick@va.gov
NR 19
TC 4
Z9 4
U1 2
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0898-2643
J9 J AGING HEALTH
JI J. Aging Health
PD FEB
PY 2009
VL 21
IS 1
BP 190
EP 207
DI 10.1177/0898264308328929
PG 18
WC Gerontology; Health Policy & Services
SC Geriatrics & Gerontology; Health Care Sciences & Services
GA 399QL
UT WOS:000262814300009
PM 19074647
ER
PT J
AU Chapko, MK
Manheim, LM
Guihan, M
Sullivan, JH
Zhou, XHA
Wang, L
Mambourg, FJ
Hedrick, SC
AF Chapko, Michael K.
Manheim, Larry M.
Guihan, Marylou
Sullivan, Jean H.
Zhou, Xiao-Hua Andrew
Wang, Li
Mambourg, Floss J.
Hedrick, Susan C.
TI Assisted Living Pilot Program Utilization and Cost Findings
SO JOURNAL OF AGING AND HEALTH
LA English
DT Article
DE assisted living; residential care facilities; long-term care; cost
ID HEALTH-CARE; FACILITIES; HOMES
AB Objective: The Department of Veterans Affairs funded assisted living, adult family home, and adult residential care for the first time in the Assisted Living Pilot Program (ALPP) This article compares the use and cost for individuals that entered ALPP and a comparison group. Method: This was a nonrandomized study. The comparison group consisted of VA patients who were eligible but did not enter an ALPP facility. The ALPP (n = 393) and comparison (n = 259) groups were followed for 12 months to assess ALPP facility, case management, and health care costs. Results: ALPP facility and ALPP case management costs were respectively $5,560 and $2,830 per individual. Total health care costs, including ALPP costs, were $11,533 higher for the ALPP group compared to the comparison group after adjusting for baseline differences. Discussion: Although ALPP successfully helped individuals transition to longer term care in these facilities, it was more costly than the comparison group.
C1 [Chapko, Michael K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Chapko, Michael K.; Zhou, Xiao-Hua Andrew; Hedrick, Susan C.] Univ Washington, Seattle, WA 98195 USA.
[Manheim, Larry M.; Guihan, Marylou] Edward Hines Jr VA Hosp, Hines, IL 60141 USA.
[Manheim, Larry M.; Guihan, Marylou] Northwestern Univ, Evanston, IL 60208 USA.
[Mambourg, Floss J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Chapko, MK (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM chapko@u.washington.edu
NR 30
TC 1
Z9 1
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0898-2643
J9 J AGING HEALTH
JI J. Aging Health
PD FEB
PY 2009
VL 21
IS 1
BP 208
EP 225
DI 10.1177/0898264308328930
PG 18
WC Gerontology; Health Policy & Services
SC Geriatrics & Gerontology; Health Care Sciences & Services
GA 399QL
UT WOS:000262814300010
PM 19144975
ER
PT J
AU Springston, EE
Gupta, RS
Kim, JS
Smith, B
Pongracic, JA
Wang, X
Holl, JL
AF Springston, E. E.
Gupta, R. S.
Kim, J. S.
Smith, B.
Pongracic, J. A.
Wang, X.
Holl, J. L.
TI Food Allergy Knowledge, Attitudes, and Beliefs in the United States
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 13-17, 2009
CL Washington, DC
SP Amer Acad Allergy, Asthma & Immunol
C1 [Springston, E. E.; Gupta, R. S.; Kim, J. S.; Pongracic, J. A.; Wang, X.; Holl, J. L.] Childrens Mem Hosp, Chicago, IL 60614 USA.
[Gupta, R. S.; Smith, B.; Holl, J. L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Smith, B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2009
VL 123
IS 2
MA 688
BP S180
EP S180
DI 10.1016/j.jaci.2008.12.679
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 410RR
UT WOS:000263596301161
ER
PT J
AU Yong, PL
Werner, RM
AF Yong, P. L.
Werner, R. M.
TI The Impact of Geographic Variation on Racial Disparities in Asthma:
Controller Medication Use among Medicaid Asthmatics in Four Large States
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 13-17, 2009
CL Washington, DC
SP Amer Acad Allergy, Asthma & Immunol
C1 [Yong, P. L.; Werner, R. M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Yong, P. L.; Werner, R. M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2009
VL 123
IS 2
MA 581
BP S152
EP S152
DI 10.1016/j.jaci.2008.12.569
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 410RR
UT WOS:000263596301054
ER
PT J
AU Nakano, T
Inoue, I
Satoh, K
Yamazaki, M
Awata, T
Kurihara, S
Goto, S
Shinoda, Y
Komoda, T
Katayama, S
AF Nakano, Takanari
Inoue, Ikuo
Satoh, Kentaro
Yamazaki, Mochihito
Awata, Takuya
Kurihara, Susumu
Goto, Sei-ichi
Shinoda, Yu-ichi
Komoda, Tsugikazu
Katayama, Shigehiro
TI Treatment with Glimepiride, but not Mitiglinide and Short-Acting
Insulin, Resists Body Weight and Abdominal Fat Reduction Under Dietary
Energy Restriction
SO JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
LA English
DT Letter
DE Obesity; Lifestyle intervention; Oral hypoglycemic agents; Type 2
diabetes mellitus; Syndrome of inappropriate insulin secretion (SIIS)
ID TYPE-2 DIABETES-MELLITUS; SECRETION; SULFONYLUREAS; KAD-1229
C1 [Nakano, Takanari; Shinoda, Yu-ichi; Komoda, Tsugikazu] Saitama Med Univ, Fac Med, Dept Biochem, Saitama, Japan.
[Yamazaki, Mochihito] Kumagaya Surg Hosp, Saitama, Japan.
[Goto, Sei-ichi] Meikai Univ, Sch Dent, Dept Comprehens Med Sci, Div Internal Med, Saitama, Japan.
[Inoue, Ikuo] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
RP Nakano, T (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM nk.takanari@gmail.com
NR 13
TC 3
Z9 3
U1 0
U2 0
PU JAPAN ATHEROSCLEROSIS SOC
PI TOKYO
PA NICHINAI-KAIKAN B1, 3-28-8 HONGO BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 1340-3478
EI 1880-3873
J9 J ATHEROSCLER THROMB
JI J. Atheroscler. Thromb.
PD FEB
PY 2009
VL 16
IS 1
BP 63
EP 66
PG 4
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 413PK
UT WOS:000263804800009
PM 19261996
ER
PT J
AU Goebel, JR
Doering, LV
Evangelista, LS
Nyamathi, AM
Maliski, SL
Asch, SM
Sherbourne, CD
Shugarman, LR
Lanto, AB
Cohen, A
Lorenz, KA
AF Goebel, Joy R.
Doering, Lynn V.
Evangelista, Lorraine S.
Nyamathi, Adeline M.
Maliski, Sally L.
Asch, Steven M.
Sherbourne, Cathy D.
Shugarman, Lisa R.
Lanto, Andy B.
Cohen, Angela
Lorenz, Karl A.
TI A Comparative Study of Pain in Heart Failure and Non-Heart Failure
Veterans
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Palliative care; non-malignant pain; chronic pain; symptoms
ID QUALITY-OF-LIFE; PALLIATIVE CARE; CARDIAC-FAILURE; HEALTH; COMMUNITY;
SYMPTOMS; DEPRESSION; MANAGEMENT; DISEASE; ASSOCIATION
AB Background: Progress has been made in addressing pain in specific diseases such as cancer, but less attention has focused on understanding pain in nonmalignant states, including heart failure (HF).
Methods and Results: From March 2006 to June 2007, 672 veterans were surveyed and scores for the Brief Pain Inventory, pain distress, clinically significant pain levels (moderate to severe pain), and pain locations were compared using univariate and multivariate models. Fifteen percent of the final sample had HF (95/634). In our study, the HF patients were older (P < .000), reported lower levels of general health (P = .018), had more co-morbidities (P < .000), were more likely to have a history of cancer (P = .035), and suffered more chest pain and fewer headaches (P = .026, P = .03, respectively) than their non-HF cohorts. When controlling for age, co-morbidity and cancer disorders, HF and non-HF patients did not differ in pain severity, interference, distress or locations. Of the patients Currently experiencing pain, 67.3% of HF patients and 68.4% of non-HF patients rated their pain as moderate or severe (pain >= 4 on a 0 to 10 scale).
Conclusions: Although HF has not been identified as a painful condition, this study suggests the burden of pain is significant for both HF and non-HF ambulatory care patients. (J Cardiac Fail 2009:15:24-30)
C1 [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Long Beach, CA 90840 USA.
[Doering, Lynn V.; Evangelista, Lorraine S.; Nyamathi, Adeline M.; Maliski, Sally L.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Asch, Steven M.; Sherbourne, Cathy D.; Shugarman, Lisa R.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA.
[Asch, Steven M.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Asch, Steven M.; Lanto, Andy B.; Cohen, Angela; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Goebel, JR (reprint author), Calif State Univ Long Beach, Dept Nursing, 1250 Bellflower Blvd, Long Beach, CA 90840 USA.
OI Cohen, Angela B./0000-0002-0620-1909
FU Veterans Administration Health Services Research and Development
[IIR03-150]; VA HSR&D Career Development Award
FX Supported by a grant (IIR03-150) from the Veterans Administration Health
Services Research and Development. Dr. Karl Lorenz was supported by a VA
HSR&D Career Development Award.
NR 64
TC 10
Z9 10
U1 2
U2 3
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD FEB
PY 2009
VL 15
IS 1
BP 24
EP 30
DI 10.1016/j.cardfail.2008.09.002
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 408NJ
UT WOS:000263441400004
PM 19181290
ER
PT J
AU Voruganti, VS
Nath, SD
Cole, SA
Thameem, F
Jowett, JB
Bauer, R
MacCluer, JW
Blangero, J
Comuzzie, AG
Abboud, HE
Arar, NH
AF Voruganti, V. Saroja
Nath, Subrata D.
Cole, Shelley A.
Thameem, Farook
Jowett, Jeremy B.
Bauer, Richard
MacCluer, Jean W.
Blangero, John
Comuzzie, Anthony G.
Abboud, Hanna E.
Arar, Nedal H.
TI Genetics of Variation in Serum Uric Acid and Cardiovascular Risk Factors
in Mexican Americans
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID QUANTITATIVE-TRAIT LOCUS; METABOLIC SYNDROME; BLOOD-PRESSURE; LINKAGE
ANALYSIS; ATHEROSCLEROSIS RISK; CHEMOKINE RECEPTOR; RENAL-DISEASE;
FAMILY; HEART; HYPERURICEMIA
AB Background: Elevated serum uric acid is associated with several cardiovascular disease (CVD) risk factors such as hypertension, inflammation, endothelial dysfunction, insulin resistance, dyslipidemia, and obesity. However, the role of uric acid as an independent risk factor for CVD is not yet clear.
Objective: The aim of the study was to localize quantitative trait loci regulating variation in serum uric acid and also establish the relationship between serum uric acid and other CVD risk factors in Mexican Americans (n = 848; men = 310, women = 538) participating in the San Antonio Family Heart Study.
Methods: Quantitative genetic analysis was conducted using variance components decomposition method, implemented in the software program SOLAR.
Results: Mean +/- SD of serum uric acid was 5.35 +/- 1.38 mg/dl. Univariate genetic analysis showed serum uric acid and other CVD risk markers to be significantly heritable (P < 0.005). Bivariate analysis showed significant correlation of serum uric acid with body mass index, waist circumference, waist/hip ratio, total body fat, plasma insulin, serum triglycerides, high-density lipoprotein cholesterol, C-reactive protein, and granulocyte macrophage-colony stimulating factor (P < 0.05). A genome-wide scan for detecting quantitative trait loci regulating serum uric acid variation showed a significant logarithm of odds (LOD) score of 4.72 (empirical LOD score = 4.62; P < 0.00001) on chromosome 3p26. One LOD support interval contains 25 genes, of which an interesting candidate gene is chemokine receptor 2.
Summary: There is a significant genetic component in the variation in serum uric acid and evidence of pleiotropy between serum uric acid and other cardiovascular risk factors. (J Clin Endocrinol Metab 94: 632-638, 2009)
C1 [Voruganti, V. Saroja; Cole, Shelley A.; MacCluer, Jean W.; Blangero, John; Comuzzie, Anthony G.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78227 USA.
[Nath, Subrata D.; Thameem, Farook; Bauer, Richard; Abboud, Hanna E.; Arar, Nedal H.] Univ Texas Hlth Sci Ctr San Antonio, George OBrien Kidney Res Ctr, Div Nephrol, San Antonio, TX 78229 USA.
[Nath, Subrata D.; Thameem, Farook; Bauer, Richard; Abboud, Hanna E.; Arar, Nedal H.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Jowett, Jeremy B.] Int Diabet Inst, Caulfield, Vic 3162, Australia.
RP Voruganti, VS (reprint author), SW Fdn Biomed Res, Dept Genet, POB 760549, San Antonio, TX 78245 USA.
EM svorugan@sfbrgenetics.org
RI Jowett, Jeremy/A-3809-2009
FU San Antonio Family Heart Study; Fredric C. Bartter General Clinical
Research Center; University of Texas Health Science Center at San
Antonio, San Antonio, Texas [M01-RR01346]
FX We thank all participants of the San Antonio Family Heart Study for
their cooperation and generous participation. We also acknowledge the
Fredric C. Bartter General Clinical Research Center, University of Texas
Health Science Center at San Antonio, San Antonio, Texas (supported by
M01-RR01346), for providing clinical support for this project.
NR 48
TC 21
Z9 23
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD FEB
PY 2009
VL 94
IS 2
BP 632
EP 638
DI 10.1210/jc.2008-0682
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 403HC
UT WOS:000263072700046
PM 19001525
ER
PT J
AU Sayers, SL
Farrow, VA
Ross, J
Oslin, DW
AF Sayers, Steven L.
Farrow, Victoria A.
Ross, Jennifer
Oslin, David W.
TI Family Problems Among Recently Returned Military Veterans Referred for a
Mental Health Evaluation
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID CONFIRMATORY FACTOR-ANALYSIS; MEMORY-CONCENTRATION TEST; US ARMY
SOLDIERS; PRIMARY-CARE; DOMESTIC VIOLENCE; SYMPTOM STRUCTURE; DSM-IV;
DEPRESSION; RELIABILITY; DEPLOYMENT
AB Context: Existing evidence suggests, that military veterans with mental health disorders have poorer Family functioning, although little research has focused on this topic.
Objective: To test whether psychiatric symptoms are associated with family reintegration problems in recently returned military veterans.
Design: Cross-sectional survey of a clinical population. Respondents who were referred to behavioral health evaluation from April 2006 through August 2007 were considered for the survey.
Setting: Philadelphia Veterans Affairs Medical Center, Pa.
Participants: 199 military veterans who served in Iraq or Afghanistan after 2001 and were referred for behavioral health evaluation from primary care (mean age = 32.7 years, SD = 9.1).
Main Outcome Measures: Measures included the Mini-International Neuropsychiatric Interview for psychiatric diagnoses, the 9-item Patient Health Questionnaire for depression diagnosis and severity, and screening measures of alcohol abuse and illicit substance use. A measure of military family readjustment problems and a screening measure of domestic abuse were developed for this study.
Results: Three fourths of the married/cohabiting veterans reported some type of family problem in the past week, such as feeling like a guest in their household (40.7%), reporting their children acting afraid or not being warm toward them (25.0%), or being unsure about their family role (37.2%). Among veterans with current or recently separated partners, 53.7% reported conflicts involving "shouting, pushing, or shoving," and 27.6% reported that this partner was "afraid " of them." Depression and posttraumatic stress disorder symptoms were both associated with higher rates of family reintegration problems.
Conclusions: Mental health problems may complicate veterans' readjustment and reintegration into family life. The findings suggest an opportunity to improve the treatment of psychiatric disorders by addressing family problems.
C1 [Sayers, Steven L.; Farrow, Victoria A.; Ross, Jennifer; Oslin, David W.] Philadelphia VA Med Ctr, VISN 4, MIRECC 116, Philadelphia, PA 19104 USA.
[Sayers, Steven L.; Ross, Jennifer; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
RP Sayers, SL (reprint author), Philadelphia VA Med Ctr, VISN 4, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM Steven.sayers@va.gov
NR 38
TC 158
Z9 161
U1 9
U2 24
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD FEB
PY 2009
VL 70
IS 2
BP 163
EP 170
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 411DD
UT WOS:000263627300002
PM 19210950
ER
PT J
AU Bartlett, BL
Tyring, SK
Fife, K
Gnann, JW
Hadala, JT
Kianifard, F
Berberd, E
AF Bartlett, Brenda L.
Tyring, Stephen K.
Fife, Kenneth
Gnann, John W., Jr.
Hadala, Joseph T.
Kianifard, Farid
Berberd, Erhan
TI Famciclovir treatment options for patients with frequent outbreaks of
recurrent genital herpes: The RELIEF trial (vol 43, pg 190, 2008)
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Correction
C1 [Bartlett, Brenda L.; Tyring, Stephen K.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX 77030 USA.
[Fife, Kenneth] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Gnann, John W., Jr.] Univ Alabama, Birmingham, AL USA.
[Gnann, John W., Jr.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Hadala, Joseph T.; Kianifard, Farid; Berberd, Erhan] Novartis Pharmaceut, E Hanover, NJ 07936 USA.
RP Tyring, SK (reprint author), Univ Texas Houston, Hlth Sci Ctr, 6655 Travis, Houston, TX 77030 USA.
EM bbartlett@ccstexas.com; styring@ccstexas.com; kfife@iupui.edu;
jgnann@uab.edu; joseph.hadala@novartis.com;
farid.kianifard@novartis.com; erhan.berber@novartis.com
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD FEB
PY 2009
VL 44
IS 2
BP 183
EP 183
DI 10.1016/j.jcv.2008.11.012
PG 1
WC Virology
SC Virology
GA 416DU
UT WOS:000263986400024
ER
PT J
AU Lauer, AM
Dooling, RJ
Leek, MR
AF Lauer, Amanda M.
Dooling, Robert J.
Leek, Marjorie R.
TI Psychophysical evidence of damaged active processing mechanisms in
Belgian Waterslager Canaries
SO JOURNAL OF COMPARATIVE PHYSIOLOGY A-NEUROETHOLOGY SENSORY NEURAL AND
BEHAVIORAL PHYSIOLOGY
LA English
DT Article
DE Psychophysical tuning curve; Harmonic complex; Active processing;
Masking; Bird hearing
ID PARAKEET MELOPSITTACUS-UNDULATUS; HEARING-IMPAIRED LISTENERS; AUDITORY
HAIR-CELLS; TUNING CURVES; SERINUS-CANARIUS; FREQUENCY-SELECTIVITY;
HARMONIC COMPLEXES; BASILAR-MEMBRANE; MASKING; THRESHOLDS
AB Belgian Waterslager canaries (BWC), bred for a distinct low-pitched song, have an inherited high-frequency hearing loss associated with hair cell abnormalities. Hair cells near the abneural edge of the papilla, which receive primarily efferent innervation in normal birds, are among the most severely affected. These cells are thought to support nonlinear active processing in the avian ear, though the mechanisms are poorly understood. Here we present psychophysical evidence that suggests degraded active processing in BWC compared to normal-hearing non-BWC. Critical ratios, psychophysical masking patterns and phase effects on masking by harmonic complexes were measured in BWC and non-BWC using operant conditioning procedures. Critical ratios were much larger in BWC than in non-BWC at high frequencies. Psychophysical tuning curves derived from the masking patterns for BWC were broadened at high frequencies. BWC also showed severely reduced phase effects on masking by harmonic complexes compared to non-BWC. As has been hypothesized previously for hearing-impaired humans, these results are consistent with a loss of active processing mechanisms in BWC.
C1 [Lauer, Amanda M.; Dooling, Robert J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA.
[Leek, Marjorie R.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97207 USA.
RP Lauer, AM (reprint author), Johns Hopkins Univ, Dept Otolaryngol, 720 Rutland Ave,521 Traylor Res Bldg, Baltimore, MD 21205 USA.
EM alauer2@jhmi.edu
OI Lauer, Amanda/0000-0003-4184-7374
FU NIH [DC01372, DC-005450, DC-00626, DC-04664]; National Institutes of
Health; Animal Welfare Act of the USA
FX This work was supported by NIH Grants DC01372 to RJD, DC-005450 to AML,
DC-00626 to MRL, and DC-04664 ( Core Center grant) to the University of
Maryland. These experiments comply with the "Principles of care,''
publication No. 86-23, revised 1985 of the National Institutes of Health
and with the Animal Welfare Act of the USA.
NR 60
TC 6
Z9 6
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7594
J9 J COMP PHYSIOL A
JI J. Comp. Physiol. A -Neuroethol. Sens. Neural Behav. Physiol.
PD FEB
PY 2009
VL 195
IS 2
BP 193
EP 202
DI 10.1007/s00359-008-0398-z
PG 10
WC Behavioral Sciences; Neurosciences; Physiology; Zoology
SC Behavioral Sciences; Neurosciences & Neurology; Physiology; Zoology
GA 402AS
UT WOS:000262987200008
PM 19082827
ER
PT J
AU Song, D
Wang, Z
Marmarelis, VZ
Berger, TW
AF Song, Dong
Wang, Zhuo
Marmarelis, Vasilis Z.
Berger, Theodore W.
TI Parametric and non-parametric modeling of short-term synaptic
plasticity. Part II: Experimental study
SO JOURNAL OF COMPUTATIONAL NEUROSCIENCE
LA English
DT Article
DE Nonlinear modeling; Facilitation. Depression; Poisson stimulus; Volterra
kernels
ID PAIRED-PULSE DEPRESSION; GLUTAMATE-RECEPTOR DESENSITIZATION;
NONLINEAR-SYSTEMS ANALYSIS; PATH-DENTATE PROJECTION; PURKINJE-CELL
SYNAPSES; NEUROMUSCULAR-JUNCTION; PRESYNAPTIC TERMINALS; RELEASE
PROBABILITY; FACILITATION; RAT
AB This paper presents a synergistic parametric and non-parametric modeling study of short-term plasticity (STP) in the Schaffer collateral to hippocampal CA1 pyramidal neuron (SC) synapse. Parametric models in the form of sets of differential and algebraic equations have been proposed on the basis of the current understanding of biological mechanisms active within the system. Non-parametric Poisson-Volterra models are obtained herein from broadband experimental input-output data. The non-parametric model is shown to provide better prediction of the experimental output than a parametric model with a single set of facilitation/depression (FD) process. The parametric model is then validated in terms of its input-output transformational properties using the non-parametric model since the latter constitutes a canonical and more complete representation of the synaptic nonlinear dynamics. Furthermore, discrepancies between the experimentally-derived non-parametric model and the equivalent non-parametric model of the parametric model suggest the presence of multiple FD processes in the SC synapses. Inclusion of an additional set of FD process in the parametric model makes it replicate better the characteristics of the experimentally-derived non-parametric model. This improved parametric model in turn provides the requisite biological interpretability that the non-parametric model lacks.
C1 [Song, Dong; Marmarelis, Vasilis Z.; Berger, Theodore W.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
[Berger, Theodore W.] Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA.
[Song, Dong; Marmarelis, Vasilis Z.; Berger, Theodore W.] Univ So Calif, Ctr Neural Engn, Los Angeles, CA 90089 USA.
[Wang, Zhuo] VA Greater Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA.
RP Song, D (reprint author), Univ So Calif, Dept Biomed Engn, 403 Hedco Neurosci Bldg, Los Angeles, CA 90089 USA.
EM dsong@usc.edu
RI Song, Dong/A-8314-2010
FU NSF ERC; DARPA; ONR, NSF; NIH/NIBIB
FX This research was supported by the NSF ERC (BMES), DARPA ( HAND),ONR,
NSF ( BITS), and NIH/NIBIB (BMSR). We thank the two anonymous reviewers
for their insightful comments on this manuscript.
NR 39
TC 15
Z9 15
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5313
J9 J COMPUT NEUROSCI
JI J. Comput. Neurosci.
PD FEB
PY 2009
VL 26
IS 1
BP 21
EP 37
DI 10.1007/s10827-008-0098-2
PG 17
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA 407QI
UT WOS:000263379000002
PM 18504530
ER
PT J
AU Finan, KR
Renton, D
Vick, CC
Hawn, MT
AF Finan, Kelly R.
Renton, David
Vick, Catherine C.
Hawn, Mary T.
TI Prevention of Post-operative Leak Following Laparoscopic Heller Myotomy
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
CT Annual Meeting of the
Society-of-American-Gastrointestinal-and-Endoscopic-Surgeons
CY APR 16-22, 2007
CL Las Vegas, NV
SP Soc Amer Gastrointestinal & Endoscop Surg
DE Esophageal achalasia; Laparoscopic surgery; Post-operative complication;
Intra-operative procedures; Heller myotomy
ID PREVIOUS ENDOSCOPIC TREATMENT; BOTULINUM TOXIN INJECTION; LONG-TERM
EFFICACY; ESOPHAGEAL ACHALASIA; TOUPET FUNDOPLICATION; FORCEFUL
DILATATION; DOR FUNDOPLICATION; ESOPHAGOMYOTOMY; DILATION; OUTCOMES
AB Laparoscopic Heller myotomy is the preferred treatment for achalasia. Post-operative leaks cause significant morbidity and impair functional outcome. This study assesses the efficacy of intra-operative leak testing on post-operative leak rate.
A retrospective analysis of 106 consecutive patients undergoing laparoscopic Heller myotomy by a single surgeon between November 2001 and August 2006 was undertaken. Intra-operative leak testing was performed in all patients. Variables associated with intra-operative mucosotomy were assessed by univariate analysis and logistic regression modeling.
Intra-operative mucosotomy occurred in 25% of patients. All mucosotomies were repaired primarily and tested with methylene-blue-stained saline. Dor fundoplication was performed in 74% of the patients. There were no post-operative leaks and patients were started on diet day of surgery. Mean LOS was 1.4(+/- 0.7) days. Logistic regression modeling demonstrated that prior myotomy was associated with a statistically significant increase in the rate of mucosotomy (p = 0.033), while previous botox injection (p = 0.193), pneumatic dilation (p = 0.599) or concomitant hiatal hernia (p = 0.874) were not significantly associated with mucosotomy.
Laparoscopic Heller myotomy for the treatment of achalasia is a safe procedure. Intra-operative leak testing minimizes the risk of post-operative leaks and expedites post-operative management. Prior endoscopic treatment does not impair operative results.
C1 [Finan, Kelly R.; Renton, David; Vick, Catherine C.; Hawn, Mary T.] Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA.
[Vick, Catherine C.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA.
RP Hawn, MT (reprint author), Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, KB 417 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM mhawn@uab.edu
NR 42
TC 6
Z9 7
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD FEB
PY 2009
VL 13
IS 2
BP 200
EP 205
DI 10.1007/s11605-008-0687-4
PG 6
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 402AU
UT WOS:000262987400004
PM 18781365
ER
PT J
AU Starrels, JL
Barg, FK
Metlay, JP
AF Starrels, Joanna L.
Barg, Frances K.
Metlay, Joshua P.
TI Patterns and Determinants of Inappropriate Antibiotic Use in Injection
Drug Users
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE antibiotics; adherence; injection drug use; self-medication
ID RESISTANT STAPHYLOCOCCUS-AUREUS; METHICILLIN-RESISTANT; ANTIRETROVIRAL
THERAPY; SAN-FRANCISCO; COMMUNITY; INFECTIONS; ADHERENCE; ABSCESSES;
METAANALYSIS; PREVALENCE
AB Inappropriate antibiotic use contributes to the emergence and spread of drug resistant infections. Though injection drug users are at increased risk for drug resistant infections, few studies have examined antibiotic use in this population.
To understand patterns and determinants of antibiotic use among injection drug users.
Five focus groups were conducted with 28 current injection drug users recruited from a syringe exchange program in Philadelphia and analyzed using the constant comparative method to identify emergent themes. Twenty-six participants also completed a written survey instrument.
Injection drug users reported frequent antibiotic exposure, with 12 of 26 participants reporting use of antibiotic medications at least once in the previous 30 days. Participants reported several patterns of antibiotic use that were potentially harmful, including delays in seeking medical care, failing to fill prescriptions, obtaining antibiotics from non-provider sources, and poor adherence to prescribed regimens. The major determinants of inappropriate antibiotic use were delayed recognition of severity of illness, reluctance to wait to be seen, previous mistreatment by providers, lack of insurance, prioritizing purchasing drugs of abuse over antibiotics, forgetting to take antibiotics because of distractions that accompany drug use, concerns about interactions between antibiotics and other substances, and an irregular diet. Additionally, injection drug users commonly misunderstood the concept of antibiotic resistance and equated it with tolerance.
Injection drug users reported potentially dangerous antibiotic use behaviors and described determinants of these behaviors. Outreach and educational interventions to improve antibiotic use should target high-risk populations, such as injection drug users, and consider their distinct antibiotic use behaviors and determinants.
C1 [Starrels, Joanna L.; Metlay, Joshua P.] Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Starrels, Joanna L.; Metlay, Joshua P.] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Starrels, Joanna L.; Metlay, Joshua P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Barg, Frances K.] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA.
[Barg, Frances K.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Starrels, Joanna L.] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA.
[Starrels, Joanna L.] Montefiore Med Ctr, Bronx, NY 10467 USA.
RP Starrels, JL (reprint author), Albert Einstein Coll Med, Div Gen Internal Med, 111 E 210th St, Bronx, NY 10467 USA.
EM jostarre@montefiore.org
FU NIDA NIH HHS [K23 DA027719]
NR 44
TC 1
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD FEB
PY 2009
VL 24
IS 2
BP 263
EP 269
DI 10.1007/s11606-008-0859-7
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 397GO
UT WOS:000262651100018
PM 19082860
ER
PT J
AU Piccini, JP
Hernandez, AF
Dibernardo, LR
Rogers, JG
Dhallwal, G
AF Piccini, Jonathan P.
Hernandez, Adrian F.
Dibernardo, Louis R.
Rogers, Joseph G.
Dhallwal, Gurpreet
TI A Change of Heart
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID RIGHT-VENTRICULAR DYSPLASIA; DYSPLASIA/CARDIOMYOPATHY
C1 [Piccini, Jonathan P.; Hernandez, Adrian F.; Rogers, Joseph G.] Duke Univ, Duke Clin Res Inst, Div Cardiovasc Med, Med Ctr, Durham, NC 27710 USA.
[Dibernardo, Louis R.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Dhallwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Dhallwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Piccini, JP (reprint author), Duke Univ, Duke Clin Res Inst, Div Cardiol, Med Ctr, DUMC 3115, Durham, NC 27710 USA.
EM jonathan.piccini@duke.edu
RI Hernandez, Adrian F./A-7818-2016
OI Hernandez, Adrian F./0000-0003-3387-9616
NR 11
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD FEB
PY 2009
VL 4
IS 2
BP 131
EP 136
DI 10.1002/jhm.426
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 413QK
UT WOS:000263807400008
PM 19219930
ER
PT J
AU Goldstein, NB
Johannes, WU
Gadeliya, AV
Green, MR
Fujita, M
Norris, DA
Shellman, YG
AF Goldstein, Nathaniel B.
Johannes, Widya U.
Gadeliya, Agnessa V.
Green, Matthew R.
Fujita, Mayumi
Norris, David A.
Shellman, Yiqun G.
TI Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression
in Melanocytic Cells
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-CELLS; BH3-ONLY PROTEIN; APOPTOSIS;
MELANOMA; SUPPRESSION; PATHWAY; CANCER; DEGRADATION; ACTIVATION
AB B-Raf and N-Ras proteins are often activated in melanoma, yet their roles in producing inherent survival signals are not fully understood. In this study, we investigated how N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis induced by detachment from the extracellular matrix (anoikis). We found that expression of constitutively active N-RAS(Q61K) and B-RAF(V600E) downregulated the proapoptotic Bim protein in an immortalized melanocyte cell line. Bim is one of the main proapoptotic mediators of anoikis. Western blot analysis showed that detachment increased Bim expression in melanocytes, and Annexin V staining indicated that detachment induced cell death significantly in melanocytes. Blocking Bim expression by using RNAi vectors or by expressing N-RAS(Q61K) significantly inhibited anoikis in melanocytes. In summary, this report indicates that N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis in part by downregulating Bim expression, suggesting that Bim is a possible treatment target for overriding melanoma's inherent defenses against cell death.
C1 [Goldstein, Nathaniel B.; Johannes, Widya U.; Gadeliya, Agnessa V.; Green, Matthew R.; Fujita, Mayumi; Norris, David A.; Shellman, Yiqun G.] Univ Colorado Denver, Sch Med, Dept Dermatol, Aurora, CO 80010 USA.
[Norris, David A.] US Dept Vet Affairs, Med Ctr, Dermatol Sect, Denver, CO USA.
RP Shellman, YG (reprint author), Univ Colorado Denver, Sch Med, Dept Dermatol, Mail Stop 8127,POB 6511, Aurora, CO 80010 USA.
EM Yiqun.Shellman@uchsc.edu
FU Dermatology Foundation Career Award; NIAMS [R01AR26427-18]; Veterans
Administrations merit grant [PN: 0012]
FX This work was supported in part by Dermatology Foundation Career Award
(YGS), NIAMS grant R01AR26427-18 (DAN), and Veterans Administrations
merit grant PN: 0012 (DAN). We thank Anne Brauweiler for her critique of
the paper.
NR 28
TC 13
Z9 13
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD FEB
PY 2009
VL 129
IS 2
BP 432
EP 437
DI 10.1038/jid.2008.227
PG 6
WC Dermatology
SC Dermatology
GA 397IH
UT WOS:000262655600024
PM 18668139
ER
PT J
AU Li, XL
Lu, L
Bush, DJ
Zhang, XW
Zheng, L
Suswam, EA
King, PH
AF Li, Xuelin
Lu, Liang
Bush, Donald J.
Zhang, Xiaowen
Zheng, Lei
Suswam, Esther A.
King, Peter H.
TI Mutant copper-zinc superoxide dismutase associated with amyotrophic
lateral sclerosis binds to adenine/uridine-rich stability elements in
the vascular endothelial growth factor 3'-untranslated region
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE RNA stability; HuR; RNA-binding proteins; electrophoresis mobility shift
assay
ID MESSENGER-RNA STABILITY; MALIGNANT GLIOMA-CELLS; CENTRAL-NERVOUS-SYSTEM;
ANGIOGENIC FACTOR; PROTEIN HUR; CU,ZN-SUPEROXIDE DISMUTASE;
GENE-EXPRESSION; IN-VITRO; ELAV; MUTATIONS
AB Vascular endothelial growth factor (VEGF) is a neurotrophic factor essential for maintenance of motor neurons. Loss of this factor produces a phenotype similar to amyotrophic lateral sclerosis (ALS). We recently showed that ALS-producing mutations of Cu/Zn-superoxide dismutase (SOD1) disrupt post-transcriptional regulation of VEGF mRNA, leading to significant loss of expression [Lu et al., J. Neurosci.27 (2007), 7929]. Mutant SOD1 was present in the ribonucleoprotein complex associated with adenine/uridine-rich elements (ARE) of the VEGF 3'-untranslated region (UTR). Here, we show by electrophoretic mobility shift assay that mutant SOD1 bound directly to the VEGF 3'-UTR with a predilection for AREs similar to the RNA stabilizer HuR. SOD1 mutants A4V and G37R showed higher affinity for the ARE than L38V or G93A. Wild-type SOD1 bound very weakly with an apparent K(d) 11- to 72-fold higher than mutant forms. Mutant SOD1 showed an additional lower shift with VEGF ARE that was accentuated in the metal-free state. A similar pattern of binding was observed with AREs of tumor necrosis factor-alpha and interleukin-8, except only a single shift predominated. Using an ELISA-based assay, we demonstrated that mutant SOD1 competes with HuR and neuronal HuC for VEGF 3'-UTR binding. To define potential RNA-binding domains, we truncated G37R, G93A and wild-type SOD1 and found that peptides from the N-terminal portion of the protein that included amino acids 32-49 could recapitulate the binding pattern of full-length protein. Thus, the strong RNA-binding affinity conferred by ALS-associated mutations of SOD1 may contribute to the post-transcriptional dysregulation of VEGF mRNA.
C1 [Li, Xuelin; Lu, Liang; Bush, Donald J.; Zhang, Xiaowen; Zheng, Lei; Suswam, Esther A.; King, Peter H.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA.
[Li, Xuelin; Lu, Liang; Zheng, Lei; King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA.
[King, Peter H.] Univ Alabama, Dept Genet, Birmingham, AL 35233 USA.
[King, Peter H.] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35233 USA.
RP King, PH (reprint author), Suite 260 Sparks Ctr,1720 7th Ave S, Birmingham, AL 35233 USA.
EM pking@uab.edu
FU NIH/NINDS [NS058538]; Department of Veterans Affairs
FX This study was supported by NIH/NINDS NS058538 (PHK) and a Merit Review
Award from Department of Veterans Affairs (PHK).
NR 76
TC 19
Z9 19
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD FEB
PY 2009
VL 108
IS 4
BP 1032
EP 1044
DI 10.1111/j.1471-4159.2008.05856.x
PG 13
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 395IF
UT WOS:000262517100017
PM 19196430
ER
PT J
AU Christine, CW
Langston, JW
Turner, RS
Starr, PA
AF Christine, Chadwick W.
Langston, J. William
Turner, Robert S.
Starr, Philip A.
TI The neurophysiology and effect of deep brain stimulation in a patient
with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism
SO JOURNAL OF NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT 9th International Congress of Parkinsons Disease and Movement Disorders
CY MAR 05-08, 2005
CL New Orleans, LA
DE deep brain stimulation; Parkinson disease; physiology; subthalamic
nucleus; toxin
ID MPTP-TREATED PRIMATE; SUBTHALAMIC NUCLEUS; NEURONAL-ACTIVITY; DISEASE;
MODEL; LEVODOPA; LESIONS
AB Parkinsonism caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure was first identified in intravenous drug users. This neurotoxicant has since been used extensively in nonhuman primates to induce an experimental model of Parkinson disease (PD). In this study, the authors examined the intraoperative physiological characteristics and efficacy of subthalamic nucleus deep brain stimulation (DBS) in 1 of only 4 known living patients with MPTP-induced parkinsonism. The physiological recordings were consistent with recordings from MPTP-treated primates and humans with PD, thus providing further validation for the MPTP model in the study of the neurophysiology of the nigrostriatal dopaminergic deficit in PD. Furthermore, DBS produced a significant clinical improvement in this patient similar to the improvement seen after DBS in patients with idiopathic PD. This unique case has important implications for translational research that employs the MPTP-primate model for symptomatic therapy in PD. (DOI: 10.3171/2008.8.JNS08882)
C1 [Christine, Chadwick W.; Starr, Philip A.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA.
[Christine, Chadwick W.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
[Langston, J. William] Parkinsons Inst, Sunnyvale, CA USA.
[Turner, Robert S.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA.
[Starr, Philip A.] San Francisco VA Med Ctr, Parkinson Dis Res Educ & Clin Ctr, San Francisco, CA USA.
RP Christine, CW (reprint author), Univ Calif San Francisco, Sch Med, Dept Neurol, 400 Parnassus Ave,Room A838, San Francisco, CA 94143 USA.
EM chad.christine@ucsf.edu
FU NINDS NIH HHS [R01 NS044551-06, R01 NS044551, R21 NS055197, R21
NS055197-01A2]
NR 15
TC 3
Z9 3
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD FEB
PY 2009
VL 110
IS 2
BP 234
EP 238
DI 10.3171/2008.8.JNS08882
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 399GI
UT WOS:000262788000005
PM 19099380
ER
PT J
AU O'Neill, SM
Ettner, SL
Lorenz, KA
AF O'Neill, Sean M.
Ettner, Susan L.
Lorenz, Karl A.
TI Are Rural Hospices at a Financial Disadvantage? Evidence from California
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
CT Annual Meeting of the
American-Academy-of-Hospice-and-Palliative-Medicine
CY FEB 08-11, 2006
CL Nashville, TN
SP Amer Acad Hospice & Palliat Med
DE Hospice; palliative care; rural health care; economics
ID ACCESS; CARE
AB Concerns have been voiced about financial pressures faced by rural hospices, because of possible implications for hospice access in rural areas. To assess whether financial performance differs between existing urban and rural hospices, we used the 2003 California Office of Statewide Health Planning and Development survey to compare revenues, costs, and profitability (with and without charitable donations). We adjusted for factors related to financial performance, including agency size, years in operation, profit status, whether hospices were freestanding or chain-, home-health or hospital-based, and the proportion of patients by insurance type and referral source, race/ethnicity, and diagnosis. One hundred forty-four (91%) hospices were urban, and 14 (9%) were rural. Mean values per patient for total revenue, total cost, and post-tax profil were $7203, $7440 and -$256, respectively, for urban hospices and $6726, $6274 and $452, respectively, for-rural hospices. Compared with urban hospices, rural hospices were at least as profitable per patient-day (+$33, P = 0.15). They were significantly more profitable (+$47, P = 0.05) when charitable donations were excluded. In summary, we found that in California, rural hospices fared no worse financially than urban hospices. These counterintuitive findings underscore the need to examine urban-rural hospice financial differences using a national sample. J Pain Symptom Manage 2009;37:189-195. (c) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [O'Neill, Sean M.] Pardee RAND Grad Sch, Santa Monica, CA 90407 USA.
[Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP O'Neill, SM (reprint author), Pardee RAND Grad Sch, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.
EM soneill@prgs.edu
OI O'Neill, Sean/0000-0001-7759-8942
NR 12
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2009
VL 37
IS 2
BP 189
EP 195
DI 10.1016/j.jpainsymman.2008.01.008
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 412BO
UT WOS:000263698400006
PM 18599260
ER
PT J
AU Bates-Jensen, BM
Guihan, M
Garber, SL
Chin, AS
Burns, SP
AF Bates-Jensen, Barbara M.
Guihan, Marylou
Garber, Susan L.
Chin, Amy S.
Burns, Stephen P.
TI Characteristics of Recurrent Pressure Ulcers in Veterans With Spinal
Cord Injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Pressure ulcers, recurrent; Spinal cord injuries; Paraplegia; Closure,
mucocutaneous flap; Wound healing; Veterans; Bates-Jensen Wound
Assessment Tool; Salzburg Pressure Ulcer Risk Score
ID SURGICAL-TREATMENT; RISK-FACTORS; SORES; PREVALENCE; PREVENTION;
COVERAGE; EXPERIENCE; PEOPLE
AB Background/Objective: To describe characteristics of recurrent pressure ulcers (PrUs) in veterans with spinal cord injury (SCI).
Design: Descriptive, cohort study.
Settings and Participants: Twenty-four veterans with SCI from 6 SCI centers in the Department of Veterans Affairs.
Methods: Data from a prospective study evaluating PrUs were analyzed for 24 veterans with 29 recurrent PrUs during 9 months. Additional retrospective medical record data were analyzed for 15 veterans who received inpatient treatment.
Results: Participants were male, 50% non-Hispanic white, with paraplegia (63%), complete SCI (83%), a mean age of 56 years, and mean time since SCI of 21 years. Most PrUs recurred (63%, n = 15 patients) in the same location as the most recent ulcer and at the ischial tuberosities (63%). Mean time to recurrence was 16.6 weeks. PrUs were stage III (28%, n = 8) or IV (45%, n = 13) with undermining (48%), necrotic slough (50%), and minimal exudate. One third were (n = 9) larger than 16 cm(2). Mean Bates-Jensen Wound Assessment Tool Score was 33.63. Inpatient medical record data (n = 15) showed 73% with documentation indicating infection treated with antibiotics (53%, n = 8 patients), osteomyelitis (47%, n = 7), and/or cellulitis (13%, n = 2) noted. Plastic surgery consultation was obtained for 67% with surgery as an option for 73% (1 without consultation). Scheduled repositioning was documented for 21%.
Conclusions: Most PrUs were severe, located at the same anatomic site, and recurred within 4 months, suggesting that the recurrent ulcers were more likely incomplete healing of the initial PrUs. This sample of veterans with SCI provides early data on recurrent PrU characteristics.
C1 [Bates-Jensen, Barbara M.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA.
[Bates-Jensen, Barbara M.] VA Greater Angeles Healthcare Syst, Ctr Clin, Los Angeles, CA USA.
[Bates-Jensen, Barbara M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Guihan, Marylou; Chin, Amy S.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA.
[Guihan, Marylou] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Garber, Susan L.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
[Burns, Stephen P.] VA Puget Sound Hlth Care Syst, SCI Serv, Seattle, WA USA.
[Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Bates-Jensen, BM (reprint author), Univ Calif Los Angeles, Sch Nursing, 5-954 Factor Bldg,700 Tiverton Ave, Los Angeles, CA 90095 USA.
EM bbatesjensen@sonnet.ucla.edu
NR 36
TC 29
Z9 30
U1 2
U2 2
PU AMER PARAPLEGIA SOC
PI JACKSON HWIGHTS
PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD FEB
PY 2009
VL 32
IS 1
BP 34
EP 42
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 413ME
UT WOS:000263796400005
PM 19264047
ER
PT J
AU Friedlander, AH
Yoshikawa, TT
Chang, DS
Feliciano, Z
Scully, C
AF Friedlander, Arthur H.
Yoshikawa, Thomas T.
Chang, Donald S.
Feliciano, Zenaida
Scully, Crispian
TI Atrial fibrillation Pathogenesis, medical-surgical management and dental
implications
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Review
DE Cardiovascular diseases; stroke; anticoagulation therapy
ID ORAL ANTICOAGULANT-THERAPY; INTERNATIONAL NORMALIZED RATIO;
DRUG-INTERACTIONS; ANTITHROMBOTIC THERAPY; VITAMIN-K;
CARDIOVERTER-DEFIBRILLATORS; CARDIOVASCULAR HEALTH; ISCHEMIC-STROKE;
RHYTHM CONTROL; RISK-FACTORS
AB Background. Atrial fibrillation (AF) is a cardiac rhythm disturbance arising from disorganized electrical activity in the atria, and it is accompanied by an irregular and often rapid ventricular response. It is the most common clinically significant dysrhythmia in the general and older population.
Types of Studies Reviewed. The authors conducted a MEDLINE search using the key terms "atrial fibrillation," "epidemiology," "pathophysiology," "treatment" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials.
Clinical Implications. The anticoagulant warfarin frequently is prescribed to prevent stroke caused by cardiogenic thromboemboli arising from stagnant blood in poorly contracting atria. Most dental procedures and a limited number of surgical procedures can be performed without altering warfarin dosage if the international normalized ratio value is within the therapeutic range of 2.0 to 3.0. Certain analgesic agents, antibiotic agents, antifungal agents and sedative hypnotics, however, should not be prescribed without consultation with the patient's physician because these medications may alter the patient's risk of hemorrhage and stroke.
Conclusions. AF affects nearly 2.5 million Americans, most of who are older than 60 years. Consultation with the patient's physician to discuss the planned dental treatment often is appropriate, especially for people, who frequently have comorbid diseases such as coronary artery disease, congestive heart failure, diabetes and thyrotoxicosis, which are treated with multiple drug regimens.
C1 [Friedlander, Arthur H.; Yoshikawa, Thomas T.] VA Greater Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Yoshikawa, Thomas T.; Chang, Donald S.; Feliciano, Zenaida] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Chang, Donald S.] UCLA VA, VA Greater Los Angeles, San Fernando Valley Program, Los Angeles, CA USA.
[Scully, Crispian] UCL, Eastman Dent Inst, WHO Collaborating Ctr Res Educ & Serv Oral Hlth D, London WC1E 6BT, England.
RP Friedlander, AH (reprint author), VA Greater Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
NR 91
TC 2
Z9 2
U1 0
U2 3
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD FEB
PY 2009
VL 140
IS 2
BP 167
EP 177
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 406EL
UT WOS:000263277700019
PM 19188413
ER
PT J
AU Arnold, SV
Alexander, KP
Masoudi, FA
Ho, PM
Xiao, L
Spertus, JA
AF Arnold, Suzanne V.
Alexander, Karen P.
Masoudi, Frederick A.
Ho, P. Michael
Xiao, Lan
Spertus, John A.
TI The Effect of Age on Functional and Mortality Outcomes After Acute
Myocardial Infarction
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE aging; functional status; quality of life; myocardial infarction
ID QUALITY-OF-LIFE; CORONARY-ARTERY-BYPASS; TIMI RISK SCORE; ACTIVITY
QUESTIONNAIRE; INTERNATIONAL TRIAL; GLOBAL REGISTRY; HEART-DISEASE;
EVENTS GRACE; HEALTH; CAPACITY
AB To determine the prevalence of post-myocardial infarction (MI) functional decline and to describe its association with chronological age in survivors of MI.
Prospective observational registry.
Nineteen U.S. hospitals.
Two thousand four hundred eighty-one patients with acute MI.
Baseline and 1-year interviews identified subjects with functional decline, defined as a more than 5-point decline in Medical Outcomes Study 12-item Short Form Questionnaire (SF-12) Physical Component score or being "too ill" to provide a follow-up interview at 1 year. The relationship between age and functional decline was evaluated using logistic regression models adjusted for baseline SF-12 score, comorbidities, sociodemographics, and treatment characteristics. One-year mortality and a combined endpoint of death or decline were also compared across age.
Of 2,009 patients who survived to 1 year, 582 (29%) experienced a functional decline. In survivors, age was not associated with functional decline in unadjusted (odds ratio (OR)=0.95/decade, 95% confidence interval (CI)=0.88-1.03) or multivariable (OR=0.94, 95% CI=0.85-1.05) models. Although age was strongly associated with 1-year mortality (adjusted hazard ratio=1.42, 95% CI=1.21-1.66), there was no association between age and the combined endpoint of death or functional decline (adjusted OR=1.02, 95% CI=0.92-1.12).
More than one in four survivors of MI experiences a significant decline in physical function by 1 year. Although age is strongly associated with mortality, it had no association with functional decline. Because older patients have the same potential for favorable functional outcomes after an MI, age alone should not preclude aggressive treatment after an MI.
C1 [Arnold, Suzanne V.; Xiao, Lan; Spertus, John A.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Masoudi, Frederick A.; Ho, P. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.
[Masoudi, Frederick A.] Denver Hlth Med Ctr, Dept Med, Denver, CO USA.
[Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Spertus, John A.] Univ Missouri, Dept Med, Div Cardiol, Kansas City, MO 64110 USA.
RP Spertus, JA (reprint author), St Lukes Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA.
EM spertusj@umkc.edu
FU Cardiovascular Therapeutics, Inc.; Cardiovascular Outcomes, Inc., Kansas
City
FX Sponsor's Role: The sponsors did not play a role in the design or
conduct of the study; in the collection, management, analysis, or
interpretation of the data; or in the preparation, review, or approval
of the manuscript.
NR 43
TC 14
Z9 14
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 209
EP 217
DI 10.1111/j.1532-5415.2008.02106.x
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200003
PM 19170779
ER
PT J
AU Little, DM
Crooks, VC
Petitti, DB
Chiu, V
Schellenberg, GD
Slezak, JM
Jacobsen, SJ
AF Little, Deborah M.
Crooks, Valerie C.
Petitti, Diana B.
Chiu, Vicki
Schellenberg, Gerard D.
Slezak, Jeff M.
Jacobsen, Steven J.
TI Mortality, Dementia, and Apolipoprotein E Genotype in Elderly White
Women in the United States
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE dementia; APOE; genotype
ID E EPSILON-4 ALLELE; CORONARY-HEART-DISEASE; ALZHEIMERS-DISEASE; APOE
GENOTYPE; CEREBROVASCULAR-DISEASE; COGNITIVE IMPAIRMENT;
POPULATION-SAMPLE; CACHE COUNTY; E PHENOTYPES; OLDEST-OLD
AB To assess the risk of death in relation to apolipoprotein E (APOE) genotype and to evaluate how APOE genotype interacts with dementia and with other major medical conditions to affect survival.
A 6-year prospective cohort study of dementia, APOE genotype and survival.
Health maintenance organization in southern California.
One thousand eight hundred forty-two white women aged 75 and older.
Dementia was determined using a multistage assessment procedure, medical record, and death certificate review.
With women with the APOE 3/3 genotype as the referent, age-adjusted hazard ratios (HRs) for death according to genotype were 1.25 (95% confidence interval (CI)=1.00-1.56) for APOE 2/4, 3/4, or 4/4 and 0.83 (95% CI=0.62-1.13) for APOE 2/3 or 2/2. Survival was associated with APOE genotype (log rank test P=.02). Women with the APOE 2/4, 3/4, or 4/4 genotype died at an earlier age, and those with APOE 2/2 or 2/3 died later than those with the APOE 3/3 genotype. After adjustment for age, education, and hormone use, HRs for death were significantly higher in women with the APOE 2/4, 3/4, or 4/4 genotype who developed dementia (HR=3.74; 95% CI=2.81-4.99) and the APOE 2/3 genotype (HR=3.23; 95%=CI=1.97-5.28) than in women without dementia and the APOE 3/3 genotype. The HRs for death were greater with other medical conditions, but no interaction with any APOE genotype was found.
In this population of elderly women, although having at least one epsilon 4 allele increased the chances of an earlier death, having dementia increased the risk of death regardless of APOE genotype.
C1 [Little, Deborah M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Schellenberg, Gerard D.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA.
RP Crooks, VC (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, 100 S Robles,2nd Floor, Pasadena, CA 91101 USA.
EM valerie.c.crooks@kp.org
OI Jacobsen, Steven/0000-0002-8174-8533
FU National Institute on Aging [AG14745]
FX Sponsor's Role: The funding organization (NIA) did not have any role in
the design or conduct of the study; collection, management, analysis, or
interpretation of the data; or preparation, review, or approval of the
manuscript.
NR 42
TC 16
Z9 16
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 231
EP 236
DI 10.1111/j.1532-5415.2008.02113.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200006
PM 19207139
ER
PT J
AU Pugh, MJV
Knoefel, JE
Mortensen, EM
Amuan, ME
Berlowitz, DR
Van Cott, AC
AF Pugh, Mary Jo V.
Knoefel, Janice E.
Mortensen, Eric M.
Amuan, Megan E.
Berlowitz, Dan R.
Van Cott, Anne C.
TI New-Onset Epilepsy Risk Factors in Older Veterans
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE epilepsy; risk factors; cohort study; race; aged
ID UNPROVOKED SEIZURES; ELDERLY PATIENTS; DISORDERS; DISEASE; HYPERTENSION;
PREVENTION; DEMENTIA; STROKE
AB To identify risk factors for new-onset geriatric epilepsy that may trigger clinicians to consider a differential diagnosis of epilepsy at symptom onset.
Retrospective cohort study.
National Veterans Affairs (VA) databases.
Veterans aged 66 and older in fiscal year 2000 (FY00) who received VA care in FY99 and FY00. Individuals with new-onset epilepsy based on a validated algorithm constituted the epilepsy cohort (n=1,843), and individuals without epilepsy constituted the geriatric cohort (n=1,023,376).
Age, sex, and race were derived from VA databases. Clinical conditions associated with new-onset geriatric epilepsy (e.g., cerebrovascular disease, dementia, brain tumor) and stroke risk-factors (e.g., hypertension, diabetes mellitus, cardiovascular disease) were identified using validated International Classification of Diseases, Ninth Revision, Clinical Modification, codes before epilepsy onset (epilepsy cohort) and in FY00 (geriatric cohort).
Multivariable logistic regression analysis indicated that patients with cerebrovascular disease (odds ratio (OR)=3.50, 95% confidence interval (CI)=3.13-3.91), cerebrovascular disease and dementia (OR=4.14, 95% CI=3.46-4.96), brain tumor (OR=2.14, 95% CI=1.46-3.13), head injury (OR=2.11, 95% CI=1.41-3.14), and other central nervous system (CNS) conditions (OR=1.57, 95% CI=1.32-1.88) were more likely to experience new-onset epilepsy. Statin prescription (OR=0.64, 95% CI=0.56-0.73), older age (>= 85 vs 66-74, OR=0.66, 95% CI=0.50-0.87), obesity (OR=0.74, 95% CI=0.62-0.87), and hypercholesterolemia (OR=0.87, 95% CI=0.76-0.98) were associated with a lower likelihood of epilepsy.
These data suggest greater epilepsy risk for older individuals with CNS insult and an additive effect of cerebrovascular disease and dementia. The statin finding requires further exploration but points to a possible target for prevention of geriatric epilepsy.
C1 [Pugh, Mary Jo V.; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat Implementat Res, Hlth Serv Res & Dev Serv, Dept Vet Affairs, San Antonio, TX USA.
[Pugh, Mary Jo V.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Internal Med, San Antonio, TX 78229 USA.
[Knoefel, Janice E.] New Mexico Vet Hlth Care Syst, Albuquerque, NM USA.
[Amuan, Megan E.; Berlowitz, Dan R.] Bedford Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Berlowitz, Dan R.; Van Cott, Anne C.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Van Cott, Anne C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Van Cott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
RP Pugh, MJV (reprint author), S Texas Vet Hlth Care Syst VERDICT, Audie L Murphy Div 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM PughM@uthscsa.edu
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563
FU VA Health Services Research and Development Service [IIR 02-274];
GlaxoSmithKline
FX Sponsor's Role: The funding source did not have a role in the study
design, methods, subject recruitment, data collections, or analysis and
preparation of the manuscript.
NR 34
TC 34
Z9 34
U1 0
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 237
EP 242
DI 10.1111/j.1532-5415.2008.02124.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200007
PM 19207140
ER
PT J
AU Wright, RM
Roumani, YF
Boudreau, R
Newman, AB
Ruby, CM
Studenski, SA
Shorr, RI
Bauer, DC
Simonsick, EM
Hilmer, SN
Hanlon, JT
AF Wright, Rollin M.
Roumani, Yazan F.
Boudreau, Robert
Newman, Anne B.
Ruby, Christine M.
Studenski, Stephanie A.
Shorr, Ronald I.
Bauer, Douglas C.
Simonsick, Eleanor M.
Hilmer, Sarah N.
Hanlon, Joseph T.
CA Hlth Aging & Body Composition Stud
TI Effect of Central Nervous System Medication Use on Decline in Cognition
in Community-Dwelling Older Adults: Findings from the Health, Aging and
Body Composition Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE cognition; aged; medications
ID BENZODIAZEPINE USE; ELDERLY PERSONS; INFLAMMATORY MARKERS; FUNCTIONAL
DECLINE; PREDICTIVE MODEL; RISK-FACTORS; DRUG-USE; DELIRIUM; IMPAIRMENT;
PERFORMANCE
AB To evaluate whether combined use of multiple central nervous system (CNS) medications over time is associated with cognitive change.
Longitudinal cohort study.
Pittsburgh, Pennsylvania, and Memphis, Tennessee.
Two thousand seven hundred thirty-seven healthy adults (aged >= 65) enrolled in the Health, Aging and Body Composition study without baseline cognitive impairment (modified Mini-Mental State Examination (3MS) score >= 80).
CNS medication (benzodiazepine- and opioid-receptor agonists, antipsychotics, antidepressants) use, duration, and dose were determined at baseline (Year 1) and Years 3 and 5. Cognitive function was measured using the 3MS at baseline and Years 3 and 5. The outcome variables were incident cognitive impairment (3MS score < 80) and cognitive decline (>= 5-point decline on 3MS). Multivariable interval-censored survival analyses were conducted.
By Year 5, 7.7% of subjects had incident cognitive impairment; 25.2% demonstrated cognitive decline. CNS medication use increased from 13.9% at baseline to 15.3% and 17.1% at Years 3 and 5, respectively. It was not associated with incident cognitive impairment (adjusted hazard ratio (adj HR)=1.11, 95% confidence interval (CI)=0.73-1.69) but was associated with cognitive decline (adj HR 1.37, 95% CI=1.11-1.70). Longer duration (adj HR=1.39, CI=1.08-1.79) and higher doses (> 3 standardized daily doses) (adj HR=1.87, 95% CI=1.25-2.79) of CNS medications suggested greater risk of cognitive decline than with nonuse.
Combined use of CNS medications, especially at higher doses, appears to be associated with cognitive decline in older adults. Future studies must explore the effect of combined CNS medication use on vulnerable older adults.
C1 [Wright, Rollin M.; Roumani, Yazan F.; Newman, Anne B.; Studenski, Stephanie A.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA.
[Boudreau, Robert; Newman, Anne B.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA.
[Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Shorr, Ronald I.] N Florida S Georgia Vet Hlth Syst, Ctr Geriatr Res Educ & Clin, Gainesville, FL USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Simonsick, Eleanor M.] Johns Hopkins Univ, Inst Med, Div Geriatr Med & Gerontol, Baltimore, MD USA.
[Simonsick, Eleanor M.; Hilmer, Sarah N.] NIA, Intramural Res Program, Baltimore, MD 21224 USA.
[Hilmer, Sarah N.] Univ Sydney, Sydney, NSW 2006, Australia.
[Hilmer, Sarah N.] Royal N Shore Hosp, Sydney, NSW, Australia.
RP Wright, RM (reprint author), Univ Pittsburgh, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM rmw27@pitt.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Hilmer, Sarah/0000-0002-5970-1501;
Boudreau, Robert/0000-0003-0162-5187
FU National Institutes of Health (NIH), National Institute on Aging; NIH c
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01AG027017]; Pittsburgh
Claude D. Pepper Older Americans Independence Center [P30AG024827]; John
A. Hartford Foundation Center
FX Sponsors' Roles: The organizations that funded this study did not
influence the interpretation of the data or the development of this
manuscript.
NR 53
TC 38
Z9 39
U1 2
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 243
EP 250
DI 10.1111/j.1532-5415.2008.02127.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200008
PM 19207141
ER
PT J
AU Nazem, S
Siderowf, AD
Duda, JE
Have, TT
Colcher, A
Horn, SS
Moberg, PJ
Wilkinson, JR
Hurtig, HI
Stern, MB
Weintraub, D
AF Nazem, Sarra
Siderowf, Andrew D.
Duda, John E.
Have, Tom Ten
Colcher, Amy
Horn, Stacy S.
Moberg, Paul J.
Wilkinson, Jayne R.
Hurtig, Howard I.
Stern, Matthew B.
Weintraub, Daniel
TI Montreal Cognitive Assessment Performance in Patients with Parkinson's
Disease with "Normal" Global Cognition According to Mini-Mental State
Examination Score
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE cognitive impairment; Parkinson's disease; Mini-Mental State
Examination; Montreal Cognitive Assessment; neuropsychology
ID COMMUNITY POPULATION; DIAGNOSTIC-CRITERIA; ELDERLY-PEOPLE; SCREENING
TOOL; IMPAIRMENT; DEMENTIA; DYSFUNCTION; PROFILE; COHORT
AB To examine Montreal Cognitive Assessment (MoCA) performance in patients with Parkinson's disease (PD) with "normal" global cognition according to Mini-Mental State Examination (MMSE) score.
A cross-sectional comparison of the MoCA and the MMSE.
Two movement disorders centers at the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center.
A convenience sample of 131 patients with idiopathic PD who were screened for cognitive and psychiatric complications.
Subjects were administered the MoCA and MMSE, and only subjects defined as having a normal age- and education-adjusted MMSE score were included in the analyses (N=100). As previously recommended in patients without PD, a MoCA score less than 26 was used to indicate the presence of at least mild cognitive impairment (MCI).
Mean MMSE and MoCA scores +/- standard deviation were 28.8 +/- 1.1 and 24.9 +/- 3.1, respectively. More than half (52.0%) of subjects with normal MMSE scores had cognitive impairment according to their MoCA score. Impairments were seen in numerous cognitive domains, including memory, visuospatial and executive abilities, attention, and language. Predictors of cognitive impairment on the MoCA using univariate analyses were male sex, older age, lower educational level, and greater disease severity; older age was the only predictor in a multivariate model.
Approximately half of patients with PD with a normal MMSE score have cognitive impairment based on the recommended MoCA cutoff score. These results suggest that MCI is common in PD and that the MoCA is a more sensitive instrument than the MMSE for its detection.
C1 [Nazem, Sarra; Moberg, Paul J.; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Siderowf, Andrew D.; Duda, John E.; Colcher, Amy; Horn, Stacy S.; Moberg, Paul J.; Hurtig, Howard I.; Stern, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Have, Tom Ten] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA.
EM weintrau@mail.med.upenn.edu
FU National Institutes of Mental Health [067894]
FX Sponsor's Role: NA.
NR 31
TC 142
Z9 159
U1 4
U2 33
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 304
EP 308
DI 10.1111/j.1532-5415.2008.02096.x
PG 5
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200017
PM 19170786
ER
PT J
AU Hanlon, JT
Aspinall, SL
Semla, TP
Weisbord, SD
Fried, LF
Good, CB
Fine, MJ
Stone, RA
Pugh, MJV
Rossi, MI
Handler, SM
AF Hanlon, Joseph T.
Aspinall, Sherrie L.
Semla, Todd P.
Weisbord, Steven D.
Fried, Linda F.
Good, C. Bernie
Fine, Michael J.
Stone, Roslyn A.
Pugh, Mary Jo V.
Rossi, Michelle I.
Handler, Steven M.
TI Consensus Guidelines for Oral Dosing of Primarily Renally Cleared
Medications in Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE aged; chronic kidney disease; suboptimal prescribing
ID PHARMACOKINETICS; EFFICACY; CARE; INSUFFICIENCY; TRIAL; ALLOPURINOL;
INFORMATION; LORATADINE; FAILURE; DISEASE
AB To establish consensus oral dosing guidelines for primarily renally cleared medications prescribed for older adults.
Literature search followed by a two-round modified Delphi survey.
A nationally representative survey of experts in geriatric clinical pharmacy.
Eleven geriatric clinical pharmacists.
After a comprehensive literature search and review by an investigative group of six physicians (2 general internal medicine, 2 nephrology, 2 geriatrics), 43 dosing recommendations for 30 medications at various levels of renal function were created. The expert panel rated its agreement with each of these 43 dosing recommendations using a 5-point Likert scale (1=strongly disagree to 5=strongly agree). Recommendation-specific means and 95% confidence intervals were estimated. Consensus was defined as a lower 95% confidence limit of greater than 4.0 for the recommendation-specific mean score.
The response rate was 81.8% (9/11) for the first round. All respondents who completed the first round also completed the second round. The expert panel reached consensus on 26 recommendations involving 18 (60%) medications. For 10 medications (chlorpropamide, colchicine, cotrimoxazole, glyburide, meperidine, nitrofurantoin, probenecid, propoxyphene, spironolactone, and triamterene), the consensus recommendation was not to use the medication in older adults below a specified level of renal function (e.g., creatinine clearance < 30 mL/min). For the remaining eight medications (acyclovir, amantadine, ciprofloxacin, gabapentin, memantine, ranitidine, rimantadine, and valacyclovir), specific recommendations for dose reduction or interval extension were made.
An expert panel of geriatric clinical pharmacists was able to reach consensus agreement on a number of oral medications that are primarily renally cleared.
C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Geriatr Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Weisbord, Steven D.; Fried, Linda F.] Univ Pittsburgh, Div Renal Electrolyte, Pittsburgh, PA 15213 USA.
[Good, C. Bernie; Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15213 USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Stone, Roslyn A.; Rossi, Michelle I.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Rossi, Michelle I.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Hanlon, Joseph T.; Aspinall, Sherrie L.; Weisbord, Steven D.; Fried, Linda F.; Good, C. Bernie; Fine, Michael J.; Stone, Roslyn A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Aspinall, Sherrie L.; Semla, Todd P.; Good, C. Bernie] Vet Affairs Ctr Medicat Safety, Hines, IL USA.
[Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Geriatr Med, Div Geriatr Med, Kaufman Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM jth14@pitt.edu
OI Handler, Steven/0000-0002-3940-3224; Pugh, Mary Jo/0000-0003-4196-7763
FU National Institutes of Health (NIH) [1 KL2 RR024154-01, 5T32AG021885,
P30AG024827, R01AG027017]; Education and Clinical Center Pilot;
Pittsburgh Veterans Affairs (VA) Geriatric Research [IIR-06-062]
FX Sponsor's Role: None.
NR 37
TC 40
Z9 40
U1 1
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 335
EP 340
DI 10.1111/j.1532-5415.2008.02098.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200022
PM 19170784
ER
PT J
AU Gupta, E
Hartronft, S
Prange, M
AF Gupta, Elena
Hartronft, Scotte
Prange, Mark
TI COCA-COLA: A NEW THERAPY FOR REFLUX
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
ID ESOPHAGECTOMY
C1 [Gupta, Elena; Hartronft, Scotte; Prange, Mark] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, Div Geriatr Gerontol & Palliat Care, San Antonio, TX 78249 USA.
RP Gupta, E (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, Div Geriatr Gerontol & Palliat Care, San Antonio, TX 78249 USA.
NR 10
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2009
VL 57
IS 2
BP 364
EP 365
DI 10.1111/j.1532-5415.2009.02076.x
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 399WE
UT WOS:000262829200033
PM 19207159
ER
PT J
AU Wiggins, KL
Smith, NL
Glazer, NL
Rosendaal, FR
Heckbert, SR
Psaty, BM
Rice, KM
Lumley, T
AF Wiggins, K. L.
Smith, N. L.
Glazer, N. L.
Rosendaal, F. R.
Heckbert, S. R.
Psaty, B. M.
Rice, K. M.
Lumley, T.
TI ABO genotype and risk of thrombotic events and hemorrhagic stroke
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE ABO genotype; genetic polymorphism; hemorrhagic stroke; ischemic stroke;
myocardial infarction; venous thrombosis
ID VON-WILLEBRAND-FACTOR; BLOOD-GROUP GENOTYPE; VENOUS THROMBOEMBOLIC
DISEASE; FACTOR-VIII LEVELS; MYOCARDIAL-INFARCTION; HAPLOTYPE
RECONSTRUCTION; POSTMENOPAUSAL WOMEN; CEREBRAL-HEMORRHAGE;
HEART-DISEASE; PLASMA-LEVELS
AB Background: The non-O alleles of the ABO genotype have been associated with an increased risk of thrombosis. Risk associated with the specific A(1), A(2) or B alleles is not well defined. Objectives: To examine the association of the ABO genotype with myocardial infarction (MI), ischemic stroke, hemorrhagic stroke, and venous thrombosis (VT). Patients and methods: We used data from two ongoing population-based case-control studies of MI, stroke, and VT. Cases included hypertensive adults and postmenopausal women with incident non-fatal MI (n = 1063), ischemic stroke (n = 469), and hemorrhagic stroke (n = 91), and postmenopausal women with incident non-fatal VT (n = 504). Controls were frequency matched to cases on age, sex, hypertension status, and year of identification. ABO genotypes were determined using single-nucleotide polymorphisms, and subjects were grouped by diplotype according to the presence of O(1), O(2), A(11), A(2) and B alleles. Logistic regression was used to test the association of diplotypes with risk of each outcome. Results: As compared with the O(1)O(1) group, the A(11) allele was associated with an increased risk of VT [odds ratio (OR) 1.79; 95% confidence interval (CI) 1.41-2.26] and MI (OR 1.23; 95% CI 1.05-1.44). The B allele was associated with an increased risk of VT (OR 1.82; 95% CI 1.29-2.57) and ischemic stroke (OR 1.59; 95% CI 1.17-2.17). The AB diplotype category was associated with a 2.7-fold risk of VT (OR 2.70; 95% CI 1.73-4.21). No other associations reached significance. Conclusions: The VT and MI findings are confirmatory, and the ischemic stroke finding with the B allele is a novel finding and needs replication.
C1 [Wiggins, K. L.; Glazer, N. L.; Psaty, B. M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.
[Smith, N. L.; Heckbert, S. R.; Psaty, B. M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA.
[Smith, N. L.] Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Rosendaal, F. R.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
[Rosendaal, F. R.] Leiden Univ, Med Ctr, Dept Haematol, Leiden, Netherlands.
[Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Rice, K. M.; Lumley, T.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Wiggins, KL (reprint author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.
EM kwiggins@u.washington.edu
RI Rice, Kenneth/A-4150-2013
OI Rice, Kenneth/0000-0001-5779-4495
FU National Heart, Lung, and Blood Institute [HL073410, HL068639, HL043201,
HL060739, HL074745, HL068986]; National Institutes of Health [AG00956]
FX This study was supported by grants HL073410, HL068639, HL043201,
HL060739, HL074745 and HL068986 from the National Heart, Lung, and Blood
Institute, AG00956 from the National Institutes of Health, and The
Leducq Foundation, Paris, France, for the development of Transatlantic
Networks of Excellence in Cardiovascular Research.
NR 42
TC 46
Z9 47
U1 1
U2 7
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1538-7933
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD FEB
PY 2009
VL 7
IS 2
BP 263
EP 269
DI 10.1111/j.1538-7836.2008.03243.x
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 399ED
UT WOS:000262782300004
PM 19036074
ER
PT J
AU Van Remmen, H
Jones, DP
AF Van Remmen, Holly
Jones, Dean P.
TI Current Thoughts on the Role of Mitochondria and Free Radicals in the
Biology of Aging
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Editorial Material
C1 [Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Jones, Dean P.] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
NR 6
TC 31
Z9 31
U1 0
U2 5
PU GERONTOLOGICAL SOC AMER
PI WASHINGTON
PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD FEB
PY 2009
VL 64
IS 2
BP 171
EP 174
DI 10.1093/gerona/gln058
PG 4
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 419AB
UT WOS:000264190400006
PM 19181714
ER
PT J
AU Schunemann, HJ
Woodhead, M
Anzueto, A
Buist, S
MacNee, W
Rabe, KF
Heffner, J
AF Schuenemann, Holger J.
Woodhead, Mark
Anzueto, Antonio
Buist, Sonia
MacNee, William
Rabe, Klaus F.
Heffner, John
TI A vision statement on guideline development for respiratory disease: the
example of COPD
SO LANCET
LA English
DT Editorial Material
ID RECOMMENDATIONS; STRENGTH; QUALITY
C1 [Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Med Ctr 2C9, CLARITY Res Grp, Hamilton, ON L8N 3Z5, Canada.
[Schuenemann, Holger J.] SUNY Buffalo, Dept Med, Buffalo, NY USA.
[Woodhead, Mark] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England.
[Woodhead, Mark] Univ Manchester, Manchester, Lancs, England.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Buist, Sonia; Heffner, John] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[MacNee, William] Queens Med Res Inst, ELEGI Colt Res Labs, UoE MRC, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland.
[Rabe, Klaus F.] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands.
RP Schunemann, HJ (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, Med Ctr 2C9, CLARITY Res Grp, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM schuneh@mcmaster.ca
OI MacNee, William/0000-0002-3692-1448
FU NHLBI NIH HHS [1R13HL 90485-01]
NR 11
TC 31
Z9 35
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB-MAR
PY 2009
VL 373
IS 9665
BP 774
EP 779
DI 10.1016/S0140-6736(08)61347-1
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 412LD
UT WOS:000263725400037
PM 18835641
ER
PT J
AU Paige, NM
Nagami, GT
AF Paige, Neil M.
Nagami, Glenn T.
TI The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew
SO MAYO CLINIC PROCEEDINGS
LA English
DT Review
ID CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; BOWEL PREPARATION;
METABOLIC EVALUATION; COMBINATION THERAPY; ALUMINUM ABSORPTION; URINE
SAMPLES; PROTEINURIA; HEMOGLOBIN; HYPERPHOSPHATEMIA
AB Renal disease is commonly encountered by primary care physicians during their day-to-day visits with patients. Common renal disorders include hypertension, proteinuria, kidney stones, and chronic kidney disease. Despite their prevalence, many physicians may be unfamiliar with the diagnosis and Initial treatment of these common renal disorders. Early recognition and intervention are Important In slowing the progression of chronic kidney disease and preventing Its complications. The evidence-based pearls In this article will help primary care physicians avoid common pitfalls In the recognition and treatment of such disorders and guide their decision to refer their patients to a specialist.
C1 [Paige, Neil M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Gen Internal Med, Los Angeles, CA 90073 USA.
[Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Nephrol Sect, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Paige, NM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Gen Internal Med, 11301 Wilshire Blvd 111A, Los Angeles, CA 90073 USA.
EM neil.paige@va.gov
NR 43
TC 10
Z9 11
U1 0
U2 1
PU MAYO CLINIC PROCEEDINGS
PI ROCHESTER
PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD FEB
PY 2009
VL 84
IS 2
BP 180
EP 186
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 402CT
UT WOS:000262992500012
PM 19181652
ER
PT J
AU Pickard, AS
Lin, HW
Knight, SL
Sharifi, R
Wu, ZG
Hung, SY
Witt, WP
Chang, CH
Bennett, CL
AF Pickard, A. Simon
Lin, Hsiang-Wen
Knight, Sara L.
Sharifi, Roohollah
Wu, Zhigang
Hung, Shih-Ying
Witt, Whitney P.
Chang, Chih-Hung
Bennett, Charles L.
TI Proxy Assessment of Health-Related Quality of Life in African American
and White Respondents With Prostate Cancer Perspective Matters
SO MEDICAL CARE
LA English
DT Article
DE quality of life; proxy; prostate cancer; Veterans
ID UROLOGIC RESEARCH ENDEAVOR; RADICAL PROSTATECTOMY; SYMPTOM EXPERIENCES;
SIGNIFICANT OTHERS; FUNCTIONAL STATUS; MEDICARE SURVEY; PATIENT HEALTH;
MEN; CAREGIVERS; OUTCOMES
AB Objectives: An emerging issue in the proxy literature is whether specifying different proxy viewpoints contributes to different health-related quality of life (HRQL) assessments, and if so, how might each perspective be informative in medical decision making. The aims of this study were to determine if informal caregiver assessments of patients with prostate cancer differed when prompted from both the patient perspective (proxy-patient) and their own viewpoint (proxy-proxy), and to identify factors associated with differences in proxy perspectives (ie, the intraproxy gap).
Research Design and Methods: Using a cross-sectional design, prostate cancer patients and their informal caregivers were recruited from urology clinics in the Jesse Brown Veterans Affairs Healthcare System in Chicago. Dyads assessed HRQL using the EQ-5D visual analog scale (VAS) and EORTC QLQ-C30.
Results: Of 87 dyads, most caregivers were female (83%) and were spouses/partners (58%). Mean difference scores between proxy-patient and proxy-proxy perspectives were statistically significant for QLQ-C30 physical and emotional functioning, and VAS (all P < 0.05), with the proxy-patient perspective closer to patient self-report. Emotional functioning had the largest difference, mean 6.0 (SD 12.8), an effect size = 0.47. Factors weakly correlated with the intraproxy gap included relationship (spouse) and proxy gender for role functioning, and health literacy (limited/functional) for physical functioning (all P < 0.05, 0.20 < r < 0.35).
Conclusions: Meaningful differences between proxy-patient and proxy-proxy perspectives on mental health were consistent with a conceptual framework for understanding proxy perspectives. Prompting different proxy viewpoints on patient health could help clinicians identify patients who may benefit from clinical intervention.
C1 [Pickard, A. Simon; Lin, Hsiang-Wen; Hung, Shih-Ying] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Dept Pharm Practice & Pharm Adm, Chicago, IL 60612 USA.
[Pickard, A. Simon; Hung, Shih-Ying; Bennett, Charles L.] Hines VA Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL USA.
[Knight, Sara L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Knight, Sara L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Knight, Sara L.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
[Sharifi, Roohollah; Wu, Zhigang] Univ Illinois, Coll Pharm, Dept Urol, Chicago, IL 60612 USA.
[Sharifi, Roohollah; Wu, Zhigang; Bennett, Charles L.] Jesse Brown Vet Affairs Hlth Syst, Chicago, IL USA.
Univ Wisconsin, Dept Social & Adm Pharm, Madison, WI USA.
[Witt, Whitney P.] Univ Wisconsin, Dept Hlth Sci Res, Sch Publ Hlth, Madison, WI USA.
[Chang, Chih-Hung] Northwestern Univ, Buehler Ctr Aging Hlth & Soc, Chicago, IL 60611 USA.
[Bennett, Charles L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Pickard, AS (reprint author), Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Dept Pharm Practice & Pharm Adm, 833 S Wood St,Rm 164,MC 886, Chicago, IL 60612 USA.
EM pickard1@uic.edu
FU National Cancer Institute/ National Institutes of Health [R03 CA 108395]
FX Supported by grant R03 CA 108395 from the National Cancer Institute/
National Institutes of Health.
NR 51
TC 12
Z9 12
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD FEB
PY 2009
VL 47
IS 2
BP 176
EP 183
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 401BN
UT WOS:000262913200007
PM 19169118
ER
PT J
AU Dhaliwal, G
AF Dhaliwal, Gurpreet
TI Medical expertise: begin with the end in mind
SO MEDICAL EDUCATION
LA English
DT Editorial Material
ID DELIBERATE PRACTICE; EDUCATION
C1 Univ Calif San Francisco Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Dhaliwal, G (reprint author), Univ Calif San Francisco Med, San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA.
EM gurpreet.dhaliwal@va.gov
NR 11
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0308-0110
J9 MED EDUC
JI Med. Educ.
PD FEB
PY 2009
VL 43
IS 2
BP 105
EP 107
DI 10.1111/j.1365-2923.2008.03262.x
PG 3
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 397EJ
UT WOS:000262644900003
PM 19161478
ER
PT J
AU Klein, AJ
Casserly, IP
Messenger, JC
Carroll, JD
Chen, SYJ
AF Klein, Andrew J.
Casserly, Ivan P.
Messenger, John C.
Carroll, John D.
Chen, S. -Y. James
TI In vivo 3D modeling of the femoropopliteal artery in human subjects
based on x-ray angiography: Methodology and validation
SO MEDICAL PHYSICS
LA English
DT Article
DE biomechanics; blood vessels; diagnostic radiography; diseases
ID SUPERFICIAL FEMORAL-ARTERY; QUANTITATIVE-ANALYSIS; 3-D RECONSTRUCTION;
CORONARY-ARTERIES; TREE; STENTS
AB Endovascular revascularization of the femoropopliteal (FP) artery has been limited by high rates of restenosis and stent fracture. The unique physical forces that are applied to the FP artery during leg movement have been implicated in these phenomena. The foundation for measuring the effects of physical forces on the FP artery in a clinically relevant environment is based on the ability to develop 3D models of this vessel in different leg positions in vivo in patients with peripheral arterial disease (PAD). By acquiring paired angiographic images of the FP artery, and using angiography-based 3D modeling algorithms previously validated in the coronary arteries, the authors generated 3D models of ten FP arteries in nine patients with PAD with the lower extremity in straight leg (SL) and crossed leg (CL) positions. Due to the length of the FP artery, overlapping paired angiographic images of the entire FP artery were required to image the entire vessel, which necessitated the development of a novel fusion process in order to generate a 3D model of the entire FP artery. The methodology of angiographic acquisition and 3D model generation of the FP artery is described. In a subset of patients, a third angiographic view (i.e., validation view) was acquired in addition to the standard paired views for the purpose of validating the 3D modeling process. The mean root-mean-square (rms) error of the point-to-point distances between the centerline of the main FP artery from the 2D validation view and the centerline from the 3D model placed in the validation view for the SL and CL positions were 0.93 +/- 0.19 mm and 1.12 +/- 0.25 mm, respectively. Similarly, the mean rms error of the same comparison for the main FP artery and sidebranches for the SL and CL positions were 1.09 +/- 0.38 mm and 1.21 +/- 0.25 mm, respectively. A separate validation of the novel fusion process was performed by comparing the 3D model of the FP artery derived from fusion of 3D models of adjacent FP segments with the 2D validation view incorporating the region of fusion. The mean rms error of vessel centerline points of the main FP artery, the main FP artery plus directly connected sidebranches, and the mean rms error of upstream, downstream, and sidebranch directional vectors at bifurcation points in the overlap region were 1.41 +/- 0.79 mm, 2.13 +/- 1.12 mm, 3.16 +/- 3.72 degrees, 3.60 +/- 5.39 degrees, and 8.68 +/- 8.42 degrees in the SL position, respectively, and 1.29 +/- 0.35 mm, 1.61 +/- 0.78 mm, 4.68 +/- 4.08 degrees, 3.41 +/- 2.23 degrees, and 5.52 +/- 4.41 degrees in the CL position, respectively. Inter- and intraobserver variability in the generation of 3D models of individual FP segments and the fusion of overlapping FP segments were assessed. The mean rms errors between the centerlines of nine 3D models of individual FP segments generated by two independent observers, and repeated measurement by the same observer were 2.78 +/- 1.26 mm and 3.50 +/- 1.15 mm, respectively. The mean rms errors between the centerline of four 3D models of fused overlapping FP segments generated by two independent observers, and repeated measurement by the same observer were 4.99 +/- 0.99 mm and 5.98 +/- 1.22 mm, respectively. This study documents the ability to generate 3D models of the entire FP artery in vivo in patients with PAD in both SL and CL positions using routine angiography, and validates the methodologies used.
C1 [Klein, Andrew J.; Casserly, Ivan P.; Messenger, John C.; Carroll, John D.; Chen, S. -Y. James] Univ Colorado Denver, Aurora, CO 80045 USA.
[Casserly, Ivan P.] Denver VA Med Ctr, Denver, CO 80220 USA.
RP Klein, AJ (reprint author), Univ Colorado Denver, Aurora, CO 80045 USA.
FU Boston Scientific Corporation
FX The authors would like to acknowledge Adam Hansgen for assistance with
graphics, the cardiac catheterization laboratory staff at the Denver VA
Medical Center for assistance during acquisition of angiographic data
(Sarah Doran, Mary Hall, Marsha Hallahan, Lori Harvey, Mary Ann Olson,
Tracy Rankin), Philip Li and Yu- Li Liang for their efforts in
reconstructing the FP arteries, and Kathy Kioussopoulos for her
assistance in preparing the clinical protocol for institutional review
board approval. This study was supported and funded by the research
grant from Boston Scientific Corporation.
NR 20
TC 5
Z9 5
U1 0
U2 2
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD FEB
PY 2009
VL 36
IS 2
BP 289
EP 310
DI 10.1118/1.3006195
PG 22
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 400FE
UT WOS:000262852600003
PM 19291969
ER
PT J
AU Cornford, E
Hyman, S
Cornford, M
Suzuki, T
Yamagata, T
Yamakawa, K
Rhee, J
Delgado-Escueta, A
AF Cornford, Eain
Hyman, Shigeyo
Cornford, Marcia
Suzuki, Toshimitsu
Yamagata, Tetsushi
Yamakawa, Kazuhiro
Rhee, Jennifer
Delgado-Escueta, Antonio
TI Immunoliposome-based, non-viral gene delivery in a knock-out mouse model
of Lafora inclusion body disease
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Meeting Abstract
CT 4th Annual World Symposium of the Lysosomal-Disease-Network
CY FEB 13-15, 2009
CL Las Vegas, NV
SP Lysosomal Dis Network
C1 [Cornford, Eain; Rhee, Jennifer; Delgado-Escueta, Antonio] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hyman, Shigeyo; Delgado-Escueta, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Cornford, Marcia] Harbor UCLA Med Ctr, Los Angeles, CA USA.
[Suzuki, Toshimitsu; Yamagata, Tetsushi; Yamakawa, Kazuhiro] RIKEN Brain Sci Inst, Saitama, Japan.
RI Yamakawa, Kazuhiro/N-5050-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD FEB
PY 2009
VL 96
IS 2
MA 30
BP S19
EP S19
DI 10.1016/j.ymgme.2008.11.031
PG 1
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
Medicine
GA 399QG
UT WOS:000262813800038
ER
PT J
AU Saxena, S
Gorbis, E
O'Neill, J
Baker, SK
Mandelkern, MA
Maidment, KM
Chang, S
Salamon, N
Brody, AL
Schwartz, JM
London, ED
AF Saxena, S.
Gorbis, E.
O'Neill, J.
Baker, S. K.
Mandelkern, M. A.
Maidment, K. M.
Chang, S.
Salamon, N.
Brody, A. L.
Schwartz, J. M.
London, E. D.
TI Rapid effects of brief intensive cognitive-behavioral therapy on brain
glucose metabolism in obsessive-compulsive disorder
SO MOLECULAR PSYCHIATRY
LA English
DT Article
DE obsessive-compulsive disorder; cognitive-behavioral therapy; intensive
treatment; functional neuroimaging; positron emission tomography;
anterior cingulate
ID CEREBRAL-BLOOD-FLOW; ANTERIOR CINGULATE CORTEX;
POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN REUPTAKE INHIBITORS; MAJOR
DEPRESSION; SYMPTOM PROVOCATION; UNMEDICATED PATIENTS; RESPONSE
PREVENTION; CONTROLLED TRIAL; FDG-PET
AB Brief intensive cognitive-behavioral therapy (CBT) using exposure and response prevention significantly improves obsessive-compulsive disorder (OCD) symptoms in as little as 4 weeks. However, it has been thought that much longer treatment was needed to produce the changes in brain function seen in neuroimaging studies of OCD. We sought to elucidate the brain mediation of response to brief intensive CBT for OCD and determine whether this treatment could induce functional brain changes previously seen after longer trials of pharmacotherapy or standard CBT. [(18)F]-fluorodeoxyglucose positron emission tomography brain scans were obtained on 10 OCD patients before and after 4 weeks of intensive individual CBT. Twelve normal controls were scanned twice, several weeks apart, without treatment. Regional glucose metabolic changes were compared between groups. OCD symptoms, depression, anxiety and overall functioning improved robustly with treatment. Significant changes in normalized regional glucose metabolism were seen after brief intensive CBT (P = 0.04). Compared to controls, OCD patients showed significant bilateral decreases in normalized thalamic metabolism with intensive CBT but had a significant increase in right dorsal anterior cingulate cortex activity that correlated strongly with the degree of improvement in OCD symptoms (P = 0.02). The rapid response of OCD to intensive CBT is mediated by a distinct pattern of changes in regional brain function. Reduction of thalamic activity may be a final common pathway for improvement in OCD, but response to intensive CBT may require activation of dorsal anterior cingulate cortex, a region involved in reappraisal and suppression of negative emotions.
C1 [Saxena, S.] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA.
[Gorbis, E.; O'Neill, J.; Baker, S. K.; Maidment, K. M.; Chang, S.; Brody, A. L.; Schwartz, J. M.; London, E. D.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Mandelkern, M. A.; Brody, A. L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Salamon, N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
RP Saxena, S (reprint author), Univ Calif San Diego, Obsess Compuls Disorders Program, Dept Psychiat, VA San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.
EM ssaxena@ucsd.edu
FU NIMH [R01 MH069433]; Brain Mapping Medical Research Organization; Brain
Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson
Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital
Group Companies Charitable Foundation; Northern Piedmont Community
Foundation; National Center for Research Resources [RR12169, RR13642,
RR08655]
FX This work was supported by an NIMH grant (R01 MH069433) to Dr Saxena and
by donations to the Westwood Institute for Anxiety Disorders (Dr
Gorbis). For generous support, we thank the Brain Mapping Medical
Research Organization, Brain Mapping Support Foundation, Pierson-
Lovelace Foundation, Ahmanson Foundation, Tamkin Foundation, Jennifer
Jones-Simon Foundation, Capital Group Companies Charitable Foundation,
Robson Family, William M and Linda R Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation, Northstar Fund and the National
Center for Research Resources grants RR12169, RR13642 and RR08655. This
work was presented in part at the American College of
Neuropsychopharmacology 43rd Annual Meeting (San Juan, Puerto Rico, 15
December 2004).
NR 70
TC 64
Z9 66
U1 4
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD FEB
PY 2009
VL 14
IS 2
BP 197
EP 205
DI 10.1038/sj.mp.4002134
PG 9
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 395VD
UT WOS:000262550700009
PM 18180761
ER
PT J
AU Tyler, KL
AF Tyler, Kenneth L.
TI Prednisolone-but not antiviral drugs-improves outcome in patients with
Bell's palsy
SO NATURE CLINICAL PRACTICE NEUROLOGY
LA English
DT Editorial Material
DE acyclovir; Bell's palsy; peripheral facial palsy; prednisolone;
valacyclovir
ID HERPES-SIMPLEX-VIRUS; DOUBLE-BLIND; VALACYCLOVIR; REACTIVATION;
MULTICENTER; ACYCLOVIR; TYPE-1; TRIAL
AB Randomized, double-blind, placebo-controlled trials have provided compelling evidence that treatment with prednisolone improves outcome in patients with acute idiopathic peripheral facial ( Bell's) palsy. The low rate of adverse effects, the small number needed to treat, and the modest cost of therapy indicate that prednisolone should be used in all patients with facial palsy of <72 h duration who do not have contraindications to steroid therapy. By contrast, the best-designed recent clinical trials have failed to suggest any significant beneficial effect on Bell's palsy of treatment with acyclovir or valacyclovir, either as single agents or in combination with prednisolone. Antiviral therapy should not, therefore, be routinely used in the treatment of Bell's palsy.
C1 [Tyler, Kenneth L.] Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80202 USA.
[Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA.
RP Tyler, KL (reprint author), Univ Colorado, Denver Hlth Sci Ctr, Dept Neurol, B-182,RC-2,12700 E 19th Ave, Aurora, CO 80045 USA.
EM ken.tyler@uchsc.edu
OI Tyler, Kenneth/0000-0003-3294-5888
NR 10
TC 6
Z9 6
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1745-834X
J9 NAT CLIN PRACT NEURO
JI Nat. Clin. Pract. Neurol.
PD FEB
PY 2009
VL 5
IS 2
BP 74
EP 75
DI 10.1038/ncpneuro1002
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 403OB
UT WOS:000263090800005
PM 19139743
ER
PT J
AU Webster, CM
Kelly, S
Koike, MA
Chock, VY
Giffard, RG
Yenari, MA
AF Webster, Carla M.
Kelly, Stephen
Koike, Maya A.
Chock, Valerie Y.
Giffard, Rona G.
Yenari, Midori A.
TI Inflammation and NF kappa B activation is decreased by hypothermia
following global cerebral ischemia
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Global cerebral ischemia; Hypothermia; Inflammation; Nuclear
factor-kappa B; Microglia
ID LEUKOCYTE-ENDOTHELIUM INTERACTION; TRANSIENT FOCAL ISCHEMIA;
CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; MILD HYPOTHERMIA;
EXPERIMENTAL STROKE; THERAPEUTIC HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA;
ARTERY OCCLUSION; MICROGLIAL ACTIVATION
AB We previously showed that hypothermia attenuates inflammation in focal cerebral ischemia (FCI) by suppressing activating kinases of nuclear factor-kappa B (NF kappa B). Here we characterize the inflammatory response in global cerebral ischemia (GCI), and the influence of mild hypothermia. Rodents were subjected to GCI by bilateral carotid artery occlusion. The inflammatory response was accompanied by microglial activation, but not neutrophil infiltration, or blood brain barrier disruption. Mild hypothermia reduced CA1 damage, decreased microglial activation and decreased nuclear NF kappa B translocation and activation. Similar anti-inflammatory effects of hypothermia were observed in a model of pure brain inflammation that does not cause brain cell death. Primary microglial cultures subjected to oxygen glucose deprivation (OGD) or stimulated with LPS under hypothermic conditions also experienced less activation and less NF kappa B translocation. However, NF kappa B regulatory proteins were not affected by hypothermia. The inflammatory response following GCI and hypothermia's anti-inflammatory mechanism is different from that observed in FCI. Published by Elsevier Inc.
C1 [Webster, Carla M.; Koike, Maya A.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Webster, Carla M.; Koike, Maya A.; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Webster, Carla M.; Koike, Maya A.; Chock, Valerie Y.; Giffard, Rona G.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA.
[Kelly, Stephen] Univ Bristol, Bristol BS1 3NY, Avon, England.
RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.
EM yenari@alum.mit.edu
RI Kelly, Stephen/A-8307-2010
FU NIH [RO1 NS40516, P50 NS14543, P01 NS37520, R01 NS53898]; AHA
[EIA0540066N]
FX This work was made possible by the following institutions and grants:
NIH RO1 NS40516 (MAY), AHA EIA0540066N (MAY), NIH P50 NS14543 and P01
NS37520 (RGG, MAY), NIH R01 NS53898 (RGG).
NR 61
TC 58
Z9 68
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD FEB
PY 2009
VL 33
IS 2
BP 301
EP 312
DI 10.1016/j.nbd.2008.11.001
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 403ZM
UT WOS:000263120500018
PM 19063968
ER
PT J
AU Humbert, IA
Fitzgerald, ME
McLaren, DG
Johnson, S
Porcaro, E
Kosmatka, K
Hind, J
Robbins, J
AF Humbert, Ianessa A.
Fitzgerald, Michelle E.
McLaren, Donald G.
Johnson, Sterling
Porcaro, Eva
Kosmatka, Kris
Hind, Jacqueline
Robbins, JoAnne
TI Neurophysiology of swallowing: Effects of age and bolus type
SO NEUROIMAGE
LA English
DT Article
ID CEREBRAL CORTICAL REPRESENTATION; PENETRATION-ASPIRATION SCALE;
HEMISPHERIC ASYMMETRIES; SUSTAINED ATTENTION; NORMAL ADULTS; CORTEX;
MOTOR; FMRI; INDIVIDUALS; DEGLUTITION
AB This study examined age-related changes in swallowing from an integrated biomechanical and functional imaging perspective in order to more comprehensively characterize changes in swallowing associated with age. We examined swallowing-related fMRI brain activity and videoflouroscopic biomechanics of three bolus types (saliva, water and barium) in 12 young and 11 older adults. We found that age-related neurophysiological changes in swallowing are evident. The group of older adults recruited more cortical regions than young adults, including the pericentral gyri and inferior frontal gyrus pars opercularis and pars triangularis (primarily right-sided). Saliva swallows elicited significantly higher BOLD responses in regions important for swallowing compared to water and barium. In separate videofluoroscopy sessions, we obtained durational measures of supine swallowing. The older cohort had significantly longer delays before the onset of the pharyngeal swallow response and increased residue of ingested material in the pharynx. These findings suggest that older adults without neurological insult elicit more cortical involvement to complete the same swallowing tasks as younger adults. (C) 2008 Elsevier Inc. All rights reserved.
C1 William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA.
Univ Wisconsin, Madison, WI 53706 USA.
RP Humbert, IA (reprint author), 98 N Broadway,Suite 413, Baltimore, MD 21231 USA.
EM ihumber1@jhmi.edu
RI McLaren, Donald/G-9906-2011
OI Johnson, Sterling/0000-0002-8501-545X
FU National Institutes of Health (NIH); NCRR; The Training and Education to
Advance MultidisciplinaryClinical- Research (TEAM) Program
[8K12RR023268-02]; National Institutes of Health and National Institute
[T32 AG20013]; William S. Middleton Memorial VA Hospital Geriatric
Research Education and Clinical Center (GRECC) [2008-16]
FX This is GRECC manuscript # 2008-16.
NR 55
TC 44
Z9 49
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2009
VL 44
IS 3
BP 982
EP 991
DI 10.1016/j.neuroimage.2008.10.012
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 392KL
UT WOS:000262301500037
PM 19010424
ER
PT J
AU Benmansour, S
Piotrowski, JP
Altamirano, AV
Frazer, A
AF Benmansour, Saloua
Piotrowski, Jonathan P.
Altamirano, Alfonso V.
Frazer, Alan
TI Impact of Ovarian Hormones on the Modulation of the Serotonin
Transporter by Fluvoxamine
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE serotonin transporter; estradiol; progesterone; fluvoxamine;
chronoamperometry; hippocampus
ID APPLIED UPTAKE INHIBITORS; ESTROGEN-RECEPTOR BETA; CLEARANCE IN-VIVO;
ASTERISK-D REPORT; MESSENGER-RNA; RAT-BRAIN; GENDER-DIFFERENCES;
PROTEIN-KINASE; FEMALE RATS; PROGESTERONE-RECEPTOR
AB Most preclinical studies examining the mechanism(s) of action of antidepressants are carried out using male animals. Blockade of serotonin transporter (SERT) function by selective serotonin reuptake inhibitors (SSRIs) is the initial event that triggers a not completely understood process that results in clinical improvement in depression. To investigate whether there are differences in the ability of SSRIs to inhibit the SERT between male and female rats at different phases of the estrous cycle, clearance of locally applied serotonin (5-HT) was measured by in vivo chronoamperometry. Local application of the SSRI, fluvoxamine, directly into the CA3 area of hippocampus increased significantly 5-HT clearance time parameters in male rats and female rats in estrus or diestrus, but not in proestrus. The contribution of ovarian steroids to this result was investigated in ovariectomized (OVX) rats treated with estradiol benzoate (EB) and/or progesterone (P). In OVX-control rats, fluvoxamine increased clearance time parameters, whereas EB and/or P treatment blocked this effect, consistent with what was seen in female rats in proestrus. This effect was gender-specific, since treatment of castrated rats with EB/P had no effect on the ability of fluvoxamine to slow 5-HT clearance. The time course of hormonal effects showed that 1-60 min after local application of 17-beta-estradiol (E-2) into the CA3 region of OVX rats, fluvoxamine had no effect on clearance time of 5-HT. E-2-BSA mimicked E-2's effects at 10 min but not at 60 min. Pretreatment with estrogen receptor antagonists blocked the effects of E-2. The finding that acutely both estradiol and progesterone can inhibit the ability of an SSRI to slow the clearance of 5-HT, may have important implications for the use of SSRIs in women.
C1 [Benmansour, Saloua; Piotrowski, Jonathan P.; Altamirano, Alfonso V.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Frazer, Alan] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol MC 7764, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM benmansour@uthscsa.edu
FU NARSAD; Department of Veterans Affairs; Forest Research Institute; Eli
Lilly and Company; Wyeth Pharmaceuticals
FX This work was supported by funds from NARSAD and the Department of
Veterans Affairs. We thank Dr Andrea Gore for help with analysis of
hormones levels and Kelly Sharp and Dr Georgianna Gould for technical
assistance.; Dr Benmansour, Mr Piotrowski, and Mr Altamirano report no
biomedical financial interests or potential conflicts of interest. Dr
Frazer reports that he has been on advisory boards for Cyberonics Inc.
and H Lundbeck A/S and that he has consulted and/or received research
support for preclinical studies from Forest Research Institute, Eli
Lilly and Company, and Wyeth Pharmaceuticals, but no support for this
study was received by any pharmaceutical company.
NR 66
TC 27
Z9 27
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD FEB
PY 2009
VL 34
IS 3
BP 555
EP 564
DI 10.1038/npp.2008.23
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 393MA
UT WOS:000262376200004
PM 18322468
ER
PT J
AU Franklin, TR
Lohoff, FW
Wang, Z
Sciortino, N
Harper, D
Li, Y
Jens, W
Cruz, J
Kampman, K
Ehrman, R
Berrettini, W
Detre, JA
O'Brien, CP
Childress, AR
AF Franklin, Teresa R.
Lohoff, Falk W.
Wang, Ze
Sciortino, Nathan
Harper, Derek
Li, Yin
Jens, Will
Cruz, Jeffrey
Kampman, Kyle
Ehrman, Ron
Berrettini, Wade
Detre, John A.
O'Brien, Charles P.
Childress, Anna Rose
TI DAT Genotype Modulates Brain and Behavioral Responses Elicited by
Cigarette Cues
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE fMRI; dopamine transporter; gene; smoking; reward; cue
ID DOPAMINE TRANSPORTER GENE; DRD4 VNTR POLYMORPHISM; NUCLEUS-ACCUMBENS;
SMOKING CUES; LIMBIC ACTIVATION; RECEPTOR GENE; CONDITIONED INCREASES;
NICOTINE DEPENDENCE; INTRAVENOUS COCAINE; STRESS-DISORDER
AB We previously demonstrated differential activation of the mesocorticolimbic reward circuitry in response to cigarette cues independent of withdrawal. Despite robust effects, we noted considerable individual variability in brain and subjective responses. As dopamine (DA) is critical for reward and its predictive signals, genetically driven variation in DA transmission may account for the observed differences. Evidence suggests that a variable number of tandem repeats (VNTRs) polymorphism in the DA transporter (DAT) SLC6A3 gene may influence DA transport. Brain and behavioral responses may be enhanced in probands carrying the 9-repeat allele. To test this hypothesis, perfusion fMR images were acquired during cue exposure in 19 smokers genotyped for the 40 bp VNTR polymorphism in the SLC6A3 gene. Contrasts between groups revealed that 9-repeat (9-repeats) had a greater response to smoking (vs nonsmoking) cues than smokers homozygous for the 10-repeat allele (10/10-repeats) bilaterally in the interconnected ventral striatal/pallidal/orbitofrontal cortex regions (VS/VP/OFC). Activity was increased in 9-repeats and decreased in 10/10-repeats in the VS/VP/OFC (p<0.001 for all analyses). Brain activity and craving was strongly correlated in 10/10-repeats in these regions and others (anterior cingulate, parahippocampal gyrus, and insula; r(2) = 0.79-0.86, p<0.001 in all regions). Alternatively, there were no significant correlations between brain and behavior in 9-repeats. There were no differences in cigarette dependence, demographics, or resting baseline neural activity between groups. These results provide evidence that genetic variation in the DAT gene contributes to the neural and behavioral responses elicited by smoking cues.
C1 [Franklin, Teresa R.; Lohoff, Falk W.; Wang, Ze; Sciortino, Nathan; Harper, Derek; Li, Yin; Jens, Will; Cruz, Jeffrey; Kampman, Kyle; Ehrman, Ron; Berrettini, Wade; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Dept Psychiat, Addict Treatment Res Ctr, Philadelphia, PA 19104 USA.
[Kampman, Kyle; Ehrman, Ron; O'Brien, Charles P.; Childress, Anna Rose] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Kampman, Kyle; Ehrman, Ron; O'Brien, Charles P.; Childress, Anna Rose] VA VISN 4 MIRECC, Philadelphia, PA USA.
[Detre, John A.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
RP Franklin, TR (reprint author), Univ Penn, Dept Psychiat, Addict Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM franklin_t@mail.trc.upenn.edu
RI Wang, Ze/A-1043-2007; Lohoff, Falk/M-7951-2016
OI Jens, William/0000-0001-5201-1412
FU NIH [DA015149, K01 DA 015426-011A1, 5-P60-DA-005186-18, NS045839,
BCS-0224007, RR02305, 1K08MH080372-01A1 VA VISN 4 MIRECC]; GCRC of the
University of Pennsylvania
FX This work was supported by NIH grants DA015149, K01 DA 015426-011A1,
5-P60-DA-005186-18, and NS045839, BCS-0224007, RR02305,
1K08MH080372-01A1 VA VISN 4 MIRECC, and the GCRC of the University of
Pennsylvania. We acknowledge the nursing staff at the University of
Pennsylvania Addiction Treatment Research for conducting physical
evaluations. We also thank our clinicians Anita Hole PhD, Jesse Suh,
PsyD, and Marta MacDougal, PsyD for conducting the psychological
evaluations. And third, we take this opportunity to thank the MRI
technicians at the Hospital of the University of Pennsylvania for
conducting the scanning sessions.
NR 80
TC 64
Z9 67
U1 6
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD FEB
PY 2009
VL 34
IS 3
BP 717
EP 728
DI 10.1038/npp.2008.124
PG 12
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 393MA
UT WOS:000262376200019
PM 18704100
ER
PT J
AU Samaha, FF
Chou, CM
AF Samaha, Frederick F.
Chou, Carol M.
TI Blockade of the Endocannabinoid System for the Reduction of
Cardiometabolic Risk Factors
SO OBESITY
LA English
DT Review
ID CANNABINOID-1 RECEPTOR BLOCKER; RANDOMIZED CONTROLLED-TRIAL;
AMERICAN-HEART-ASSOCIATION; DIET-INDUCED OBESITY; ADIPOSE-TISSUE;
ENERGY-BALANCE; CARDIOVASCULAR-DISEASE; CB1 RECEPTORS; SCIENTIFIC
STATEMENT; ANTAGONIST SR141716
C1 [Chou, Carol M.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Samaha, Frederick F.] Philadelphia Vet Affairs Med Ctr, Cardiovasc Sect, Philadelphia, PA USA.
[Samaha, Frederick F.] Univ Penn, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA.
RP Chou, CM (reprint author), Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
EM cchou@mail.med.upenn.edu
NR 41
TC 1
Z9 1
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD FEB
PY 2009
VL 17
IS 2
BP 220
EP 225
DI 10.1038/oby.2008.476
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 400VJ
UT WOS:000262897200004
PM 19039319
ER
PT J
AU White-Gilbertson, S
Mullen, T
Senkal, C
Lu, P
Ogretmen, B
Obeid, L
Voelkel-Johnson, C
AF White-Gilbertson, S.
Mullen, T.
Senkal, C.
Lu, P.
Ogretmen, B.
Obeid, L.
Voelkel-Johnson, C.
TI Ceramide synthase 6 modulates TRAIL sensitivity and nuclear
translocation of active caspase-3 in colon cancer cells
SO ONCOGENE
LA English
DT Article
DE TRAIL; ceramide; apoptosis; ceramide synthase; longevity assurance
homologue
ID LONGEVITY ASSURANCE GENE-1; INDUCED APOPTOSIS; FAMILY-MEMBERS; HUMAN
HEAD; RESISTANCE; DEATH; METASTASIS; ACTIVATION; GROWTH; IDENTIFICATION
AB We have previously shown that the death receptor ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces an increase of intracellular C(16)-ceramide in sensitive SW480 but not in resistant SW620 cells. Resistance in SW620 cells was overcome by exogenous ceramide, leading us to propose that defective ceramide signaling contributes to TRAIL resistance. In this study we found that the increase in C16-ceramide in SW480 cells was inhibited by fumonisin B1, an inhibitor of ceramide synthases (CerS). Protein analysis revealed that TRAIL-resistant SW620 cells expressed lower levels of ceramide synthase 6 (CerS6, also known as longevity assurance homologue 6), which prompted us to investigate the effect of CerS6 modulation on TRAIL phenotype. RNAi against CerS6 resulted in a specific and significant decrease of the C(16)-ceramide species, which was sufficient to inhibit TRAIL-induced apoptosis. In cells with decreased levels of CerS6, caspase-3 was activated but failed to translocate into the nucleus. CerS6 localized primarily to the perinuclear region, suggesting this enzyme may be important in regulation of nuclear permeability. Moderate elevation in CerS6 expression was sufficient to reverse TRAIL resistance in SW620 cells. These results suggest that modulation of CerS6 expression may constitute a new therapeutic strategy to alter apoptotic susceptibility.
C1 [White-Gilbertson, S.; Lu, P.; Voelkel-Johnson, C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA.
[Mullen, T.; Obeid, L.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA.
[Senkal, C.; Ogretmen, B.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA.
[Obeid, L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Voelkel-Johnson, C (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, POB 250504,173 Ashley Ave, Charleston, SC 29403 USA.
EM johnsocv@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU NCI NIH HHS [CA-097132, CA-088932, P01 CA097132, P01 CA097132-060004,
P01CA097132, R01 CA088932, R01 CA088932-07]; NCRR NIH HHS [1P20-RR17698,
C06 RR018823, P20 RR017698, P20 RR017698-01, P20 RR017698-02, P20
RR017698-03]; NIA NIH HHS [AG016583, R01 AG016583]; NIDCR NIH HHS
[DE016572, R01 DE016572, R01 DE016572-04]; NIEHS NIH HHS [1T32ES012878,
T32 ES012878]
NR 50
TC 65
Z9 68
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB
PY 2009
VL 28
IS 8
BP 1132
EP 1141
DI 10.1038/onc.2008.468
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 412KE
UT WOS:000263722900008
PM 19137010
ER
PT J
AU Kulbersh, JS
Day, TA
Gillespie, MB
Young, MRI
AF Kulbersh, Jonathan S.
Day, Terry A.
Gillespie, M. Boyd
Young, M. Rita I.
TI 1 alpha,25-Dihydroxyvitamin D-3 to skew intratumoral levels of immune
inhibitory CD34(+) progenitor cells into dendritic cells
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
ID NECK-CANCER PATIENTS; PERIPHERAL-BLOOD; HEAD; TUMOR; DIFFERENTIATION;
SUPPRESSION; CARCINOMAS; MELANOMA
AB OBJECTIVES: Prior studies showed that immune inhibitory CD34(+) progenitor cells, whose numbers are increased in head and neck squamous cell carcinoma (HNSCC) patients, can be differentiated into immune stimulatory dendritic cells by culture with 1 alpha,25-dihydroxyvitamin D-3 (1,25[OH](2)D-3'). This was extended to a pilot study to diminish intratumoral levels of CD34(+) progenitor cells by inducing their maturation into dendritic cells with 1,25(OH)(2)D-3.
STUDY DESIGN: Newly diagnosed HNSCC patients were untreated for 3 weeks or received 3 weeks of 1,25(OH)(2)D-3 treatment befoer surgical treatment.
SUBJECTS AND METHODS: HNSCC tissue was collected by biopsy from six patients who had no prior 1,25(OH)(2)D-3 treatment and at the time of surgical treatment from six untreated patients and 11 patients who completed 1,25(OH)(2)D-3 treatment. Tissues were analyzed by immunohistochemistry for levels of CD34(+) cells and dendritic cells.
RESULTS: After 1,25(OH)(2)D-3 treatment, intratumoral levels of CD34(+) cells and levels of immature dendritic cells declined. However, levels of intratumoral mature dendritic cells increased. Clinical effects of 1,25(OH)(2)D-3 treatment are premature to analyze.
CONCLUSIONS: Treatment of HNSCC patients with 1,25(OH)(2)D-3 reduced levels of immune inhibitory CD34(+) cells while increasing maturation of dendritic cells. This supports added studies to determine the effect of 1,25(OH)(2)D-3 on intratumoral immune competence.
C1 [Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
[Kulbersh, Jonathan S.; Day, Terry A.; Gillespie, M. Boyd; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA.
EM rita.young@va.gov
FU Research Service of the Department of Veterans Affairs; National
Institutes of Health [R01CA85266, R01CA97813]
FX Supported by the Research Service of the Department of Veterans Affairs
and by grants R01CA85266 and R01CA97813 from the National Institutes of
Health to MRIY.
NR 18
TC 16
Z9 17
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD FEB
PY 2009
VL 140
IS 2
BP 235
EP 240
DI 10.1016/j.otohns.2008.11.011
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 404LL
UT WOS:000263153500018
PM 19201295
ER
PT J
AU Parker, LE
Kirchner, JE
Bonner, YM
Fickel, JJ
Ritchie, MJ
Simons, CE
Yano, EM
AF Parker, Louise E.
Kirchner, JoAnn E.
Bonner, Laura M.
Fickel, Jacqueline J.
Ritchie, Mona J.
Simons, Carol E.
Yano, Elizabeth M.
TI Creating a Quality-Improvement Dialogue: Utilizing Knowledge From
Frontline Staff, Managers, and Experts to Foster Health Care Quality
Improvement
SO QUALITATIVE HEALTH RESEARCH
LA English
DT Article
DE health care decision making; health care professionals; health care
workplace; quality improvement; research dissemination and utilization;
research implementation
ID DEPRESSION; PRACTITIONERS; PARTICIPATION; DECISIONS; ACADEMICS; BEHAVIOR
AB There is a growing consensus that a hybrid of two common approaches to quality improvement (QI), local participatory QI and expert QI, might be the best method for achieving quality care. Achieving such a hybrid requires that content experts establish an ongoing dialogue with both frontline staff members and managers. In this study we examined frontline staff members' and managers' preferences regarding how to conduct such a dialogue, and we provide practical suggestions for implementation. The two groups shared a number of preferences (e.g., verbal face-to-face exchanges, discussions focused on quality of care). There were also some differences. For example, although managers were interested in discussions of business aspects (e.g., costs), frontline staff members were concerned with workload issues. Finally, although informants acknowledged that engaging in a QI dialogue was time consuming, they also believed it was essential if health care organizations are to improve the quality of care they provide.
C1 [Parker, Louise E.; Kirchner, JoAnn E.] VA Ctr Mental Hlth Care & Outcomes Res, HSR&D Res Enhancement Award Program, N Little Rock, AR USA.
[Parker, Louise E.; Ritchie, Mona J.] VA Mental Hlth Qual Enhancement Res Initiat Coord, N Little Rock, AR USA.
[Kirchner, JoAnn E.] VA S Cent Mental Illness Res, Educ & Clin Ctr, N Little Rock, AR USA.
[Bonner, Laura M.] VA Puget Sound Hlth Care Syst, HSR&D NW Ctr Excellence, Seattle, WA USA.
[Fickel, Jacqueline J.; Yano, Elizabeth M.] VA HSR&D Ctr Excellence Study Hlth Care Provider, Sepulveda, CA USA.
[Simons, Carol E.] VA Puget Sound Hlth Care Syst, HSR&D NW Ctr Excellence Outcomes Res Older Adults, Seattle, WA USA.
RP Parker, LE (reprint author), VA Ctr Mental Hlth Care & Outcomes Res, HSR&D Res Enhancement Award Program, N Little Rock, AR USA.
NR 39
TC 36
Z9 36
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-7323
J9 QUAL HEALTH RES
JI Qual. Health Res.
PD FEB
PY 2009
VL 19
IS 2
BP 229
EP 242
DI 10.1177/1049732308329481
PG 14
WC Information Science & Library Science; Social Sciences,
Interdisciplinary; Social Sciences, Biomedical
SC Information Science & Library Science; Social Sciences - Other Topics;
Biomedical Social Sciences
GA 396SX
UT WOS:000262612500007
PM 19092141
ER
PT J
AU Boockvar, KS
Liu, S
Goldstein, N
Nebeker, J
Siu, A
Fried, T
AF Boockvar, K. S.
Liu, S.
Goldstein, N.
Nebeker, J.
Siu, A.
Fried, T.
TI Prescribing discrepancies likely to cause adverse drug events after
patient transfer
SO QUALITY & SAFETY IN HEALTH CARE
LA English
DT Article
ID MEDICATION RECONCILIATION; HOSPITALIZATION; SYSTEM; SAFETY; ERRORS; CARE
AB Background: Medication-prescribing discrepancies are used as a quality measure for patients transferred between sites of care. The objective of this study was to quantify the rate of adverse drug events (ADEs) caused by prescribing discrepancies and the discrimination of an index of high-risk transition drug prescribing.
Methods: We examined medical records of patients transferred between seven nursing homes and three hospitals between 1999 and 2005 in New York and Connecticut for transfer- associated prescribing discrepancies. ADEs caused by discrepancies were determined by two clinician raters. We calculated the fraction of medication discrepancies that caused ADEs in each of 22 drug classes by calculating positive predictive values (PPVs). We calculated the discrimination of a count of high-risk drug discrepancies, selected from published lists of high-risk medications and using observed PPVs.
Results: 208 patients were hospitalised 304 times. Overall, 65 of 1350 prescribing discrepancies caused ADEs, for a PPV of 0.048 (95% CI 0.037 to 0.061). PPVs by drug class ranged from 0 to 0.28. Drug classes with the highest PPVs were opioid analgesics, metronidazole, and non-opioid analgesics. Patients with 0, 1-2 and >= 3 high-risk discrepancies had a 13%, 23% and 47% chance of experiencing a discrepancy-related ADE, respectively.
Conclusions: Discrepancies in certain drug classes more often caused ADEs than other types of discrepancies in hospitalised nursing-home patients. Information about ADEs caused by medication discrepancies can be used to enhance measurement of care quality, identify high-risk patients and inform the development of decision-support tools at the time of patient transfer.
C1 [Boockvar, K. S.; Goldstein, N.; Siu, A.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Geriatr, New York, NY USA.
[Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Boockvar, K. S.] Jewish Home & Hosp, New York, NY USA.
[Liu, S.; Fried, T.] Yale Univ, Sch Med, New Haven, CT USA.
[Nebeker, J.] VA Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA.
[Fried, T.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA.
RP Boockvar, KS (reprint author), VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM kenneth.boockvar@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU VA Health Services Research and Development Service; New York State
Department of Health; Doris Duke Clinical Research Fellowship
FX Financial support was provided by the VA Health Services Research and
Development Service and the New York State Department of Health. SL is
the recipient of a Doris Duke Clinical Research Fellowship.
NR 29
TC 47
Z9 47
U1 1
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1475-3898
J9 QUAL SAF HEALTH CARE
JI Qual. Saf. Health Care
PD FEB
PY 2009
VL 18
IS 1
BP 32
EP 36
DI 10.1136/qshc.2007.025957
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 404UJ
UT WOS:000263178200007
PM 19204129
ER
PT J
AU Turner, AP
Williams, RM
Sloan, AP
Haselkorn, JK
AF Turner, Aaron P.
Williams, Rhonda M.
Sloan, Alicia P.
Haselkorn, Jodie K.
TI Injection Anxiety Remains a Long-term Barrier to Medication Adherence in
Multiple Sclerosis
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE multiple sclerosis; medication adherence; anxiety; health behavior
ID DISEASE-MODIFYING THERAPIES; QUALITY-OF-LIFE; SELF-INJECT; PATIENT
COMPLIANCE; CLINICAL-PRACTICE; IMPAIRMENT; DISABILITY; MS; DYSFUNCTION;
VETERANS
AB Objective: To evaluate the contribution injection anxiety to disease modifying therapy (DMT) adherence among individuals with multiple sclerosis (MS). Injection anxiety has been associated with medication discontinuation early in the course of treatment, but little is known about the relationship between injection anxiety and sustained DMT adherence over time. Method. Eighty-nine outpatients receiving care at a Veterans Administration MS clinic completed a telephone survey at baseline and monthly telephone follow-up for 6 months. Results: Participants were established DMT users (M = 3.43 years, SD = 3.29), with relatively high adherence overall (over 80% achieved 80% adherence or greater). Using logistic regression and controlling for demographics, MS disability, type of DMT, and time on DMT, the authors found that baseline injection anxiety predicted lower levels of adherence at 4 months and 6 months, with a similar trend at 2 months. Conclusion: Sustained adherence to DMT remains a challenge for a subset of individuals with MS well beyond the initial period of acclimation. Injection anxiety is an important and promising target of psychological intervention during all periods of medication use.
C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, VA Multiple Sclerosis Ctr Excellence W, VA Ctr Excellence Substance Abuse Treatment & Edu, Seattle, WA 98108 USA.
[Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, VA Puget Sound Hlth Care Syst, VA Multiple Sclerosis Ctr Excellence W, Seattle, WA 98195 USA.
[Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, VA Multiple Sclerosis Ctr Excellence W, VA Ctr Excellence Substance Abuse Treatment & Edu, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
EM Aaron.Turner@va.gov
OI sloan, alicia/0000-0003-4891-3266; Turner, Aaron/0000-0001-6897-8003
NR 39
TC 42
Z9 42
U1 2
U2 5
PU EDUCATIONAL PUBLISHING FOUNDATION
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD FEB
PY 2009
VL 54
IS 1
BP 116
EP 121
DI 10.1037/a0014460
PG 6
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 410WJ
UT WOS:000263608700014
PM 19618711
ER
PT J
AU Fraunfelder, FW
Winthrop, K
Suhler, E
Choi, D
Fraunfelder, FT
AF Fraunfelder, Frederick W.
Winthrop, Kevin
Suhler, Eric
Choi, Dongseok
Fraunfelder, Frederick T.
TI Untitled
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Letter
ID BISPHOSPHONATES; SCLERITIS
C1 [Fraunfelder, Frederick W.; Winthrop, Kevin; Suhler, Eric; Choi, Dongseok; Fraunfelder, Frederick T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
[Winthrop, Kevin] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA.
[Winthrop, Kevin; Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Suhler, Eric] Portland VA Med Ctr, Portland, OR USA.
RP Fraunfelder, FW (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
NR 5
TC 3
Z9 3
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2009
VL 29
IS 2
BP 285
EP 286
PG 2
WC Ophthalmology
SC Ophthalmology
GA 407BR
UT WOS:000263339100029
PM 19202428
ER
PT J
AU Batki, SL
Meszaros, ZS
Strutynski, K
Dimmock, JA
Leontieva, L
Ploutz-Snyder, R
Canfield, K
Drayer, RA
AF Batki, Steven L.
Meszaros, Zsuzsa S.
Strutynski, Katherine
Dimmock, Jacqueline A.
Leontieva, Luba
Ploutz-Snyder, Robert
Canfield, Kelly
Drayer, Rebecca A.
TI Medical comorbidity in patients with schizophrenia and alcohol
dependence
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Alcohol; Medical illness; Substance abuse; Comorbidity
ID ILLNESS RATING-SCALE; SUBSTANCE-ABUSE; MENTAL-ILLNESS; CO-MORBIDITY;
SEVERITY; HEALTH; VALIDATION; DISORDERS; MORTALITY; PEOPLE
AB Background: Schizophrenia and alcohol dependence are major risk factors for a variety of medical problems, yet there has been little research on the medical status of patients in whom both conditions coexist.
Methods: We assessed the prevalence and severity of medical illness in 80 patients with schizophrenia or schizoaffective disorder and comorbid alcohol use disorders who entered a controlled trial of monitored naltrexone treatment, and analyzed the relationship between medical illness burden and demographic variables, alcohol and other substance use, and psychosis. Participants underwent physical examination, laboratory tests, medical record review and standardized assessments of medical illness burden, alcohol and other substance use, and psychosis. Nested block multiple regression analyses were used to assess the contribution to illness burden made by demographic variables, alcohol and substance use, and psychosis severity.
Results: 83% of participants had at least one chronic medical illness, hypertension being the most common (43%). Medical comorbidity in this cohort was more severe than for schizophrenia patients in the CATIE trial (Chwastiak, L. Rosenheck, R., McEvoy, J.P., Keefe, R.S., Swartz, M.S., Lieberman,J.A., 2006. Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatr. Serv., 57(8), 1102-1109.); the prevalence of hypertension, chronic obstructive pulmonary disease, and coronary artery disease, was more than twice greater. Medical illness burden correlated with alcohol use severity, but appeared to be independent of other substance use or psychosis severity.
Conclusions: Patients with co-occurring alcohol use disorder may have significantly more medical illness burden than patients with schizophrenia or schizoaffective disorder alone. Interventions to reduce alcohol use may be necessary to lessen medical morbidity. Published by Elsevier B.V.
C1 [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr 116P, Addict Psychiat Res Program, San Francisco, CA 94121 USA.
[Batki, Steven L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Batki, Steven L.; Meszaros, Zsuzsa S.; Strutynski, Katherine; Dimmock, Jacqueline A.; Leontieva, Luba; Canfield, Kelly] SUNY Upstate Med Univ, Dept Psychiat, New York, NY USA.
[Batki, Steven L.; Drayer, Rebecca A.] VA Ctr Integrated Healthcare Syracuse, New York, NY USA.
[Ploutz-Snyder, Robert] NASA, Houston, TX USA.
[Drayer, Rebecca A.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
RP Batki, SL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr 116P, Addict Psychiat Res Program, 4150 Clement St, San Francisco, CA 94121 USA.
EM steven.batki@ucsf.edu
FU National Institutes of Health/the National Institute on Alcoholism and
Alcohol Abuse (NIH/NIAAA) [RO1 AA013655]
FX The sponsor, the National Institutes of Health/the National Institute on
Alcoholism and Alcohol Abuse (NIH/NIAAA) had no role in the study
design, in the collection, analysis and interpretation of data, in the
writing of the report, or in the decision to Submit the paper for
publication.; This research was supported by NIH/NIAAA grant "Naltrexone
Treatment of Alcohol Abuse in Schizophrenia" number: RO1 AA013655 to Dr.
Batki. The assistance of Michelle Cavallerano, Sara DeRycke, and Lisa
Gallinger is gratefully acknowledged.
NR 30
TC 25
Z9 28
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD FEB
PY 2009
VL 107
IS 2-3
BP 139
EP 146
DI 10.1016/j.schres.2008.10.016
PG 8
WC Psychiatry
SC Psychiatry
GA 407XM
UT WOS:000263397600005
PM 19022627
ER
PT J
AU Kleinman, L
Lieberman, J
Dube, S
Mohs, R
Zhao, Y
Kinon, B
Carpenter, W
Harvey, PD
Green, MF
Keefe, RSE
Frank, L
Bowman, L
Revicki, DA
AF Kleinman, Leah
Lieberman, Jeffrey
Dube, Sanjay
Mohs, Richard
Zhao, Yang
Kinon, Bruce
Carpenter, William
Harvey, Philip D.
Green, Michael F.
Keefe, Richard S. E.
Frank, Lori
Bowman, Lee
Revicki, Dennis A.
TI Development and psychometric performance of the schizophrenia objective
functioning instrument: An interviewer administered measure of function
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Functioning; Outcomes assessment; Schizophrenia; Cognitive impairment;
Reliability; Validity
ID QUALITY-OF-LIFE; NEUROCOGNITIVE DEFICITS; COGNITIVE IMPAIRMENT;
SOCIAL-ADJUSTMENT; OLDER OUTPATIENTS; WORK PERFORMANCE; SCALE; VALIDITY;
REHABILITATION; CONSEQUENCES
AB Existing measures for functional assessment do not adequately address the relationship between cognitive impairment and function. The Schizophrenia Outcomes Functioning Interview (SOFI) was developed to measure community functioning related to cognitive impairment and psychopathology.
Following review of existing measures and discussion with experts, caregivers, and patients, content was generated for four domains: 1) living situation; 2) IADLs; 3) productive activities; and 4) social functioning. The final SOFI was constructed with items informing domain scores, and an interviewer-completed global rating for each domain.
Psychometric characteristics of the SOFI were evaluated in a sample of 104 community residing patients with schizophrenia and their informants. Test-retest reliability was evaluated in a subsample of patient-informant dyads using ICC; all values were >0.70 for both patient-interviews (SOFI-P) and informant-interviews (SOFI-I). Inter-rater reliability ICCs ranged from 0.50 to 0.79 on a different sub-sample. The SOFI demonstrated adequate construct validity based on correlations with the PSP (range 0.58 to 0.76; p < 0.0001) and the QLS (p < 0.001). Some correlations between SOFI and PETiT scores were low to moderate (p < 0.05). Discriminant validity was supported based on SOFI score comparisons for patient groups based on PANSS and BACS scores (p < 0.05); SOFI scores differed between borderline and moderately ill patients as measured by the CGI-S (p < 0.05).
The SOFI expands on existing measures and more comprehensively captures functioning of patients in the real world than other performance-based (proxy) measures. The SOFI has good evidence supporting reliability and construct validity, and may be a useful measure of functional outcomes in schizophrenia. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Kleinman, Leah] United BioSource Corp, Seattle, WA USA.
[Lieberman, Jeffrey] Columbia Univ, New York, NY USA.
[Dube, Sanjay; Mohs, Richard; Zhao, Yang; Kinon, Bruce; Bowman, Lee] Eli Lilly & Co, Indianapolis, IN 46285 USA.
[Carpenter, William] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA.
[Carpenter, William] VISN 5 MIRECC, Baltimore, MD USA.
[Harvey, Philip D.] Mt Sinai Sch Med, New York, NY USA.
[Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Keefe, Richard S. E.] Duke Univ, Med Ctr, Durham, NC USA.
[Frank, Lori; Revicki, Dennis A.] United BioSource Corp, Bethesda, MD USA.
RP Kleinman, L (reprint author), United BioSource Corp, Seattle, WA USA.
EM leah.kleinman@unitedbiosource.com
NR 45
TC 21
Z9 21
U1 7
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD FEB
PY 2009
VL 107
IS 2-3
BP 275
EP 285
DI 10.1016/j.schres.2008.10.002
PG 11
WC Psychiatry
SC Psychiatry
GA 407XM
UT WOS:000263397600026
PM 19013769
ER
PT J
AU Kern, RS
Green, MF
Nuechterlein, KH
Keefe, RSE
AF Kern, Robert S.
Green, Michael F.
Nuechterlein, Keith H.
Keefe, Richard S. E.
TI Commentary on O'Halloran et al
SO SCHIZOPHRENIA RESEARCH
LA English
DT Letter
ID CONSENSUS COGNITIVE BATTERY; SCHIZOPHRENIA; TRIALS
C1 [Kern, Robert S.; Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Kern, Robert S.; Green, Michael F.] Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, VISN 22, Los Angeles, CA USA.
[Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
[Keefe, Richard S. E.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210 A, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM rkern@ucla.edu
NR 6
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD FEB
PY 2009
VL 107
IS 2-3
BP 327
EP 329
DI 10.1016/j.schres.2008.10.015
PG 3
WC Psychiatry
SC Psychiatry
GA 407XM
UT WOS:000263397600034
PM 19013770
ER
PT J
AU Restrepo, MI
Anzueto, A
AF Restrepo, Marcos I.
Anzueto, Antonio
TI The Role of Gram-Negative Bacteria in Healthcare-Associated Pneumonia
SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Review
DE Pneumonia; healthcare-associated; outcomes
ID HOME-ACQUIRED PNEUMONIA; STAPHYLOCOCCUS-AUREUS INFECTION;
LONG-TERM-CARE; RISK-FACTORS; MANAGEMENT; EPIDEMIOLOGY; OUTCOMES;
DEFINITION; PREVENTION; GUIDELINES
AB Healthcare-associated pneumonia (HCAP) is a unique entity that differs from community-acquired pneumonia in both bacteriology and outcomes and has similarities to hospital-acquired pneumonia and ventilator-associated pneumonia. HCAP patients are at higher risk of potential multidrug-resistant pathogens, including resistant grain-negative organisms, especially Pseudomonas aeruginosa and Acinetobacter spp., but also extended-spectrum beta-lactamases (ESBLs). This manuscript reviews the epidemiology, etiology, and clinical outcomes of hospitalized HCAP patients due to gram-negative bacteria. We win focus our attention on the potential multidrug-resistant pathogens to suggest a new treatment approach for these patients.
C1 [Restrepo, Marcos I.] Audie L Murphy Div San Antonio, S Texas Vet Hlth Care Syst, VERDICT 11C6, Div Pulm & Crit Care Med, San Antonio, TX 78284 USA.
[Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Restrepo, MI (reprint author), Audie L Murphy Div San Antonio, S Texas Vet Hlth Care Syst, VERDICT 11C6, Div Pulm & Crit Care Med, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
NR 30
TC 18
Z9 20
U1 0
U2 1
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1069-3424
J9 SEMIN RESP CRIT CARE
JI Semin. Respir. Crit. Care Med.
PD FEB
PY 2009
VL 30
IS 1
BP 61
EP 66
DI 10.1055/s-0028-1119810
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 427SF
UT WOS:000264798700009
PM 19199188
ER
PT J
AU O'Hearn, DJ
Gold, AR
Gold, MS
Diggs, P
Scharf, SM
AF O'Hearn, Daniel J.
Gold, Avram R.
Gold, Morris S.
Diggs, Paul
Scharf, Steven M.
TI Lower extremity edema and pulmonary hypertension in morbidly obese
patients with obstructive sleep apnea
SO SLEEP AND BREATHING
LA English
DT Article
DE Edema; Pulmonary hypertension; Morbid obesity; Obstructive sleep apnea
ID LEFT-VENTRICULAR HYPERTROPHY; POSITIVE AIRWAY PRESSURE; CARDIAC-OUTPUT;
COR-PULMONALE; HEART-FAILURE; LUNG-DISEASE; CLINICAL FEATURES;
CYSTIC-FIBROSIS; HEMODYNAMICS; DYSFUNCTION
AB In 70 consecutive male patients with obstructive sleep apnea (OSA) diagnosed at the Northport VA Medical Center Sleep Disorders Center, we have characterized the association between obesity, OSA, and pulmonary hypertension (PH).
By including anthropometric, pulmonary function, and sleep study parameters in a multivariate logistic regression model, we found that a BMI of > 40 kg/m(2) and the minimum oxygen saturation in non-rapid eye movement (NREM) sleep predicted the presence of pretibial edema in this sleep apnea population. We then characterized the hemodynamics of those OSA patients that had lower extremity edema. Twenty-nine of the 70 consecutive patients with sleep apnea (41%) had pretibial edema, and right heart catheterization data was obtained for 28 (97%) of these patients.
Ninety-three percent (26/28) of the patients had right heart failure (mean RAP > 5 mm Hg; RAP range = 0-32 mmHg) and PH (PA mean a parts per thousand yenaEuro parts per thousand 20 mm Hg) was present in 86% (24/28.) The OSA patients with lower extremity edema had an increased cardiac output (7.0 + 1.4 l/min) with a normal cardiac index (2.9 + 0.5 l/min/m(2)) in the setting of an elevated pulmonary capillary wedge pressure (PCWP 17 +/- 7 mmHg) and a normal pulmonary vascular resistance (122 + 70 dynes s cm(-5)). While PCWP, FEV(1)% predicted, and the minimum oxygen saturation in NREM sleep all independently predicted PH, PCWP was the most important predictor of PH.
We conclude that pulmonary hypertension is commonly seen in patients with OSA with pretibial edema and that pretibial edema is a highly specific sign of PH in OSA patients. Pulmonary hypertension appears to result from an elevated back pressure and diastolic dysfunction with contributions from lung function and nocturnal oxygen saturation.
C1 Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Portland, OR 97239 USA.
[Gold, Avram R.; Diggs, Paul] Northport VA Med Ctr NY, Dept Med, Northport, NY USA.
[Gold, Avram R.; Diggs, Paul] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA.
[Gold, Morris S.] Novartis Consumer Hlth, Summit, NJ USA.
[Scharf, Steven M.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP O'Hearn, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, P3-PULM,POB 1034, Portland, OR 97239 USA.
EM ohearnd@ohsu.edu
FU Novartis Consumer Health
FX The authors wish to acknowledge Dr. John P. Dervan and the many
attending physicians and fellows of the Cardiology Division of
SUNY-Stony Brook School of Medicine who diligently obtained the
catheterization data that made this study possible. The authors have no
conflicts of interest to report. The work performed by Morris Gold was
not connected to his position at Novartis Consumer Health.
NR 69
TC 9
Z9 9
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1520-9512
J9 SLEEP BREATH
JI Sleep Breath.
PD FEB
PY 2009
VL 13
IS 1
BP 25
EP 34
DI 10.1007/s11325-008-0200-z
PG 10
WC Clinical Neurology; Respiratory System
SC Neurosciences & Neurology; Respiratory System
GA 387NU
UT WOS:000261959700005
PM 18615260
ER
PT J
AU Brausch, AM
Gutierrez, PM
AF Brausch, Amy M.
Gutierrez, Peter M.
TI The Role of Body Image and Disordered Eating as Risk Factors for
Depression and Suicidal Ideation in Adolescents
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID ATTITUDES TEST; FEMALE ADOLESCENTS; GENDER DIFFERENCES; BULIMIA-NERVOSA;
SOCIAL SUPPORT; SELF-ESTEEM; WEIGHT; DISSATISFACTION; HOPELESSNESS;
BEHAVIORS
AB There is much empirical literature on factors for adolescent suicide risk, but body image and disordered eating are rarely included in these models. In the current study, disordered eating and body image were examined as risk factors for suicide ideation since these factors are prevalent in adolescence, particularly for females. It was hypothesized that disordered eating and body image, in addition to depressive symptoms, would contribute to suicide ideation. It was also hypothesized that these relationships would be stronger for females than for males. Structural equation modeling was used to test a model of risk for suicide ideation incorporating the above factors in a sample of 392 high school students. Results indicated that disordered eating contributed to both suicide ideation and depressive symptoms, while body image only contributed to depressive symptoms. Depressive symptoms contributed to suicide ideation. The model was found to be cross-validated with males and females, and no gender differences emerged. Implications of these findings and their importance in constructing future models of adolescent suicide risk are discussed.
C1 [Brausch, Amy M.] Eastern Illinois Univ, Dept Psychol, Charleston, IL 61920 USA.
[Gutierrez, Peter M.] Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA.
RP Brausch, AM (reprint author), Eastern Illinois Univ, Dept Psychol, 600 Lincoln Ave, Charleston, IL 61920 USA.
EM abrausch@eiu.edu
OI Gutierrez, Peter/0000-0001-8981-8404
NR 37
TC 38
Z9 40
U1 2
U2 15
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD FEB
PY 2009
VL 39
IS 1
BP 58
EP 71
PG 14
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 417PR
UT WOS:000264089100007
PM 19298151
ER
PT J
AU Walker, RH
Koch, RJ
Moore, C
Meshul, CK
AF Walker, Ruth H.
Koch, Rick J.
Moore, Cynthia
Meshul, Charles K.
TI Subthalamic Nucleus Stimulation and Lesioning Have Distinct
State-Dependent Effects Upon Striatal Dopamine Metabolism
SO SYNAPSE
LA English
DT Article
DE deep brain stimulation; microdialysis; Parkinson's disease; rat;
6-hydroxydopamine
ID HIGH-FREQUENCY STIMULATION; DEEP BRAIN-STIMULATION; NIGRA PARS
RETICULATA; RAT SUBSTANTIA-NIGRA; INDUCED CELLULAR DEFECTS; MEDIAL
FRONTAL-CORTEX; IN-VIVO MICRODIALYSIS; PARKINSONS-DISEASE;
6-HYDROXYDOPAMINE-LESIONED RATS; BASAL GANGLIA
AB The mechanism by which deep brain stimulation (DBS) of the subthalamic nucleus (STN) achieves its effects in Parkinson's disease (PD) is not known. In animal models of PD, stimulation and lesioning of the STN have some effects which are the same, but others which differ, in reversing cellular and behavioral changes induced by dopamine depletion. We compared the effects of short-term STN stimulation and lesions upon extracellular levels of dopamine and metabolites using in vivo microdialysis of the dorsal striatum of awake, intact and unilateral 6-hydroxydopamine (60HDA)-lesioned rats. STN stimulation in control rats decreased striatal dopamine levels and caused a relative increase in dopamine metabolism, as expressed by HVA/dopamine and DOPAC/dopamine ratios. This suggests an increase in both vesicular dopamine release (metabolized to HVA), and release from the cytoplasmic dopamine pool (metabolized to DOPAC). STN lesions in control rats increased the HVA/dopamine ratio, also suggesting a relative increase in vesicular dopamine release. These results indicate that STN stimulation and lesioning can affect striatal dopamine metabolism in the intact system. In 60HDA-lesioned rats at baseline, metabolic ratios were markedly decreased as compared with controls. STN lesions of 60HDA-lesioned rats did not affect relative metabolic ratios as compared with baseline levels. In 6-OHDA-lesioned rats, STN stimulation decreased extracellular levels of dopamine, and, to a greater extent, metabolites, resulting in a decrease in metabolic ratios. This further decrease in dopamine turnover with STN stimulation would serve to maintain dopamine levels in the dopamine-depleted striatum, and may account for the therapeutic benefit of DBS in Parkinson's disease. Synapse 63:136-146, 2009. Published 2008 Wiley-Liss, Inc.
C1 [Walker, Ruth H.; Koch, Rick J.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Moore, Cynthia; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA.
[Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
FU Parkinson's Disease Foundation International Research; Department of
Veterans Affairs Merit awards
FX Parkinson's Disease Foundation International Research Grant, Department
of Veterans Affairs Merit awards.
NR 70
TC 13
Z9 13
U1 1
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-4476
J9 SYNAPSE
JI Synapse
PD FEB
PY 2009
VL 63
IS 2
BP 136
EP 146
DI 10.1002/syn.20592
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 389EK
UT WOS:000262073500006
PM 19021215
ER
PT J
AU Gore, JL
Litwin, MS
AF Gore, John L.
Litwin, Mark S.
CA Urologic Dis Amer Project
TI Quality of care in bladder cancer: trends in urinary diversion following
radical cystectomy
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article
DE Bladder cancer; Quality of care; Urinary diversion
ID ILEAL CONDUIT; ORTHOTOPIC NEOBLADDER; LIFE; RECONSTRUCTION;
SUBSTITUTION; GUIDELINES; SPECIMENS; OUTCOMES; WOMEN
AB Quality-of-care indicators have not yet been defined for patients with bladder cancer. Nonetheless, certain aspects of bladder cancer care can be evaluated to quantify the quality of care delivered. We sought to determine trends in continent urinary diversion to evaluate the adoption of this more optimal reconstruction.
Subjects who underwent radical cystectomy for a primary diagnosis of bladder cancer were identified from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample. We identified covariates independently associated with utilization of continent urinary diversion after radical cystectomy using multivariate logistic regression modeling. We then examined trends in diversion type based on patient and hospital characteristics and examined the impact of hospital volume on use of continent reconstruction.
Our weighted sample included 5,075 subjects (14.3%) who underwent continent urinary diversion and 30,295 subjects (85.7%) who underwent an ileal conduit. Independent correlates of continent diversion included younger age, male gender, having private insurance, and undergoing surgery at an urban teaching hospital. Hospitals performing continent diversions on more than 40% of their cystectomies had a yearly cystectomy volume of 0.8 surgeries. Subjects treated at high-volume hospitals trended toward lower rates of comorbid conditions.
We identified substantial disparities in continent diversion which, based on yearly trends, are unlikely to improve in the near future. Continent reconstructions are not the exclusive domain of high-volume cystectomy centers. Yet efforts to increase rates of this complex reconstruction must concentrate on technique dissemination and better definition of the quality-of-life detriments incurred by cystectomy patients.
C1 [Gore, John L.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Gore, John L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gore, John L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA.
[Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Litwin, Mark S.] RAND Corp, Santa Monica, CA USA.
RP Gore, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Box 951738, Los Angeles, CA 90095 USA.
EM jgore@mednet.ucla.edu
OI Gore, John/0000-0002-2847-5062
FU NIDDK NIH HHS [N01 DK012460]
NR 21
TC 33
Z9 33
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-4983
J9 WORLD J UROL
JI World J. Urol.
PD FEB
PY 2009
VL 27
IS 1
BP 45
EP 50
DI 10.1007/s00345-008-0348-y
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 398AS
UT WOS:000262704200008
PM 19020881
ER
PT J
AU Subak, LL
Wing, R
West, DS
Franklin, F
Vittinghoff, E
Creasman, JM
Richter, HE
Myers, D
Burgio, KL
Gorin, AA
Macer, J
Kusek, JW
Grady, D
AF Subak, Leslee L.
Wing, Rena
West, Delia Smith
Franklin, Frank
Vittinghoff, Eric
Creasman, Jennifer M.
Richter, Holly E.
Myers, Deborah
Burgio, Kathryn L.
Gorin, Amy A.
Macer, Judith
Kusek, John W.
Grady, Deborah
CA PRIDE Investigators
TI Weight Loss to Treat Urinary Incontinence in Overweight and Obese Women.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; MIDDLE-AGED WOMEN;
CARDIOVASCULAR-DISEASE; STRESS-INCONTINENCE; STYLE INTERVENTION;
RISK-FACTORS; FOLLOW-UP; SURGERY; HEALTH
AB Background: Obesity is an established and modifiable risk factor for urinary incontinence, but conclusive evidence for a beneficial effect of weight loss on urinary incontinence is lacking.
Methods: We randomly assigned 338 overweight and obese women with at least 10 urinary-incontinence episodes per week to an intensive 6-month weight-loss program that included diet, exercise, and behavior modification (226 patients) or to a structured education program (112 patients).
Results: The mean (+/-SD) age of the participants was 53+/-11 years. The body-mass index (BMI) (the weight in kilograms divided by the square of the height in meters) and the weekly number of incontinence episodes as recorded in a 7-day diary of voiding were similar in the intervention group and the control group at baseline (BMI, 36+/-6 and 36+/-5, respectively; incontinence episodes, 24+/-18 and 24+/-16, respectively). The women in the intervention group had a mean weight loss of 8.0% (7.8 kg), as compared with 1.6% (1.5 kg) in the control group (P<0.001). After 6 months, the mean weekly number of incontinence episodes decreased by 47% in the intervention group, as compared with 28% in the control group (P=0.01). As compared with the control group, the intervention group had a greater decrease in the frequency of stress-incontinence episodes (P=0.02), but not of urge-incontinence episodes (P=0.14). A higher proportion of the intervention group than of the control group had a clinically relevant reduction of 70% or more in the frequency of all incontinence episodes (P<0.001), stress-incontinence episodes (P=0.009), and urge-incontinence episodes (P=0.04).
Conclusions: A 6-month behavioral intervention targeting weight loss reduced the frequency of self-reported urinary-incontinence episodes among overweight and obese women as compared with a control group. A decrease in urinary incontinence may be another benefit among the extensive health improvements associated with moderate weight reduction. (ClinicalTrials.gov number, NCT00091988.)
N Engl J Med 2009;360:481-90.
C1 [Subak, Leslee L.; Vittinghoff, Eric; Creasman, Jennifer M.; Macer, Judith; Grady, Deborah] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA.
[Wing, Rena] Miriam Hosp, Providence, RI 02906 USA.
[Wing, Rena; Myers, Deborah] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[West, Delia Smith] Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA.
[Franklin, Frank; Richter, Holly E.; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL USA.
[Burgio, Kathryn L.] Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA.
[Gorin, Amy A.] Univ Connecticut, Storrs, CT USA.
[Kusek, John W.] NIDDKD, Bethesda, MD 20892 USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Subak, LL (reprint author), Univ Calif San Francisco, Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA.
EM subakl@obgyn.ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases [U01
DK067860, U01 DK067861, U01 DK067862]; Office of Research on Women's
Health; Pfizer; Bionovo; Astellas; GlaxoSmithKline
FX Supported by grants from the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) (U01 DK067860, U01 DK067861, and
U01 DK067862) and from the Office of Research on Women's Health.; Dr.
Subak reports serving on an advisory board for Pfizer and receiving
grant support from Pfizer; Dr. Grady, receiving grant support from
Bionovo; Dr. Kusek, owning stock in Eli Lilly, Pfizer, and deCODE
Genetics; and Dr. Burgio, serving on an advisory board for Pfizer,
receiving grant support from Pfizer, and receiving advisory-board fees
from Astellas and GlaxoSmithKline. No other potential conflict of
interest relevant to this article was reported.; The views expressed are
those of the authors and do not necessarily represent the official views
of the NIDDK or the National Institutes of Health.
NR 36
TC 202
Z9 208
U1 1
U2 11
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 29
PY 2009
VL 360
IS 5
BP 481
EP 490
DI 10.1056/NEJMoa0806375
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 399PS
UT WOS:000262812400007
PM 19179316
ER
PT J
AU Lanoy, E
Dores, GM
Madeleine, MM
Toro, JR
Fraumeni, JF
Engels, EA
AF Lanoy, Emilie
Dores, Graca M.
Madeleine, Margaret M.
Toro, Jorge R.
Fraumeni, Joseph F., Jr.
Engels, Eric A.
TI Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in
the United States
SO AIDS
LA English
DT Article
DE AIDS; appendageal carcinoma; epidemiology; melanoma; Merkel cell
carcinoma; sebaceous carcinoma; skin cancer
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MUIR-TORRE-SYNDROME; SQUAMOUS-CELL
CARCINOMA; CUTANEOUS HUMAN PAPILLOMAVIRUSES; ORGAN TRANSPLANT
RECIPIENTS; SEBACEOUS GLAND CARCINOMA; SUN-EXPOSED SKIN; MICROSATELLITE
INSTABILITY; HIV-INFECTION; RISK-FACTORS
AB Objective: Immunosuppression may increase risk for some skin cancers. We evaluated skin cancer epidemiology among persons with AIDS.
Design: We linked data from population-based US AIDS and cancer registries to evaluate risk of nonkeratinocytic skin cancers (melanoma, Merkel cell carcinoma, and appendageal carcinomas, including sebaceous carcinoma) in 497 142 persons with AIDS.
Methods: Standardized incidence ratios (SIRs) were calculated to relate skin cancer risk to that in the general population. We used logistic regression to compare risk according to demographic factors, CD4 cell count, and a geographic index of ultraviolet radiation exposure.
Results: From 60 months before to 60 months after AIDS onset, persons with AIDS had elevated risks of melanoma (SIR=1.3, 95% confidence interval 1.1-1.4, n=292 cases) and, more strongly, of Merkel cell carcinoma (SIR=11, 95% confidence interval 6.3-17, n=17) and sebaceous carcinoma (SIR=8.1, 95% confidence interval 3.2-17, n=7). Risk for appendageal carcinomas increased with progressive time relative to AIDS onset (P trend 0.03). Risk of these skin cancers was higher in non-Hispanic whites than other racial/ethnic groups, and melanoma risk was highest among men who have sex with men. Melanoma risk was unrelated to CD4 cell count at AIDS onset (P=0.32). Risks for melanoma and appendageal carcinomas rose with increasing ultraviolet radiation exposure (P trend <10 (4) and P trend -10 (3), respectively).
Conclusion: Among persons with AIDS, there is a modest excess risk of melanoma, which is not strongly related to immunosuppression and may relate to ultraviolet radiation exposure. In contrast, the greatly increased risks for Merkel cell and sebaceous carcinoma suggest an etiologic role for immunosuppression. (c) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Lanoy, Emilie; Dores, Graca M.; Toro, Jorge R.; Fraumeni, Joseph F., Jr.; Engels, Eric A.] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA.
[Lanoy, Emilie] Univ Paris 06, INSERM, U720, Paris, France.
[Lanoy, Emilie] Univ Paris 06, UPMC, UMR S720, Paris, France.
[Dores, Graca M.] US Dept Vet Affairs, Med Ctr, Med Serv, Oklahoma City, OK USA.
[Madeleine, Margaret M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Engels, EA (reprint author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Room 7076, Rockville, MD 20892 USA.
EM engelse@exchange.nih.gov
RI Lanoy, Emilie/A-8541-2011
OI Lanoy, Emilie/0000-0002-4789-7770
FU Intramural Research Program of the National Cancer Institute
FX We are grateful for the contributions of many staff members at the
HIV/AIDS and cancer registries who collected the data, prepared data
files for the mathces, and facilitated the record linkages.; E.L. and
E.A.E. designed the study and conducted the statistical analyses.
G.M.D., J.R.T, and J.F.F contributed expertise regarding, skin cancer.
All authors contributed expertise regarding epidemiology methods and
participated in the interpretation of the data. M.M.M. and E.A.E.
provided data for the study. E.L. and E.A.E. drafted the article, and
all authors contributed to critical revision of the article.; The study
was supported by the Intramural Research Program of the National Cancer
Institute.
NR 42
TC 39
Z9 39
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 28
PY 2009
VL 23
IS 3
BP 385
EP 393
DI 10.1097/QAD.0b013e3283213046
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 406WH
UT WOS:000263325100013
PM 19114864
ER
PT J
AU N'Diaye, EN
Branda, CS
Branda, SS
Nevarez, L
Colonna, M
Lowell, C
Hamerman, JA
Seaman, WE
AF N'Diaye, Elsa-Noah
Branda, Catherine S.
Branda, Steven S.
Nevarez, Lisette
Colonna, Marco
Lowell, Clifford
Hamerman, Jessica A.
Seaman, William E.
TI TREM-2 (triggering receptor expressed on myeloid cells 2) is a
phagocytic receptor for bacteria
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID TYROSINE KINASE; CUTTING EDGE; RHO-GTPASES; MACROPHAGES; SYK;
MECHANISMS; DAP12; ACTIVATION; PROTEIN; FAMILY
AB Phagocytosis, which is essential for the immune response to pathogens, is initiated by specific interactions between pathogens and cell surface receptors expressed by phagocytes. This study identifies triggering receptor expressed on myeloid cells 2 (TREM-2) and its signaling counterpart DAP12 as a molecular complex that promotes phagocytosis of bacteria. Expression of TREM-2-DAP12 enables nonphagocytic Chinese hamster ovary cells to internalize bacteria. This function depends on actin cytoskeleton dynamics and the activity of the small guanosine triphosphatases Rac and Cdc42. Internalization also requires src kinase activity and tyrosine phosphorylation. In bone marrow-derived macrophages, phagocytosis is decreased in the absence of DAP12 and can be restored by expression of TREM-2-DAP12. Depletion of TREM-2 inhibits both binding and uptake of bacteria. Finally, TREM-2-dependent phagocytosis is impaired in Syk-deficient macrophages. This study highlights a novel role for TREM-2-DAP12 in the immune response to bacterial pathogens.
C1 [N'Diaye, Elsa-Noah; Nevarez, Lisette; Seaman, William E.] San Francisco VA Med Ctr, Macrophage Biol Lab, San Francisco, CA 94121 USA.
[Branda, Catherine S.; Branda, Steven S.] Sandia Natl Labs, Livermore, CA 94550 USA.
[Colonna, Marco] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[Lowell, Clifford] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hamerman, Jessica A.] Benaroya Res Inst, Seattle, WA 98101 USA.
RP Seaman, WE (reprint author), San Francisco VA Med Ctr, Macrophage Biol Lab, San Francisco, CA 94121 USA.
EM bseaman@medicine.ucsf.edu
OI Colonna, Marco/0000-0001-5222-4987
FU Laboratory Directed Research and Development program at Sandia National
Laboratories; Lockheed Martin Company [DE-AC04-94AL85000]; National
Institutes of Health [RO1 CA87922, GM062114]
FX This work was supported by the Laboratory Directed Research and
Development program at Sandia National Laboratories. Sandia is a
multiprogram laboratory operated by Sandia Corporation, a Lockheed
Martin Company, for the U. S. Department of Energy's National Nuclear
Security Administration under contract DE-AC04-94AL85000. Additional
support was provided by National Institutes of Health grant RO1 CA87922
(to W. E. Seaman), by National Institutes of Health grant GM062114 to
the Alliance for Cellular Signaling, and by the Veterans Administration.
NR 36
TC 79
Z9 80
U1 2
U2 8
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD JAN 28
PY 2009
VL 184
IS 2
BP 215
EP 223
DI 10.1083/jcb.200808080
PG 9
WC Cell Biology
SC Cell Biology
GA 404LO
UT WOS:000263153900017
PM 19171755
ER
PT J
AU Doshi, JA
Zhu, JS
Lee, BY
Kimmel, SE
Volpp, KG
AF Doshi, Jalpa A.
Zhu, Jingsan
Lee, Bruce Y.
Kimmel, Stephen E.
Volpp, Kevin G.
TI Impact of a Prescription Copayment Increase on Lipid-Lowering Medication
Adherence in Veterans
SO CIRCULATION
LA English
DT Article
DE coronary disease; medication adherence; fees, pharmaceutical; statins;
veterans
ID ACUTE MYOCARDIAL-INFARCTION; PHARMACY BENEFITS; STATIN THERAPY;
PERSISTENCE; COST; CHOLESTEROL; DATABASES; PROGRAM; DRUGS; CARE
AB Background-In February 2002, the Department of Veterans Affairs (VA) increased copayments from $2 to $7 per 30-day drug supply of each medication for many veterans. We examined the impact of the copayment increase on lipid-lowering medication adherence.
Methods and Results-This quasiexperimental study used electronic records of 5604 veterans receiving care at the Philadelphia VA Medical Center from November 1999 to April 2004. The all copayment group included veterans subject to copayments for all drugs with no annual cap. Veterans subject to copayments for drugs only if indicated for a non-service-connected condition with an annual cap of $840 for out-of-pocket costs made up the some copayment group. Veterans who remained copayment exempt formed a natural control group (no copayment group). Patients were identified as adherent if the proportion of days covered with lipid-lowering medications was >= 80%. Patients were identified as having a continuous gap if they had at least 1 continuous episode with no lipid-lowering medications for >= 90 days. A difference-in-difference approach compared changes in lipid-lowering medication adherence during the 24 months before and after copayment increase among veterans subject to the copayment change with those who were not. Adherence declined in all 3 groups after the copayment increase. However, the percentage of patients who were adherent (proportion of days covered >= 80%) declined significantly more in the all copayment (- 19.2%) and some copayment (- 19.3%) groups relative to the exempt group (- 11.9%). The incidence of a continuous gap increased significantly at twice the rate in both copayment groups (all copayment group, 24.6%; some copayment group, 24.1%) as the exempt group (11.7%). Compared with the exempt group, the odds of having a continuous gap in the after relative to the before period were significantly higher in both the all copayment group (odds ratio, 3.04; 95% confidence interval, 2.29 to 4.03) and the some copayment group (odds ratio, 1.85; 95% confidence interval, 1.43 to 2.40). Similar results were seen in subgroups of patients at high risk for coronary heart disease, high medication users, and elderly veterans.
Conclusion-The copayment increase adversely affected lipid-lowering medication adherence among veterans, including those at high coronary heart disease risk. (Circulation. 2009; 119: 390-397.)
C1 [Doshi, Jalpa A.; Zhu, Jingsan; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Res & Promot, Philadelphia, PA USA.
[Doshi, Jalpa A.; Zhu, Jingsan; Kimmel, Stephen E.; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Kimmel, Stephen E.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Kimmel, Stephen E.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Doshi, Jalpa A.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA.
[Lee, Bruce Y.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Lee, Bruce Y.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
RP Doshi, JA (reprint author), 1222 Blockley Hall, Philadelphia, PA 19104 USA.
EM jdoshi@mail.med.upenn.edu
FU VA Center for Health Equity Research and Promotion; American Heart
Association Pharmaceutical Roundtable Award [0675066N]; Commonwealth of
Pennsylvania [540625]; National Institute of Aging [R01 AG024451-01];
Penn Institute on Aging
FX We are grateful for funding support from the VA Center for Health Equity
Research and Promotion; the American Heart Association Pharmaceutical
Roundtable Award (grant 0675066N); the Commonwealth of Pennsylvania
(grant 540625); the National Institute of Aging (R01 AG024451-01); and
the Penn Institute on Aging. The funding organizations or sponsors
played no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review, or approval of the manuscript.
NR 24
TC 95
Z9 98
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JAN 27
PY 2009
VL 119
IS 3
BP 390
EP U53
DI 10.1161/CIRCULATIONAHA.108.783944
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 399EX
UT WOS:000262784300007
PM 19139387
ER
PT J
AU Schuh, LA
Adair, JC
Drogan, O
Kissela, BM
Morgenlander, JC
Corboy, JR
AF Schuh, L. A.
Adair, J. C.
Drogan, O.
Kissela, B. M.
Morgenlander, J. C.
Corboy, J. R.
TI Education Research: Neurology residency training in the new millennium
SO NEUROLOGY
LA English
DT Editorial Material
AB Objective: To survey adult neurology program directors (ANPD) to identify their most pressing needs at a time of dramatic change in neurology resident education.
Methods: All US ANPD were surveyed in 2007 using an instrument adjusted from a 1999 survey instrument. The goal was to characterize current program content, the institution and evaluation of the core competencies, program director characteristics, program director support, the institution of work duty hour requirements, resident support, and the curriculum needs of program directors and programs.
Results: A response rate of 82.9% was obtained. There is a significant disconnect between administration time spent by ANPD and departmental/institutional support of this, with ANPD spending approximately 35% of a 50-hour week on administration with only 16.7% salary support. Rearrangement of rotations or services has been the most common mode for ANPD to deal with work duty hour requirements, with few programs employing mid level providers. Most ANPD do not feel work duty hour reform has improved resident education. More residents are entering fellowships following graduation than documented in the past. Curriculum deficiencies still exist for ANPD to meet all Neurology Program Requirements, especially for nontraditional neurology topics outside the conventional bounds of clinical neurology (e. g., practice management). Nearly one quarter of neurology residency programs do not have a meeting or book fund for every resident in the program.
Conclusions: Adult neurology program directors (ANPDs) face multiple important financial and organizational hurdles. At a time of increasing complexity in medical education, ANPDs need more institutional support. Neurology (R) 2009; 72: e15-e20
C1 [Schuh, L. A.] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA.
[Adair, J. C.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA.
[Drogan, O.] Amer Acad Neurol Staff, St Paul, MN USA.
[Kissela, B. M.] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA.
[Morgenlander, J. C.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Corboy, J. R.] Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Denver, CO USA.
[Corboy, J. R.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO USA.
RP Schuh, LA (reprint author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.
EM lschuh@neuro.hfh.edu
OI Kissela, Brett/0000-0002-9773-4013
NR 4
TC 15
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JAN 27
PY 2009
VL 72
IS 4
BP E15
EP E20
DI 10.1212/01.wnl.0000342389.60811.ca
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 399CK
UT WOS:000262777800029
PM 19171823
ER
PT J
AU Martin, TM
Bye, L
Modi, N
Stanford, MR
Vaughan, R
Smith, JR
Wade, NK
Mackensen, F
Suhler, EB
Rosenbaum, JT
Wallace, GR
AF Martin, Tammy M.
Bye, Louise
Modi, Neil
Stanford, Miles R.
Vaughan, Robert
Smith, Justine R.
Wade, N. Kevin
Mackensen, Friederike
Suhler, Eric B.
Rosenbaum, James T.
Wallace, Graham R.
TI Genotype analysis of polymorphisms in autoimmune susceptibility genes,
CTLA-4 and PTPN22, in an acute anterior uveitis cohort
SO MOLECULAR VISION
LA English
DT Article
ID LYMPHOID TYROSINE PHOSPHATASE; ANKYLOSING-SPONDYLITIS; INFLAMMATORY
DISEASE; GRAVES-DISEASE; SPONDYLOARTHROPATHIES; ASSOCIATION;
MANIFESTATION; INFLIXIMAB; HLA-B27; VARIANT
AB Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis and is thought to be autoimmune in nature. Recent studies have described genes that act as master controllers of autoimmunity. Protein tyrosine phosphatase type 22 (PTPN22) and Cytotoxic T lymphocyte antigen-4 (CTLA-4) are two of these genes, and single nucleotide polymorphisms (SNPs) in the genes encoding these molecules have been associated with several autoimmune diseases. In this study we have analyzed SNPs in PTPN22 and CTLA-4 in patients with AAU.
Methods: The functional protein tyrosine phosphatase type 22 (PTPN22) SNP (R620W rs2476601, 1858C/T), and two CTLA-4 SNPs (rs5742909, -318C/T and rs231775, 49A/G) were analyzed in 140 patients with AAU and 92 healthy controls by sequence-specific primer-polymerase chain reaction (SSP-PCR). Data was analyzed by chi(2) analysis and Fisher's exact test.
Results: There was no significant association between PTPN22 620W, CTLA-4 -318C/T, or CTLA-4 49A/G and AAU. Similarly, there was no association with the three SNPs when patients were classified by race or gender. Finally, there was no association with the presence of ankylosing spondylitis in the patient cohort.
Conclusions: The data do not support an association between SNPs in PTPN22 and CTLA-4, genes regarded as genetic master switches of autoimmunity. This raises the issue of the etiology of AAU and the possibility that it should be regarded as an autoinflammatory rather than an autoimmune condition.
C1 [Wallace, Graham R.] Univ Birmingham, Birmingham & Midland Eye Ctr, City Hosp, Acad Unit Ophthalmol, Birmingham B18 7QU, W Midlands, England.
[Martin, Tammy M.; Smith, Justine R.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bye, Louise; Modi, Neil; Stanford, Miles R.; Vaughan, Robert] Kings Coll London, London WC2R 2LS, England.
[Wade, N. Kevin] Kerrisdale Profess Ctr, Vancouver, BC, Canada.
[Mackensen, Friederike] Heidelberg Univ, Heidelberg, Germany.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
RP Wallace, GR (reprint author), Univ Birmingham, Birmingham & Midland Eye Ctr, City Hosp, Acad Unit Ophthalmol, Dudley Rd, Birmingham B18 7QU, W Midlands, England.
EM g.r.wallace@bham.ac.uk
FU Research to Prevent Blindness; National Institutes of Health
[R01-EY-013139]; Birmingham Eye Foundation
FX Supported by Research to Prevent Blindness awards to the Casey Eye
Institute, and Drs. Martin, Smith and Rosenbaum; and National Institutes
of Health R01-EY-013139. The Birmingham Eye Foundation (G. R. Wallace).
The authors wish to thank the individuals with uveitis, referring
physicians, and the Spondylitis Association of America for their
cooperation. We appreciate the expert assistance of Carrie Austin, Trudy
Doyle, Kelley Goodwin and Elli Kondeatis in subject enrollment and
technical help.
NR 28
TC 16
Z9 17
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 26
PY 2009
VL 15
IS 20-23
BP 208
EP 212
PG 5
WC Biochemistry & Molecular Biology; Ophthalmology
SC Biochemistry & Molecular Biology; Ophthalmology
GA 421NC
UT WOS:000264364600001
PM 19180256
ER
PT J
AU Kiln, T
Leitner, JW
Adochio, R
Draznin, B
AF Kiln, Toni
Leitner, J. Wayne
Adochio, Rebecca
Draznin, Boris
TI Knockdown of JNK rescues 3T3-L1 adipocytes from insulin resistance
induced by mitochondrial dysfunction
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Insulin resistance; Mitochondrial dysfunction; JNK; 3T3-L1 adipocytes
ID PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYPE-2 DIABETIC PARENTS;
PROTEIN-KINASE-C; SKELETAL-MUSCLE; SERINE PHOSPHORYLATION;
LIPID-CONTENT; FATTY-ACIDS; TRIGLYCERIDE; IRS-1; SPECTROSCOPY
AB Mitochondrial dysfunction has been linked to etiology of insulin resistance, however the mechanism remains unknown. In this study we investigated whether mitochondrial dysfunction induced by cyanide p-trifluoromethoxyphenyl-hydrazone (FCCP) alters insulin sensitivity in 3T3-L1 adipocytes and which cellular signaling molecules might be involved. Fully differentiated 3T3-L1 adipocytes were treated with 10 mu M FCCP for 1 h, resulting in increased serine-307 phosphorylation of IRS-1 and decreased insulin-stimulated tyrosine phosphorylation, association of p85 alpha subunit of phosphatidylinositol 3-kinase (PI 3-kinase) with IRS-1, decreased insulin-stimulated PI 3-kinase activity and H-3-2-deoxyglucose (2DOG) uptake. A partial (46%) knockdown of JNK1 blocked FCCP-induced serine phosphorylation of IRS-1 and restored insulin-stimulated tyrosine phosphorylation of IRS-1, association of p85 alpha subunit of PI 3-kinase with IRS-1. activation of PI 3-kinase, and stimulation of 2DOG uptake. Thus, FCCP-induced mitochondrial dysfunction may cause insulin resistance that is ameliorated by reduction of JNK1 expression. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Adochio, Rebecca; Draznin, Boris] Univ Colorado, Denver Sch Med, Dept Med, Aurora, CO 80045 USA.
[Leitner, J. Wayne; Draznin, Boris] Univ Colorado, Denver Sch Med, Denver VA Med Ctr, Res Serv, Aurora, CO 80045 USA.
[Kiln, Toni] Univ Colorado, Denver Sch Med, Dept Pediat, Aurora, CO 80045 USA.
RP Draznin, B (reprint author), Univ Colorado, Denver Sch Med, Dept Med, Mail Stop 8106,12631 E 17th Pl, Aurora, CO 80045 USA.
EM Boris.Draznin@ucdenven.edu
FU Research Service of the Department of Veterans Affairs
FX This work was supported by the Research Service of the Department of
Veterans Affairs.
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 23
PY 2009
VL 378
IS 4
BP 772
EP 776
DI 10.1016/j.bbrc.2008.11.121
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 394LE
UT WOS:000262447400017
ER
PT J
AU Vetter, ML
Cardillo, S
Rickels, MR
Iqbal, N
AF Vetter, Marion L.
Cardillo, Serena
Rickels, Michael R.
Iqbal, Nayyar
TI Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes
Mellitus
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Review
ID GASTRIC BYPASS-SURGERY; GLUCAGON-LIKE PEPTIDE-1; MORBIDLY OBESE
SUBJECTS; BETA-CELL FUNCTION; INDUCED WEIGHT-LOSS; PLASMA GHRELIN;
INHIBITORY POLYPEPTIDE; GLUCOSE-METABOLISM; GUT HORMONE; FOOD-INTAKE
AB Bariatric surgery leads to substantial and durable weight reduction. Nearly 30% of patients who undergo bariatric surgery have type 2 diabetes, and for many of them, diabetes resolves after surgery (84% to 98% for bypass procedures and 48% to 68% for restrictive procedures). Glycemic control improves in part because of caloric restriction but also because gut peptide secretion changes. Gut peptides, which mediate the enteroinsular axis, include the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, as well as ghrelin and peptide YY. Bariatric surgery (particularly bypass procedures) alters secretion of these gut hormones, which results in enhanced insulin secretion and sensitivity. This review discusses the various bariatric procedures and how they alter the enteroinsular axis. Familiarity with these effects can help physicians decide among the different surgical procedures and avoid postoperative hypoglycemia.
C1 [Vetter, Marion L.] Hosp Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Vetter, ML (reprint author), Hosp Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, 1 Maloney Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM marion.vetter@uphs.upenn.edu
NR 94
TC 97
Z9 104
U1 0
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JAN 20
PY 2009
VL 150
IS 2
BP 94
EP U54
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 397ID
UT WOS:000262655200004
PM 19153412
ER
PT J
AU Qaseem, A
Snow, V
Shekelle, P
Hopkins, R
Owens, DK
AF Qaseem, Amir
Snow, Vincenza
Shekelle, Paul
Hopkins, Robert, Jr.
Owens, Douglas K.
CA Clinical Efficacy Assessment Subco
TI Screening for HIV in Health Care Settings: A Guidance Statement From the
American College of Physicians and HIV Medicine Association
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; COST-EFFECTIVENESS;
EMERGENCY-DEPARTMENT; RECOMMENDATIONS; TRANSMISSION; INFECTION; TESTS
AB Description: The American College of Physicians (ACP) developed this guidance statement to present the available evidence on screening for HIV in health care settings.
Methods: This guidance statement is derived from an appraisal of available guidelines on screening for HIV. Authors searched the National Guideline Clearinghouse to identify guidelines on screening for HIV in the United States and used the AGREE ( Appraisal of Guidelines Research and Evaluation) instrument to evaluate guidelines from the U. S. Preventive Services Task Force and the Centers for Disease Control and Prevention.
Guidance Statement 1: ACP recommends that clinicians adopt routine screening for HIV and encourage patients to be tested.
Guidance Statement 2: ACP recommends that clinicians determine the need for repeat screening on an individual basis.
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA USA.
RAND Corp, Santa Monica, CA USA.
Univ Arkansas, Little Rock, AR 72204 USA.
Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA.
Stanford Univ, Stanford, CA 94305 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
FU ACP operating budget
FX Financial support for the development of this guideline comes
exclusively from the ACP operating budget.
NR 42
TC 91
Z9 91
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JAN 20
PY 2009
VL 150
IS 2
BP 125
EP U86
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 397ID
UT WOS:000262655200007
PM 19047022
ER
PT J
AU Zhao, WD
Qin, WP
Pan, JP
Wu, Y
Bauman, WA
Cardozo, C
AF Zhao, Weidong
Qin, Weiping
Pan, Jiangping
Wu, Yong
Bauman, William A.
Cardozo, Christopher
TI Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of
MAFbx, and protein catabolism upon the glucocorticoid receptor
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Glucocorticoids; Muscle atrophy; MAFbx; Atrogin-1; MuRF1; FOXO1; Akt;
Glucocorticoiod receptor
ID SKELETAL-MUSCLE ATROPHY; FOXO TRANSCRIPTION FACTORS; GROWTH-FACTOR-I;
UBIQUITIN LIGASES; GENE-EXPRESSION; PATHWAY; DEGRADATION; MURF1;
IDENTIFICATION; MECHANISMS
AB The muscle ubiquitin ligases MAFbx and MuRF1 are upregulated in and promote muscle atrophy. Upregulation of MAFbx and MuRF1 by glucocorticoids has been linked to activation of FOXO1 and FOXO3A resulting from reduced Akt activity. We determined the requirements for the glucocorticoid receptor (GR) in these biological responses in C2C12 cells in which GR expression was knocked down by stable expression of an shRNA. Loss of GR prevented dexamethasone-induced increases in protein catabolism. Loss of GR. or inhibition of ligand binding to GR with RU486, prevented upregulation of MAFbx and MuRF1 by dexamethasone. Loss of GR also prevented dexamethasone-induced decreases in Akt phosphorylation, and increases in the fraction of FOXO1 that was unphosphorylated. The findings establish a requirement for the GR in activating molecular signals that promote muscle protein catabolism. Published by Elsevier Inc.
C1 [Zhao, Weidong; Qin, Weiping; Pan, Jiangping; Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA.
[Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Chris.Cardozo@mssm.edu
FU Veterans Health Administration, Rehabilitation Research and Development
Service [134162C, 133347K, 133522R]
FX The research reported here was Supported by the Veterans Health
Administration, Rehabilitation Research and Development Service
(134162C, 133347K, 133522R).
NR 24
TC 27
Z9 28
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 16
PY 2009
VL 378
IS 3
BP 668
EP 672
DI 10.1016/j.bbrc.2008.11.123
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 393AL
UT WOS:000262343200066
PM 19059383
ER
PT J
AU Nakayama, M
Hisatsune, J
Yamasaki, E
Isomoto, H
Kurazono, H
Hatakeyama, M
Azuma, T
Yamaoka, Y
Yahiro, K
Moss, J
Hirayama, T
AF Nakayama, Masaaki
Hisatsune, Junzo
Yamasaki, Eiki
Isomoto, Hajime
Kurazono, Hisao
Hatakeyama, Masanori
Azuma, Takeshi
Yamaoka, Yoshio
Yahiro, Kinnosuke
Moss, Joel
Hirayama, Toshiya
TI Helicobacter pylori VacA-induced Inhibition of GSK3 through the PI3K/Akt
Signaling Pathway
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; GASTRIC EPITHELIAL-CELLS; BETA-CATENIN SIGNAL; AZ-521 CELLS;
VACUOLATING TOXIN; WNT PATHWAY; ACTIVATION; PROTEIN; INDUCTION;
CYTOTOXIN
AB Helicobacter pylori VacA toxin contributes to the pathogenesis and severity of gastric injury. We found that incubation of AZ-521 cells with VacA resulted in phosphorylation of protein kinase B (Akt) and glycogen synthase kinase-3 beta (GSK3 beta) through a PI3K-dependent pathway. Following phosphorylation and inhibition of GSK3 beta,beta-catenin was released from a GSK3 beta/beta-catenin complex, with subsequent nuclear translocation. Methyl-beta-cyclodextrin (MCD) and phosphatidylinositol-specific phospholipase C (PIPLC), but not 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) and bafilomycin A1, inhibited VacA-induced phosphorylation of Akt, indicating that it does not require VacA internalization and is independent of vacuolation. VacA treatment of AZ-521 cells transfected with TOPtkLuciferase reporter plasmid or control FOPtkLucifease reporter plasmid resulted in activation of TOPtkLuciferase, but not FOPtkLucifease. In addition, VacA transactivated the beta-catenin-dependent cyclin D1 promoter in a luciferase reporter assay. Infection of AZ-521 cells by a vacA mutant strain of H. pylori failed to induce phosphorylation of Akt and GSK3 beta, or release of beta-catenin from a GSK3 beta/beta-catenin complex. Taken together, these results support the conclusion that VacA activates the PI3K/Akt signaling pathway, resulting in phosphorylation and inhibition of GSK3 beta, and subsequent translocation of beta-catenin to the nucleus, consistent with effects of VacA on beta-catenin-regulated transcriptional activity. These data introduce the possibility that Wnt-dependent signaling might play a role in the pathogenesis of H. pylori infection, including the development of gastric cancer.
C1 [Nakayama, Masaaki; Hisatsune, Junzo; Hirayama, Toshiya] Nagasaki Univ, Dept Bacteriol, Inst Trop Med, Nagasaki 8528523, Japan.
[Yamasaki, Eiki; Kurazono, Hisao] Obihiro Univ Agr & Vet Med, Dept Appl Vet Med & Publ Hlth, Obihiro, Hokkaido 0808555, Japan.
[Isomoto, Hajime] Nagasaki Univ, Dept Endoscopy, Sch Med, Nagasaki 8528523, Japan.
[Hatakeyama, Masanori] Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan.
[Azuma, Takeshi] Kobe Univ, Sch Med, Dept Gastroenterol, Kobe, Hyogo 6500017, Japan.
[Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA.
[Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA.
[Yahiro, Kinnosuke; Moss, Joel] NHLBI, Translat Med Branch, NIH, Bethesda, MD 20892 USA.
RP Hirayama, T (reprint author), Nagasaki Univ, Dept Bacteriol, Inst Trop Med, Nagasaki 8528523, Japan.
EM hirayama@net.nagasaki-u.ac.jp
FU Intramural Research Program of the NHLBI; National Institutes of Health;
Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This work was supported, in whole or in part, by the Intramural Research
Program of the NHLBI, National Institutes of Health (to J. M.). This
work was also supported by Grants-in-aid for Scientific Research from
the Ministry of Education, Culture, Sports, Science and Technology of
Japan. The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked "advertisement" in accordance with 18 U. S. C. Section 1734
solely to indicate this fact.
NR 36
TC 56
Z9 59
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 16
PY 2009
VL 284
IS 3
BP 1612
EP 1619
DI 10.1074/jbc.M806981200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 392VK
UT WOS:000262330100029
PM 18996844
ER
PT J
AU Aqel, RA
Hage, FG
Ellipeddi, P
Blackmon, L
McElderry, HT
Kay, GN
Plumb, V
Iskandrian, AE
AF Aqel, Raed A.
Hage, Fadi G.
Ellipeddi, Pavani
Blackmon, Linda
McElderry, Hugh T.
Kay, G. Neal
Plumb, Vance
Iskandrian, Ami E.
TI Usefulness of Three Posterior Chest Leads for the Detection of Posterior
Wall Acute Myocardial Infarction
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ST-SEGMENT ELEVATION; PERCUTANEOUS CORONARY INTERVENTION; 12-LEAD
ELECTROCARDIOGRAM; STANDARD; ECG; FIBRINOLYSIS; ANGIOPLASTY; DIAGNOSIS;
REGISTRY; THERAPY
AB A significant proportion of patients with myocardial infarction are missed upon initial presentation to the emergency department. The 12-lead electrocardiogram (ECG) has a low sensitivity for the detection of acute myocardial infarction, especially if the culprit lesion is in the left circumflex artery (LCA). This study was designed to evaluate the benefit of adding 3 posterior chest leads on top of the 12-lead ECG to detect ischemia resulting from LC disease, using a model of temporary balloon occlusion to produce ischemia. We studied 53 consecutive patients who underwent clinically indicated coronary interventions. At the time of coronary angiography, the balloon was inflated to produce complete occlusion of the proximal LCA. We recorded and analyzed the changes noted on the 15-lead ECG, which included 3 posterior leads in addition to the standard 12 leads. In response to acute occlusion of the LCA, the posterior chest leads showed more ST elevation than the other leads, and more patients had ST elevation in the posterior leads than in any other lead. The 15-lead ECG was able to detect >= 0.5 mm (74% vs 38%, p<0.0001) and >= 1 mm (62% vs 34%, p<0.0001) ST elevation in any 2 contiguous leads more frequently than the 12-lead ECG. In conclusion, the 15-lead ECG identified more patients with posterior myocardial wall ischemia because of temporary balloon occlusion of the LC than the 12-lead ECG. This information may enhance the detection of posterior MI in the emergency department and potentially facilitate early institution of reperfusion therapy. (C) 2009 Elsevier Inc. (Am J Cardiol 2009;103:159-164)
C1 [Aqel, Raed A.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
RP Aqel, RA (reprint author), Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
EM raed.aqel@med.va.gov
OI Hage, Fadi/0000-0002-1397-4942
NR 26
TC 10
Z9 11
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JAN 15
PY 2009
VL 103
IS 2
BP 159
EP 164
DI 10.1016/j.amjcard.2008.09.008
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 396AJ
UT WOS:000262564300003
PM 19121429
ER
PT J
AU Kramarenko, II
Bunni, MA
Morinelli, TA
Raymond, JR
Garnovskaya, MN
AF Kramarenko, Inga I.
Bunni, Marlene A.
Morinelli, Thomas A.
Raymond, John R.
Garnovskaya, Maria N.
TI Identification of functional bradykinin B-2 receptors endogenously
expressed in HEK293 cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE G protein-coupled receptors; Signal transduction; Intracellular Ca2(+);
Na+/H+ exchange; Extracellular signal-regulated protein kinase 1 and 2
ID ARACHIDONIC-ACID RELEASE; EPITHELIAL-CELLS; MESANGIAL CELLS; NA+/H+
EXCHANGE; SMOOTH-MUSCLE; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION;
PROTEIN-KINASE; MIMCD-3 CELLS; MAP KINASE
AB The human embryonic kidney (HEK) 293 cell line is widely used in cell biology research. Although HEK293 cells have been meticulously studied, our knowledge about endogenous G protein-coupled receptors (GPCR) in these cells is incomplete. While studying the effects of bradykinin (BK), a potent growth factor for renal cells, we unexpectedly discovered that BK activates extracellular signal-regulated protein kinase 1 and 2 (ERK) in HEK293 cells. Thus, we hypothesized that HEK293 cells possess endogenous BK receptors. RT-PCR demonstrated the presence of mRNAs for BK B-1 and BK B-2 receptors in HEK293 cells. Western blotting with BK B-1 and BK B-2 receptor antibodies confirmed this result at the protein level. To establish that BK receptors are functional, we employed fluorescent measurements of intracellular Ca2+, measured changes in extracellular acidification rate (ECAR) as a reflection of the Na+/H+ exchange (NHE) with a Cytosensor (TM) microphysiometer, and assessed ERK activation by Western blotting with a phospho-specific ERK antibody. Exposure of HEK293 cells to BK produced a concentration-dependent rise in intracellular Ca2+, (EC50 = 36.5 +/- 8.0 x 10 (9) M), a rapid increase in tyrosine phosphorylation of ERK (EC50 = 9.8 +/- 0.4 x 10 (9) M), and elevation in ECAR by similar to 20%. All of these signals were blocked by HOE-140 (B-2 receptor antagonist) but not by des-Arg(10)-HOE-140 (B-1 receptor antagonist). We conclude that HEK293 cells express endogenous functional BK B-2 receptors, which couple to the mobilization of intracellular Ca2+, increases in ECAR and increases in ERK phosphorylation. Published by Elsevier Inc.
C1 [Kramarenko, Inga I.; Bunni, Marlene A.; Morinelli, Thomas A.; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Kramarenko, Inga I.; Bunni, Marlene A.; Morinelli, Thomas A.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29401 USA.
RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Dept Med Nephrol, 96 Jonathan Lucas St,MSC 629, Charleston, SC 29425 USA.
EM garnovsk@musc.edu
FU Department of Veterans Affairs; AHA [GIA 0655445U]; National Institutes
of Health [DK52448, GM63909]; M.U.S.C. Division of Nephrology and
Dialysis Clinics, Incorporated
FX This work was supported by grants from the Department of Veterans
Affairs (Merit Awards and a REAP Award to MNG and JRR), AHA (GIA
0655445U to MNG), the National Institutes of Health (DK52448 and GM63909
to JRR), and a laboratory endowment jointly supported by the M.U.S.C.
Division of Nephrology and Dialysis Clinics, Incorporated (JRR).
NR 33
TC 12
Z9 12
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JAN 15
PY 2009
VL 77
IS 2
BP 269
EP 276
DI 10.1016/j.bcp.2008.09.027
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 394ZW
UT WOS:000262492700014
PM 18938142
ER
PT J
AU Chen, Y
Craigen, WJ
Riley, DJ
AF Chen, Yumay
Craigen, William J.
Riley, Daniel J.
TI Nek1 regulates cell death and mitochondrial membrane permeability
through phosphorylation of VDAC1
SO CELL CYCLE
LA English
DT Article
DE cytochrome c; polycystic kidney disease; kat mouse; Nek1; VDAC1;
apoptosis; DNA damage
ID DEPENDENT ANION CHANNEL; POLYCYSTIC KIDNEY-DISEASE; DNA-DAMAGE RESPONSE;
PROTEIN-KINASE; TRANSITION PORE; CYCLOPHILIN-D; CYTOCHROME-C;
ASPERGILLUS-NIDULANS; HEXOKINASE-I; APOPTOSIS
AB The mammalian NIMA-related protein kinase 1 (Nek1) is important for keeping cells alive after DNA damage, but the mechanism by which injured cells die without functional Nek1 has not yet been demonstrated. Here we show that Nek1 regulates the pathway to mitochondrial cell death through phosphorylation of voltage dependent anion channel 1 (VDAC1) on serine 193. Nek1 associates with VDAC1 in a yeast two-hybrid system, as well as by GST pull-down assays and by reciprocal immunoprecipitation. A portion of Nek1 in cells also localizes at mitochondria. Ectopic expression of a kinase-dead Nek1 mutant results in cell death, which is immediately preceded by loss of the Nek1-dependent VDAC1-S193 phosphorylation. UV irradiation of Nek1-deficient cells or silencing of endogenous Nek1 expression similarly results in loss of the specific S193 phosphorylation before cells die. Nek1-deficient cells are characterized by exaggerated mitochondrial membrane permeability (MMP) and accelerated cell death. Ectopic expression of a VDAC1-Ser193Ala mutant, which cannot be phosphorylated by Nek1, also results in cell death. A VDAC1-Ser193Glu mutant, designed to mimic constitutive phosphorylation by Nek1, rescues exaggerated MMP and keeps cells alive after DNA damaging injury, but only transiently. The direct interaction between Nek1 and VDAC1 provides a mechanism to explain how Nek1 prevents excessive cell death, as well as the first direct evidence that a specific kinase regulates VDAC1 activity.
C1 [Chen, Yumay; Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, San Antonio, TX 78229 USA.
[Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, Dept Surg, San Antonio, TX 78229 USA.
[Craigen, William J.] Baylor Coll Med, Dept Mol & Human Genet, San Antonio, TX USA.
[Riley, Daniel J.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Renal Res Div, San Antonio, TX USA.
RP Chen, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM cheny@uthscsa.edu
FU PKD Foundation; American Society of Nephrology; National Kidney
Foundation; NIH [RO1-DK067339, P50-DK061597, RO1-DK61626]
FX This work was supported by grants from the PKD Foundation, the American
Society of Nephrology, the National Kidney Foundation, and the NIH
(RO1-DK067339) to Y. C.; a George M. O'Brien Kidney Research Center
grant from the NIH to Y. C. (P50-DK061597, Hanna E. Abboud, Program
Director); and a grant from the NIH to D. J. R. (RO1-DK61626). We thank
Rosaria Polci, Patricia Litchfield, and Sergio Garcia for assistance
with early stages of the project and with technical matters; and a
Veterans Administration Renal Research Excellence Award Program to the
South Texas Veterans Health Care System, Audie L. Murphy Division for
core facility support.
NR 54
TC 27
Z9 27
U1 2
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JAN 15
PY 2009
VL 8
IS 2
BP 257
EP 267
DI 10.4161/cc.8.2.7551
PG 11
WC Cell Biology
SC Cell Biology
GA 396WT
UT WOS:000262622800016
PM 19158487
ER
PT J
AU Wu, JD
Atteridge, CL
Wang, XJ
Seya, T
Plymate, SR
AF Wu, Jennifer D.
Atteridge, Catherine L.
Wang, Xuanjun
Seya, Tsukasa
Plymate, Stephen R.
TI Obstructing Shedding of the Immunostimulatory MHC Class I Chain-Related
Gene B Prevents Tumor Formation
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ACTIVATING IMMUNORECEPTOR NKG2D; CELL-MEDIATED REJECTION; NK CELLS;
RETINOIC-ACID; DOWN-REGULATION; CUTTING EDGE; LIGANDS; EXPRESSION;
RECEPTOR; MICA
AB Purpose: Clinical observations have suggested that shedding of the MHC class I chain - related molecule (MIC) may be one of the mechanisms by which tumors evade host immunosurveillance and progress. However, this hypothesis has never been proven. In this study, we tested this hypothesis using a prostate tumor model and investigated the effect of shedding of MIC on tumor development.
Experimental Design: We generated a shedding-resistant noncleavable form of MICB (MICB.A2). We overexpressed MICB.A2, the wild-type MICB, and the recombinant soluble MICB (rsMICB) in mouse prostate tumor TRAMP-C2 (TC2) cells and implanted these cells into severe combined immunodeficient mice.
Results: No tumors were developed in animals that were implanted with TC2-MICB.A2 cells, whereas all the animals that were implanted with TC2, TC2-MICB, or TC2-rsMICB cells developed tumors. When a NKG2D-specific antibody CX5 or purified rsMICB was administered to animals before tumor implantation, all animals that were implanted with TC2-MICB.A2 cells developed tumors. In vitro cytotoxicity assay revealed the loss of NKG2D-mediated natural killer cell function in these prechallenged animals, suggesting that persistent levels of soluble MICB in the serum can impair natural killer cell function and thus allow tumor growth.
Conclusions: These data suggest that MIC shedding may contribute significantly to tumor formation by transformed cells and that inhibition of MIC shedding to sustain the NKG2D receptor-MIC ligand recognition may have potential clinical implication in targeted cancer treatment.
C1 [Wu, Jennifer D.; Atteridge, Catherine L.; Wang, Xuanjun; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA 98104 USA.
[Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Seya, Tsukasa] Hokkaido Univ, Dept Microbiol & Immunol, Grad Sch Med, Sapporo, Hokkaido, Japan.
RP Wu, JD (reprint author), Univ Washington, Dept Med, 325 9th Ave,Box 359625, Seattle, WA 98104 USA.
EM wuj@u.washington.edu
RI Seya, Tsukasa/A-4336-2012
OI wang, xuanjun/0000-0003-1211-506X
FU DOD-USMRC New Investigators [W81XWH-04-1-0577]; IDEA Development
[W81XWH-06-1-0014]; W Prostate SPORE Program; NIH [1K01CA116002]
FX Grant support: DOD-USMRC New Investigators Grant W81XWH-04-1-0577 and
IDEA Development Award W81XWH-06-1-0014, NW Prostate SPORE Program, and
NIH Temin Award 1K01CA116002 (J.D.Wu).
NR 41
TC 30
Z9 30
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 15
PY 2009
VL 15
IS 2
BP 632
EP 640
DI 10.1158/1078-0432.CCR-08-1305
PG 9
WC Oncology
SC Oncology
GA 397VD
UT WOS:000262689300026
PM 19147769
ER
PT J
AU Lo Re, V
Amorosa, VK
Localio, AR
O'Flynn, R
Teal, V
Dorey-Stein, Z
Kostman, JR
Gross, R
AF Lo Re, Vincent, III
Amorosa, Valerianna K.
Localio, A. Russell
O'Flynn, Rose
Teal, Valerie
Dorey-Stein, Zachariah
Kostman, Jay R.
Gross, Robert
TI Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 24th International Conference on Pharmacoepidemiology and Therapeutic
Risk Management
CY AUG 17-20, 2008
CL Copenhagen, DENMARK
ID INTERFERON-ALPHA-2B PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A;
ANTIRETROVIRAL THERAPY; COMBINATION THERAPY; SUSTAINED RESPONSE;
PHARMACY RECORDS; VIRAL LOAD; MANAGEMENT; INFECTION; IMPACT
AB Background. Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy.
Methods. We conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages.
Results. The mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with >= 85% adherence than for those with < 85% adherence (3.23 vs. 2.57 log IU/mL;). When patients who received Pp. 04 a suboptimal ribavirin dosage were excluded, the decrease in viral load was 1.00 log IU/mL greater for persons with >= 85% adherence (3.32 vs. 2.32 log IU/mL;). Early virologic response was more common among Pp. 01 patients with >= 85% adherence than it was among those with < 85% adherence to treatment with pegylated interferon (73% vs. 29%; P=.02) and ribavirin (73% vs. 55%; P=.08
Conclusions. Adherence of >= 85% to pegylated interferon and ribavirin treatment was associated with increased HCV suppression. Decreases in HCV load became greater when patients with >= 85% adherence to their regimen continued to receive their recommended weight-based ribavirin dosage.
C1 [Lo Re, Vincent, III; Localio, A. Russell; Teal, Valerie; Gross, Robert] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Lo Re, Vincent, III; Amorosa, Valerianna K.; Dorey-Stein, Zachariah; Kostman, Jay R.; Gross, Robert] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA.
[Lo Re, Vincent, III; Localio, A. Russell; Teal, Valerie; Gross, Robert] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Lo Re, Vincent, III; Localio, A. Russell; Gross, Robert] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA.
[Lo Re, Vincent, III; Amorosa, Valerianna K.; O'Flynn, Rose; Gross, Robert] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Lo Re, V (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 809 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM vincentl@mail.med.upenn.edu
RI Lo Re, Vincent/N-7817-2015
OI Teal, Valerie/0000-0001-7116-5353
FU AHRQ HHS [HS 10399, U18 HS010399]; NIAID NIH HHS [K01 AI070001-02, K01
AI 070001, K01 AI070001]
NR 17
TC 29
Z9 31
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 15
PY 2009
VL 48
IS 2
BP 186
EP 193
DI 10.1086/595685
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 389JJ
UT WOS:000262088400009
PM 19086908
ER
PT J
AU Riley, DE
Krieger, JN
AF Riley, Donald E.
Krieger, John N.
TI Embryonic nervous system genes predominate in searches for dinucleotide
simple sequence repeats flanked by conserved sequences
SO GENE
LA English
DT Article
DE Highly conserved elements; HCEs; Simple sequence repeats; SSRs;
Dinucleotide simple sequence repeats; diSSRs; Microsatellites; Nervous
system; Development
ID BINDING PROTEIN; ULTRACONSERVED ELEMENTS; SYNAPTIC VESICLES;
MESSENGER-RNAS; HUMAN GENOME; EXPRESSION; EVOLUTION; BRAIN; MOUSE;
REGIONS
AB To study evolution of dinucleotide simple sequence repeats (diSSRs) we searched recently available mammalian genomes for UTR-localized diSSRs with conserved upstream flanking sequences (CFS). There were 252 reported Homo sapiens genes containing the repeats (AC)n, (GT)n, (AG)n or (CT)n in their UTRs including 22 (8.7%) with diSSR-upstream flanking sequences conserved comparing divergent mammalian lineages represented by Homo sapiens and the marsupial, Monodelphis domestica. Of these 22 genes, 19 had known functions including 18 (95%) that proved critical for mammalian nervous systems (Fishers exact test, P<0.0001). The remaining gene, Cd2ap, proved critical for development of kidney podocytes, cells that have multiple similarities to neurons. Gene functions included voltage and chloride channels, synapse-associated proteins, neurotransmitter receptors, axon and dendrite pathfinders, a NeuroD potentiator and other neuronal activities. Repeat length polymorphism was confirmed for 68% of CFS diSSRs even though these repeats were nestled among highly conserved sequences. This finding supports a hypothesis that SSR polymorphism has functional implications. A parallel study was performed on the self-complementary diSSRs (AT)n and (GC)n. When flanked by conserved sequences, the self-complementary diSSR (AT)n was also associated with genes expressed in the developing nervous system. Our findings implicate functional roles for diSSRs in nervous system development. Published by Elsevier B.V.
C1 [Riley, Donald E.; Krieger, John N.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Riley, Donald E.; Krieger, John N.] VA Puget Sound Hlth Care Syst, Dept Res, Seattle, WA 98012 USA.
RP Riley, DE (reprint author), Puget Sound Hlth Care Syst VA, Room 517,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA.
FU NIDDK NIH HHS [R01 DK038955-15]
NR 57
TC 13
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD JAN 15
PY 2009
VL 429
IS 1-2
BP 74
EP 79
DI 10.1016/j.gene.2008.09.025
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 399CL
UT WOS:000262777900011
PM 18952158
ER
PT J
AU Riley, DE
Krieger, JN
AF Riley, Donald E.
Krieger, John N.
TI UTR dinucleotide simple sequence repeat evolution exhibits recurring
patterns including regulatory sequence motif replacements
SO GENE
LA English
DT Article
DE SSR, simple sequence repeat; HCE, highly conserved element; STR, short
tandem repeats; Microsatellites; Nervous system; Development;
Post-transcriptional regulation; ARE, AU-rich elements
ID MESSENGER-RNA TRAFFICKING; 3'-UNTRANSLATED REGION; ELEMENTS; MULTIPLE;
PROTEINS; HUR; MICROSATELLITES; STABILIZATION; EXPRESSION; ALIGNMENT
AB New genome sequence information was used to study evolution of 22 dinucleotide simple sequence repeat (diSSR) sites whose upstream flanking sequences were shown to be conserved comparing Homo sapiens with the marsupial, Monodelphis domestica. Among mammals, most of these diSSR sites were conserved both upstream and downstream of the diSSR. However, individual diSSRs were frequently replaced by alternative repeats. Conserved among mammals examined, the Vsnl1 gene's 3' UTR-localized (AC)n repeat replaced an A-rich tract in non-mammalian vertebrates examined. The Sema6D gene's (GT)n was also well conserved among mammals examined. Such conservation provides evidence of a functional role. The UTR-localized diSSRs of other genes evolved by replacing alternative diSSRs, by replacing mononucleotide-rich tracts and, in fewer cases, by expansion from short repeating sequences. Extension of the study to less conserved diSSR sites revealed that some diSSRs replaced post-transcriptional regulatory motifs, such as AU-rich elements (AREs) and C-rich tracts. The Mtap2 gene's UTR-localized (AC)n was located within a known dendritic targeting element. These evolutionary replacements suggest that some diSSRs belong to a broader group of weak-folding repetitive sequences with potential regulatory roles. Published by Elsevier B.V.
C1 Univ Washington, Dept Urol, Seattle, WA 98195 USA.
VA Puget Sound Hlth Care Syst, Dept Res, Seattle, WA 98012 USA.
RP Riley, DE (reprint author), Sound Hlth Care Syst VA, Room 517,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA.
EM dri@u.washington.edu
FU NIDDK NIH HHS [R01 DK038955-15]
NR 28
TC 17
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD JAN 15
PY 2009
VL 429
IS 1-2
BP 80
EP 86
DI 10.1016/j.gene.2008.09.030
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 399CL
UT WOS:000262777900012
PM 18955121
ER
PT J
AU Paintlia, AS
Paintlia, MK
Singh, I
Skoff, RB
Singh, AK
AF Paintlia, Ajaib S.
Paintlia, Manjeet K.
Singh, Inderjit
Skoff, Robert B.
Singh, Avtar K.
TI Combination Therapy of Lovastatin and Rolipram Provides Neuroprotection
and Promotes Neurorepair in Inflammatory Demyelination Model of Multiple
Sclerosis
SO GLIA
LA English
DT Article
DE combination therapy; EAE/MS; demyelination; inflammation
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC
ENCEPHALOMYELITIS; COA REDUCTASE INHIBITOR; TRAUMATIC BRAIN-INJURY;
GLATIRAMER ACETATE; SPINAL-CORD; PHOSPHODIESTERASE INHIBITOR; AXONAL
REGENERATION; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH
AB Drug combination therapies for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS) are gaining momentum over monotherapy. Over the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression of MS in affected individuals via different mechanisms of action. In this study, we evaluated the effectiveness of lovastatin (LOV) and rolipram (RLP) in combination therapy to promote neurorepair in an inflammatory CNS demyelination model of MS, experimental autoimmune encephalomyelitis (EAE). Combination treatment with suboptimal doses of these drugs in an established case of EAE (clinical disease score >= 2.0) significantly attenuated the infiltration of inflammatory cells and protected myelin sheath and axonal integrity in the CNS. It was accompanied with elevated level of cyclic AMP and activation of its associated protein kinase A. Interestingly, combination treatment with these drugs impeded neurodegeneration and promoted neurorepair in established EAE animals (clinical disease score >= 3.5) as verified by quantitative real-time polymerase chain reaction, immunohistochemistry and electron microscopic analyses. These effects of combination therapy were minimal and/or absent with either drug alone in these settings. Together, these data suggest that combination therapy with LOV and RLP has the potential to provide neuroprotection and promote neurorepair in MS, and may have uses in other related CNS demyelinating diseases. (C) 2008 Wiley-Liss, Inc.
C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Skoff, Robert B.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA.
[Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA.
EM paintlia@musc.edu; singhi@musc.edu
OI Paintlia, Ajaib/0000-0003-4525-5333
FU NIH [NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455,
C06-RR018823]; Merck Company
FX NIH; Grant number: NS-22576, NS-34741, NS-37766, NS-40144, NS-038236,
C06-RR015455, C06-RR018823; Grant sponsor; Merck & Company.
NR 65
TC 36
Z9 37
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-1491
J9 GLIA
JI Glia
PD JAN 15
PY 2009
VL 57
IS 2
BP 182
EP 193
DI 10.1002/glia.20745
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 383OA
UT WOS:000261681700005
PM 18720408
ER
PT J
AU Wen, Y
Feng, J
Scott, DR
Marcus, EA
Sachs, G
AF Wen, Yi
Feng, Jing
Scott, David R.
Marcus, Elizabeth A.
Sachs, George
TI The pH-Responsive Regulon of HP0244 (FlgS), the Cytoplasmic Histidine
Kinase of Helicobacter pylori
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID HP0165-HP0166 2-COMPONENT SYSTEM; ALPHA-CARBONIC ANHYDRASE;
SIGNAL-TRANSDUCTION; RALSTONIA-EUTROPHA; ACID ACCLIMATION;
GENE-EXPRESSION; RESISTANCE DETERMINANT; ALCALIGENES-EUTROPHUS;
NUCLEOTIDE-SEQUENCE; H-2 SENSOR
AB Helicobacter pylori colonizes the acidic gastric environment, in contrast to all other neutralophiles, whose acid resistance and tolerance responses allow only gastric transit. This acid adaptation is dependent on regulation of gene expression in response to pH changes in the periplasm and cytoplasm. The cytoplasmic histidine kinase, HP0244, which until now was thought only to regulate flagellar gene expression via its cognate response regulator, HP0703, was found to generate a response to declining medium pH. Although not required for survival at pH 4.5, HP0244 is required for survival at pH 2.5 with 10 mM urea after 30 min. Transcriptional profiling of a HP0244 deletion mutant grown at pH 7.4 confirmed the contribution of HP0244 to sigma(54) activation via HP0703 to coordinate flagellar biosynthesis by a pH-independent regulon that includes 14 flagellar genes. Microarray analysis of cells grown at pH 4.5 without urea revealed an additional 22 genes, including 4 acid acclimation genes (ureA, ureB, ureI, and amiE) that are positively regulated by HP0244. Additionally, 86 differentially expressed genes, including 3 acid acclimation genes (ureF, rocF [arginase], and ansB [asparaginase]), were found in cells grown at pH 2.5 with 30 mM urea. Hence, HP0244 has, in addition to the pH-independent flagellar regulon, a pH-dependent regulon, which allows adaptation to a wider range of environmental acid conditions. An acid survival study using an HP0703 mutant and an electrophoretic mobility shift assay with in vitro-phosphorylated HP0703 showed that HP0703 does not contribute to acid survival and does not bind to the promoter regions of several genes in the HP0244 pH-dependent regulon, suggesting that there is a pathway outside the HP0703 regulon which transduces the acid-responsive signal sensed by HP0244.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90073 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Wen, Y (reprint author), 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA.
EM ywen@ucla.edu
FU U.S. Veterans Administration; NIH [DK46917, 53462, 58333]; The CURE
Digestive Diseases Research Center at UCLA
FX This work was supported by U.S. Veterans Administration and NIH grants
DK46917, 53462, and 58333 and by a pilot and feasibility grant from The
CURE Digestive Diseases Research Center at UCLA.
NR 52
TC 25
Z9 27
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD JAN 15
PY 2009
VL 191
IS 2
BP 449
EP 460
DI 10.1128/JB.01219-08
PG 12
WC Microbiology
SC Microbiology
GA 389TP
UT WOS:000262117700001
PM 18978046
ER
PT J
AU Lipe, H
Bird, T
AF Lipe, Hillary
Bird, Thomas
TI Late onset Huntington Disease: Clinical and genetic characteristics of
34 cases
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Huntington Disease; Late onset; Neurogenetics; CAG repeat expansion
ID AGE; PROGRESSION; DURATION; REPEAT
AB We performed a retrospective observational study of thirty-four persons with late onset of Huntington Disease (HD) (onset range 60-79 years). CAG trinucleotide expansion size ranged from 38-44 repeats. Even at this late age a significant negative correlation (r = -0.421, p < 0.05) was found between the length of repeat and age of onset. important characteristics of these older subjects were: (1) Most (68%) were the first in the family to have a diagnosis of HD, (2) Motor problems were the initial symptoms at onset, (3) Disability increased and varied from mild to severe (4) Disease duration was somewhat shorter (12 years) than that reported for mid life onset, (5) Death was often related to diseases of old age, Such as cancer and cerebrovascular disease, (6) Serious falls were a major risk and (7) Global dementia may be associated with coincident Alzheimer disease. Recognizing these characteristics will help physicians and other health care providers better identify and follow the late onset presentation of this disease. Published by Elsevier B.V.
C1 [Lipe, Hillary; Bird, Thomas] VA Puget Sound Hlth Care Syst, Geriat Res & Clin Ctr, Seattle, WA 98109 USA.
[Bird, Thomas] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Bird, Thomas] Univ Washington, Dept Med, Seattle, WA 98195 USA.
RP Bird, T (reprint author), VA Puget Sound Hlth Care Syst, Geriat Res & Clin Ctr, 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98109 USA.
EM tomnroz@u.washington.edu
FU Department of Veterans Affairs research funds; Huntington's Disease
Society of America
FX Supported by the Department of Veterans Affairs research funds and the
Huntington's Disease Society of America. Our appreciation to Our
colleagues and the staff of the Medical Genetics clinic at the
University of Washington for identifying late onset cases. Thanks to DG
Cook and S Elmore for assistance with the figures.
NR 17
TC 22
Z9 22
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2009
VL 276
IS 1-2
BP 159
EP 162
DI 10.1016/j.jns.2008.09.029
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 404BH
UT WOS:000263125200035
PM 18977004
ER
PT J
AU Szumski, NR
Cheng, EM
AF Szumski, Nicholas R.
Cheng, Eric M.
TI Optimizing Algorithms to Identify Parkinson's Disease Cases Within an
Administrative Database
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; ICD-9-CM codes; administrative data; predictive
value; sensitivity; specificity
ID INTERNATIONAL CLASSIFICATION; ACCURACY; CODES; DIAGNOSIS; ICD-9-CM
AB Patients assigned file diagnostic ICD-9-CM code for Parkinson's disease (PD) in an administrative database may not truly carry that diagnosis because Of the Various error sources. Improved ability to identify PD cases within databases may facilitate specific research goals. Experienced chart reviewers abstracted the working diagnosis of all 577 patients assigned diagnostic code 332.0 (PD) during 1 year at it VA Healthcare System. We then tested the ability of various algorithms making use of PD and non-PD diagnostic codes, specialty of clinics visited, and medication prescription data to predict the abstracted working diagnosis. Chart review determined 436 (75.6%) patients to be PD or Possibly PD, and 141 (24.4%) to lie Not PD. Our tiered consensus algorithm preferentially used data from specialists over nonspecialists improved PPV to 83.2% (P = 0.003 vs. baseline). When presence of a PD prescription was an additional criterion, PPV increased further to 88.2% (P = 0.04 vs. without medication criterion), but sensitivity decreased from 87.4 to 77.1% (P = 0.0001). We demonstrate that algorithms provide better identification of PD cases than using a single Occurrence of the diagnostic code for PD, and modifications of such algorithms can be tuned to maximize parameters that best meet the goals of a particular database query. 0 2008 Movement Disorder Society
C1 [Szumski, Nicholas R.; Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Szumski, Nicholas R.; Cheng, Eric M.] SW Parkinsons Dis Res Educ & Clin Ctr PADRECC, Los Angeles, CA USA.
[Szumski, Nicholas R.; Cheng, Eric M.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
RP Szumski, NR (reprint author), Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza,RNRC A-153, Los Angeles, CA 90095 USA.
EM nszumski@mednet.ucla.edu
FU Southwest Parkinson's Disease Research, Education, and Clinical Center
[PADRECC]; NINDS career development award [K23NS058571]
FX Research supported by the Southwest Parkinson's Disease Research,
Education, and Clinical Center (PADRECC). Dr. Cheng is supported by an
NINDS career development award (K23NS058571). We thank Stefanie D.
Vassar for her help in compiling data and performing statistical
analyses.
NR 15
TC 17
Z9 18
U1 2
U2 5
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JAN 15
PY 2009
VL 24
IS 1
BP 51
EP 56
DI 10.1002/mds.22283
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 402CW
UT WOS:000262992800006
PM 18816696
ER
PT J
AU Qin, W
Ho, L
Wang, J
Peskind, E
Pasinetti, GM
AF Qin, Weiping
Ho, Lap
Wang, Jun
Peskind, Elaine
Pasinetti, Giulio Maria
TI S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic
alpha-Secretase Activity Acts via Selective Promotion of ADAM-10
SO PLOS ONE
LA English
DT Article
AB Alzheimer's disease (AD) is the most common cause of dementia among older people. At present, there is no cure for the disease and as of now there are no early diagnostic tests for AD. There is an urgency to develop a novel promising biomarker for early diagnosis of AD. Using surface-enhanced laser desorption ionization-mass spectrometry SELDI-(MS) proteomic technology, we identified and purified a novel 11.7-kDa metal-binding protein biomarker whose content is increased in the cerebrospinal fluid (CSF) and in the brain of AD dementia subjects as a function of clinical dementia. Following purification and protein-sequence analysis, we identified and classified this biomarker as S100A7, a protein known to be involved in immune responses. Using an adenoviral- S100A7 expression system, we continued to examine the potential role of S100A7 in AD amyloid neuropathology in in vitro model of AD. We found that the expression of exogenous S100A7 in primary cortico-hippocampal neuron cultures derived from Tg2576 transgenic embryos inhibits the generation of beta-amyloid (A beta)(1-42) and A beta(1-40) peptides, coincidental with a selective promotion of "non- amyloidogenic'' alpha-secretase activity via promotion of ADAM (a disintegrin and metalloproteinase)-10. Finally, a selective expression of human S100A7 in the brain of transgenic mice results in significant promotion of alpha-secretase activity. Our study for the first time suggests that S100A7 may be a novel biomarker of AD dementia and supports the hypothesis that promotion of S100A7 expression in the brain may selectively promote alpha-secretase activity in the brain of AD precluding the generation of amyloidogenic peptides. If in the future we find that S1000A7 protein content in CSF is sensitive to drug intervention experimentally and eventually in the clinical setting, S100A7 might be developed as novel surrogate index (biomarker) of therapeutic efficacy in the characterization of novel drug agents for the treatment of AD.
C1 [Qin, Weiping; Ho, Lap; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA.
[Ho, Lap; Wang, Jun; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GCRC, Bronx, NY USA.
[Peskind, Elaine] Univ Washington, Sch Med, Seattle, WA 98195 USA.
RP Qin, WP (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
EM giulio.pasinetti@mssm.edu
FU James J. Peters VA GRECC Program; NIA [AG02219]
FX These studies were supported by James J. Peters VA GRECC Program and NIA
AG02219 to GMP. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 41
TC 34
Z9 35
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 13
PY 2009
VL 4
IS 1
AR e4183
DI 10.1371/journal.pone.0004183
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 437IE
UT WOS:000265479600002
PM 19159013
ER
PT J
AU Yu, J
Kindy, MS
Gattoni-Celli, S
AF Yu, Jin
Kindy, Mark S.
Gattoni-Celli, Sebastiano
TI Semi-allogeneic vaccines and tumor-induced immune tolerance
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID REGULATORY T-CELLS; HYBRIDS; CANCER; IMMUNOTHERAPY; EXPRESSION
AB Experimental results from studies with inbred mice and their syngeneic tumors indicated that the inoculation of semi-allogeneic cell hybrids (derived from the fusion between syngeneic tumor cells and an allogeneic cell line) protects the animal host from a subsequent lethal challenge with unmodified syngeneic tumor cells. Semi-allogeneic somatic cell hybrids were generated by the fusion of EL-4 T lymphoma cells (H-2(b)) and BALB/c-derived renal adenocarcinoma RAG cells (H-2(d)). Cell hybrids were injected intra-peritoneally (i.p.) in C57BL/6 mice (H-2(b)) before challenging the mice with a tumorigenic dose of EL-4 cells. Semi-allogeneic tumor cell hybrids could not form a tumor in the animal host because they expressed allogeneic determinants (H-2(d)) and were rejected as a transplant. However, they conferred protection against a tumorigenic challenge of EL-4 cells compared to control mice that were mock-vaccinated with i.p.-injected phosphate-buffered saline (PBS) and in which EL-4 lymphomas grew rapidly to a large size in the peritoneal cavity. Screening of spleen-derived RNA by means of focused microarray technology showed up-regulation of genes involved in the Th-1-type immune response and in the activation of dendritic antigen-presenting cells (APC). The results of our studies confirm the role of APC in mediating the immune protection induced by semi-allogeneic vaccines by activating a Th-1 response; these studies also reveal that semi-allogeneic vaccines are able to interfere with or even block the tumor-mediated induction of immune tolerance, a key mechanism underlying the suppression of antitumor immunity in the immune competent host.
C1 [Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Kindy, Mark S.; Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
[Kindy, Mark S.; Gattoni-Celli, Sebastiano] SemiAlloGen Inc, Mt Pleasant, SC 29466 USA.
RP Gattoni-Celli, S (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM yujin@musc.edu; kindyms@musc.edu; gattonis@musc.edu
FU National Science Foundation [EPS-0132573, EPS-0447660]; Veterans
Administration Merit Review; SCLaunch
FX The authors wish to acknowledge support by the National Science
Foundation EPSCoR grants (MSK, EPS-0132573 and EPS-0447660), Veterans
Administration Merit Review (MSK) and support from SCLaunch to
Semi-AlloGen.
NR 16
TC 1
Z9 1
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JAN 8
PY 2009
VL 7
AR 3
DI 10.1186/1479-5876-7-3
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 409WZ
UT WOS:000263537800001
PM 19133135
ER
PT J
AU Segar, TM
Kasckow, JW
Welge, JA
Herman, JP
AF Segar, Tracy M.
Kasckow, John W.
Welge, Jeffrey A.
Herman, James P.
TI Heterogeneity of neuroendocrine stress responses in aging rat strains
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Aging; Stress; HPA; ACTH; Corticosterone; Homoscedasticity
ID PITUITARY-ADRENAL AXIS; INDIVIDUAL-DIFFERENCES; BROWN-NORWAY; AGE;
BRAIN; CORTICOSTERONE; MEMORY; IMPAIRMENT; RESPONSIVENESS; HIPPOCAMPUS
AB Hyperactivity of the hypothalamo-pituitary-adrenocortical (HPA) axis is linked with age-related decrements in cognition and neuronal survival. However. the nature and extent of age-related HPA axis deficits vary considerably across and indeed, within strains. The current study was designed to assess variance in HPA axis function using two rodent models commonly used in aging Studies: Fischer 344 (F344) and F344/Brown-Norway F1 hybrid rats (F344/BN). We examined both basal and stress-induced ACTH and corticosterone (CORT) release in two stress contexts thought to differ in intensity: novel environment ('mild') and restraint ('intense'). Variability of the data was tested with a modification of the Brown-Forsythe test of homoscedasticity. The results indicated that F344 rats exhibit greater peak HPA responses. Furthermore, in most cases variability was increased in aged rats relative to young and middle-aged rats of the same strain, indicative of the emergence of individual differences in stress responsivity amongst older rats. The results suggest that these older rat strains may be useful models to further assess individual differences in neuroendocrine aging. Published by Elsevier Inc.
C1 VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA.
[Segar, Tracy M.; Welge, Jeffrey A.; Herman, James P.] Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45237 USA.
[Kasckow, John W.] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
RP Kasckow, JW (reprint author), VA Pittsburgh Hlth Care Syst, Behav Hlth 116A,7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM kasckowjw@upmc.edu
RI Herman, James/D-4960-2015
OI Herman, James/0000-0003-3571-2406
FU VA Pittsburgh VISN 4 MIRECC [AG12962, AG10836]
FX This research was supported by AG12962 and AG10836 (JPH) as well as the
VA Pittsburgh VISN 4 MIRECC site (JWK). We Would also like to thank Ben
Packard, Amy Bruestle, Amy Furay, Michelle Ostrander, Yve Ulrich-Lai,
Helmer Figueiredo, Nancy Mueller, Nate Evanson and Ingrid Thomas for
their expertise and assistance.
NR 43
TC 17
Z9 19
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD JAN 8
PY 2009
VL 96
IS 1
BP 6
EP 11
DI 10.1016/j.physbeh.2008.07.024
PG 6
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA 402LA
UT WOS:000263014000002
PM 18722394
ER
PT J
AU Weaver, FM
Follett, K
Stern, M
Hur, K
Harris, C
Marks, WJ
Rothlind, J
Sagher, O
Reda, D
Moy, CS
Pahwa, R
Burchiel, K
Hogarth, P
Lai, EC
Duda, JE
Holloway, K
Samii, A
Horn, S
Bronstein, J
Stoner, G
Heemskerk, J
Huang, GD
AF Weaver, Frances M.
Follett, Kenneth
Stern, Matthew
Hur, Kwan
Harris, Crystal
Marks, William J., Jr.
Rothlind, Johannes
Sagher, Oren
Reda, Domenic
Moy, Claudia S.
Pahwa, Rajesh
Burchiel, Kim
Hogarth, Penelope
Lai, Eugene C.
Duda, John E.
Holloway, Kathryn
Samii, Ali
Horn, Stacy
Bronstein, Jeff
Stoner, Gatana
Heemskerk, Jill
Huang, Grant D.
CA CSP 468 Study Grp
TI Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients
With Advanced Parkinson Disease A Randomized Controlled Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID QUALITY-OF-LIFE; SUBTHALAMIC STIMULATION; MOTOR FLUCTUATIONS; ADVERSE
EVENTS; FOLLOW-UP; MULTICENTER; NUCLEUS; METAANALYSIS; VALIDATION
AB Context Deep brain stimulation is an accepted treatment for advanced Parkinson disease ( PD), although there are few randomized trials comparing treatments, and most studies exclude older patients.
Objective To compare 6- month outcomes for patients with PD who received deep brain stimulation or best medical therapy.
Design, Setting, and Patients Randomized controlled trial of patients who received either deep brain stimulation or best medical therapy, stratified by study site and patient age ( < 70 years vs >= 70 years) at 7 Veterans Affairs and 6 university hospitals between May 2002 and October 2005. A total of 255 patients with PD ( Hoehn and Yahr stage >= 2 while not taking medications) were enrolled; 25% were aged 70 years or older. The final 6- month follow- up visit occurred in May 2006.
Intervention Bilateral deep brain stimulation of the subthalamic nucleus ( n= 60) or globus pallidus ( n= 61). Patients receiving best medical therapy ( n= 134) were actively managed by movement disorder neurologists.
Main Outcome Measures The primary outcome was time spent in the "on" state ( good motor control with unimpeded motor function) without troubling dyskinesia, using motor diaries. Other outcomes included motor function, quality of life, neurocognitive function, and adverse events.
Results Patients who received deep brain stimulation gained a mean of 4.6 h/ d of on time without troubling dyskinesia compared with 0 h/ d for patients who received best medical therapy ( between group mean difference, 4.5 h/ d [ 95% CI, 3.7- 5.4 h/ d]; P <. 001). Motor function improved significantly ( P <. 001) with deep brain stimulation vs best medical therapy, such that 71% of deep brain stimulation patients and 32% of best medical therapy patients experienced clinically meaningful motor function improvements ( >= 5 points). Compared with the best medical therapy group, the deep brain stimulation group experienced significant improvements in the summary measure of quality of life and on 7 of 8 PD quality- of- life scores ( P <. 001). Neurocognitive testing revealed small decrements in some areas of information processing for patients receiving deep brain stimulation vs best medical therapy. At least 1 serious adverse event occurred in 49 deep brain stimulation patients and 15 best medical therapy patients ( P <. 001), including 39 adverse events related to the surgical procedure and 1 death secondary to cerebral hemorrhage.
Conclusion In this randomized controlled trial of patients with advanced PD, deep brain stimulation was more effective than best medical therapy in improving on time without troubling dyskinesias, motor function, and quality of life at 6 months, but was associated with an increased risk of serious adverse events.
Trial Registration clinicaltrials. gov Identifier: NCT00056563.
C1 [Weaver, Frances M.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[Hur, Kwan; Reda, Domenic] Edward Hines Jr VA Hosp, Cooperat Studies Coordinating Ctr, Hines, IL 60141 USA.
[Weaver, Frances M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
[Follett, Kenneth] Univ Nebraska, Dept Neurosurg, Omaha, NE 68182 USA.
[Stern, Matthew; Duda, John E.; Horn, Stacy] Univ Penn Hlth Syst, Dept Neurol, Philadelphia, PA USA.
[Stern, Matthew; Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Harris, Crystal] Clin Res Pharm, VA Cooperat Studies Program, Albuquerque, NM USA.
[Marks, William J., Jr.; Rothlind, Johannes] San Francisco VA Med Ctr, San Francisco, CA USA.
[Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Rothlind, Johannes] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Sagher, Oren] Univ Michigan, Med Ctr, Dept Neurosurg, Ann Arbor, MI 48109 USA.
[Moy, Claudia S.; Heemskerk, Jill] NINDS, Rockville, MD USA.
[Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
[Burchiel, Kim; Hogarth, Penelope] Portland VA Med Ctr, Portland, OR USA.
[Burchiel, Kim] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA.
[Hogarth, Penelope] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Lai, Eugene C.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Lai, Eugene C.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Holloway, Kathryn] Richmond VA Med Ctr, Richmond, VA USA.
[Holloway, Kathryn] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA.
[Samii, Ali] Puget Sound Hlth Care Syst, Seattle, WA USA.
[Bronstein, Jeff] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Stoner, Gatana] Univ Iowa Health Care, Dept Neurosurg, Iowa City, IA USA.
[Huang, Grant D.] VA Off Res & Dev, Dept Vet Affairs, Cooperat Studies Program Cent Off, Washington, DC USA.
RP Weaver, FM (reprint author), Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H, Hines, IL 60141 USA.
EM Frances.Weaver@va.gov
FU The Cooperative Studies Program of the Department of Veterans Affairs
Office of Research and Development; National Institute of Neurological
Disorders and Stroke; Medtronic Neuromodulation
FX The Cooperative Studies Program of the Department of Veterans Affairs
Office of Research and Development, the National Institute of
Neurological Disorders and Stroke, and Medtronic Neuromodulation
provided financial support for this study.
NR 31
TC 546
Z9 561
U1 7
U2 52
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 7
PY 2009
VL 301
IS 1
BP 63
EP 73
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 391FY
UT WOS:000262220400021
PM 19126811
ER
PT J
AU Carabello, BA
AF Carabello, Blase A.
TI Role of Mitral Valve Surgery for Secondary Mitral Regurgitation in Heart
Failure Reply
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Letter
ID TRIAL
C1 Vet Affairs Med Ctr, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Carabello, BA (reprint author), Vet Affairs Med Ctr, Houston Vet Affairs Med Ctr, Bldg 100,Room 4C211,2002 Holcombe, Houston, TX 77030 USA.
EM blaseanthony.carabello@med.va.gov
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JAN 6
PY 2009
VL 53
IS 1
BP 75
EP 75
DI 10.1016/j.jacc.2008.09.021
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 389IF
UT WOS:000262085400014
ER
PT J
AU Bird, TD
AF Bird, Thomas D.
TI A new disease mimicking Refsum syndrome
SO NEUROLOGY
LA English
DT Editorial Material
C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Bird, TD (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
EM tomnroz@u.washington.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JAN 6
PY 2009
VL 72
IS 1
BP 13
EP 13
DI 10.1212/01.wnl.0000334358.71615.fd
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 390KL
UT WOS:000262162600003
PM 19005173
ER
PT J
AU Mocroft, A
Wyatt, C
Szczech, L
Neuhaus, J
El-Sadr, W
Tracy, R
Kuller, L
Shlipak, M
Angus, B
Klinker, H
Ross, M
AF Mocroft, Amanda
Wyatt, Christina
Szczech, Lynda
Neuhaus, Jacquie
El-Sadr, Wafaa
Tracy, Russell
Kuller, Lewis
Shlipak, Michael
Angus, Brian
Klinker, Harting
Ross, Michael
CA Insight Smart Study Grp
TI Interruption of antiretroviral therapy is associated with increased
plasma cystatin C
SO AIDS
LA English
DT Article
DE cystatin C; randomized trial; treatment interruption
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE;
IMMUNODEFICIENCY-VIRUS-INFECTION; TUBULAR EPITHELIAL-CELLS;
CARDIOVASCULAR-DISEASE; SERUM CREATININE; RENAL-FUNCTION;
HIV-1-ASSOCIATED NEPHROPATHY; REFERENCE RANGES; HIV-1 INFECTION
AB Background: Cystatin C has been proposed as an alternative marker of renal function. We sought to determine whether participants randomized to episodic use of antiretroviral therapy guided by CD4(+) cell count (drug conservation) had altered cystatin C levels compared with those randomized to Continuous antiretroviral therapy (viral suppression) in the Strategies for Management of Antiretroviral Therapy trial, and to identify factors associated with increased cystatin C.
Methods: Cystatin C was measured in plasma collected at randomization, 1, 2, 4, 8 and 12 months after randomization in a random sample of 249 and 250 participants in the drug conservation and viral suppression groups, respectively. Logistic regression was used to model the odds of at least 0.15 mg/dl increase in cystatin C (1 SD) in the first month after randomization, adjusting for demographic and clinical characteristics.
Results: At randomization, mean (SD) cystatin C level was 0.99 (0.26 mg/dl) and 1.01 (0.28 mg/dl) in the drug conservation and viral Suppression arms, respectively (P = 0.29). In the first month after randomization, 21.8 and 10.6% had at least 0.15 mg/dl increase in cystatin C in the drug conservation and viral suppression arms, respectively (P=0.0008). The difference in cystatin C between the treatment arms was maintained through 1 year after randomization. After adjustment, participants in the viral suppression arm had significantly reduced odds of at least 0.15 mg/dl increase in cystatin C in the first month (odds ratio 0.42; 95% confidence interval 0.23-0.74, P = 0.0023).
Conclusion: These results demonstrate that interruption of antiretroviral therapy is associated with an increase in cystatin C, which may reflect worsened renal function. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Mocroft, Amanda] UCL, Sch Med, Res Dept Infect & Populat Hlth, London NW3 2PF, England.
[Wyatt, Christina; Ross, Michael] Mt Sinai Sch Med, New York, NY USA.
[Szczech, Lynda] Duke Univ, Med Ctr, Durham, NC 27706 USA.
[Neuhaus, Jacquie] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
[El-Sadr, Wafaa] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, New York, NY 10032 USA.
[El-Sadr, Wafaa] Columbia Univ, New York, NY USA.
[Tracy, Russell] Univ Vermont, Coll Med, Burlington, VT 05405 USA.
[Kuller, Lewis] Univ Pittsburgh, Pittsburgh, PA USA.
[Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
[Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford OX1 2JD, England.
[Angus, Brian] MRC, HIV Clin Trials Unit, London, England.
[Klinker, Harting] Klinikum Univ Wurzburg, Wurzburg, Germany.
RP Mocroft, A (reprint author), UCL, Sch Med, Res Dept Infect & Populat Hlth, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.
EM a.mocroft@pcps.ucl.ac.uk
RI Mocroft, Amanda/C-1527-2008; Mocroft, Amanda/G-8748-2011; SHCS, int.
coll. B/G-4090-2011; SHCS, all/G-4072-2011; Pulido,
Federico/B-8417-2009; Brites, Carlos/D-1353-2013
OI Pulido, Federico/0000-0002-7414-8812; Koirala,
Janak/0000-0002-3608-474X; Brites, Carlos/0000-0002-4673-6991;
Gayet-Ageron, Angele/0000-0002-6164-9693; Magenta,
Lorenzo/0000-0002-7644-3647; Okhuysen, Pablo/0000-0002-1596-3411; Angus,
Brian/0000-0003-3598-7784
FU NIAID; NIH [U01AI042170, U01A1068641, U01A146362]
FX This study was supported by NIAID, NIH grants U01AI042170, U01A1068641
and U01A146362 Clinical Trials.gov identifier: NCT00027352.
NR 44
TC 36
Z9 38
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 2
PY 2009
VL 23
IS 1
BP 71
EP 82
DI 10.1097/QAD.0b013e32831cc129
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 390XS
UT WOS:000262197600010
PM 19050388
ER
PT J
AU Bhattacharya, A
Muller, FL
Liu, YH
Sabia, M
Liang, HY
Song, W
Jang, YC
Ran, QT
Van Remmen, H
AF Bhattacharya, Arunabh
Muller, Florian L.
Liu, Yuhong
Sabia, Marian
Liang, Hanyu
Song, Wook
Jang, Youngmok C.
Ran, Qitao
Van Remmen, Holly
TI Denervation Induces Cytosolic Phospholipase A(2)-mediated Fatty Acid
Hydroperoxide Generation by Muscle Mitochondria
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; AGING SKELETAL-MUSCLE;
GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; SELENOORGANIC COMPOUND;
SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; BIOLOGICAL-SYSTEMS; INDUCED
APOPTOSIS; MICE DEFICIENT
AB Previously, we demonstrated that mitochondria from denervated muscle exhibited dramatically higher Amplex Red dependent fluorescence (thought to be highly specific for hydrogen peroxide) compared with control muscle mitochondria. We now demonstrate that catalase only partially inhibits the Amplex Red signal in mitochondria from denervated muscle. In contrast, ebselen (a glutathione peroxidase mimetic and inhibitor of fatty acid hydroperoxides) significantly inhibits the Amplex Red signal. This suggests that the majority of the Amplex Red signal in mitochondria from denervated muscle is not derived from hydrogen peroxide. Because Amplex Red cannot react with substrates in the lipid environment, we hypothesize that lipid hydroperoxides formed within the mitochondrial lipid bilayer are released as fatty acid hydroperoxides and react with the Amplex Red probe. We also suggest that the release of fatty acid hydroperoxides from denervated muscle mitochondria may be an important determinant of muscle atrophy. In support of this, muscle atrophy and the Amplex Red signal are inhibited in caloric restricted mice and in transgenic mice that overexpress the lipid hydroperoxide-detoxifying enzyme glutathione peroxidase 4. Finally, we propose that cytosolic phospholipase A(2) may be a potential source of these hydroperoxides.
C1 [Bhattacharya, Arunabh; Liu, Yuhong; Liang, Hanyu; Song, Wook; Ran, Qitao; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Bhattacharya, Arunabh; Muller, Florian L.; Liu, Yuhong; Liang, Hanyu; Jang, Youngmok C.; Ran, Qitao; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Sabia, Marian; Ran, Qitao; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
RI Liang, Hanyu/A-1066-2010
FU National Institutes of Health [AG20591]; Muscular Dystrophy Association
[MDA 3879]; Veterans Affairs merit grant
FX This work was supported, in whole or in part, by National Institutes of
Health Grant AG20591 (to H. V. R.). This work was also supported by
Muscular Dystrophy Association Grant MDA 3879 (to H. V. R.) and a
Veterans Affairs merit grant (to H. V. R.). The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked "advertisement" in accordance
with 18 U. S. C. Section 1734 solely to indicate this fact.
NR 54
TC 30
Z9 30
U1 1
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 2
PY 2009
VL 284
IS 1
BP 46
EP 55
DI 10.1074/jbc.M806311200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 387TP
UT WOS:000261974800006
PM 19001413
ER
PT B
AU Sundara-Rajan, K
Rowe, GI
Simon, AJ
Klute, GK
Ledoux, WR
Mamishev, AV
AF Sundara-Rajan, Kishore
Rowe, Gabriel I.
Simon, Anthony J.
Klute, Glenn K.
Ledoux, William R.
Mamishev, Alexander V.
BE Evans, BM
TI Shear Sensor for Lower Limb Prosthetic Applications
SO 2009 FIRST ANNUAL ORNL BIOMEDICAL SCIENCE & ENGINEERING CONFERENCE:
EXPLORING THE INTERSECTIONS OF INTERDISCIPLINARY BIOMEDICAL RESEARCH
LA English
DT Proceedings Paper
CT 1st Annual ORNL Biomedical Science and Engineering Conference
CY MAR 18-19, 2009
CL Oak Ridge, TN
SP Oak Ridge Natl Lab
AB Lower limb amputees using a prosthetic device often suffer from mechanically-induced skin injuries. Shear stresses are believed to play a significant role in the formation of these skin injuries. The work presented in this paper is aimed at creating a new class of adaptive prosthetic and orthotic interfaces involving a capacitive shear stress sensor. The sensor design and transfer function are discussed. A few preliminary test results demonstrating the functionality of the sensor are also presented.
C1 [Sundara-Rajan, Kishore; Rowe, Gabriel I.; Simon, Anthony J.; Mamishev, Alexander V.] Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA.
[Klute, Glenn K.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA.
[Klute, Glenn K.; Ledoux, William R.] Univ Washington, Dept Engn Mech, Seattle, WA USA.
RP Sundara-Rajan, K (reprint author), Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA.
EM kishore@u.washington.edu
FU U.S. National Institute of Health under Grant [R21HD052109-02];
Department of Veterans Affairs Grant [A4843C]
FX This work was supported in part by the U.S. National Institute of Health
under Grant R21HD052109-02 and the Department of Veterans Affairs Grant
A4843C.
NR 11
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4244-3837-2
PY 2009
BP 61
EP +
PG 2
WC Engineering, Biomedical
SC Engineering
GA BMB15
UT WOS:000271720900011
ER
PT J
AU Bader, B
Velayos-Baeza, A
Walker, RH
Danek, A
AF Bader, Benedikt
Velayos-Baeza, Antonio
Walker, Ruth H.
Danek, Adrian
TI Dominant transmission of chorea-acanthocytosis with VPS13A mutations
remains speculative
SO ACTA NEUROPATHOLOGICA
LA English
DT Letter
ID CHAC GENE
C1 [Bader, Benedikt; Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany.
[Velayos-Baeza, Antonio] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA.
[Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA.
RP Bader, B (reprint author), Univ Munich, Neurol Klin & Poliklin, Munich, Germany.
EM benedikt.bader@med.uni-muenchen.de
RI Danek, Adrian/G-7339-2011
OI Danek, Adrian/0000-0001-8857-5383
NR 10
TC 8
Z9 8
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD JAN
PY 2009
VL 117
IS 1
BP 95
EP 96
DI 10.1007/s00401-008-0418-7
PG 2
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 376LN
UT WOS:000261185200011
PM 18661137
ER
PT J
AU Yehuda, R
Schmeidler, J
Labinsky, E
Bell, A
Morris, A
Zemelman, S
Grossman, RA
AF Yehuda, R.
Schmeidler, R.
Labinsky, E.
Bell, A.
Morris, A.
Zemelman, S.
Grossman, R. A.
TI Ten-year follow-up study of PTSD diagnosis, symptom severity and
psychosocial indices in aging holocaust survivors
SO ACTA PSYCHIATRICA SCANDINAVICA
LA English
DT Article
DE holocaust survivors; longitudinal course; post-traumatic stress
disorder; morale; traumatic loss
ID POSTTRAUMATIC-STRESS-DISORDER; WORLD-WAR-II; FORMER PRISONERS;
LONGITUDINAL ASSESSMENT; LIFETIME TRAUMA; COMBAT VETERANS; IMPACT; SCALE
AB Objective: We performed a longitudinal study of holocaust survivors with and without post-traumatic stress disorder ( PTSD) by assessing symptoms and other measures at two intervals, approximately 10 years apart.
Method: The original cohort consisted of 63 community-dwelling subjects, of whom 40 were available for follow-up.
Results: There was a general diminution in PTSD symptom severity over time. However, in 10% of the subjects (n = 4), new instances of delayed onset PTSD developed between time 1 and time 2. Self-report ratings at both assessments revealed a worsening of trauma-related symptoms over time in persons without PTSD at time 1, but an improvement in those with PTSD at time 1.
Conclusion: The findings suggest that a nuanced characterization of PTSD trajectory over time is more reflective of PTSD symptomatology than simple diagnostic status at one time. The possibility of delayed onset trajectory complicates any simplistic overall trajectory summarizing the longitudinal course of PTSD.
C1 [Yehuda, R.; Schmeidler, R.; Labinsky, E.; Bell, A.; Morris, A.; Zemelman, S.; Grossman, R. A.] Mt Sinai Sch Med, Dept Psychiat, Div Traumat Stress Studies, New York, NY USA.
[Yehuda, R.; Schmeidler, R.; Labinsky, E.; Bell, A.; Morris, A.; Zemelman, S.; Grossman, R. A.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Yehuda, R (reprint author), Bronx Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@va.gov
FU NIMH [R01 MH 64675-01, 5 M01 RR00071]; National Institute of Health
FX This work was supported by NIMH R01 MH 64675-01 entitled 'Biology of
Risk and PTD in Holocaust Survivor spring' and in part by a grant (5 M01
RR00071) for the Mount Sinai General Clinical Research Center from the
National Institute of Health. The authors acknowledge Ms Shira Kaufman
and Mr William Blair for research coordination, and Drs Lisa Tischler
and Alicia Hirsch for diagnostic evaluations and consensus conferencing.
The authors report no financial or other relationship relevant to the
subject of this article.
NR 30
TC 26
Z9 26
U1 0
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-690X
J9 ACTA PSYCHIAT SCAND
JI Acta Psychiatr. Scand.
PD JAN
PY 2009
VL 119
IS 1
BP 25
EP 34
DI 10.1111/j.1600-0447.2008.01248.x
PG 10
WC Psychiatry
SC Psychiatry
GA 394LX
UT WOS:000262449300004
PM 18785948
ER
PT S
AU Matute-Bello, G
Martin, TR
AF Matute-Bello, Gustavo
Martin, Thomas R.
BE Choi, AMK
TI Apoptosis in the Pathogenesis and Resolution of Acute Lung Injury
SO Acute Respiratory Distress Syndrome, 2nd Edition
SE Lung Biology in Health and Disease
LA English
DT Article; Book Chapter
ID RESPIRATORY-DISTRESS-SYNDROME; ENDOTHELIAL-CELL APOPTOSIS; ALVEOLAR
EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; FAS-INDUCED APOPTOSIS;
NEUTROPHIL APOPTOSIS; IN-VIVO; PULMONARY INFLAMMATION; FIBROBLAST
APOPTOSIS; CASPASE INHIBITOR
C1 [Matute-Bello, Gustavo; Martin, Thomas R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Martin, Thomas R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Matute-Bello, G (reprint author), Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
NR 80
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND
SN 0362-3181
BN 978-1-4200-8841-0; 978-1-4200-8840-3
J9 LUNG BIOL HEALTH DIS
PY 2009
VL 233
BP 93
EP 108
PG 16
WC Respiratory System
SC Respiratory System
GA BD6KI
UT WOS:000362321700010
ER
PT S
AU Anzueto, A
Gattinoni, L
AF Anzueto, Antonio
Gattinoni, Luciano
BE Choi, AMK
TI Prone Position in ARDS
SO Acute Respiratory Distress Syndrome, 2nd Edition
SE Lung Biology in Health and Disease
LA English
DT Article; Book Chapter
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; INHALED NITRIC-OXIDE;
END-EXPIRATORY PRESSURE; PULMONARY BLOOD-FLOW; MECHANICAL VENTILATION;
REGIONAL DISTRIBUTION; VERTICAL-DISTRIBUTION; AIRWAY PRESSURE; INSPIRED
GAS
C1 [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Gattinoni, Luciano] Osped Maggiore Policlin, Milan, Italy.
RP Anzueto, A (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
NR 80
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND
SN 0362-3181
BN 978-1-4200-8841-0; 978-1-4200-8840-3
J9 LUNG BIOL HEALTH DIS
PY 2009
VL 233
BP 313
EP 334
PG 22
WC Respiratory System
SC Respiratory System
GA BD6KI
UT WOS:000362321700020
ER
PT J
AU Gleason, CE
Carlsson, CM
Barnet, JH
Meade, SA
Setchell, KDR
Atwood, CS
Johnson, SC
Ries, ML
Asthana, S
AF Gleason, Carey E.
Carlsson, Cynthia M.
Barnet, Jodi H.
Meade, Sarah A.
Setchell, Kenneth D. R.
Atwood, Craig S.
Johnson, Sterling C.
Ries, Michele L.
Asthana, Sanjay
TI A preliminary study of the safety, feasibility and cognitive efficacy of
soy isoflavone supplements in older men and women
SO AGE AND AGEING
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; POSTMENOPAUSAL
WOMEN; PHARMACOKINETICS; CONSUMPTION; FREQUENCY; LIPIDS; SERUM; EQUOL
AB Background: a small number of reports exist on the cognitive effects of soy isoflavones, the findings from which are mixed. Isoflavone efficacy is dependent upon conversion of glycosides contained in soy foods and supplements to the biologically active aglycons. Of particular interest is the production of the metabolite, equol, which is dependent upon intestinal microflora and an integrous digestive system, both being altered by age and age-associated conditions. Unfortunately, few studies enrolled adults over the age of 70, and none included older men.
Objective: we examined safety, feasibility and cognitive efficacy of soy isoflavone administration in older nondemented men and women (age 62-89 years).
Design and Methods: in this randomised, placebo-controlled, double-blind pilot study, subjects ingested either 100 mg/day soy isoflavones (glycoside weight) or matching placebo tablets for 6 months.
Results: active and placebo-treated subjects exhibited a comparable side-effect profile. Plasma levels of genistein and daidzein (P < 0.001), but not equol, increased with isoflavone administration. While similar at baseline, the two groups differed across 6 months of treatment on 8 of 11 cognitive tests administered. Isoflavone-treated subjects improved on tests of visual-spatial memory (P < 0.01) and construction (P = 0.01), verbal fluency (P < 0.01) and speeded dexterity (P = 0.04). Placebo-treated participants were faster than isoflavone-treated subjects on two tests of executive function (P < 0.05).
Conclusions: these data suggest that administration of 100 mg/day of isoflavones was well tolerated. Plasma genistein and daidzein levels, but not equol, increased with isoflavone administration. Finally, data support the potential cognitive effects of soy isoflavones in older adults.
C1 [Gleason, Carey E.; Carlsson, Cynthia M.; Meade, Sarah A.; Atwood, Craig S.; Johnson, Sterling C.; Ries, Michele L.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Madison VA GRECC 11G, Sect Geriatr & Gerontol, Madison, WI 53705 USA.
[Gleason, Carey E.; Carlsson, Cynthia M.; Atwood, Craig S.; Johnson, Sterling C.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA.
[Barnet, Jodi H.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA.
[Meade, Sarah A.] Univ Wisconsin, Wisconsin Alzheimers Inst, Madison, WI 53719 USA.
[Setchell, Kenneth D. R.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA.
[Setchell, Kenneth D. R.] Cincinnati Childrens Hosp, Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA.
RP Gleason, CE (reprint author), Univ Wisconsin, Dept Med, Madison VA GRECC 11G, Sect Geriatr & Gerontol, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM ceg@medicine.wisc.edu
FU UW General Clinical Research Center from the National Center for
Research Resources, National Institutes of Health [M01 RR03186]; NIH/NIA
[K23 AG024302]
FX Work was supported by grants: M01 RR03186 awarded to The UW General
Clinical Research Center from the National Center for Research
Resources, National Institutes of Health and K23 AG024302 NIH/NIA
(C.E.G.). Archer Daniels Midland provided Novasoy brand isoflavones
tablets and matching placebo. Sponsors of the project played no role in
the design, execution, analysis or interpretation of the data or writing
of the study.
NR 32
TC 30
Z9 31
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
J9 AGE AGEING
JI Age Ageing
PD JAN
PY 2009
VL 38
IS 1
BP 86
EP 93
DI 10.1093/ageing/afn227
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 395IP
UT WOS:000262518100017
PM 19054783
ER
PT J
AU Paukert, AL
LeMaire, A
Cully, JA
AF Paukert, Amber Lynn
LeMaire, Ashley
Cully, Jeffrey A.
TI Predictors of depressive symptoms in older veterans with heart failure
SO AGING & MENTAL HEALTH
LA English
DT Article
DE depression; locus of control; illness intrusiveness; anxiety; geriatric
ID PERCEIVED SOCIAL SUPPORT; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES;
MULTIDIMENSIONAL SCALE; ILLNESS INTRUSIVENESS; ELDERLY-PATIENTS;
HEALTH-STATUS; PREVALENCE; VALIDATION; DISEASE
AB Objectives: This study collected data on demographic factors, heart failure physical limitations, perception of heart failure intrusiveness, coping mechanisms, locus of control, self-efficacy and social support for 104 older veterans with heart failure (HF) to determine the factors' relative importance in predicting depressive symptoms. Method: Participants were veterans at least 60 years of age with HF who were screened for depression and anxiety with the Geriatric Depression Scale and Geriatric Anxiety Inventory, respectively, so that the final sample consisted of equal numbers with and without significant levels of anxiety and depression. Other measures included the Kansas City Cardiomyopathy Questionnaire, Heart Failure Illness Intrusiveness Rating Scale, Brief-COPE, Multidimensional Health Locus of Control Scale, Chronic Disease Self-Efficacy and Multidimensional Scale of Perceived Social Support. Results: Correlational analyses indicated that depressive symptoms were significantly associated with physical limitations from HF, HF perceptions of intrusiveness, maladaptive coping, attributing locus of control to chance and HF self-efficacy. Including these variables in one regression equation predicting depressive symptoms indicated that perceptions of intrusiveness from HF and attributing locus of control to chance were the only variables to predict depressive symptoms independent of the influence of other significant bivariate predictors. Conclusion: Even if physical limitations, maladaptive coping and self-efficacy are held constant, decreasing perceptions of HF intrusiveness and locus of control to chance reduce depressive symptoms. These two cognitive/perceptual factors may play a salient role in treatment of depression among older HF patients.
C1 [Paukert, Amber Lynn] Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Paukert, Amber Lynn; LeMaire, Ashley; Cully, Jeffrey A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Paukert, Amber Lynn; Cully, Jeffrey A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Cully, Jeffrey A.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA.
RP Paukert, AL (reprint author), Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
EM Amber.Paukert@VA.gov
NR 65
TC 25
Z9 25
U1 4
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1360-7863
J9 AGING MENT HEALTH
JI Aging Ment. Health
PY 2009
VL 13
IS 4
BP 601
EP 610
AR PII 913279815
DI 10.1080/13607860802459823
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 474JP
UT WOS:000268279900013
PM 19629786
ER
PT J
AU Pinkerton, SD
Bogart, LM
Howerton, D
Snyder, S
Becker, K
Asch, SM
AF Pinkerton, Steven D.
Bogart, Laura M.
Howerton, Devery
Snyder, Susan
Becker, Kirsten
Asch, Steven M.
TI Cost of OraQuick oral fluid rapid HIV testing at 35 community clinics
and community-based organizations in the USA
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE HIV; rapid testing; cost; community-based organizations
ID UNITED-STATES; PREVENTION; INFECTION; VIRUS
AB The US Centers for Disease Control and Prevention recommends the expanded use of rapid HIV antibody tests in community settings to increase the proportion of persons who are aware of their HIV status. The cost of providing rapid testing services in these settings is not known. We conducted a cost survey of non-profit community clinics and community-based organizations (CBOs). The final study sample for the cost analyses included 28 community clinics and seven CBOs that offered rapid HIV testing, all of which used OraSure's OraQuick oral fluid assay. Overall, the mean per-client rapid testing cost was $36.68 for HIV-negative clients (2006 dollars, provider perspective) and $44.22 for preliminary-positive clients. Personnel costs accounted for 55.6% of overall testing costs for negative clients and 63.2% for preliminary-positive clients. This study contributes unique empirical data about the costs of OralQuick rapid testing that can be used by clinic and CBO directors to assess the economic impact of implementing rapid testing at their sites. The findings also could be used to inform discussions regarding national and local HIV testing policies.
C1 [Pinkerton, Steven D.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Ctr AIDS Intervent Res, Milwaukee, WI 53226 USA.
[Bogart, Laura M.; Becker, Kirsten; Asch, Steven M.] RAND Corp, Hlth Program, Santa Monica, CA USA.
[Bogart, Laura M.] Harvard Univ, Sch Med, Childrens Hosp Boston, Cambridge, MA 02138 USA.
[Howerton, Devery; Snyder, Susan] Ctr Dis Control & Prevent, Div Lab Syst, Lab Practice Evaluat & Genom Branch, Atlanta, GA USA.
[Asch, Steven M.] VA Greater Los Angeles Healthcare Network, Los Angeles, CA USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Pinkerton, SD (reprint author), Med Coll Wisconsin, Dept Psychiat & Behav Med, Ctr AIDS Intervent Res, Milwaukee, WI 53226 USA.
EM pinkrton@mcw.edu
FU NIMH NIH HHS [P30-MH52776]; PHS HHS [U65/CCU924523-01]
NR 20
TC 7
Z9 7
U1 1
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PY 2009
VL 21
IS 9
BP 1157
EP 1162
DI 10.1080/09540120902729940
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 515MX
UT WOS:000271477000010
PM 20024775
ER
PT J
AU Savas, LS
White, DL
Wieman, M
Daci, K
Fitzgerald, S
Smith, SL
Tan, G
Graham, DP
Cully, JA
El-Serag, HB
AF Savas, L. S.
White, D. L.
Wieman, M.
Daci, K.
Fitzgerald, S.
Smith, S. Laday
Tan, G.
Graham, D. P.
Cully, J. A.
El-Serag, H. B.
TI Irritable bowel syndrome and dyspepsia among women veterans: prevalence
and association with psychological distress
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; FUNCTIONAL GASTROINTESTINAL DISORDERS;
DEPRESSION INVENTORY-II; PSYCHOSOCIAL-ASPECTS; ABDOMINAL-PAIN;
HEALTH-STATUS; RISK-FACTORS; POPULATION; SYMPTOMS; DISEASE
AB Background The burden of functional GI disorders and their associations with psychological distress in women veterans is unclear.
Aim To examine 1-year prevalence of irritable bowel syndrome (IBS) and dyspepsia symptoms and their associations with anxiety, depression and post-traumatic stress disorder (PTSD) among women veterans receiving primary care at a Veteran Affairs Medical Center Women's Clinic.
Methods Irritable bowel syndrome, dyspepsia and psychological distress were assessed using the validated self-administered Bowel Disorder Questionnaire, the Beck Depression and Anxiety Inventories, as well as the Mississippi Scale for Combat-Related Post-Traumatic Stress Disorder Questionnaire.
Results We enrolled 248 women (84% participation rate). Ninety-three (38%) reported IBS and 51 (21%) dyspepsia symptoms. Women with IBS and dyspepsia reported higher mean scores of anxiety (IBS: 24 vs. 12, P < 0.0005 and dyspepsia: 26 vs. 12, P < 0.0005), depression (IBS: 22 vs. 11, P = 0.0005 and dyspepsia: 23 vs. 11, P < 0.0005) and PTSD (IBS: 87 vs. 69, P < 0.001 and dyspepsia: 86 vs. 69, P < 0.0005). Age-and ethnicity-adjusted logistic regression analyses showed a 3-to 46-fold increase in odds of IBS and dyspepsia among women with anxiety, depression or PTSD.
Conclusion Women veterans have high prevalence of IBS and dyspepsia symptoms, both of which are highly associated with presence of depression, anxiety and PTSD.
C1 [Savas, L. S.; White, D. L.; Wieman, M.; Fitzgerald, S.; Cully, J. A.; El-Serag, H. B.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Savas, L. S.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA.
[White, D. L.; Wieman, M.; Graham, D. P.; Cully, J. A.; El-Serag, H. B.] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA.
[White, D. L.; Daci, K.; El-Serag, H. B.] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA.
[White, D. L.; Daci, K.; El-Serag, H. B.] Michael E DeBakey Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA.
[Smith, S. Laday] Michael E DeBakey Dept Vet Affairs Med Ctr, Omen Vet Program, Houston, TX USA.
[Smith, S. Laday] Baylor Coll Med, Dept Anesthesiol & Phys Med & Rehabil, Houston, TX 77030 USA.
[Graham, D. P.; Cully, J. A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Cully, J. A.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA.
RP El-Serag, HB (reprint author), Houston VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 152, Houston, TX 77030 USA.
EM hasheme@bcm.tmc.edu
RI Graham, David /J-1158-2014
FU Novartis pharmaceuticals; National Institute of Health [K-24
DK07815403]; Health Resources and Services [5 T32 HP10031-09]; Veterans
Health Administration, HSR D Service [CDA-2; 05-288]
FX Declaration of personal interests: Hashim El-Serag has served as a
consultant and an advisory board member for Novartis Pharmaceuticals.
None of the authors is an employee, owns stocks or shares, or has
patents that constitute a conflict of interest. Hashem B. El-Serag was
responsible for the study design. Hashem B. El-Serag, Donna L. White and
Lara S. Savas were responsible for the interpretation of results and
manuscript. Data analysis was done by Lara S. Savas. All authors
reviewed and revised the manuscript of the paper and approved its final
version. All analyses and writing was conducted solely by the listed
authors. There are no conflicts of interest. Declaration of funding
interests: This material is based upon work supported in part by Health
Services Research and Development (HSR& D) Service, Office of Research
and Development, Department of Veterans Affairs. This study is partly
funded by a grant from Novartis pharmaceuticals to Dr El-Serag. Dr
El-Serag is supported by National Institute of Health grant K-24
DK07815403. Dr Savas is supported by the National Research Service Award
5 T32 HP10031-09 funded by the Health Resources and Services. Dr Cully
is supported by a Career Development Award (CDA-2; 05-288) from the
Veterans Health Administration, HSR& D Service.
NR 58
TC 32
Z9 33
U1 2
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JAN 1
PY 2009
VL 29
IS 1
BP 115
EP 125
DI 10.1111/j.1365-2036.2008.03847.x
PG 11
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 384ZB
UT WOS:000261781600013
PM 18785989
ER
PT J
AU Reifel, N
Bayhylle, R
Harada, N
Villa, V
AF Reifel, Nancy
Bayhylle, Ruth
Harada, Nancy
Villa, Valentine
TI American Indian Veterans' Views about Their Choices in Health Care: VA,
IHS, and Medicare
SO AMERICAN INDIAN CULTURE AND RESEARCH JOURNAL
LA English
DT Article
ID SYSTEM; SERVICES; HISTORY
C1 [Bayhylle, Ruth] Univ Calif Los Angeles, Dept Informat Studies, Los Angeles, CA 90024 USA.
[Bayhylle, Ruth] Native Amer Vet Grp, Los Angeles, CA USA.
[Harada, Nancy] Vet Adm Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Hlth Serv Res, Los Angeles, CA USA.
[Villa, Valentine] Calif State Coll, Los Angeles, CA USA.
[Villa, Valentine] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
NR 22
TC 0
Z9 0
U1 1
U2 2
PU U C L A, AMER INDIAN STUDIES CENTER
PI LOS ANGELES
PA 3220 CAMPBELL HALL, BOX 951548, LOS ANGELES, CA 90095-1548 USA
SN 0161-6463
J9 AM INDIAN CULT RES J
JI Am. Indian Cult. Res. J.
PY 2009
VL 33
IS 3
BP 23
EP 33
PG 11
WC History
SC History
GA 502NB
UT WOS:000270466000003
ER
PT J
AU Naik, A
Dyer, C
Kunik, M
McCullough, L
AF Naik, Aanand D.
Dyer, Carmel B.
Kunik, Mark E.
McCullough, Laurence B.
TI Patient Autonomy for the Management of Chronic Conditions: A
Two-Component Re-Conceptualization
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Article
DE autonomy; decision-making; capacity; executive control functions; older
adults; functional assessment
ID EXECUTIVE CONTROL FUNCTIONS; INFORMED CONSENT; DECISION-MAKING; ELDERLY
PERSONS; CARE; IMPAIRMENT; COMPETENCE; INSTRUMENT; LITERACY; CAPACITY
AB The clinical application of the concept of patient autonomy has centered on the ability to deliberate and make treatment decisions (decisional autonomy) to the virtual exclusion of the capacity to execute the treatment plan (executive autonomy). However, the one-component concept of autonomy is problematic in the context of multiple chronic conditions. Adherence to complex treatments commonly breaks down when patients have functional, educational, and cognitive barriers that impair their capacity to plan, sequence, and carry out tasks associated with chronic care. The purpose of this article is to call for a two-component re-conceptualization of autonomy and to argue that the clinical assessment of capacity for patients with chronic conditions should be expanded to include both autonomous decision-making and autonomous execution of the agreed-upon treatment plan. We explain how the concept of autonomy should be expanded to include both decisional and executive autonomy, describe the biopsychosocial correlates of the two-component concept of autonomy, and recommend diagnostic and treatment strategies to support patients with deficits in executive autonomy.
C1 [Naik, Aanand D.; Kunik, Mark E.] Houston Ctr Qual Care Utilizat Studies, Baylor Coll Med, Michael DeBakey VA Med Ctr, Houston, TX USA.
[McCullough, Laurence B.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
[Dyer, Carmel B.] Univ Texas Houston, Sch Med, Houston, TX USA.
RP Naik, A (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.tmc.edu
FU Houston Center for Quality of Care & Utilization Studies; Michael E.
DeBakey Veterans Affairs Medical Center; Consortium for Research in
Elder Self-Neglect of Texas (NIH) [P20-RR020626]; Greenwall Foundation;
National Institute of Aging [K23AG027144]; [FP90-020]
FX This article is the result of work supported with resources and the use
of facilities at the Houston Center for Quality of Care & Utilization
Studies (FP90-020), Michael E. DeBakey Veterans Affairs Medical Center,
the Consortium for Research in Elder Self-Neglect of Texas (NIH
P20-RR020626), and a bioethics grant from the Greenwall Foundation. Dr.
Naik is also supported by the National Institute of Aging (K23AG027144).
The authors would like to thank Sonora Hudson for her careful review of
a prior version of the manuscript.
NR 47
TC 34
Z9 34
U1 1
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PY 2009
VL 9
IS 2
BP 23
EP 30
AR PII 908346820
DI 10.1080/15265160802654111
PG 8
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 400ZG
UT WOS:000262907300011
PM 19180389
ER
PT J
AU Naik, AD
Dyer, CB
Kunik, ME
McCullough, LB
AF Naik, Aanand D.
Dyer, Carmel B.
Kunik, Mark E.
McCullough, Laurence B.
TI Response to Commentaries on Patient Autonomy for the Management of
Chronic Conditions: A Two-Component Re-Conceptualization
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Letter
C1 [McCullough, Laurence B.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
[Dyer, Carmel B.] Univ Texas Houston, Sch Med, Houston, TX USA.
RP Naik, A (reprint author), Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.tmc.edu
FU NIA NIH HHS [K23 AG027144]
NR 11
TC 4
Z9 4
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PY 2009
VL 9
IS 2
BP W3
EP W5
AR PII 908347610
DI 10.1080/15265160802670984
PG 3
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 400ZG
UT WOS:000262907300026
PM 19180379
ER
PT J
AU Stoelb, BL
Jensen, MP
Tackett, MJ
AF Stoelb, Brenda L.
Jensen, Mark P.
Tackett, M. Jan
TI Hypnotic Analgesia for Combat-Related Spinal Cord Injury Pain: A Case
Study
SO AMERICAN JOURNAL OF CLINICAL HYPNOSIS
LA English
DT Article
DE Spinal cord injury; pain; chronic pain; hypnosis; self-hypnosis training
ID VETERANS; HYPNOTHERAPY; NONVETERANS; PREVALENCE; DISABILITY; HYPNOSIS;
SAMPLE; MEN
AB A U.S. Army soldier stationed in Iraq developed myriad pain problems after sustaining a high-level spinal cord injury (SCI) from a gunshot wound. These problems were negatively impacting his ability to participate fully in his physical rehabilitation and care. Ten sessions of self-hypnosis training were administered to the patient over a 5-week period to help him address these problems. Both the patient and his occupational therapist reported a substantial reduction in pain over the course of treatment, which allowed the patient to actively engage in his therapies. Six months post treatment, the patient reported continued use of the hypnosis strategies taught, which effectively reduced his experience of pain. This case study demonstrates the efficacy of hypnotic analgesia treatment for U.S. military veterans who are experiencing pain problems due to traumatic or combat-related SCIs.
C1 [Stoelb, Brenda L.; Jensen, Mark P.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA.
[Tackett, M. Jan] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Stoelb, BL (reprint author), Univ Washington, Dept Rehabil Med, Sch Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98195 USA.
EM bstoelb@u.washington.edu
NR 25
TC 1
Z9 1
U1 0
U2 7
PU AMER SOC CLINICAL HYPNOSIS
PI BLOOMINGDALE
PA 140 N BLOOMINGDALE RD, BLOOMINGDALE, IL 60108-1017 USA
SN 0002-9157
J9 AM J CLIN HYPN
JI Am. J. Clin. Hypn.
PD JAN
PY 2009
VL 51
IS 3
BP 273
EP 280
PG 8
WC Psychology, Clinical
SC Psychology
GA 397SB
UT WOS:000262681300005
PM 19216212
ER
PT J
AU Al-Ghananeem, AM
Herman, BH
Abbassi, M
Yu, E
Miotto, K
O'Brien, CP
Ling, W
Montgomery, A
Walsh, R
AF Al-Ghananeem, Abeer M.
Herman, Barbara H.
Abbassi, Maggie
Yu, Elmer
Miotto, Karen
O'Brien, Charles P.
Ling, Walter
Montgomery, Ann
Walsh, Robert
TI Urine and Plasma Pharmacokinetics of Lofexidine after Oral Delivery in
Opiate-Dependent Patients
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Article
DE Clinical trial; lofexidine; oral delivery; pharmacokinetics; urine
AB Objectives: The objective of this study was to investigate lofexidine urine and plasma pharmacokinetics using three different dosing regimens in opioid dependent subjects. To date, there have been no published studies on lofexidine appearance and excretion in urine of opioid dependent subjects. Methods: Subjects were stabilized with 100 mg morphine sulphate on days 3-8 of the study. The dosing regimens of lofexidine hydrochloride were .8 mg twice a day (BID), 1.2 mg BID, or .8 mg three times a day (TID) on days 9 through 16 of the study. Plasma and urine samples were collected at appropriate time points. Area under the concentration-time curve (AUC), maximum concentration in plasma (C(max)), time when maximum concentration was reached (T(max)) and fraction excreted unchanged in urine (Fe) were calculated. Results: The average half-life obtained from all profiles was 12.1 +/- 6.3 hr. Steady-state (SS) was reached by study day 15. The plasma pharmacokinetic parameters for 1.2 mg BID and .8 mg TID dosing regimens did not seem to be different at steady state (day 15). T(max) was not statistically significantly different across dosing regimens. Fe values ranged between .01% and 34% with high variability within the same dosing regimen. For the total dose of 2.4 mg/day the two dosing regimens that were evaluated, namely 1.2 mg BID and .8 mg TID, did not show a significant statistical difference in plasma and urine pharmacokinetic parameters. Conclusion: Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine urine pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis.
C1 [Al-Ghananeem, Abeer M.; Abbassi, Maggie] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
[Herman, Barbara H.; Montgomery, Ann; Walsh, Robert] Natl Inst Drug Abuse, DPMCDA, NIH, Bethesda, MD USA.
[Yu, Elmer; O'Brien, Charles P.] Univ Penn, Philadelphia, PA 19104 USA.
[Yu, Elmer; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Miotto, Karen; Ling, Walter] Univ Calif Los Angeles, David Geffen Sch Med, Long Beach Vet Affairs Med Ctr, Los Angeles, CA 90095 USA.
RP Al-Ghananeem, AM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 927 Rose St, Lexington, KY 40536 USA.
EM amalg0@email.uky.edu
NR 17
TC 0
Z9 0
U1 1
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0095-2990
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PY 2009
VL 35
IS 5
BP 311
EP 315
DI 10.1080/00952990903060135
PG 5
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 562EG
UT WOS:000275031700009
PM 19637105
ER
PT J
AU Karlamangla, AS
Sarkisian, CA
Kado, DM
Dedes, H
Liao, DH
Kim, S
Reuben, DB
Greendale, GA
Moore, AA
AF Karlamangla, Arun S.
Sarkisian, Catherine A.
Kado, Deborah M.
Dedes, Howard
Liao, Diana H.
Kim, Sungjin
Reuben, David B.
Greendale, Gail A.
Moore, Alison A.
TI Light to Moderate Alcohol Consumption and Disability: Variable Benefits
by Health Status
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; BODY-MASS INDEX; UNITED-STATES; OLDER PERSONS;
FOLLOW-UP; LATE-LIFE; AGED 65; DRINKING; WOMEN; RISK
AB In adults, light to moderate alcohol consumption is associated with lower risks for heart disease, diabetes, and mortality. This study examined whether light to moderate alcohol use is also associated with lower risk of incident physical disability over two 5-year periods in 4,276 noninstitutionalized adults in the United States, aged 50 years or older, by using data from 3 waves of the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study surveys from 1982 to 1992. Light/moderate drinking (< 15 drinks per week and < 5 per drinking day or 4 per drinking day for women) was associated with reduced risk for incident disability or death over 5 years, compared with abstention (adjusted odds ratio = 0.77; P = 0.008). Among survivors, light/moderate drinking was associated with lower risk for incident disability, compared with abstention (adjusted odds ratio = 0.75; P = 0.009). In stratified analyses, disability risk decreased with light/moderate drinking in a dose-dependent fashion in men and women with good or better self-reported health but not in men or women with fair or worse self-reported health. Alcohol consumption in moderation might reduce the risk of developing physical disability in older adults in good health but not in those in poor health.
C1 [Karlamangla, Arun S.; Kado, Deborah M.; Dedes, Howard; Liao, Diana H.; Kim, Sungjin; Reuben, David B.; Greendale, Gail A.; Moore, Alison A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Moore, AA (reprint author), Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM aamoore@mednet.ucla.edu
FU John A. Hartford Foundation/American Federation for Aging Research
Medical Student Geriatric Scholars Program; National Institute on
Alcohol Abuse and Alcoholism [R01-AA-013937, R01-AA-013990,
R01-DA-020944]; Claude D. Pepper Older Americans Independence Center;
National Institute on Aging [5P30 AG028748]
FX This work was supported by the John A. Hartford Foundation/American
Federation for Aging Research Medical Student Geriatric Scholars Program
(to H. D.); the National Institute on Alcohol Abuse and Alcoholism
(grants R01-AA-013937, R01-AA-013990, and R01-DA-020944 to A. A. M.);
and the Claude D. Pepper Older Americans Independence Center, National
Institute on Aging (grant 5P30 AG028748 to A. S. K.).
NR 45
TC 24
Z9 24
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JAN 1
PY 2009
VL 169
IS 1
BP 96
EP 104
DI 10.1093/aje/kwn294
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 390GL
UT WOS:000262152200012
PM 19022829
ER
PT J
AU Muddana, V
Whitcomb, DC
Khalid, A
Slivka, A
Papachristou, GI
AF Muddana, Venkata
Whitcomb, David C.
Khalid, Asif
Slivka, Adam
Papachristou, Georgios I.
TI Elevated Serum Creatinine as a Marker of Pancreatic Necrosis in Acute
Pancreatitis
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID INTRAVENOUS CONTRAST-MEDIUM; NECROTIZING PANCREATITIS;
COMPUTED-TOMOGRAPHY; RISK-FACTOR; HEMOCONCENTRATION; SEVERITY;
MICROCIRCULATION; ANTIPROTEASES; IMPAIRMENT; FAILURE
AB OBJECTIVES: Pancreatic necrosis is a serious complication of acute pancreatitis. The identification of simple laboratory tests to detect subjects at risk of pancreatic necrosis may direct management and improve outcome. This study focuses on the association between routine laboratory tests and the development of pancreatic necrosis in patients with acute pancreatitis.
METHODS: In a cohort of 185 patients with acute pancreatitis prospectively enrolled in the Severity of Acute Pancreatitis Study, patients with contrast-enhanced computerized tomography performed were selected (n = 129). Serum hematocrit, creatinine, and urea nitrogen on admission and peak values within 48 h of admission were analyzed. The volume of intravenous fluid resuscitation was calculated for each patient.
RESULTS: Of 129 patients, 35 (27%) had evidence of pancreatic necrosis. Receiver operating characteristic curves for pancreatic necrosis revealed an area under the curve of 0.79 for admission hematocrit, 0.77 for peak creatinine, and 0.72 for peak urea nitrogen. Binary logistic regression yielded that all three tests were significantly associated with pancreatic necrosis (P < 0.0001), with the highest odds ratio, 34.5, for peak creatinine. The volume of intravenous fluid resuscitation was similar in patients with and without necrosis. Low admission hematocrit (= 44.8%) yielded a negative predictive value of 89%; elevated peak creatinine (> 1.8 mg/dl) within 48 h yielded a positive predictive value of 93%.
CONCLUSIONS: We confirm that a low admission hematocrit indicates a low risk of pancreatic necrosis (PNec) in patients with acute pancreatitis. In contrast, an increase in creatinine within the first 48 h is strongly associated with the development of PNec. This finding may have important clinical implications and warrants further investigation.
C1 [Muddana, Venkata; Whitcomb, David C.; Khalid, Asif; Slivka, Adam; Papachristou, Georgios I.] Univ Pittsburgh, Sch Med, Dept Med, UPMC Presbyterian Hosp,Div Gastroenterol Hepatol, Pittsburgh, PA 15213 USA.
[Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA 15213 USA.
[Khalid, Asif; Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol, Dept Med, Pittsburgh, PA USA.
RP Papachristou, GI (reprint author), Univ Pittsburgh, Sch Med, Dept Med, UPMC Presbyterian Hosp,Div Gastroenterol Hepatol, Mezzanine Level 2,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM papachristoug@dom.pitt.edu
FU VA Stars and Stripes Healthcare Network 2007 Competitive Pilot Project
Fund (GIP); NIH [R01 DK61451]
FX This work was supported by the VA Stars and Stripes Healthcare Network
2007 Competitive Pilot Project Fund (GIP) and NIH R01 DK61451 (DCW).
NR 32
TC 47
Z9 53
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JAN
PY 2009
VL 104
IS 1
BP 164
EP 170
DI 10.1038/ajg.2008.66
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 391WV
UT WOS:000262265800027
PM 19098865
ER
PT J
AU Brandt, LJ
Chey, WD
Foxx-Orenstein, AE
Quigley, EMM
Schiller, LR
Schoenfeld, PS
Spiegel, BM
Talley, NJ
Moayyedi, P
AF Brandt, Lawrence J.
Chey, William D.
Foxx-Orenstein, Amy E.
Quigley, Eamonn M. M.
Schiller, Lawrence R.
Schoenfeld, Philip S.
Spiegel, Brennan M.
Talley, Nicholas J.
Moayyedi, Paul
TI An Evidence-Based Position Statement on the Management of Irritable
Bowel Syndrome
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
ID RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL;
INTESTINAL BACTERIAL OVERGROWTH; DOUBLE-BLIND TRIAL; 5-HT3 RECEPTOR
ANTAGONIST; PREDOMINANCE IBS-D; CORTICOTROPIN-RELEASING HORMONE; CHRONIC
IDIOPATHIC CONSTIPATION; COST-EFFECTIVENESS ANALYSIS
C1 [Brandt, Lawrence J.; Moayyedi, Paul] Montefiore Med Ctr, Div Gastroenterol, Bronx, NY 10467 USA.
[Chey, William D.] Univ Michigan Hlth Syst, Div Gastroenterol, Ann Arbor, MI USA.
[Foxx-Orenstein, Amy E.] Mayo Clin, Dept Internal Med, Div Gastroenterol & Hepatol, Rochester, MN USA.
[Quigley, Eamonn M. M.] Cork Univ Hosp, Dept Med, Cork, Ireland.
[Schiller, Lawrence R.] Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA.
[Schoenfeld, Philip S.] Vet Affairs Ann Arbor Healthcare Syst, Div Gastroenterol, Ann Arbor, MI USA.
[Spiegel, Brennan M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Talley, Nicholas J.] Mayo Clin, Dept Med, Jacksonville, FL 32224 USA.
[Moayyedi, Paul] McMaster Univ, Med Ctr, Div Gastroenterol, Dept Med, Hamilton, ON, Canada.
RP Brandt, LJ (reprint author), Montefiore Med Ctr, Div Gastroenterol, 111 E 210 St, Bronx, NY 10467 USA.
RI Talley, nicholas/D-5399-2013
OI Talley, nicholas/0000-0003-2537-3092
NR 320
TC 301
Z9 316
U1 7
U2 25
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JAN
PY 2009
VL 104
SU 1
BP S1
EP S36
DI 10.1038/ajg.2008.122
PG 36
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 391XB
UT WOS:000262266400001
ER
PT J
AU Frick, KD
Burton, LC
Clark, R
Mader, SI
Naughton, WB
Burl, JB
Greenough, WB
Steinwachs, DM
Leff, B
AF Frick, Kevin D.
Burton, Lynda C.
Clark, Rebecca
Mader, Scott I.
Naughton, W. Bruce
Burl, Jeffrey B.
Greenough, William B., III
Steinwachs, Donald M.
Leff, Bruce
TI Substitutive Hospital at Home for Older Persons: Effects on Costs
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; MINIMIZATION ANALYSIS; EARLY DISCHARGE;
INPATIENT INTERVENTIONS; CARE; HEALTH; PROGRAM
AB Objective:To compare the cost of substitutive Hospital at Home care versus traditional inpatient care for older patients with community-acquired pneumonia, exacerbation of chronic obstructive pulmonary disease, exacerbation of congestive heart failure, or cellulitis.
Study Design: Prospective nonrandomized clinical trial involving 455 community-dwelling older patients in 3 Medicare managed care health systems and at a Department of Veterans Affairs medical center.
Methods: Costs were analyzed across all patients, within each of the separate health systems, and by condition. Generalized linear models controlling for confounders and using a log link and gamma family specification were used to make inferences about the statistical significance of cost differences. tTests were used to make inferences regarding differences in follow-up utilization.
Results: The costs of the Hospital at Home intervention were significantly lower than those of usual acute hospital care (mean [SD], $5081 [$4427] vs $7480 [$8113]; P<.001). Laboratory and procedure expenditures were lower across all study sites and at each site individually. There were minimal significant differences in health service utilization between the study groups during the 8 weeks after the index hospitalization. As-treated analysis results were consistent with Hospital at Home costs being lower.
Conclusions: Total costs seem to be lower when substitutive Hospital at Home care is available for patients with congestive heart failure or chronic obstructive pulmonary disease. This result may be related to the study-based requirement for continuous nursing input. Savings may be possible, particularly for care of conditions that typically use substantial laboratory tests and procedures in traditional acute settings.
C1 [Frick, Kevin D.; Burton, Lynda C.; Clark, Rebecca; Naughton, W. Bruce; Steinwachs, Donald M.; Leff, Bruce] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
[Mader, Scott I.] Portland VA Med Ctr, Portland, OR USA.
[Mader, Scott I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Naughton, W. Bruce] SUNY Buffalo, Buffalo, NY 14260 USA.
[Burl, Jeffrey B.] Fallon Clin Inc, Worcester, MA USA.
[Naughton, W. Bruce; Leff, Bruce] Johns Hopkins Sch Med, Baltimore, MD USA.
RP Frick, KD (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 624 N Broadway,Rm 606, Baltimore, MD 21205 USA.
EM kfrick@jhsph.edu
FU John A. Hartford Foundation of New York [98309-G]; Department of
Veterans Affairs New Clinical Initiative [99-027a]
FX This study was supported by grant 98309-G from the John A. Hartford
Foundation of New York and was supplemented at Portland Veterans Affairs
Medical Center by Department of Veterans Affairs New Clinical Initiative
Program grant 99-027a.
NR 32
TC 9
Z9 9
U1 1
U2 1
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JAN
PY 2009
VL 15
IS 1
BP 49
EP 56
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 400HA
UT WOS:000262857400005
PM 19146364
ER
PT J
AU Smith, MEB
Desai, SS
Allen, ES
Saha, S
Hunter, AJ
AF Smith, M. E. Beth
Desai, Sima S.
Allen, Elizabeth S.
Saha, Somnath
Hunter, Alan J.
TI Impact of Shorter Inpatient Faculty Rotations on Resident Learning
Experience
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article; Proceedings Paper
CT National Meeting of the Alliance-for-Academic-Internal-Medicine
CY OCT, 2006
CL New Orleans, LA
SP Alliance Acad Internal Med
ID MEDICAL-EDUCATION; FACTORIAL VALIDATION; PHYSICIAN BURNOUT;
INTERNAL-MEDICINE; CARE; STRATEGIES; FRAMEWORK; PROGRAM; NIH
C1 [Smith, M. E. Beth] Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, Portland, OR 97239 USA.
[Desai, Sima S.; Hunter, Alan J.] Oregon Hlth & Sci Univ, Div Hosp Med, Dept Med, Portland, OR 97239 USA.
[Allen, Elizabeth S.; Saha, Somnath] Portland VA Med Ctr, Div Gen Med & Geriatr, Portland, OR USA.
RP Smith, MEB (reprint author), Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, 3181 SW Sam Jackson Pk Rd,Mail Code CH9G, Portland, OR 97239 USA.
EM smithbet@ohsu.edu
NR 21
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD JAN
PY 2009
VL 122
IS 1
BP 96
EP 100
DI 10.1016/j.amjmed.2008.09.031
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 387XZ
UT WOS:000261986200018
PM 19114177
ER
PT J
AU Shlipak, MG
Katz, R
Kestenbaum, B
Fried, LF
Newman, AB
Siscovick, DS
Stevens, L
Sarnak, MJ
AF Shlipak, Michael G.
Katz, Ronit
Kestenbaum, Bryan
Fried, Linda F.
Newman, Anne B.
Siscovick, David S.
Stevens, Lesley
Sarnak, Mark J.
TI Rate of Kidney Function Decline in Older Adults: A Comparison Using
Creatinine and Cystatin C
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Glomerular filtration rate; Creatinine; Cystatin C; Chronic kidney
disease
ID GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; STAGE RENAL-DISEASE;
CARDIOVASCULAR EVENTS; MORTALITY RISK; SERUM CREATININE; PROGRESSION;
GFR; FAILURE; DEATH
AB Background/Aims: The aim of this study was to determine the decline in the estimated glomerular filtration rate (eGFR) in elderly persons and to compare estimates based on creatinine and cystatin C. Methods: In the Cardiovascular Health Study, GFR changes in an elderly cohort were estimated from serum creatinine and cystatin C measured at baseline, year 3 and year 7 in 4,380 participants (age 72 +/- 5 years at entry). Outcomes were mean eGFR decline, incident chronic kidney disease (CKD) and rapid decline in eGFR (annual loss >3 ml/min/1.73 m(2)). Results: Mean annual eGFR loss as estimated from creatinine was 0.4 +/- 3.6 ml/min/1.73 m(2), with 16% of the participants experiencing a rapid decline. Mean eGFR loss as estimated from cystatin C was 1.8 +/- 2.6, with 25% of the participants experiencing a rapid decline (p<0.001 for both). Among participants without baseline CKD, incident CKD was detected at year 7 in 10% (n=263) using creatinine and 19% (n=544) using cystatin C (p<0.001). Increasing age was the strongest predictor of rapid decline; adjusted odds ratios were 1.38 (1.16-1.65), 1.62 (1.31-1.99) and 2.96 (2.28-3.84) for participants aged 70-74, 75-79 and 80+ at baseline, compared with those aged 65-69. Conclusion: In elderly persons, cystatin C estimated substantially larger declines in kidney function than creatinine did. Defining the optimal measurement of kidney function in elderly persons should be a high priority for future research. Copyright (C) 2009 S. Karger AG, Basel
C1 [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Dept Biostat, Seattle, WA 98195 USA.
[Kestenbaum, Bryan] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA.
[Fried, Linda F.] Univ Pittsburgh, Grad Sch Publ Hlth, Renal Sect, Med Serv,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA.
[Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Stevens, Lesley; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA USA.
RP Shlipak, MG (reprint author), VA Med Ctr 111A1, Gen Internal Med Sect, 4150 Clement St, San Francisco, CA 94121 USA.
EM michael.shlipak@ucsf.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Heart, Lung and Blood Institute (NHLBI) [R01 HL073208-01, R01
DK066488]; National Institute of Diabetes and Digestive and Kidney
Diseases; National Institutes of Health [R01AG027002, K24DK078204-01];
NHLBI [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103]
FX This work was supported by contracts R01 HL073208-01 and R01 DK066488
from the National Heart, Lung and Blood Institute (NHLBI) and the
National Institute of Diabetes and Digestive and Kidney Diseases,
respectively. In addition, this work was supported by the American
Federation for Aging Research by a Paul Beeson Scholars Program award
and R01AG027002 and K24DK078204-01 from the National Institutes of
Health. The CHS is supported by contracts N01-HC-85079 through
N01-HC-85086, N01-HC-35129, and N01 HC-15103 from the NHLBI. This study
was funded through contracts with the NHLBI and included substantial
NHLBI involvement in data collection, analysis and interpretation, as
well as manuscript preparation. A full list of participating CHS
investigators and institutions can be found at http://www.chs-nhlbi.org.
NR 27
TC 60
Z9 63
U1 1
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2009
VL 30
IS 3
BP 171
EP 178
DI 10.1159/000212381
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 485PN
UT WOS:000269136000001
PM 19349699
ER
PT J
AU Fried, LF
Katz, R
Cushman, M
Sarnak, M
Shlipak, MG
Kuller, L
Newman, AB
AF Fried, Linda F.
Katz, Ronit
Cushman, Mary
Sarnak, Mark
Shlipak, Michael G.
Kuller, Lewis
Newman, Anne B.
TI Change in Cardiovascular Risk Factors with Progression of Kidney Disease
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article; Proceedings Paper
CT 46th Annual Conference on Cardiovascular Disease Epidemiology and
Prevention
CY MAR 02-05, 2006
CL Phoenix, AZ
SP Amer Heart Assoc, Natl Heart, Lung & Blood Inst
DE Cardiovascular risk factors; Chronic kidney disease; Disease
progression; Inflammation; Lipids
ID C-REACTIVE PROTEIN; RENAL-INSUFFICIENCY; VENOUS THROMBOEMBOLISM; ELDERLY
PERSONS; CYSTATIN-C; MORTALITY; HEALTH; ATHEROSCLEROSIS; INFLAMMATION;
CLEARANCE
AB Background: Prior studies evaluating the relationship of kidney disease with cardiovascular risk factors have been limited by their cross-sectional design. We evaluated the change in lipids, inflammatory and procoagulant biomarkers with decline in kidney function in a nested case-cohort study in the Cardiovascular Health Study, a community-based study of adults aged >65 years. Methods: Individuals with an increase in serum creatinine >= 0.3 mg/dl (baseline to 3 years later, n = 207) were matched to controls of similar age, race, gender, diabetes and baseline serum creatinine, but whose change in creatinine was <0.3 mg/dl. Baseline and change in risk factors were analyzed with conditional logistic regression. Results: Changes in C-reactive protein were similar. In contrast, cases had larger increases in fibrinogen (OR 1.38 per standard deviation, 95% confidence interval 1.08-1.76) and factor VIII [1.38 (1.10-1.72)] and larger decreases in HDL [OR 0.80 (0.64, 1.00)]. Change in interleukin-6 was greater in cases than controls, but this did not persist after multivariate adjustment. However, in linear regression, change in interleukin-6 was correlated with change in creatinine. Conclusion: Cardiovascular risk factors and kidney function may change concurrently. This could lead to an increased risk of cardiovascular disease as kidney function worsens. Copyright (C) 2008 S. Karger AG, Basel
C1 [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr Div, Pittsburgh, PA 15240 USA.
[Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Fried, Linda F.; Kuller, Lewis; Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Katz, Ronit] Univ Washington, Coordinating Ctr, Seattle, WA 98195 USA.
[Cushman, Mary] Univ Vermont, Dept Med, Thrombosis & Hemostasis Program, Burlington, VT 05401 USA.
[Sarnak, Mark] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Fried, LF (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr Div, Mailstop 111F-U, Pittsburgh, PA 15240 USA.
EM linda.fried@va.gov
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU NHLBI NIH HHS [N01 HC015103, N01 HC-55222, N01 HC035129, N01 HC045133,
N01-HC-75150, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082,
N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01HC55222,
N01HC75150, N01HC85079, N01HC85086, U01 HL080295]; NIA NIH HHS [R01
AG027002]
NR 31
TC 7
Z9 8
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2009
VL 29
IS 4
BP 334
EP 341
DI 10.1159/000166598
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 375RX
UT WOS:000261132100007
PM 18948687
ER
PT J
AU Jolly, SE
Li, S
Chen, SC
Narva, AS
Jurkovitz, CT
Norris, KC
Shlipak, MG
AF Jolly, Stacey E.
Li, Suying
Chen, Shu-Cheng
Narva, Andrew S.
Jurkovitz, Claudine T.
Norris, Keith C.
Shlipak, Michael G.
TI Risk Factors for Chronic Kidney Disease among American Indians and
Alaska Natives - Findings from the Kidney Early Evaluation Program
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Chronic kidney disease; Risk factors; American Indians; Alaska Natives
ID GLOMERULAR-FILTRATION-RATE; TYPE-2 DIABETES-MELLITUS; SERUM CREATININE
VALUES; STAGE RENAL-DISEASE; UNITED-STATES; COLLABORATIVE APPROACH;
NATIONAL-HEALTH; HEART-FAILURE; PIMA-INDIANS; FOLLOW-UP
AB Background: American Indians and Alaska Natives (AIAN) have a high incidence of end-stage renal disease. Less is known about chronic kidney disease (CKD) among AIAN and whether risk factors differ for low estimated glomerular filtration rate (eGFR) versus albuminuria with a normal eGFR. Methods: Cross-sectional study examining the associations of age, sex, smoking, obesity, diabetes, hypertension, family history, and geographic region with CKD among a screened population of AIAN participants in the Kidney Early Evaluation Program from 2000 to 2006. CKD was defined by the presence of either a low eGFR, < 60 ml/min/1.73 m(2), or albuminuria, a urine albumin/creatinine ratio >= 30 mg/g. Results: The prevalence of any CKD was 29%, of low eGFR was 17%, and of albuminuria with a normal eGFR was 12%. Older age was the strongest predictor of low eGFR (61+ years OR 8.42, 95% Cl 5.92-11.98), followed by hypertension (OR 2.38, 95% Cl 1.74-3.26). In contrast, diabetes (OR 2.04, 95% Cl 1.57-2.64) and hypertension (OR 2.63, 95% Cl 1.93-3.59) were the only predictors of albuminuria among persons with a normal eGFR. Conclusion: The burden of CKD was high among this screened population of AIAN, and different risk factor patterns were associated with low eGFR and albuminuria. Innovative programs and longitudinal research are needed to address CKD among AIAN. Copyright (c) 2008 S. Karger AG, Basel
C1 [Jolly, Stacey E.; Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Li, Suying; Chen, Shu-Cheng] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA.
[Narva, Andrew S.] NIDDK, Bethesda, MD USA.
[Jurkovitz, Claudine T.] Christiana Care Hlth Syst, Ctr Outcomes Res, Newark, DE USA.
[Norris, Keith C.] Charles R Drew Univ, Dept Internal Med, Los Angeles, CA USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Jolly, SE (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Campus Mailbox 1364, San Francisco, CA 94143 USA.
EM stacey.jolly@ucsf.edu
FU Health Resources and Services Administration Faculty Development
[D55HP05165]; American Heart Association's Established Investigator;
[R01-DK066488]; [R01-AG027002]
FX Dr. Jolly was supported by Health Resources and Services Administration
Faculty Development in Primary Care Grant D55HP05165 for this study. Dr.
Shlipak's effort on this paper was supported by R01-DK066488,
R01-AG027002, and the American Heart Association's Established
Investigator Award.
NR 32
TC 9
Z9 9
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2009
VL 29
IS 5
DI 10.1159/000174857
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 428SO
UT WOS:000264870200014
PM 19011277
ER
PT J
AU Slack, D
Nelson, L
Patterson, D
Burns, S
Hakimi, K
Robinson, L
AF Slack, David
Nelson, Lonnie
Patterson, David
Burns, Stephen
Hakimi, Kevin
Robinson, Lawrence
TI The Feasibility of Hypnotic Analgesia in Ameliorating Pain and Anxiety
Among Adults Undergoing Needle Electromyography
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Electromyography (EMG); Hypnosis; Hypnotic Analgesia
ID HYPNOSIS; PERCEPTION; ABSORPTION; DISTRESS; OPENNESS; CANCER
AB Objective: Our hypothesis was that hypnotic analgesia reduces pain and anxiety during electromyography (EMG).
Design: We performed a prospective randomized, controlled clinical trial at outpatient electrodiagnostic clinics in teaching hospitals. Just before EMG, 26 subjects were randomized to one of three 20-min audio programs: education about EMG (EDU) (n = 8); hypnotic induction without analgesic suggestion (n = 10); or hypnotic induction with analgesic suggestion (n = 8). The blinded electromyographer provided a posthypnotic suggestion at the start of EMG. After EMG, subjects rated worst and average pain and anxiety using visual analog scales.
Results: Mean values for the EDU, hypnotic induction without analgesic suggestion, and hypnotic induction with analgesic suggestion groups were not significantly different (mean +/- SD): worst pain 67 +/- 25, 42 +/- 18, and 49 +/- 30; average pain 35 +/- 26, 27 +/- 14, and 25 +/- 22; and anxiety 44 +/- 41, 42 +/- 23, and 22 +/- 24. When hypnosis groups were merged (n = 18) and compared with the EDU condition (n = 8), average and worst pain and anxiety were less for the hypnosis group than EDU, but this was statistically significant only for worst pain (hypnosis, 46 +/- 24 vs. EDU, 67 +/- 35; P = 0.049) with a 31% average reduction.
Conclusions: A short hypnotic induction seems to reduce worst pain during electromyography.
C1 [Nelson, Lonnie; Patterson, David; Burns, Stephen; Hakimi, Kevin; Robinson, Lawrence] Univ Washington, Harborview Med Ctr, Sch Med,Dept Rehabil Med, Electrodiagnost Clin, Seattle, WA 98195 USA.
[Slack, David] Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, Electrodiagnost Clin, Seattle, WA USA.
RP Robinson, L (reprint author), Univ Washington, Harborview Med Ctr, Sch Med,Dept Rehabil Med, Electrodiagnost Clin, Box 356380, Seattle, WA 98195 USA.
FU National Institutes of Health [R01 GM42725-09A1]
FX This study was supported in part by grant R01 GM42725-09A1 from the
National Institutes of Health.
NR 24
TC 10
Z9 10
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD JAN
PY 2009
VL 88
IS 1
BP 21
EP 29
DI 10.1097/PHM.0b013e31818e00bd
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 388NS
UT WOS:000262027100004
PM 18971768
ER
PT J
AU Quinn, LS
Anderson, BG
Strait-Bodey, L
Stroud, AM
Argiles, JM
AF Quinn, LeBris S.
Anderson, Barbara G.
Strait-Bodey, Lena
Stroud, Ashley M.
Argiles, Josep M.
TI Oversecretion of interleukin-15 from skeletal muscle reduces adiposity
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE adipose tissue; obesity; cytokines; adipokines; myokines; bone; skeletal
muscle; interleukin-15; body composition
ID MECHANISMS LINKING OBESITY; TUMOR-BEARING RATS; INSULIN-RESISTANCE;
BODY-COMPOSITION; TRANSGENIC MICE; NATURAL-KILLER; ENERGY-BALANCE;
CRUCIAL ROLE; FAT; IL-15
AB Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argiles JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 296: E191-E202, 2009. First published November 11, 2008; doi: 10.1152/ajpendo.90506.2008.-Obesity is a risk factor for development of insulin resistance, type 2 diabetes, cardiovascular disease, osteoarthritis, and some forms of cancer. Many of the adverse health consequences of excess fat deposition are caused by increased secretion of proinflammatory adipokines by adipose tissue. Reciprocal muscle-to-fat signaling factors, or myokines, are starting to be identified. Interleukin-15 (IL-15) is a cytokine that is highly expressed in muscle tissue and that, on the basis of cell culture experiments, has been proposed to act as a circulating myokine that inhibits adipose tissue deposition. To test this hypothesis in vivo, two lines of transgenic mice that overexpressed IL-15 mRNA and protein in skeletal muscle tissue were constructed. By substitution of the inefficient native IL-15 signal peptide with a more efficient signal peptide, one of the transgenic mouse lines also exhibited elevated secretion of IL-15 in the circulation. Overexpression of IL-15 in muscle tissue without secretion in the bloodstream resulted in no differences in body composition. Elevated circulating levels of IL-15 resulted in significant reductions in body fat and increased bone mineral content, without appreciably affecting lean body mass or levels of other cytokines. Elevated circulating levels of IL-15 also inhibited adiposity induced by consumption of a high-fat/high-energy diet in male, but not female, transgenic mice. Female mice with elevated serum IL-15 exhibited increased deposition of lean body mass on a low-fat/low-energy diet and a high-fat/high-energy diet. These findings indicate that muscle-derived circulating IL-15 can modulate adipose tissue deposition and support addition of IL-15 to the growing list of potential myokines that are increasingly being implicated in regulation of body composition.
C1 [Quinn, LeBris S.] VA Puget Sound Hlth Care Syst, Amer Lake Div 151, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA.
[Strait-Bodey, Lena; Stroud, Ashley M.] VA Puget Sound Hlth Care Syst, Res Serv, Tacoma, WA 98493 USA.
[Quinn, LeBris S.; Anderson, Barbara G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
[Quinn, LeBris S.; Stroud, Ashley M.] Seattle Inst Biomed & Clin Res, Seattle, WA USA.
[Argiles, Josep M.] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Barcelona, Spain.
RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div 151, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA.
EM quinnL@u.washington.edu
FU United States Department of Agriculture Cooperative State Research,
Education [2005-35206-15264]; National Institute on Aging (NIA)
[RO1AG-024136, 5P30AG-013280]; National Institute of Diabetes and
Digestive and Kidney Diseases [5P30DK-17047]
FX This work was supported by National Research Initiative Competitive
Grant no. 2005-35206-15264 from the United States Department of
Agriculture Cooperative State Research, Education, and Extension Service
Animal Growth and Nutrient Utilization Program to L. S. Quinn, National
Institute on Aging (NIA) Grant RO1AG-024136 ( L. S. Quinn), the
Transgenic Resource Core of the University of Washington Nathan Shock
Center of Excellence in the Basic Biology of Aging (NIA Grant
5P30AG-013280), the Molecular Genetics Core of the University of
Washington Diabetes Endocrinology Research Center ( National Institute
of Diabetes and Digestive and Kidney Diseases Grant 5P30DK-17047), and
by use of resources and facilities at the Veterans Affairs Puget Sound
Health Care System, Seattle/Tacoma, WA.
NR 74
TC 73
Z9 79
U1 0
U2 12
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JAN
PY 2009
VL 296
IS 1
BP E191
EP E202
DI 10.1152/ajpendo.90506.2008
PG 12
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 388XU
UT WOS:000262054400022
PM 19001550
ER
PT J
AU Bem, RA
van Woensel, JBM
Bos, AP
Koski, A
Farnand, AW
Domachowske, JB
Rosenberg, HF
Martin, TR
Matute-Bello, G
AF Bem, Reinout A.
van Woensel, Job B. M.
Bos, Albert P.
Koski, Amy
Farnand, Alex W.
Domachowske, Joseph B.
Rosenberg, Helene F.
Martin, Thomas R.
Matute-Bello, Gustavo
TI Mechanical ventilation enhances lung inflammation and caspase activity
in a model of mouse pneumovirus infection
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE respiratory syncytial virus; acute lung injury
ID RESPIRATORY SYNCYTIAL VIRUS; EPITHELIAL-CELL APOPTOSIS; TIDAL VOLUME
VENTILATION; DISTRESS-SYNDROME; PNEUMONIA VIRUS; ORGAN DYSFUNCTION;
VIRAL BRONCHIOLITIS; CYTOKINE RESPONSE; FAS LIGAND; RAT LUNGS
AB Bem RA, van Woensel JB, Bos AP, Koski A, Farnand AW, Domachowske JB, Rosenberg HF, Martin TR, Matute-Bello G. Mechanical ventilation enhances lung inflammation and caspase activity in a model of mouse pneumovirus infection. Am J Physiol Lung Cell Mol Physiol 296: L46-L56, 2009. First published November 7, 2008; doi:10.1152/ajplung.00467.2007.-Severe infection with respiratory syncytial virus (RSV) in children can progress to respiratory distress and acute lung injury (ALI). Accumulating evidence suggests that mechanical ventilation (MV) is an important cofactor in the development of ALI by modulating the host immune responses to bacteria. This study investigates whether MV enhances the host response to pneumonia virus of mice (PVM), a mouse pneumovirus that has been used as a model for RSV infection in humans. BALB/c mice were inoculated intranasally with diluted clarified lung homogenates from mice infected with PVM strain J3666 or uninfected controls. Four days after inoculation, the mice were subjected to 4 h of MV (tidal volume, 10 ml/kg) or allowed to breathe spontaneously. When compared with that of mice inoculated with PVM only, the administration of MV to PVM-infected mice resulted in increased bronchoalveolar lavage fluid concentrations of the cytokines macrophage inflammatory protein (MIP)-2, MIP-1 alpha (CCL3), and IL-6; increased alveolar-capillary permeability to high molecular weight proteins; and increased caspase-3 activity in lung homogenates. We conclude that MV enhances the activation of inflammatory and caspase cell death pathways in response to pneumovirus infection. We speculate that MV potentially contributes to the development of lung injury in patients with RSV infection.
C1 [Bem, Reinout A.; van Woensel, Job B. M.; Bos, Albert P.] Univ Amsterdam, Acad Med Ctr, Pediat Intens Care Unit, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands.
[Koski, Amy; Martin, Thomas R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Farnand, Alex W.; Matute-Bello, Gustavo] Univ Washington, Sch Med, Dept Med, Ctr Lung Biol,Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Domachowske, Joseph B.] SUNY Upstate Med Univ, Syracuse, NY USA.
[Rosenberg, Helene F.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA.
RP Matute-Bello, G (reprint author), Univ Washington Med, S Lake Union Campus,815 Mercer St,Box 358052, Seattle, WA 98109 USA.
FU National Heart, Lung, and Blood Institute [HL-083044, HL-073996];
American Lung Association
FX This work was supported in part by National Heart, Lung, and Blood
Institute Grants HL-083044 and HL-073996 and by the American Lung
Association.
NR 57
TC 21
Z9 22
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JAN
PY 2009
VL 296
IS 1
BP L46
EP L56
DI 10.1152/ajplung.00467.2007
PG 11
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA 388YR
UT WOS:000262056900007
PM 18996903
ER
PT J
AU Figlewicz, DP
Benoit, SC
AF Figlewicz, Dianne P.
Benoit, Stephen C.
TI Insulin, leptin, and food reward: update 2008
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
PHYSIOLOGY
LA English
DT Review
DE motivation; food intake; dopamine
ID CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; MELANIN-CONCENTRATING
HORMONE; HYPOTHALAMIC NEUROPEPTIDE-Y; VENTRAL TEGMENTAL AREA; OBESE
ZUCKER RATS; CONDITIONED PLACE PREFERENCE; RECEPTOR MESSENGER-RNA;
AGOUTI-RELATED PEPTIDE; MODERATE-FAT DIET
AB Figlewicz DP, Benoit SC. Insulin, leptin, and food reward: update 2008. Am J Physiol Regul Integr Comp Physiol 296: R9-R19, 2009. First published October 22, 2008; doi:10.1152/ajpregu.90725.2008.- The hormones insulin and leptin have been demonstrated to act in the central nervous system (CNS) as regulators of energy homeostasis at medial hypothalamic sites. In a previous review, we described new research demonstrating that, in addition to these direct homeostatic actions at the hypothalamus, CNS circuitry that subserves reward and motivation is also a direct and an indirect target for insulin and leptin action. Specifically, insulin and leptin can decrease food reward behaviors and modulate the function of neurotransmitter systems and neural circuitry that mediate food reward, i.e., midbrain dopamine and opioidergic pathways. Here we summarize new behavioral, systems, and cellular evidence in support of this hypothesis and in the context of research into the homeostatic roles of both hormones in the CNS. We discuss some current issues in the field that should provide additional insight into this hypothetical model. The understanding of neuroendocrine modulation of food reward, as well as food reward modulation by diet and obesity, may point to new directions for therapeutic approaches to overeating or eating disorders.
C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA.
[Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Benoit, Stephen C.] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA.
RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 So Columbian Way, Seattle, WA 98108 USA.
EM latte@u.washington.edu
FU Department of Veterans Affairs; National Institute of Diabetes and
Digestive and Kidney Diseases [DK-40963, DK-066223]
FX This work is supported by a Career Scientist Award from the Department
of Veterans Affairs and National Institute of Diabetes and Digestive and
Kidney Diseases Grants DK-40963 (D. P. Figlewicz, Lattemann) and
DK-066223 (S. C. Benoit).
NR 198
TC 102
Z9 104
U1 5
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD JAN
PY 2009
VL 296
IS 1
BP R9
EP R19
DI 10.1152/ajpregu.90725.2008
PG 11
WC Physiology
SC Physiology
GA 388YM
UT WOS:000262056300002
PM 18945945
ER
PT J
AU Nazeer, K
Janech, MG
Lin, JJC
Ryan, KJ
Arthur, JM
Budisavljevic, MN
AF Nazeer, Khurram
Janech, Michael G.
Lin, Jim J. -C.
Ryan, Kevin J.
Arthur, John M.
Budisavljevic, Milos N.
TI Changes in protein profiles during course of experimental
glomerulonephritis
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE two-dimensional electrophoresis; mass spectrometry; anti-Thy-1
glomerulonephritis; tropomyosin
ID MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS; SMOOTH MUSCLE ACTIN;
TROPOMYOSIN ISOFORMS; EXPRESSION; CELLS; CYTOSKELETON; PROGRESSION;
MICROARRAY; NEPHRITIS; INJURY
AB Nazeer K, Janech MG, Lin JJ, Ryan KJ, Arthur JM, Budisavljevic MN. Changes in protein profiles during course of experimental glomerulonephritis. Am J Physiol Renal Physiol 296: F186-F193, 2009. First published November 5, 2008; doi: 10.1152/ajprenal.90222.2008. Better characterization of the molecular mechanisms underlying glomerular cell proliferation may improve our understanding of the pathogenesis of glomerulonephritis and yield disease-specific markers. We used two-dimensional gel electrophoresis (2DE) and mass spectrometry (MS) to generate expression profiles of glomerular proteins in the course of anti-Thy-1 nephritis. Glomeruli were isolated from Wistar rats by sieving, and proteins were separated by 2DE. In preliminary studies using normal rats, we identified known glomerular proteins from microfilaments [tropomyosin (Tm)] and intermediate filaments (vimentin and lamin A), proteins involved in assembly (alpha-actinin-4, F-actin capping protein) and membrane cytoskeletal linking (ezrin), as well as several enzymes (protein disulfide isomerase, ATP synthase, and aldehyde dehydrogenase). Comparison of glomerular protein abundance between normal rats and rats in the early phase of anti-Thy-1 nephritis yielded 28 differentially expressed protein spots. MS analysis identified 16 differentially expressed proteins including Tm. Altered Tm abundance in the course of anti-Thy-1 nephritis was confirmed, and specific isoforms were characterized by Western blotting. We demonstrated a complex change in Tm isoform abundance in the course of anti-Thy-1 nephritis. The early mesangiolytic phase of the disease was characterized by decreased abundance of low-molecular-weight isoforms Tm5a/5b and increased abundance of high-molecular-weight isoforms Tm6, Tm1, Tm2, and Tm3. The late proliferative phase of the disease was associated with increased abundance of isoforms Tm5a/5b, Tm6, and Tm1 and decreased abundance of Tm3. Isoforms Tm4 and Tm5 remained unchanged in the course of this model of experimental glomerulonephritis. Characterization of Tm isoform abundance in the course of clinical glomerulonephritis may identify disease-specific markers.
C1 [Janech, Michael G.; Ryan, Kevin J.; Arthur, John M.; Budisavljevic, Milos N.] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA.
[Nazeer, Khurram] Univ Louisville, Dept Med, Louisville, KY 40292 USA.
[Lin, Jim J. -C.] Univ Iowa, Dept Biol Sci, Iowa City, IA USA.
[Janech, Michael G.; Arthur, John M.; Budisavljevic, Milos N.] Ralph H Johnson Dept Vet Affairs Med Ctr, Dept Med, Charleston, SC USA.
RP Budisavljevic, MN (reprint author), Med Univ S Carolina, Div Nephrol, Dept Med, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.
EM budisamn@musc.edu
OI Janech, Michael/0000-0002-3202-4811
FU Department of Veterans Affairs; Dialysis Clinics, Inc [DCI 2340]
FX Support for this project came from the Department of Veterans Affairs
and Grant DCI 2340 from Dialysis Clinics, Inc.
NR 20
TC 8
Z9 10
U1 1
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD JAN
PY 2009
VL 296
IS 1
BP F186
EP F193
DI 10.1152/ajprenal.90222.2008
PG 8
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 389NU
UT WOS:000262101200021
PM 18987115
ER
PT J
AU Eisenman, DP
Glik, D
Ong, M
Zhou, Q
Tseng, CH
Long, A
Fielding, J
Asch, S
AF Eisenman, David P.
Glik, Deborah
Ong, Michael
Zhou, Qiong
Tseng, Chi-Hong
Long, Anna
Fielding, Jonathan
Asch, Steven
TI Terrorism-Related Fear and Avoidance Behavior in a Multiethnic Urban
Population
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID SEPTEMBER 11; ATTACKS; BIOTERRORISM; PREPAREDNESS; STRESS; HEALTH;
EXPERIENCES; RISK
AB Objectives. We sought to determine whether groups traditionally most vulnerable to disasters would be more likely than would be others to perceive population level risk as high (as measured by the estimated color-coded alert level) would worry more about terrorism, and would avoid activities because of terrorism concerns.
Methods. We conducted a random digit dial survey of the Los Angeles County population October 2004 through January 2005 in 6 languages. We asked respondents what color alert level the country was under, how often they worry about terrorist attacks, and how often they avoid activities because of terrorism. Multivariate regression modeled correlates of worry and avoidance, including mental illness, disability, demographic factors, and estimated color-coded alert level.
Results. Persons who are mentally ill, those who are disabled, African Americans, Latinos, Chinese Americans, Korean Americans, and non-US citizens were more likely to perceive population-level risk as high, as measured by the estimated color-coded alert level. These groups also reported more worry and avoidance behaviors because of concerns about terrorism.
Conclusions. Vulnerable populations experience a disproportionate burden of the psychosocial impact of terrorism threats and our national response. Further studies should investigate the specific behaviors affected and further elucidate disparities in the disaster burden associated with terrorism and terrorism policies. (Am J Public Health. 2009;99:168-174. doi:10.2105/AJPH. 2007.124206)
C1 [Eisenman, David P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA.
[Eisenman, David P.; Asch, Steven] RAND Corp, Santa Monica, CA USA.
[Glik, Deborah; Fielding, Jonathan] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Asch, Steven] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Long, Anna; Fielding, Jonathan] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
RP Eisenman, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA.
EM deisenman@mednet.ucla.edu
RI Ong, Michael/F-7397-2013
FU Centers for Disease Control and Prevention [UB90/CCU917012-06,
K01-CD000049-02]
FX Funding for this study was provided to D. P. Eisenman through a grant to
the Los Angeles County Department of Public Health from the Centers for
Disease Control and Prevention (UB90/CCU917012-06) and from another
award to D. P. Eisenman from the Centers for Disease Control and
Prevention (K01-CD000049-02).
NR 45
TC 20
Z9 21
U1 2
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JAN
PY 2009
VL 99
IS 1
BP 168
EP 174
DI 10.2105/AJPH.2007.124206
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 391OA
UT WOS:000262241400027
PM 19008521
ER
PT J
AU Badesch, DB
Feldman, J
Keogh, A
Mathier, MA
Oudiz, RJ
Shapiro, S
Farber, H
McGoon, M
Frost, A
Rubin, LJ
AF Badesch, D. B.
Feldman, J.
Keogh, A.
Mathier, M. A.
Oudiz, R. J.
Shapiro, S.
Farber, H.
McGoon, M.
Frost, A.
Rubin, L. J.
CA ARIES-3 Study Grp
TI ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with
Pulmonary Hypertension
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Badesch, D. B.] Univ Colorado, Denver, CO 80202 USA.
[Feldman, J.] Arizona Pulm Specialists Ltd, Phoenix, AZ USA.
[Keogh, A.] St Vincents Hosp, Sydney, NSW 2010, Australia.
[Mathier, M. A.] Univ Pittsburgh, Pittsburgh, PA USA.
[Oudiz, R. J.] Harbor UCLA, LA Biomed Res Inst, Torrance, CA USA.
[Shapiro, S.] VA Greater LA Healthcare Syst, Los Angeles, CA USA.
[Shapiro, S.] David Geffen UCLA Sch Med, Los Angeles, CA USA.
[Farber, H.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[McGoon, M.] Mayo Clin, Rochester, MN USA.
[Frost, A.] Baylor Coll Med, Houston, TX 77030 USA.
[Rubin, L. J.] UCSD, La Jolla, CA USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A3357
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733102592
ER
PT J
AU Chandrasena, AR
Ho, G
Araujo, L
Mao, Y
Pan, J
Frank, JA
AF Chandrasena, A. R.
Ho, G.
Araujo, L.
Mao, Y.
Pan, J.
Frank, J. A.
TI Regulation of Paracellular Transport by Differential Claudin Expression
in Alveolar Epithelial Cells.
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Chandrasena, A. R.; Ho, G.; Araujo, L.; Pan, J.; Frank, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Chandrasena, A. R.; Frank, J. A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Mao, Y.; Frank, J. A.] NCIRE VHRI, San Francisco, CA USA.
EM anita.chandrasena@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A3560
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733102794
ER
PT J
AU Conhaim, RL
Watson, KE
Dovi, WF
Harms, BA
AF Conhaim, R. L.
Watson, K. E.
Dovi, W. F.
Harms, B. A.
TI Microthrombus Formation Continues in Rat Lungs for up to 24 Hours
Following Acute Hemorrhage
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Conhaim, R. L.; Watson, K. E.; Harms, B. A.] Univ Wisconsin, Sch Med, Madison, WI USA.
[Dovi, W. F.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A3870
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733103223
ER
PT J
AU Coppersmith, JC
Gylys-Colwell, IM
Dougherty, CM
Schneider, C
Hunziker, J
Short, V
Sablinsky, M
Steele, BG
AF Coppersmith, J. C.
Gylys-Colwell, I. M.
Dougherty, C. M.
Schneider, C.
Hunziker, J.
Short, V.
Sablinsky, M.
Steele, B. G.
TI Combined Rehabilitation Program for Chronic Obstructive Pulmonary
Disease (COPD) and Heart Failure (HF).
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Coppersmith, J. C.; Gylys-Colwell, I. M.; Schneider, C.; Hunziker, J.; Short, V.; Sablinsky, M.; Steele, B. G.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Dougherty, C. M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A2370
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733101489
ER
PT J
AU de Molina, RMM
Mortensen, EM
Copeland, LA
Pugh, MJV
Anzueto, A
Restrepo, MI
AF de Molina, R. M. Malo
Mortensen, E. M.
Copeland, L. A.
Pugh, M. J. V.
Anzueto, A.
Restrepo, M. I.
TI Outpatient Inhaled Corticosteroid (ICS) Therapy Decreases Mortality in
Patients with Chronic Obstructive Pulmonary Disease (COPD) and Pneumonia
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [de Molina, R. M. Malo; Anzueto, A.; Restrepo, M. I.] Univ Texas Hlth Care Syst, San Antonio, TX USA.
[de Molina, R. M. Malo; Mortensen, E. M.; Copeland, L. A.; Pugh, M. J. V.; Restrepo, M. I.] S Texas Vet Hlth Care Syst VERDICT, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A6115
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733105706
ER
PT J
AU Fan, VS
Udris, EM
Au, DH
AF Fan, V. S.
Udris, E. M.
Au, D. H.
TI Factors Associated with Self-Efficacy in COPD
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Fan, V. S.; Udris, E. M.; Au, D. H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A1077
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733100078
ER
PT J
AU Herrero, R
Kajikawa, O
Matute-Bello, G
Fu, X
Wong, VA
Martin, TR
AF Herrero, R.
Kajikawa, O.
Matute-Bello, G.
Fu, X.
Wong, V. A.
Martin, T. R.
TI The N-Terminal Sequence of Soluble FasL Determines Its Bioactivity
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Herrero, R.; Kajikawa, O.; Matute-Bello, G.; Wong, V. A.] VA Puget Sound, Seattle, WA USA.
[Herrero, R.; Kajikawa, O.; Matute-Bello, G.; Fu, X.; Wong, V. A.] U Washington, Seattle, WA USA.
EM rherrero@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A2496
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733101615
ER
PT J
AU Ho, G
Mao, Y
Chandrasena, A
Lam, D
Frank, JA
AF Ho, G.
Mao, Y.
Chandrasena, A.
Lam, D.
Frank, J. A.
TI The Contribution of Claudin 4 to In Vitro Alveolar Epithelial Barrier
Repair
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Ho, G.; Chandrasena, A.; Frank, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lam, D.; Frank, J. A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Mao, Y.; Frank, J. A.] NCIRE VHRI, San Francisco, CA USA.
EM gwendolyn.ho@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A2395
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733101514
ER
PT J
AU Koff, PB
Min, S
Freitag, TJ
James, SS
Keith, RL
Kveton, C
Carwin, S
Stelzner, TJ
Brand, DW
Ritzwoller, DP
Beck, AL
Voelkel, NF
Vandivier, RW
AF Koff, P. B.
Min, S.
Freitag, T. J.
James, S. S.
Keith, R. L.
Kveton, C.
Carwin, S.
Stelzner, T. J.
Brand, D. W.
Ritzwoller, D. P.
Beck, A. L.
Voelkel, N. F.
Vandivier, R. W.
TI Proactive Integrated Care Reduces Critical Care & Improves
Quality-of-Life in COPD
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Koff, P. B.; Freitag, T. J.; James, S. S.] Univ CO Hosp, Aurora, CO USA.
[Min, S.; Keith, R. L.; Vandivier, R. W.] Univ CO Hlth Sci Ctr, Dept Med, Aurora, CO USA.
[Keith, R. L.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
[Kveton, C.; Carwin, S.; Stelzner, T. J.; Brand, D. W.; Ritzwoller, D. P.; Beck, A. L.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA.
[Voelkel, N. F.] VA Commonwealth Univ, Dept Med, Richmond, VA USA.
EM patricia.koff@uch.edu
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A3100
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733102335
ER
PT J
AU Kurahashi, K
Kajikawa, O
Matute-Bello, G
Martin, TR
AF Kurahashi, K.
Kajikawa, O.
Matute-Bello, G.
Martin, T. R.
TI FasL and LPS Have Synergistic Effects on Inflammation of Epithelial
Cells.
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Kurahashi, K.; Kajikawa, O.; Matute-Bello, G.; Martin, T. R.] VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA USA.
[Kurahashi, K.; Kajikawa, O.; Matute-Bello, G.; Martin, T. R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Kurahashi, K.] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Yokohama, Kanagawa 232, Japan.
EM yasuk@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A5642
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733105233
ER
PT J
AU Lipke, AB
Wong, VA
Matute-Bello, G
Martin, TR
AF Lipke, A. B.
Wong, V. A.
Matute-Bello, G.
Martin, T. R.
TI Mechanisms of Enhanced Lung Injury in Febrile Hyperthermia: Role of
Alveolar Epithelial Apoptosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Lipke, A. B.; Wong, V. A.; Martin, T. R.] VA Puget Sound, Seattle, WA USA.
[Matute-Bello, G.] Ctr Lung Biol, Seattle, WA USA.
EM ablipke@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A3862
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733103215
ER
PT J
AU Mao, Y
Chandrasena, A
Araujo, L
Ho, G
Frank, JA
AF Mao, Y.
Chandrasena, A.
Araujo, L.
Ho, G.
Frank, J. A.
TI Claudin 4 Is Induced in the Alveolar Epithelium by a JNK-Dependent
Mechanism
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Chandrasena, A.; Araujo, L.; Ho, G.; Frank, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Frank, J. A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Mao, Y.; Frank, J. A.] NCIRE VHRI, San Francisco, CA USA.
EM james.frank@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A5001
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733104465
ER
PT J
AU Mortensen, EM
Copeland, LA
Pugh, MJ
de Molina, RM
Restrepo, MI
Anzueto, A
AF Mortensen, E. M.
Copeland, L. A.
Pugh, M. J.
de Molina, R. Malo
Restrepo, M. I.
Anzueto, A.
TI Impact of Prior Statin and ACE Inhibitor Use on Mortality for Subjects
Hospitalized with COPD Exacerbations.
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Mortensen, E. M.; Copeland, L. A.; Pugh, M. J.; de Molina, R. Malo; Restrepo, M. I.; Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Mortensen, E. M.; Copeland, L. A.; Pugh, M. J.; de Molina, R. Malo; Restrepo, M. I.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
EM mortensene@uthscsa.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A5354
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733104818
ER
PT J
AU Nyendak, M
Swarbrick, G
Null, M
Cansler, M
Frieder, M
Mayanja-Kizza, H
Mugerwa, RD
Boom, WH
Zalwango, S
Rajaraman, V
Sherman, D
Mori, T
McWeeney, S
Park, B
Lewinsohn, DA
Lewinsohn, DM
AF Nyendak, M.
Swarbrick, G.
Null, M.
Cansler, M.
Frieder, M.
Mayanja-Kizza, H.
Mugerwa, R. D.
Boom, W. H.
Zalwango, S.
Rajaraman, V.
Sherman, D.
Mori, T.
McWeeney, S.
Park, B.
Lewinsohn, D. A.
Lewinsohn, D. M.
TI The Diagnostic Potential of the CD8(+) T Cell Response: Identification
of Immunodominant CD8(+) T Cell Antigens and the Potential To
Differentiate Latent from Active Tuberculosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Nyendak, M.; Swarbrick, G.; Null, M.; Cansler, M.; Rajaraman, V.; Mori, T.; McWeeney, S.; Park, B.; Lewinsohn, D. A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Swarbrick, G.; Null, M.; Cansler, M.; Frieder, M.; Lewinsohn, D. M.] Portland VA Med Ctr, Portland, OR USA.
[Mayanja-Kizza, H.; Mugerwa, R. D.; Zalwango, S.] Makerere Univ, Kampala, Uganda.
[Boom, W. H.] Case Western Reserve Univ, TB Res Unit, Cleveland, OH 44106 USA.
[Sherman, D.] Univ Washington, Seattle, WA 98195 USA.
EM nyendakm@ohsu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A1016
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733100017
ER
PT J
AU Slatore, CG
Udris, EM
Cecere, LM
Moss, BR
Bryson, CL
Au, DH
AF Slatore, C. G.
Udris, E. M.
Cecere, L. M.
Moss, B. R.
Bryson, C. L.
Au, D. H.
TI Provider Communication among Patients with Chronic Obstructive Pulmonary
Disease: Association with Patient Reported Outcomes
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Slatore, C. G.; Udris, E. M.; Cecere, L. M.; Moss, B. R.; Bryson, C. L.; Au, D. H.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev, Seattle, WA USA.
EM cslatore@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A5200
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733104664
ER
PT J
AU Slatore, CG
Au, DH
Gould, MK
AF Slatore, C. G.
Au, D. H.
Gould, M. K.
TI Insurance Status and Disparities in Outcomes of Lung Cancer Care: A
Systematic Review.
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Slatore, C. G.; Au, D. H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Gould, M. K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
EM cslatore@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A3748
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733103101
ER
PT J
AU Minowada, G
Miller, YE
AF Minowada, George
Miller, York E.
TI Overexpression of Sprouty 2 in Mouse Lung Epithelium Inhibits
Urethane-Induced Tumorigenesis
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE Sprouty; lung cancer; mouse; chemoprevention; Ras
ID K-RAS; MOLECULAR PATHOGENESIS; SIGNAL-TRANSDUCTION; A/J MICE; GROWTH;
CANCER; PATHWAY; TUMORS; EXPRESSION; PULMONARY
AB Members of the Sprouty family encode novel proteins that are thought to function primarily as intracellular antagonists of the Ras-signaling pathway. Increased Ras signaling is a critical characteristic of human lung adenocarcinoma, the most common type of non-small cell lung cancer. Sprouty 2 is expressed in the lung epithelium, the tissue layer from which lung cancers arise. We hypothesized that overexpression of Sprouty 2 in the distal lung epithelium would inhibit lung tumorigenesis. To test the hypothesis, the consequences of overexpressing Sprouty 2 in the distal lung epithelium on urethane-induced mouse lung tumorigenesis were determined. Urethane is a chemical carcinogen found in tobacco smoke that causes activating mutations in Kras and induces lung tumors in mice. Sprouty 2-overexpressor mice developed significantly fewer lung tumors compared with their littermate controls (113.2 +/- 1.1 versus 18.1 +/- 1.3, P = 0.006). Tumor diameter was also significantly smaller in Sprouty 2 overexpressors (0.85 mm +/- 0.03 versus 0.95 mm +/- 0.02, P = 0.005). Sprouty 2 overexpression did not alter Kras mutational frequencies in urethane-induced tumors, suggesting that the tumor-suppressing effect of Sprouty 2 overexpression acts at a stage after Kras mutation, perhaps by interfering with receptor tyrosine kinase-induced signaling. These results demonstrate that Sprouty 2 overexpression inhibited both tumor initiation and subsequent tumor growth.
C1 [Miller, York E.] Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA.
[Miller, York E.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80220 USA.
[Minowada, George] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA.
[Minowada, George] Case Western Reserve Univ, Univ Hosp Cleveland, Div Pulm & Crit Care Med, Cleveland, OH 44106 USA.
RP Miller, YE (reprint author), Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Pulm 111A, Denver, CO 80220 USA.
EM york.miller@uchsc.edu
FU University of California, San Francisco; Skin Diseases Research Center
FX The first author developed the conditional Spry2GOF
transgenic line as a postdoctoral fellow in Gail Martin's laboratory at
the University of California, San Francisco. The authors thank her for
her support and encouragement. The authors thank the histopathology core
facility in the Skin Diseases Research Center for processing,
sectioning, and staining of tissue, and the sequencing core facility in
the orthopedics department for sequencing. An early version of this work
was presented at the 2003 Thomas L. Petty Aspen Lung Conference and
reported in abstract form (31).
NR 31
TC 19
Z9 19
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JAN
PY 2009
VL 40
IS 1
BP 31
EP 37
DI 10.1165/rcmb.2008-0147OC
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 388XW
UT WOS:000262054700005
PM 18635814
ER
PT J
AU Chennupati, SK
Chiu, AG
Tamashiro, E
Banks, CA
Cohen, MB
Bleier, BS
Kofonow, JM
Tam, E
Cohen, NA
AF Chennupati, Sri Kiran
Chiu, Alexander G.
Tamashiro, Edwin
Banks, Caroline A.
Cohen, Michael B.
Bleier, Benjamin S.
Kofonow, Jennifer M.
Tam, Eric
Cohen, Noam A.
TI Effects of an LL-37-derived antimicrobial peptide in an animal model of
biofilm Pseudomonas sinusitis
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
DE Animal model; antimicrobial peptide; biofilm; cathelicidin; LL-37;
Pseudomonas; sinusitis; topical therapies
ID CHRONIC RHINOSINUSITIS; BACTERIAL BIOFILMS; IN-VITRO;
STAPHYLOCOCCUS-AUREUS; TOPICAL TOBRAMYCIN; LL-37; MUCOSA; INFECTIONS;
SPECIMENS; SURGERY
AB Background: LL-37, all innate immunity protein expressed within sinonasal mucosa, has in vitro antibacterial and antifungal properties as Well as efficacy against preformed Pseudomonas aeruginosa biofilms. We hypothesize that a 24 amino acid peptide derivative of LL-37 will show efficacy against biofilm-forming P. aeruginosa in ail established animal model of sinusitis.
Methods: Five groups of six New Zealand rabbits were each infected with P. aeruginosa (PAO-1) and fitted with irrigating catheters 7 days later. Each group was instilled with either one of three different concentrations of peptide, a positive control of topical tobramycin, or the carrier solution without the peptide once a day for 10 days. Nasal diluent was collected throughout the irrigation period to assess for persistence or resolution of infection by determining colony-forming units (CFU). At study end, sinus mucosa was harvested for histological assessment of inflammation and SEM evaluation for ciliary integrity and presence Of biofilms.
Results: Topical tobramycin at 400X minimum inhibitory concentration and 2.5 mg/mL of peptide were effective in significantly lowering CFUs after 10 days of irrigation. Histological evaluation showed increased signs of inflammation in a dose-dependent manner within mucosa and bone of the groups receiving the peptide. SEM analysis showed ciliary loss in a dose-dependent manner. Biofilms were present ill all groups except for the highest concentration of peptide and tobramycin.
Conclusion: High concentrations of LL-37-derived peptide showed in vivo ability to eradicate Pseudomonas biofilms and decrease bacterial counts. However, increasing concentrations of peptide showed proinflammatory and ciliotoxic effects oil sinus mucosa.
C1 [Chennupati, Sri Kiran; Chiu, Alexander G.; Tamashiro, Edwin; Bleier, Benjamin S.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Tamashiro, Edwin; Kofonow, Jennifer M.; Tam, Eric; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Div Otolaryngol, Philadelphia, PA USA.
[Banks, Caroline A.; Cohen, Michael B.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
RP Chiu, AG (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 5 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.
EM alexander.chiu@uphs.upenn.edu
RI Chiu, Alexander/J-1230-2014; Tamashiro, Edwin/C-5062-2012
OI Chiu, Alexander/0000-0002-7592-6575; Tamashiro,
Edwin/0000-0002-3153-6292; Cohen, Noam/0000-0002-9462-3932
NR 42
TC 38
Z9 38
U1 0
U2 6
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
J9 AMJ RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD JAN-FEB
PY 2009
VL 23
IS 1
BP 46
EP 51
DI 10.2500/ajra.2009.23.3261
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 430NN
UT WOS:000264995900010
PM 19379612
ER
PT J
AU Ellis, C
Egede, LE
AF Ellis, Charles
Egede, Leonard E.
TI Stroke Recognition Among Individuals With Stroke Risk Factors
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE stroke; cardiovascular disease; hypertension; diabetes; smoking; survey
research
ID AMERICAN-HEART-ASSOCIATION; EMERGENCY-DEPARTMENT; WARNING SIGNS;
HEALTH-CARE; KNOWLEDGE; AWARENESS; DELAY; SYMPTOMS; TIME; EPIDEMIOLOGY
AB Background: This study examined recognition of all 5 early warning signs/symptoms of stroke and appropriate first action to call 9-1-1 across stroke risk groups, Methods: Data from 264,684 adults from the 2003 Behavioral Risk Factor Surveillance System were examined. Recognition of the 5 warning signs/symptoms of stroke and appropriate first action to call 9-1-1 was compared among 3 stroke risk groups no stroke risk factors, stroke risk factors, and prior stroke, using multiple logistic regression controlling for covariates. Results: Recognition of the 5 individual warning signs of stroke ranged from 82% to 98%. Cumulative recognition of all 5 warning signs of stroke ranged from 30.8% in individuals with prior stroke to 12.6% in those with no stroke risk factors,. Cumulative recognition of all 5 warning signs of stroke and taking appropriate action to call 9-1-1 ranged from 26.1% in individuals with prior stroke to 11.2% in those with no stroke risk factors. Adjusted odds ratios for recognition of all 5 symptoms was 3.35 for individuals with previous stroke and 1.15 for individuals with stroke risk factors, compared with the reference group (individuals without stroke risk factors). Adjusted odds ratios for recognition of all 5 symptoms and taking appropriate action to call 9-1-1 was 3.06 for individuals with previous stroke and 1.14 for individuals with stroke risk factors, Conclusions: Recognition of individual stroke warning symptoms is high in general. Cumulative recognition of stroke warning signs and taking appropriate action is very low, although higher in those with prior stroke.
C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
[Ellis, Charles] Med Univ S Carolina, Dept Rehabil Sci, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
EM egedel@musc.edu
NR 32
TC 15
Z9 19
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JAN
PY 2009
VL 337
IS 1
BP 5
EP 10
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 400MQ
UT WOS:000262872700002
PM 19057378
ER
PT J
AU Webb, R
Jeffries, M
Sawalha, AH
AF Webb, Ryan
Jeffries, Matlock
Sawalha, Amr H.
TI Uric Acid Directly Promotes Human T-Cell Activation
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Uric acid; T cells; Gout; Autoimmunity
ID ENDOGENOUS ADJUVANTS; IMMUNE-SYSTEM; PATHOGENESIS
AB Background: Abnormally high serum uric acid levels have been associated with several disease conditions including gout and kidney stone disease. More recently, it was shown that uric acid crystals stimulate dendritic cell maturation, activate the NALP3 inflamasome, and enhance antigen-specific immune responses. We hypothesize that uric acid can also stimulate T cells directly and in the absence of antigen presentation. Methods: Purified primary human T cells were incubated with and without uric acid at concentrations of 50, 100, 150, and 200 mu g/mL. The expression of T-cell activation markers CD25 and CD70 was assessed by flow cytometry. In other experiments, Jurkat T cells were used and the expression of the costimulatory molecule CD70 was determined at the mRNA level. Result: Uric acid directly activates primary human T cells in tire absence of antigen presentation. Furthermore, primary human T cells and Jurkat T cells treated with uric acid overexpress the costimulatory molecule CD70, which plays an important role in T cell-B cell interaction and antibody production. Conclusions: The finding that uric acid directly promotes T-cell activation in ail antigen-independent system is novel and might play a mechanistic role in the inflammatory response observed in gouty arthritis and other immune-mediated diseases.
C1 [Webb, Ryan; Jeffries, Matlock; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA.
[Jeffries, Matlock; Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Sawalha, Amr H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA.
EM amr-sawalha@omrf.ouhsc.edu
OI Jeffries, Matlock/0000-0001-9516-4312
FU National Center for Research Resources [P20-RR015577]; University of
Oklahoma College of Medicine
FX This study was supported by NIH Grant number P20-RR015577 from the
National Center for Research Resources and by funding from the
University of Oklahoma College of Medicine.
NR 14
TC 21
Z9 31
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JAN
PY 2009
VL 337
IS 1
BP 23
EP 27
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 400MQ
UT WOS:000262872700005
PM 19057377
ER
PT J
AU Wharton, W
Gleason, CE
Lorenze, KR
Markgraf, TS
Ries, ML
Carlsson, CM
Asthana, S
AF Wharton, Whitney
Gleason, Carey E.
Lorenze, Katelin R.
Markgraf, Tamara S.
Ries, Michele L.
Carlsson, Cynthia M.
Asthana, Sanjay
TI Potential role of estrogen in the pathobiology and prevention of
Alzheimer's disease
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Review
DE Estrogen; estrogen therapy; hormone therapy; cognition; Alzheimer's
disease; postmenopausal cognition; women's health initiative
AB Over a decade of converging findings from clinical, observational and basic science research indicate that estrogen administration during the menopausal transition exerts beneficial effects on cognition and decreases a woman's risk of developing Alzheimer's disease (AD) later in life. This review article stresses the research focus of AD prevention, and introduces hormone therapy (HT) as a probable catalyst that may achieve this goal. Furthermore, this article outlines 3 mechanisms proposed to mediate estrogen's beneficial effects, discusses the controversy surrounding HT administration, and presents the most promising estrogen related research in AD prevention and treatment. Although controversial, cumulative evidence suggests that the potential of estrogen initiated during perimenopause to prevent AD needs to be systematically evaluated.
C1 [Wharton, Whitney; Gleason, Carey E.; Lorenze, Katelin R.; Markgraf, Tamara S.; Ries, Michele L.; Carlsson, Cynthia M.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
[Wharton, Whitney; Gleason, Carey E.; Lorenze, Katelin R.; Markgraf, Tamara S.; Ries, Michele L.; Carlsson, Cynthia M.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
RP Wharton, W (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton VA Hosp, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA.
EM wlwharto@medicine.wisc.edu
FU NIH [AG029624, K07AG021582, K23AG024302, K23AG026752]
FX This research was conducted with the help of the Section of Geriatrics
and Gerontology, Department of Medicine at the University of Wisconsin,
Madison and the Geriatric Research, Education and Clinical Center
(GRECC), William S. Middleton Memorial Veterans Hospital. This research
was supported by NIH grants AG029624, K07AG021582, K23AG024302 and
K23AG026752. VA manuscript number 2008-31.
NR 172
TC 7
Z9 7
U1 2
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2009
VL 1
IS 2
BP 131
EP 147
PG 17
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA V28PW
UT WOS:000208693700004
PM 19956426
ER
PT J
AU Cacciarelli, TV
Wagener, M
Karuman, P
Wannstedt, C
Akoad, M
AF Cacciarelli, Thomas V.
Wagener, Marilyn
Karuman, Philip
Wannstedt, Cheryl
Akoad, Mohamed
TI The Fate of "Refused" Imported and Locally Procurred Cadaver Donor Liver
Allografts and Impact on Survival
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 9th Joint Meeting of the
American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati
on
CY MAY 30-JUN 03, 2009
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 [Cacciarelli, Thomas V.; Karuman, Philip; Wannstedt, Cheryl] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Wagener, Marilyn] Univ Pittsburgh, Pittsburgh, PA USA.
[Akoad, Mohamed] Lahey Clin Fdn, Burlington, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2009
VL 9
BP 451
EP 451
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 431NQ
UT WOS:000265068800914
ER
PT J
AU Ahmad, J
Wagner, M
Francis, FF
Karuman, P
Cacciarelli, TV
AF Ahmad, Jawad
Wagner, Marilyn
Francis, Fadi F.
Karuman, Phillip
Cacciarelli, Thomas V.
TI Impact of the MELD System on Long-Term Outcome after Liver
Transplantation in United States Veterans
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 9th Joint Meeting of the
American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati
on
CY MAY 30-JUN 03, 2009
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 [Ahmad, Jawad; Wagner, Marilyn; Francis, Fadi F.; Karuman, Phillip] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Ahmad, Jawad] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2009
VL 9
BP 455
EP 455
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 431NQ
UT WOS:000265068800927
ER
PT J
AU Sun, HY
Cacciarelli, TV
Wagener, MM
Singh, N
AF Sun, Hsin-Yun
Cacciarelli, Thomas V.
Wagener, Marilyn M.
Singh, Nina
TI Impact of Pre-Transplant Infections on Clinical Outcomes in Liver
Transplant Recipients.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 9th Joint Meeting of the
American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati
on
CY MAY 30-JUN 03, 2009
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 [Sun, Hsin-Yun; Cacciarelli, Thomas V.; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Taipei, Taiwan.
[Cacciarelli, Thomas V.; Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2009
VL 9
BP 637
EP 637
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 431NQ
UT WOS:000265068801623
ER
PT J
AU Murray, DR
Osaki, S
Jewel-Ripp, P
Johnson, MR
Lozonschi, L
Edwards, NM
Kohmoto, T
AF Murray, David R.
Osaki, Satoru
Jewel-Ripp, Polly
Johnson, Maryl R.
Lozonschi, Lucian
Edwards, Niloo M.
Kohmoto, Takushi
TI Ventricular Assist Device Therapy in United States Veterans: A Single
Center 5-Year Experience.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 9th Joint Meeting of the
American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati
on
CY MAY 30-JUN 03, 2009
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 [Murray, David R.; Osaki, Satoru; Jewel-Ripp, Polly; Lozonschi, Lucian; Edwards, Niloo M.; Kohmoto, Takushi] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Osaki, Satoru; Lozonschi, Lucian; Edwards, Niloo M.; Kohmoto, Takushi] Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiothorac Surg, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2009
VL 9
BP 655
EP 655
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 431NQ
UT WOS:000265068801688
ER
PT J
AU Becker, WC
Meghani, SH
Barth, KS
Wiedemer, N
Gallagher, RM
AF Becker, William C.
Meghani, Salimah H.
Barth, Kelly S.
Wiedemer, Nancy
Gallagher, Rollin M.
TI Characteristics and Outcomes of Patients Discharged from the Opioid
Renewal Clinic at the Philadelphia VA Medical Center
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID CHRONIC PAIN PATIENTS; PRIMARY-CARE; SUBSTANCE-ABUSE; THERAPY;
MANAGEMENT
AB The Opioid Renewal Clinic (ORC) is a pharmacist-run program that assists primary care providers in the management of chronic pain patients with aberrant behavior or high risk of prescription opioid abuse. In this study, charts of all discharged patients over a 22-month span (n = 86) were reviewed for outcomes for two years after discharge. The most frequent reason for discharge from the program was recurrent positive urine drug screens for illicit substances (n = 40; 47%). Only 15 (17%) were seen for addiction treatment in the two-year follow-up period. Forty-one percent of patients (n = 35) were prescribed opioids within two years of discharge. There was a positive correlation between length of time in the ORC and receipt of opioids post discharge. These outcomes reveal areas of need in the management of this complex population.
C1 [Becker, William C.; Wiedemer, Nancy; Gallagher, Rollin M.] Philadelphia Vet Affairs Med Ctr, VISN4 MIRECC, Philadelphia, PA USA.
Univ Penn, Sch Nursing, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA.
[Barth, Kelly S.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
RP Becker, WC (reprint author), VAMC 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM William.Becker4@va.gov
OI Becker, William/0000-0002-0788-1467
NR 13
TC 3
Z9 3
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PY 2009
VL 18
IS 2
BP 135
EP 139
AR PII 909499370
DI 10.1080/10550490902772496
PG 5
WC Substance Abuse
SC Substance Abuse
GA 418GX
UT WOS:000264137800006
PM 19283565
ER
PT J
AU Newton, TF
La Garza, R
Kalechstein, AD
Tziortzis, D
Jacobsen, CA
AF Newton, Thomas F.
De La Garza, Richard, II
Kalechstein, Ari D.
Tziortzis, Desey
Jacobsen, Caitlin A.
TI Theories of Addiction: Methamphetamine Users' Explanations for
Continuing Drug Use and Relapse
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; COCAINE-DEPENDENT PATIENTS;
DSM-IV; IMPULSIVITY; REWARD; ABUSE; WITHDRAWAL; BEHAVIOR; BRAIN;
DYSREGULATION
AB A variety of preclinical models have been constructed to emphasize unique aspects of addiction-like behavior. These include Negative Reinforcement (Pain Avoidance), Positive Reinforcement (Pleasure Seeking), Incentive Salience (Craving), Stimulus Response Learning (Habits), and Inhibitory Control Dysfunction (Impulsivity). We used a survey to better understand why methamphetamine-dependent research volunteers (N = 73) continue to use methamphetamine, or relapse to methamphetamine use after a period of cessation of use. All participants met DSM-IV criteria for methamphetamine abuse or dependence, and did not meet criteria for other current Axis I psychiatric disorders or dependence on other drugs of abuse, other than nicotine. The questionnaire consisted of a series of face-valid questions regarding drug use, which in this case referred to methamphetamine use. Examples of questions include: Do you use drugs mostly to make bad feelings like boredom, loneliness, or apathy go away?, Do you use drugs mostly because you want to get high?, Do you use drugs mostly because of cravings?, Do you find yourself getting ready to take drugs without thinking about it?, and Do you impulsively take drugs?. The scale was anchored at 1 (not at all) and 7 (very much). For each question, the numbers of participants rating each question negatively (1 or 2), neither negatively or affirmatively (3-5), and affirmatively (6 or 7) were tabulated. The greatest number of respondents (56%) affirmed that they used drugs due to pleasure seeking. The next highest categories selected were impulsivity (27%) and habits(25%). Surprisingly, many participants reported that pain avoidance (30%) and craving (30%) were not important for their drug use. Results from this study support the contention that methamphetamine users (and probably other drug users as well) are more heterogeneous than is often appreciated, and imply that treatment development might be more successful if treatments targeted subtypes of patients, though a range of limitations to the approach used are acknowledged.
C1 [Newton, Thomas F.; De La Garza, Richard, II] Baylor Coll Med, Menninger Dept Psychiatry& Behav Sci, Houston, TX 77030 USA.
[Newton, Thomas F.; De La Garza, Richard, II] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Kalechstein, Ari D.; Tziortzis, Desey; Jacobsen, Caitlin A.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
RP Newton, TF (reprint author), Baylor Coll Med, Menninger Dept Psychiatry& Behav Sci, 1 Baylor Plaza,BCM350, Houston, TX 77030 USA.
EM tnewton@bcm.edu
RI De La Garza, Richard/B-2489-2014
OI De La Garza, Richard/0000-0003-1943-4469; newton,
thomas/0000-0002-3198-5901
FU NIDA NIH HHS [K24 DA017754, R21 DA017182, R01 DA023468]
NR 51
TC 23
Z9 23
U1 2
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PY 2009
VL 18
IS 4
BP 294
EP 300
AR PII 911211983
DI 10.1080/10550490902925920
PG 7
WC Substance Abuse
SC Substance Abuse
GA 446FJ
UT WOS:000266105800005
PM 19444733
ER
PT J
AU Gordon, AJ
Liberto, J
Granda, S
Salmon-Cox, S
Andree, T
McNicholas, L
AF Gordon, Adam J.
Liberto, Joseph
Granda, Stephanie
Salmon-Cox, Sara
Andree, Tykia
McNicholas, Laura
TI Physician Training is Never a Failure
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Letter
ID OFFICE-BASED TREATMENT; OPIOID DEPENDENCE; ADDICTION MEDICINE;
PRIMARY-CARE; BUPRENORPHINE; NALOXONE; UPDATE
C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, VISN 4, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Liberto, Joseph] VA Maryland Healthcare Syst, Baltimore, MD USA.
[Liberto, Joseph] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Granda, Stephanie] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA.
[McNicholas, Laura] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, VISN 4, Ctr Hlth Equ Res & Promot, Mailcode 151 C-H,7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM adam.gordon@va.gov
NR 16
TC 6
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PY 2009
VL 18
IS 4
BP 337
EP 338
AR PII 911212111
DI 10.1080/10550490902931373
PG 2
WC Substance Abuse
SC Substance Abuse
GA 446FJ
UT WOS:000266105800040
ER
PT J
AU Thase, ME
Sloan, DM
AF Thase, Michael E.
Sloan, Diane M.
BE Schatzberg, AF
Nemeroff, CB
TI Venlafaxine and Desvenlafaxine
SO AMERICAN PSYCHIATRIC PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 4TH
EDITION
LA English
DT Article; Book Chapter
ID GENERALIZED ANXIETY DISORDER; MAJOR DEPRESSIVE DISORDER; RANDOMIZED
CONTROLLED-TRIAL; EXTENDED-RELEASE VENLAFAXINE; SEROTONIN REUPTAKE
INHIBITORS; PLACEBO-CONTROLLED TRIAL; PREMENSTRUAL DYSPHORIC DISORDER;
TREATMENT-RESISTANT DEPRESSION; POSTTRAUMATIC-STRESS-DISORDER;
OBSESSIVE-COMPULSIVE DISORDER
C1 [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Sloan, Diane M.] Advogent, Wayne, NJ USA.
RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
NR 140
TC 2
Z9 2
U1 0
U2 1
PU AMER PSYCHIATRIC PRESS, INC
PI WASHINGTON
PA 1400 K ST NW, WASHINGTON, DC 20005 USA
BN 978-1-58562-309-9
PY 2009
BP 439
EP 452
PG 14
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA BCF29
UT WOS:000310050700023
ER
PT J
AU Marder, SR
Wirshing, DA
AF Marder, Stephen R.
Wirshing, Donna A.
BE Schatzberg, AF
Nemeroff, CB
TI Clozapine
SO AMERICAN PSYCHIATRIC PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 4TH
EDITION
LA English
DT Article; Book Chapter
ID DRUG-INDUCED PSYCHOSIS; INDUCED WEIGHT-GAIN; CHILDHOOD-ONSET
SCHIZOPHRENIA; SENSORIMOTOR GATING DEFICITS; SERUM TRIGLYCERIDE LEVELS;
COLONY-STIMULATING FACTOR; SUBSTANCE USE DISORDER; INDUCED
AGRANULOCYTOSIS; DOUBLE-BLIND; TREATMENT-RESISTANT
C1 [Marder, Stephen R.] Univ Calif Los Angeles, Sect Psychosis, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Marder, Stephen R.] W Los Angeles Vet Affairs Med Ctr, Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Wirshing, Donna A.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
RP Marder, SR (reprint author), Univ Calif Los Angeles, Sect Psychosis, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
NR 149
TC 1
Z9 1
U1 3
U2 4
PU AMER PSYCHIATRIC PRESS, INC
PI WASHINGTON
PA 1400 K ST NW, WASHINGTON, DC 20005 USA
BN 978-1-58562-309-9
PY 2009
BP 555
EP 571
PG 17
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA BCF29
UT WOS:000310050700029
ER
PT J
AU Ballon, JS
Wirshing, DA
Schulz, SC
AF Ballon, Jacob S.
Wirshing, Donna A.
Schulz, S. Charles
BE Schatzberg, AF
Nemeroff, CB
TI Olanzapine
SO AMERICAN PSYCHIATRIC PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 4TH
EDITION
LA English
DT Article; Book Chapter
ID PLACEBO-CONTROLLED-TRIAL; OBSESSIVE-COMPULSIVE DISORDER; INDUCED
WEIGHT-GAIN; BORDERLINE PERSONALITY-DISORDER; ATYPICAL
ANTIPSYCHOTIC-DRUGS; PROMINENT NEGATIVE SYMPTOMS; RANDOMIZED
CONTROLLED-TRIAL; D-2 RECEPTOR OCCUPANCY; METHYL-D-ASPARTATE; ORALLY
DISINTEGRATING OLANZAPINE
C1 [Ballon, Jacob S.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Schulz, S. Charles] Univ Minnesota, Dept Psychiat, Sch Med, Riverside, CA USA.
[Wirshing, Donna A.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Wirshing, Donna A.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Ballon, JS (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
NR 202
TC 1
Z9 1
U1 1
U2 1
PU AMER PSYCHIATRIC PRESS, INC
PI WASHINGTON
PA 1400 K ST NW, WASHINGTON, DC 20005 USA
BN 978-1-58562-309-9
PY 2009
BP 573
EP 598
PG 26
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA BCF29
UT WOS:000310050700030
ER
PT J
AU Ali, R
Cusi, K
AF Ali, Rafeeq
Cusi, Kenneth
TI New diagnostic and treatment approaches in non-alcoholic fatty liver
disease (NAFLD)
SO ANNALS OF MEDICINE
LA English
DT Review
DE Fatty liver; insulin resistance; NAFLD; NASH; obesity;
thiazolidinediones; type 2 diabetes mellitus
ID TYPE-2 DIABETIC-PATIENTS; HEPATIC INSULIN-RESISTANCE; ACTIVATED
PROTEIN-KINASE; MAGNETIC-RESONANCE-SPECTROSCOPY; PLACEBO-CONTROLLED
TRIAL; SEVERELY OBESE SUBJECTS; LIFE-STYLE MODIFICATION; II RECEPTOR
ANTAGONIST; GASTRIC BYPASS-SURGERY; NECROSIS-FACTOR-ALPHA
AB Non-alcoholic fatty liver disease or NAFLD is a chronic liver condition characterized by hepatic steatosis and associated with insulin resistance and type 2 diabetes mellitus (T2DM). In many patients fat accumulation leads to steatohepatitis (NASH) with chronic necrosis, inflammation, and fibrosis, and eventually to the development of cirrhosis. Obese and T2DM patients are at the greatest risk for NASH and progressive disease. New diagnostic techniques, such as magnetic resonance imaging and spectroscopy (MRS), have enhanced our way to non-invasively quantify liver fat and suggest that the epidemic of NAFLD is much larger than previously believed. However, the diagnosis of NAFLD for clinicians remains difficult due to a number of factors: limited awareness, non-specific symptoms, few laboratory findings, and the need for a liver biopsy to confirm the diagnosis. Traditional treatment approaches have centered on weight loss, but data are limited on its long-term efficacy, and the overall compliance is poor. Recently, pioglitazone has been shown to be safe and effective in patients with NASH and may radically change our approach to the disease. Still, many aspects remain poorly understood. Taken together, wider use of new diagnostic methods and treatment approaches appears to signal the dawn of a new era in the management of NAFLD.
C1 [Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78284 USA.
[Ali, Rafeeq] Univ Texas Hlth Sci Ctr San Antonio, Div Endocrinol, San Antonio, TX 78284 USA.
[Cusi, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Room 3-380S,7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
EM cusi@uthscsa.edu
NR 125
TC 61
Z9 78
U1 0
U2 4
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PY 2009
VL 41
IS 4
BP 265
EP 278
AR PII 907688313
DI 10.1080/07853890802552437
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 434QY
UT WOS:000265290400003
PM 19353360
ER
PT J
AU Garvey, WT
AF Garvey, W. Timothy
TI NUTRITION AND CONTROL OF DIABETES IN HOSPITALIZED PATIENTS
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Meeting Abstract
C1 [Garvey, W. Timothy] Birmingham VAMC, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PY 2009
VL 55
SU 1
BP 57
EP 57
PG 1
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 507CF
UT WOS:000270827200211
ER
PT J
AU Bilimoria, KY
Bentrem, DJ
Wayne, JD
Ko, CY
Bennett, CL
Talamonti, MS
AF Bilimoria, Karl Y.
Bentrem, David J.
Wayne, Jeffrey D.
Ko, Clifford Y.
Bennett, Chales L.
Talamonti, Mark S.
TI Small Bowel Cancer in the United States Changes in Epidemiology,
Treatment, and Survival Over the Lost 20 Years
SO ANNALS OF SURGERY
LA English
DT Article
ID CARCINOID-TUMORS; CLINICAL CHARACTERISTICS; REGISTRY; METASTASES;
RESECTION; QUALITY; LIVER
AB Background: Previous Studies have shown an increasing incidence of small bowel tumors in the United States. Our objective was to assess this increase by examining changes in histology-specific incidence, treatment, and survival.
Methods: Patients with small bowel malignancies were identified front the National Cancer Data Base (NCDB, 1985-2005) and the Surveillance Epidemiology and End Results (SEER, 1973-2004) database. Age-adjusted incidence rates were calculated using SEER. Treatment and survival trends over time were examined using the National Cancer Data Base. Regression models were developed to assess survival over time.
Results: Sixty-seven thousand eight hundred forty-three patients were identified with small bowel malignancies: 37.4% carcinoid, 36.9% adenocarcinomas, 8.4% stromal tumors, and 17.3% lymphomas. From 1973 to 2004, the incidence of carcinoid tumors increased more than 4-fold (2.1 to 9.3 per million), whereas changes in adenocarcinomas, stromal tumors, and lymphomas were less pronounced. From 1985 to 2005, utilization of surgery increased significantly for carcinoid tumors from 78.8% to 87.4% (P < 0.0001). Adjuvant chemotherapy utilization for adenocarcinoma increased from 8.1 % in 1985 to 23.8% in 2005 (P < 0.0001). Treatment over time was generally unchanged for lymphoma and stromal tumors. Five-year survival after resection remained unchanged overtime for all histologic subtypes even after adjusting for changes in patient demographics, tumor characteristics, and treatment approaches.
Conclusions: The overall incidence of small intestine malignancies has increased considerably, primarily because of carcinoid rumors which are now the most common small bowel cancer. With current treatments, Survival has remained relatively unchanged over the last 20 years. Novel therapeutic options need to be investigated.
C1 [Bilimoria, Karl Y.; Ko, Clifford Y.] Northwestern Univ, Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.; Bentrem, David J.; Wayne, Jeffrey D.; Talamonti, Mark S.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bennett, Chales L.] Northwestern Univ, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
[Talamonti, Mark S.] Evanston NW Healthcare, Dept Surg, Chicago, IL USA.
RP Bilimoria, KY (reprint author), Northwestern Univ, Amer Coll Surg, Canc Programs, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA.
EM k-bilimoria@northwestern.edu
FU American Cancer Society [IRG 93-037-12]
FX The National Cancer Data Base is supported by the American College of
Surgeons, the Commission on Cancer, and the American Cancer Society.
Supported by the American College of Surgeons Clinical Scholars in
Residence (to K.Y.B.) and a grant from the American Cancer Society (ACS
IRG 93-037-12) (to D.J.13.).
NR 34
TC 151
Z9 164
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD JAN
PY 2009
VL 249
IS 1
BP 63
EP 71
DI 10.1097/SLA.0b013e31818c4641
PG 9
WC Surgery
SC Surgery
GA 391FN
UT WOS:000262219300011
PM 19106677
ER
PT S
AU Stengel, A
Tache, Y
AF Stengel, Andreas
Tache, Yvette
TI Neuroendocrine Control of the Gut During Stress: Corticotropin-Releasing
Factor Signaling Pathways in the Spotlight
SO ANNUAL REVIEW OF PHYSIOLOGY
SE Annual Review of Physiology
LA English
DT Review; Book Chapter
DE motility; CRF antagonists; colon; stomach; urocortin
ID IRRITABLE-BOWEL-SYNDROME; CENTRAL-NERVOUS-SYSTEM; COLONIC MOTOR
FUNCTION; DORSAL VAGAL COMPLEX; FACTOR-RECEPTOR SUBTYPE-1; HORMONE
TYPE-1 RECEPTOR; WATER-AVOIDANCE STRESS; FACTOR CRF ANTAGONIST;
BINDING-PROTEIN; RAT-BRAIN
AB Stress affects the gastrointestinal tract as part of the visceral response. Various stressors induce similar profiles Of gut motor function alterations, including inhibition of gastric emptying, stimulation of colonic propulsive motility, and hypersensitivity to colorectal distension. In recent years, substantial progress has been made in our understanding of the underlying mechanisms of stress's impact on gut function. Activation of corticotropin-releasing factor (CRF) signaling pathways mediates both the inhibition of upper gastrointestinal (GI) and the stimulation of lower GI motor function through interaction with different CRF receptor subtypes. Here, we review how various stressors affect the gut, with special emphasis on the central and peripheral CRF signaling systems.
C1 [Stengel, Andreas] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Ctr Neurobiol Stress, Cure Digest Dis Res Ctr, Los Angeles, CA 90073 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Stengel, A (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU NIAMS NIH HHS [P50 AR 049550]; NIDDK NIH HHS [DK57238, R01 DK057238-08,
R01 DK-33061, R01 DK033061, P30 DK041301, R01 DK057238, DK-41301]
NR 174
TC 51
Z9 59
U1 0
U2 6
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0066-4278
BN 978-0-8243-0371-6
J9 ANNU REV PHYSIOL
JI Annu. Rev. Physiol.
PY 2009
VL 71
BP 219
EP 239
DI 10.1146/annurev.physiol.010908.163221
PG 21
WC Physiology
SC Physiology
GA 423II
UT WOS:000264489600011
PM 18928406
ER
PT J
AU Finegold, SM
Molitoris, D
Vaisanen, ML
AF Finegold, S. M.
Molitoris, D.
Vaisanen, M.-L.
TI Study of the In Vitro Activities of Rifaximin and Comparator Agents
against 536 Anaerobic Intestinal Bacteria from the Perspective of
Potential Utility in Pathology Involving Bowel Flora
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID VOLUNTEERS
AB Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 mu g/ml. Ninety percent of the strains tested were inhibited by 256 mu g/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam.
C1 [Finegold, S. M.] VA Greater Angeles Healthcare Syst, Med Serv, Los Angeles, CA USA.
[Finegold, S. M.; Molitoris, D.; Vaisanen, M.-L.] VA Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Finegold, S. M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Finegold, S. M.] Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA.
RP Finegold, SM (reprint author), Greater Los Angeles VAMC, 11301 Wilshire Blvd,Bldg 304,Rm E3-237, Los Angeles, CA 90073 USA.
EM sidfinegol@aol.com
FU Salix Pharmaceuticals, Inc., Morrisville, NC
FX This study was supported in part by a grant from Salix Pharmaceuticals,
Inc., Morrisville, NC.
NR 12
TC 15
Z9 15
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2009
VL 53
IS 1
BP 281
EP 286
DI 10.1128/AAC.00441-08
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 387JW
UT WOS:000261949500040
PM 18955526
ER
PT J
AU Thompson, GR
Wiederhold, NP
Fothergill, AW
Vallor, AC
Wickes, BL
Patterson, TF
AF Thompson, George R., III
Wiederhold, Nathan P.
Fothergill, Annette W.
Vallor, Ana C.
Wickes, Brian L.
Patterson, Thomas F.
TI Antifungal Susceptibilities among Different Serotypes of Cryptococcus
gattii and Cryptococcus neoformans
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IN-VITRO SUSCEPTIBILITIES; 2 VARIETIES; EPIDEMIOLOGY; INFECTION; DRUGS;
HOST
AB We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.
C1 [Thompson, George R., III; Wiederhold, Nathan P.; Vallor, Ana C.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA.
[Fothergill, Annette W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA.
[Wickes, Brian L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA.
[Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
[Thompson, George R., III; Wiederhold, Nathan P.; Vallor, Ana C.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM thompsong2@uthscsa.edu
OI Wiederhold, Nathan/0000-0002-2225-5122
FU NIH [NOI-A1-25475]; Pfizer; ScheringPlough; Merck; Nektar Therapeutics
FX G. R. T., A. W. F, A. C. V., and B. L. W. report no conflicts of
interest. N. P. W. has received research support from Pfizer and
ScheringPlough. T. F. P. has received research support from Merck,
Pfizer, ScheringPlough, and Nektar Therapeutics and has served on the
speaker's bureau for Merck and Pfizer and as a consultant for Basilea,
Merck, Nektar, Pfizer, and Toyama.
NR 20
TC 70
Z9 71
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2009
VL 53
IS 1
BP 309
EP 311
DI 10.1128/AAC.01216-08
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 387JW
UT WOS:000261949500047
PM 18955539
ER
PT B
AU Lopez-Ribot, JL
Patterson, TF
AF Lopez-Ribot, Jose L.
Patterson, Thomas F.
BE Mayers, DL
TI Fungal Drug Resistance: Azoles
SO ANTIMICROBIAL DRUG RESISTANCE, VOL 1: MECHANISMS OF DRUG RESISTANCE
SE Infectious Disease
LA English
DT Article; Book Chapter
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CANDIDA-ALBICANS STRAINS; YEAST
MULTIDRUG-RESISTANCE; AMINO-ACID SUBSTITUTIONS; ABC TRANSPORTERS CDR1;
MESSENGER-RNA LEVELS; ANTIFUNGAL AGENTS; FLUCONAZOLE RESISTANCE;
OROPHARYNGEAL CANDIDIASIS; INFECTED PATIENTS
C1 [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio, TX 78229 USA.
[Patterson, Thomas F.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
[Lopez-Ribot, Jose L.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA.
[Lopez-Ribot, Jose L.] Univ Texas San Antonio, S Texas Ctr Emerging Infect Dis, San Antonio, TX USA.
RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio, TX 78229 USA.
EM patterson@uthscsa.edu
NR 61
TC 0
Z9 0
U1 1
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
BN 978-1-60327-592-7
J9 INFECT DIS
PY 2009
BP 307
EP 312
DI 10.1007/978-1-59745-180-2_26
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA BKN91
UT WOS:000268730400026
ER
PT J
AU Gowen, BB
Fairman, J
Dow, S
Troyer, R
Wong, MH
Jung, KH
Melby, PC
Morrey, JD
AF Gowen, Brian B.
Fairman, Jeff
Dow, Steven
Troyer, Ryan
Wong, Min-Hui
Jung, Kie-Hoon
Melby, Peter C.
Morrey, John D.
TI Prophylaxis with cationic liposome-DNA complexes protects hamsters from
phleboviral disease: Importance of liposomal delivery and CpG motifs
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Liposomes; Antiviral; CpG; Rift Valley fever; Punta Toro virus;
Phlebovirus
ID RIFT-VALLEY FEVER; PUNTA-TORO-VIRUS; INNATE IMMUNE-RESPONSE;
BACTERIAL-DNA; TLR9-INDEPENDENT PATHWAYS; HEMORRHAGIC-FEVER; DENDRITIC
CELLS; RHESUS-MONKEYS; INFECTION; PATHOGENESIS
AB Cationic liposome-DNA complexes (CLDC) are cationic/neutral lipid carriers complexed with plasmid DNA that when administered systemically results in a robust T(H)1 cytokine response. CLDC have been shown to be effective in prophylaxis and therapeutic treatment of animal models of viral disease. To determine the contribution of liposomal delivery and CpG content of the plasmid DNA to the efficacy of CLDC; plasmid, CpG-free plasmid DNA, or CpG-containing oligodeoxynucleotides (ODN) with and without liposomes, as well as poly(I:C(12)U), were evaluated for their ability to elicit protection against lethal Punta Toro virus (PTV, Bunyaviridae, phlebovirus) challenge in hamsters. CLDC-containing plasmid significantly improved survival, decreased systemic and liver viral loads, and reduced liver damage due to progression of viral infection. Mouse-reactive ODNs complexed with liposomes failed to protect hamsters, whereas ODNs known to cross-react with human and mouse (CpG 2006) or non-liposomal poly(I:C(12)U) showed survival benefit but did not limit liver injury. Liposomes complexed with a non-CpG motif-containing plasmid reduced liver viral load and tissue damage, but did not protect hamsters from death. To evaluate the mechanisms of the enhanced activity of CLDC, microarray experiments examined differences in the gene expression profile. The results suggest a broad T(H)1 response elicited by liposomal delivery of a diverse sequence containing CpG and non-CpG elements may be a more effective antiviral treatment than other nucleic acid based immunotherapeutics. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Gowen, Brian B.; Wong, Min-Hui; Jung, Kie-Hoon; Morrey, John D.] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
[Gowen, Brian B.; Wong, Min-Hui; Jung, Kie-Hoon; Morrey, John D.] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA.
[Fairman, Jeff] Juvaris BioTherapeut, Buringame, CA USA.
[Dow, Steven; Troyer, Ryan] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
[Melby, Peter C.] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
[Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Gowen, BB (reprint author), Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
EM bgowen@cc.usu.edu
FU Virology Branch, National Institute of Allergy and Infectious Diseases,
National Institutes of Health [N01-AI-15435]; National Institute of
Allergy and Infectious Diseases, National Institutes of Health
[1R43AI060146-01A2]
FX This work was supported by contract grant N01-AI-15435 from the Virology
Branch, National Institute of Allergy and Infectious Diseases, National
Institutes of Health and grant 1R43AI060146-01A2 from the National
Institute of Allergy and Infectious Diseases, National Institutes of
Health
NR 43
TC 16
Z9 18
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD JAN
PY 2009
VL 81
IS 1
BP 37
EP 46
DI 10.1016/j.antiviral.2008.09.001
PG 10
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 396KF
UT WOS:000262589900005
PM 18840471
ER
PT J
AU Hula, WD
Hula, SNA
Doyle, PJ
AF Hula, William D.
Hula, Shannon N. Austermann
Doyle, Patrick J.
TI A preliminary evaluation of the reliability and validity of a
self-reported communicative functioning item pool
SO APHASIOLOGY
LA English
DT Article
CT 38th Annual Clinical Aphasiology Conference
CY MAY 27-JUN 01, 2008
CL Jackson Hole, WY
DE Assessment; Aphasia; Psychometrics
ID QUALITY-OF-LIFE; STROKE SURVIVORS; RASCH ANALYSIS; SCALE; RATINGS;
BURDEN
AB Background: Item banking, an approach to test development based in item response theory (IRT), is beginning to be applied to the measurement of communicative functioning in aphasia. This approach involves calibrating a set of test items responding to a particular latent trait to a common measurement scale. One method for validating such scales is to examine the degree to which obtained item calibration estimates agree with a priori item rankings based on theory or expert opinion. Aims: The purpose of this study was to evaluate the utility of magnitude estimation (ME) procedures for validating item banks containing self-reported functional performance items, and to make a preliminary analysis of the validity of a proposed item pool for measuring self-reported communicative functioning in aphasia. Methods Procedures: A total of 14 raters made ME ratings of physical and communicative functioning items. These ratings were evaluated for their intra and inter-observer reliability and, for subsets of the items, their correspondence with previously published IRT calibration estimates was also evaluated. Outcomes Results: Intra-rater reliability was moderate to high, and inter-rater reliability was high. Correspondence with IRT calibrations was high for physical items, and moderate for communication items. The distribution of ME ratings for the communication items was negatively skewed. Conclusions: ME procedures have utility for investigating the validity of functional performance items. The results suggest that communicative functioning may have a more complex latent structure than physical functioning, and that the proposed item pool might benefit from the inclusion of additional items at the lower end of the scale.
C1 [Hula, William D.; Hula, Shannon N. Austermann; Doyle, Patrick J.] Dept Vet Affairs Med Ctr, Pittsburgh, PA USA.
[Hula, William D.; Doyle, Patrick J.] Univ Pittsburgh, Pittsburgh, PA USA.
RP Hula, WD (reprint author), Ctr Geriatr Res Educ & Clin, VA Pittsburgh Healthcare Syst, 7180 Highland Dr,132A-H Pittsburgh, Pittsburgh, PA 15206 USA.
EM William.hula@va.gov
NR 27
TC 2
Z9 2
U1 1
U2 2
PU PSYCHOLOGY PRESS
PI HOVE
PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND
SN 0268-7038
J9 APHASIOLOGY
JI Aphasiology
PY 2009
VL 23
IS 7-8
BP 783
EP 796
AR PII 909565759
DI 10.1080/02687030802526064
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA 468QR
UT WOS:000267835400002
ER
PT J
AU Sung, JE
McNeil, MR
Pratt, SR
Dickey, MW
Hula, WD
Szuminsky, NJ
Doyle, PJ
AF Sung, Jee Eun
McNeil, Malcolm R.
Pratt, Sheila R.
Dickey, Michael Walsh
Hula, William D.
Szuminsky, Neil J.
Doyle, Patrick J.
TI Verbal working memory and its relationship to sentence-level reading and
listening comprehension in persons with aphasia
SO APHASIOLOGY
LA English
DT Article
CT 38th Annual Clinical Aphasiology Conference
CY MAY 27-JUN 01, 2008
CL Jackson Hole, WY
DE Working memory; Aphasia; Sentence comprehension; Aphasia severity
ID INDIVIDUAL-DIFFERENCES; CAPACITY; ADULTS; TASK
AB Background: Working memory (WM) has gained recent attention as a cognitive construct that may account for language comprehension deficits in persons with aphasia (PWA) (Caspari, Parkinson, LaPointe, Katz, 1998; Martin, Kohen, Kalinyak-Fliszar, 2008; Wright, Downey, Gravier, Love, Shapiro, 2007). However, few studies have investigated individual differences in performance on sentence comprehension tasks as a function of WM capacity in PWA when WM demands are manipulated. Aims: The purposes of the current study were: (1) to examine the relationships among verbal WM, sentence comprehension, and severity of impairment in PWA and (2) to investigate the differential performance of high versus low verbal WM groups on sentence comprehension tasks in which task demands were manipulated by the length of the sentence stimuli, complexity of syntactic structure, and by presentation method which varied the time over which the linguistic material was available for computation. Methods Procedures: A total of 20 PWA were divided into high and low WM groups based on a listening version of a WM sentence span task. Each participant completed a listening version (CRTT) and three reading versions (CRTT-R) of the Computerised Revised Token Test as the sentence comprehension tasks. Outcomes Results: The WM task significantly predicted performance on the CRTT conditions in which information was only temporarily available, thereby imposing greater WM demands on sentence comprehension. The verbal WM task was significantly correlated with aphasia severity and a principal components analysis revealed that the WM task, overall aphasia severity, and overall reading impairment level loaded on a single factor with 76% of shared variance. The low WM group's performance was significantly lower than the high WM group on the CRTT subtests with syntactically more complex structures and on the CRTT conditions with temporally restricted presentation methods. Conclusions: This verbal WM task was significantly and moderately correlated with the overall severity of aphasia as well as with both listening and reading sentence comprehension. The WM group differences emerged only in sentence comprehension tasks with greater WM demands. These results are consistent with the notion that WM effects are most evident when WM capacity is sufficiently taxed by the task demands (e.g., Caplan Waters, 1999; Just Carpenter, 1992).
C1 [Sung, Jee Eun] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Sung, JE (reprint author), Univ Pittsburgh, 4033 Forbes Tower, Pittsburgh, PA 15260 USA.
EM jee311@gmail.com
RI Pratt, Sheila/H-7139-2013
OI Dickey, Michael Walsh/0000-0002-9068-3313
NR 25
TC 18
Z9 18
U1 2
U2 14
PU PSYCHOLOGY PRESS
PI HOVE
PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND
SN 0268-7038
J9 APHASIOLOGY
JI Aphasiology
PY 2009
VL 23
IS 7-8
BP 1040
EP 1052
AR PII 909574662
DI 10.1080/02687030802592884
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA 468QR
UT WOS:000267835400021
ER
PT J
AU Allen, DN
Goldstein, G
Caponigro, JM
Donohue, B
AF Allen, Daniel N.
Goldstein, Gerald
Caponigro, Janelle M.
Donohue, Bradley
TI The Effects of Alcoholism Comorbidity on Neurocognitive Function
Following Traumatic Brain Injury
SO APPLIED NEUROPSYCHOLOGY
LA English
DT Article
DE alcoholism; Halstead-Reitan Neuropsychological Battery; traumatic brain
injury
ID YOUNG-ADULTS; ABUSE; SCHIZOPHRENIA; INTOXICATION; CONSUMPTION;
DYSFUNCTION; LEVEL
AB Alcoholism and traumatic brain injury (TBI) often produce neuropsychological deficits. However, the extent and manner by which these factors interact is unclear. In this study, it was hypothesized that alcoholism would have compounding cognitive effects in individuals with TBI and alcoholism. Participants were divided into three groups, including a patient comparison (PC) group and groups with TBI with or without alcoholism histories. Participants were administered the Wechsler Adult Intelligence Scale-Revised and major components of the Halstead-Reitan Neuropsychological Test Battery. Comparing the groups on test performance, the TBI groups performed significantly worse than the PC group but did not significantly differ from each other. Thus, the effects of TBI on cognitive function overshadow preexisting deficits from the alcoholism.
C1 [Allen, Daniel N.; Donohue, Bradley] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA.
[Goldstein, Gerald; Caponigro, Janelle M.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Allen, DN (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA.
EM daniel.allen@unlv.edu
NR 30
TC 3
Z9 3
U1 2
U2 4
PU PSYCHOLOGY PRESS
PI HOVE
PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND
SN 0908-4282
J9 APPL NEUROPSYCHOL
JI Appl. Neuropsychol.
PY 2009
VL 16
IS 3
BP 186
EP 192
DI 10.1080/09084280903098687
PG 7
WC Clinical Neurology; Psychology
SC Neurosciences & Neurology; Psychology
GA 500LD
UT WOS:000270301000007
PM 20183171
ER
PT J
AU Moghadam-Kia, S
Chilek, K
Gaines, E
Costner, M
Rose, M
Okawa, J
Werth, VP
AF Moghadam-Kia, Siamak
Chilek, Katherine
Gaines, Elizabeth
Costner, Melissa
Rose, Mathew
Okawa, Joyce
Werth, Victoria P.
TI A Cutaneous Lupus Erythematosus Database: Review of The First 116
Prospectively Enrolled Patients
SO ARCHIVES OF DERMATOLOGICAL RESEARCH
LA English
DT Meeting Abstract
C1 [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Moghadam-Kia, Siamak; Chilek, Katherine; Gaines, Elizabeth; Rose, Mathew; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-3696
J9 ARCH DERMATOL RES
JI Arch. Dermatol. Res.
PD JAN
PY 2009
VL 301
IS 1
BP 45
EP 45
PG 1
WC Dermatology
SC Dermatology
GA 387QG
UT WOS:000261966100050
ER
PT J
AU Kwarciak, AM
Sisto, SA
Yarossi, M
Price, R
Komaroff, E
Boninger, ML
AF Kwarciak, Andrew M.
Sisto, Sue Ann
Yarossi, Mathew
Price, Robert
Komaroff, Eugene
Boninger, Michael L.
TI Redefining the Manual Wheelchair Stroke Cycle: Identification and Impact
of Nonpropulsive Pushrim Contact
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Biomechanics; Rehabilitation; Wheelchair
ID SPINAL-CORD-INJURY; SHOULDER JOINT KINETICS; UPPER EXTREMITY PAIN; 2
SPEEDS; PROPULSION BIOMECHANICS; MECHANICAL EFFICIENCY; SEAT POSITION;
USERS; INDIVIDUALS; PARAPLEGIA
AB Objectives: To create a comprehensive definition of the manual wheelchair stroke cycle, which includes multiple periods of pushrim contact, and to show its improved clinical benefit to wheelchair propulsion analyses.
Design: Cross-sectional biomechanics study.
Setting: Three motion analysis laboratories.
Participants: Persons (N=54) with paraplegia who use a manual wheelchair.
Interventions: Not applicable.
Main Outcome Measures: Pushrim forces, axle moments, and contact angles measured during wheelchair propulsion.
Results: Total force on the pushrim was used to define pushrim contact and positive axle moment was used to identify the included period of propulsive contact. During most strokes, periods of nonpropulsive contact existed before and after propulsive contact. Within these periods, braking moments were applied to the pushrim, resulting in negative power output, or power loss. Including nonpropulsive data decreased mean stroke moment and power. The magnitude and the angle over which braking moments and power loss occurred increased with wheel speed. Mean braking moment and power loss within the initial contact period were significantly (P<.001) related to stroke pattern.
Conclusions: The proposed definition of the stroke cycle provides a thorough and practical description of wheelchair propulsion. Researchers and clinicians should use this definition to understand and minimize the impact of nonpropulsive contact throughout the stroke.
C1 [Kwarciak, Andrew M.; Sisto, Sue Ann; Yarossi, Mathew; Komaroff, Eugene] Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ 07052 USA.
[Sisto, Sue Ann; Komaroff, Eugene] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
[Sisto, Sue Ann] SUNY Stony Brook, Dept Rehabil Sci, Stony Brook, NY 11794 USA.
[Price, Robert] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Boninger, Michael L.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn & Rehabil Sci & Technol, Pittsburgh, PA USA.
[Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Med Ctr Hlth Syst, Pittsburgh, PA USA.
RP Kwarciak, AM (reprint author), Kessler Med Rehabil Res & Educ Ctr, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.
EM akwarciak@kesslerfoundation.net
OI Boninger, Michael/0000-0001-6966-919X
FU National Institute on Disability and Rehabilitation Research
[H133A011107]; Henry H. Kessler Foundation.
FX Supported by the National Institute on Disability and Rehabilitation
Research (grain no. H133A011107) and by the Henry H. Kessler Foundation.
NR 37
TC 20
Z9 20
U1 2
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD JAN
PY 2009
VL 90
IS 1
BP 20
EP 26
DI 10.1016/j.apmr.2008.07.013
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 397IY
UT WOS:000262657600004
PM 19154825
ER
PT J
AU Muehlenkamp, JJ
Williams, KL
Gutierrez, PM
Claes, L
AF Muehlenkamp, Jennifer J.
Williams, Kirsten L.
Gutierrez, Peter M.
Claes, Laurence
TI Rates of Non-Suicidal Self-Injury in High School Students Across Five
Years
SO ARCHIVES OF SUICIDE RESEARCH
LA English
DT Article
DE adolescents; deliberate self-harm; high-school students; non-suicidal
self-injury; suicide
ID SUICIDE ATTEMPTS; COMMUNITY SAMPLE; RISK-FACTORS; ADOLESCENTS; HARM;
BEHAVIOR; TRENDS
AB It is believed that the rate of non-suicidal self-injury (NSSI) among high school students is increasing. However, no known research has examined the rates of NSSI among non-clinical, high school samples of adolescents across several years. The current study utilized archival data from five academic years [2001 to 2005 (N = 1393)] to address this limitation by examining the lifetime prevalence rates of NSSI in urban high school students within the Midwestern United States. Results indicate a significant difference in rates across years by gender. Females showed a significant increase in their rates of NSSI compared to males, who showed a significant decline, during the last 3 years of the study. Implications of these findings for school personnel and directions for future research discussed.
C1 [Muehlenkamp, Jennifer J.] Univ Wisconsin, Dept Psychol, Eau Claire, WI 54702 USA.
[Muehlenkamp, Jennifer J.; Williams, Kirsten L.] Univ N Dakota, Grand Forks, ND 58201 USA.
[Gutierrez, Peter M.] Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA.
[Claes, Laurence] Catholic Univ Louvain, B-3000 Louvain, Belgium.
RP Muehlenkamp, JJ (reprint author), Univ Wisconsin, Dept Psychol, 277 Hibbard Hall, Eau Claire, WI 54702 USA.
EM muehlejj@uwec.edu
OI Gutierrez, Peter/0000-0001-8981-8404
NR 25
TC 20
Z9 21
U1 2
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1381-1118
J9 ARCH SUICIDE RES
JI Arch. Suicide Res.
PY 2009
VL 13
IS 4
BP 317
EP 329
DI 10.1080/13811110903266368
PG 13
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 579XO
UT WOS:000276410900002
PM 19813109
ER
PT J
AU Amstadter, AB
Koenen, KC
Ruggiero, KJ
Acierno, R
Galea, S
Kilpatrick, DG
Gelernter, J
AF Amstadter, Ananda B.
Koenen, Karestan C.
Ruggiero, Kenneth J.
Acierno, Ron
Galea, Sandro
Kilpatrick, Dean G.
Gelernter, Joel
TI Variation in RGS2 is Associated with Suicidal Ideation in an
Epidemiological Study of Adults Exposed to the 2004 Florida Hurricanes
SO ARCHIVES OF SUICIDE RESEARCH
LA English
DT Article
DE gene association; RGS2; suicidal ideation; suicide; trauma
ID POPULATION GROUP ASSIGNMENT; POSTTRAUMATIC-STRESS; GENE POLYMORPHISMS;
SOCIAL SUPPORT; RISK-FACTORS; BEHAVIOR; ANXIETY; MARKERS; MODULATORS;
GENOTYPE
AB This study examined whether rs4606, a single nucleotide polymorphism (SNP) in the translated region at the 3' end of RGS2, was related to suicidal ideation in an epidemiologic sample of adults living in areas affected by the 2004 Florida hurricanes. An epidemiologic sample of residents of Florida was recruited via random digit-dial procedures after the 2004 Florida hurricanes; participants were interviewed about suicidal ideation, hurricane exposure, and social support. Participants who returned buccal DNA samples via mail (n = 607) were included here. Rs4606 in RGS2 was associated with increased symptoms of current suicidal ideation (p < 0.01). Each "C" allele was associated with 5.59 times increased risk of having current ideation. No gene-by-environment interactions were found, perhaps due to low power. RGS2 rs4606 is related to risk of current suicidal ideation in stressor-exposed adults.
C1 [Amstadter, Ananda B.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ruggiero, Kenneth J.; Acierno, Ron; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.; Acierno, Ron] Ralph Johnson VA Med Ctr, Charleston, SC USA.
[Galea, Sandro] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
RP Amstadter, AB (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,2-S, Charleston, SC 29425 USA.
EM amstadt@musc.edu
FU NIDA NIH HHS [K24 DA015105, K24 DA15105]; NIMH NIH HHS [F32 MH083469,
F32 MH083469-01, K08 MH070627, K08 MH070627-06, K08-MH070627, MH05220,
MH07055, MH078928, R01 MH078928, R01 MH078928-01A1, R21 MH074469-02];
PHS HHS [083469]
NR 31
TC 6
Z9 6
U1 4
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1381-1118
J9 ARCH SUICIDE RES
JI Arch. Suicide Res.
PY 2009
VL 13
IS 4
BP 349
EP 357
DI 10.1080/13811110903266541
PG 9
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 579XO
UT WOS:000276410900005
PM 19813112
ER
PT J
AU Gaffo, AL
Edwards, NL
Saag, KG
AF Gaffo, Angelo L.
Edwards, N. Lawrence
Saag, Kenneth G.
TI Hyperuricemia and cardiovascular disease: how strong is the evidence for
a causal link?
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Review
ID SERUM URIC-ACID; INTIMA-MEDIA THICKNESS; ALL-CAUSE MORTALITY; GLOMERULAR
HYPERTENSION; BLOOD-PRESSURE; LONG-TERM; INDEPENDENT PREDICTOR;
METABOLIC SYNDROME; OXIDATIVE STRESS; KIDNEY-FUNCTION
AB An association between high levels of serum urate and cardiovascular disease has been proposed for many decades. However, it was only recently that compelling basic science data, small clinical trials, and epidemiological studies have provided support to the idea of a true causal effect. In this review we present recently published data that study the association between hyperuricemia and selected cardiovascular diseases, with a final conclusion about the possibility of this association being causal.
C1 [Saag, Kenneth G.] Univ Alabama, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Edwards, N. Lawrence] Univ Florida, Div Rheumatol, Gainesville, FL 32610 USA.
[Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Saag, KG (reprint author), Univ Alabama, Div Clin Immunol & Rheumatol, FOT 820,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM ksaag@uab.edu
FU Takeda; Savient; Merck
FX Research grants were received from Takeda, Savient and Merck.
NR 51
TC 30
Z9 32
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2009
VL 11
IS 4
AR 240
DI 10.1186/ar2761
PG 7
WC Rheumatology
SC Rheumatology
GA 508MU
UT WOS:000270936400011
PM 19725932
ER
PT J
AU Tian, L
Luo, NL
Klein, RL
Chung, BH
Garvey, WT
Fu, YC
AF Tian, Ling
Luo, Nanlan
Klein, Richard L.
Chung, B. Hong
Garvey, W. Timothy
Fu, Yuchang
TI Adiponectin reduces lipid accumulation in macrophage foam cells
SO ATHEROSCLEROSIS
LA English
DT Article
DE Adiponectin; Lipid accumulation; Macrophage foam cells; Atherosclerosis
ID LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; PLASMA-PROTEIN
ADIPONECTIN; ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; CHOLESTEROL EFFLUX;
METABOLIC SYNDROME; DEFICIENT MICE; ATHEROSCLEROSIS; DIFFERENTIATION
AB Adiponectin is one of several, important metabolically active cytokines secreted from adipocytes. Low circulating levels of this adipokine have been associated epidemiologically with obesity. insulin resistance, type 11 diabetes, and cardiovascular disease. To determine if adiponectin can modulate lipid metabolism in macrophages, we expressed the adiponectin gene in human THP-1 macrophage foam Cells using a lentiviral vector expression system and demonstrated that macrophages transduced with the adiponectin gene had decreased lipid accumulation compared with control macrophages transduced with the LacZ gene. Macrophages transduced with the adiponectin gene also exhibited decreased oxidized low-density lipoprotein (oxLDL) uptake and increased HDL-mediated cholesterol efflux.
Additional studies Suggest two potential mechanisms for the reduced lipid accumulation in these adiponectin-transduced macrophage foam cells. The first mechanism involves the PPAR gamma and LXR signaling pathways which up-regulate the expression of ABCA1 and promote lipid efflux front these cells. The second mechanism involves decreased lipid uptake and increased lipid hydrolysis which may result front decreased SR-AI and increased SR-BI and HSL gene activities in the transformed macrophage foam cells. We also demonstrated that the expression of two proatherogenic cytokines, MCP-1 and TNF alpha. were decreased in the adiponectin-transduced macrophage foam cells.
These results suggest that adiponectin may modulate Multiple pathways of lipid metabolism in macrophages. Our Studies provide new insights into potential mechanisms of adiponectin-mediated alterations in lipid metabolism and macrophage foam cell formation which may impact the development of atherosclerosis. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Tian, Ling; Luo, Nanlan; Chung, B. Hong; Garvey, W. Timothy; Fu, Yuchang] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Fu, YC (reprint author), Univ Alabama, Dept Nutr Sci, Shelby Bldg 1213, Birmingham, AL 35294 USA.
EM yfu@uab.edu
RI Tian, Ling/J-6417-2012
FU National Institutes of Health [PO1-HL55782, DK38764, P20 RR16434];
Medical Research Service of the Department of Veterans Affairs; American
Diabetes Association [1-07-RA-49]
FX This work was supported by grants from the National Institutes of Health
(PO1-HL55782, DK38764) and the Merit Review Program of the Medical
Research Service of the Department of Veterans Affairs to WTG and RLK:
by grants from National Institutes of Health (P20 RR16434) and American
Diabetes Association (1-07-RA-49) to YF
NR 30
TC 61
Z9 67
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2009
VL 202
IS 1
BP 152
EP 161
DI 10.1016/j.atherosclerosis.2008.04.011
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 398JW
UT WOS:000262729400021
PM 18511057
ER
PT J
AU Carlson, NE
Brenner, LA
Wierman, ME
Harrison-Felix, C
Morey, C
Gallagher, S
Ripley, D
AF Carlson, N. E.
Brenner, L. A.
Wierman, M. E.
Harrison-Felix, C.
Morey, C.
Gallagher, S.
Ripley, D.
TI Hypogonadism on admission to acute rehabilitation is correlated with
lower functional status at admission and discharge
SO BRAIN INJURY
LA English
DT Article
DE Endocrine dysfunction; physical function; testosterone; traumatic brain
injury
ID TRAUMATIC BRAIN-INJURY; LOW TESTOSTERONE LEVELS; SEX-HORMONES;
HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE;
COGNITIVE FUNCTION; PRACTICAL SCALE; INFECTED MEN; ELDERLY-MEN
AB Primary objective: To investigate the association between hormone levels and functional status during acute TBI rehabilitation. Research design: Retrospective cohort study of 43 men with moderate-to-severe TBI admitted to an acute rehabilitation unit during a 1 year period. Methods and procedures: Labs were drawn on admission, including total and free testosterone (T), prolactin, adrenocorticotropin hormone (ACTH), cortisol, thyroid stimulating hormone (TSH), free thyroxine (fT4) and insulin-like growth factor (IGF-1). Functional Independence Measure (FIM) scores were obtained at admission and discharge. Main outcome and results: Associations between admission hormone levels and the main outcomes, admission and discharge FIM scores, were assessed using linear regression. Lower total and free T-levels at admission were associated with lower total FIM scores at admission (p 0.038) and discharge (p 0.046). Higher cortisol levels at admission were significantly associated with lower admission (p = 0.012) and discharge (p = 0.036) scores on the cognitive-FIM. Prolactin, TSH, fT4 and IGF-1 were not correlated with functional status. Conclusions: In men, lower total and free T-levels at admission to acute rehabilitation correlate with lower admission and discharge FIM scores. These data support the need for studies to investigate the impact of physiological testosterone therapy on outcomes during and post-rehabilitation.
C1 [Carlson, N. E.] Univ Colorado Denver, Dept Biostat & Informat, Aurora, CO 80045 USA.
[Brenner, L. A.] VA VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA.
[Brenner, L. A.; Harrison-Felix, C.; Morey, C.; Ripley, D.] Craig Hosp, Rocky Mt Reg Traumat Brain Injury Syst, Englewood, CO USA.
[Wierman, M. E.] Univ Colorado, Dept Psychiat, Denver, CO USA.
[Brenner, L. A.] Univ Colorado, Dept Neurol, Denver, CO USA.
[Brenner, L. A.; Harrison-Felix, C.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO USA.
[Wierman, M. E.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA.
[Wierman, M. E.] Denver VA Med Ctr, Res Serv, Denver, CO USA.
[Gallagher, S.] Childrens Hosp, Denver, CO 80218 USA.
RP Carlson, NE (reprint author), Univ Colorado Denver, Dept Biostat & Informat, 17000 E 17th PL,MS C245, Aurora, CO 80045 USA.
EM nichole.carlson@ucdenver.edu
NR 48
TC 15
Z9 15
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PY 2009
VL 23
IS 4
BP 336
EP 344
AR PII 909972518
DI 10.1080/02699050902788535
PG 9
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 425MY
UT WOS:000264643000008
PM 19330595
ER
PT J
AU Saunders, LL
Selassie, AW
Hill, EG
Nicholas, JS
Horner, MD
Corrigan, JD
Lackland, DT
AF Saunders, Lee L.
Selassie, Anbesaw W.
Hill, Elizabeth G.
Nicholas, Joyce S.
Horner, Michael David
Corrigan, John D.
Lackland, Daniel T.
TI A population-based study of repetitive traumatic brain injury among
persons with traumatic brain injury
SO BRAIN INJURY
LA English
DT Article
DE Brain injuries; epilepsy; seizures; epidemiology; survival analysis
ID PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION;
SOCIOECONOMIC-STATUS; UNITED-STATES; HEAD TRAUMA; RATES;
HOSPITALIZATION; COLLEGIATE; SEIZURES; OUTCOMES
AB Primary objective: The objective was to estimate and compare the hazards of repetitive traumatic brain injury (RTBI) events as a function of the index TBI severity, in a cohort of TBI hospital discharges include in the South Carolina Traumatic Brain Injury Follow-up Registry. Research design: Retrospective cohort. Methods and procedures: There were 4357 persons with TBI who were followed from the index hospital discharge through 31 December 2005 for RTBI events through the statewide hospital discharge (HD) and emergency department (ED) records. Prentice, Williams, Peterson total time/conditional probability model (PWP-CP) for recurrent events survival analysis was used to assess RTBI as a function of index TBI severity. Main outcomes and results: Index TBI severity approached significance in its relationship with RTBI, with persons with a severe index TBI experiencing events at a higher rate than those with a mild/moderate index TBI. Among the other covariates evaluated, epilepsy/seizure disorder, race, gender, payer status, cause of injury and having a prior history of TBI were associated with RTBI. Conclusions: While TBI severity approached significance with RTBI, other variables, such as epilepsy/seizure disorder, seem to have a more significant relationship with RTBI.
C1 [Saunders, Lee L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Selassie, Anbesaw W.; Hill, Elizabeth G.; Nicholas, Joyce S.; Lackland, Daniel T.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
[Horner, Michael David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA.
[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.
RP Saunders, LL (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.
EM saundel@musc.edu
FU Division of Injury Response, National Center for Injury Prevention and
Control (CIPC), Centers for Disease Control and Prevention (CDC)
[U17/CCU421926]
FX This study was supported by Grant No. U17/CCU421926 from the Division of
Injury Response, National Center for Injury Prevention and Control
(CIPC), Centers for Disease Control and Prevention (CDC) ( PI: Anbesaw
W. Selassie). The study was performed pursuant to a jointly financed
cooperative arrangement between the NCPIC, the National Center for
Chronic Disease Prevention and Health Promotion, CDC and the Social
Security Administration (SSA), Office of Disability Income and Support
Programs. The opinions and conclusions expressed are solely the authors'
and should not be construed as representing the opinions or policy of
CDC, SSA, or any agency of the federal government.
NR 33
TC 10
Z9 10
U1 5
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PY 2009
VL 23
IS 11
BP 866
EP 872
AR PII 915242880
DI 10.1080/02699050903283213
PG 7
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 498JY
UT WOS:000270137300002
PM 20100122
ER
PT J
AU Xiang, N
Zhao, R
Zhong, WX
AF Xiang, Nong
Zhao, Rui
Zhong, Weixiong
TI Sodium selenite induces apoptosis by generation of superoxide via the
mitochondrial-dependent pathway in human prostate cancer cells
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Antioxidant enzymes; Apoptosis; Mitochondria; Selenium Superoxide
ID OXIDATIVE STRESS; CARCINOSTATIC ACTIVITY; IONIZING-RADIATION; HEPG(2)
CELLS; PREVENTION; SELENOMETHIONINE; RISK; CHEMOPREVENTION;
METHIONINASE; INVOLVEMENT
AB Purpose Studies have demonstrated that selenium supplementation reduces the incidence of cancer, particularly prostate cancer. Evidence from experimental studies suggests that apoptosis is a key event in cancer chemoprevention by selenium and reactive oxygen species play a role in induction of apoptosis by selenium compounds. The current study was designed to investigate the role of superoxide and mitochondria in selenite-induced apoptosis in human prostate cancer cells.
Methods LNCaP cells were transduced with adenoviral constructs to overexpress four primary antioxidant enzymes: manganese superoxide dismutase (MnSOD), copper-zinc superoxide dismutase (CuZnSOD), catalase (CAT), or glutathione peroxidase 1 (GPx1). Cell viability, apoptosis, and superoxide production induced by sodium selenite were analyzed by the MTT assay, chemiluminescence, flow cytometry, western blot analysis, and Hoechst 33342 staining following overexpression of these antioxidant enzymes.
Results Our study shows the following results: (1) selenite induced cancer cell death and apoptosis by producing superoxide radicals; ( 2) selenite-induced superoxide production, cell death, and apoptosis were inhibited by overexpression of MnSOD, but not by CuZnSOD, CAT, or GPx1; and (3) selenite treatment resulted in a decrease in mitochondrial membrane potential, release of cytochrome c into the cytosol, and activation of caspases 9 and 3, events that were suppressed by overexpression of MnSOD.
Conclusions This study demonstrates that selenite induces cell death and apoptosis by production of superoxide in mitochondria and activation of the mitochondrial apoptotic pathway and MnSOD plays an important role in protection against prooxidant effects of superoxide from selenite. The data suggest that superoxide production in mitochondria is, at least in part, a key event in selenium-induced apoptosis in prostate cancer cells.
C1 [Xiang, Nong; Zhao, Rui; Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53792 USA.
[Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA.
RP Zhong, WX (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53792 USA.
EM wzhong3@wisc.edu
FU National Cancer Institute [CA114281]; Office of Research and
Development, Biomedical Laboratory Research and Development Service,
Department of Veterans Affairs
FX We thank Dr. Jeanne Bourdeau-Heller for her technical assistance. This
work was funded, in part, by grants from the National Cancer Institute
(CA114281) and the Office of Research and Development, Biomedical
Laboratory Research and Development Service, Department of Veterans
Affairs.
NR 44
TC 55
Z9 60
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD JAN
PY 2009
VL 63
IS 2
BP 351
EP 362
DI 10.1007/s00280-008-0745-3
PG 12
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 377XX
UT WOS:000261286800018
PM 18379781
ER
PT J
AU Latini, DM
Hart, SL
Coon, DW
Knight, SJ
AF Latini, David M.
Hart, Stacely L.
Coon, David W.
Knight, Sara J.
TI Sexual Rehabilitation After Localized Prostate Cancer Current
Interventions and Future Directions
SO CANCER JOURNAL
LA English
DT Article
DE prostate cancer; symptom management; psychosocial interventions;
conceptual model
ID QUALITY-OF-LIFE; SELF-MANAGEMENT PROGRAM; LOW-INCOME PATIENTS; RADICAL
PROSTATECTOMY; ERECTILE DYSFUNCTION; STRESS-MANAGEMENT;
RANDOMIZED-TRIAL; SUPPORT GROUPS; HEALTH-STATUS; STEPPED CARE
AB Many published articles have documented the impact of prostate-cancer treatment on sexual functioning in men treated for localized disease. Surprisingly, the literature on interventions to rehabilitate men's sexual functioning is much more limited. In this article, we review the sexual-rehabilitation interventions for prostate-cancer patients and identify a number of common themes across interventions. We also identify areas where further research is needed and propose a conceptual model based on psychologic and nursing theories and informed by the published research.
C1 [Latini, David M.] Michael E DeBakey VA Med Ctr, Dev Ctr Excellence, Houston, TX USA.
[Latini, David M.] Michael E DeBakey VA Med Ctr, Hlth Serv Res, Houston, TX USA.
[Latini, David M.] Michael E DeBakey VA Med Ctr, Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX USA.
[Latini, David M.] Michael E DeBakey VA Med Ctr, Scott Dept Urol, Houston, TX USA.
[Hart, Stacely L.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada.
[Coon, David W.] Arizona State Univ, Coll Nursing & Healthcare Innovat, Phoenix, AZ USA.
[Knight, Sara J.] Univ Calif San Francisco, San Francisco Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Knight, Sara J.] Genitourinary Canc Epidemiol & Populat Sci Progra, Dept Psychiat, San Francisco, CA USA.
[Knight, Sara J.] Genitourinary Canc Epidemiol & Populat Sci Progra, Dept Urol, San Francisco, CA USA.
[Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Latini, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, HSR&D Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM david.latini@va.gov
RI Hart, Stacey/E-4819-2011
OI Latini, David/0000-0002-6161-4861
FU National Cancer Institute [R03 CA101586, R03 CA128475]; Health Services
Research & Development Center of Excellence; Michael E. DeBakey Veterans
Affairs Medical Center [HFP90-020]; American Cancer Society
[06-083-01-CPPB]
FX Supported by National Cancer Institute grants R03 CA101586 (to D.M.L.)
and R03 CA128475 (to D.W.C.), in part by Health Services Research &
Development Center of Excellence, Michael E. DeBakey Veterans Affairs
Medical Center grant HFP90-020, and the American Cancer Society Grant
06-083-01-CPPB (to D.M.L.).
NR 60
TC 15
Z9 16
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1528-9117
J9 CANCER J
JI Cancer J.
PD JAN-FEB
PY 2009
VL 15
IS 1
BP 34
EP 40
PG 7
WC Oncology
SC Oncology
GA 405FA
UT WOS:000263207000007
PM 19197171
ER
PT J
AU Knight, SJ
Latini, DM
AF Knight, Sara J.
Latini, David M.
TI Sexual Side Effects and Prostate Cancer Treatment Decisions Patient
Information Needs and Preferences
SO CANCER JOURNAL
LA English
DT Article
DE prostate; cancer treatment; sexual side effects
ID QUALITY-OF-LIFE; TREATMENT CHOICES; HEALTH STATES; UTILITIES; MEN; AIDS;
PREDICTORS; MANAGEMENT; CARCINOMA; OUTCOMES
AB Prostate cancer treatment decision making requires complex trade-offs among treatment outcomes, and sexual function is a central consideration for most men. Although sexual function is included in prostate cancer decision models, survival and fear of recurrence and cancer progression weigh more heavily in these decisions for many men than concerns about treatment impact on sexuality. In this article, we discuss the importance of sexuality in men's treatment decisions for prostate cancer. We focus on men's preferences for maintaining sexual function and their needs for information about the risk of sexual side effects with prostate cancer treatment. Our review suggests that among men diagnosed with prostate cancer sexual function is less important to men than concerns about survival, but is more highly valued than other side effects and treatment characteristics. However, there is evidence that concerns about sexuality are not in proportion with the associated risk for sexual problems with prostate cancer treatment and men acknowledge unmet needs for information about sexuality in making prostate cancer treatment decisions.
C1 [Knight, Sara J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Program Improve Care Vet Complex Comorbid Condit, San Francisco, CA 94121 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA.
[Latini, David M.] Baylor Coll Med, Michael E DcBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Scott Dept Urol, Houston, TX 77030 USA.
[Latini, David M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
RP Knight, SJ (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Program Improve Care Vet Complex Comorbid Condit, 4150 Clement St, San Francisco, CA 94121 USA.
EM sara.knight@med.va.gov
OI Latini, David/0000-0002-6161-4861
FU Veterans Administration (VA) Health Services Research and Development
[IIR02-142-1]; Health Services Research & Development Center of
Excellence [HFP90-020]; Mentored Research Scholar [06-083-01-CPPB];
American Cancer Society
FX The contents of this work are solely the responsibility of the author
and do not necessarily represent the official views of the Department of
Veterans Affairs.
NR 45
TC 14
Z9 15
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1528-9117
J9 CANCER J
JI Cancer J.
PD JAN-FEB
PY 2009
VL 15
IS 1
BP 41
EP 44
PG 4
WC Oncology
SC Oncology
GA 405FA
UT WOS:000263207000008
PM 19197172
ER
PT J
AU Tabassam, FH
Graham, DY
Yamaoka, Y
AF Tabassam, Fazal H.
Graham, David Y.
Yamaoka, Yoshio
TI Helicobacter pylori activate epidermal growth factor receptor- and
phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase
kinase 3 beta phosphorylation
SO CELLULAR MICROBIOLOGY
LA English
DT Article
ID GASTRIC EPITHELIAL-CELLS; NF-KAPPA-B; MUCOSAL INTERLEUKIN-8 PRODUCTION;
PROMOTER ACTIVATION; DOWN-REGULATION; CANCER CELLS; PROTEIN; PATHWAY;
OIPA; CHEMORESISTANCE
AB The signalling pathways leading to the development of Helicobacter pylori-induced gastric cancer remain poorly understood. We tested the hypothesis that H. pylori infections involve the activation of Akt signalling in human gastric epithelial cancer cells. Immunoblot, immunofluorescence and kinase assays show that H. pylori infection of gastric epithelial cells induced phosphorylation of Akt at Ser 473 and Thr 308. Mutations in the H. pylori virulence factor OipA dramatically reduced phosphorylation of Ser 473, while the cag pathogenicity island mutants predominantly inhibited phosphorylation of Thr 308. As the downstream of Akt activation, H. pylori infection inactivated the inactivation of glycogen synthase kinase 3 beta at Ser 9 by its phosphorylation. As the upstream of Akt activation, H. pylori infection activated epidermal growth factor receptor (EGFR) at Tyr 992, phosphatidylinositol 3-OH kinase (PI3K) p85 subunit and PI3K-dependent kinase 1 at Ser 241. Pharmacologic inhibitors of PI3K or mitogen-activated protein kinase kinase (MEK), Akt knock-down and EGFR knock-down showed that H. pylori infection induced the activation of EGFR -> PI3K -> PI3K-dependent kinase 1 -> Akt -> extracellular signal-regulated kinase signalling pathways, the inactivation of glycogen synthase kinase 3 beta and interleukin-8 production. The combined functions of cag pathogenicity island and OipA were necessary and sufficient for full activation of signalling at each level. We propose activation of these pathways as a novel mechanism for H. pylori-mediated carcinogenesis.
C1 [Yamaoka, Yoshio] Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA.
Baylor Coll Med, Houston, TX 77030 USA.
RP Yamaoka, Y (reprint author), Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA.
EM yyamaoka@bcm.tmc.edu
FU Office of Research and Development Medical Research Service Department
of Veterans Affairs [DK56338]; NIH [DK 62813]
FX This material is based upon work supported in part by the Office of
Research and Development Medical Research Service Department of Veterans
Affairs, by Public Health Service Grant DK56338 that funds the Texas
Medical Center Digestive Diseases Center. The project described was also
supported by Grant Number DK 62813 from NIH. Their contents are solely
the responsibility of the authors and do not necessarily represent the
official views of the VA or NIH.
NR 49
TC 53
Z9 53
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-5814
J9 CELL MICROBIOL
JI Cell Microbiol.
PD JAN
PY 2009
VL 11
IS 1
BP 70
EP 82
DI 10.1111/j.1462-5822.2008.01237.x
PG 13
WC Cell Biology; Microbiology
SC Cell Biology; Microbiology
GA 390FQ
UT WOS:000262150100006
PM 18782353
ER
PT J
AU Zimmerman, B
Simaan, M
Lee, MH
Luttrell, LM
Laporte, SA
AF Zimmerman, Brandon
Simaan, May
Lee, Mi-Hye
Luttrell, Louis M.
Laporte, Stephane A.
TI c-Src-mediated phosphorylation of AP-2 reveals a general mechanism for
receptors internalizing through the clathrin pathway
SO CELLULAR SIGNALLING
LA English
DT Article
DE G protein-coupled receptors; AT1R; beta arrestins; c-Src; AP-2;
Clathrin; EGF receptor
ID PROTEIN-COUPLED RECEPTORS; INTRACELLULAR TRAFFICKING PATHWAYS;
AGONIST-INDUCED INTERNALIZATION; ACTIVATING-FACTOR RECEPTOR;
GROWTH-FACTOR RECEPTOR; II TYPE-1 RECEPTOR; TYROSINE PHOSPHORYLATION;
BETA-ARRESTIN; ADAPTER PROTEIN-2; MU-2 SUBUNIT
AB Clathrin-mediated endocytosis is a complex process regulated at many different levels. We showed previously that activation of the angiotensin type 1 receptor (AT1R), which belongs to the G protein-coupled receptor (GPCR) family, leads to c-Src-dependent tyrosine phosphorylation of beta 2-adaptin, a subunit of the clathrin adaptor AP-2. The phosphorylation of beta 2-adaptin on tyrosine residue 737 (Y737) negatively regulates its interaction with beta arrestin, another important clathrin adaptor for GPCR internalization. Here we sought to determine whether AP-2 phosphorylation represents a general mechanism for different receptors internalizing through the clathrin pathway. Using a specifically designed antibody against the phosphorylated form of Y737 on beta 2-adaptin, we demonstrate that this residue is phosphorylated by AT1R in different cell types like HEK293, COS-7 and vascular smooth muscle cells. Using RNA interference approaches, we reveal that this agonist-mediated event is both beta arrestin- and c-Src-dependent, and that it occurs at the plasma membrane in clathrin-coated vesicles (CCVs). We further show that this is not only a common event employed by other GPCRs like the beta 2-adrenergic, vasopressin V2, bradykinin type 2, platelet-activating factor and endothelin A receptors but that the epidermal growth factor receptor is capable of eliciting the phosphorylation of AP-2 in CCVs. Our results imply that tyrosine phosphorylation of Y737 on beta 2-adaptin is a common regulatory mechanism employed by different receptors undergoing clathrin-dependent endocytosis, and suggest a wider function for this event than originally anticipated. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Zimmerman, Brandon; Simaan, May; Laporte, Stephane A.] McGill Univ, Royal Victoria Hosp, Dept Med, Hormones & Canc Res Unit,Hlth Ctr,Res Inst, Montreal, PQ H3A 1A1, Canada.
[Zimmerman, Brandon; Laporte, Stephane A.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
[Lee, Mi-Hye; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Lee, Mi-Hye; Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Lee, Mi-Hye; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Laporte, SA (reprint author), McGill Univ, Royal Victoria Hosp, Dept Med, Hormones & Canc Res Unit,Hlth Ctr,Res Inst, 687 Pine Ave W,Room H7-64, Montreal, PQ H3A 1A1, Canada.
EM stephane.laporte@mcgill.ca
RI Laporte, Stephane/F-3282-2012
FU Canadian Institutes of Health Research (CIHR); CIHR; McGill University
Health Center Research Institute (MUHC-RI); Fonds de la Recherche en
Sante du Quebec (FRSQ)
FX We thank Drs Witold A. Neugebauer and Emanuel Escher (Universite de
Sherbrooke) for peptide synthesis and the Angiotensin II analog. This
work was supported by a Canadian Institutes of Health Research (CIHR)
Operating Grant and a CIHR Confocal Maintenance Grant to S.A.L. B.Z.
holds a CIHR studentship award. M.S. holds a Fellowship award from the
McGill University Health Center Research Institute (MUHC-RI), which is a
recognized Fonds de la Recherche en Sante du Quebec (FRSQ) supported
Institute. SAL holds a Canada Research Chair in Molecular Endocrinology.
NR 41
TC 31
Z9 33
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JAN
PY 2009
VL 21
IS 1
BP 103
EP 110
DI 10.1016/j.cellsig.2008.09.013
PG 8
WC Cell Biology
SC Cell Biology
GA 389AB
UT WOS:000262060900013
PM 18938240
ER
PT J
AU Lerner, A
Bagic, A
Hanakawa, T
Boudreau, EA
Pagan, F
Mari, Z
Bara-Jimenez, W
Aksu, M
Sato, S
Murphy, DL
Hallett, M
AF Lerner, Alicja
Bagic, Anto
Hanakawa, Takashi
Boudreau, Eilis A.
Pagan, Fernando
Mari, Zoltan
Bara-Jimenez, William
Aksu, Murat
Sato, Susumu
Murphy, Dennis L.
Hallett, Mark
TI Involvement of Insula and Cingulate Cortices in Control and Suppression
of Natural Urges
SO CEREBRAL CORTEX
LA English
DT Article
ID EVENT-RELATED FMRI; OBSESSIVE-COMPULSIVE DISORDER; OLD-WORLD MONKEY;
STOP-SIGNAL TASK; RESPONSE-INHIBITION; FUNCTIONAL MRI; PHYSIOLOGICAL
CONDITION; VOLUNTARY SUPPRESSION; TOURETTE-SYNDROME; BRAIN RESPONSES
AB The physiology of control and suppression of natural urges is not well understood. We used [(15)O]H(2)O positron-emission tomography imaging to identify neural circuits involved in suppression of spontaneous blinking as a model of normal urges. Suppression of blinking was associated with prominent activation of bilateral insular-claustrum regions, right more than left; activation was also found in bilateral anterior cingulate cortex (ACC), supplementary motor areas, and the face area of the primary motor cortex bilaterally. These results suggest a central role for the insula possibly together with ACC in suppression of blinking.
C1 [Lerner, Alicja; Hallett, Mark] Natl Inst Neurol Disorders & Stroke, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA.
[Bagic, Anto] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Hanakawa, Takashi] Natl Ctr Neurol & Psychiat, Dept Cort Funct Disorder, Tokyo 1878502, Japan.
[Boudreau, Eilis A.] Portland VA Med Ctr, Hlth Sci Res & Dev Program, Portland, OR 97239 USA.
[Pagan, Fernando] Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA.
[Mari, Zoltan] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.
[Bara-Jimenez, William] Bethesda Neurosci Clin, Bethesda, MD 20885 USA.
[Aksu, Murat] Erciyes Univ, Fac Med, Dept Neurol, TR-38039 Kayseri, Turkey.
[Sato, Susumu] Natl Inst Neurol Disorders & Stroke, EEG Sect, Bethesda, MD 20892 USA.
[Murphy, Dennis L.] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA.
RP Lerner, A (reprint author), Natl Inst Neurol Disorders & Stroke, Human Motor Control Sect, NIH, 10 Ctr Dr,Bldg 10, Bethesda, MD 20892 USA.
EM lernera@mail.nih.gov
FU Intramural Research Programs of the National Institute of Neurological
Disorders and Stroke; National Institute of Mental Health with the
National Institutes of Health
FX Intramural Research Programs of the National Institute of Neurological
Disorders and Stroke and the National Institute of Mental Health with
the National Institutes of Health.
NR 69
TC 43
Z9 46
U1 4
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
J9 CEREB CORTEX
JI Cereb. Cortex
PD JAN
PY 2009
VL 19
IS 1
BP 218
EP 223
DI 10.1093/cercor/bhn074
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 383ND
UT WOS:000261679400021
PM 18469316
ER
PT J
AU Pandhi, N
Smith, MA
Kind, AJH
Frytak, JR
Finch, MD
AF Pandhi, Nancy
Smith, Maureen A.
Kind, Amy J. H.
Frytak, Jennifer R.
Finch, Michael D.
TI The Quality of Diabetes Care following Hospitalization for Ischemic
Stroke
SO CEREBROVASCULAR DISEASES
LA English
DT Article
DE Cerebrovascular accident; Diabetes mellitus; Quality of care
ID HEALTH-CARE; RACIAL DISPARITIES; UNITED-STATES; RISK-FACTORS;
PREVENTION; HISPANICS; AMERICAN; VETERANS; DISEASE; BLACKS
AB Background: Follow-up is critically important for stroke survivors with diabetes, yet there is limited research about the quality of diabetes care that these patients receive. We investigated performance on diabetes quality of care indicators for stroke survivors overall and by race. Methods: Claims data was extracted for 1,460 Medicare beneficiaries with preexisting diabetes who survived hospitalization for acute ischemic stroke in 2000. Adjusted probabilities of receiving HbA1c, LDL and dilated eye exams were estimated using logistic regression. Results: 53% had a dilated eye exam, 60% received an LDL check, 73% percent had their HbA1c checked at least once and only 51% received two or more HbA1c checks. In the unadjusted results, blacks were significantly less likely than whites to receive these tests. Conclusions: Care of stroke survivors, particularly blacks, shows gaps according to guidelines. Copyright (C) 2009 S. Karger AG, Basel
C1 [Pandhi, Nancy; Smith, Maureen A.; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
[Pandhi, Nancy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA.
[Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, Madison, WI USA.
[Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI USA.
[Frytak, Jennifer R.] i3 Innovus, Minneapolis, MN USA.
[Finch, Michael D.] Finch & King Inc, Minneapolis, MN USA.
RP Pandhi, N (reprint author), 557 WARF Off Bldg,610 Walnut St, Madison, WI 53726 USA.
EM nancy.pandhi@fammed.wisc.edu
FU National Institute of Aging [R01-AG19747]; Community-Academic
Partnerships core of the University of Wisconsin Institute for Clinical
and Translational Research (UW ICTR) funded through an NIH [1 UL1
RR025011]
FX This study was supported by a grant (R01-AG19747) from the National
Institute of Aging (Principal Investigator: Maureen Smith, MD, PhD).
This project was also supported by the Community-Academic Partnerships
core of the University of Wisconsin Institute for Clinical and
Translational Research (UW ICTR) funded through an NIH Clinical and
Translational Science Award (CTSA), grant No. 1 UL1 RR025011.
NR 28
TC 4
Z9 4
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2009
VL 27
IS 3
BP 235
EP 240
DI 10.1159/000196821
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 409VN
UT WOS:000263534000005
PM 19176956
ER
PT J
AU Kuschner, WG
Gruenewald, DA
Clum, N
Beal, A
Ezeji-Okoye, SC
AF Kuschner, Ware G.
Gruenewald, David A.
Clum, Nancy
Beal, Alice
Ezeji-Okoye, Stephen C.
TI Implementation of ICU Palliative Care Guidelines and Procedures A
Quality Improvement Initiative Following an Investigation of Alleged
Euthanasia
SO CHEST
LA English
DT Article
DE end-of-life care; guidelines; ICU; life support; palliative care
ID LIFE-SUSTAINING TREATMENT; INTENSIVE-CARE; END; UNIT; WITHDRAWAL;
SUPPORT; STATEMENT; DEATH
AB Ethical conflicts are commonly encountered in the course of delivering end-of-life care in the ICU. Some ethical concerns have legal dimensions, including concerns about inappropriate hastening of death. Despite these concerns, many lCUs do not have explicit policies and procedures for withdrawal of life-sustaining treatments. We, describe a US Office of Inspector General (OIG) investigation of end-of-life care practices in our ICU. The investigation focused on care delivered to four critically ill patients with terminal diseases and an ICU nurse's concern that the patients had been subjected to euthanasia. The OIG investigation also assessed the validity of allegations that patient flow in and out of our ICU wits inappropriately influenced by, scheduled surgeries and that end-of-life care policies in our ICU were not clear. Although the investigation did not substantiate the allegations of euthanasia or inappropriate ICU patient flow, it did find that the policies that discuss end-of-life care issues were not clear and allowed for wide-ranging interpretations.
Acting on the OIG recommendations, we developed a quality improvement initiative addressing end-of-life care in our ICU, intended to enhance communication and understanding about palliative care practices in our ICU, to prevent ethical conflicts surrounding end-of-life care, and to improve patient care. The initiative included the introduction of newly developed ICU comfort care guidelines, a physician order set, and a physician template note. Additionally, we implemented an educational program for ICU staff. Staff feedback regarding the initiative has been highly favorable, and the nurse whose concerns led to the investigation was satisfied not only with the investigation but also the policies and procedures that were subsequently introduced in our ICU. (CHEST 2009; 135:26-32)
C1 [Kuschner, Ware G.] Palo Alto Hlth Care Syst, US Dept Vet Affairs, Pulm & Crit Care Med Sect, Med Serv, Palo Alto, CA 94304 USA.
[Gruenewald, David A.] Puget Sound Hlth Care Syst, US Dept Vet Affairs, Geriatr & Extended Care Serv, Seattle, WA USA.
[Beal, Alice] New York Harbor Hlth Care Syst, US Dept Vet Affairs, Med Serv, Brooklyn, NY USA.
RP Kuschner, WG (reprint author), Palo Alto Hlth Care Syst, US Dept Vet Affairs, Pulm & Crit Care Med Sect, Med Serv, 3801 Miranda Ave,Mail Code 111P, Palo Alto, CA 94304 USA.
EM ware.kuschnermd@ca.gov
NR 26
TC 10
Z9 13
U1 0
U2 0
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JAN
PY 2009
VL 135
IS 1
BP 26
EP 32
DI 10.1378/chest.08-1685
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 392LN
UT WOS:000262304300008
PM 19136403
ER
PT J
AU Parashar, S
Rumsfeld, JS
Reid, KJ
Buchanan, D
Dawood, N
Khizer, S
Lichtman, J
Vaccarino, V
AF Parashar, Susmita
Rumsfeld, John S.
Reid, Kimberly J.
Buchanan, Donna
Dawood, Nazeera
Khizer, Saadia
Lichtman, Judith
Vaccarino, Viola
CA PREMIER Registry Investigators
TI Impact of Depression on Sex Differences in Outcome After Myocardial
Infarction
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE sex; depression; myocardial infarction; women
ID CORONARY-ARTERY-DISEASE; HEART-DISEASE; GENDER-DIFFERENCES; PATIENT
OUTCOMES; MORTALITY; EVENTS; ANGINA; CARE; ASSOCIATION; SYMPTOMS
AB Background-Women have an unexplained worse outcome after myocardial infarction (MI) compared with men in many studies. Depressive symptoms predict adverse post-MI outcomes and are more prevalent among women than men. We examined whether depressive symptoms contribute to women's worse outcomes after MI.
Methods and Results-In a prospective multicenter study ( PREMIER), 2411 ( 807 women) MI patients were enrolled. Depressive symptoms were assessed with the Patient Health Questionnaire. Outcomes included 1-year rehospitalization, presence of angina using the Seattle Angina Questionnaire, and 2-year mortality. Multivariable analyses were used to evaluate the association between sex and these outcomes, adjusting for clinical characteristics. The depressive symptoms score was added to the models to evaluate whether it attenuated the association between sex and outcomes. Depressive symptoms were more prevalent in women compared with men (29% versus 18.8%, P < 0.001). After adjusting for demographic factors, comorbidities, and MI severity, women had a mildly higher risk of rehospitalization ( hazard ratio, 1.20; 95% CI, 1.04 to 1.40), angina ( odds ratio, 1.32; 95% CI, 1.00 to 1.75), and mortality ( hazard ratio, 1.27; 95% CI, 0.98 to 1.64). After adding depressive symptoms to the multivariable models, the relationship further declined toward the null, particularly for rehospitalization ( hazard ratio, 1.14; 95% CI, 0.98 to 1.34) and angina (odds ratio, 1.22; 95% CI, 0.91 to 1.63), whereas there was little change in the estimate for mortality ( hazard ratio, 1.24; 95% CI, 0.95 to 1.62). Depressive symptoms were significantly associated with each of the study outcomes with a similar magnitude of effect in both women and men.
Conclusions-A higher prevalence of depressive symptoms in women modestly contributes to their higher rates of rehospitalization and angina compared with men but not mortality after MI. Our results support the recent recommendations of improving recognition of depressive symptoms after MI. ( Circ Cardiovasc Qual Outcomes. 2009;2:33-40.)
C1 [Parashar, Susmita] Emory Univ, Sch Med, Dept Med, Div Cardiol,EPICORE, Atlanta, GA 30307 USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Reid, Kimberly J.; Buchanan, Donna] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Lichtman, Judith] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
RP Parashar, S (reprint author), Emory Univ, Sch Med, Dept Med, Div Cardiol,EPICORE, 1256 Briarcliff Rd,Bldg A,Suite 1 N, Atlanta, GA 30307 USA.
EM susmita.parashar@emory.edu
FU Emory University General Clinical Research Center [NIH MO1-RR00039];
National Institutes of Health [K12RR17643, P50 HL077113]; Mentored
Clinical Scientist Development [1K23RR023171]; [K24HL077506]
FX Cardiovascular Therapeutics and Cardiovascular Outcomes funded the
PREMIER data collection and analysis. This study was also supported by
the Emory University General Clinical Research Center ( NIH MO1-RR00039)
and National Institutes of Health grant K12RR17643. Dr Parashar is
supported by Mentored Clinical Scientist Development Award 1K23RR023171.
Dr Vaccarino is supported by grant K24HL077506. Ms Reid is supported
through National Institutes of Health grant P50 HL077113. Ms Reid had
full access to all the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis.
NR 31
TC 34
Z9 35
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JAN
PY 2009
VL 2
IS 1
BP 33
EP 40
DI 10.1161/CIRCOUTCOMES.108.818500
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 575NL
UT WOS:000276073800007
PM 20031810
ER
PT J
AU Miyauchi, K
Takaya, N
Hirose, T
Ikeda, F
Kawamori, R
Ohishi, H
Yoshida, K
Yamamoto, M
Arai, H
Urabe, T
Hattori, N
Suzuki, M
Maehara, T
Sase, K
Hatsukami, TS
Yuan, C
Daida, H
AF Miyauchi, Katsumi
Takaya, Norihide
Hirose, Takahisa
Ikeda, Fuki
Kawamori, Ryuzo
Ohishi, Hidenori
Yoshida, Kensaku
Yamamoto, Munetaka
Arai, Hajime
Urabe, Takao
Hattori, Nobutaka
Suzuki, Michimasa
Maehara, Tadayuki
Sase, Kazuhiro
Hatsukami, Thomas S.
Yuan, Chun
Daida, Hiroyuki
TI Rationale and Design of the Carotid Plaque in Human for All Evaluations
With Aggressive Rosuvastatin Therapy (CHALLENGER Trial) - Evaluation by
Magnetic Resonance Imaging
SO CIRCULATION JOURNAL
LA English
DT Article
DE Carotid intima-media thickness; Carotid plaque; High-resolution magnetic
resonance imaging; Plaque stability; Rosuvastatin
ID ACUTE CORONARY SYNDROME; INTRAVASCULAR ULTRASOUND; HEART-DISEASE;
ATHEROSCLEROSIS; PREVENTION; PRAVASTATIN; REPRODUCIBILITY;
STABILIZATION; ATHEROMA; JAPANESE
AB Background Intensive lipid-lowering therapy with statins reduces levels of low-density lipoprotein (LDL)-C cholesterol (C) and improves plaque volume and composition in patients with cardiovascular disease. Furthermore. rosuvastatin ameliorated carotid stenosis in the ASTEROID study, and altered the composition of plaques in a predominantly Caucasian study population in the ORION study. However, it is not known whether statin therapy achieves similar quantitative improvement in carotid artery plaque in other ethnic groups.
Methods and Results Fifty patients with hypercholesterolemia (LDL-C >= 120 mg/dl) and a maximum carotid intima-media thickness >= 1.8 mm will be enrolled and treated with rosuvastatin at a dose of 5 mg/day for 96 weeks. The primary endpoints will be the percent change of carotid plaque volume and the change in plaque composition after 96 weeks of treatment, as evaluated by magnetic resonance imaging.
Conclusions The CHALLENGER study will provide a noninvasive assessment of the changes in carotid plaque volume and composition achieved by reduction of LDL levels in Japanese patients with carotid stenosis oil long-term rosuvastatin therapy.
C1 [Daida, Hiroyuki] Juntendo Univ, Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1130033, Japan.
[Hirose, Takahisa; Ikeda, Fuki; Kawamori, Ryuzo] Juntendo Univ, Sch Med, Dept Med, Tokyo 1130033, Japan.
[Hirose, Takahisa; Ikeda, Fuki; Kawamori, Ryuzo] Juntendo Univ, Sch Med, Dept Endocrinol & Metab, Tokyo 1130033, Japan.
[Ohishi, Hidenori; Yoshida, Kensaku; Yamamoto, Munetaka; Arai, Hajime] Juntendo Univ, Sch Med, Dept Neurosurg, Tokyo 1130033, Japan.
[Urabe, Takao; Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1130033, Japan.
[Suzuki, Michimasa; Maehara, Tadayuki] Juntendo Univ, Sch Med, Dept Radiol, Tokyo 1130033, Japan.
[Sase, Kazuhiro] Juntendo Univ, Sch Med, Dept Clin Pharmacol, Tokyo 1130033, Japan.
[Hatsukami, Thomas S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Hatsukami, Thomas S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Daida, H (reprint author), Juntendo Univ, Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 3-1-3 Hongo, Tokyo 1130033, Japan.
EM daida@med.juntendo.ac.jp
NR 27
TC 10
Z9 10
U1 0
U2 1
PU JAPANESE CIRCULATION SOC
PI KYOTO
PA KINKI INVENTION CENTER, 14 YOSHIDA KAWAHARACHO, SAKYO-KU, KYOTO,
606-8305, JAPAN
SN 1346-9843
J9 CIRC J
JI Circ. J.
PD JAN
PY 2009
VL 73
IS 1
BP 111
EP 115
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 388ZI
UT WOS:000262058800019
PM 19057091
ER
PT J
AU Allen, RS
Phillips, LL
Pekmezi, D
Crowther, MR
Prentice-Dunn, S
AF Allen, Rebecca S.
Phillips, Laura L.
Pekmezi, Dorothy
Crowther, Martha R.
Prentice-Dunn, Steven
TI Living Well with Living Wills: Application of Protection Motivation
Theory to Living Wills Among Older Caucasian and African American Adults
SO CLINICAL GERONTOLOGIST
LA English
DT Article
DE living wills; race/ethnicity and health; protection motivation theory;
preventive health
ID LIFE-SUSTAINING TREATMENTS; ADVANCE DIRECTIVES; DECISION-MAKING;
INDIVIDUAL-DIFFERENCES; FAMILY CAREGIVERS; END; PREFERENCES; HEALTH;
INFORMATION; RESPONSES
AB Using protection motivation theory, we examined racial differences in intent to complete a living will, rational problem solving (e.g., information seeking), and maladaptive coping responses (i.e., wishful thinking) to a health crisis. Sixty healthy, older adults without living wills responded to written vignettes, including information about living wills as an effective coping mechanism to avoid a health crisis. Use of adaptive coping responses predicted intent to execute a living will. A significant race-by-threat interaction predicted use of rational problem solving, with Caucasians more likely to seek information in response to perceived threat in comparison with African Americans. A significant race-by-adaptive-coping interaction predicted maladaptive coping, indicating that Caucasians were more variable in their maladaptive responses. The effectiveness of health care messages regarding living wills for older adults may be enhanced by focusing on racial differences in response to perceived health threat and perceived adaptive coping information.
C1 [Allen, Rebecca S.; Crowther, Martha R.; Prentice-Dunn, Steven] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA.
[Allen, Rebecca S.; Crowther, Martha R.] Ctr Mental Hlth & Aging, Tuscaloosa, AL USA.
[Phillips, Laura L.] Houston Vet Affairs Med Ctr, Houston, TX USA.
[Pekmezi, Dorothy] Miriam Hosp, Providence, RI 02906 USA.
[Pekmezi, Dorothy] Brown Med Sch, Ctr Behav & Prevent Med, Providence, RI USA.
RP Allen, RS (reprint author), Univ Alabama, Dept Psychol, Box 870348, Tuscaloosa, AL 35487 USA.
EM rsallen@bama.ua.edu
OI Allen, Rebecca Sue/0000-0002-2563-4996
FU National Institute on Aging [K01AG00943]; Department of Psychology at
The University of Alabama
FX Portions of this article were presented at the 56th annual
scientific meeting of the Gerontological Society of America, San Diego,
CA, November 2003. Funding from the National Institute on Aging
(K01AG00943) to Rebecca S. Allen partially supported data collection for
this project and preparation of this manuscript. Additionally, funding
for data collection was provided by the Department of Psychology at The
University of Alabama as part of Dorothy Pekmezi's undergraduate honors
thesis.
NR 26
TC 6
Z9 6
U1 2
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0731-7115
J9 CLIN GERONTOLOGIST
JI Clin. Gerontol.
PY 2009
VL 32
IS 1
BP 44
EP 59
DI 10.1080/07317110802474643
PG 16
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 675UP
UT WOS:000283864400004
PM 19337566
ER
PT J
AU Moghadam-Kia, S
Klein, R
Chilek, K
Gaines, E
Costner, M
Rose, M
Okawa, J
Werth, V
AF Moghadam-Kia, Siamak
Klein, Rachel
Chilek, Katherine
Gaines, Elizabeth
Costner, Melissa
Rose, Mathew
Okawa, Joyce
Werth, Victoria
TI Characteristics of Patients with Refractory Cutaneous Lupus
Erythematosus: A Database Analysis of 152 Patients Seen at an Outpatient
Dermatology Clinic
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 11-14, 2009
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 [Moghadam-Kia, Siamak; Klein, Rachel; Chilek, Katherine; Gaines, Elizabeth; Rose, Mathew; Okawa, Joyce; Werth, Victoria] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Costner, Melissa] Univ Texas SW, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2009
VL 131
BP S129
EP S129
DI 10.1016/j.clim.2009.03.382
PG 1
WC Immunology
SC Immunology
GA 449PK
UT WOS:000266342300374
ER
PT J
AU Gist, S
Tio-Matos, I
Falzgraf, S
Cameron, S
Beebe, M
AF Gist, Steve
Tio-Matos, Iris
Falzgraf, Sharon
Cameron, Shirley
Beebe, Michael
TI Wound care in the geriatric client
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE wound care; pressure ulcers; vascular ulcers; diabetic ulcers;
debridement; elderly
AB With our aging population, chronic diseases that compromise skin integrity such as diabetes, peripheral vascular disease (venous hypertension, arterial insufficiency) are becoming increasingly common. Skin breakdown with ulcer and chronic wound formation is a frequent consequence of these diseases. Types of ulcers include pressure ulcers, vascular ulcers (arterial and venous hypertension), and neuropathic ulcers. Treatment of these ulcers involves recognizing the four stages of healing: coagulation, inflammation, proliferation, and maturation. Chronic wounds are frequently stalled in the inflammatory stage. Moving past the inflammation stage requires considering the bacterial burden, necrotic tissue, and moisture balance of the wound being treated. Bacterial overgrowth or infection needs to be treated with topical or systemic agents. In most cases, necrotic tissue needs to be debrided and moisture balance needs to be addressed by wetting dry tissue and drying wet tissue. Special dressings have been developed to accomplish these tasks. They include films, hydrocolloids, hydrogel dressings, foams, hydrofibers, composite and alginate dressings.
C1 VA Puget Sound Hlth Care Syst, Geriatr Program, Amer Lake Div, Tacoma, WA USA.
VA Puget Sound Hlth Care Syst, Extended Care Program, Amer Lake Div, Tacoma, WA USA.
RP Beebe, M (reprint author), VA Puget Sound Hlth Care Syst, Integrated Geriatr Programs, Tacoma, WA USA.
EM michael.beebe@va.gov
NR 48
TC 28
Z9 28
U1 1
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9092
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2009
VL 4
BP 269
EP 287
PG 19
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA V21WZ
UT WOS:000208239000030
PM 19554098
ER
PT J
AU Chakkera, HA
Chertow, GM
O'Hare, AM
Amend, WJ
Gonwa, TA
AF Chakkera, Harini A.
Chertow, Glenn M.
O'Hare, Ann M.
Amend, William J., Jr.
Gonwa, Thomas A.
TI Regional Variation in Kidney Transplant Outcomes: Trends Over Time
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID UNITED-STATES; VASCULAR ACCESS; HEMODIALYSIS; VARIABILITY; MANAGEMENT;
SURGERY; US
AB Background and objectives: Clinical outcomes after kidney transplant have improved considerably in the United States over the past several decades. However, the degree to which this has occurred uniformly across the country is unknown.
Design, setting, participants, & measurements: Regional variations in graft failure after kidney transplant during three different time periods were examined. These time periods were chosen to coincide with major shifts in immunosuppressant usage: Era 1, cyclosporine usage, 3.988 through 1989; Era 2, introduction of tacrolimus and mycophenolate mofetil, 1994 through 1995; and Era 3, widespread use of tacrolimus and mycophenolate mofetil, 1998 through 1999. Patient data were obtained from the United States Renal Data System database. For each period, regional differences in time from transplant to graft failure (organ removal, death, or return to dialysis) were examined. For each region, differences in graft failure over time were examined.
Results: One-year graft survival rates ranged from 76% to 83% between regions in Era 1 (n = 13,669), from 84% to 89% in Era 2 (n = 17,456), and from 87.5%, to 92% in Era 3 (n = 20,375). Three-year graft survival ranged from 65% to 75% between regions in Era 1, from 84% to 89% in Era 2, and from 77% to 86%) in Era 3. Adjusted models for donor and recipient characteristics showed improvements in graft survival over time in all United Network for Organ Sharing regions with minimal variation across regions.
Conclusions: Regional differences in graft survival after kidney transplant are minimal, particularly when compared with the dramatic improvements in graft survival that have occurred over time.
C1 [Chakkera, Harini A.] Mayo Clin, Div Transplant Med, Scottsdale, AZ USA.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA.
[O'Hare, Ann M.] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA.
[O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA.
[Amend, William J., Jr.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Gonwa, Thomas A.] Mayo Clin, Div Transplant Med, Jacksonville, FL 32224 USA.
RP Chakkera, HA (reprint author), Mayo Clin Hosp, Div Transplantat, MCSB, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.
EM chakkera.harini@mayo.edu
FU Health Resources and Services Administration [234-2005-370011C]
FX This,vas Supported in part by Health Resources and Services
Administration contract 234-2005-370011C. The content is the
responsibility Of the authors alone and does not necessarily reflect the
view of the Department of Health and Human Services.
NR 18
TC 5
Z9 6
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JAN
PY 2009
VL 4
IS 1
BP 152
EP 159
DI 10.2215/CJN.02050408
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 397SA
UT WOS:000262681200024
PM 18922989
ER
PT J
AU Iverson, GL
Langlois, JA
McCrea, MA
Kelly, JP
AF Iverson, Grant L.
Langlois, Jean A.
McCrea, Michael A.
Kelly, James P.
TI CHALLENGES ASSOCIATED WITH POST-DEPLOYMENT SCREENING FOR MILD TRAUMATIC
BRAIN INJURY IN MILITARY PERSONNEL
SO CLINICAL NEUROPSYCHOLOGIST
LA English
DT Article
DE Mild Traumatic Brain Injury; Military; Screening; Epidemiology
ID POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; CONCUSSION; IRAQ; METAANALYSIS;
AFGHANISTAN; DISORDER; CARE
AB There is ongoing debate regarding the epidemiology of mild traumatic brain injury (MTBI) in military personnel. Accurate and timely estimates of the incidence of brain injury and the prevalence of long-term problems associated with brain injuries among active duty service members and veterans are essential for (a) operational planning, and (b) to allocate sufficient resources for rehabilitation and ongoing services and supports. The purpose of this article is to discuss challenges associated with post-deployment screening for MTBI. Multiple screening methods have been used in military, Veterans Affairs, and independent studies, which complicate cross-study comparisons of the resulting epidemiological data. We believe that post-deployment screening is important and necessary-but no screening methodology will be flawless, and false positives and false negatives are inevitable. Additional research is necessary to refine the sequential screening methodology, with the goal of minimizing false negatives during initial post-deployment screening and minimizing false positives during follow-up evaluations.
C1 [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada.
[Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada.
[Langlois, Jean A.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA.
[McCrea, Michael A.] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA.
[McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.
[Kelly, James P.] Univ Colorado, Dept Neurosurg, Denver Sch Med, Denver, CO 80202 USA.
[Kelly, James P.] Univ Colorado, Dept Phys Med & Rehabil, Denver Sch Med, Denver, CO 80202 USA.
[Kelly, James P.] Def Ctr Excellence Psychol Hlth, Natl Intrepid Ctr Excellence, Washington, DC USA.
[Kelly, James P.] US Dept Def, TBI, Washington, DC 20305 USA.
RP Iverson, GL (reprint author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.
EM giverson@interchange.ubc.ca
NR 24
TC 53
Z9 53
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1385-4046
J9 CLIN NEUROPSYCHOL
JI Clin. Neuropsychol.
PY 2009
VL 23
IS 8
BP 1299
EP 1314
DI 10.1080/13854040903153902
PG 16
WC Psychology, Clinical; Clinical Neurology; Psychology
SC Psychology; Neurosciences & Neurology
GA 524KF
UT WOS:000272141500005
PM 19882473
ER
PT J
AU Cruciani, M
Lipsky, BA
Mengoli, C
de Lalla, F
AF Cruciani, M.
Lipsky, B. A.
Mengoli, C.
de Lalla, F.
TI Granulocyte-colony stimulating factors as adjunctive therapy for
diabetic foot infections
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID MONONUCLEAR-CELL IMPLANTATION; CRITICAL LIMB ISCHEMIA;
MEDICAL-TREATMENT; CONTROLLED-TRIAL; AUTOLOGOUS TRANSPLANTATION; LOCAL
CARE; ULCERS; IMPROVES; FILGRASTIM; METAANALYSIS
AB Background
G-CSF increases the release of neutrophil endothelial progenitor cells from the bone marrow, and improves neutrophil functions, which are often impaired in people with diabetes.
Objectives
To examine the effects of adjunctive G-CSF compared with placebo or no growth factor added to usual care on rates of infection, cure and wound healing in people with diabetes who have a foot infection.
Search strategy
We searched the Cochrane Wounds Group Specialised Register (Searched 16/3/09); the Cochrane Central Register of Controlled Trials (The Cochrane Library, issue 1 2009); Ovid MEDLINE (1950 to March Week 1 2009); Ovid EMBASE (1980 to 2009 Week 11); EBSCO CINAHL (1982 to March Week 2 2009); LookSmart's Find Articles (January 1990 to January 2008); conference proceedings and references lists in the included studies.
Selection criteria
Randomised controlled trials (RCTs) that evaluated the effect of adding G-CSF to usual care in people with a diabetic foot infection.
Data collection and analysis
Three review authors independently assessed trial eligibility, methodological quality and extracted data. Relative risk (RR), or for continuous outcomes, mean differences (MD), with 95% confidence intervals (CI) were reported. In the case of low or no heterogeneity studies were pooled using a fixed-effect model.
Main results
We identified and included five eligible trials with a total of 167 patients. The investigators administered various G-CSF preparations, at different doses and for different durations of time. Adding G-CSF did not significantly affect the likelihood of resolution of infection or wound healing, but it was associated with a significantly reduced likelihood of lower extremity surgical interventions (RR 0.37; 95 % CI 0.20 to 0.68), including amputation (RR 0.41; 95 % CI 0.18 to 0.95). Moreover, providing G-CSF reduced the duration of hospital stay ( MD, -1.40 days; 95% CI, -2.27 to -0.53 days), but did not significantly affect the duration of systemic antibiotic therapy (MD, -0.27 days; 95 % CI, -1.30 to 0.77 days).
Authors' conclusions
The available evidence is limited, but suggests that adjunctive G-CSF treatment in people with a diabetic foot infection, including infected ulcers, does not appear to increase the likelihood of resolution of infection or healing of the foot ulcer. However, it does appear to reduce the need for surgical interventions, especially amputations, and the duration of hospitalisation. Clinicians might consider adding G-CSF to the usual treatment of diabetic foot infections, especially in patients with a limb-threatening infection, but it is not clear which patients might benefit.
C1 [Cruciani, M.] G Fracastoro Hosp, Ctr Prevent Med, I-37135 Verona, Italy.
[Cruciani, M.] G Fracastoro Hosp, HIV Outpatient Clin, I-37135 Verona, Italy.
[Lipsky, B. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Mengoli, C.] Univ Padua, Dept Histol Microbiol & Med Biotechnol, Padua, Italy.
[de Lalla, F.] Osped san Bortolo, Dept Infect Dis, Vicenza, Italy.
RP Cruciani, M (reprint author), G Fracastoro Hosp, Ctr Prevent Med, Via Germania 20, I-37135 Verona, Italy.
EM crucianimario@virgilio.it
OI Lipsky, Benjamin A./0000-0001-9886-5114; Mengoli,
Carlo/0000-0002-7422-0554
NR 66
TC 16
Z9 16
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 3
AR CD006810
DI 10.1002/14651858.CD006810.pub2
PG 35
WC Medicine, General & Internal
SC General & Internal Medicine
GA 471EE
UT WOS:000268037500012
PM 19588405
ER
PT J
AU Kogai, T
Brent, GA
AF Kogai, Takahiko
Brent, Gregory A.
BE Preedy, VR
Burrow, GN
Watson, RR
TI Regulation and Enhancement of Endogenous Sodium Iodide Symporter
Expression: NIS Regulatory Pathways in Thyroid and Breast Cancer
SO COMPREHENSIVE HANDBOOK OF IODINE: NUTRITIONAL, BIOCHEMICAL, PATHOLOGICAL
AND THERAPEUTIC ASPECTS
LA English
DT Article; Book Chapter
ID HUMAN CHORIONIC-GONADOTROPIN; CHORIOCARCINOMA CELL-LINE; SODIUM/IODIDE
SYMPORTER; GENE-EXPRESSION; NA+/I-SYMPORTER; RADIOIODIDE UPTAKE;
TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; UPSTREAM ENHANCER;
CARCINOMA CELLS
AB The sodium iodide symporter (NIS) gene is expressed at a high level in the thyroid gland and the lactating breast. Thyroid-stimulating hormone, or thyrotropin (TSH) is the major regulator of NIS expression in the normal thyroid and also stimulates NIS in more than 80% of differentiated thyroid cancers. TSH stimulates NIS gene expression through the proximal promoter and the NIS far upstream enhancer (NUE). The NUE requires at least two transcription factors, Pax-8 and CREB, for stimulation. Reduced expression of these transcription factors may contribute to the reduction in NIS expression that is seen in some differentiated thyroid cancer. High levels of endogenous TSH, or administration of recombinant TSH, are required to enhance the iodide uptake in thyroid cancer before radioiodide therapy. NIS gene expression in lactating breast tissue is primarily regulated by oxytocin and prolactin. A modest level of NIS expression has been reported in approximately 80% of cases of breast cancers. A number of strategies have been used to enhance NIS expression and radioiodide uptake in thyroid cancer and breast cancer. These include redifferentiation agents, such as retinoic acid and other nuclear hormone receptor ligands, as well as epigenetic modifiers. The results from application of these agents to in vitro models of thyroid and breast cancer will be described. Insights into NIS regulation, as well as agents that promote endogenous NIS expression, should lead to new approaches to using radioiodine in the treatment of thyroid and breast cancers.
C1 [Kogai, Takahiko; Brent, Gregory A.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Med, David Geffen Sch Med,Mol Endocrinol Lab, Los Angeles, CA 90073 USA.
[Kogai, Takahiko; Brent, Gregory A.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Physiol, David Geffen Sch Med,Mol Endocrinol Lab, Los Angeles, CA 90073 USA.
RP Kogai, T (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Med, David Geffen Sch Med,Mol Endocrinol Lab, Los Angeles, CA 90073 USA.
NR 46
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
BN 978-0-08-092086-3
PY 2009
BP 221
EP 230
DI 10.1016/B978-0-12-374135-6.00023-6
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition
& Dietetics
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition
& Dietetics
GA BCR55
UT WOS:000311104900024
ER
PT B
AU Rehman, SU
Ahmed, MM
Hutchison, FN
AF Rehman, Shakaib U.
Ahmed, Mohammed M.
Hutchison, Florence N.
BE Preedy, VR
Burrow, GN
Watson, RR
TI Goiter in the Elderly: The Role of Iodine
SO COMPREHENSIVE HANDBOOK OF IODINE: NUTRITIONAL, BIOCHEMICAL, PATHOLOGICAL
AND THERAPEUTIC ASPECTS
LA English
DT Article; Book Chapter
ID PERCUTANEOUS ETHANOL INJECTION; NODULAR THYROID-DISEASE; OPERATIVE
MANAGEMENT; INTRATHORACIC GOITER; SURGICAL-MANAGEMENT; SUBSTERNAL
GOITER; THERAPY; OBSTRUCTION; DISORDERS; HYPERTHYROIDISM
AB The term goiter means thyroid enlargement, either diffuse or nodular. The incidence of goiter increases with age. The most common type of goiter in the elderly is multinodular goiter. Graves' disease is very rare in older adults. The most common cause of goiter worldwide is iodine deficiency. It is becoming less of a problem in developed countries, due to the addition of iodine to salt and bread. Goiter commonly presents as neck mass. Although most patients with goiter do not have any symptom other than neck swelling, occasionally patients complain of dysphagia, dysphonia, or pain. Many goiters do not cause any thyroidal hormonal abnormality (euthyroid status). Some can present with either excess thyroidal hormonal activity (hyperthyroidism) or deficiency of thyroid hormones (hypothyroidism). Proper work-up for elderly patients with goiter includes a thorough history, detailed clinical examination, thyroid hormone assays, e. g., TSH, T4, T3, and an ultrasound or CT scan. Most goiters are benign in nature and may not require tissue diagnosis. In some elderly patients, fine needle aspiration and biopsy may be considered to rule out malignancy. Most elderly patients with nodular goiter are treated best by surgical removal, while radioiodine therapy and/or antithyroid drugs are the most effective therapy for non-nodular goiter.
C1 [Rehman, Shakaib U.; Hutchison, Florence N.] Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29401 USA.
[Rehman, Shakaib U.; Hutchison, Florence N.] Med Univ S Carolina, Charleston, SC 29401 USA.
[Ahmed, Mohammed M.] Univ Toledo, Dept Med, Toledo, OH 43614 USA.
RP Rehman, SU (reprint author), Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29401 USA.
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
BN 978-0-08-092086-3; 978-0-12-374135-6
PY 2009
BP 323
EP 329
DI 10.1016/B978-0-12-374135-6.00034-0
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition
& Dietetics
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition
& Dietetics
GA BCR55
UT WOS:000311104900035
ER
PT J
AU Flory, JD
Yehuda, R
Grossman, R
New, AS
Mitropoulou, V
Siever, LJ
AF Flory, Janine D.
Yehuda, Rachel
Grossman, Robert
New, Antonia S.
Mitropoulou, Vivian
Siever, Larry J.
TI Childhood trauma and basal cortisol in people with personality disorders
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; ABUSE; NEGLECT; DEPRESSION; BEHAVIOR
AB This study examined the influence of various forms of childhood abuse on basal cortisol levels in a sample of adults with Axis II personality disorders. Participants included 63 adults (n = 19 women) who provided basal plasma cortisol samples and completed the Childhood Trauma Questionnaire. Linear regression analyses that included all 5 subscales (ie, sexual abuse, physical abuse, emotional abuse, physical neglect and emotional neglect) demonstrated that physical abuse was related to lower cortisol levels (beta = -.43 P = .007), consistent with prior literature. In contrast, physical neglect was associated with higher cortisol (beta = .36, P = .02), after controlling for other forms of abuse. Results are consistent with the view that childhood trauma has long-lasting neurobiological effects and suggest that different forms of trauma may have distinct biological effects. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Flory, Janine D.] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA.
[Flory, Janine D.; Yehuda, Rachel; Grossman, Robert; New, Antonia S.; Mitropoulou, Vivian; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Yehuda, Rachel; New, Antonia S.; Siever, Larry J.] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA.
RP Flory, JD (reprint author), CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA.
EM janine.flory@qc.cuny.edu
FU Mount Sinai General Clinical Research Center [MH069979, RO1 MH056606,
RO1 MH063875, RO3 MH58697, MO1 RR0071]
FX This work was supported by MH069979 (JDF) RO1 MH056606 (LJS), RO1
MH063875 (LJS), RO3 MH58697 (RG), and MO1 RR0071 (Mount Sinai General
Clinical Research Center).
NR 21
TC 25
Z9 25
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PD JAN-FEB
PY 2009
VL 50
IS 1
BP 34
EP 37
DI 10.1016/j.comppsych.2008.05.007
PG 4
WC Psychiatry
SC Psychiatry
GA 389KA
UT WOS:000262090100006
PM 19059511
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Transposed Markov matrix as a new decision tool of how to choose among
competing investment options in academic medicine
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
DE decision analysis; decision tree; Markov chain; stochastic modelling
AB Medical institutions face the challenge of promoting excellence in a variety of competing focus areas, such as grants, publications, income, research, faculty, variety, patient care and teaching. A transposed Markov chain is used analyse the interactions between the various focus areas and their transition towards steady-state. In contradistinction with a regular Markov chain, in the transposed chain used for the present analysis, the sum of inputs (rather than outputs) of each individual state is 100%, whereas the outputs are left to assume any possible value. The mathematics of calculating the steady state conditions of a transposed Markov matrix are similar to those of a regular Markov matrix. The analysis shows that a focus area more dependent on other areas is also more likely to lose its investment, whereas largely self-reliant areas will generate the largest return. Full strength of all academic focus areas can be achieved only by investments in all areas. In academic systems with one or several exclusively self-reliant focus areas, only investment in these particular areas will invigorate the system, as all other investments are bound to dissipate over time. The newly developed decision tool of a transposed Markov matrix could be helpful in stochastic modelling of medical phenomena.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM sonnenbe@ohsu.edu
NR 11
TC 2
Z9 2
U1 1
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1748-670X
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PY 2009
VL 10
IS 1
BP 1
EP 7
AR PII 789782974
DI 10.1080/17486700701865323
PG 7
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 428LD
UT WOS:000264848500001
ER
PT J
AU Lang, JD
Matute-Bello, G
AF Lang, John D.
Matute-Bello, Gustavo
TI Lymphocytes, apoptosis and sepsis: making the jump from mice to humans
SO CRITICAL CARE
LA English
DT Editorial Material
ID MONOCYTE DEACTIVATION; UNITED-STATES; DOUBLE-BLIND; PHASE-III; RECEPTOR;
TRIAL; EPIDEMIOLOGY; DEATH
AB Sepsis is an important clinical problem with a mortality rate of 20% to 30%. Lymphocyte apoptosis has been recognized as an important step in the pathogenesis of experimental sepsis, by inducing a state of 'immune paralysis' that renders the host vulnerable to invading pathogens. The importance of lymphocyte apoptosis in human disease is now confirmed by Weber and colleagues, who demonstrate extensive apoptosis in circulating lymphocytes from patients with severe sepsis. Weber and colleagues' data set the basis for further studies aimed at modulating lymphocyte apoptosis in sepsis.
C1 [Matute-Bello, Gustavo] Univ Washington, Dept Med, Ctr Lung Biol, Div Pulm & Crit Care Med, Seattle, WA 98109 USA.
[Lang, John D.] VA Puget Sound HealthCare Syst, Seattle, WA 98108 USA.
[Lang, John D.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.
RP Matute-Bello, G (reprint author), Univ Washington, Dept Med, Ctr Lung Biol, Div Pulm & Crit Care Med, Seattle, WA 98109 USA.
NR 14
TC 26
Z9 32
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1466-609X
J9 CRIT CARE
JI Crit. Care
PY 2009
VL 13
IS 1
AR 109
DI 10.1186/cc7144
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 421IC
UT WOS:000264351600037
PM 19216722
ER
PT J
AU Palevsky, PM
O'Connor, TZ
Chertow, GM
Crowley, ST
Zhang, JH
Kellum, JA
AF Palevsky, Paul M.
O'Connor, Theresa Z.
Chertow, Glenn M.
Crowley, Susan T.
Zhang, Jane Hongyuan
Kellum, John A.
CA US Dept Vet Affairs Natl Inst Hlth
TI Intensity of renal replacement therapy in acute kidney injury:
perspective from within the Acute Renal Failure Trial Network Study
SO CRITICAL CARE
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION;
INTERMITTENT HEMODIALYSIS; RANDOMIZED-TRIAL; DIALYSIS; SUPPORT; SURVIVAL
AB Determination of the optimal dose of renal replacement therapy in critically ill patients with acute kidney injury has been controversial. Questions have recently been raised regarding the design and execution of the US Department of Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) Study, which demonstrated no improvement in 60-day all-cause mortality with more intensive management of renal replacement therapy. In the present article we present our rationale for these aspects of the design and conduct of the study, including our use of both intermittent and continuous modalities of renal support, our approach to initiation of study therapy and the volume management during study therapy. In addition, the article presents data on hypotension during therapy and recovery of kidney function in the perspective of other studies of renal support in acute kidney injury. Finally, we address the implications of the ATN Study results for clinical practice from the perspective of the study investigators.
C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA.
[O'Connor, Theresa Z.; Crowley, Susan T.; Zhang, Jane Hongyuan] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Crowley, Susan T.] Yale Univ, Sch Med, New Haven, CT 06520 USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM Palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
FU Department of Veterans Affairs Office of Research and Development;
National Institute of Diabetes and Digestive and Kidney Diseases
[Y1-DK-3508-01]
FX Supported by the Cooperative Studies Program of the Department of
Veterans Affairs Office of Research and Development and by the National
Institute of Diabetes and Digestive and Kidney Diseases (interagency
agreement Y1-DK-3508-01).
NR 32
TC 22
Z9 25
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
J9 CRIT CARE
JI Crit. Care
PY 2009
VL 13
IS 4
AR 310
DI 10.1186/cc7901
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA 525OL
UT WOS:000272225600066
PM 19678919
ER
PT J
AU Renaud, B
Labarere, J
Coma, E
Santin, A
Hayon, J
Gurgui, M
Camus, N
Roupie, E
Hemery, F
Herve, J
Salloum, M
Fine, MJ
Brun-Buisson, C
AF Renaud, Bertrand
Labarere, Jose
Coma, Eva
Santin, Aline
Hayon, Jan
Gurgui, Merce
Camus, Nicolas
Roupie, Eric
Hemery, Francois
Herve, Jerome
Salloum, Mirna
Fine, Michael J.
Brun-Buisson, Christian
TI Risk stratification of early admission to the intensive care unit of
patients with no major criteria of severe community-acquired pneumonia:
development of an international prediction rule
SO CRITICAL CARE
LA English
DT Article
ID SYSTEMIC INFLAMMATORY RESPONSE; SURVIVING SEPSIS CAMPAIGN; SEPTIC SHOCK;
CONTROLLED-TRIAL; DECISION RULES; GUIDELINES; MANAGEMENT; OUTCOMES;
ADULTS; MULTICENTER
AB Introduction To identify risk factors for early (< three days) intensive care unit (ICU) admission of patients hospitalised with community-acquired pneumonia (CAP) and not requiring immediate ICU admission, and to stratify the risk of ICU admission on days 1 to 3.
Methods Using the original data from four North American and European prospective multicentre cohort studies of patients with CAP, we derived and validated a prediction rule for ICU admission on days 1 to 3 of emergency department (ED) presentation, for patients presenting with no obvious reason for immediate ICU admission (not requiring immediate respiratory or circulatory support).
Results A total of 6560 patients were included (4593 and 1967 in the derivation and validation cohort, respectively), 303 (4.6%) of whom were admitted to an ICU on days 1 to 3. The Risk of Early Admission to ICU index (REA-ICU index) comprised 11 criteria independently associated with ICU admission: male gender, age younger than 80 years, comorbid conditions, respiratory rate of 30 breaths/minute or higher, heart rate of 125 beats/minute or higher, multilobar infiltrate or pleural effusion, white blood cell count less than 3 or 20 G/L or above, hypoxaemia (oxygen saturation < 90% or arterial partial pressure of oxygen (PaO2) < 60 mmHg), blood urea nitrogen of 11 mmol/L or higher, pH less than 7.35 and sodium less than 130 mEq/L. The REA-ICU index stratified patients into four risk classes with a risk of ICU admission on days 1 to 3 ranging from 0.7 to 31%. The area under the curve was 0.81 (95% confidence interval (CI) = 0.78 to 0.83) in the overall population.
Conclusions The REA-ICU index accurately stratifies the risk of ICU admission on days 1 to 3 for patients presenting to the ED with CAP and no obvious indication for immediate ICU admission and therefore may assist orientation decisions.
C1 [Renaud, Bertrand; Santin, Aline; Camus, Nicolas; Herve, Jerome; Salloum, Mirna] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Emergency Med, F-94010 Creteil, France.
[Labarere, Jose; Brun-Buisson, Christian] CHU Grenoble, Unite Evaluat Med, F-38043 Grenoble, France.
[Coma, Eva] USAC, Inst Catala Oncol, Hosp Duran & Reynals, Serv Atencio Continuada, Barcelona 08907, Spain.
[Hayon, Jan] Ctr Hosp Intercommunal Poissy St Germain, Dept Intens Care Med, F-78100 St Germain En Laye, France.
[Gurgui, Merce] Hosp Santa Creu & Sant Pau, Dept Emergency Med, Barcelona, Spain.
[Camus, Nicolas; Brun-Buisson, Christian] Univ Paris 12, Fac Med, F-94000 Creteil, France.
[Roupie, Eric] CHU Caen, Dept Emergency Med, Hop Cote Nacre, F-14033 Caen, France.
[Roupie, Eric] Univ Caen Basse Normandie, Fac Med, F-14032 Caen, France.
[Hemery, Francois] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Informat Hosp, PMSI & Rech Clin, F-94010 Creteil, France.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA.
[Fine, Michael J.] Univ Pittsburgh, UPMC Montefiore Hosp, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Brun-Buisson, Christian] Grp Hosp Henri Mondor Albert Chenevier, AP HP, F-94010 Creteil, France.
RP Renaud, B (reprint author), Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Emergency Med, F-94010 Creteil, France.
EM bertrand.renaud@hmn.aphp.fr
RI Labarere, Jose/N-1688-2014
OI Labarere, Jose/0000-0001-7621-6586
FU "Direction de la Recherche Clinique d'Ile de France" [AOM 89-145]
FX This study was funded by the "Direction de la Recherche Clinique d'Ile
de France" as part of the "Programme Hospitalier de Recherche Clinique"
(Grant N degrees AOM 89-145).
NR 33
TC 47
Z9 48
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2009
VL 13
IS 2
AR R54
DI 10.1186/cc7781
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA 453UN
UT WOS:000266638500026
PM 19358736
ER
PT J
AU Moore, SA
AF Moore, Sally A.
TI Cognitive abnormalities in posttraumatic stress disorder
SO CURRENT OPINION IN PSYCHIATRY
LA English
DT Article
DE cognition; information processing; memory; posttraumatic stress
disorder; trauma
ID AUTOBIOGRAPHICAL MEMORY SPECIFICITY; FALSE MEMORIES; INTERPERSONAL
TRAUMA; OVERGENERAL MEMORY; EXECUTIVE CONTROL; INVENTORY PTCI; PTSD;
DEPRESSION; SYMPTOMS; VICTIMS
AB Purpose of review
The current review aims to describe and evaluate research on cognitive difficulties associated with posttraumatic stress disorder (PTSD) published between January 2007 and June 2008.
Recent findings
The reviewed studies provide additional evidence that negative appraisals and decrements on verbal and autobiographical memory tasks are exhibited by individuals with PTSD relative to controls and may represent preexisting risk factors for PTSD rather than a result or concomitant of PTSD symptoms. In addition, the reviewed findings provide further evidence for source monitoring difficulties and attentional biases toward trauma-relevant information in PTSD. Recent research also provides evidence that, although memories of traumatic events differ in PTSD relative to other types of memories and memories of depressed individuals, they are likely on the same continuum as nontraumatic memories rather than qualitatively different.
Summary
Individuals with PTSD experience cognitive alterations ranging from impairments in overall memory functioning to difficulties specific to trauma-related cues. These cognitive difficulties appear to be importantly related to the development and/or maintenance of the disorder. At this point, it is unclear whether common mechanisms may account for these diverse cognitive difficulties and whether cognitive impairments are attributable to comorbid depression.
C1 [Moore, Sally A.] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA.
[Moore, Sally A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
RP Moore, SA (reprint author), VA Puget Sound Healthcare Syst, MH 116,1660 S Columbian Way, Seattle, WA 98108 USA.
EM sally.moore2@va.gov
NR 55
TC 38
Z9 39
U1 5
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7367
J9 CURR OPIN PSYCHIATR
JI Curr. Opin. Psychiatr.
PD JAN
PY 2009
VL 22
IS 1
BP 19
EP 24
DI 10.1097/YCO.0b013e328314e3bb
PG 6
WC Psychiatry
SC Psychiatry
GA 393UH
UT WOS:000262398400005
PM 19122530
ER
PT J
AU Teng, E
Tingus, KD
Lu, PH
Cummings, JL
AF Teng, Edmond
Tingus, Kathleen D.
Lu, Po H.
Cummings, Jeffrey L.
TI Persistence of Neuropsychological Testing Deficits in Mild Cognitive
Impairment
SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
LA English
DT Article
DE Alzheimer disease; Memory; Cognition; Dementia; Psychometrics
ID OSTERRIETH COMPLEX FIGURE; VASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE;
NORMATIVE DATA; CLINICAL SUBTYPES; MEMORY IMPAIRMENT; TEST-PERFORMANCE;
OLDER-ADULTS; DEMENTIA; CONVERSION
AB Background: The significant variability across studies of mild cognitive impairment (MCI) in rates of progression to Alzheimer's disease (AD) and reversion to normal cognition may be due to differences in specific neuropsychological tests and thresholds used to define MCI. Methods: We assessed 115 subjects with amnestic (AMN) or non-amnestic (NON) MCI on a standardized neuropsychological battery at baseline and after a mean follow-up of 16.4 months to determine the prevalence and persistence of deficits identified with specific tests. Results: The prevalence of impaired performance varied widely across tests. Deficits were more persistent in the AMN group than in the NON group. Baseline deficits in Visual Reproduction II and the California Verbal Learning Test were the best predictors of persistent memory impairment. Subjects who at baseline were impaired on multiple memory tests or had poorer overall memory performance were more likely to exhibit persistent memory deficits. Conclusions: The use of different neuropsychological tests and thresholds to diagnose MCI identified subsets of subjects with different rates of persistence of cognitive impairment. Standardization of the operational definition of cognitive impairment in MCI may result in more consistent predictions of progression to AD. Copyright (C) 2009 S. Karger AG, Basel
C1 [Teng, Edmond; Tingus, Kathleen D.; Lu, Po H.; Cummings, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Cummings, Jeffrey L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA.
RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit, Bldg 500 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eteng@ucla.edu
FU National Institute on Aging [P50 AG 16570]; Alzheimer's Disease Research
Centers of California; Sidell-Kag an Foundation
FX This research was supported by the National Institute on Aging (P50 AG
16570), the Alzheimer's Disease Research Centers of California, and the
Sidell-Kag an Foundation. We would like to thank Charmaine Lowe, Myha
Ngo, Alice Yau, and Michelle Zeller for their assistance with data
management.
NR 77
TC 19
Z9 20
U1 1
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-8008
J9 DEMENT GERIATR COGN
JI Dement. Geriatr. Cogn. Disord.
PY 2009
VL 28
IS 2
BP 168
EP 178
DI 10.1159/000235732
PG 11
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 494DA
UT WOS:000269788500010
PM 19707017
ER
PT J
AU Lesser, GT
Haroutunian, V
Purohit, DP
Beeri, MS
Schmeidler, J
Honkanen, L
Neufeld, R
Libow, LS
AF Lesser, Gerson T.
Haroutunian, Vahram
Purohit, Dushyant P.
Beeri, Michal Schnaider
Schmeidler, James
Honkanen, Linda
Neufeld, Richard
Libow, Leslie S.
TI Serum Lipids Are Related to Alzheimer's Pathology in Nursing Home
Residents
SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
LA English
DT Article
DE Lipids and dementia; Alzheimer's disease; Neuropathology of dementia;
Nursing home; Cholesterol; Serum lipids
ID DIFFERENT DIAGNOSTIC-CRITERIA; MILD COGNITIVE IMPAIRMENT; VASCULAR
RISK-FACTORS; LATE-ONSET DEMENTIA; APOLIPOPROTEIN-E;
DENSITY-LIPOPROTEIN; CHOLESTEROL LEVEL; NEURITIC PLAQUES; APOE GENOTYPE;
OLDER PERSONS
AB Background: Studies of associations between serum lipids and Alzheimer's disease ( AD) or other dementias in the elderly show conflicting results, perhaps due to misclassification of the various dementias. Methods: For 358 nursing home residents, serum lipids were studied at admission and diagnoses established at autopsy. We used defined neuropathological criteria to distinguish the presence of AD and to avoid errors of clinical dementia assessment. Results: Residents with any AD pathology, as compared to those without AD pathology, had higher mean serum total cholesterol (TC; 200.4 vs. 185.9 mg/dl; p = 0.02) and higher mean low-density lipoprotein cholesterol (LDL; 124.5 vs. 111.5 mg/dl; p = 0.03). Further, mean TC, LDL and high-density lipoprotein cholesterol levels all increased progressively with increasing pathological certainty of AD ( p for trend = 0.001, 0.02 and 0.02). Conclusions: TC and LDL were significantly related to pathologically defined AD. If serum lipids have a role in the pathogenesis of AD, interventions may modify the course of disease. Copyright (c) 2009 S. Karger AG, Basel
C1 [Lesser, Gerson T.; Honkanen, Linda; Neufeld, Richard; Libow, Leslie S.] Jewish Home & Hosp, New York, NY 10025 USA.
[Lesser, Gerson T.; Neufeld, Richard; Libow, Leslie S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA.
[Haroutunian, Vahram; Beeri, Michal Schnaider; Schmeidler, James] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Purohit, Dushyant P.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA.
[Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, New York, NY USA.
RP Lesser, GT (reprint author), Jewish Home & Hosp, 120 W 106th St, New York, NY 10025 USA.
EM glesser@jhha.org
FU Dextra Baldwin McGonagle Foundation; NIA [AG02219]; NIH [M01-RR-00071]
FX This work was supported by the Dextra Baldwin McGonagle Foundation,
Joseph E. and Norma G. Saul Foundation, NIA grant AG02219 and NIH grant
M01-RR-00071.
NR 63
TC 22
Z9 23
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-8008
J9 DEMENT GERIATR COGN
JI Dement. Geriatr. Cogn. Disord.
PY 2009
VL 27
IS 1
BP 42
EP 49
DI 10.1159/000189268
PG 8
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 400WD
UT WOS:000262899200006
PM 19129700
ER
PT J
AU Carrion-Baralt, JR
Melendez-Cabrero, J
Beeri, MS
Sano, M
Silverman, JM
AF Carrion-Baralt, Jose R.
Melendez-Cabrero, Josefina
Beeri, Michal Schnaider
Sano, Mary
Silverman, Jeremy M.
TI The Neuropsychological Performance of Nondemented Puerto Rican
Nonagenarians
SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
LA English
DT Article
DE Successful cognitive aging; Puerto Rican nonagenarians; Oldest old
population
ID BOSTON NAMING TEST; AFRICAN-AMERICANS; ALZHEIMER-DISEASE; BATTERY;
CERAD; NORMS; UTILITY; ELDERS; ADULTS; TRAIL
AB Background/Aims: While the oldest old are the fastest growing segment of the US population, normative neuropsychological data for nondemented oldest old Spanish speakers are nonexistent. This study sought to evaluate the neuropsychological performance of nondemented nonagenarians residing in Puerto Rico and to compare their results with those of a similar English-speaking sample from New York. Methods: We studied 81 subjects who had a complete CERAD neuropsychological assessment in Spanish. We used multiple regression analysis to predict performance on the CERAD battery and ANCOVA to compare the Puerto Rico and New York samples. Results: In 10 out of the 13 neuropsychological tests administered, education was a significant predictor of performance. There were significant differences between the Puerto Rico and New York groups only in the Trail Making Tests. Conclusions: In this Puerto Rican sample, education was the strongest predictor of neuropsychological performance, which is consistent with previous studies. When education level is properly accounted for, the performance of Puerto Rican nonagenarians in the CERAD battery does not differ from the performance of US English-speaking nonagenarians. Copyright (c) 2009 S. Karger AG, Basel
C1 [Carrion-Baralt, Jose R.] San Juan VA Med Ctr, Res & Dev Serv 151, San Juan, PR 00921 USA.
[Carrion-Baralt, Jose R.; Melendez-Cabrero, Josefina; Beeri, Michal Schnaider; Sano, Mary; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Sano, Mary; Silverman, Jeremy M.] James J Peters Bronx Veteran Affairs Med Ctr, Bronx, NY USA.
RP Carrion-Baralt, JR (reprint author), San Juan VA Med Ctr, Res & Dev Serv 151, 10 Casia St, San Juan, PR 00921 USA.
EM jose.carrion-baralt@mssm.edu
FU NIA [1 K01 AG025203, 1 K01 AG023515, P50-AG05138, P01-AG02219]; US
Alzheimer's Association grants
FX This research was supported by NIA grants 1 K01 AG025203 (for
J.R.C.-B.), 1 K01 AG023515 (for M. S. B.), P50-AG05138 (for M. S.),
project 4 in P01-AG02219 (for J.M.S.) and two US Alzheimer's Association
grants (for J.R.C.-B. and J.M.S.).
NR 24
TC 5
Z9 5
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-8008
J9 DEMENT GERIATR COGN
JI Dement. Geriatr. Cogn. Disord.
PY 2009
VL 27
IS 4
BP 353
EP 360
DI 10.1159/000209213
PG 8
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 428SQ
UT WOS:000264870500008
PM 19293568
ER
PT J
AU Gleason, CE
Gangnon, RE
Fischer, BL
Mahoney, JE
AF Gleason, Carey E.
Gangnon, Ronald E.
Fischer, Barbara L.
Mahoney, Jane E.
TI Increased Risk for Falling Associated with Subtle Cognitive Impairment:
Secondary Analysis of a Randomized Clinical Trial
SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
LA English
DT Article
DE Accidental falls; Falls; Mini Mental State Exam; Cognition; Geriatrics;
Older adults; Risk factors
ID COMMUNITY; DEMENTIA; GAIT; SELECTION; PEOPLE; ADULTS
AB Background/Aims: Having dementia increases patients' risk for accidental falls. However, it is unknown if having mild cognitive deficits also elevates a person's risk for falls. This study sought to clarify the relationship between subtle cognitive impairment, measured with a widely-used, clinic-based assessment, the Mini Mental State Exam (MMSE), and risk for falls. Methods: In a secondary analysis of the Kenosha County Falls Prevention Study, a randomized controlled trial targeting older adults at risk for falls, we examined the association between baseline MMSE and prospective rate of falls over 12 months in 172 subjects randomized to control group. Results: Using univariate analysis, the rate of falls increased with each unit decrease in MMSE score down to at least 22 (rate ratio 1.25, 95% confidence interval (CI) 1.09-1.45, p = 0.0026). Using stepwise multivariate regression, controlling for ability to perform activities of daily living, use of assistive device, current exercise, and arthritis, the association between MMSE score and falls rate persisted ( rate ratio 1.20, 95% CI 1.03-1.40, p = 0.021). Conclusion: Minimal decrements on the MMSE were associated with elevations in rate of falls, suggesting that subtle cognitive deficits reflected in MMSE scores above a cut-off consistent with a diagnosis of dementia, can influence risk for falls. Copyright (C) 2009 S. Karger AG, Basel
C1 [Gleason, Carey E.; Mahoney, Jane E.] Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Madison, WI 53705 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat, Madison, WI 53705 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Dept Med Informat, Madison, WI 53705 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53705 USA.
[Fischer, Barbara L.] William S Middleton Mem Vet Adm Med Ctr, Mental Hlth Serv, Madison, WI USA.
[Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA.
RP Gleason, CE (reprint author), Univ Wisconsin, Dept Med, Sect Geriatr, Madison VA GRECC, Room D4211,2500 Overlook Terrace, Madison, WI 53705 USA.
EM ceg@medicine.wisc.edu
FU NIH-NIA [K23 AG024302]; Kenosha County Multi-Factorial Falls Prevention
Program for Older Adults; Wisconsin Family Care Aging and/or Disability
Resource Center Prevention; Wm. S. Middleton Memorial VA, Madison, Wisc
FX This work was supported by NIH-NIA grant K23 AG024302 (PI: C.E.G.), the
Kenosha County Multi-Factorial Falls Prevention Program for Older
Adults; A Wisconsin Family Care Aging and/or Disability Resource Center
Prevention Funding Grant (PI: J.E.M.); and the Geriatric Research,
Education and Clinical Center and Mental Health Service of the Wm. S.
Middleton Memorial VA, Madison, Wisc. This is GRECC Manuscript Number:
2007-015.
NR 24
TC 37
Z9 39
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-8008
EI 1421-9824
J9 DEMENT GERIATR COGN
JI Dement. Geriatr. Cogn. Disord.
PY 2009
VL 27
IS 6
BP 557
EP 563
DI 10.1159/000228257
PG 7
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 485XY
UT WOS:000269160500010
PM 19602883
ER
PT J
AU Vexler, ZS
Yenari, MA
AF Vexler, Zinaida S.
Yenari, Midori A.
TI Does Inflammation after Stroke Affect the Developing Brain Differently
than Adult Brain?
SO DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article; Proceedings Paper
CT 6th Hershey Conference on Developmental Brain Injury
CY JUN 04-07, 2008
CL Ecquevilly, FRANCE
SP Natl Inst Neurolog Disorders & Stroke
DE Stroke; Hypoxia-ischemia; Cytokine; Chemokine; Microglia;
Neuroprotection; Neurogenesis
ID FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MONOCYTE
CHEMOATTRACTANT PROTEIN-1; NITRIC-OXIDE SYNTHASE;
CENTRAL-NERVOUS-SYSTEM; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
SUBVENTRICULAR ZONE NEUROGENESIS; NEONATAL HYPOXIA-ISCHEMIA; LONG-TERM
NEUROPROTECTION
AB The immature brain is prone to hypoxic-ischemic encephalopathy and stroke. The incidence of arterial stroke in newborns is similar to that in the elderly. However, the pathogenesis of ischemic brain injury is profoundly affected by age at the time of the insult. Necrosis is a dominant type of neuronal cell death in adult brain, whereas widespread neuronal apoptosis is unique for the early postnatal synaptogenesis period. The inflammatory response, in conjunction with excitotoxic and oxidative responses, is the major contributor to ischemic injury in both the immature and adult brain, but there are several areas where these responses diverge. We discuss the contribution of various inflammatory mechanisms to injury and repair after cerebral ischemia in the context of CNS immaturity. In particular, we discuss the role of lower expression of selectins, a more limited leukocyte transmigration, undeveloped complement pathways, a more rapid microglial activation, differences in cytokine and chemokine interplay, and a different threshold to oxidative stress in the immature brain. We also discuss differences in activation of intracellular pathways, especially nuclear factor kappa B and mitogen-activated protein kinases. Finally, we discuss emerging data on both the supportive and adverse roles of inflammation in plasticity and repair after stroke. Copyright (C) 2009 S. Karger AG, Basel
C1 [Vexler, Zinaida S.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Vexler, ZS (reprint author), Univ Calif San Francisco, Dept Neurol, 521 Parnassus Ave,C215, San Francisco, CA 94143 USA.
EM Zena.Vexler@ucsf.edu
FU NINDS NIH HHS [R01 NS040516, R01 NS044025, R01 NS40516, R01 NS44025]
NR 222
TC 65
Z9 66
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-5866
J9 DEV NEUROSCI-BASEL
JI Dev. Neurosci.
PY 2009
VL 31
IS 5
BP 378
EP 393
DI 10.1159/000232556
PG 16
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA 491JH
UT WOS:000269574200002
PM 19672067
ER
PT J
AU Sale, MM
Lu, LY
Spruill, IJ
Fernandes, JK
Lok, KH
Divers, J
Langefeld, CD
Garvey, WT
AF Sale, Michele M.
Lu, Lingyi
Spruill, Ida J.
Fernandes, Jyotika K.
Lok, Kerry H.
Divers, Jasmin
Langefeld, Carl D.
Garvey, W. Timothy
TI Genome-Wide Linkage Scan in Gullah-Speaking African American Families
With Type 2 Diabetes The Sea Islands Genetic African American Registry
(Project SuGAR)
SO DIABETES
LA English
DT Article; Proceedings Paper
CT 68th Annual Meeting of the American-Diabetes-Association
CY JUN 06-10, 2008
CL San Francisco, CA
SP Amer Diabet Assoc
ID SINGLE NUCLEOTIDE POLYMORPHISMS; FACTOR-7-LIKE-2 TCF7L2 GENE;
SUSCEPTIBILITY GENES; ASSOCIATION ANALYSIS; IDENTIFICATION; VARIANTS;
MELLITUS; POPULATIONS; AFFINITIES; LOCUS
AB OBJECTIVE-The Gullah-speaking African American population from the Sea Islands of South Carolina is characterized by a low degree of European admixture and high rates of type 2 diabetes and diabetic complications. Affected relative pairs with type 2 diabetes were recruited through the Sea Islands Genetic African American Registry (Project SuGAR).
RESEARCH DESIGN AND METHODS-We conducted a genome-wide linkage scan, genotyping 5,974 single nucleotide polymorphisms in 471 affected subjects and 50 unaffected relatives from 197 pedigrees. Data were analyzed using a multipoint engine for rapid likelihood inference and ordered subsets analyses (OSAs) for age at type 2 diabetes diagnosis, waist circumference, waist-to-hip ratio, and BMI. We searched for heterogeneity and interactions using a conditional logistic regression likelihood approach.
RESULTS-Linkage peaks on chromosome 14 at 123-124 cM were detected for type 2 diabetes (logarithm of odds [LOD] 2. 10) and for the subset with later age at type 2 diabetes diagnosis (maximum LOD 4.05). Two linkage peaks on chromosome 7 were detected at 44-45 cM for type 2 diabetes (LOD 1.18) and at 78 cM for type 2 diabetes (LOD 1.64) and the subset with earlier age at type 2 diabetes diagnosis (maximum LOD 3.93). The chromosome 14 locus and a peak on 7p at 29.5 cM were identified as important in the multilocus model. Other regions that provided modest evidence for linkage included chromosome 1 at 167.5 cM (LOD 1.51) and chromosome 3 at 121.0 cM (LOD 1.61).
CONCLUSIONS-This study revealed a novel type 2 diabetes locus in an African American population on 14q that appears to reduce age of disease onset and confirmed two loci on chromosome 7. Diabetes 58:260-267, 2009
C1 [Sale, Michele M.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA.
[Sale, Michele M.] Univ Virginia, Dept Med, Charlottesville, VA USA.
[Sale, Michele M.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA USA.
[Lu, Lingyi; Divers, Jasmin; Langefeld, Carl D.] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC 27109 USA.
[Spruill, Ida J.; Fernandes, Jyotika K.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Lok, Kerry H.; Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Sale, MM (reprint author), Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA.
EM msale@virginia.edu
FU NCRR NIH HHS [P20 RR017696, M01-RR-1070, P20-RR-17696, M01
RR007122-150269, M01 RR007122, M01 RR001070]; NHGRI NIH HHS
[N01HG65403]; NIDDK NIH HHS [R01 DK066358-01, R01 DK066358-03, DK-66358,
R01 DK066358-02, P30-DK-56336, R01 DK047461, P30 DK056336, R01 DK066358]
NR 36
TC 16
Z9 16
U1 2
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD JAN
PY 2009
VL 58
IS 1
BP 260
EP 267
DI 10.2337/db08-0198
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 390TR
UT WOS:000262187100038
PM 18835935
ER
PT J
AU Coletta, DK
Schneider, J
Hu, SL
Dyer, TD
Puppala, S
Farook, VS
Arya, R
Lehman, DM
Blangero, J
DeFronzo, RA
Duggirala, R
Jenkinson, CP
AF Coletta, Dawn K.
Schneider, Jennifer
Hu, Shirley L.
Dyer, Thomas D.
Puppala, Sobha
Farook, Vidya S.
Arya, Rector
Lehman, Donna M.
Blangero, John
DeFronzo, Ralph A.
Duggirala, Ravindranath
Jenkinson, Christopher P.
TI Genome-Wide Linkage Scan for Genes Influencing Plasma Triglyceride
Levels in the Veterans Administration Genetic Epidemiology Study
SO DIABETES
LA English
DT Article
ID OLD ORDER AMISH; MEXICAN-AMERICANS; SUSCEPTIBILITY LOCUS;
INSULIN-RESISTANCE; QUANTITATIVE TRAITS; ASSOCIATION; DISEASE; FAMILY;
SEGREGATION; CHOLESTEROL
AB OBJECTIVE-Elevated plasma triglyceride concentration is a component of the insulin resistance syndrome and is commonly associated with type 2 diabetes, obesity, and coronary heart disease. The goal. of our study was to perform a genome-wide linkage scan to identify genetic regions that influence variation in plasma triglyceride levels in families that are enriched with individuals with type 2 diabetes.
RESEARCH DESIGN AND METHODS-We used phenotypic and genotypic data from 1,026 individuals distributed across 294 Mexican-American families, who were ascertained for type 2 diabetes, from the Veterans Administration Genetic Epidemiology Study (VAGES). Plasma triglyceride values were transformed, and a variance-components technique was used to conduct multipoint linkage analysis.
RESULTS-After adjusting for the significant effects of sex and BMI, heritability for plasma triglycerides was estimated as 46 +/- 7% (P < 0.0001). Multipoint linkage analysis yielded the strongest evidence for linkage of plasma triglycerides near marker D12S391 on chromosome 12p (logarithm of odds [LOD] = 2.4). Our linkage signal on chromosome 12p provides independent replication of a similar finding in another Mexican-American sample from the San Antonio Family Diabetes Study (SAFDS). Combined multipoint linkage analysis of the VAGES and SAFDS data yielded significant evidence for linkage of plasma triglycerides to a genetic location between markers GATA49D12 and D12S391 on 12p (LOD = 3.8, empirical P value = 2.0 X 10(-5)). This region on 12p harbors the gene-encoding adiponectin receptor 2 (AdipoR2), where we previously have shown that multiple single nucleotide polymorphisms are associated with plasma triglyceride concentrations in the SAFDS. In the present study, we provided suggestive evidence in favor of association for rs929434 with triglyceride concentrations in the VAGES.
CONCLUSIONS-Collectively, these results provide strong evidence for a major locus on chromosome 12p that influences plasma triglyceride levels in Mexican Americans. Diabetes 58: 279-284, 2009
C1 [Coletta, Dawn K.; Hu, Shirley L.; DeFronzo, Ralph A.; Jenkinson, Christopher P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78229 USA.
[Schneider, Jennifer; Dyer, Thomas D.; Puppala, Sobha; Farook, Vidya S.; Blangero, John; Duggirala, Ravindranath; Jenkinson, Christopher P.] SW Fdn Biomed Res, San Antonio, TX 78284 USA.
[Arya, Rector; Lehman, Donna M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA.
[DeFronzo, Ralph A.; Jenkinson, Christopher P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Coletta, DK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78229 USA.
EM dawn.coletta@asu.edu
RI Coletta, Dawn/G-6382-2016
OI Coletta, Dawn/0000-0001-5819-5152
FU Veterans Administration Epidemiologic; National Institutes of Health
[DK42273, DK47482, DK53889, DK70746]; American Heart Association
National Scientist Development
FX We thank Marcel J. Fourcaudot and Lenore M. Rodriguez for excellent
technical assistance. We thank our nurses (James King, John Kincaid,
Rose Kaminski-Graham, and Norma Diaz) for their excellent care of the
patients throughout the study. We thank the participants of VAGES and
are grateful for their participation and cooperation.
NR 38
TC 12
Z9 13
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD JAN
PY 2009
VL 58
IS 1
BP 279
EP 284
DI 10.2337/db08-0491
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 390TR
UT WOS:000262187100041
PM 18931038
ER
PT B
AU Watson, GS
Craft, S
AF Watson, G. Stennis
Craft, Suzanne
BE Biessels, GJ
Luchsinger, JA
TI The Role of Insulin Resistance in Age-Related Cognitive Decline and
Dementia
SO DIABETES AND THE BRAIN
SE Contemporary Diabetes
LA English
DT Article; Book Chapter
DE Alzheimer's disease; Apolipoprotein E; Beta amyloid; Diabetes; Diet and
exercise; Glucose; Inflammation; Insulin; Insulin resistance; IGF-1;
Intranasal; Memory; PPAR-gamma
ID CENTRAL-NERVOUS-SYSTEM; IMPAIRED GLUCOSE-TOLERANCE; APOLIPOPROTEIN-E
GENOTYPE; GROWTH-FACTOR EXPRESSION; SPORADIC ALZHEIMERS-DISEASE; AMYLOID
PRECURSOR PROTEIN; OXIDE SYNTHASE EXPRESSION; NECROSIS-FACTOR-ALPHA;
FREE FATTY-ACIDS; PEROXISOME PROLIFERATOR
AB The role of insulin in peripheral energy metabolism has been well described, and converging evidence has identified a role for insulin in central nervous system functions. Epidemiological studies support an important relationship between diabetes and other insulin-resistant conditions, and cognitive functioning. For example, diabetes increases the risk for memory loss, and treating diabetes can reverse memory loss. These studies have also identified a reciprocal relationship between insulin resistance and dementia, such that one condition increases the risk for the other. A substantial body of work has explored the role of insulin in regulating brain glucose metabolism, memory function, inflammatory responses, and amyloid concentrations. Knowledge of these relationships has suggested that increasing brain insulin activity may have a beneficial impact on memory and may serve as the basis for novel therapeutic strategies for Alzheimer's disease. Three such strategies include intranasal administration of insulin, drugs that improve insulin sensitivity, and diet and exercise
C1 [Watson, G. Stennis; Craft, Suzanne] Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound, Seattle, WA 98108 USA.
RP Watson, GS (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound, Seattle, WA 98108 USA.
EM gswatson@u.washington.edu; scraft@u.washington.edu
NR 107
TC 0
Z9 0
U1 1
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
BN 978-1-60327-850-8
J9 CONTEMP DIABETES
PY 2009
BP 433
EP 457
DI 10.1007/978-1-60327-850-8_18
D2 10.1007/978-1-60327-850-8
PG 25
WC Endocrinology & Metabolism; Medicine, General & Internal; Neurosciences
SC Endocrinology & Metabolism; General & Internal Medicine; Neurosciences &
Neurology
GA BLZ66
UT WOS:000271604300018
ER
PT J
AU Maciejewski, ML
Liu, CF
Fihn, SD
AF Maciejewski, Matthew L.
Liu, Chuan-Fen
Fihn, Stephan D.
TI Performance of Comorbidity, Risk Adjustment, and Functional Status
Measures in Expenditure Prediction for Patients With Diabetes
SO DIABETES CARE
LA English
DT Article
ID REPORTED HEALTH-STATUS; CASE-MIX; SEVERITY INDEX; CARE; VALIDATION;
QUALITY; MODEL; POPULATION; MORTALITY; SELECTION
AB OBJECTIVE - To compare the ability of generic comorbidity and risk adjustment measures, a diabetes-specific measure, and a self-reported functional status measure to explain variation in health care expenditures for individuals with diabetes.
RESEARCH DESIGN AND METHODS - This study included a retrospective cohort of 3,092 diabetic veterans participating in a multisite trial. Two comorbidity measures, four risk adjusters, a functional Status measure, a diabetes complication count, and baseline expenditures were constructed from administrative and survey data. Outpatient, inpatient, and total expenditure models were estimated using ordinary least squares regression. Adjusted R(2) statistics and predictive ratios were compared across measures to assess overall explanatory power and explanatory power of low- and high-cost subgroups.
RESULTS - Administrative data-based risk adjusters performed better than the comorbidity, functional status, and diabetes-specific measures in all expenditure models. The diagnostic cost groups (DCGs) measure had the greatest predictive power overall and for the low- and high-cost subgroups, while the diabetes-specific measure had the lowest predictive power. A model with DCGs and the diabetes-specific measure modestly improved predictive power.
CONCLUSIONS - Existing generic measures can be useful for diabetes-specific research and policy applications, but more predictive diabetes-specific measures are needed.
C1 [Maciejewski, Matthew L.] Durham VA Med Ctr, Hlth Serv Res & Dev, Dept Vet Affairs, Durham, NC USA.
[Maciejewski, Matthew L.] Univ N Carolina, Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA.
[Liu, Chuan-Fen; Fihn, Stephan D.] Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Washington, DC USA.
[Liu, Chuan-Fen; Fihn, Stephan D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Hlth Serv Res & Dev, Dept Vet Affairs, Durham, NC USA.
EM matthew.maciejewski@va.gov
FU Department of Veterans Affairs; Veterans Health Administration; Office
of Research and Development; Health Services Research and Development
Service (HSRD) [LIP 61-105, SDR 96-002, IIR 99-376]
FX No potential conflicts of interest relevant to this article were
reported. Comments from Sarah Krein, the manuscript editor, two
anonymous reviewers, and Outstanding research assistance from Mark
Perkins are appreciated.
NR 25
TC 25
Z9 25
U1 1
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JAN
PY 2009
VL 32
IS 1
BP 75
EP 80
DI 10.2337/dc08-1099
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 390UA
UT WOS:000262188000016
PM 18945927
ER
PT J
AU Izumi, Y
Satterfield, K
Lee, S
Harkless, LB
Lavery, LA
AF Izumi, Yuki
Satterfield, Kathleen
Lee, Shuko
Harkless, Lawrence B.
Lavery, Lawrence A.
TI Mortality of first-time amputees in diabetics: A 10-year observation
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Diabetic foot; Mortality; Amputation
ID LOWER-EXTREMITY AMPUTATION; 6.5-YEAR FOLLOW-UP; MAJOR AMPUTATION;
LOWER-LIMB; FOOT PROBLEMS; SURVIVAL; POPULATION; DISEASE; REAMPUTATION;
PROGNOSIS
AB Aims: We analyze mortality of first-time diabetic amputees by stratifying by level of amputation, differentiating short-term and long-term mortality.
Methods: We evaluated 277 diabetic patients who received their first lower extremity amputation (LEA) during 1993-97. Subjects were followed until December 2003, and categorized by level of amputation. We compared the mortality difference by level for 0-10 years, 0-10 months, and 10 months-10 years, and examined the association of comorbid conditions and death for each level.
Results: We found a significant difference in mortality by amputation level for 0-10 years (p < 0.05) and < 10 months (p < 0.01) survival, but not for the one of 10 months-10 years. For major amputees deceased within 10 months, sepsis was as frequent a cause of death as cardiovascular disease. in distal. amputees, CVD, CAD and ESRD were strongly associated with death, but only CAD was associated death among major amputees.
Conclusion: For diabetic patients undergoing first LEAS, the mortality of major amputees was worse than that of minor amputees due to the difference in first 10-month mortality. The history of comorbid conditions in first-time major amputees was less important than in minor amputees since sepsis was the frequent cause of death in major amputees in this early period. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Izumi, Yuki] Natl Hosp Org, Kyoto Med Ctr, WHO, Collaborating Ctr Diabet, Kyoto 6128555, Japan.
[Satterfield, Kathleen] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthopaed, San Antonio, TX 78229 USA.
[Lee, Shuko] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Res & Dev Serv, San Antonio, TX USA.
[Harkless, Lawrence B.] Western Univ Hlth Sci, Coll Podiatr Med, Pomona, CA 91766 USA.
[Lavery, Lawrence A.] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Temple, TX 76508 USA.
[Lavery, Lawrence A.] Scott & White Hosp, Temple, TX USA.
RP Izumi, Y (reprint author), Natl Hosp Org, Kyoto Med Ctr, WHO, Collaborating Ctr Diabet, 1-1 Mukaihata Cho Fukakusa, Kyoto 6128555, Japan.
EM dfootjapan@hotmail.co.jp
OI Lavery, Lawrence/0000-0002-7920-9952
NR 22
TC 27
Z9 28
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0168-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD JAN
PY 2009
VL 83
IS 1
BP 126
EP 131
DI 10.1016/j.diabres.2008.09.005
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 398VC
UT WOS:000262758600019
PM 19097667
ER
PT J
AU Bradesi, S
Mayer, EA
AF Bradesi, Sylvie
Mayer, Emeran A.
TI Experimental Models of Stress and Pain: Do They Help to Develop New
Therapies?
SO DIGESTIVE DISEASES
LA English
DT Article
DE Irritable bowel syndrome; Animal models; Human experimental medicine
models; Drug development; Predictive validity; Intermediate phenotypes
ID IRRITABLE-BOWEL-SYNDROME; FUNCTIONAL GASTROINTESTINAL DISORDERS;
BRAIN-GUT AXIS; NOXIOUS COLORECTAL DISTENSION; PSEUDO-AFFECTIVE
RESPONSES; 5-HT3 RECEPTOR ANTAGONIST; KAPPA-AGONIST FEDOTOZINE; FACTOR-I
RECEPTORS; COLONIC DISTENSION; ANIMAL-MODELS
AB The majority of functional gastrointestinal disorders are characterised by recurrent abdominal pain, with stress playing an important role in first onset and exacerbation of existing symptoms. These disorders are currently defined by symptom criteria, while their pathophysiology remains controversial and incompletely understood. Modeling these disorders in humans and animals has been difficult. While some of the models have adequate face and construct validity, the predictive validity of most of the models has been disappointing, which has put into question the traditional modeling approach. Similar problems have been encountered in drug development for pain and psychiatric disorders. New approaches have been proposed in the form of reverse translation, which include better characterisation of biological intermediate phenotypes in human disease which can be modeled in humans and in animals. Continuation of the current approach focusing on complex clinical phenotypes is likely to be ineffective for the development of novel and effect treatments. Copyright (C) 2010 S. Karger AG, Basel
C1 [Bradesi, Sylvie] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Dept Physiol, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Dept Psychiat, Los Angeles, CA 90095 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bradesi, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Bldg 115 CURE,11303 Wilshire Blvd, Los Angeles, CA 90095 USA.
EM sbradesi@ucla.edu
FU Boehringer Ingelheim International GmbH; GSK; Novartis; Avera; Danone
FX S. Bradesi has received research support from Boehringer Ingelheim
International GmbH. E. A. Mayer is a consultant for GSK, Novartis,
Lilly, Avery, Forrest, Ironwood and Danone and has received research
support from GSK, Novartis, Avera and Danone.
NR 92
TC 6
Z9 6
U1 5
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0257-2753
J9 DIGEST DIS
JI Dig. Dis.
PY 2009
VL 27
SU 1
BP 55
EP 67
DI 10.1159/000268122
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 566FM
UT WOS:000275355500009
PM 20203498
ER
PT J
AU Kaunitz, JD
AF Kaunitz, Jonathan D.
TI Gastroenterology Research Group and Digestive Diseases and Sciences
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
C1 Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA.
RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA.
EM jake@ucla.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JAN
PY 2009
VL 54
IS 1
BP 5
EP 5
DI 10.1007/s10620-008-0625-z
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 383DD
UT WOS:000261653400002
ER
PT J
AU Sporner, ML
Fitzgerald, SG
Dicianno, BE
Collins, D
Teodorski, E
Pasquina, PF
Cooper, RA
AF Sporner, Michelle L.
Fitzgerald, Shirley G.
Dicianno, Brad E.
Collins, Diane
Teodorski, Emily
Pasquina, Paul F.
Cooper, Rory A.
TI Psychosocial impact of participation in the National Veterans Wheelchair
Games and Winter Sports Clinic
SO DISABILITY AND REHABILITATION
LA English
DT Article
DE Exercise; sports; wheelchairs; activities of daily living; quality of
life
ID SPINAL-CORD-INJURY; PHYSICAL-ACTIVITY; MENTAL-HEALTH; CONTROLLED-TRIAL;
EXERCISE; PREVENTION; DEPRESSION; DEPLOYMENT; MOOD; IRAQ
AB Purpose. The purpose of this study was to determine the characteristics of individuals who participate in the National Veterans Wheelchair Games (NVWG) and the Winter Sports Clinic (WSC) for veterans with disabilities. In addition, it was of interest to determine how these events had impacted their lives. Method. Participants were recruited at the 20th Winter Sports Clinic, held in Snowmass Colorado and the 26th National Veterans Wheelchair Games held in Anchorage, Alaska. Data of interest included demographic, sport participation information, community integration, self-esteem, and quality of life. A secondary data analysis was completed to determine how comparable individuals who attended the NVWG/WSC were to individuals who did not participate in these events. Results. The 132 participants were a mean age of 47.4 + 13.4 and lived with a disability for an average of 13.4 + 12.1. Participants felt that the NVWG/WSC increased their knowledge of sports equipment (92%), learning sports (89%), mobility skills (84%), and acceptance of disability (84%). The majority of participants stated that the NVWG/WSC improved their life. Of those who participated at the NVWG/WSC, they tended to be more mobile, but have increased physical and cognitive limitations as measured by the CHART when compared to the non-attendees. Conclusions. Recommending veterans participate in events such as the NVWG and WSC can provide psychosocial benefits to veterans with disabilities.
C1 [Sporner, Michelle L.; Collins, Diane] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Fitzgerald, Shirley G.] James Haley Tampa VA, Patient Safety Ctr, Tampa, FL USA.
[Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Teodorski, Emily] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Pasquina, Paul F.] Dept Orthoped & Rehabil, Walter Reed Army Med Ctr, Washington, DC USA.
[Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Sporner, Michelle L.; Dicianno, Brad E.; Collins, Diane; Teodorski, Emily; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Sporner, Michelle L.; Collins, Diane; Cooper, Rory A.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.
[Fitzgerald, Shirley G.] James A Haley Tampa VA, Patient Safety Ctr, Tampa, FL USA.
[Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.
[Pasquina, Paul F.] Walter Reed Army Med Ctr, Dept Orthoped & Rehabil, Washington, DC 20307 USA.
RP Fitzgerald, SG (reprint author), Patient Safety Ctr Inquiry, 11605 N Nebraska Ave, Tampa, FL 33612 USA.
EM Shirley.Fitzgerald@va.gov
OI Dicianno, Brad/0000-0003-0738-0192
FU VA Center of Excellence, VA Pittsburgh Healthcare System; The
Telemedicine and Advanced Technology Research Center [06053001]; HSRRB
[A-13839]; Center of Excellence for Wheelchairs and Associated
Rehabilitation Engineering [VA B3142C]
FX This project was completed solely at the VA Center of Excellence, VA
Pittsburgh Healthcare System. This study was supported by The
Telemedicine and Advanced Technology Research Center under Proposal
Number 06053001, HSRRB Log Number A-13839 and Center of Excellence for
Wheelchairs and Associated Rehabilitation Engineering (VA B3142C).
NR 36
TC 19
Z9 20
U1 4
U2 30
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0963-8288
J9 DISABIL REHABIL
JI Disabil. Rehabil.
PY 2009
VL 31
IS 5
BP 410
EP 418
AR PII 792789939
DI 10.1080/09638280802030923
PG 9
WC Rehabilitation
SC Rehabilitation
GA 417SM
UT WOS:000264098200009
PM 18608391
ER
PT J
AU Bull, LM
White, DL
Bray, M
Nurgalieva, Z
El-Serag, HB
AF Bull, L. M.
White, D. L.
Bray, M.
Nurgalieva, Z.
El-Serag, H. B.
TI Phase I and II enzyme polymorphisms as risk factors for Barrett's
esophagus and esophageal adenocarcinoma: a systematic review and
meta-analysis
SO DISEASES OF THE ESOPHAGUS
LA English
DT Review
DE Barrett's esophagus; epidemiology; esophageal adenocarcinoma; genetic
association; GST; single-nucleotide polymorphism (SNP)
ID GLUTATHIONE-S-TRANSFERASE; MICROSOMAL EPOXIDE HYDROLASE;
SQUAMOUS-CELL-CARCINOMA; ARYLAMINE N-ACETYLTRANSFERASE; LUNG-CANCER
RISK; GENETIC POLYMORPHISMS; REFLUX ESOPHAGITIS; MOLECULAR-GENETICS;
C609T POLYMORPHISM; ALLELIC VARIANTS
AB P>Although several studies have examined the association between phase I/II enzyme polymorphisms and esophageal adenocarcinoma (EAC) and/or Barrett's esophagus (BE), their overall findings remain unclear. We performed a systematic review and meta-analysis to determine whether phase I/II polymorphisms are independent risk factors for either BE or EAC. We employed keyword searches in multiple databases to identify studies published before October 1, 2007. Single-nucleotide polymorphisms (SNPs) examined in >= 3 studies were meta-analyzed to obtain a pooled estimate of effect. Meta-analysis suggested the minor allele for GSTP1 Val105 conveys modest excess risk (odds ratio [OR](BE) = 1.50, 95% confidence interval [CI] 1.16-1.95; OR(EAC) = 1.20, 95% CI 0.94-1.54). No excess risk was observed with GSTM1 null (OR(BE) = 0.77, 95% CI: 0.56-1.08; OR(EAC) = 1.08, 95% CI: 0.79-1.48), GSTT1 null (OR(BE) = 1.35, 95% CI: 0.91-2.01; OR(EAC) = 0.84, 95% CI: 0.48-1.49), or CYP1A Val462 (OR(EAC) = 0.89, 95% CI: 0.40-1.97). Insufficient data existed to meta-analyze remaining SNPs. Our review identified GSTP1(Ile105Val) as a possible risk factor for BE and EAC in Caucasian males. No excess risk was observed for other phase I/II polymorphisms with sufficient data to meta-analyze. Additional studies are needed to determine if GSTP1 conveys excess risk in females or non-Caucasians and to evaluate other phase I/II polymorphisms.
C1 [Bull, L. M.; White, D. L.; Bray, M.; Nurgalieva, Z.; El-Serag, H. B.] Baylor Coll Med, Houston, TX 77030 USA.
RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd MS 152, Houston, TX 77030 USA.
EM hasheme@bcm.tmc.edu
FU Helis Foundation
FX The study is supported in part by a grant from the Helis Foundation.
NR 92
TC 11
Z9 11
U1 1
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1120-8694
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PY 2009
VL 22
IS 7
BP 571
EP 587
DI 10.1111/j.1442-2050.2009.00947.x
PG 17
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 497OX
UT WOS:000270070500005
PM 19222528
ER
PT J
AU Montenovo, M
Tatum, RP
Figueredo, E
Martin, AV
Vu, H
Quiroga, E
Pellegrini, CA
Oelschlager, BK
AF Montenovo, M.
Tatum, R. P.
Figueredo, E.
Martin, A. Valeria
Vu, H.
Quiroga, E.
Pellegrini, C. A.
Oelschlager, B. K.
TI Does combined multichannel intraluminal esophageal impedance and
manometry predict postoperative dysphagia after laparoscopic Nissen
fundoplication?
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE dysphagia; esophageal motility; fundoplication; impedance
ID GASTROESOPHAGEAL-REFLUX DISEASE; RANDOMIZED CLINICAL-TRIAL; ANTIREFLUX
SURGERY; MOTILITY; THERAPY; PERISTALSIS; SYMPTOMS
AB P>Laparoscopic Nissen fundoplication (LNF) is an effective treatment for gastroesophageal reflux disease; however, some patients develop dysphagia postoperatively. Manometry is used to evaluate disorders of peristalsis, but has not been proven useful to identify which patients may be at risk for postoperative dysphagia. Multichannel intraluminal impedance (MII) evaluates the effective clearance of a swallowed bolus through the esophagus. We hypothesized that MII combined with manometry may detect those patients most at risk of developing dysphagia after LNF. Between March 2003 and January 2007, 74 patients who agreed to participate in this study were prospectively enrolled. All patients completed a preoperative symptom questionnaire, MII/manometry, and 24-h pH monitoring. All patients underwent LNF. Symptom questionnaires were administered postoperatively at a median of 18 months (range: 6-46 months), and we defined dysphagia (both preoperatively and postoperatively) as occurring more than once a month with a severity >= 4 (0-10 Symptom Severity Index). Thirty-two patients (43%) reported preoperative dysphagia, but there was no significant difference in pH monitoring, lower esophageal sphincter pressure/relaxation, peristalsis, liquid or viscous bolus transit (MII), or bolus transit time (MII) between patients with and without preoperative dysphagia. In those patients reporting preoperative dysphagia, the severity of dysphagia improved significantly from 6.8 +/- 2 to 2.6 +/- 3.4 (P < 0.001) after LNF. Thirteen (17%) patients reported dysphagia postoperatively, 10 of whom (75%) reported some degree of preoperative dysphagia. The presence of postoperative dysphagia was significantly more common in patients with preoperative dysphagia (P = 0.01). Patients with postoperative dysphagia had similar lower esophageal sphincter pressure and relaxation, peristalsis, and esophageal clearance to those without dysphagia. Neither MII nor manometry predicts dysphagia in patients with gastroesophageal reflux disease or its occurrence after LNF. The presence of dysphagia preoperatively is the only predictor of dysphagia after LNF.
C1 [Tatum, R. P.] Univ Washington, VA Puget Sound HCS, Dept Surg, Swallowing Ctr, Seattle, WA 98108 USA.
RP Tatum, RP (reprint author), Univ Washington, VA Puget Sound HCS, Dept Surg, Swallowing Ctr, 1660 S Columbian Way S-112-Gs,Box 358280, Seattle, WA 98108 USA.
EM rtatum@u.washington.edu
NR 27
TC 18
Z9 21
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1120-8694
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PY 2009
VL 22
IS 8
BP 656
EP 663
DI 10.1111/j.1442-2050.2009.00988.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 524FE
UT WOS:000272128400005
PM 19515186
ER
PT J
AU Suh, JJ
Langleben, DD
Ehrman, RN
Hakun, JG
Wang, Z
Li, Y
Busch, SI
O'Brien, CP
Childress, AR
AF Suh, Jesse J.
Langleben, Daniel D.
Ehrman, Ronald N.
Hakun, Jonathan G.
Wang, Ze
Li, Yin
Busch, Samantha I.
O'Brien, Charles P.
Childress, Anna Rose
TI Low prefrontal perfusion linked to depression symptoms in
methadone-maintained opiate-dependent patients
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Opiate dependence; Depression; Methadone-maintenance; Affect regulation;
Comorbidity; Prefrontal cortex
ID CEREBRAL-BLOOD-FLOW; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; HAMILTON
RATING-SCALE; MAJOR DEPRESSION; SUBSTANCE USE; COGNITIVE REGULATION;
UNIPOLAR DEPRESSION; ANTERIOR CINGULATE; EXCHANGE PROGRAM; HEROIN USERS
AB Background: Clinically depressed patients Without substance use disorders, compared to controls, exhibit significantly lower resting regional cerebral blood flow (rCBF) in the prefrontal cortex (PFC). In this study, we examined the link between resting rCBF in the PFC and current depressive symptoms in methadone-maintained opiate-dependent (MM) patients with or without major depression.
Methods: Arterial spin labeled perfusion fMRI at 3 Tesla was used to measure resting rCBF in 21 MM patients. Per-fusion data were analyzed using SPM2. The relationship between Beck Depression Inventory (BDI) score and resting rCBF was examined in a single regression analysis.
Results: The BDI scores ranged between 0 and 18 (m = 7.0, S.D. = 4.8), and 30% of the sample had mild to moderate depression symptoms according to BDI scores. A negative correlation was observed between BDI scores and relative rCBF in the bilateral ventrolateral prefrontal cortex, and middle frontal gyri.
Conclusions: The inverse relationship between prefrontal paralimbic rCBF and depression Scores Suggests a link between reduced fronto-limbic activity and depressive symptoms in MM patients. A significant subgroup of opiate-dependent patients has clinical or sub-clinical depression that is often undetected; our data identify brain Substrates of depression symptoms that may also be a potential marker of relapse in this population. Treatment strategies targeting these brain regions may improve Outcomes in depressed Substance abusers. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Suh, Jesse J.; Langleben, Daniel D.; Ehrman, Ronald N.; Hakun, Jonathan G.; Wang, Ze; Li, Yin; Busch, Samantha I.; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Sch Med, Dept Psychiat, Ctr Studies Addict, Philadelphia, PA 19104 USA.
[Langleben, Daniel D.; Ehrman, Ronald N.; O'Brien, Charles P.; Childress, Anna Rose] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Suh, JJ (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Studies Addict, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM Suh_J@mail.trc.upenn.edu
RI Wang, Ze/A-1043-2007; Langleben, Daniel/K-7407-2014
FU National Institute of Drug Abuse [T32 DA0724 1, K23 DAO 15746, RO1
DA10241, RO1 DA15149, P60 DA05186, P50 DA12756]; Veterans Affairs
Medical Center-Philadelphia [VA VISN 4 MIRECC]; Alexander Foundation
FX This study is supported by grants from the National Institute of Drug
Abuse (T32 DA0724 1, K23 DAO 15746; RO1 DA10241, RO1 DA15149, P60
DA05186, P50 DA12756), the Veterans Affairs Medical Center-Philadelphia
(VA VISN 4 MIRECC), and Alexander Foundation.
NR 65
TC 3
Z9 7
U1 5
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JAN 1
PY 2009
VL 99
IS 1-3
BP 11
EP 17
DI 10.1016/j.drugalcdep.2008.06.007
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 397ZH
UT WOS:000262700500002
PM 18674871
ER
PT J
AU Farren, CK
Scimeca, M
Wu, R
Malley, SO
AF Farren, Conor K.
Scimeca, Michael
Wu, Ran
Malley, Stephanie O.
TI A double-blind, placebo-controlled study of sertraline with naltrexone
for alcohol dependence
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol dependence; Sertraline; Naltrexone; Clinical trial; Alcohol
typology
ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; DEPRESSED
ALCOHOLICS; CLINICAL-EVIDENCE; DRINKING; FLUOXETINE; SEROTONIN; ABUSE;
RATS; PHARMACOTHERAPY
AB Introduction: Significant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining alcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-controlled study examined whether the efficacy of naltrexone Would be augmented by Concurrent treatment with sertraline, a selective serotonin receptor uptake inhibitor (SSRI).
Methods: One hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and 30 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined and simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group relapse prevention psychotherapy on a weekly basis.
Results: Compliance and attendance rates were comparable and high, The groups did not differ on the two primary outcomes, time to first drink and time to relapse to heavy drinking, or oil secondary treatment outcomes. With the exception of sexual side effects which were more common in the combination group, most adverse event, were similar for the two conditions.
Conclusions: As the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the combined use of sertraline and naltrexone above naltrexone alone. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Farren, Conor K.; Wu, Ran; Malley, Stephanie O.] Yale Univ, Sch Med, Dept Psychiat, Subst Abuse Treatment Unit, New Haven, CT 06419 USA.
[Farren, Conor K.; Scimeca, Michael] Bronx Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Psychiat, Bronx, NY 10468 USA.
RP Farren, CK (reprint author), St Patricks Hosp, James St, Dublin 8, Ireland.
EM cfarren@stpatsmail.com
FU Mount Sinai GCRC [RO1AA11122, K05AA014715]; Pfizer Inc.; National
Institutes of Health [RO1AA11122, K05AA014715]; State of Connecticut,
Department of Mental Health and Addiction Services
FX This study was supported by National Institutes of Health grants
RO1AA11122, K05AA014715, by the Mount Sinai GCRC, and by the State of
Connecticut, Department of Mental Health and Addiction Services. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute on
Alcohol Abuse and Alcoholism or the National Institute of Health.
NR 34
TC 11
Z9 13
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JAN 1
PY 2009
VL 99
IS 1-3
BP 317
EP 321
DI 10.1016/j.drugalcdep.2008.06.006
PG 5
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 397ZH
UT WOS:000262700500034
PM 18644685
ER
PT J
AU Yong, PL
Bigman, C
Flynn, DN
Mittermaier, D
Long, JA
AF Yong, Pierre L.
Bigman, Cabral
Flynn, David N.
Mittermaier, Danielle
Long, Judith A.
TI Messages about Black-Box Warnings A Comparative Analysis of Reports from
the FDA and Lay Media in the US
SO DRUG SAFETY
LA English
DT Article
ID PRESCRIPTION MEDICATIONS; NEWSPAPER COVERAGE; NEWS COVERAGE; BEHAVIOR;
COMMUNICATION
AB Background: The US FDA and lay media are important sources of information for the public about the risks of adverse events associated with drugs, yet the quality of FDA and US lay media reports about medication 'black-box' warnings, which highlight potentially severe adverse events from medications, is unknown.
Objective: To determine and compare the content of FDA and US lay media reports about medication black-box warnings.
Methods: We assessed FDA and US lay media reports about medication black-box warnings published or aired between I January 2003 and 31 December 2007 for the presence of six core message components, including (i) the affected drug's brand name; (ii) generic name; (iii) treatment indication; (iv) reason for the black-box warning; (v) clinical recommendations for patients, such as warning signs and symptoms of the adverse effect addressed by the black-box warning; and (vi) encouragement to discuss the issue with a healthcare provider, and additional characteristics.
Results: FDA reports presented more core information than lay media reports (median 5 vs 3 message components; p < 0.001). FDA reports were more likely to mention generic names (84.6% vs 18.1%; p < 0.001) of affected drugs, while lay media reports less frequently detailed clinical recommendations for patients (43.9% vs 96.2%; p<0.001). Only 10.6% of lay media reports encouraged patients to seek additional information from their healthcare provider, compared with 48.1% of FDA reports (p < 0.001).
Conclusions: FDA and US lay media reports about medication black-box warnings presented different information. This may reflect a difference in underlying motivation for reporting of news about risks of adverse drug events. It may also indicate a lack of agreement and understanding about the best methods to communicate risk information to the public, thus indicating areas for future research.
C1 [Yong, Pierre L.] Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Yong, Pierre L.; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA.
[Yong, Pierre L.; Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Yong, Pierre L.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Bigman, Cabral; Mittermaier, Danielle] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA.
[Flynn, David N.; Long, Judith A.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
RP Yong, PL (reprint author), Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, 1303A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM pyong@nas.edu
OI Bigman, Cabral/0000-0002-4510-7878
NR 30
TC 4
Z9 4
U1 0
U2 3
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
ZEALAND
SN 0114-5916
J9 DRUG SAFETY
JI Drug Saf.
PY 2009
VL 32
IS 12
BP 1147
EP 1157
PG 11
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
Toxicology
GA 531MM
UT WOS:000272670400006
PM 19916582
ER
PT J
AU Patel, M
AF Patel, Mukesh
TI Community-Associated Meticillin-Resistant Staphylococcus aureus
Infections Epidemiology, Recognition and Management
SO DRUGS
LA English
DT Review
ID ACQUIRED METHICILLIN-RESISTANT; PANTON-VALENTINE LEUKOCIDIN;
SKIN-STRUCTURE INFECTIONS; INDUCIBLE CLINDAMYCIN RESISTANCE; CHROMOSOMAL
CASSETTE MEC; SOFT-TISSUE INFECTIONS; MINIMUM INHIBITORY CONCENTRATION;
VENTILATOR-ASSOCIATED PNEUMONIA; PROSTHETIC JOINT INFECTIONS;
CARE-ASSOCIATED INFECTIONS
AB Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more frequent. The most common manifestation of CA-MRSA infection is skin and soft tissue infection, although necrotizing pneumonia, sepsis and osteoarticular infections can occur. CA-MRSA strains have become endemic in many communities and are genetically distinct from previously identified MRSA strains. CA-MRSA may be more capable colonizers of humans and more virulent than other S. aureus strains. Specific mechanisms of pathogenicity have not been elucidated, but several factors have been proposed as responsible for the virulence of CA-MRSA, including the Panton-Valentine leukocidin, phenol-soluble modulins and type I arginine catabolic mobile element. The movement of CA-MRSA strains into the nosocomial setting limits the utility of using clinical risk factors alone to designate community- or healthcare-associated status. Identification of unique genetic characteristics and genotyping are valuable tools for MRSA epidemiological studies. Although the optimum pharmacological therapy for CA-MRSA infections has not been determined, many CA-MRSA strains remain broadly susceptible to several non-p-lactam antibacterial agents. Empirical antibacterial therapy should include an MRSA-active agent, particularly in areas where CA-MRSA is endemic.
C1 [Patel, Mukesh] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA.
[Patel, Mukesh] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Patel, M (reprint author), Univ Alabama Birmingham, Div Infect Dis, THT 229,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM mukesh@uab.edu
NR 214
TC 25
Z9 28
U1 1
U2 6
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PY 2009
VL 69
IS 6
BP 693
EP 716
PG 24
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 455WW
UT WOS:000266800200004
PM 19405550
ER
PT J
AU Gazdag, G
Mann, SC
Ungvari, GS
Caroff, SN
AF Gazdag, Gabor
Mann, Stephan C.
Ungvari, Gabor S.
Caroff, Stanley N.
BE Swartz, CM
TI Clinical evidence for the efficacy of electroconvulsive therapy in the
treatment of catatonia and psychoses
SO ELECTROCONVULSIVE AND NEUROMODULATION THERAPIES
LA English
DT Article; Book Chapter
ID LIFE-THREATENING CATATONIA; SCHIZOAFFECTIVE DISORDER; ELDERLY-PATIENTS;
LETHAL CATATONIA; 1ST-EPISODE SCHIZOPHRENIA; REFRACTORY SCHIZOPHRENIA;
MALIGNANT CATATONIA; CONVULSIVE THERAPY; ORGANIC CATATONIA; MANIC
EPISODES
C1 [Gazdag, Gabor] Jahn Ferenc Hosp, Inpatient Sect, Dept Psychiat, Budapest, Hungary.
[Mann, Stephan C.] Univ Louisville, Sch Med, Dept Psychiat & Behav Sci, Louisville, KY 40292 USA.
[Mann, Stephan C.] Cent Montgomery Mental Hlth & Mental Retardat Ctr, Norristown, PA USA.
[Ungvari, Gabor S.] Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China.
[Ungvari, Gabor S.] Shatin Hosp, Dept Psychiat, Shatin, Hong Kong, Peoples R China.
[Caroff, Stanley N.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Caroff, Stanley N.] Vet Affairs Med Ctr, Inpatient Sect, Behav Hlth Serv, Philadelphia, PA USA.
RP Gazdag, G (reprint author), Jahn Ferenc Hosp, Inpatient Sect, Dept Psychiat, Budapest, Hungary.
NR 122
TC 4
Z9 4
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND
BN 978-0-521-88388-7
PY 2009
BP 124
EP 148
DI 10.1017/CBO9780511576393.008
D2 10.1017/CBO9780511576393
PG 25
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA BDX12
UT WOS:000315519200008
ER
PT J
AU Harrington, AT
Castellanos, JA
Ziedalski, TM
Clarridge, JE
Cookson, BT
AF Harrington, Amanda T.
Castellanos, Jaime A.
Ziedalski, Tomasz M.
Clarridge, Jill E., III
Cookson, Brad T.
TI Isolation of Bordetella avium and Novel Bordetella Strain from Patients
with Respiratory Disease
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID BRONCHISEPTICA
AB Bordetella avium is thought to be strictly an avian pathogen. However, 16S rRNA gene sequencing identified 2 isolates from 2 humans with respiratory disease as B. avium and a novel B. avium-like strain. Thus, B. avium and B. avium-like organisms are rare opportunistic human pathogens..
C1 [Harrington, Amanda T.; Clarridge, Jill E., III; Cookson, Brad T.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Castellanos, Jaime A.] Baylor Coll Med, Houston, TX 77030 USA.
[Ziedalski, Tomasz M.] Western Washington Med Grp, Everett, WA USA.
RP Cookson, BT (reprint author), Univ Washington, Dept Lab Med, Box 357110,1959 NE Pacific St, Seattle, WA 98195 USA.
EM cookson@u.washington.edu
NR 7
TC 17
Z9 20
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JAN
PY 2009
VL 15
IS 1
BP 72
EP 74
DI 10.3201/eid1501.071677
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 393AG
UT WOS:000262342700016
PM 19116056
ER
PT J
AU Houser, CR
AF Houser, C. R.
BE Schwartzkroin, PA
TI Plasticity and Reorganization of GABA Neurons in Epilepsy
SO ENCYCLOPEDIA OF BASIC EPILEPSY RESEARCH, VOLS 1-3
LA English
DT Article; Book Chapter
ID TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; GABAERGIC
INTERNEURONS; PILOCARPINE MODEL; MOUSE MODEL; VULNERABILITY;
HIPPOCAMPUS; RECEPTORS; SYSTEM
C1 [Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Houser, C. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-373961-2
PY 2009
BP 619
EP 625
PG 7
WC Medicine, Research & Experimental; Clinical Neurology
SC Research & Experimental Medicine; Neurosciences & Neurology
GA BFJ85
UT WOS:000320162800106
ER
PT J
AU Davies, TF
Latif, R
Yin, XM
AF Davies, Terry F.
Latif, Rauf
Yin, Xiaoming
TI INHERITING AUTOIMMUNE THYROID DISEASE
SO ENDOCRINE PRACTICE
LA English
DT Editorial Material
ID GENOME-WIDE ASSOCIATION; GRAVES-DISEASE; SUSCEPTIBILITY LOCI;
HASHIMOTOS-THYROIDITIS; GENETIC-HETEROGENEITY; WHICKHAM SURVEY;
FAMILIES; PEROXIDASE; HLA; AUTOANTIBODIES
C1 [Davies, Terry F.; Latif, Rauf; Yin, Xiaoming] James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY USA.
RP Davies, TF (reprint author), Mt Sinai Med Ctr, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM terry.davies@mssm.edu
FU NIDDK NIH HHS [DK052464, DK069713]
NR 26
TC 1
Z9 1
U1 0
U2 1
PU AMER ASSOC CLIN ENDOCRINOL
PI JACKSONVILLE
PA 1000 RIVERSIDE AVE, STE 205, JACKSONVILLE, FL 32204 USA
SN 1530-891X
J9 ENDOCR PRACT
JI Endocr. Pract.
PD JAN-FEB
PY 2009
VL 15
IS 1
BP 63
EP 66
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 437NO
UT WOS:000265494400014
PM 19211403
ER
PT J
AU Bokov, AF
Ko, DJ
Richardson, A
AF Bokov, Alex F.
Ko, Daijin
Richardson, Arlan
TI The Effect Of Gonadectomy And Estradiol On Sensitivity To Oxidative
Stress
SO ENDOCRINE RESEARCH
LA English
DT Review
DE Estradiol; Paraquat; Oxidative Stress; Mice; Gonadectomy
ID RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; ERYTHROCYTE
GLUTATHIONE-PEROXIDASE; DISMUTASE MIMETIC PROTECTS; HEALTH INITIATIVE
MEMORY; CORONARY HEART-DISEASE; INDUCED LUNG INJURY; POSTMENOPAUSAL
WOMEN; PARAQUAT TOXICITY; SUPEROXIDE-DISMUTASE
AB The sexual dimorphism of life span and caloric restriction effects in numerous species suggest that estradiol (E2) is protective against oxidative damage. The only direct test of E2's protective effect in mice against in vivo oxidative stress to date may have been confounded by E2's direct chemical action as an antioxidant because it was administered at very high dosages. Therefore, we have identified a low yet physiologically effective dose of E2. We then administered this dose using subcutaneous time-release pellets to ovariectomized mice. Two weeks after E2 pellet implantation, sham-operated, ovariectomized, and ovariectomized E2-supplemented female mice were injected with a lethal dose of paraquat and their survival was followed. It was observed that ovariectomy exacerbates paraquat-induced mortality and is rescued by E2 supplementation. An equivalent experiment was performed on sham-operated, orchidectomized, and E2-supplemented orchidectomized male mice. The survival of male mice was improved by orchidectomy, and E2 gave no further benefit. We interpret the results to mean that E2 is protective against oxidative stress through its regulatory role and that testosterone diminishes protection against oxidative stress.
C1 [Bokov, Alex F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Ko, Daijin] Univ Texas San Antonio, Coll Business, Dept Management Sci & Stat, San Antonio, TX USA.
[Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Bokov, AF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM bokov@uthscsa.edu
FU National Institutes of Health [AGO-21890, AG-19316, AG-13319, AG-23843,
AG-26557]; San Antonio Nathan Shock Aging Center [1P30-AG13319];
Department of Veterans Affairs Merit Grant; Research Enhancement Award
Program; Department of Veterans Affairs
FX The authors gratefully acknowledge support from the National Institutes
of Health: AGO-21890 (A. F. B); AG-19316, AG-13319, AG-23843, and
AG-26557 (A. R.); the San Antonio Nathan Shock Aging Center
(1P30-AG13319) (A. R.); Department of Veterans Affairs Merit Grant (A.
R.); and a Research Enhancement Award Program from the Department of
Veterans Affairs (A. R.)
NR 117
TC 9
Z9 9
U1 1
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0743-5800
EI 1532-4206
J9 ENDOCR RES
JI Endocr. Res.
PY 2009
VL 34
IS 1-2
BP 43
EP 58
AR PII 910860504
DI 10.1080/07435800902913600
PG 16
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 462QO
UT WOS:000267370900005
PM 19557590
ER
PT S
AU Frieder, M
Lewinsohn, DM
AF Frieder, Marisa
Lewinsohn, David M.
BE Reineke, U
Schutkowski, M
TI T-Cell Epitope Mapping in Mycobacterium tuberculosis Using PepMixes
Created by Micro-Scale SPOT (TM)- Synthesis
SO EPITOPE MAPPING PROTOCOLS, SECOND EDITION
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE Tuberculosis; CD8+T cells; Immunodominance; Antigen/epitope discovery;
Elispot; Peptide library
ID INFECTION; IDENTIFICATION; RESISTANCE; ANTIGEN; MICE; LYMPHOCYTES;
COMPLEX; MACROPHAGES; PROTECTION; DEFICIENT
AB Mycobacterium tuberculosis (Mtb) remains a major threat to human health worldwide. Although treatment of infection is an important part of tuberculosis control, an improved vaccine is essential for the elimination of this disease. Control of infection with Mtb is dependent on the cellular immune system, which in turn requires an understanding of those antigens that are capable Of stimulating CD4+ and CD8+ T-cell responses. Peptide libraries provide a high-throughput system for identifying novel T-cell epitopes. They can also be used to assess the hierarchy of immunodominance of these novel antigens and epitopes that are associated with infection with Mtb. This T-cell-driven means of antigen discovery is well adapted to vaccine development as wen as developing the tools necessary to understand the natural history of this important human pathogen.
C1 [Frieder, Marisa; Lewinsohn, David M.] Portland VA Med Ctr, Pulm & CCM, R&D 11, Portland, OR USA.
RP Frieder, M (reprint author), Portland VA Med Ctr, Pulm & CCM, R&D 11, Portland, OR USA.
RI Lewinsohn, David/I-4936-2013
OI Lewinsohn, David/0000-0001-9906-9494
NR 28
TC 3
Z9 4
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-934115-17-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2009
VL 524
BP 369
EP 382
DI 10.1007/978-1-59745-450-6_27
D2 10.1007/978-1-59745-450-6
PG 14
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA BKJ95
UT WOS:000268335800027
PM 19377959
ER
PT J
AU Restrepo, MI
Mortensen, EM
Waterer, GW
Wunderink, RG
Coalson, JJ
Anzueto, A
AF Restrepo, M. I.
Mortensen, E. M.
Waterer, G. W.
Wunderink, R. G.
Coalson, J. J.
Anzueto, A.
TI Impact of macrolide therapy on mortality for patients with severe sepsis
due to pneumonia
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
DE Antibiotics; community-acquired pneumonia; outcomes; sepsis
ID COMMUNITY-ACQUIRED PNEUMONIA; BACTEREMIC PNEUMOCOCCAL PNEUMONIA;
RESPIRATORY-TRACT INFECTIONS; BETA-LACTAM; ANTIMICROBIAL THERAPY;
UNITED-STATES; CLARITHROMYCIN; EPIDEMIOLOGY; GUIDELINES; MANAGEMENT
AB Recent studies suggest that macrolides may have beneficial effects for patients at risk for certain infections. The current authors examined the effect of macrolide therapy on 30-and 90-day mortality for patients with severe sepsis caused by pneumonia.
A retrospective cohort study was conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had chest radiography consistent with, and had a discharge diagnosis of pneumonia and clinical criteria of severe sepsis. Subjects were considered to be on macrolides if they received at least one dose within 48 h of admission.
Severe sepsis was present in 237 (30.1%) subjects, out of whom 104 (43.9%) received macrolides. Mortality was 20.3% at 30 days and 24.5% at 90 days. In the multivariable analysis, the use of macrolide was associated with decreased mortality at 30 days (hazard ratio (HR) 0.3, 95% confidence interval (CI) 0.2-0.7) and at 90 days (HR 0.3, 95% CI 0.2-0.6) in patients with severe sepsis and in patients with macrolide-resistant pathogens (HR 0.1, 95% CI 0.02-0.5).
Macrolide use was associated with decreased mortality in patients with severe sepsis due to pneumonia and macrolide-resistant pathogens. Confirmatory studies are needed to determine whether macrolide therapy may be protective for patients with sepsis.
C1 [Restrepo, M. I.; Mortensen, E. M.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Vet Affairs Hosp, Vet Evidence Based Res Disseminat Implementat Ctr, San Antonio, TX 78229 USA.
[Restrepo, M. I.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX 78229 USA.
Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Coalson, J. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Div Gen Med, San Antonio, TX 78229 USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Waterer, G. W.] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp Unit, Perth, WA 6009, Australia.
RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst Audie L Murphy Div, VERDICT 1106, 7400 Menon Minter Blvd, San Antonio, TX 78229 USA.
EM restrepo@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
OI Mortensen, Eric/0000-0002-3880-5563; Wunderink,
Richard/0000-0002-8527-4195
FU Howard Hughes Medical Institute [00378-001]
NR 30
TC 92
Z9 95
U1 0
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JAN
PY 2009
VL 33
IS 1
BP 153
EP 159
DI 10.1183/09031936.00054108
PG 7
WC Respiratory System
SC Respiratory System
GA 430KM
UT WOS:000264988000023
PM 18768577
ER
PT J
AU Caplan, L
Saag, KG
AF Caplan, Liron
Saag, Kenneth G.
TI Glucocorticoids and the risk of osteoporosis
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE adverse effects; glucocorticoids; osteoporosis
ID BONE-MINERAL DENSITY; CORTICOSTEROID-INDUCED OSTEOPOROSIS; VERTEBRAL
FRACTURE RISK; RHEUMATOID-ARTHRITIS PATIENTS; RANDOMIZED
CONTROLLED-TRIALS; RECEPTOR GENE POLYMORPHISMS; HIGH-DOSE
GLUCOCORTICOIDS; ORAL CORTICOSTEROIDS; HIP FRACTURE; POSTMENOPAUSAL
WOMEN
AB Background: Glucocorticoid-induced osteoporosis (GIO) refers to a clinical condition in which a class of corticosteroids increases the susceptibility of bones to fracture. Numerous recent studies have improved our understanding of the underlying biology of this condition, whereas data from randomized controlled trials have provided clinicians with more options for prevention of GIO. Objective: To review the pathophysiology and epidemiology of GIO, as well as current pharmacologic treatment and prevention modalities available. To review the state of healthcare provider concordance with GIO prevention guidelines. Methods: Representative examples of various cellular and molecular processes underlying GIO were included, with an emphasis towards more recent discoveries. The data used to describe the epidemiology of GIO were derived from both randomized controlled studies and observational studies, framed through a discussion of known osteoporosis risk factors. Results/conclusion: Progress has been made in clarifying the pathophysiologic mechanisms that result in GIO. Although the options for preventions and treatment of GIO continue to expand, provider compliance with preventive measures remains suboptimal.
C1 [Caplan, Liron] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80045 USA.
[Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA.
RP Caplan, L (reprint author), Univ Colorado, Denver Vet Affairs Med Ctr, POB 6511,B115, Denver, CO 80045 USA.
EM liron.caplan@uchsc.edu
NR 149
TC 19
Z9 23
U1 4
U2 10
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD JAN
PY 2009
VL 8
IS 1
BP 33
EP 47
DI 10.1517/14740330802648194
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 401FW
UT WOS:000262926300005
PM 19236216
ER
PT J
AU Kavirajan, H
AF Kavirajan, Harish
TI Memantine: a comprehensive review of safety and efficacy
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE age-associated memory impairment; alcohol dependence; Alzheimer's;
amyotropic lateral sclerosis; attention deficit hyperactivity disorder;
autism; bipolar disorder; cholinesterase inhibitor; cocaine dependence;
dementia; frontotemporal dementia; glaucoma; headache; Huntington's
disease; major depression; memantine; migraine; neuropathic pain;
nicotine dependence; nystagmus; obsessive-compulsive disorder; opiate
dependence; pervasive development disorder; phantom limb pain;
pharmacology; postherpetic neuralgia; post-traumatic stress disorder;
safety; schizophrenia; substance abuse; vascular dementia
ID PLACEBO-CONTROLLED TRIAL; RECEPTOR ANTAGONIST MEMANTINE;
OBSESSIVE-COMPULSIVE DISORDER; MODERATE ALZHEIMERS-DISEASE; MAJOR
DEPRESSIVE DISORDER; OPEN-LABEL EXTENSION; PHANTOM LIMB PAIN;
DOUBLE-BLIND; VASCULAR DEMENTIA; NMDA-RECEPTOR
AB Background: Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor. It is now approved only for treatment of mode rate-to-severe Alzheimer's disease (AD). However, as a growing body of evidence indicates that disturbed glutamate neurotransmission may be central to the pathophysiology of such conditions as obesity, schizophrenia, depression, substance abuse, pain disorders and glaucoma, clinical trials have explored the role of memantine in these and other disorders. Objective: To provide a comprehensive review of the safety and efficacy of memantine across the range of clinical applications in which it has been studied. Methods: A search was done on Pubmed using keyword 'memantine' to identify clinical trials of memantine. Results/conclusion: At present, clinical trial evidence supports the use of memantine in only moderate-to-severe AD. Preliminary studies suggest benefit in frontotemporal dementia, alcohol dependence, post-traumatic stress disorder, headache and obesity, but rigorous clinical trials are needed to confirm these results. Available data indicate that across a range of clinical applications, memantine is a safe and well-tolerated drug.
C1 [Kavirajan, Harish] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 92626 USA.
[Kavirajan, Harish] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 92626 USA.
RP Kavirajan, H (reprint author), VA Greater Los Angeles Healthcare Syst, 950 S Coast Dr,Ste 202, Los Angeles, CA 92626 USA.
EM hkaviraj@gmail.com
NR 83
TC 31
Z9 35
U1 1
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1474-0338
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD JAN
PY 2009
VL 8
IS 1
BP 89
EP 109
DI 10.1517/14740330802528420
PG 21
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 401FW
UT WOS:000262926300010
PM 19236221
ER
PT J
AU Snider, AJ
Kawamori, T
Bradshaw, SG
Orr, KA
Gilkeson, GS
Hannun, YA
Obeid, LM
AF Snider, Ashley J.
Kawamori, Toshihiko
Bradshaw, Sarah G.
Orr, K. Alexa
Gilkeson, Gary S.
Hannun, Yusuf A.
Obeid, Lina M.
TI A role for sphingosine kinase 1 in dextran sulfate sodium-induced
colitis
SO FASEB JOURNAL
LA English
DT Article
DE sphingosine-1-phosphate; tumor necrosis factor alpha; cyclooxygenase-2;
inflammation; ceramide
ID INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; TNF-ALPHA; LYMPHOCYTE
TRAFFICKING; COLON CARCINOGENESIS; ENDOTHELIAL-CELLS; COX-2 INHIBITOR;
DENDRITIC CELLS; MICE; 1-PHOSPHATE
AB The bioactive lipid sphingosine-1-phosphate (S1P) is emerging as an important mediator of immune and inflammatory responses. S1P formation is catalyzed by sphingosine kinase (SK), of which the SK1 isoenzyme is activated by tumor necrosis alpha (TNF-alpha). SK1 has been shown to be required for mediating TNF-alpha inflammatory responses in cells, including induction of cyclooxygenase 2 (COX-2). Because TNF-alpha and COX-2 are increased in patients with inflammatory bowel disease (IBD), we investigated the role of SK1 in a murine model of colitis. SK1(-/-) mice treated with dextran sulfate sodium (DSS) had significantly less blood loss, weight loss, colon shortening, colon histological damage, and splenomegaly than did wild-type (WT) mice. In addition, SK1(-/-) mice had no systemic inflammatory response. Moreover, WT but not SK1(-/-) mice treated with dextran sulfate sodium had significant increases in blood S1P levels, colon SK1 message and activity, and colon neutrophilic infiltrate. Unlike WT mice, SK1(-/-) mice failed to show colonic COX-2 induction despite an exaggerated TNF-alpha response; thus implicating for the first time SK1 in TNF-alpha-mediated COX-2 induction in vivo. Inhibition of SK1 may prove to be a valuable therapeutic target by inhibiting systemic and local inflammation in IBD.-Snider, A. J., Kawamori, T., Bradshaw, S. G., Orr, K. A., Gilkeson, G. S., Hannun, Y. A., Obeid, L. M. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J. 23, 143-152 (2009)
C1 [Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Orr, K. Alexa] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29425 USA.
[Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Bradshaw, Sarah G.; Gilkeson, Gary S.; Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,MSC 779, Charleston, SC 29425 USA.
EM obeidl@musc.edu
RI Kawamori, Toshihiko/G-7636-2012
OI obeid, lina/0000-0002-0734-0847
FU U.S. National Institutes of Health (NIH) [GM062887, C06 RR018823];
Veterans Affairs (VA) Merit Award; American College of Rheumatology
Research and Education Foundation's
FX This work was supported by U.S. National Institutes of Health (NIH)
grant GM062887 and a Veterans Affairs (VA) Merit Award (L.M.O.) and by
the American College of Rheumatology Research and Education Foundation's
Within Our Reach: Finding a Cure for Arthritis campaign (G.S.G.). Lipid
analysis was conducted by the Lipidomics Core at MUSC and was supported
by NIH grant C06 RR018823. We thank Dr. Richard Proia (NIDDK, Bethesda,
MD, USA) for supplying the SK1-/- mice; George Washington,
DeAnna Baker, Samer Maalouf, and Tatsuya Kaneshiro for technical help;
Margaret H. Romano and the Core Histology Laboratory for their technical
assistance; Chris Clarke for careful examination of the manuscript; and
Kathy Wiita-Fisk for her administrative assistance.
NR 52
TC 78
Z9 82
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD JAN
PY 2009
VL 23
IS 1
BP 143
EP 152
DI 10.1096/fj.08-118109
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 389LZ
UT WOS:000262095500017
PM 18815359
ER
PT J
AU Daines, SB
Rohr, ES
Pace, AP
Fassbind, MJ
Sangeorzan, BJ
Ledoux, WR
AF Daines, S. Bradley
Rohr, Eric S.
Pace, Andrew P.
Fassbind, Michael J.
Sangeorzan, Bruce J.
Ledoux, William R.
TI Cadaveric Simulation of a Pes Cavus Foot
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Article
DE Pes Cavus; Foot Deformity; Foot Structure; Cadaver; Muscle Imbalance
ID OSTEOTOMY; FEET
AB Background: The pes cavus deformity has been well described in the literature; relative bony positions have been determined and specific muscle imbalances have been summarized. However, we are unaware of a cadaveric model that has been used to generate this foot pathology. The purpose of this study was to create such a model for future work on surgical and conservative treatment simulation. Materials and Methods: We used a custom designed, pneumatically actuated loading frame to apply forces to otherwise normal cadaveric feet while measuring bony motion as well as force beneath the foot. The dorsal tarsometatarsal and the dorsal intercuneiform ligaments were attenuated and three muscle imbalances, each similar to imbalances believed to cause the pes cavus deformity, were applied while bony motion and plantar forces were measured. Results: Only one of the muscle imbalances (overpull of the Achilles tendon, tibialis anterior, tibialis posterior, flexor hallucis longus and flexor digitorum longus) was successful at consistently generating the changes seen in pes cavus feet. This imbalance led to statistically significant changes including hindfoot inversion, talar dorsiflexion, medial midfoot plantar flexion and inversion, forefoot plantar flexion and adduction and an increase in force on the lateral mid- and forefoot. Conclusion: We have created a cadaveric model that approximates the general changes of the pes cavus deformity compared to normal feet. These changes mirror the general patterns of deformity produced by several disease mechanisms. Clinical Relevance: Future work will entail increasing the severity of the model and exploring various pes cavus treatment strategies.
C1 [Ledoux, William R.] RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, Seattle, WA 98108 USA.
RP Ledoux, WR (reprint author), RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, MS 151,1600 S Columbian Way, Seattle, WA 98108 USA.
EM wrledoux@u.washington.edu
RI Ledoux, William/K-6815-2015
OI Ledoux, William/0000-0003-4982-7714
FU University of Washington School of Medicine; Department of Veterans
Affairs, Rehabilitation RD Service [A2661C]
FX This work was supported in part by the Medical Student Research and
Training Program at the University of Washington School of Medicine, and
the Department of Veterans Affairs, Rehabilitation R&D Service grant
number A2661C.
NR 20
TC 2
Z9 2
U1 0
U2 2
PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC
PI SEATTLE
PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA
SN 1071-1007
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD JAN
PY 2009
VL 30
IS 1
BP 44
EP 50
DI 10.3113/FAI.2009.0044
PG 7
WC Orthopedics
SC Orthopedics
GA 390IC
UT WOS:000262156500008
PM 19176185
ER
PT J
AU Shan, WH
Oberley, TD
AF Shan, Weihua
Oberley, Terry D.
TI Compartmental Redox Regulation of Androgen-Induced Prostate Cancer Cell
Growth and Survival
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 16th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine
CY NOV 18-22, 2009
CL San Francisco, CA
SP Soc Free Rad Biol & Med
C1 [Shan, Weihua; Oberley, Terry D.] Univ Wisconsin, Sch Med, Madison, WI 53706 USA.
[Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PY 2009
VL 47
BP S175
EP S175
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 522HM
UT WOS:000271988500508
ER
PT J
AU Siedlak, SL
Casadesus, G
Webber, KM
Pappolla, MA
Atwood, CS
Smith, MA
Perry, G
AF Siedlak, Sandra L.
Casadesus, Gemma
Webber, Kate M.
Pappolla, Miguel A.
Atwood, Craig S.
Smith, Mark A.
Perry, George
TI Chronic antioxidant therapy reduces oxidative stress in a mouse model of
Alzheimer's disease
SO FREE RADICAL RESEARCH
LA English
DT Article
DE Alzheimer's disease; amyloid-beta; antioxidant; R-alpha lipoic acid;
transgenic mice
ID ALPHA-LIPOIC-ACID; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN;
TRANSGENIC MICE; LIPID-PEROXIDATION; MITOCHONDRIAL DYSFUNCTION;
NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY PATHOLOGY;
LUTEINIZING-HORMONE; PROMINENT FEATURE
AB Oxidative modifications are a hallmark of oxidative imbalance in the brains of individuals with Alzheimer's, Parkinson's and prion diseases and their respective animal models. While the causes of oxidative stress are relatively well-documented, the effects of chronically reducing oxidative stress on cognition, pathology and biochemistry require further clarification. To address this, young and aged control and amyloid-beta protein precursor-over-expressing mice were fed a diet with added R-alpha lipoic acid for 10 months to determine the effect of chronic antioxidant administration on the cognition and neuropathology and biochemistry of the brain. Both wild type and transgenic mice treated with R-alpha lipoic acid displayed significant reductions in markers of oxidative modifications. On the other hand, R-alpha lipoic acid had little effect on Y-maze performance throughout the study and did not decrease end-point amyloid-beta load. These results suggest that, despite the clear role of oxidative stress in mediating amyloid pathology and cognitive decline in ageing and A beta PP-transgenic mice, long-term antioxidant therapy, at levels within tolerable nutritional guidelines and which reduce oxidative modifications, have limited benefit.
C1 [Perry, George] Univ Texas San Antonio, Coll Sci, San Antonio, TX 78249 USA.
[Siedlak, Sandra L.; Webber, Kate M.; Smith, Mark A.; Perry, George] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
[Casadesus, Gemma] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA.
[Pappolla, Miguel A.] LSU Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA USA.
[Atwood, Craig S.] Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Educ & Clin Ctr, Dept Med & Geriatr Res, Madison, WI USA.
RP Perry, G (reprint author), Univ Texas San Antonio, Coll Sci, 1 UTSA Circle, San Antonio, TX 78249 USA.
EM george.perry@utsa.edu
RI Smith, Mark/A-9053-2009; Perry, George/A-8611-2009
OI Perry, George/0000-0002-6547-0172
FU National Institutes of Health; Alzheimer's Association; Philip Morris
USA Inc.; Philip Morris International.
FX Work in the authors' laboratories is supported by the National
Institutes of Health, the Alzheimer's Association and Philip Morris USA
Inc. and Philip Morris International.
NR 86
TC 38
Z9 38
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1071-5762
J9 FREE RADICAL RES
JI Free Radic. Res.
PY 2009
VL 43
IS 2
BP 156
EP 164
DI 10.1080/10715760802644694
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 405EB
UT WOS:000263204400008
PM 19160110
ER
PT J
AU Radant, AD
Dobie, DJ
Peskind, ER
Murburg, MM
Petrie, EC
Kanter, ED
Raskind, MA
Wilkinson, CW
AF Radant, Allen D.
Dobie, Dorcas J.
Peskind, Elaine R.
Murburg, M. Michele
Petrie, Eric C.
Kanter, Evan D.
Raskind, Murray A.
Wilkinson, Charles W.
TI Adrenocortical responsiveness to infusions of physiological doses of
ACTH is not altered in posttraumatic stress disorder
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE PTSD; HPA axis; ACTH; adrenal responsiveness; cortisol; DHEA; human
ID PITUITARY-ADRENAL AXIS; AGE-RELATED-CHANGES; 1 MU-G; FEEDBACK
INHIBITION; SALIVARY CORTISOL; PLASMA ADRENOCORTICOTROPIN;
HEALTHY-SUBJECTS; COMBAT VETERANS; SYNACTHEN TEST; PTSD
AB Early studies of posttraumatic stress disorder (PTSD) reported that abnormal function of the hypothalamic-pituitary-adrenocortical (HPA) system was associated with the disorder. However, subsequent studies attempting to identify a specific aspect of HPA dysfunction that characterizes PTSD have been marked by considerable inconsistency of results. A facet of HPA regulation that has been considered but not definitively investigated is the possibility that the responsiveness of the adrenal cortex to physiological concentrations of adrenocorticotropin (ACTH) is diminished in PTSD. Relationships between PTSD and the adrenal androgen dehydroepiandrosterone (DHEA) have also been postulated. In this study we investigated the magnitude and time course of changes in concentrations of plasma cortisol and DHEA in response to bolus infusions of physiological doses of ACTH(1-24) in PTSD patients and control subjects. We found no evidence for PTSD-related alterations in cortisol or DHEA secretion in response to stimulation by low doses of ACTH and conclude that adrenocortical responsiveness is normal in PTSD. Results from this and other studies suggest that the occurrence of defects in HPA function in PTSD may be specific responses to particular combinations of trauma type, genetic susceptibility, and individual history.
C1 [Radant, Allen D.; Dobie, Dorcas J.; Peskind, Elaine R.; Petrie, Eric C.; Kanter, Evan D.; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, Northwest Network, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA.
[Radant, Allen D.; Dobie, Dorcas J.; Peskind, Elaine R.; Petrie, Eric C.; Kanter, Evan D.; Raskind, Murray A.; Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.
RP Wilkinson, CW (reprint author), VA Puget Sound Hlth Care Syst, Northwest Network, VISN Mental Illness Res Educ & Clin Ctr 20, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wilkinso@u.washington.edu
FU Northwest Network VISN 20 Mental Illness Research; Education and
Clinical Center (MIRECC); VA Puget Sound Geriatric Research; Education
and Clinical Center (GRECC); Office of Research and Development Medical
Research Service, Department of Veterans Affairs
FX For their excellent assistance that made this study possible, we thank
Jane Hammett RN, and Jennifer Acselrod RN, for nursing care of study
participants, Jill Perander, Robert Beckham III, Shawna Feely, and
Kristina Purganan for recruitment and study coordination, Libby
Colasurdo and Carl Sikkema for hormone assays, Molly Chinn for
assistance in preparing ACTH doses, and Nadia Czajkiewicz for graphic
design. This material is based upon work supported by the Northwest
Network VISN 20 Mental Illness Research, Education and Clinical Center
(MIRECC), the VA Puget Sound Geriatric Research, Education and Clinical
Center (GRECC), and the Office of Research and Development Medical
Research Service, Department of Veterans Affairs.
NR 65
TC 5
Z9 5
U1 1
U2 3
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PY 2009
VL 3
AR 40
DI 10.3389/neuro.08.040.2009
PG 8
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA V18VE
UT WOS:000208031500039
PM 19893760
ER
PT J
AU Lanford, RE
Evans, MJ
Lohmann, V
Lindenbach, B
Gale, M
Rehermann, B
Chang, KM
Lemon, SM
AF Lanford, Robert E.
Evans, Matthew J.
Lohmann, Volker
Lindenbach, Brett
Gale, Michael, Jr.
Rehermann, Barbara
Chang, Kyong-Mi
Lemon, Stanley M.
TI The Accelerating Pace of HCV Research: A Summary of the 15th
International Symposium on Hepatitis C Virus and Related Viruses
SO GASTROENTEROLOGY
LA English
DT Editorial Material
C1 Univ Texas Med Branch, Inst Human Infect & Immun, 6200 Galveston Natl Lab, Galveston, TX 77555 USA.
Southwest Fdn Biomed Res, San Antonio, TX USA.
Mt Sinai Sch Med, Dept Microbiol, New York, NY USA.
Univ Heidelberg, Dept Molec Virol, Heidelberg, Germany.
Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT USA.
Univ Washington, Dept Immunol, Seattle, WA USA.
NIDDKD, Liver Dis Branch, Immunol Sect, Bethesda, MD USA.
Univ Penn, Philadelphia, PA USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Lemon, SM (reprint author), Univ Texas Med Branch, Inst Human Infect & Immun, 6200 Galveston Natl Lab, 301 Univ Blvd, Galveston, TX 77555 USA.
EM smlemon@utmb.edu
OI Lohmann, Volker/0000-0001-8719-7608; Gale, Michael/0000-0002-6332-7436;
Evans, Matthew/0000-0002-4991-3877
FU Intramural NIH HHS; NCI NIH HHS [K01-CA107092, K01 CA107092]; NIAID NIH
HHS [K99 AI077800, K99-AI077800, R01 AI047519, R01 AI060389,
R01-AI060389, R01-AI47519, U19 AI040035, U19-AI040035]; NIDA NIH HHS
[R01 DA024563]
NR 0
TC 10
Z9 11
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JAN
PY 2009
VL 136
IS 1
BP 9
EP 16
DI 10.1053/j.gastro.2008.11.019
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 388OG
UT WOS:000262028500045
PM 19026648
ER
PT J
AU Chung, CH
Shugrue, C
Nagar, A
Doll, JA
Cornwell, M
Gattu, A
Kolodecik, T
Pandol, SJ
Gorelick, F
AF Chung, Chuhan
Shugrue, Christine
Nagar, Anil
Doll, Jennifer A.
Cornwell, Mona
Gattu, Arijeet
Kolodecik, Tom
Pandol, Stephen J.
Gorelick, Fred
TI Ethanol Exposure Depletes Hepatic Pigment Epithelium-Derived Factor, a
Novel Lipid Regulator
SO GASTROENTEROLOGY
LA English
DT Article
ID ALCOHOLIC LIVER-DISEASE; STELLATE CELL ACTIVATION; MATRIX
METALLOPROTEINASES; SECRETED PROTEINS; FATTY LIVER; PPAR-ALPHA;
IDENTIFICATION; STEATOSIS; FIBROSIS; DIFFERENTIATION
AB Background & Aims: Ethanol abuse can lead to hepatic steatosis and evolve into cirrhosis and hepatocellular carcinoma. Pigment epithelium-derived factor (PEDF) is a multifunctional secreted glycoprotein. that is expressed by hepatocytes. Proteomic, experimental, and clinical studies implicate PEDF's role in lipid regulation. Because matrix metalloproteinase (MMP)-2/9 activity regulates PEDF levels, we investigated whether PEDF degradation by MMPs has a permissive role in ethanol-induced hepatic steatosis. Methods: PEDF levels were examined in liver biopsy specimens from patients with ethanol-induced steatosis. Hepatic PEDF levels and MMP activity were assessed in 2 animal models of ethanol feeding (rats on an alcohol-containing liquid diet and mice given intragastric infusion of ethanol). The consequences of PEDF depletion in the liver were examined in PEDF-null mice. Results: Liver biopsy samples from patients with ethanol-induced steatosis had reduced PEDF levels, compared with normal liver samples. Ethanol-fed animals had histologic steatosis and increased liver triglyceride content (P < .05), as well as reduced levels of hepatic PEDF and increased MMP-2/9 activity. Ethanol-exposed hepatic lysates degraded PEDF in a MMP-2/9-dependent manner, and liver sections demonstrated abundant MMP-2/9 activity in situ. Addition of recombinant PEDF to PEDF-null hepatocytes, reduced their triglyceride content. Conclusions: Ethanol exposure leads to marked loss of hepatic PEDF in human livers and in 2 animal models of ethanol feeding. Loss of PEDF contributes to the accumulation of lipids in ethanol-induced hepatic steatosis.
C1 [Chung, Chuhan; Shugrue, Christine; Nagar, Anil; Gattu, Arijeet; Kolodecik, Tom; Gorelick, Fred] Yale Univ, Sch Med, Dept Med, Sect Digest Dis, New Haven, CT 06510 USA.
[Chung, Chuhan; Nagar, Anil; Gorelick, Fred] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Doll, Jennifer A.; Cornwell, Mona] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Pandol, Stephen J.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Chung, CH (reprint author), Yale Univ, Sch Med, Dept Med, Sect Digest Dis, GI Res Bldg, West Haven, CT 06516 USA.
EM chuhan.chung@yale.edu
FU American Liver Foundation; NIH [DK34989, P60 AA11999, DK54021]; VA Merit
Award
FX The authors disclose the following: Supported by an American Liver
Foundation grant; NIH Liver Center Core DK34989 (to C.C.), P60 AA11999
(to S.J.P.), DK54021; and VA Merit Award (to F.S.G.).
NR 35
TC 23
Z9 25
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JAN
PY 2009
VL 136
IS 1
BP 331
EP 340
DI 10.1053/j.gastro.2008.09.065
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 388OG
UT WOS:000262028500041
PM 18996124
ER
PT J
AU Jou, J
Radowsky, J
Gangnon, R
Sadowski, E
Kays, S
Hind, J
Gaumnitz, E
Taylor, A
Robbins, J
AF Jou, Janice
Radowsky, Jason
Gangnon, Ronald
Sadowski, Elizabeth
Kays, Stephanie
Hind, Jacqueline
Gaumnitz, Eric
Taylor, Andrew
Robbins, JoAnne
TI Esophageal Clearance Patterns in Normal Older Adults as Documented with
Videofluoroscopic Esophagram
SO GASTROENTEROLOGY RESEARCH AND PRACTICE
LA English
DT Article
ID HEALTHY-SUBJECTS; MANOMETRY; MOTILITY; AGE; VOLUNTEERS; IMPEDANCE;
BARIUM
AB Normal esophageal bolus transport in asymptomatic healthy older adults has not been well defined, potentially leading to ambiguity in differentiating esophageal swallowing patterns of dysphagic and healthy individuals. This pilot study of 24 young (4564 years) and old (65+years) men and women was designed to assess radiographic esophageal bolus movement patterns in healthy adults using videofluoroscopic recording. Healthy, asymptomatic adults underwent videofluoroscopic esophagram to evaluate for the presence of ineffective esophageal clearance, namely, intraesophageal stasis and intraesophageal reflux. Intraesophageal stasis and intraesophageal reflux were visualized radiographically in these normal subjects. Intraesophageal stasis occurred significantly more frequently with semisolid (96%) compared with liquid (16%) barium, suggesting that a variety of barium consistencies, as opposed to only the traditional fluids, would better define the spectrum of esophageal transport. Intraesophageal reflux was observed more frequently in older males than in their younger counterparts. The rates of intraesophageal stasis and intraesophageal reflux were potentially high given that successive bolus presentations were spaced 10 seconds apart. These findings suggest a need for a more comprehensive definition regarding the range of normal esophageal bolus transport to (a) prevent misdiagnosis of dysphagia and (b) to enhance generalization to functional eating, which involves solid foods in addition to liquids. Copyright (C) 2009 Janice Jou et al.
C1 [Jou, Janice; Radowsky, Jason; Kays, Stephanie; Hind, Jacqueline; Gaumnitz, Eric; Robbins, JoAnne] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Gastroenterol & Hepatol, Madison, WI 53792 USA.
[Radowsky, Jason; Kays, Stephanie; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA.
[Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA.
[Sadowski, Elizabeth; Taylor, Andrew] Univ Wisconsin, Sch Med & Pulic Hlth, Dept Radiol, Madison, WI 53792 USA.
RP Robbins, J (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Gastroenterol & Hepatol, Madison, WI 53792 USA.
EM jrobbin2@wisc.edu
FU Geriatric Research, Education and Clinical Center (GRECC); William S.
Middleton Memorial VA Hospital
FX This work supported by the Geriatric Research, Education and Clinical
Center (GRECC), and William S. Middleton Memorial VA Hospital. The
authors would like to thank Abby Duane, BS, for manuscript preparation
and also extend their appreciation to the Department of Radiology
University of Wisconsin. This is GRECC manuscript 2006-12.
NR 24
TC 7
Z9 7
U1 0
U2 1
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-6121
J9 GASTROENT RES PRACT
JI Gastroenterol. Res. Pract.
PY 2009
AR 965062
DI 10.1155/2009/965062
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 689FJ
UT WOS:000284912400001
ER
PT J
AU Shergill, AK
Asundi, KR
Barr, A
Shah, JN
Ryan, JC
McQuaid, KR
Rempel, D
AF Shergill, Amandeep K.
Asundi, Krishna R.
Barr, Alan
Shah, Janak N.
Ryan, James C.
McQuaid, Kenneth R.
Rempel, David
TI Pinch force and forearm-muscle load during routine colonoscopy: a pilot
study
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID CUMULATIVE TRAUMA DISORDERS; OVERUSE
AB Background and Objective: Overuse injuries of the hand, wrist, forearm, and shoulder are common among endoscopists and may be from repetitive pinching and gripping forces or awkward posturing. In this pilot study, we evaluated distal upper-extremity musculoskeletal load during colonoscopy (1) to confirm the feasibility of performing ergonomic measurements in endoscopists and (2) to identify tasks that may contribute to overuse injuries.
Design and Subjects: Three experienced gastroenterologists were evaluated during 3 colonoscopies each
Setting: Veterans Affairs Medical Center, San Francisco, California.
Main Outcome Measurement: Right-thumb pinch force using a thumb-force sensor and bilateral forearm-muscle activity using electromyography.
Results: The mean duration of the 9 colonoscopies was 19.5 minutes. The highest mean (SD) right-thumb peak pinch forces occurred during left (10.4 [4.1] N) and right (10.1 [4.5] N) colon insertion, which exceeded the injury threshold of 10 N. Mean peak forearm-muscle activity was also greatest during left and right colon insertion. Activity of the left abductor pollicis longus, left extensor carpi radialis, and right extensor carpi radialis exceeded the American Conference of industrial Hygienists (ACGIH) hand activity level (HAL) action limit. The left extensor carpi radialis was at the ACGIH HAL threshold limit.
Limitations: The small sample size, no force measurement for the left thumb, and all the gastroenterologists were men.
Conclusion: The pinch forces and forearm-muscle loads applied during routine colonoscopy may pose a risk for overuse injuries at the elbow and wrist.
C1 [Shergill, Amandeep K.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, VA Med Ctr, San Francisco, CA 94121 USA.
[Shergill, Amandeep K.; Shah, Janak N.; Ryan, James C.; McQuaid, Kenneth R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Barr, Alan; Rempel, David] Univ Calif San Francisco, Dept Med, Div Occupat Med, San Francisco, CA 94121 USA.
[Barr, Alan; Rempel, David] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
[Asundi, Krishna R.] Harvard Univ, Sch Med, Dept Environm Hlth, Boston, MA USA.
RP Shergill, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, VA Med Ctr, 4150 Clement St,Bldg 203,111B1, San Francisco, CA 94121 USA.
EM amandeep.shergill@ucsf.edu
RI Rempel, David/E-8424-2013
NR 10
TC 23
Z9 24
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JAN
PY 2009
VL 69
IS 1
BP 142
EP 146
DI 10.1016/j.gie.2008.09.030
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 391VI
UT WOS:000262261900023
PM 19111694
ER
PT S
AU Yehuda, R
AF Yehuda, Rachel
BE Judd, LL
Sternberg, EM
TI Status of Glucocorticoid Alterations in Post-traumatic Stress Disorder
SO GLUCOCORTICOIDS AND MOOD CLINICAL MANIFESTATIONS, RISK FACTORS, AND
MOLECULAR MECHANISMS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Glucocorticoids and Mood - Clinical Manifestations, Risk
Factors and Molecular Mechanisms
CY JUN 20-21, 2008
CL San Diego, CA
DE acth; cortisol; depression; dexamethasone; glucocorticoid receptors
ID PITUITARY-ADRENAL AXIS; DEXAMETHASONE-SUPPRESSION TEST; URINARY
CORTISOL-LEVELS; BORDERLINE PERSONALITY-DISORDER;
CORTICOTROPIN-RELEASING-FACTOR; MAJOR DEPRESSIVE DISORDER; VEHICLE
ACCIDENT VICTIMS; HORMONE STIMULATION TEST; CIVILIAN TRAUMA VICTIMS;
CHILDHOOD SEXUAL ABUSE
AB The current status of glucocorticoid alterations in post-traumatic stress disorder (PTSD) will be described in this chapter. Emphasis will be placed on data that suggest that at least some glucocorticoid-related observations in PTSD reflect pretraumatic glucocorticoid status. Recent observations have provided some evidence that pretraumatic glucocorticoid alterations may arise from genetic, epigenetic, and possibly other environmental influences that serve to increase the likelihood of developing PTSD following trauma exposure, as well as modulate attendant biological alterations associated with its pathophysiology. Current studies in the field of PTSD employ glucocorticoid challenge strategies to delineate effects of exogenously administered glucocorticoids on neuroendocrine, cognitive, and brain function. Results of these studies have provided an important rationale for using glucocorticoid strategies in the treatment of PTSD.
C1 [Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Program, New York, NY USA.
[Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, PTSD Program, Bronx, NY USA.
RP Yehuda, R (reprint author), Bronx VA, OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Rachel.Yehuda@med.va.gov
FU NIH [R01 N4H064675-02, R01 MH64104-01]; VA Merit Funds; DOD funds
FX This work was Supported by NIH: R01 N4H064675-02, R01 MH64104-01. VA
Merit Funds, and DOD funds. The author wishes to acknowledge Janelle
Wolaltmann, Casey Sarapas, Chuck Burton, and Michelle Pelcovitz for
assisting in the preparation of this manuscript.
NR 140
TC 162
Z9 171
U1 5
U2 27
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077-8923
BN 978-1-57331-748-1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2009
VL 1179
BP 56
EP 69
DI 10.1111/j.1749-6632.2009.04979.x
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BMJ24
UT WOS:000272551200004
PM 19906232
ER
PT J
AU Hess, CJ
Feller, N
Denkers, F
Kelder, A
Merle, PA
Heinrich, MC
Harlow, A
Berkhof, J
Ossenkoppele, GJ
Waisfisz, Q
Schuurhuis, GJ
AF Hess, Corine J.
Feller, Nicole
Denkers, Fedor
Kelder, Angele
Merle, Pauline A.
Heinrich, Michael C.
Harlow, Amy
Berkhof, Johannes
Ossenkoppele, Gert J.
Waisfisz, Quinten
Schuurhuis, Gerrit J.
TI Correlation of minimal residual disease cell frequency with molecular
genotype in patients with acute myeloid leukemia
SO Haematologica-The Hematology Journal
LA English
DT Article
DE acute myeloid leukemia; minimal residual disease; FLT3
ID RESISTANCE PROTEIN-ACTIVITY; P-GLYCOPROTEIN; FLOW-CYTOMETRY; MUTATIONS;
AML; DIAGNOSIS; THERAPY; SURVIVAL; RELAPSE
AB Background
About 70-80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, especially for younger patients. With the vastly increasing number of targeted therapies there is a strong need for short-term end-points to efficiently test such therapies for further pursuance. Minimal residual disease assessment may offer such an end-point since it is a strong independent prognostic factor. As proof of principle we examined this concept for FLT3-ITD status at diagnosis.
Design and Methods
We determined FLT3-ITD status in bone marrow samples from 196 patients with newly diagnosed acute myeloid leukemia. The frequencies of residual leukemic cells of these 196 patients were assessed in 267 follow-up bone marrow samples using immunophenotypic assessment of minimal residual disease.
Results
The median frequency of residual leukemic cells after the first cycle of chemotherapy was 8.5-fold higher in patients with FLT3-ITD than in those with wild type FLT3. Such a difference translates into differences in survival, even if other potentially outcome-modulating mutations, such as NPM1, KIT, NRAS, KRAS, FLT3-exon 20 and PTPN11 are included in the analysis.
Conclusions
This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point.
C1 [Schuurhuis, Gerrit J.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, BR248, NL-1081 HV Amsterdam, Netherlands.
[Heinrich, Michael C.; Harlow, Amy] Oregon Hlth & Sci Univ, Inst Canc, Dept Pathol & Med, Portland, OR 97201 USA.
[Heinrich, Michael C.; Harlow, Amy] Portland VA Med Ctr, Portland, OR USA.
[Berkhof, Johannes] Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands.
RP Schuurhuis, GJ (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Hematol, BR248, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.
EM gj.schuurhuis@vumc.nl
FU Leukemia and Lymphoma Society; VA merit Review Grant
FX Funding: this manuscript was supported in part by funding from the
Leukemia and Lymphoma Society (MCH) and a VA merit Review Grant (MCH).
NR 20
TC 6
Z9 6
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JAN
PY 2009
VL 94
IS 1
BP 46
EP 53
DI 10.3324/haematol.13110
PG 8
WC Hematology
SC Hematology
GA 396LL
UT WOS:000262593100009
PM 19042917
ER
PT B
AU Ritchie, CS
Kvale, E
AF Ritchie, Christine Seel
Kvale, Elizabeth
BE Bales, CW
Ritchie, CS
TI Nutrition at the End of Life: Ethical Issues
SO HANDBOOK OF CLINICAL NUTRITION AND AGING, SECOND EDITION
SE Nutrition and Health Series
LA English
DT Article; Book Chapter
DE Nutrition support; terminal illness; palliative treatment
ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ARTIFICIAL NUTRITION; ADVANCED
DEMENTIA; HYDRATION; IMPACT; CARE
AB Because of the importance of food as an integral part of life, health-care providers need to be well versed in the issues surrounding nutrition and hydration in terminal illness in order to assist patients and their families in treatment decisions.
Case law in the United States considers enteral nutrition to be medical treatment and as such recognizes a patient's right to refuse artificial nutritional support.
The decision about feeding should be consistent with the overall goals of care: for example, curative treatment, rehabilitative treatment or palliative treatment.
C1 [Ritchie, Christine Seel] Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA.
[Kvale, Elizabeth] Univ Alabama, Div Gerontol, Birmingham, AL USA.
[Kvale, Elizabeth] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Ritchie, CS (reprint author), Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA.
NR 24
TC 1
Z9 1
U1 1
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
BN 978-1-60327-384-8
J9 NUTR HEALTH SER
JI Nutr. Health Ser.
PY 2009
BP 235
EP 244
DI 10.1007/978-1-60327-385-5_13
PG 10
WC Geriatrics & Gerontology; Gerontology; Public, Environmental &
Occupational Health; Medicine, General & Internal; Nutrition & Dietetics
SC Geriatrics & Gerontology; Public, Environmental & Occupational Health;
General & Internal Medicine; Nutrition & Dietetics
GA BJT85
UT WOS:000267149000013
ER
PT B
AU Kvale, E
Ritchie, CS
Balducci, L
AF Kvale, Elizabeth
Ritchie, Christine Seel
Balducci, Lodovico
BE Bales, CW
Ritchie, CS
TI Nutrition Support in Cancer
SO HANDBOOK OF CLINICAL NUTRITION AND AGING, SECOND EDITION
SE Nutrition and Health Series
LA English
DT Article; Book Chapter
DE Cancer; aging; cachexia; inflammation
ID COMPREHENSIVE GERIATRIC ASSESSMENT; RESTING ENERGY-EXPENDITURE;
ANOREXIA-CACHEXIA SYNDROME; LONG-TERM SURVIVAL; FISH-OIL CAPSULES;
LEUKEMIA GROUP-B; QUALITY-OF-LIFE; CONTROLLED-TRIAL; NECK-CANCER;
WEIGHT-LOSS
AB Older cancer patients have unique qualities related to aging that place them at nutritional risk during cancer treatment.
Routine assessment of nutritional risk is indicated in older cancer patients.
Comprehensive geriatric assessment of older cancer patients can assist with determination of which older patients can tolerate cancer treatment with acceptable levels of morbidity and mortality.
Dietary counseling and nutritional intervention (especially protein supplementation) should be incorporated into the care of nutritionally compromised older cancer patients as needed.
Cancer is a frequent indication for enteral nutrition support (when there is intact gut function) or total parenteral nutrition.
Management of nutritional compromise should be guided by patient-centered goals of care that incorporate the existing evidence-base into decision-making.
C1 [Kvale, Elizabeth] Univ Alabama, Div Gerontol, Birmingham, AL 35294 USA.
[Kvale, Elizabeth] Birmingham VA Med Ctr, Birmingham, AL USA.
[Balducci, Lodovico] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Ritchie, Christine Seel] Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
RP Kvale, E (reprint author), Univ Alabama, Div Gerontol, Birmingham, AL 35294 USA.
NR 99
TC 0
Z9 0
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
BN 978-1-60327-384-8
J9 NUTR HEALTH SER
JI Nutr. Health Ser.
PY 2009
BP 355
EP 372
DI 10.1007/978-1-60327-385-5_19
PG 18
WC Geriatrics & Gerontology; Gerontology; Public, Environmental &
Occupational Health; Medicine, General & Internal; Nutrition & Dietetics
SC Geriatrics & Gerontology; Public, Environmental & Occupational Health;
General & Internal Medicine; Nutrition & Dietetics
GA BJT85
UT WOS:000267149000019
ER
PT B
AU Fan, J
AF Fan, Jie
BE Hagg, R
Kohlund, S
TI Receptor Cross-Talk Mechanisms of Neutrophil Priming
SO HANDBOOK OF GRANULOCYTES : CLASSIFICATION, TOXIC MATERIALS PRODUCED AND
PATHOLOGY
SE Human Anatomy and Physiology
LA English
DT Article; Book Chapter
ID TOLL-LIKE RECEPTOR-4; MOBILITY GROUP BOX-1; MEDIATES HEPATIC-INJURY;
MULTIPLE ORGAN FAILURE; TLR2 UP-REGULATION; FACTOR-KAPPA-B; NADPH
OXIDASE; HEMORRHAGIC-SHOCK; INNATE IMMUNITY; MYD88-INDEPENDENT PATHWAY
AB Severe trauma and hemorrhage renders the patient more susceptible to a second, seemingly trivial, inflammatory stimulus, the so-called "two-hit" hypothesis. The post-trauma sepsis, which involves activation of innate immunity, can lead to severe multi-organ failure (MOF) or systemic inflammatory response syndrome (SIRS), and death. Studies have suggested that inflammatory cell priming caused by a first hit is the mechanism for enhanced response of the cell to a second hit.
Polymorphonuclear neutrophils (PMN) are essential effector cells of the innate immune system. The accumulation of PMN in tissue is considered a critical event in organ inflammation and injury, and has been the target of preventative strategies. PMN migration is a result of a cascade of cellular events, in which PMN, endothelial cells (EC), and macrophages (M phi) act in concert. Recent studies explored interrelated novel findings indicating that receptor cross-talk mechanisms occurring in PMN, EC, and M phi are important determinants for priming PMN migration in a sepsis setting. This chapter will focus on the detailed receptor cross-talk mechanisms underlying PMN priming. In M phi and EC, lipopolysaccharide (LPS) acts through Toll-like receptor (TLR)4 signaling to up-regulate TLR2. Oxidant signaling derived from PMN NAD(P)H oxidase enhances the TLR2 upregulation through PMN-M phi or PMN-EC interaction, resulting in an amplified release of cytokines and chemokines from the M phi and expression of adhesion molecules in the EC in response to TLR2 ligands, thereby promoting PMN migration. Furthermore, hemorrhagic shock is potent in activating PMN NAD(P)H oxidase through high-mobility group box 1 (HMGB1)-TLR4-p38 MAPK signaling, and therefore initiates the mechanisms of cell priming. On the other hand, LPS through TLR4 on PMN and phosphoinositide 3-kinase gamma (PI3K gamma) signaling down-regulates the expression of G protein-coupled receptor kinases (GRK)2 and GRK5 in response to chemokine, thereby decreases chemokine receptor desensitization and augments the PMN migration. Taken together, receptor cross-talk mechanisms are important determinants for cell priming and subsequent augmented PMN infiltration in sepsis.
C1 [Fan, Jie] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Fan, J (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.
NR 86
TC 0
Z9 0
U1 0
U2 0
PU NOVA SCIENCE PUBLISHERS, INC
PI HAUPPAUGE
PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA
BN 978-1-60741-582-4
J9 HUM ANAT PHYSIOL
PY 2009
BP 205
EP 228
PG 24
WC Anatomy & Morphology; Physiology
SC Anatomy & Morphology; Physiology
GA BPC23
UT WOS:000278499700007
ER
PT B
AU Horan, WP
Greenwood, TA
Braff, DL
Gur, RE
Green, MF
AF Horan, William P.
Greenwood, Tiffany A.
Braff, David L.
Gur, Raquel E.
Green, Michael F.
BE Ritsner, MS
TI The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic
Studies of Schizophrenia
SO HANDBOOK OF NEUROPSYCHIATRIC BIOMARKERS, ENDOPHENOTYPES AND GENES, VOL
1: NEUROPSYCHOLOGICAL ENDOPHENOTYPES AND BIOMARKERS
LA English
DT Article; Book Chapter
DE Schizophrenia; endophenotype; neurocognition
ID VERBAL WORKING-MEMORY; DORSOLATERAL PREFRONTAL CORTEX; TRAIT LINKAGE
ANALYSIS; 4-MONTH FOLLOW-UP; SUSTAINED ATTENTION; NEUROPSYCHOLOGICAL
DEFICITS; NONPSYCHOTIC RELATIVES; COGNITIVE NEUROSCIENCE; NAIVE
PATIENTS; 1ST-DEGREE RELATIVES
AB Neurocognitive deficits are core features of schizophrenia and are among the most promising candidate endophenotypes for genetic studies of this disorder. The detection of gene-endophenotype associations requires large family cohort or case-control samples that are often only possible to collect through multisite collaborations, which presents considerable challenges for the use of endophenotypes. This chapter focuses on the rationale for using neurocognitive tasks of working memory, attention, and verbal declarative memory in large-scale, collaborative efforts to apply an endophenotype approach to schizophrenia. As an example, we describe the Consortium on the Genetics of Schizophrenia (COGS), a seven-site research network that investigates the genetic architecture of these neurocognitive and other candidate endophenotypes in families with schizophrenia. After providing a brief overview of the rigorous recruitment, data acquisition, and quality assurance procedures established by the COGS, we present recent results from this project that support utility of these procedures and the validity of neurocognitive endophenotypes. We conclude with a discussion of preliminary COGS findings that point toward specific candidate genes and future directions for this and other large-scale endophenotype studies of schizophrenia.
C1 [Greenwood, Tiffany A.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA 90024 USA.
[Gur, Raquel E.] Univ Penn, Dept Psychiat, Med Ctr, Philadelphia, PA 19104 USA.
[Green, Michael F.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA.
[Horan, William P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gur, Raquel E.] Univ Penn, Dept Neurol, Med Ctr, Philadelphia, PA 19104 USA.
[Gur, Raquel E.] Univ Penn, Dept Radiol, Med Ctr, Philadelphia, PA 19104 USA.
[Gur, Raquel E.] Univ Penn, Neuropsychiat Sect, Med Ctr, Philadelphia, PA 19104 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Semel Inst, Los Angeles, CA 90024 USA.
EM horan@ucla.edu; tgreenwood@ucsd.edu; DBraff@ucsd.edu; raquel@upenn.edu;
mgreen@ucla.edu
NR 111
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-1-4020-9463-7
PY 2009
BP 177
EP 193
DI 10.1007/978-1-4020-9464-4_12
D2 10.1007/978-1-4020-9464-4
PG 17
WC Genetics & Heredity; Neurosciences; Psychiatry; Psychology
SC Genetics & Heredity; Neurosciences & Neurology; Psychiatry; Psychology
GA BKM02
UT WOS:000268464200012
ER
PT B
AU Chaiswing, L
Oberley, TD
AF Chaiswing, Luksana
Oberley, Terry D.
BE Meridith, AT
TI Redox State and Prostate Cancer Behavior
SO HANDBOOK OF PROSTATE CANCER CELL RESEARCH: GROWTH, SIGNALLING AND
SURVIVAL
SE Cancer Etiology Diagnosis and Treatments
LA English
DT Article; Book Chapter
ID DAMAGE; TRANSDUCTION; PERSPECTIVE
AB Cellular or tissue reduction-oxidation (redox) state is the result of the net balance of molecular reducing and oxidizing equivalents, and can be subdivided into intra-or extracellular redox state (inside or outside the cell), respectively. Under physiological conditions, redox state regulates cell metabolism, survival, and the cell cycle. Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer deaths in males in the U.S.A. Many studies have documented that prostate cancer cell lines have altered levels of intracellular reactive oxygen species/reactive nitrogen species and/or antioxidant levels in relation to nonmalignant cells. This abnormal intracellular redox state may play an important role in prostate cancer cell cycle progression and cell survival through regulation of redox- modulated transcription factors. Our laboratory recently reported that prostate cancer cells in the cell cultures exhibited an increased glutathione/glutathione disulfide ratio in the media in comparison to immortalized but nonmalignant prostate epithelial cells, suggesting an alteration of extracellular redox state of prostate cancer cells. We also demonstrated that modulation of extracellular redox state by overexpression of extracellular superoxide dismutase resulted in inhibition of prostate cancer cell invasiveness through a mechanism responsive to superoxide radical and/or nitric oxide. We propose that both intra- and extracellular redox states play complementary role(s) in regulation of prostate cancer cell proliferation and/or invasion. This possible relationship between redox states may lead to the development of anti-cancer therapeutics utilizing redox-modulating compounds that are specifically designed to target prostate cancer cells and/or the prostate cancer microenviromnent.
C1 [Chaiswing, Luksana] Univ Wisconsin, William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53706 USA.
Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI USA.
RP Chaiswing, L (reprint author), Univ Wisconsin, William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53706 USA.
NR 16
TC 0
Z9 0
U1 1
U2 2
PU NOVA SCIENCE PUBLISHERS, INC
PI HAUPPAUGE
PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA
BN 978-1-60741-954-9
J9 CANCER ETIOL DIAGN T
PY 2009
BP 489
EP 495
PG 7
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA BNU54
UT WOS:000275598000017
ER
PT J
AU El-Serag, HB
Engels, EA
Landgren, O
Chiao, E
Henderson, L
Amaratunge, HC
Giordano, TP
AF El-Serag, Hashem B.
Engels, Eric A.
Landgren, Ola
Chiao, Elizabeth
Henderson, Louise
Amaratunge, Harshinie C.
Giordano, Thomas P.
TI Risk of Hepatobiliary and Pancreatic Cancers After Hepatitis C Virus
Infection: A Population-Based Study of US Veterans
SO HEPATOLOGY
LA English
DT Article
ID ADMINISTRATION MEDICAL SYSTEM; UNITED-STATES; INTRAHEPATIC
CHOLANGIOCARCINOMA; EXTRAHEPATIC CHOLANGIOCARCINOMA; LIVER; CIRRHOSIS;
ASCERTAINMENT; PREVALENCE; CARCINOMA; AFFAIRS
AB Hepatitis C virus (HCV) may increase the risk of hepatopancreaticobiliary tumors other than hepatocellular carcinoma (HCC). Previous case control studies indicated a possible association between HCV and intrahepatic cholangiocarcinoma (ICC). Little is known about the association between HCV and extrahepatic cholangiocarcinoma (ECC) or pancreatic cancer. We conducted a cohort study including 146,394 HCV-infected and 572,293 HCV-uninfected patients who received care at Veterans Affairs health care facilities. Patients with two visits between 1996 and 2004 with HCV infection were included, as were up to four matched HCV-uninfected subjects for each HCV-infected subject. Risks of ICC, ECC, pancreatic cancer, and HCC were assessed using proportional hazards regression. In the 1.37 million person-years of follow-up, which began 6 months after the baseline visit, there were 75 cases of ECC, 37 cases of ICC, 617 cases of pancreatic cancer, and 1679 cases of HCC. As expected, the risk of HCC associated with HCV was very high (hazard ratio [HR], 15.09; 95% confidence interval [95% CI], 13.44, 16.94). Risk for ICC was elevated with HCV infection 2.55; 1.31, 4.95), but risk for ECC was not significantly increased (1.50; 0.60, 1.85). Adjustments for cirrhosis, diabetes, inflammatory bowel disease, hepatitis B, alcoholism, and alcoholic liver disease did not reduce the risk for ICC below twofold. The risk of pancreatic cancer was slightly elevated (1.23; 1.02, 1.49), but was attenuated after adjusting for alcohol use, pancreatitis, and other variables. Conclusions. Findings indicated that HCV infection conferred a more than twofold elevated risk of ICC. Absence of an association with ECC was consistent in adjusted and unadjusted models. A significant association with pancreatic cancer was erased by alcohol use and other variables. (HEPATOLOGY 2009;49:116-123.)
C1 [El-Serag, Hashem B.; Chiao, Elizabeth; Henderson, Louise; Amaratunge, Harshinie C.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[El-Serag, Hashem B.; Chiao, Elizabeth; Henderson, Louise; Amaratunge, Harshinie C.; Giordano, Thomas P.] Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Engels, Eric A.; Landgren, Ola] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
RP El-Serag, HB (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hasheme@bcm.tmc.edu
FU National Cancer Institute, National Institutes of Health; Michael E.
DeBakey Veterans Affairs Medical Center; Department of Veterans Affairs,
Houston; NIH [K24 DK078154-01]
FX Supported by the Intramural Program of the National Cancer Institute,
National Institutes of Health, and the Michael E. DeBakey Veterans
Affairs Medical Center, Department of Veterans Affairs, Houston, TX. Dr.
El-Sang is sup